PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	MOSSIE, K; JALLAL, B; ALVES, F; SURES, I; PLOWMAN, GD; ULLRICH, A				MOSSIE, K; JALLAL, B; ALVES, F; SURES, I; PLOWMAN, GD; ULLRICH, A			COLON-CARCINOMA KINASE-4 DEFINES A NEW SUBCLASS OF THE RECEPTOR TYROSINE KINASE FAMILY	ONCOGENE			English	Note						RECEPTOR TYROSINE KINASE FAMILY; COLON CARCINOMA; SIGNAL TRANSDUCTION	GROWTH-FACTOR RECEPTOR; HUMAN INSULIN-RECEPTOR; SIGNAL TRANSDUCTION; STRUCTURAL BASIS; HUMAN-BREAST; CELLS; EXPRESSION; GENE; CDNA; SUPERFAMILY	Complementary DNA (cDNA) encoding a novel member of the receptor tyrosine kinase (RTK) family has been isolated from colon carcinoma tissue. Colon carcinoma kinase 4 (CCK-4) mRNA is highly expressed in human lung tissue and at lower levels in the thyroid gland and ovary. While no mRNA was found in human adult colon tissues, expression varied remarkably in colon carcinoma-derived cell lines. CCK-4 cDNA encodes a chicken KLG-related, 1071 amino acid-long transmembrane glycoprotein containing several genetic alterations within the RTK consensus sequences. These define CCK-4 as a catalytically inactive member of the RTK family of proteins and, in analogy to HER3, suggest a potentially tumor-characteristic role as a signal amplifier or modulator for an as yet unidentified kinase-competent partner.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY; SUGEN INC,REDWOOD CITY,CA 94063	Max Planck Society			PLOWMAN, Greg D/E-2012-2011					ALIMANDI M, 1995, ONCOGENE, V10, P1813; ALVES F, 1995, ONCOGENE, V10, P609; BROWN LF, 1993, CANCER RES, V553, P4727; CARTER TH, 1994, CRIT REV ONCOGENESIS, V5, P389, DOI 10.1615/CritRevOncog.v5.i4.40; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Faletto D L, 1993, EXS, V65, P107; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JALLAL B, 1992, J BIOL CHEM, V267, P4357; Kluftinger A M, 1992, Surg Oncol, V1, P97, DOI 10.1016/0960-7404(92)90062-P; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Mendelsohn J, 1992, J Natl Cancer Inst Monogr, P125; MORAN MF, 1988, ONCOGENE, V3, P665; MURGUE B, 1994, CANCER RES, V54, P5206; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PATI UK, 1992, GENE, V114, P285, DOI 10.1016/0378-1119(92)90589-H; Plowman G. D., 1994, DRUG NEWS PERSPECT, V7, P334; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHIBUYA M, 1990, ONCOGENE, V5, P519; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TOYOTA M, 1993, TUMOR BIOL, V14, P295, DOI 10.1159/000217842; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Yamori T, 1993, Gan To Kagaku Ryoho, V20, P393; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	31	127	137	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2179	2184						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478540				2022-12-28	WOS:A1995TF29700031
J	CARNERO, A; LIYANAGE, M; STABEL, S; LACAL, JC				CARNERO, A; LIYANAGE, M; STABEL, S; LACAL, JC			EVIDENCE FOR DIFFERENT SIGNALING PATHWAYS OF PKC-ZETA AND RAS-P21 IN XENOPUS OOCYTES	ONCOGENE			English	Article						OOCYTE MATURATION; PROTEIN KINASE C-ZETA; RAS-P21; MPF AND CDC2 KINASE; MAP KINASE; S6 KINASE II	PROTEIN-KINASE-C; MAP KINASE; CELL-CYCLE; TYROSINE PHOSPHORYLATION; MEIOTIC MATURATION; ONCOGENE PRODUCT; LAEVIS OOCYTES; ACTIVATION; TRANSDUCTION; EXPRESSION	Considerable effort has been devoted to identifying critical steps in mitogenic signal transduction pathways. Recently, the atypical PKC zeta isoform has attracted great interest since it has been reported to induce GVBD in Xenopus oocytes and transformation of NIH3T3 fibroblasts, two processes closely linked with the regulation of cell division. Furthermore, PKC zeta has been proposed as an essential effector for ras-p21 function and therefore may be an essential component of the signalling pathway(s) activated by mitogens. In this study we have analysed the responses induced in Xenopus oocytes after microinjection of purified recombinant PKC zeta protein. Microinjection of PKC zeta induced the early activation of MPF which precedes GVBD and also induced the activation of MAP kinase and S6 kinase II. The activation of MPF, MAP kinase and S6 kinase II by PKC zeta was sensitive to cycloheximide, while induction of GVBD was independent of protein synthesis. These results indicate that PKC zeta induces the activation of at least two pathways, only one of them leading to the activation of MAP kinase. By contrast, neither the induction of GVBD nor the activation of MPF, MAPK and S6 kinase II induced by the ras-p21 protein were dependent on protein synthesis. Thus, the comparison of these responses suggests that PKC zeta most likely does not mediate the uas-induced signal transduction pathway in Xenopus laevis oocytes.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN; MAX PLANCK GESELL,MAX DELLBRUCK LAB,D-50829 COLOGNE,GERMANY	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Max Planck Society			Lacal, Juan Carlos/AAL-2235-2020; IBIS, CANCER/P-3323-2015; Lacal, Juan Carlos/N-9064-2015	Carnero, Amancio/0000-0003-4357-3979; Lacal, Juan Carlos/0000-0002-1908-2777				ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; CACACE AM, 1993, ONCOGENE, V8, P2095; CARNERO A, 1994, ONCOGENE, V9, P1387; CARNERO A, 1995, MOL CELL BIOL, V15, P1094; CARNERO A, 1993, J CELL BIOCHEM, V52, P440, DOI 10.1002/jcb.240520408; CARNERO A, 1994, J CELL BIOCHEM, V55, P1; CARRERO A, 1994, J CELL BIOCHEM, V54, P478; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1995, BIOCHEM BIOPH RES CO, V213, P266, DOI 10.1006/bbrc.1995.2125; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; JACOBS T, 1992, DEV BIOL, V153, P1, DOI 10.1016/0012-1606(92)90087-W; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LACAL JC, 1986, CELL, V44, P609, DOI 10.1016/0092-8674(86)90270-9; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MONTANER S, 1995, ONCOGENE, V10, P2213; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEBREDA AR, 1993, ONCOGENE, V8, P467; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; PRICE BD, 1989, BIOCHEM J, V260, P157, DOI 10.1042/bj2600157; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SETH A, 1991, J BIOL CHEM, V266, P23521; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; STABEL S, 1994, SEMIN CANCER BIOL, V5, P277; Stabel S., 1993, INTRACELLULAR MESSEN, P167; STABEL S, 1993, METH NEUROSCI, V18, P154; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1992, J BIOL CHEM, V267, P4799; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; YEW N, 1992, NATURE, V355, P645	66	19	19	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1541	1547						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478578				2022-12-28	WOS:A1995TC53500012
J	FUKASAWA, K; ZHOU, RP; MATTEN, WT; ARMSTRONG, AJ; DAAR, I; OSKARSSON, M; SATHYANARAYANA, BK; MACLVOR, L; WOOD, TG; VANDEWOUDE, GF				FUKASAWA, K; ZHOU, RP; MATTEN, WT; ARMSTRONG, AJ; DAAR, I; OSKARSSON, M; SATHYANARAYANA, BK; MACLVOR, L; WOOD, TG; VANDEWOUDE, GF			MUTAGENIC ANALYSIS OF FUNCTIONAL DOMAINS OF THE MOS PROTOONCOGENE AND IDENTIFICATION OF THE SITES IMPORTANT FOR MAPK ACTIVATION AND DNA-BINDING	ONCOGENE			English	Article						MOS; MAP KINASE; TRANSFORMATION; OOCYTE MATURATION	XENOPUS-OOCYTES; V-MOS; PROTOONCOGENE PRODUCT; MEIOTIC MATURATION; KINASE-ACTIVITY; MEIOSIS-II; TUBULIN; INVITRO; CELLS; TRANSFORMATION	We constructed in-frame deletion/replacement mutations in the Xenopus mos proto-oncogene that lie within conserved Mos-specific codons, but outside of the regions that are conserved among the src kinase family of genes, All gene products were assayed in vine for kinase activity and in vivo for their ability to induce oocyte maturation, embryonic cleavage arrest and cellular transformation, Most mutations in Mos eliminated both kinase and biological activity, However, a mutation in Mos that removed two basic amino acid residues (R94 and K97) downstream from the lysine at the ATP binding site (K90) markedly enhanced autophosphorylation activity, Moreover, this mutant displayed markedly reduced biological activity, lacked transforming activity, and failed to activate mitogen activated protein kinase (MAPK), A second mutant Mos product, lacking amino acids R45-A54, displayed a five-fold increase in cellular transforming activity, This Mos mutant specifically localized to the cytoplasm; in contrast to wild-type (wt) Mos that localized to both the nucleus and the cytoplasm, These data indicate that Mos transforming activity is mediated via signalling exerted in the cytoplasm, presumably through MAPK, and that nuclear localization of the oncogene product interferes with transforming activity, We also show that amino acids R45-A54 are important for Mos DNA binding activity.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702; UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,RECOMBINANT DNA LAB,GALVESTON,TX 77555	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Texas System; University of Texas Medical Branch Galveston			Wood, Thomas/B-6172-2012; Wood, Thomas/GWZ-2481-2022	Wood, Thomas/0000-0001-8962-8571; Daar, Ira/0000-0003-2657-526X				BAI W, 1992, ONCOGENE, V7, P493; BAI WL, 1992, ONCOGENE, V7, P1757; BLAIR DG, 1986, CELL, V46, P785, DOI 10.1016/0092-8674(86)90354-5; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DAAR IO, 1991, MOL CELL BIOL, V11, P5985, DOI 10.1128/MCB.11.12.5985; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FUKASAWA K, 1995, ONCOGENE, V10, P1; FUKASAWA K, 1995, P NATL ACAD SCI USA, V92, P3430, DOI 10.1073/pnas.92.8.3430; FUKASAWA K, 1994, CELL GROWTH DIFFER, V5, P1093; GARD DL, 1992, DEV BIOL, V151, P516, DOI 10.1016/0012-1606(92)90190-R; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; HAWLEY RS, 1993, TRENDS GENET, V9, P310; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUCHON D, 1981, REPROD NUTR DEV, V21, P135, DOI 10.1051/rnd:19810112; JESSUS C, 1986, BIOL CELL, V56, P113, DOI 10.1111/j.1768-322X.1986.tb00448.x; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; OKAZAKI K, 1991, JPN J CANCER RES, V82, P250, DOI 10.1111/j.1349-7006.1991.tb01837.x; OKAZAKI K, 1995, JPN J CANCER RES, P1149; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RIEDER CL, 1993, MORPHOGENESIS MITOTI, P183; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SETH A, 1987, P NATL ACAD SCI USA, V84, P3560, DOI 10.1073/pnas.84.11.3560; SETH A, 1988, LOCALIZATION NUCLEIC, P82; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; VERLHAC MH, 1993, DEV BIOL, V158, P330, DOI 10.1006/dbio.1993.1192; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WANG XM, 1994, P NATL ACAD SCI USA, V91, P8329, DOI 10.1073/pnas.91.18.8329; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1992, MOL CELL BIOL, V12, P3583, DOI 10.1128/MCB.12.8.3583; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	52	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1447	1457						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478569				2022-12-28	WOS:A1995TC53500003
J	HALL, M; BATES, S; PETERS, G				HALL, M; BATES, S; PETERS, G			EVIDENCE FOR DIFFERENT MODES OF ACTION OF CYCLIN-DEPENDENT KINASE INHIBITORS - P15 AND P16 BIND TO KINASES, P21 AND P27 BIND TO CYCLINS	ONCOGENE			English	Article						CDKN1; CDKN2; CYCLINS; IN VITRO BINDING	SUBUNIT	A number of low molecular weight proteins have recently been identified that specifically inhibit the function of cyclin-dependent protein kinases in mammalian cells. These fall into two distinct families based on primary sequence comparisons and probable modes of action. Using a simple in vitro binding assay, we show that p21(CDKN1) and the related p27(KIP1) can efficiently interact with cyclins D1, D2, D3, E and A, and to a lesser extent with cyclin B. By generating a deleted form of cyclin D1 that binds to p21 and p27 but not to Cdks, we confirm that these interactions do not depend on stoichiometric amounts of the relevant kinase subunit. Moreover, p21 and p27 do not detectably associate with kinase subunits unless a cyclin is present. This is in sharp contrast to the properties of p16(CDKN2) and p15(MTS2/INK4b) which bind to Cdk4 and Cdk6 in the absence of any cyclin. These data suggest that p21 and p27 act as broad spectrum regulators of cyclin dependent kinase function by participating in ternary complexes whereas the p16 family specifically interfere with the formation of cyclin D-dependent kinase complexes.	IMPERIAL CANC RES FUND, ONCOL MOLEC LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK				Hall, marcia/0000-0003-0039-5041				BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CLARKE PR, 1995, CURR BIOL, V5, P40, DOI 10.1016/S0960-9822(95)00013-3; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEN J, 1994, CANCER RES, V54, P6353; JIANG HP, 1994, ONCOGENE, V9, P3397; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LI Y, 1994, ONCOGENE, V9, P2261; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OTSUKI T, 1995, CANCER RES, V55, P1436; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEAFF RJ, 1995, CURR BIOL, V5, P28, DOI 10.1016/S0960-9822(95)00009-1; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAHARA H, 1995, ONCOGENE, V10, P835; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG W, 1995, CANCER RES, V55, P668	52	190	200	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1581	1588						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478582				2022-12-28	WOS:A1995TC53500016
J	TIKHONENKO, AT; BLACK, DJ; LINIAL, ML				TIKHONENKO, AT; BLACK, DJ; LINIAL, ML			V-MYC IS INVARIABLY REQUIRED TO SUSTAIN RAPID PROLIFERATION OF INFECTED-CELLS BUT IN STABLE CELL-LINES BECOMES DISPENSABLE FOR OTHER TRAITS OF THE TRANSFORMED PHENOTYPE	ONCOGENE			English	Article						MYC; GLUCORTICOID RECEPTOR; TRANSFORMATION; PROLIFERATION	HUMAN C-MYC; AVIAN LEUKEMIA VIRUSES; EMBRYO FIBROBLASTS; DNA-BINDING; GLUCOCORTICOID RECEPTOR; N-MYC; NUCLEAR-LOCALIZATION; GENE; CHICKEN; EXPRESSION	The v-myc-containing retrovirus MC29 induces neoplastic transformation of avian embryo cells. To determine which traits of the transformed phenotype are directly controlled by v-Myc, we engineered a conditional MC29 mutant (GRIM) expressing v-Myc as a fusion protein with the glucocorticoid receptor and the retroviral Gag polyprotein. Only in the presence of glucocorticoids such as dexamethasone is GRIM capable of transforming embryo cells, from which six stable GRIM-lines have been derived. Although their survival in culture no longer requires functional v-Myc, hormone deprivation causes all six GRIM clones as web as acutely infected fibroblast cultures to either withdraw from cell cycle completely or to grow much more slowly and to much lower densities. However, removal of dexamethasone does not allow GRIM-transformed mass cultures and most of the clones to revert to normal shapes or to reconstruct actin cables. Furthermore, most clones do not require the hormone sustain anchorage-independent growth. We propose that certain secondary events have let the GRIM-clones sustain immortality, transformed morphology, and anchorage-independent growth independently of v-Myc. None of these events, however, has obliterated the requirement for v-Myc in cell division control. We thus conclude that enhanced proliferation is the primary effect of v-Myc expression.			TIKHONENKO, AT (corresponding author), FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Thomas-Tikhonenko, Andrei/E-5329-2011	Thomas-Tikhonenko, Andrei/0000-0002-2739-2206	NATIONAL CANCER INSTITUTE [R01CA058809] Funding Source: NIH RePORTER; NCI NIH HHS [CA58809] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BECKER D, 1977, J VIROL, V21, P1042, DOI 10.1128/JVI.21.3.1042-1055.1977; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BIEGALKE BJ, 1987, J VIROL, V61, P2138, DOI 10.1128/JVI.61.7.2138-2142.1987; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHEN C, 1989, J VIROL, V63, P5092, DOI 10.1128/JVI.63.12.5092-5100.1989; CROUCH DH, 1990, ONCOGENE, V5, P683; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DEHM P, 1971, BIOCHIM BIOPHYS ACTA, V240, P358, DOI 10.1016/0005-2787(71)90529-6; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ENRIETTO PJ, 1983, VIROLOGY, V124, P164, DOI 10.1016/0042-6822(83)90300-8; FARINA SF, 1992, J VIROL, V66, P2698, DOI 10.1128/JVI.66.5.2698-2708.1992; FRYKBERG L, 1987, ONCOGENE, V1, P415; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LINIAL M, 1982, VIROLOGY, V119, P382, DOI 10.1016/0042-6822(82)90097-6; MA A, 1993, ONCOGENE, V8, P1093; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; OLSON WC, 1990, HYBRIDOMA, V9, P331, DOI 10.1089/hyb.1990.9.331; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RAMSAY G, 1980, NATURE, V288, P170, DOI 10.1038/288170a0; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; ROYERPOKORA B, 1978, CELL, V13, P751, DOI 10.1016/0092-8674(78)90225-8; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHAW J, 1985, J VIROL, V56, P943, DOI 10.1128/JVI.56.3.943-950.1985; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SYMONDS G, 1989, ONCOGENE, V4, P285; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; TIKHONENKO AT, 1993, MOL CELL BIOL, V13, P3623, DOI 10.1128/MCB.13.6.3623; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG E, 1976, P NATL ACAD SCI USA, V73, P4065, DOI 10.1073/pnas.73.11.4065; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498	52	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1499	1508						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478574				2022-12-28	WOS:A1995TC53500008
J	PIERCEALL, WE; WOODARD, AS; MORROW, JS; RIMM, D; FEARON, ER				PIERCEALL, WE; WOODARD, AS; MORROW, JS; RIMM, D; FEARON, ER			FREQUENT ALTERATIONS IN E-CADHERIN AND ALPHA-CATENIN AND BETA-CATENIN EXPRESSION IN HUMAN BREAST-CANCER CELL-LINES	ONCOGENE			English	Article						BREAST CANCER; E-CADHERIN; A-CATENIN; BETA-CATENIN; CYTOSKELETON; CELL-CELL INTERACTIONS	ADHESION MOLECULE; CYTOPLASMIC DOMAIN; COLORECTAL-CANCER; PROSTATE-CANCER; P-CADHERIN; CARCINOMAS; PROTEIN; PLAKOGLOBIN; ASSOCIATION; INVASIVENESS	Alterations in intercellular junction and membrane cytoskeletal proteins may underlie some of the morphological, invasive and metastatic properties of cancer. E-cadherin, a transmembrane protein that functions in epithelial cell-cell interactions at adherens junctions, is linked to the membrane cytoskeletal matrix through interactions with alpha- and beta-catenin. We have carried out studies of E-cadherin and alpha- and beta-catenin in 18 breast cancer cell lines to determine the prevalence and nature of alterations in these genes in breast cancer. Ten lines failed to express E-cadherin protein at detectable levels and seven failed to produce detectable levels of E-cadherin transcripts. In a line lacking E-cadherin expression (SK-BR-3) a homozygous deletion of a large portion of the E-cadherin gene was noted. Localized sequence alterations in E-cadherin transcripts were not identified in any lines. In contrast to the results of a previous study, no relationship was identified between E-caderin expression and HER-2/NEU expression. Two of the 18 lines had no detectable alpha-catenin protein and six others had reduced levels. The two lines lacking alpha-catenin protein had reduced or undetectable levels of alpha-catenin transcripts, while no consistent changes in alpha-catenin transcript levels were seen in the lines with reduced, but detectable, levels of alpha-catenin protein. Similarly, although two lines lacked beta-catenin protein, in most lines the levels of beta-catenin transcripts and protein were not well correlated with one another. Our findings suggest that alterations in E-cadherin and alpha- and beta-catenin expression are frequent in human breast cancer-derived cell lines, and that in some cases the decreased expression may result from mutations in the genes. Furthermore, the frequent alterations in the expression of these proteins argue that loss of function in the E-cadherin-catenin pathway may be critical in the development of many breast cancers.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT BIOL,NEW HAVEN,CT 06510	Yale University; Yale University				Rimm, David/0000-0001-5820-4397				BECKER KF, 1994, CANCER RES, V54, P3845; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BIRCHMEIER W, 1993, SEMIN CANCER BIOL, V4, P231; BRABANT G, 1993, CANCER RES, V53, P4987; BRINGUIER PP, 1993, CANCER RES, V5, P3241; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1284, DOI 10.1006/bbrc.1994.2321; BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; CARTER BS, 1991, P NATL ACAD SCI USA, V87, P8751; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V16, P156; CROALL DE, 1986, BIOCHIM BIOPHYS ACTA, V882, P287, DOI 10.1016/0304-4165(86)90250-3; DOKI Y, 1993, CANCER RES, V53, P3421; DORUDI S, 1993, AM J PATHOL, V142, P981; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GAMALLO C, 1993, AM J PATHOL, V142, P987; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; KADOWAKI T, 1994, CANCER RES, V54, P291; KASHGARIAN M, 1985, KIDNEY INT, V28, P899, DOI 10.1038/ki.1985.216; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; LINDBLOM A, 1993, CANCER RES, V53, P3707; MAYER B, 1993, CANCER RES, V53, P1690; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MOLL R, 1993, AM J PATHOL, V143, P1731; MORTON RA, 1993, CANCER RES, V53, P3585; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OCHIAI A, 1994, JPN J CANCER RES, V85, P266, DOI 10.1111/j.1349-7006.1994.tb02092.x; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; ODA T, 1993, BIOCHEM BIOPH RES CO, V193, P897, DOI 10.1006/bbrc.1993.1710; OKA H, 1993, CANCER RES, V53, P1696; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PFIEFER M, 1990, CELL, V63, P1167; PRESS MF, 1993, CANCER RES, V53, P4960; RASBRIDGE SA, 1993, J PATHOL, V169, P245, DOI 10.1002/path.1711690211; REALE MA, 1994, CANCER RES, V54, P4493; RIMM DL, 1995, LAB INVEST, V72, P590; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SATO T, 1990, CANCER RES, V50, P7184; SCHIPPER JH, 1991, CANCER RES, V52, P2916; SHATKIN AJ, 1969, FUNDAMENTAL TECHNIQU, P231; SHIMOYAMA Y, 1991, CANCER LETT, V57, P131, DOI 10.1016/0304-3835(91)90206-W; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOMMERS CL, 1994, CANCER RES, V54, P3544; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; UMBAS R, 1992, CANCER RES, V52, P5104; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M	66	132	136	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1319	1326						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478552				2022-12-28	WOS:A1995RY96700012
J	PRAML, C; FINKE, LH; HERFARTH, C; SCHLAG, P; SCHWAB, M; AMLER, L				PRAML, C; FINKE, LH; HERFARTH, C; SCHLAG, P; SCHWAB, M; AMLER, L			DELETION MAPPING DEFINES DIFFERENT REGIONS IN 1P34.2-PTER THAT MAY HARBOR GENETIC INFORMATION RELATED TO HUMAN COLORECTAL-CANCER	ONCOGENE			English	Article						CHROMOSOME 1; LOSS OF HETEROZYGOSITY (LOH); MICROSATELLITE; MOM1; TUMOR SUPPRESSOR-GENE	MULTIPLE INTESTINAL NEOPLASIA; FAMILIAL ADENOMATOUS POLYPOSIS; HUMAN CHROMOSOME-1; COLON-CARCINOMA; CELL-LINE; SHORT ARM; IDENTIFICATION; TUMORS; MOUSE; LOCUS	Cytogenetic and molecular analyses of colorectal cancer cells have revealed deletions at 1p as prominent alterations, suggesting that genetic information on the short arm of chromosome 1 has a role in tumorigenesis. In this study we have used 33 microsatellite markers to fine map deletions at 1p in primary colorectal carcinomas. We found 1p-deletions in 84% of the cases (31/37). High frequencies of loss of heterozygosity (LOH), often the result of small independent interstitial deletions in the same tumor, defined three regions, that may harbor genetic information relevant for colorectal cancer: (i) region A between D1S243 and D1S468 (7cM; 1p36.3); (ii) region B between D1S436 and D1S199 (7cM; 1p35.1-36.31) and (iii) region C between D1S496 and D1S255 (1cM; 1p34.2-35). In addition we identified seven cell lines with LOH at 1p, all of which have deletions that span at least from the distal border of region A to the proximal border of region C.	MDC, UKVR ROBERT ROSSLE KLIN, CHIRURG ONKOL ABT, D-13122 BERLIN, GERMANY; UNIV HEIDELBERG, CHIRURG KLIN, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg	PRAML, C (corresponding author), GERMAN CANC RES CTR, DEPT CYTOGENET 0130, NEUENHEIMER FELD 280, D-69120 HEIDELBERG, GERMANY.							AMLER LC, 1995, ONCOGENE, V10, P1095; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARDI G, 1993, CANCER RES, V53, P1895; BARDI G, 1995, GENE CHROMOSOME CANC, V12, P97, DOI 10.1002/gcc.2870120204; BOMME L, 1994, GENE CHROMOSOME CANC, V10, P190, DOI 10.1002/gcc.2870100307; BRUDERLEIN S, 1990, GENE CHROMOSOME CANC, V2, P63, DOI 10.1002/gcc.2870020112; CHENG NC, 1995, ONCOGENE, V10, P291; COUTURIERTURPIN MH, 1992, HUM GENET, V88, P431, DOI 10.1007/BF00215678; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DRACOPOLI NC, 1994, CYTOGENET CELL GENET, V67, P143, DOI 10.1159/000133816; ENGELSTEIN M, 1993, GENOMICS, V15, P251, DOI 10.1006/geno.1993.1054; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LEISTER I, 1990, CANCER RES, V50, P7232; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; MARTH JD, 1986, P NATL ACAD SCI USA, V83, P7400, DOI 10.1073/pnas.83.19.7400; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MIYAKI M, 1990, CANCER RES, V50, P7166; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NADEAU JH, 1991, MAMM GENOME, V1, P461; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; REICHMANN A, 1984, CANCER GENET CYTOGEN, V12, P295, DOI 10.1016/0165-4608(84)90062-1; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; TANAKA K, 1993, ONCOGENE, V8, P2253; VANROY N, 1993, GENOMICS, V18, P71, DOI 10.1006/geno.1993.1427; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOLPI EV, 1994, CYTOGENET CELL GENET, V67, P187, DOI 10.1159/000133819; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; YANGFENG TL, 1985, AM J HUM GENET, V37, P1117; YANOSHITA R, 1992, CANCER RES, V52, P3965; YOUNG J, 1994, ONCOGENE, V9, P1053; YOUNG J, 1992, CANCER RES, V52, P285	42	101	104	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1357	1362						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478557				2022-12-28	WOS:A1995RY96700017
J	SIEGEL, J; FRITSCHE, M; MAI, S; BRANDNER, G; HESS, RD				SIEGEL, J; FRITSCHE, M; MAI, S; BRANDNER, G; HESS, RD			ENHANCED P53 ACTIVITY AND ACCUMULATION IN RESPONSE TO DNA-DAMAGE UPON DNA TRANSFECTION	ONCOGENE			English	Article						P53; P53 ACCUMULATION; P53 SENSITIZATION; DNA DAMAGE; DNA TRANSFECTION; CALICHEAMICIN GAMMA-1	CELLULAR TUMOR-ANTIGEN; DOUBLE-STRAND BREAKS; MONOCLONAL-ANTIBODIES; MAMMALIAN-CELLS; RESTRICTION ENDONUCLEASES; CHROMOSOMAL-ABERRATIONS; SUPPRESSOR PROTEIN; IONIZING-RADIATION; MOUSE CELLS; CHO CELLS	In response to DNA damage the wild-type tumor suppressor protein p53 accumulates in the nucleus of rodent and primate cells. To investigate the minimal requirement for this reaction the cellular DNA was restricted by two alternative ways: (i) by calicheamicin gamma 1, an enediyne, which causes direct, sequence-specific DNA damage, as shown by fluorimetric analysis of DNA unwinding and by poly(ADP-ribose) polymerase activation. The dose-dependent DNA damage correlated with the nuclear p53 accumulation. In addition, restriction was generated (ii) by the intracellular introduction of the restriction enzyme PvuII, which generates blunt-ended DNA breaks, applying a mild hypotonic shock (pellet method). Previous transfection of linear or circular, single- or ds, DNA, followed by mitomycin C-treatment, lead to a dramatic increase in nuclear p53 accumulation and p53 activity according to electrophoretic mobility shift analysis. The nature of transfected DNA was irrelevant for enhanced accumulation. The data suggest, that the cellular p53 response to DNA damage is sensitized by uptake of exogenous DNA.	UNIV FREIBURG,INST MED MIKROBIOL & HYG,VIROL ABT,D-79104 FREIBURG,GERMANY; INST EXPTL KREBSFORSCH,TUMORBIOL KLIN,D-79106 FREIBURG,GERMANY; BASEL INST IMMUNOL,CH-4058 BASEL,SWITZERLAND	University of Freiburg			mai, sj/HGE-8908-2022					ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; AUER D, 1976, NATURWISSENSCHAFTEN, V63, P391, DOI 10.1007/BF00607946; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BHATTACHARYYA D, 1988, CARCINOGENESIS, V9, P683, DOI 10.1093/carcin/9.4.683; BIRNBOIM HC, 1981, CANCER RES, V41, P1889; BRAIN R, 1994, ONCOGENE, V9, P1775; BRYANT PE, 1989, MUTAT RES, V213, P233, DOI 10.1016/0027-5107(89)90155-3; BURKLE A, 1993, CARCINOGENESIS, V14, P559, DOI 10.1093/carcin/14.4.559; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; COLEMAN WB, 1994, CARCINOGENESIS, V15, P145, DOI 10.1093/carcin/15.2.145; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; COSTA ND, 1990, INT J RADIAT BIOL, V57, P933, DOI 10.1080/09553009014551051; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONEHOWER LA, 1992, NATURE, V356, P79; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FRITSCHE M, 1993, ONCOGENE, V8, P307; FRITSCHE M, 1991, THESIS FREIBURG; FRITSCHE M, 1991, J CANCER RES CLIN S, V117, pS30; GANNON JV, 1990, EMBO J, V9, P1591; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HESS R, 1994, TOXICOL LETT, V72, P43, DOI 10.1016/0378-4274(94)90008-6; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1991, CANCER RES, V51, P6304; KRAMER M, 1990, RADIAT ENVIRON BIOPH, V29, P303, DOI 10.1007/BF01210410; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LEHMANN AR, 1985, MUTAT RES, V150, P61, DOI 10.1016/0027-5107(85)90101-0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LJUNGMAN M, 1989, CARCINOGENESIS, V10, P447, DOI 10.1093/carcin/10.3.447; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUCKEHUHLE C, 1989, MOL CELL BIOL, V9, P4812; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCWHIR J, 1993, NAT GENET, V3, P217; MESSMER UK, 1994, FEBS LETT, V355, P23; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MONDAL S, 1976, NATURE, V260, P710, DOI 10.1038/260710a0; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; MORTEN JEN, 1988, CARCINOGENESIS, V9, P45, DOI 10.1093/carcin/9.1.45; MOSNER J, 1995, J CANCER RES CLIN S2, V121, pB20; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NICOLAOU KC, 1992, SCIENCE, V256, P1172, DOI 10.1126/science.256.5060.1172; Nicolau K.C., 1991, ANGEW CHEM, V103, P1453; OBE G, 1985, MUTAT RES, V150, P359; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SCHMIDT RJ, 1995, J CANC RES CLIN O S2, V121, pA12; SCHULZELUTUM A, 1994, INT J ONCOL, V5, P1405; SHERLEY JL, 1991, J BIOL CHEM, V266, P24815; SIEGEL J, 1993, J CANCER RES CLIN S2, V119, pS84; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; STEWART N, 1995, ONCOGENE, V10, P109; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WILSON RE, 1993, ONCOGENE, V8, P3229; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YAMAIZUMI M, 1994, ONCOGENE, V10, P2775; ZEIN N, 1988, SCIENCE, V240, P1198, DOI 10.1126/science.3240341; ZHAN QM, 1994, ONCOGENE, V9, P3743	72	42	42	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1363	1370						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478558				2022-12-28	WOS:A1995RY96700018
J	MEDEMA, JP; DEVRIESSMITS, AMM; BOS, JL				MEDEMA, JP; DEVRIESSMITS, AMM; BOS, JL			CALCIUM INDUCES TYROSINE PHOSPHORYLATION OF A NOVEL P120GAP-ASSOCIATED PROTEIN OF 65 KDA	ONCOGENE			English	Article						KERATINOCYTES; SIGNAL TRANSDUCTION; P2LRAS	GTPASE-ACTIVATING PROTEIN; INDUCED KERATINOCYTE DIFFERENTIATION; MOUSE EPIDERMAL-CELLS; MOLECULAR-CLONING; KINASE-ACTIVITY; GAP; ASSOCIATION; RECEPTOR; SRC; RAS	Several tyrosine-phosphorylated proteins have been identified that associate with p120GAP, the GTPase activating protein of p21ras. In keratinocytes, calcium induced the tyrosine phosphorylation of a 65 kDa p120GAP-associated protein (p65Ca). This protein did not comigrate with two previously reported p120GAP-associated proteins, i.e. a 68 kDa protein from src-transformed cells (p68) and an insulin-induced protein of 60 kDa (p60(2C4)). P65Ca was neither recognized by poly(U)-sepharose, which efficiently precipitates p68, nor did it crossreact with antibodies against p68. In addition, a monoclonal antibody directed to p60(2C4) did not recognize p65Ca. From these results we conclude that p65Ca is different from p68 and p60(2C4) and thus, a novel p120GAP-associated protein. Since calcium has an important, tyrosine kinase dependent, role in the differentiation of keratinocytes, phosphorylation of p65Ca may be important for this differentiation process. However, surprisingly, calcium induced the phosphorylation of a similar-sized p120GAP-associated 65 kDa protein in fibroblast cell lines.	UNIV UTRECHT, PHYSIOL CHEM LAB, 3584 CG UTRECHT, NETHERLANDS	Utrecht University				Medema, Jan Paul/0000-0003-3045-2924				BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; Buxton R S, 1992, Semin Cell Biol, V3, P157; DUDEN R, 1988, J CELL BIOL, V107, P1049, DOI 10.1083/jcb.107.3.1049; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FILVAROFF E, 1994, J BIOL CHEM, V269, P21735; FILVAROFF E, 1992, MOL CELL BIOL, V12, P5319, DOI 10.1128/MCB.12.12.5319; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENNINGS H, 1983, EXP CELL RES, V143, P127, DOI 10.1016/0014-4827(83)90115-5; HODIVALA KJ, 1994, J CELL BIOL, V124, P589, DOI 10.1083/jcb.124.4.589; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; MEDEMA JP, 1994, MOL CELL BIOL, V14, P7078, DOI 10.1128/MCB.14.11.7078; MENON GK, 1991, ARCH DERMATOL, V127, P57, DOI 10.1001/archderm.127.1.57; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; OGAWA W, 1994, J BIOL CHEM, V269, P29602; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; PRONK GJ, 1992, ONCOGENE, V7, P389; SCHERUBL H, 1990, FEBS LETT, V273, P51, DOI 10.1016/0014-5793(90)81048-S; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; STOLER AB, 1993, J CELL BIOL, V122, P1103, DOI 10.1083/jcb.122.5.1103; STROOP SD, 1993, J BIOL CHEM, V268, P19927; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; WHEELOCK MJ, 1992, J CELL BIOL, V117, P415, DOI 10.1083/jcb.117.2.415; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; ZHAO YH, 1992, P NATL ACAD SCI USA, V89, P8298, DOI 10.1073/pnas.89.17.8298	36	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					757	762						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7544452				2022-12-28	WOS:A1995RQ46900018
J	GRIECO, D; SANTORO, M; DATHAN, NA; FUSCO, A				GRIECO, D; SANTORO, M; DATHAN, NA; FUSCO, A			ACTIVATED RET ONCOGENE PRODUCTS INDUCE MATURATION OF XENOPUS OOCYTES	ONCOGENE			English	Article						RET/PTC; RAS; MPF	TRANSFORMING GENE; TYROSINE KINASE; PROTEIN-KINASE; RAS PROTEINS; PROTOONCOGENE; CARCINOMAS; EXPRESSION; MUTATIONS; FUSION	The RET proto-oncogene encodes a transmembrane receptor of the tyrosine kinase family, recently found to be the gene responsible for the multiple endocrine neoplasia type 2A and 2B syndromes, RET was found specifically activated, by gene rearrangement, in human thyroid carcinomas of the papillary subtype, In most cases the activation consisted of an in frame fusion of the RET tyrosine-kinase domain, at the carboxy-terminus, with heterologous genes at the amino-terminus. These chimeric oncogenes are collectively named RET/PTC, Two forms of these gene products, RET/PTC1 and RET/PTC3, have been tested for their ability to induce meiotic maturation in Xenopus oocytes, Injection of RET/PTC mRNAs into immature oocytes induced maturation-promoting-factor (MPF) activation and germinal vesicle breakdown (GVBD), The injected oocytes expressed polypeptides recognized by an anti-RET gene product antibody as well as by an anti-phosphotyrosine antibody, indicating activation of the tyrosine-kinase domain, The RET/PTC induced maturation was dependent on endogenous ras; in fact, the coinjection of RET/PTC mRNA with a neutralizing anti-ras antibody blocked oocytes maturation without interfering with the accumulation and tyrosine-phosphorylation of the RET/PTC protein.	UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria	GRIECO, D (corresponding author), COLUMBIA UNIV,INST CANC RES,701 W 168TH ST,NEW YORK,NY 10032, USA.			Fusco, Alfredo/0000-0003-3332-5197; GRIECO, Domenico/0000-0002-7131-5742				AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; DAAR IO, 1991, MOL CELL BIOL, V11, P5985, DOI 10.1128/MCB.11.12.5985; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; LANZI C, 1992, ONCOGENE, V7, P2189; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MALLER JL, 1985, P NATL ACAD SCI USA, V82, P272, DOI 10.1073/pnas.82.2.272; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OPRESKO LK, 1990, J CELL BIOL, V111, P1661, DOI 10.1083/jcb.111.4.1661; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1994, ONCOGENE, V9, P509; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SPIVAK JG, 1994, MOL CELL BIOL, V4, P1631; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0	31	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					113	117						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624118				2022-12-28	WOS:A1995RJ29500014
J	MCVICAR, DW; LAL, BK; LLOYD, A; KAWAMURA, M; CHEN, YQ; ZHANG, XY; STAPLES, JE; ORTALDO, JR; OSHEA, JJ				MCVICAR, DW; LAL, BK; LLOYD, A; KAWAMURA, M; CHEN, YQ; ZHANG, XY; STAPLES, JE; ORTALDO, JR; OSHEA, JJ			MOLECULAR-CLONING OF LSK, A CARBOXYL-TERMINAL SRC KINASE (CSK) RELATED GENE, EXPRESSED IN LEUKOCYTES	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; NATURAL-KILLER-CELLS; SH3 DOMAINS; SIGNAL TRANSDUCTION; LYMPHOCYTES-T; NK CELLS; PHOSPHORYLATES; RECEPTORS; P50(CSK); ENCODES	Regulation of the activity of src-family kinases is thought to occur, in part, through the phosphorylation of conserved carboxyl-terminal tyrosine residues. Although the src-family includes several molecules with tissue or cell-type restricted expression, the only kinase implicated in the regulatory phosphorylation of these enzymes is p50(csk). Herein we report the molecular cloning of a tissue specific p50(csk)-related gene. Like p50(csk), the deduced protein sequence of this novel cDNA includes a tyrosine kinase catalytic domain, SH2 and SH3 domains, a short amino terminus, and no autophosphorylation or carboxyl-terminal tyrosine residues. Additionally, neither this novel kinase nor p50(csk) contain the amino-terminal myristoylation site characteristic of the src-family. However, whereas csk is ubiquitously expressed, mRNA corresponding to this novel gene is expressed in brain, natural killer (NK) cells, and activated T cells but not in a variety of other tissues and cell lines. In agreement with the mRNA expression pattern, antiserum reactive with the predicted carboxyl-terminus of the cDNA recognizes a 57 kDa polypeptide in immunoblots of NK cells and PHA-activated T cells, Because of its limited expression and high homology to p50(csk), we named this gene lsk; leukocyte carboxyl-terminal src kinase related gene. Identification of a molecule like lsk suggests the existence of tissue specific src-regulatory pathways that function in activated lymphocytes.	NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, MOLEC IMMUNOREGULAT LAB, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	MCVICAR, DW (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, LEUKOCYTE CELL BIOL SECT, EXPTL IMMUNOL LAB, FREDERICK, MD 21702 USA.		McVicar, Daniel/G-1970-2015; Lal, Brajesh/AAA-2620-2022; Lloyd, Andrew/AAF-6071-2022; Lloyd, Andrew/AFJ-8960-2022; Lloyd, Andrew/E-7334-2017	Lloyd, Andrew/0000-0001-6277-8887; Lloyd, Andrew/0000-0001-6277-8887; McVicar, Daniel/0000-0002-1112-5111				BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; BROOKER GW, 1993, CELL, V73, P813; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; COOKE M P, 1989, New Biologist, V1, P66; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LANIER LL, 1992, IMMUNOL TODAY, V13, P392, DOI 10.1016/0167-5699(92)90087-N; LANIER LL, 1986, J IMMUNOL, V136, P4480; LI M, 1993, FOCUS, V15, P19; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACAULEY A, 1993, ONCOGENE, V8, P117; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; ORTALDO JR, 1986, J EXP MED, V164, P1193, DOI 10.1084/jem.164.4.1193; OSHEA JJ, 1992, J IMMUNOL, V148, P2497; PARTANEN J, 1991, ONCOGENE, V6, P2013; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; REIF AE, 1964, J EXP MED, V120, P413, DOI 10.1084/jem.120.3.413; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAKEYA T, 1983, CELL, V47, P277; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; YOUNG HA, 1987, J IMMUNOL, V139, P724	40	54	57	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					2037	2044						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	7516063				2022-12-28	WOS:A1994NR68500028
J	JAMAL, HH; CANOGAUCI, DF; BUICK, RN; FILMUS, J				JAMAL, HH; CANOGAUCI, DF; BUICK, RN; FILMUS, J			ACTIVATED RAS AND SRC INDUCE CD44 OVEREXPRESSION IN RAT INTESTINAL EPITHELIAL-CELLS	ONCOGENE			English	Article							HUMAN-COLON CARCINOMA; PP60C-SRC PROTEIN-KINASE; RECEPTOR CD44; EXPRESSION; HYALURONATE; EXONS; MUTATIONS; ONCOGENE; MOLECULE; CONFERS	CD44 is an adhesion molecule that is involved in the progression of several tumor types, including those originating in the intestine. There are several alternatively spliced forms of CD44. Here we show that intestinal epithelial cells express the standard form of CD44 (CD44s). The same form of CD44 is found in IEC-18, a cell line derived from normal rat intestinal crypts. Upon transfection of IEC-18 cells with vas or src, two oncogenes that are frequently activated in intestinal tumors, a significant induction of CD44s is observed. A causal role for vas in this induction is shown by using IEC clones transfected with an inducible vas expression vector. The oncogene-transformed IEC clones display a high degree of hyaluronic acid-dependent cell-cell adhesion that is not observed in the parental IEC-18 cells suggesting that ras- and src-induced overexpression of CD44 c;ln alter the adhesion properties of intestinal cells.	SUNNYBROOK HLTH SCI CTR,DIV CANC RES,TORONTO M4N 3M5,ON,CANADA; ONTARIO CANC INST,TORONTO M4X 1K9,ON,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON,CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto								BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIRCH M, 1991, CANCER RES, V51, P6660; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; CANOGAUCI DF, 1993, EXP CELL RES, V208, P344, DOI 10.1006/excr.1993.1255; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; COOPER DL, 1992, BIOCHEM BIOPH RES CO, V182, P569, DOI 10.1016/0006-291X(92)91770-Q; FILMUS J, 1992, ONCOGENE, V7, P521; FILMUS J, 1993, ONCOGENE, V8, P1017; FILMUS J, 1988, MOL CELL BIOL, V8, P4243, DOI 10.1128/MCB.8.10.4243; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HOFMANN M, 1993, CANCER RES, V53, P1516; KENNEL SJ, 1993, J CELL SCI, V104, P373; KUPPNER MC, 1992, INT J CANCER, V50, P572, DOI 10.1002/ijc.2910500414; LIOTTA LA, 1976, CANCER RES, V36, P889; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; OUDEJANS J J, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P293; PATTERSON DJ, 1987, MOL IMMUNOL, V24, P1281; QUARONI A, 1981, J NATL CANCER I, V67, P1353; QURESHI SA, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCREATON GR, 1993, J BIOL CHEM, V268, P12235; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TOLG C, 1993, NUCLEIC ACIDS RES, V21, P1225, DOI 10.1093/nar/21.5.1225; UNDERHILL C, 1992, J CELL SCI, V103, P293; WARREN SL, 1988, MOL CELL BIOL, V8, P632, DOI 10.1128/MCB.8.2.632; ZHAO JM, 1993, EXP CELL RES, V204, P82, DOI 10.1006/excr.1993.1011	41	57	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					417	423						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	7507229				2022-12-28	WOS:A1994MW24800008
J	BAKKUS, MHC; BRAKELVANPEER, KMJ; ADRIAANSEN, HJ; WIERENGAWOLF, AF; VANDENAKKER, TW; DICKEEVINGER, MJ; BENNER, R				BAKKUS, MHC; BRAKELVANPEER, KMJ; ADRIAANSEN, HJ; WIERENGAWOLF, AF; VANDENAKKER, TW; DICKEEVINGER, MJ; BENNER, R			DETECTION OF ONCOGENE EXPRESSION BY FLUORESCENT INSITU HYBRIDIZATION IN COMBINATION WITH IMMUNOFLUORESCENT STAINING OF CELL-SURFACE MARKERS	ONCOGENE			English	Article									UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,DEPT HEMATOL,HOUSTON,TX 77030; ACAD HOSP ROTTERDAM DIJKZIGT,ROTTERDAM,NETHERLANDS	University of Texas System; UTMD Anderson Cancer Center; Erasmus University Rotterdam; Erasmus MC	BAKKUS, MHC (corresponding author), ERASMUS UNIV,DEPT IMMUNOL,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.							ANGERER LM, 1981, NUCLEIC ACIDS RES, V9, P2819, DOI 10.1093/nar/9.12.2819; BAUMAN JGJ, 1988, CYTOMETRY, V9, P517, DOI 10.1002/cyto.990090602; BENHAM FJ, 1984, EMBO J, V3, P2635, DOI 10.1002/j.1460-2075.1984.tb02186.x; BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; BRAHIC M, 1984, P NATL ACAD SCI USA, V81, P5455; BRESSER J, 1987, GENE ANAL TECH, V4, P89, DOI 10.1016/0735-0651(87)90002-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COGHLAN JP, 1985, ANAL BIOCHEM, V149, P1, DOI 10.1016/0003-2697(85)90472-5; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DIRKS RW, 1989, J HISTOCHEM CYTOCHEM, V37, P7, DOI 10.1177/37.1.2642295; EVINGERHODGES MJ, 1988, LEUKEMIA, V2, P45; FERRARI S, 1985, CANCER RES, V7, P833; GALLAGHER R, 1979, BLOOD, V54, P713; GARSON JA, 1987, NUCLEIC ACIDS RES, V15, P4761, DOI 10.1093/nar/15.12.4761; HAYASHI S, 1978, J HISTOCHEM CYTOCHEM, V26, P677, DOI 10.1177/26.8.99471; HOEFLER H, 1986, HISTOCHEM J, V18, P597, DOI 10.1007/BF01675295; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOPMAN AHN, 1986, HISTOCHEMISTRY, V85, P1, DOI 10.1007/BF00508646; LAWRENCE JB, 1985, NUCLEIC ACIDS RES, V13, P1777; LAWRENCE JB, 1988, CELL, V52, P51; LOZIO CB, 1975, BLOOD, V45, P321; Maniatis T., 1982, MOL CLONING; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NILSSON K, 1970, CLIN EXP IMMUNOL, V7, P477; PAIETTA E, 1987, BLOOD, V70, P1151; SHIVERS BD, 1986, J HISTOCHEM CYTOCHEM, V34, P39, DOI 10.1177/34.1.3510246; SINGER RH, 1986, BIOTECHNIQUES, V4, P230; VANDONGEN JJM, 1987, APPLICATION MONOCLON, P87; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490	32	12	15	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1989	4	10					1255	1262						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2677919				2022-12-28	WOS:A1989AU50800014
J	MORELLO, D; ASSELIN, C; LAVENU, A; MARCU, KB; BABINET, C				MORELLO, D; ASSELIN, C; LAVENU, A; MARCU, KB; BABINET, C			TISSUE-SPECIFIC POST-TRANSCRIPTIONAL REGULATION OF C-MYC EXPRESSION IN NORMAL AND H-2K/HUMAN C-MYC TRANSGENIC MICE	ONCOGENE			English	Article									SUNY STONY BROOK,DEPT BIOCHEM,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	MORELLO, D (corresponding author), INST PASTEUR,UNITE GENET MAMMIFERES,DEPT IMMUNOL,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.				NATIONAL CANCER INSTITUTE [R01CA036246] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36246] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; ASSELIN C, 1989, IN PRESS ONC RES; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BREGEGERE F, 1981, NATURE, V292, P78, DOI 10.1038/292078a0; COWLEY BD, 1987, P NATL ACAD SCI USA, V84, P8394, DOI 10.1073/pnas.84.23.8394; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1988, ONCOGENE, V3, P387; FAUSTO N, 1987, S FUNDAM CANCER RES, V39, P69; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LINDSTEN T, 1988, EMBO J, V7, P2787, DOI 10.1002/j.1460-2075.1988.tb03133.x; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MARCU KB, 1986, CURR TOP MICROBIOL, V132, P345; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MORELLO D, 1989, ONCOGENE RES, V4, P111; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1987, ONCOGENE, V1, P243; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; PANDURO A, 1987, GENE DEV, V1, P1172, DOI 10.1101/gad.1.10.1172; PAUL J, 1969, CELL TISSUE KINET, V2, P283, DOI 10.1111/j.1365-2184.1969.tb00238.x; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; SCHNEIDERSCHAULIES J, 1987, EUR J IMMUNOL, V17, P713, DOI 10.1002/eji.1830170521; STARNAUD R, 1988, ONCOGENE, V3, P553; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363	45	28	29	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					955	961						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2668846				2022-12-28	WOS:A1989AJ29700002
J	DOTTO, GP; ELFOULY, MH; NELSON, C; TROSKO, JE				DOTTO, GP; ELFOULY, MH; NELSON, C; TROSKO, JE			SIMILAR AND SYNERGISTIC INHIBITION OF GAP-JUNCTIONAL COMMUNICATION BY RAS TRANSFORMATION AND TUMOR PROMOTER TREATMENT OF MOUSE PRIMARY KERATINOCYTES	ONCOGENE			English	Article									MICHIGAN STATE UNIV, DEPT PEDIAT & HUMAN DEV, E LANSING, MI 48824 USA	Michigan State University	DOTTO, GP (corresponding author), YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06510 USA.		Trosko, James/J-5954-2019		NATIONAL CANCER INSTITUTE [R01CA021104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039190] Funding Source: NIH RePORTER; NCI NIH HHS [CA21104] Funding Source: Medline; NIAMS NIH HHS [AR-39190-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BIGNAMI M, 1981, IN PRESS MOL CARCINO, V1; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CHANG CC, 1985, P NATL ACAD SCI USA, V82, P5360, DOI 10.1073/pnas.82.16.5360; CHANG CC, 1987, CANCER RES, V47, P1634; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; DOTTO GP, 1985, NATURE, V318, P472; EL-FOULY M H, 1986, American Journal of Human Genetics, V39, pA30; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENNINGS H, 1983, NATURE, V304, P67, DOI 10.1038/304067a0; HSIAO WLW, 1984, SCIENCE, V226, P552, DOI 10.1126/science.6436974; JANSSENTIMMEN U, 1986, CARCINOGENESIS, V7, P1475, DOI 10.1093/carcin/7.9.1475; KALIMI GH, 1984, CARCINOGENESIS, V5, P1671, DOI 10.1093/carcin/5.12.1671; KAM E, 1987, EXP CELL RES, V173, P431, DOI 10.1016/0014-4827(87)90283-7; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; MURRAY AW, 1979, BIOCHEM BIOPH RES CO, V91, P395, DOI 10.1016/0006-291X(79)91535-3; PASTI G, 1988, CANCER RES, V48, P447; PITTS JD, 1986, J CELL SCI, P239, DOI 10.1242/jcs.1986.Supplement_4.15; POTTER VR, 1983, PROG NUCLEIC ACID RE, V29, P161, DOI 10.1016/S0079-6603(08)60445-6; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; YAMASAKI H, 1987, CANCER RES, V47, P5658; YOTTI LP, 1979, SCIENCE, V206, P1089, DOI 10.1126/science.493994; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0	30	39	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1989	4	5					637	641						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2657578				2022-12-28	WOS:A1989U768800015
J	HOUCK, KA; MICHALOPOULOS, GK; STROM, SC				HOUCK, KA; MICHALOPOULOS, GK; STROM, SC			INTRODUCTION OF A HA-RAS ONCOGENE INTO RAT-LIVER EPITHELIAL-CELLS AND PARENCHYMAL HEPATOCYTES CONFERS RESISTANCE TO THE GROWTH INHIBITORY EFFECTS OF TGF-BETA	ONCOGENE			English	Article									DUKE UNIV,MED CTR,DEPT PATHOL,POB 3432,DURHAM,NC 27710; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PATHOL,RICHMOND,VA 23298	Duke University; Virginia Commonwealth University			Houck, Keith/G-8654-2014	Houck, Keith/0000-0002-0055-2249	NATIONAL CANCER INSTITUTE [R01CA030241, R01CA043632, R01CA035373, R37CA030241] Funding Source: NIH RePORTER; NCI NIH HHS [CA-43632, CA-35373, CA-30241] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANZANO MA, 1985, MOL CELL BIOL, V5, P242, DOI 10.1128/MCB.5.1.242; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3761, DOI 10.1073/pnas.75.8.3761; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CARR BI, 1986, CANCER RES, V44, P2230; COFFEY RJ, 1986, CANCER RES, V46, P1164; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; FISZERSZAFARZ B, 1981, ANAL BIOCHEM, V110, P165, DOI 10.1016/0003-2697(81)90130-5; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GRISHAM JW, 1983, MOL CELL BIOCHEM, V53-4, P23; HOUCK KA, 1988, J CELL PHYSIOL, V135, P551, DOI 10.1002/jcp.1041350327; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; JIRTLE RL, 1981, CANCER RES, V41, P3512; KESKIOJA J, 1988, J CELL BIOL, V106, P451, DOI 10.1083/jcb.106.2.451; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LAIHO M, 1986, EXP CELL RES, V164, P399, DOI 10.1016/0014-4827(86)90038-8; LIN P, 1987, BIOCHEM BIOPH RES CO, V143, P26, DOI 10.1016/0006-291X(87)90624-3; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MCMAHON JB, 1986, CANCER RES, V46, P4665; MOSES HL, 1981, CANCER RES, V41, P2842; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SAND TE, 1985, ACTA ENDOCRINOL-COP, V109, P369, DOI 10.1530/acta.0.1090369; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; SPARKS RL, 1986, EXP CELL RES, V165, P345, DOI 10.1016/0014-4827(86)90588-4; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; TSAO MS, 1985, CANCER RES, V45, P4428; TUCKER RF, 1984, P NATL ACAD SCI-BIOL, V81, P6757, DOI 10.1073/pnas.81.21.6757; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; WILLIAMS GM, 1971, EXP CELL RES, V69, P106, DOI 10.1016/0014-4827(71)90316-8; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0	48	81	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					19	25						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2783773				2022-12-28	WOS:A1989U567400003
J	ZHOU, DJ; AHUJA, H; CLINE, MJ				ZHOU, DJ; AHUJA, H; CLINE, MJ			PROTO-ONCOGENE ABNORMALITIES IN HUMAN-BREAST CANCER - C-ERBB-2 AMPLIFICATION DOES NOT CORRELATE WITH RECURRENCE OF DISEASE	ONCOGENE			English	Article									UNIV CALIF LOS ANGELES,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [CA 15619] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA015619] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1988, SCIENCE, V240, P1795, DOI 10.1126/science.3289120; BERGER MS, 1988, CANCER RES, V48, P1238; BONADONNA G, 1987, NEOPLASMS BREAST MED, P959; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CLINE MJ, 1987, J CLIN ONCOL, V5, P999, DOI 10.1200/JCO.1987.5.7.999; Cutler S J, 1974, Semin Oncol, V1, P91; DIXON WJ, 1983, BMDP STATISTICAL SOF; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MASUDA H, 1987, MOL BIOL MED, V4, P213; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STENKVIST B, 1982, CANCER-AM CANCER SOC, V50, P2884, DOI 10.1002/1097-0142(19821215)50:12<2884::AID-CNCR2820501231>3.0.CO;2-K; THEILLET C, 1986, CANCER RES, V46, P4776; VARLEY JM, 1987, ONCOGENE, V1, P423; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; YOKOTA J, 1986, LANCET, V1, P765; ZHOU DJ, 1987, CANCER RES, V47, P6123	22	161	163	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					105	108						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2915899				2022-12-28	WOS:A1989U567400016
J	STARNAUD, R; NEPVEU, A; MARCU, KB; MCBURNEY, MW				STARNAUD, R; NEPVEU, A; MARCU, KB; MCBURNEY, MW			2 TRANSIENT INCREASES IN C-MYC GENE-EXPRESSION DURING NEUROECTODERMAL DIFFERENTIATION OF MOUSE EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article									UNIV OTTAWA,DEPT MED,451 SMYTH RD,OTTAWA K1H 8M5,ONTARIO,CANADA; ROYAL VICTORIA HOSP,LUDWIG INST CANC RES,MONTREAL BRANCH,MONTREAL H3A 1A1,QUEBEC,CANADA; SUNY STONY BROOK,DEPT BIOCHEM,STONY BROOK,NY 11794	University of Ottawa; Ludwig Institute for Cancer Research; McGill University; Royal Victoria Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			/AAB-8315-2020					AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; CAMPIONEPICCARDO J, 1985, EXP CELL RES, V156, P544, DOI 10.1016/0014-4827(85)90561-0; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DAMBLYCHAUDIERE C, 1987, GENE DEV, V1, P297, DOI 10.1101/gad.1.3.297; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DENIS N, 1987, EXP CELL RES, V172, P212, DOI 10.1016/0014-4827(87)90107-8; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; EDWARDS SA, 1986, EXP CELL RES, V165, P473, DOI 10.1016/0014-4827(86)90600-2; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; JIMENEZ F, 1979, NATURE, V282, P310, DOI 10.1038/282310a0; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCCACHREN SS, 1986, BLOOD, V68, P412; MUMMERY CL, 1987, DEV BIOL, V121, P10, DOI 10.1016/0012-1606(87)90133-3; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1985, NATURE, V317, P440, DOI 10.1038/317440a0; NEPVEU A, 1987, ONCOGENE, V1, P243; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; RAY D, 1987, MOL CELL BIOL, V7, P940, DOI 10.1128/MCB.7.2.940; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; RUPPERT C, 1986, EMBO J, V5, P1897, DOI 10.1002/j.1460-2075.1986.tb04442.x; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEJERSEN T, 1987, EXP CELL RES, V172, P304, DOI 10.1016/0014-4827(87)90389-2; SEJERSEN T, 1986, J CELL PHYSIOL, V127, P274, DOI 10.1002/jcp.1041270213; SMITH SC, 1987, J CELL PHYSIOL, V131, P74, DOI 10.1002/jcp.1041310112; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; SWARTWOUT SG, 1987, MOL CELL BIOL, V7, P2052, DOI 10.1128/MCB.7.6.2052; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	67	34	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					553	559						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3078960				2022-12-28	WOS:A1988R516300011
J	PICHON, F; SEUWEN, K; POUYSSEGUR, J; LAGARDE, AE				PICHON, F; SEUWEN, K; POUYSSEGUR, J; LAGARDE, AE			PROGRESSIVE RELAXATION OF GO-ARREST CONTROLS AND ALTERED RESPONSIVENESS TO INSULIN, EGF AND THROMBIN IN CCL39 LUNG FIBROBLASTS OVER-EXPRESSING MYC AND RAS ONCOGENES	ONCOGENE			English	Article									MT SINAI HOSP,RES INST,DIV CANC & CELL BIOL,ROOM 876,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MED GENET,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV NICE,FAC SCI,CTR BIOCHIM,F-06034 NICE,FRANCE	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; UDICE-French Research Universities; Universite Cote d'Azur								ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BALK SD, 1985, P NATL ACAD SCI USA, V82, P5781, DOI 10.1073/pnas.82.17.5781; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; BUTNICK NZ, 1985, MOL CELL BIOL, V5, P3009, DOI 10.1128/MCB.5.11.3009; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHADWICK DE, 1988, J NATL CANCER I, V80, P318, DOI 10.1093/jnci/80.5.318; CHAMBARD JC, 1983, J BIOL CHEM, V258, P1706; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1987, ONCOGENE RES, V1, P64; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DENHARDT DT, 1986, BIOCHIM BIOPHYS ACTA, V865, P83, DOI 10.1016/0304-419X(86)90024-7; DURKIN JP, 1986, MOL CELL BIOL, V6, P1386, DOI 10.1128/MCB.6.5.1386; DURNAM DM, 1984, MOL CELL BIOL, V4, P484, DOI 10.1128/MCB.4.3.484; FALCONE G, 1987, EXP CELL RES, V168, P273, DOI 10.1016/0014-4827(87)90435-6; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOSANG M, 1985, J CELL BIOCHEM, V29, P265, DOI 10.1002/jcb.240290310; HUME CR, 1988, ONCOGENE, V2, P223; JOHNSSON A, 1986, EMBO J, V5, P1535, DOI 10.1002/j.1460-2075.1986.tb04394.x; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KAPLAN PL, 1982, P NATL ACAD SCI-BIOL, V79, P485, DOI 10.1073/pnas.79.2.485; KARIN M, 1981, EUR J BIOCHEM, V118, P527, DOI 10.1111/j.1432-1033.1981.tb05551.x; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LEOF EB, 1987, MOL CELL BIOL, V7, P2649, DOI 10.1128/MCB.7.7.2649; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NICOLAIEW N, 1986, EXP CELL RES, V166, P357, DOI 10.1016/0014-4827(86)90482-9; OWEN RD, 1987, MOL CELL BIOL, V7, P2512, DOI 10.1128/MCB.7.7.2512; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; PEREZRODRIGUEZ R, 1981, J CELL PHYSIOL, V109, P387, DOI 10.1002/jcp.1041090303; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; REIN A, 1985, MOL CELL BIOL, V5, P2257, DOI 10.1128/MCB.5.9.2257; RENWICK DE, 1986, JNCI-J NATL CANCER I, V77, P105; REYNOLDS VL, 1987, ONCOGENE, V1, P323; ROBERTS AB, 1985, NATURE, V315, P237, DOI 10.1038/315237a0; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; TRIMBLE WS, 1986, NATURE, V321, P782, DOI 10.1038/321782a0; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; VANOBBERGHENSCHILLING E, 1983, EXP CELL RES, V147, P369, DOI 10.1016/0014-4827(83)90219-7; VENNSTROM B, 1987, ONCOGENE, V1, P271; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZERLIN M, 1987, ONCOGENE, V1, P19; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	60	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					373	381						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3078948				2022-12-28	WOS:A1988Q773900004
J	JAFFE, BD; SABATH, DE; JOHNSON, GD; MOSCINSKI, LC; JOHNSON, KR; ROVERA, G; NAUSEEF, WM; PRYSTOWSKY, MB				JAFFE, BD; SABATH, DE; JOHNSON, GD; MOSCINSKI, LC; JOHNSON, KR; ROVERA, G; NAUSEEF, WM; PRYSTOWSKY, MB			MYELOPEROXIDASE AND ONCOGENE EXPRESSION IN GM-CSF INDUCED BONE-MARROW DIFFERENTIATION	ONCOGENE			English	Article									UNIV PENN, SCH MED, DEPT PATHOL, 36TH & HAMILTON WALK, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, MED LAB, PHILADELPHIA, PA 19104 USA; WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA; VET ADM MED CTR, DEPT MED, IOWA CITY, IA 52240 USA; UNIV IOWA, IOWA CITY, IA 52242 USA	University of Pennsylvania; University of Pennsylvania; The Wistar Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa				Nauseef, William/0000-0003-4032-757X	NCI NIH HHS [CA-09140] Funding Source: Medline; NIAID NIH HHS [AI-21681] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM-07170] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007170] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); BLRD VA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)		ANDERSEN MR, 1982, ARCH BIOCHEM BIOPHYS, V214, P273, DOI 10.1016/0003-9861(82)90031-5; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BRADLEY TR, 1966, AUST J EXP BIOL MED, V44, P287, DOI 10.1038/icb.1966.28; CEROTTINI JC, 1984, J EXP MED, V40, P703; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLOTTA F, 1987, J EXP MED, V165, P1224, DOI 10.1084/jem.165.4.1224; CRAMER E, 1985, BLOOD, V65, P423; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DEIMANN W, 1985, BLOOD, V66, P514; EMILIA G, 1986, BRIT J HAEMATOL, V62, P287, DOI 10.1111/j.1365-2141.1986.tb02931.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FILMUS J, 1985, CANCER RES, V45, P822; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; GOLDWASSER E, 1983, NORMAL NEOPLASTIC HE, P301; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GOWDA SD, 1986, J CLIN INVEST, V77, P271, DOI 10.1172/JCI112287; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HASILIK A, 1984, EMBO J, V3, P2671, DOI 10.1002/j.1460-2075.1984.tb02192.x; HEIDORN K, 1987, BLOOD, V70, P456; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOEFFLER HP, 1985, BLOOD, V65, P484; KUN SC, 1986, BLOOD, V68, P1411; LAVU S, 1985, CANCER CELL, V3, P301; MANIATIS T, 1982, MOL CLONING LABORATO, P466; METCALF D, 1982, J CELL PHYSIOL, V111, P275, DOI 10.1002/jcp.1041110308; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; NAUSEEF WM, 1986, BLOOD, V67, P1504; NAUSEEF WM, 1986, BLOOD, V67, P865; NAUSEEF WM, 1986, BLOOD, V68, P442; OLSSON I, 1984, BIOCHEM J, V223, P911, DOI 10.1042/bj2230911; PARNES JR, 1981, P NATL ACAD SCI-BIOL, V78, P2253, DOI 10.1073/pnas.78.4.2253; PRYSTOWSKY MB, 1983, EXP HEMATOL, V11, P931; PRYSTOWSKY MB, 1984, AM J PATHOL, V114, P149; REED JC, 1985, MOL CELL BIOL, V5, P3361, DOI 10.1128/MCB.5.12.3361; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SPEAR BT, 1985, J EXP MED, V162, P1802, DOI 10.1084/jem.162.6.1802; STANLEY IJ, 1983, J CELL BIOCHEM, V23, P241, DOI 10.1002/jcb.240230121; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; YEN A, 1986, CANCER RES, V46, P4156	44	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1988	2	2					167	174						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	2835725				2022-12-28	WOS:A1988M086000010
J	VANDEVIJVER, MJ; MOOI, WJ; WISMAN, P; PETERSE, JL; NUSSE, R				VANDEVIJVER, MJ; MOOI, WJ; WISMAN, P; PETERSE, JL; NUSSE, R			IMMUNOHISTOCHEMICAL DETECTION OF THE NEU PROTEIN IN TISSUE-SECTIONS OF HUMAN-BREAST TUMORS WITH AMPLIFIED NEU DNA	ONCOGENE			English	Article									NETHERLANDS CANC INST,DIV MOLEC BIOL,1066 CX AMSTERDAM,NETHERLANDS; NETHERLANDS CANC INST,DEPT PATHOL,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute; Netherlands Cancer Institute				van de Vijver, Marc/0000-0002-0385-4787				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; HAUSTEIN D, 1975, BIOCHEMISTRY-US, V14, P1826, DOI 10.1021/bi00680a004; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YOKOTA J, 1986, LANCET, V1, P765	14	111	111	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					175	178						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	3285295				2022-12-28	WOS:A1988M086000011
J	MURTY, VVVS; BOSL, GJ; HOULDSWORTH, J; MEYERS, M; MUKHERJEE, AB; REUTER, V; CHAGANTI, RSK				MURTY, VVVS; BOSL, GJ; HOULDSWORTH, J; MEYERS, M; MUKHERJEE, AB; REUTER, V; CHAGANTI, RSK			ALLELIC LOSS AND SOMATIC DIFFERENTIATION IN HUMAN MALE GERM-CELL TUMORS	ONCOGENE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; CYTOGENETIC ANALYSIS; SUPPRESSOR GENES; KIT RECEPTOR; LONG ARM; METASTASIS; EXPRESSION; CANCER; CHROMOSOME-12; MUTATIONS	The complex but poorly understood human male germ cell tumors offer unusual opportunities for the genetic analysis of malignant transformation and embryonal differentiation in a pluripotential stem cell Lineage. Histologically, these tumors are divided into two major subgroups, seminomas which are characterized by inability to express embryonal differentiation, and nonseminomas which are characterized by ability to express embryonal as well as extraembryonal patterns of differentiation. To understand the role of genetic factors in the development of these tumors and the regulation of differentiation expressed by them, we carried out a detailed allelotype analysis by the loss of heterozygosity assay. This analysis revealed frequent deletions in known tumor suppressor genes (RB1, DCC, NME), a number of previously described sites of candidate tumor suppressor genes (3p, 9p, 9q, 10q, 11p, 11q and 17p), as well as several novel sites (2p, 3q, 5p, 12q, 18p and 20p). Our results also showed that well differentiated teratomas exhibit a significantly higher level of allelic loss compared to the less differentiated embryonal carcinomas. In addition, certain loci and genes exhibited frequent non-random deletion in teratomas (D3S32, D3S42, D5S12, D10S25, D11S12, RB1, TP53, NME1, NME2, D17S4, D18S6 and D20S6) and embryonal carcinomas (IFNB, D9S27). Among these loci, the NME genes were notable for a high degree of genetic loss (> 70%) in teratomas. These results suggested that nonrandom loss or inactivation of certain genes may be associated with tumor development and loss or inactivation of other genes mag be associated with somatic differentiation.	MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,CYTOGENET SERV,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR,NEW YORK,NY 10021; FORDHAM UNIV,DEPT BIOL SCI,NEW YORK,NY 10458	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Fordham University	MURTY, VVVS (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [P01CA005826, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [CA-05826, CA-08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACKER JM, 1993, ONCOGENE, V8, P497; COLLINS D. H., 1964, BRIT J UROL, V36, P1; CUTICCHIA AJ, 1993, GENOME PRIORITY REPO, V1; DMITROVSKY E, 1990, ONCOGENE, V5, P543; FLEISCHMAN RA, 1993, TRENDS GENET, V9, P285, DOI 10.1016/0168-9525(93)90015-A; GODDARD AD, 1993, ADV HUM GENET, V21, P321; HEIMDAL K, 1993, GENE CHROMOSOME CANC, V6, P92, DOI 10.1002/gcc.2870060205; MANOVA K, 1993, DEV BIOL, V157, P85, DOI 10.1006/dbio.1993.1114; MATHEW S, 1992, GENOMICS, V14, P775, DOI 10.1016/S0888-7543(05)80184-3; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; MURTY VVVS, 1990, CANCER GENET CYTOGEN, V50, P67, DOI 10.1016/0165-4608(90)90239-7; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; PENG HQ, 1993, CANCER RES, V53, P3574; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; PUGH RCB, 1976, PATHOLOGY TESTIS, P245; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; RODRIGUEZ E, 1994, IN PRESS CANCER RES; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STROHMEYER T, 1991, P NATL ACAD SCI USA, V88, P6662, DOI 10.1073/pnas.88.15.6662; STROHMEYER T, 1991, CANCER RES, V51, P1811; ULBRIGHT TM, 1987, SEMIN DIAGN PATHOL, V4, P304; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WANG N, 1981, CANCER RES, V41, P2135	27	77	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2245	2251						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7518576				2022-12-28	WOS:A1994NX62900016
J	MIGLARESE, MR; MANNIONHENDERSON, J; WU, H; PARSONS, JT; BENDER, TP				MIGLARESE, MR; MANNIONHENDERSON, J; WU, H; PARSONS, JT; BENDER, TP			THE PROTEIN-TYROSINE KINASE SUBSTRATE CORTACTIN IS DIFFERENTIALLY EXPRESSED IN MURINE-B LYMPHOID TUMORS	ONCOGENE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; ACTIN-BINDING PROTEIN; CENTROCYTIC LYMPHOMA; SIGNAL TRANSDUCTION; RIBONUCLEIC-ACID; MULTIPLE-MYELOMA; CHROMOSOME 11Q13; HUMAN CARCINOMAS; PHOSPHOLIPASE-C; MESSENGER-RNAS	Src family protein tyrosine kinases (PTKs) actively participate in signal transduction during lymphocyte activation. However, little is known about the roles of PTKs acid their substrates in lymphocyte differentiation. To identify PTK substrates that may be differentially expressed during B lymphopoiesis, we screened a panel of murine B lymphoid tumor cell lines representing various developmental stages using monoclonal antibodies (MAbs) specific for pp60(src) substrates. A MAb specific for cortactin, a filamentous-actin binding pp60(src) substrate, immunoprecipitated proteins from murine plasmacytoma cell lines but not from pre-B cell lymphoma or B cell lymphoma cell lines. We have cloned a murine cortactin cDNA which encodes a member of a family of proteins distinguished by amino-terminal repeat domains and carboxy-terminal Src Homology 3 domains. Two members of this family (cortactin and HS1) were differentially expressed in murine B lymphoid tumor cell lines; both were detected in plasmacytoma cell lines, however HS1 was additionally detected in pre-B lymphoma and B lymphoma cell lines. Cortactin RNA was detected in most murine tissues, but was not detected in B lymphocytes or plasma cells. We hypothesize that cortactin expression is associated with transformed plasma cells and not with the terminal differentiation of normal B lymphocytes to plasma cells.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NCI NIH HHS [CA09109, CA29243, P01CA40042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042, R01CA029243, R37CA029243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BERGSAGEL PL, 1992, ONCOGENE, V7, P2059; BERGSAGEL PL, 1992, J IMMUNOL, V148, P590; BROOKES S, 1993, GENE CHROMOSOME CANC, V6, P222, DOI 10.1002/gcc.2870060406; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER MD, 1984, FUNDAMENTAL IMMUNOLO, P43; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FIEDLER W, 1992, BRIT J HAEMATOL, V81, P58, DOI 10.1111/j.1365-2141.1992.tb08171.x; GAZDAR AF, 1986, BLOOD, V67, P1542; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KEARNEY JF, 1975, J IMMUNOL, V115, P671; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KINNON C, 1993, IMMUNOL TODAY, V14, P554, DOI 10.1016/0167-5699(93)90187-P; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LADANYI M, 1992, AM J PATHOL, V141, P949; LAMMIE GA, 1992, ONCOGENE, V7, P2381; MAA MC, 1992, ONCOGENE, V7, P2429; MAGE M, 1981, EUR J IMMUNOL, V11, P228, DOI 10.1002/eji.1830110312; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCMAHON AP, 1987, DIFFERENTIATION, V34, P68, DOI 10.1111/j.1432-0436.1987.tb00052.x; MEDEIROS LJ, 1990, BLOOD, V76, P2086; MELAMED I, 1991, J IMMUNOL, V147, P1139; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; PAWSON T, 1988, ONCOGENE, V3, P491; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RAFFELD M, 1992, LEUKEMIA LYMPHOMA, V8, P161, DOI 10.3109/10428199209054902; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TAGA T, 1992, CRIT REV IMMUNOL, V11, P265; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILLIAMS ME, 1993, LEUKEMIA, V7, P1437; WILLIAMS ME, 1993, LEUKEMIA, V7, P241; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WONG S, 1992, ONCOGENE, V7, P2407; WORD CJ, 1981, MOL IMMUNOL, V18, P311, DOI 10.1016/0161-5890(81)90055-9; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; ZHAN X, 1993, J BIOL CHEM, V268, P24427	64	40	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					1989	1997						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	7516062				2022-12-28	WOS:A1994NR68500023
J	ISHIZAKA, Y; OCHIAI, M; TAHIRA, T; SUGIMURA, T; NAGAO, M				ISHIZAKA, Y; OCHIAI, M; TAHIRA, T; SUGIMURA, T; NAGAO, M			ACTIVATION OF THE RET-II ONCOGENE WITHOUT A SEQUENCE ENCODING A TRANSMEMBRANE DOMAIN AND TRANSFORMING ACTIVITY OF 2 RET-II ONCOGENE PRODUCTS DIFFERING IN CARBOXY-TERMINI DUE TO ALTERNATIVE SPLICING	ONCOGENE			English	Article											ISHIZAKA, Y (corresponding author), NATL CANC CTR RES INST,DIV CARCINOGENESIS,1-1 TSUKIJI,5 CHOME,CHUO KU,TOKYO 104,JAPAN.							BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; ISHIZAKA Y, 1987, CARCINOGENESIS, V8, P1575, DOI 10.1093/carcin/8.11.1575; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maniatis T., 1982, MOL CLONING; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHENONG GLC, 1987, EMBO J, V6, P4035; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAKAHASHI M, 1988, ONCOGENE, V3, P571; WATSON CJ, 1985, DNA CLONING PRACTICA, V1, P79; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	25	62	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					789	794						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2734021				2022-12-28	WOS:A1989AA66000015
J	TANG, A; WU, KJ; HASHIMOTO, T; LIU, WY; TAKAHASHI, R; SHI, XH; MIHARA, K; ZHANG, FH; CHEN, YY; DU, C; QIAN, J; LIN, YG; MURPHREE, AL; QIU, WR; THOMPSON, T; BENEDICT, WF; FUNG, YKT				TANG, A; WU, KJ; HASHIMOTO, T; LIU, WY; TAKAHASHI, R; SHI, XH; MIHARA, K; ZHANG, FH; CHEN, YY; DU, C; QIAN, J; LIN, YG; MURPHREE, AL; QIU, WR; THOMPSON, T; BENEDICT, WF; FUNG, YKT			GENOMIC ORGANIZATION OF THE HUMAN RETINOBLASTOMA GENE	ONCOGENE			English	Article									UNIV SO CALIF,CHILDRENS HOSP,SCH MED,DEPT PEDIAT MICROBIOL & OPHTHALMOL,LOS ANGELES,CA 90027	Children's Hospital Los Angeles; University of Southern California					NATIONAL CANCER INSTITUTE [R29CA044754, R01CA044754] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007846] Funding Source: NIH RePORTER; NCI NIH HHS [CA44754] Funding Source: Medline; NEI NIH HHS [EY06195, EY07846] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; YOKOTA J, 1988, ONCOGENE, V3, P471	20	74	76	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					401	407						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2717184				2022-12-28	WOS:A1989U567700002
J	MITCHELL, CD; COWELL, JK				MITCHELL, CD; COWELL, JK			PREDISPOSITION TO RETINOBLASTOMA DUE TO A TRANSLOCATION WITHIN THE 4.7R LOCUS	ONCOGENE			English	Article											MITCHELL, CD (corresponding author), INST CHILD HLTH,DEPT HAEMATOL & ONCOL,IMPERIAL CANC RES FUND,MOLEC GENET LAB,30 GUILDFORD ST,LONDON WC1,ENGLAND.			Cowell, John/0000-0002-2079-5950				BLANQUET V, 1987, HUM GENET, V76, P102; BOOKSTEIN R, 1988, P NATL ACAD SCI USA, V85, P221; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COWELL JK, 1980, J NATL CANCER I, V65, P955; COWELL JK, 1986, HUM GENET, V72, P164; COWELL JK, 1987, CANCER GENET CYTOGEN, V27, P27, DOI 10.1016/0165-4608(87)90256-1; COWELL JK, 1986, HUMAN CYTOGENETICS P, P202; COWELL JK, 1987, BRIT J CANCER, V555, P661; DAVISON EV, 1979, CLIN GENET, V15, P505; DRYJA TP, 1984, NEW ENGL J MED, V310, P550, DOI 10.1056/NEJM198403013100902; DUNN J, COMMUNICATION; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YT, 1987, SCIENCE, V36, P1657; GODDARD AD, 1988, MOL CELL BIOL, V8, P2082, DOI 10.1128/MCB.8.5.2082; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARNDEN D, 1984, ADV CANCER RES, V41, P185, DOI 10.1016/S0065-230X(08)60017-2; LALANDE M, 1984, CANCER GENET CYTOGEN, V13, P283, DOI 10.1016/0165-4608(84)90073-6; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; Maniatis T., 1982, MOL CLONING; MITCHELL CD, 1988, IN PRESS HUMAN GENET; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPARKES RS, 1983, SCIENCE, V219, P971, DOI 10.1126/science.6823558; SQUIRE J, 1985, HUM GENET, V70, P291, DOI 10.1007/BF00295364; TURLEAU C, 1983, ANN GENET-PARIS, V26, P158; TURLEAU C, 1985, CANCER GENET CYTOGEN, V16, P321, DOI 10.1016/0165-4608(85)90240-7; VOGEL F, 1979, HUM GENET, V52, P1; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x	32	38	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					253	257						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2927947				2022-12-28	WOS:A1989U567500019
J	SCHWAB, M; OEHLMANN, R; BRUDERLEIN, S; WAKAMATSU, Y				SCHWAB, M; OEHLMANN, R; BRUDERLEIN, S; WAKAMATSU, Y			AMPLIFIED DNA IN CELLS OF GENETIC MELANOMA OF XIPHOPHORUS	ONCOGENE			English	Article									KYOTO UNIV,YOSHIDA COLL,BIOL LAB,KYOTO 606,JAPAN	Kyoto University	SCHWAB, M (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,INST EXPTL PATHOL,NEUENHEIMER FELD 280,D-6900 HEIDELBERG,FED REP GER.							ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ANDERS F, 1967, EXPERIENTIA, V23, P1, DOI 10.1007/BF02142235; ANDERS F, 1984, ADV CANCER RES, V42, P191, DOI 10.1016/S0065-230X(08)60459-5; Friedman B, 1934, AM NAT, V68, P446, DOI 10.1086/280562; Gordon M, 1928, J HERED, V19, P551, DOI 10.1093/oxfordjournals.jhered.a102942; Gordon M, 1927, GENETICS, V12, P253; OZATO K, 1983, DIFFERENTIATION, V24, P181, DOI 10.1111/j.1432-0436.1983.tb01318.x; RONINSON IB, 1983, NUCLEIC ACIDS RES, V11, P5413, DOI 10.1093/nar/11.16.5413; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHWAB M, 1987, TRENDS GENET, V3, P38, DOI 10.1016/0168-9525(87)90164-8; SCHWAB M, 1982, MOL GEN GENET, V188, P410, DOI 10.1007/BF00330042; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SCHWAB M, 1985, NATURE, V315, P345, DOI 10.1038/315345a0; SCHWAB M, 1981, DIFFERENTIATION, V19, P77, DOI 10.1111/j.1432-0436.1981.tb01132.x; SCHWAB M, 1985, TRENDS GENET, V1, P271, DOI 10.1016/0168-9525(85)90103-9; SCHWAB M, 1986, ADV CANCER RES, V47, P63, DOI 10.1016/S0065-230X(08)60198-0; SCHWAB M, 1986, ONCOGENES GROWTH CON, P332; SCHWAB M, 1988, IN PRESS CIBA F S, V142; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; VIELKIND U, 1976, J EXP ZOOL, V196, P197, DOI 10.1002/jez.1401960207; WAKAMATSU Y, 1984, DEV GROWTH DIFFER, V26, P503; WEITH A, 1987, EMBO J, V6, P1295, DOI 10.1002/j.1460-2075.1987.tb02367.x	24	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					139	144						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2927944				2022-12-28	WOS:A1989U567500003
J	WALSER, A; DEPPERT, W				WALSER, A; DEPPERT, W			A NOVEL MECHANISM FOR COVALENT ATTACHMENT OF FATTY-ACID TO SV40 LARGE T-ANTIGEN	ONCOGENE			English	Note									UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,D-2000 HAMBURG 20,FED REP GER	Heinrich Pette Institute; University of Hamburg								BERGER M, 1984, EMBO J, V3, P713, DOI 10.1002/j.1460-2075.1984.tb01874.x; BERGER M, 1984, J BIOL CHEM, V259, P7245; BRADLEY MK, 1984, P NATL ACAD SCI-BIOL, V81, P6574, DOI 10.1073/pnas.81.21.6574; BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; CAROLL RB, 1988, ONCOGENE, V2, P437; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; Flint S. J, 1981, DNA TUMOR VIRUSES; FOLCH J, 1957, J BIOL CHEM, V226, P497; GOLDMAN N, 1981, CELL, V24, P567, DOI 10.1016/0092-8674(81)90347-0; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; JANATOVA J, 1981, BIOCHEMISTRY-US, V20, P2394, DOI 10.1021/bi00512a005; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KIT S, 1969, INT J CANCER, V4, P384, DOI 10.1002/ijc.2910040403; KLOCKMANN U, 1983, FEBS LETT, V151, P257, DOI 10.1016/0014-5793(83)80081-7; KLOCKMANN U, 1984, MOL CELL BIOL, V4, P1542, DOI 10.1128/MCB.4.8.1542; KLOCKMANN U, 1983, EMBO J, V2, P1151, DOI 10.1002/j.1460-2075.1983.tb01560.x; MACK D, 1987, J BIOL CHEM, V262, P4297; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MAGEE AI, 1982, BIOCHIM BIOPHYS ACTA, V694, P279, DOI 10.1016/0304-4157(82)90008-9; OLSON EN, 1986, PROTEIN COMPARTMENTA, P87; OMARY MB, 1981, J BIOL CHEM, V256, P2888; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; TACK BF, 1980, P NATL ACAD SCI-BIOL, V77, P5764, DOI 10.1073/pnas.77.10.5764; THOMAS ML, 1982, P NATL ACAD SCI-BIOL, V79, P1054, DOI 10.1073/pnas.79.4.1054; WOLD F, 1986, TRENDS BIOCHEM SCI, V11, P58, DOI 10.1016/0968-0004(86)90254-9	26	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					249	252						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2927946				2022-12-28	WOS:A1989U567500018
J	DHUT, S; DOREY, EL; HORTON, MA; GANESAN, TS; YOUNG, BD				DHUT, S; DOREY, EL; HORTON, MA; GANESAN, TS; YOUNG, BD			IDENTIFICATION OF 2 NORMAL BCR GENE-PRODUCTS IN THE CYTOPLASM	ONCOGENE			English	Article									ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT MED ONCOL,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT HAEMATOL,LONDON EC1A 7BE,ENGLAND	Cancer Research UK; University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; Queen Mary University London			GANESAN, Trivadi Sundaram/AAU-1499-2020	GANESAN, Trivadi Sundaram/0000-0002-4671-8099				BARBAS JA, 1988, EMBO J, V7, P625, DOI 10.1002/j.1460-2075.1988.tb02856.x; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; COLLINS S, 1987, MOL CELL BIOL, V7, P2870, DOI 10.1128/MCB.7.8.2870; CROCE CM, 1987, P NATL ACAD SCI USA, V84, P7174, DOI 10.1073/pnas.84.20.7174; DREAZEN O, 1988, HAEMATOLOGY, V25, P35; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LIFSHITZ B, 1988, ONCOGENE, V2, P113; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; WHITE JG, 1987, NATURE, V328, P183, DOI 10.1038/328183a0	16	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					561	566						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3078961				2022-12-28	WOS:A1988R516300012
J	THIELE, CJ; DEUTSCH, LA; ISRAEL, MA				THIELE, CJ; DEUTSCH, LA; ISRAEL, MA			THE EXPRESSION OF MULTIPLE PROTO-ONCOGENES IS DIFFERENTIALLY REGULATED DURING RETINOIC ACID-INDUCED MATURATION OF HUMAN NEURO-BLASTOMA CELL-LINES	ONCOGENE			English	Article											THIELE, CJ (corresponding author), NCI,CLIN ONCOL PROGRAM,PEDIAT BRANCH,MOLEC GENET SECT,BETHESDA,MD 20892, USA.							BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BITTER GA, 1978, BIOCHEMISTRY-US, V17, P2198, DOI 10.1021/bi00604a028; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Evans A E, 1976, Natl Cancer Inst Monogr, V44, P49; FARBER E, 1984, CANCER RES, V44, P4217; FOX F, 1959, CANCER, V12, P108, DOI 10.1002/1097-0142(195901/02)12:1<108::AID-CNCR2820120116>3.0.CO;2-H; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GLEICHENHAUS N, 1985, ADV CANCER RES, P291; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GROSSO LE, 1985, CANCER RES, V45, P847; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; REYMOND CD, 1986, NATURE, V323, P340, DOI 10.1038/323340a0; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; SCHNEIDER MD, 1987, MOL CELL BIOL, V7, P1973, DOI 10.1128/MCB.7.5.1973; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SIDELL N, 1982, J NATL CANCER I, V68, P589; SIDELL N, 1985, ADV NEUROBLASTOMA RE, P39; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1988, IN PRESS ADV NEUROBL; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; WEST GJ, 1977, CANCER RES, V37, P1372; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0	52	68	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					281	288						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	3060792				2022-12-28	WOS:A1988Q436700006
J	CARDIFF, RD; GUMERLOCK, PH; SOONG, MM; DANDEKAR, S; BARRY, PA; YOUNG, LJT; MEYERS, FJ				CARDIFF, RD; GUMERLOCK, PH; SOONG, MM; DANDEKAR, S; BARRY, PA; YOUNG, LJT; MEYERS, FJ			C-H-RAS-1 EXPRESSION IN 7,12-DIMETHYL BENZANTHRACENE-INDUCED BALB/C MOUSE MAMMARY HYPERPLASIAS AND THEIR TUMORS	ONCOGENE			English	Article									UNIV CALIF DAVIS,SACRAMENTO MED CTR,MED CTR,DEPT INTERNAL MED,SACRAMENTO,CA 95817	University of California System; University of California Davis	CARDIFF, RD (corresponding author), UNIV CALIF DAVIS,SCH MED,DEPT PATHOL,DAVIS,CA 95616, USA.				NATIONAL CANCER INSTITUTE [R01CA036493] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA36493] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHLEY RL, 1982, J NATL CANCER I, V69, P639; ASHLEY RL, 1980, CANCER RES, V40, P4232; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BLAIR PB, 1962, BIOLOGICAL INTERACTI, P371; CARDIFF RD, 1977, CANCER, V39, P2734, DOI 10.1002/1097-0142(197706)39:6<2734::AID-CNCR2820390661>3.0.CO;2-U; CARDIFF RD, 1984, ADV CANCER RES, V42, P167, DOI 10.1016/S0065-230X(08)60458-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; DELLAPENNA D, 1986, ANAL BIOCHEM, V152, P329, DOI 10.1016/0003-2697(86)90417-3; DEOME KB, 1959, CANCER RES, V19, P515; DER CJ, 1983, CELL, V32, P201, DOI 10.1016/0092-8674(83)90510-X; DIPPLE A, 1979, CANCER RES, V39, P1154; DIPPLE A, 1978, CHEM-BIOL INTERACT, V20, P17, DOI 10.1016/0009-2797(78)90077-7; DIPPLE A, 1983, CANCER RES, V43, P4132; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FAULKIN LJ, 1966, J NATL CANCER I, V36, P289; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GARDNER MB, 1980, J NATL CANCER I, V64, P1251; GOODMAN JI, 1986, TIPS, P354; GRAHAM R, 1976, VIROLOGY, V52, P456; GUMERLOCK PH, 1988, UNPUB J IMMUNOLOGIC; HARPER JR, 1986, MOL CELL BIOL, V6, P3144, DOI 10.1128/MCB.6.9.3144; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; HSIAO WLW, 1987, MOL CELL BIOL, V7, P3380, DOI 10.1128/MCB.7.10.3380; IYER AP, 1981, J NATL CANCER I, V66, P893; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MEDINA D, 1976, CANCER RES, V36, P2589; MEDINA D, 1978, BREAST CANCER, V2, P47; MEDINA D, 1973, METHOD CANCER RES, V7, P3; MILLER EC, 1976, CHEM CARCINOGENS, P737; Morris D. W., 1987, ADV VIRAL ONCOL, V7, P123; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; PATHAK VK, 1987, J NATL CANCER I, V78, P327; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WISER MF, 1986, ANAL BIOCHEM, V155, P71, DOI 10.1016/0003-2697(86)90226-5; WONG G, 1986, CANCER RES, V46, P6029; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	50	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					205	213						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	2842717				2022-12-28	WOS:A1988Q053400012
J	YOKOTA, J; WADA, M; YOSHIDA, T; NOGUCHI, M; TERASAKI, T; SHIMOSATO, Y; SUGIMURA, T; TERADA, M				YOKOTA, J; WADA, M; YOSHIDA, T; NOGUCHI, M; TERASAKI, T; SHIMOSATO, Y; SUGIMURA, T; TERADA, M			HETEROGENEITY OF LUNG-CANCER CELLS WITH RESPECT TO THE AMPLIFICATION AND REARRANGEMENT OF MYC FAMILY ONCOGENES	ONCOGENE			English	Article											YOKOTA, J (corresponding author), NATL CANC CTR,RES INST,1-1 TSUKIJI 5 CHOME,CHUO KU,TOKYO 104,JAPAN.							ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BLICK MB, 1986, LEUKEMIA RES, V10, P1401, DOI 10.1016/0145-2126(86)90006-8; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1987, CANCER RES, V47, P4248; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; ERIKSON J, 1986, SCIENCE, V232, P884, DOI 10.1126/science.3486470; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; GARSON JA, 1986, LANCET, V1, P1496; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; JOHNSON BE, 1986, J CLIN INVEST, V78, P525, DOI 10.1172/JCI112604; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MCCARTHY DM, 1984, LANCET, V2, P1362; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NEEL BG, 1982, P NATL ACAD SCI-BIOL, V79, P7842, DOI 10.1073/pnas.79.24.7842; OCADIZ R, 1987, CANCER RES, V47, P4173; RIOU G, 1987, LANCET, V1, P761; ROSEN N, 1986, CANCER RES, V46, P4139; SAGLIO G, 1986, CANCER RES, V46, P1413; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIMA EA, 1986, P NATL ACAD SCI USA, V83, P3439, DOI 10.1073/pnas.83.10.3439; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; TAYA Y, 1987, ADV VIRAL ONCOL, V7, P141; TERASAKI T, 1986, JPN J CLIN ONCOL, V16, P293; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; WATSON R, 1982, P NATL ACAD SCI US, V79, P4978; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; YOKOTA J, 1986, LANCET, V1, P765; YOSHIMOTO K, 1986, JPN J CANCER RES, V77, P731; 1987, TNM CLASSIFICATION M; 1981, INT HISTOLOGICAL TYP, V1	38	93	93	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					607	611						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	2838790				2022-12-28	WOS:A1988N841500012
J	BYRD, PJ; GRAND, RJA; GALLIMORE, PH				BYRD, PJ; GRAND, RJA; GALLIMORE, PH			DIFFERENTIAL TRANSFORMATION OF PRIMARY HUMAN-EMBRYO RETINAL CELLS BY ADENOVIRUS E1 REGIONS AND COMBINATIONS OF E1A + RAS	ONCOGENE			English	Article											BYRD, PJ (corresponding author), MED SCH BIRMINGHAM,DEPT CANC STUDIES,CANC RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.							BARBACID M, 1986, CARCINOGENESIS, V7, P1037, DOI 10.1093/carcin/7.7.1037; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; BYRD PJ, 1982, J GEN VIROL, V60, P279, DOI 10.1099/0022-1317-60-2-279; BYRD PJ, 1982, NATURE, V298, P67; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHANG S E, 1986, Biochimica et Biophysica Acta, V823, P161, DOI 10.1016/0304-419X(86)90001-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLIMORE PH, 1985, CANCER RES, V45, P2670; GRABHAM PW, 1988, IN PRESS EXP EYE RES; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GRAND RJA, 1987, ONCOGENE, V1, P305; GRAND RJA, 1984, J GEN VIROL, V65, P2149, DOI 10.1099/0022-1317-65-12-2149; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; JOCHEMSEN AG, 1986, J VIROL, V59, P684, DOI 10.1128/JVI.59.3.684-691.1986; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LOWY DR, 1986, CANCER SURV, V5, P275; MARSHALL CJ, 1984, CANCER SURV, V3, P183; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARASKEVA C, 1982, J VIROL, V44, P759, DOI 10.1128/JVI.44.2.759-764.1982; Peto R, 1977, ORIGINS HUMAN CANC C, P1403; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RULEY HE, 1983, NATURE, V304, P609; SANTOS E, 1985, S SOC GENERAL MICROB, P291; SENNEAR AW, 1986, MOL CELL BIOL, V6, P1253; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STILLMAN B, 1986, CANCER SURV, V5, P389; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WEINSTEIN IB, 1984, CANCER CELL, V1, P229; WOLFE J, 1984, EMBO J, V3, P1997, DOI 10.1002/j.1460-2075.1984.tb02081.x; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607	49	51	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					477	484						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	2967455				2022-12-28	WOS:A1988N434800009
J	NISHIKURA, K; MURRAY, JM				NISHIKURA, K; MURRAY, JM			THE MECHANISM OF INACTIVATION OF THE NORMAL C-MYC GENE LOCUS IN HUMAN BURKITT-LYMPHOMA CELLS	ONCOGENE			English	Article									UNIV PENN,SCH MED,DEPT ANAT,PHILADELPHIA,PA 19104	University of Pennsylvania	NISHIKURA, K (corresponding author), WISTAR INST ANAT & BIOL,36TH ST SPRUCE,PHILADELPHIA,PA 19104, USA.							ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P6922, DOI 10.1073/pnas.80.22.6922; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DUNNICK W, 1985, GENE, V39, P287, DOI 10.1016/0378-1119(85)90325-7; DYSON PJ, 1985, P NATL ACAD SCI USA, V82, P1984, DOI 10.1073/pnas.82.7.1984; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P7581, DOI 10.1073/pnas.80.24.7581; FAHRLANDER PD, 1985, EMBO J, V4, P3195, DOI 10.1002/j.1460-2075.1985.tb04065.x; GAZIN C, 1986, EMBO J, V5, P2241, DOI 10.1002/j.1460-2075.1986.tb04491.x; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LEY TJ, 1982, P NATL ACAD SCI-BIOL, V79, P4775, DOI 10.1073/pnas.79.15.4775; MANIATIS T, 1975, BIOCHEMISTRY-US, V14, P3787, DOI 10.1021/bi00688a010; Maxam A M, 1980, Methods Enzymol, V65, P499; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NISHIKURA K, 1984, SCIENCE, V224, P399, DOI 10.1126/science.6424234; NISHIKURA K, 1985, MOL CELL BIOL, V5, P1434, DOI 10.1128/MCB.5.6.1434; NISHIKURA K, 1985, P NATL ACAD SCI USA, V82, P2900, DOI 10.1073/pnas.82.9.2900; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SWARTWOUT SG, 1987, MOL CELL BIOL, V7, P2052, DOI 10.1128/MCB.7.6.2052; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837	36	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					493	498						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	3131718				2022-12-28	WOS:A1988N434800011
J	TSUJIMOTO, Y; LOUIE, E; BASHIR, MM; CROCE, CM				TSUJIMOTO, Y; LOUIE, E; BASHIR, MM; CROCE, CM			THE RECIPROCAL PARTNERS OF BOTH THE T(14-18) AND THE T(11-14) TRANSLOCATIONS INVOLVED IN B-CELL NEOPLASMS ARE REARRANGED BY THE SAME MECHANISM	ONCOGENE			English	Article											TSUJIMOTO, Y (corresponding author), WISTAR INST ANAT & BIOL,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NATIONAL CANCER INSTITUTE [R35CA039860] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; FUKUHARA S, 1979, CANCER RES, V39, P3119; HALUSKA FG, 1987, P NATL ACAD SCI USA, V84, P6835, DOI 10.1073/pnas.84.19.6835; HALUSKA FG, 1986, NATURE, V324, P158, DOI 10.1038/324158a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SIEBENLIST U, 1981, NATURE, V294, P631, DOI 10.1038/294631a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VANDENBERGHE H, 1984, CANCER GENET CYTOGEN, V11, P381, DOI 10.1016/0165-4608(84)90017-7; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; YUNIS JJ, 1982, NEW ENGL J MED, V307, P1231, DOI 10.1056/NEJM198211113072002	19	89	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					347	351						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3129686				2022-12-28	WOS:A1988M947200006
J	DONIGER, J				DONIGER, J			ALTERNATIVE SPLICING RESULTS IN A TRUNCATED N-RAS PROTEIN	ONCOGENE			English	Article											DONIGER, J (corresponding author), NCI,DIV CANC ETIOL,BIOL LAB,BLDG 37,RM 2A19,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; Doniger J, 1985, Carcinog Compr Surv, V9, P51; DONIGER J, 1987, ONCOGENE, V1, P331; DONIGER J, 1987, J BIOL CHEM, V262, P3813; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SUKUMAR S, 1984, SCIENCE, V223, P1197, DOI 10.1126/science.6322298; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0	13	0	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					293	294						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3281097				2022-12-28	WOS:A1988M593100014
J	SADOWSKI, I; PAWSON, T; LAGARDE, A				SADOWSKI, I; PAWSON, T; LAGARDE, A			V-FPS PROTEIN-TYROSINE KINASE COORDINATELY ENHANCES THE MALIGNANCY AND GROWTH-FACTOR RESPONSIVENESS OF PRE-NEOPLASTIC LUNG FIBROBLASTS	ONCOGENE			English	Article									MT SINAI HOSP,RES INST,DIV CANC & CELL BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; MT SINAI HOSP,RES INST,DIV MOLEC & DEV BIOL,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MED GENET,TORONTO M5G 1X5,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Pawson, Tony J/E-4578-2013					ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BOSCA L, 1986, BIOCHEM J, V236, P595, DOI 10.1042/bj2360595; BRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277, DOI 10.1073/pnas.83.14.5277; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARMIER JF, 1986, CELL, V44, P159, DOI 10.1016/0092-8674(86)90494-0; CHAMBARD JC, 1983, J BIOL CHEM, V258, P1706; COLLARD JG, 1987, CANCER RES, V47, P754; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FOSTER DA, 1983, J VIROL, V48, P744, DOI 10.1128/JVI.48.3.744-751.1983; GARBISA S, 1987, CANCER RES, V47, P1523; GUYDEN JC, 1982, VIROLOGY, V122, P71, DOI 10.1016/0042-6822(82)90378-6; HANAFUSA T, 1981, J VIROL, V38, P347, DOI 10.1128/JVI.38.1.347-355.1981; HANAFUSA T, 1980, P NATL ACAD SCI-BIOL, V77, P3009, DOI 10.1073/pnas.77.5.3009; JACKOWSKI S, 1986, J BIOL CHEM, V261, P4978; KAPLAN PL, 1982, P NATL ACAD SCI-BIOL, V79, P485, DOI 10.1073/pnas.79.2.485; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOHNO M, 1986, BIOCHEM J, V238, P451, DOI 10.1042/bj2380451; LALLEMAIN G, 1986, J CELL PHYSIOL, V129, P167, DOI 10.1002/jcp.1041290207; LEE WH, 1981, J VIROL, V38, P1064, DOI 10.1128/JVI.38.3.1064-1076.1981; LEE WH, 1980, P NATL ACAD SCI-BIOL, V77, P2018, DOI 10.1073/pnas.77.4.2018; MCDONALD I, 1985, MOL CELL BIOL, V5, P2543; MOSS P, 1984, J VIROL, V52, P557, DOI 10.1128/JVI.52.2.557-565.1984; PEREZRODRIGUEZ R, 1981, CELL BIOL INT REP, V5, P347, DOI 10.1016/0309-1651(81)90004-7; PEREZRODRIGUEZ R, 1981, J CELL PHYSIOL, V109, P387, DOI 10.1002/jcp.1041090303; PEREZRODRIGUEZ R, 1982, INT J CANCER, V29, P309, DOI 10.1002/ijc.2910290314; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RENWICK DE, 1986, JNCI-J NATL CANCER I, V77, P105; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; VANOBBERGHENSCHILLING E, 1983, J CELL PHYSIOL, V115, P123, DOI 10.1002/jcp.1041150204; VANOBBERGHENSCHILLING E, 1983, EXP CELL RES, V147, P369, DOI 10.1016/0014-4827(83)90219-7; VOUSDEN KH, 1986, INT J CANCER, V37, P425, DOI 10.1002/ijc.2910370315; WAGHORNE C, 1987, ONCOGENE, V1, P149; WHEELER EF, 1986, NATURE, V324, P377, DOI 10.1038/324377a0; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659	43	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					241	247						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3281093				2022-12-28	WOS:A1988M593100006
J	VANDERRAUWELAERT, E; MAISIN, JR; MERREGAERT, J				VANDERRAUWELAERT, E; MAISIN, JR; MERREGAERT, J			PROVIRUS INTEGRATION AND MYC AMPLIFICATION IN SR-90 INDUCED OSTEOSARCOMAS OF CF1 MICE	ONCOGENE			English	Article									UNIV INSTELLING ANTWERP,DEPT BIOCHEM,BIOTECHNOL LAB,UNIV PLEIN 1,B-2610 WILRIJK,BELGIUM; CEN SCK,DEPT BIOL,B-2400 MOL,BELGIUM	University of Antwerp; Belgian Nuclear Research Centre (SCK-CEN)								ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; BUCKLER CE, 1982, J VIROL, V41, P228, DOI 10.1128/JVI.41.1.228-236.1982; BUCKLER CE, 1982, J VIROL, V43, P629, DOI 10.1128/JVI.43.2.629-640.1982; CHATTOPADHYAY SK, 1981, VIROLOGY, V113, P465, DOI 10.1016/0042-6822(81)90175-6; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; CUYPERS HTM, 1986, J VIROL, V60, P230, DOI 10.1128/JVI.60.1.230-241.1986; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DUESBERG PH, 1987, CANCER RES, V47, P1199; ERFLE V, 1980, INT J CANCER, V26, P107, DOI 10.1002/ijc.2910260117; ERFLE V, 1986, LEUKEMIA RES, V10, P905, DOI 10.1016/0145-2126(86)90322-X; FINKEL MP, 1961, RADIOLOGY, V77, P269, DOI 10.1148/77.2.269; FINKEL MP, 1976, MALIGNANT BONE TUMOR, P92; FINKEL MP, 1973, BONE CERTAIN ASPECTS, P353; GOSSNER W, 1986, LEUKEMIA RES, V10, P897, DOI 10.1016/0145-2126(86)90321-8; HERR W, 1982, NATURE, V296, P865, DOI 10.1038/296865a0; HERR W, 1983, J VIROL, V46, P70, DOI 10.1128/JVI.46.1.70-82.1983; JANOWSKI M, 1986, LEUKEMIA RES, V10, P833, DOI 10.1016/0145-2126(86)90304-8; JOLICOEUR P, 1983, MOL CELL BIOL, V3, P1675, DOI 10.1128/MCB.3.9.1675; KHAN AS, 1982, J VIROL, V44, P625, DOI 10.1128/JVI.44.2.625-636.1982; KHAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P2699, DOI 10.1073/pnas.80.9.2699; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LI Y, 1984, P NATL ACAD SCI-BIOL, V81, P6808, DOI 10.1073/pnas.81.21.6808; LOUTIT JF, 1977, NATURE, V266, P355, DOI 10.1038/266355a0; MCGRATH MS, 1979, CELL, V17, P65, DOI 10.1016/0092-8674(79)90295-2; MERREGAERT J, 1984, CR SOC BIOL, V178, P171; MOORE JL, 1982, J VIROL, V43, P1038, DOI 10.1128/JVI.43.3.1038-1045.1982; NEEL BG, 1981, CELL, V23, P323, DOI 10.1016/0092-8674(81)90128-8; ODONNELL PV, 1985, J VIROL, V55, P500, DOI 10.1128/JVI.55.2.500-503.1985; ONEILL RR, 1986, J VIROL, V58, P359, DOI 10.1128/JVI.58.2.359-366.1986; OU CY, 1983, NUCLEIC ACIDS RES, V11, P5603, DOI 10.1093/nar/11.16.5603; PEDERSEN FS, 1986, LEUKEMIA RES, V10, P923, DOI 10.1016/0145-2126(86)90324-3; REICIN A, 1986, MOL CELL BIOL, V6, P4088, DOI 10.1128/MCB.6.11.4088; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SCHON A, 1986, INT J CANCER, V38, P67, DOI 10.1002/ijc.2910380112; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEFFEN D, 1984, P NATL ACAD SCI-BIOL, V81, P2097, DOI 10.1073/pnas.81.7.2097; STEFFEN D, 1984, P NATL ACAD SCI US, V81, P2101; TEICH N, 1985, RNA TUMOR VIRUSES MO, P187; TSICHLIS PN, 1985, J VIROL, V56, P938, DOI 10.1128/JVI.56.3.938-942.1985; TSICHLIS PN, 1983, NATURE, V302, P445, DOI 10.1038/302445a0; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683	43	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					215	222						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	2832803				2022-12-28	WOS:A1988M593100002
J	HILDT, E; URBAN, S; HOFSCHNEIDER, PH				HILDT, E; URBAN, S; HOFSCHNEIDER, PH			CHARACTERIZATION OF ESSENTIAL DOMAINS FOR THE FUNCTIONALITY OF THE MHBS(T) TRANSCRIPTIONAL ACTIVATOR AND IDENTIFICATION OF A MINIMAL MHBS(T) ACTIVATOR	ONCOGENE			English	Article						HEPATITIS B VIRUS; MHBS(T) ACTIVATOR; SURFACE PROTEIN	HEPATITIS-B VIRUS; HUMAN HEPATOCELLULAR-CARCINOMA; LARGE ENVELOPE POLYPEPTIDE; NF-KAPPA-B; SURFACE-ANTIGEN; RNA-POLYMERASE; TRANSACTIVATOR MHBS(T); ENDOPLASMIC-RETICULUM; TRANSGENIC MICE; MAMMALIAN-CELLS	Integrated hepatitis B virus DNA derived from hepatocellular carcinomas can express, in one third of the cases investigated so far, a transcriptional activator encoded from 3' terminal truncated surface (preS/S) genes resulting in a C-terminally truncated middle surface protein (MHBs(t). Since MHBs(t), in contrast to the secreted MHBs, is retained in the secretory pathway at the ER, the question as to whether the retention generates the transcriptional activator function was investigated. Through fusion of MHBs to the ER-retention signal KDEL, it was shown that the intracellular retention does not generate the transcriptional activator function. Tryptic digestions of microsomal vesicles revealed that the amino terminal domain of MHBs(t) directs into the cytoplasmic compartment, whereas in MHBs this domain directs into the lumen of the ER. This structural difference appears to be why transcriptional activator function arises. Through deletion analysis it was shown that non-membrane-associated MHBs(t) proteins are also functional activators. Non-membrane associated MHBs(t) proteins represent a second class of MHBs(t) proteins. These MHBs(t)-proteins are homogenously distributed all over the cell and show no difference in functionality as compared to the membrane-associated MHBs(t) proteins. MHBs(t53) (truncated at aa53) was shown to be a minimal activator of this class. Both classes of MHBs(t) proteins were found to form dimers; an amphiphatic alpha helix was identified within aa 41-52, which is involved in mediating the dimerization. The integrity of this domain was also revealed to be a prerequisite for the functionality of the activator, suggesting a linkage between dimerization and functionality.			HILDT, E (corresponding author), MAX PLANCK INST BIOCHEM,DEPT VIRUS RES,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.		Hildt, Eberhard/A-1040-2015					BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; CASELMANN WH, 1990, P NATL ACAD SCI USA, V87, P2790; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; CHISARI FV, 1986, J VIROL, V60, P880, DOI 10.1128/JVI.60.3.880-887.1986; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EBLE BE, 1987, MOL CELL BIOL, V7, P3591, DOI 10.1128/MCB.7.10.3591; FUERST TR, 1989, J MOL BIOL, V206, P333, DOI 10.1016/0022-2836(89)90483-X; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HILDT E, 1993, ONCOGENE, V8, P3359; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; IMAI M, 1987, J VIROL, V61, P3555, DOI 10.1128/JVI.61.11.3555-3560.1987; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; LAUER U, 1992, J VIROL, V66, P5284, DOI 10.1128/JVI.66.9.5284-5289.1992; LAUER U, 1994, HEPATOLOGY, V19, P23, DOI 10.1002/hep.1840190106; MATSUBARA K, 1991, MOL BIOL HEPATITIS B, P245; Meyer D I, 1991, Trends Cell Biol, V1, P154, DOI 10.1016/0962-8924(91)90016-3; MEYER M, 1992, EMBO J, V11, P2991, DOI 10.1002/j.1460-2075.1992.tb05369.x; MIMMS LT, 1990, VIROLOGY, V176, P604, DOI 10.1016/0042-6822(90)90031-L; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; NATOLI G, 1992, VIROLOGY, V187, P663, DOI 10.1016/0042-6822(92)90469-6; NEURATH AR, 1987, MOL IMMUNOL, V24, P975, DOI 10.1016/0161-5890(87)90009-5; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLUTER V, 1994, ONCOGENE, V9, P3335; SHERKER AH, 1991, ANNU REV MICROBIOL, V45, P475; STIBBE W, 1983, DEV BIOL STAND, V54, P33; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WILL H, 1985, P NATL ACAD SCI USA, V82, P891, DOI 10.1073/pnas.82.3.891; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; YAMAMOTO S, 1993, BIOCHEM BIOPH RES CO, V197, P1209, DOI 10.1006/bbrc.1993.2605; ZAHM P, 1988, ONCOGENE, V3, P169	39	56	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2055	2066						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478525				2022-12-28	WOS:A1995TF29700016
J	THOMAS, RS; TYMMS, MJ; SETH, A; SHANNON, MF; KOLA, I				THOMAS, RS; TYMMS, MJ; SETH, A; SHANNON, MF; KOLA, I			ETS1 TRANSACTIVATES THE HUMAN GM-CSF PROMOTER IN JURKAT T-CELLS STIMULATED WITH PMA AND IONOMYCIN	ONCOGENE			English	Article						GRANULOCYTE-MACROPHAGE; COLONY-STIMULATING FACTOR; GM-CSF; ETS1; ELF1; TRANSCRIPTION	LONG TERMINAL REPEAT; VIRUS TYPE-I; DNA-BINDING; LEUKEMIA-VIRUS; INFLAMMATORY RESPONSES; TRANSCRIPTION FACTORS; C-ETS-1 PROTEIN; GENE PROMOTER; ACTIVATION; EXPRESSION	Activation of T helper cells results in coordinate expression of a number of cytokines involved in differentiation, proliferation and activation of the haematopoietic system. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one such cytokine whose increased expression results partly from increases in transcription. Cis-acting elements with NF kappa B, AP-1 and ETS-like motifs have been identified in the promoter region of the GM-CSF gene, which are important for transcriptional activity following PMA and ionomycin stimulation. A number of the ETS family of transcription factors are expressed in T cells, including ETS1 and ELF1. Here we describe the ability of these factors to interact with a site (GM5), located within the CLE0 element, -47 to -40 upstream of the GM-CSF transcription initiation site. Exogenous ETS1, but not ELF1, can transactivate GM-CSF, through the GM5 site, in a PMA/ionomycin dependent manner. Other unidentified ETS-like factors present in Jurkat cells are also capable of binding GM5. Mutation of the core ETS binding site from -GGAA- to -GGAT- prevents the binding of ETS-like factors with the exception of ETS1. The GM-CSF promoter, modified in this way to be ETS1 specific, is fully responsive to PMA/ionomycin induction, in addition to ETS1 transactivation in the presence of PMA and ionomycin. Together these data suggest that ETS1 may be involved in mediating the increased GM-CSF production associated with T cell activation.	MONASH UNIV,MONASH MED CTR,INST REPROD & DEV,MOLEC GENET & DEV GRP,MELBOURNE,VIC 3168,AUSTRALIA; NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702; INST MED & VET SCI,HANSON CTR CANC RES,DIV HUMAN IMMUNOL,ADELAIDE,SA 5000,AUSTRALIA	Monash University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Institute Medical & Veterinary Science Australia			Thomas, Ross/C-6434-2008; Kola, Ismail/C-5254-2013					ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; ASCIONE R, 1992, INT J ONCOL, V1, P631; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BRORSON KA, 1991, J IMMUNOL, V147, P3601; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; FISHER CI, 1991, J IMMUNOL, V6, P1743; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FISHER RJ, 1991, ONCOGENE, V6, P2249; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GITLIN SD, 1991, J VIROL, V65, P5513, DOI 10.1128/JVI.65.10.5513-5523.1991; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUNTHER CV, 1994, MOL CELL BIOL, V14, P7569, DOI 10.1128/MCB.14.11.7569; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KOYANONAKAGAWA N, 1993, INT IMMUNOL, V5, P345, DOI 10.1093/intimm/5.4.345; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MIYAJIMA A, 1988, FASEB J, V2, P2462, DOI 10.1096/fasebj.2.9.2836253; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; NIMER SD, 1988, MOL CELL BIOL, V8, P1979, DOI 10.1128/MCB.8.5.1979; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; POGNONEC P, 1989, ONCOGENE, V4, P691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; POGNONEC P, 1990, ONCOGENE, V5, P603; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAZANAJAONA D, 1992, CELL GROWTH DIFFER, V3, P299; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; SUGIMOTO K, 1990, INT IMMUNOL, V2, P787, DOI 10.1093/intimm/2.8.787; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452	54	40	40	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2135	2143						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478534				2022-12-28	WOS:A1995TF29700025
J	NAKAGAWA, K; CONRAD, NK; WILLIAMS, JP; JOHNSON, BE; KELLEY, MJ				NAKAGAWA, K; CONRAD, NK; WILLIAMS, JP; JOHNSON, BE; KELLEY, MJ			MECHANISM OF INACTIVATION OF CDKN2 AND MTS2 IN NON-SMALL-CELL LUNG-CANCER AND ASSOCIATION WITH ADVANCED-STAGE	ONCOGENE			English	Article						P16(INK4); CDKN2; P15(IMK4B); POINT MUTATION; LUNG NEOPLASM	P53 GENE-MUTATIONS; LINES; IDENTIFICATION; FEATURES	The CDKN2 tumor suppressor gene encodes an inhibitor of type D cyclin dependent kinases. CDKN2 is homozygously deleted in approximately 25% of nonsmall cell lung cancer (NSCLC) cell lines and these deletions are associated with advanced stage cancer. Conflicting reports of the frequency of CDKN2 alterations in NSCLC tumors prompted us to examine the relationship of these alterations and those of the related gene, MTS2, with patient stage and site of cancer. One hundred twenty-five NSCLC samples (71 cell lines and 54 tumors) were examined by PCR-SSCP. Twenty of 71 (28%) tumor cell lines had homozygous deletions, and six (8%) had point mutations compared to 4 (7%) with point mutations among 54 tumor samples. All mutations mere observed in tumors or cell lines from patients with stage III or IV disease. Two patients with no mutations in their primary tumor had a CDKN2 point mutation detected in a metastatic tumor. Point mutations were G:C to T:A transversion on the coding strand in five of 10 and resulted in nonsense mutations in seven of 10. Undetectable CDKN2 mRNA, in the absence of detectable genetic alteration, was noted in a similar fraction of cell lines derived from patients with stage I or IZ disease [two of seven (29%)] and stage Hi or TV disease [15 of 49 (31%)]. Homozygous deletion of MTS2 was found in 17 of 20 cell lines with CDKN2 deletions; no point mutations of MTS2 were identified by SSCP in the 125 samples. Thus, CDKN2 is a frequent target of genetic alterations at 9p21 in NSCLC. Both deletions and point mutations of CDKN2 are closely associated with tumor dissemination.	NATL CANC INST, NAVAL MED ONCOL BRANCH, BETHESDA, MD 20889 USA; NATL NAVAL MED CTR, DEPT LAB, BETHESDA, MD 20889 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center			Kelley, Michael/AAC-8939-2019	Kelley, Michael/0000-0001-9523-6080				CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CARNEY DN, 1985, CANCER RES, V45, P2913; DAVIS LG, 1994, BASIC METHODS MOL BI, P306; GAZDAR AF, 1985, CANCER RES, V45, P2924; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GREER CE, 1991, AM J CLIN PATHOL, V95, P117, DOI 10.1093/ajcp/95.2.117; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HAYASHI K, 1993, HUM MUTAT, V2, P338, DOI 10.1002/humu.1380020503; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; Herman J. G., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P201; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JOHNSON BE, 1993, CHEST, V103, pS1, DOI 10.1378/chest.103.1_Supplement.1S; KAMB A, 1994, SCIENCE, V265, P416, DOI 10.1126/science.265.5170.416; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAVANAUGH DY, 1995, P AN M AM SOC CLIN, V14, P546; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; KELLEY MJ, 1992, P NATL ACAD SCI USA, V89, P9287, DOI 10.1073/pnas.89.19.9287; KELLEY MJ, 1994, LUNG CANCER, V11, P58; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; LIU Q, 1995, ONCOGENE, V10, P1061; MITSUDOMI T, 1993, CHEST, V104, P362, DOI 10.1378/chest.104.2.362; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MOULTON T, 1995, AM J PATHOL, V146, P613; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHAW GL, 1993, CANCER RES, V53, P5181; SHIMIZU E, 1994, ONCOGENE, V9, P2441; SOZZI G, 1992, CANCER RES, V52, P6079; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STEVENSON H, 1990, ANN INTERN MED, V113, P764, DOI 10.7326/0003-4819-113-10-764; SUGIO K, 1994, CANCER RES, V54, P5811; WALKER DG, 1995, CANCER RES, V55, P20; WASHIMI O, 1995, CANCER RES, V55, P514; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XU L, 1994, CANCER RES, V54, P5262; ZHANG SY, 1994, CANCER RES, V54, P5050	43	71	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1843	1851						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478613				2022-12-28	WOS:A1995TD09400020
J	BRUMMER, J; NEUMAIER, M; GOPFERT, C; WAGENER, C				BRUMMER, J; NEUMAIER, M; GOPFERT, C; WAGENER, C			ASSOCIATION OF PP60(C-SRC) WITH BILIARY GLYCOPROTEIN (CD66A), AN ADHESION MOLECULE OF THE CARCINOEMBRYONIC ANTIGEN FAMILY DOWN-REGULATED IN COLORECTAL CARCINOMAS	ONCOGENE			English	Article						SRC; TYROSINE KINASE; ONCOGENE; TUMOR-SUPPRESSOR; CELL ADHESION	GENE FAMILY; MONOCLONAL-ANTIBODIES; MODEL SYSTEM; ECTO-ATPASE; CELL-LINES; MEMBER; EXPRESSION; PP60C-SRC; CLONING; PROTEIN	CD66a, also known as 'biliary glycoprotein (BGP)', is the human homologue of a cell adhesion molecule (CAM) of the rat (Cell-CAM). CD66a, which belongs to the carcinoembryonic antigen family and the immunoglobulin superfamily, is expressed in cells of myeloid and epithelial origin. The cytoplasmic domain of the major isoform of CD66a (CD66a(cyt)) contains. two tyrosine residues in amino acid motifs potentially interacting with protein tyrosine kinases of the Src family. Here we provide evidence that CD66a is associated with pp60(c-src). From membrane fractions of granulocytes and the colonic cell line HT29, phosphokinase activity was co-immunoprecipitated with CD66a when monoclonal CD66 antibodies or an antiserum against the recombinant cytoplasmic domain of CD66a were used. From the dissociated immunecomplexes, a phosphokinase of M(r) 60 000 was reprecipitated using antibodies against pp60(c-src). In vitro, the recombinant cytoplasmic domain was a substrate and binding partner of pp60(c-src). Phosphopeptides corresponding to the tyrosine containing amino acid sequences of CD66a, activated the kinase activity of pp60(c-src) to a greater extent than a phosphopeptide containing Tyr(527) from the SH2-binding regulatory domain of pp60(c-src). The down-regulation of CD66a in about 80% of colorectal carcinomas may contribute to a dysregulation of pp60(c-src) in colorectal cancer.	UNIV HAMBURG, HOSP EPPENDORF, MED KLIN, KLIN CHEM ABT, D-20246 HAMBURG, GERMANY	University of Hamburg								AFAR DEH, 1992, BIOCHIM BIOPHYS ACTA, V1134, P46, DOI 10.1016/0167-4889(92)90026-8; AURIVILLIUS M, 1990, FEBS LETT, V264, P267, DOI 10.1016/0014-5793(90)80264-J; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; HARLOW E, 1988, ANTIBODIES LABORATOR; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HSIEH JT, 1995, CANCER RES, V55, P190; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; LIN SH, 1989, J BIOL CHEM, V264, P14408; NAGEL G, 1993, EUR J BIOCHEM, V214, P27, DOI 10.1111/j.1432-1033.1993.tb17892.x; NEUMAIER M, 1985, J IMMUNOL, V135, P3604; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; SKUBITZ KM, 1993, FEBS LETT, V318, P200, DOI 10.1016/0014-5793(93)80021-L; SKUBITZ KM, 1994, LEUKOCYTE TYPINE, V5; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STOCKS SC, 1993, BIOCHEM BIOPH RES CO, V195, P478, DOI 10.1006/bbrc.1993.2068; STOFFEL A, 1993, J IMMUNOL, V150, P4978; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; THOMPSON J, 1994, J BIOL CHEM, V269, P32924; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; WAGENER C, 1983, J IMMUNOL, V130, P2302; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	25	123	123	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1649	1655						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478590				2022-12-28	WOS:A1995TC53500024
J	VIGLIETTO, G; MAGLIONE, D; RAMBALDI, M; CERUTTI, J; ROMANO, A; TRAPASSO, F; FEDELE, M; IPPOLITO, P; CHIAPPETTA, G; BOTTI, G; FUSCO, A; PERSICO, MG				VIGLIETTO, G; MAGLIONE, D; RAMBALDI, M; CERUTTI, J; ROMANO, A; TRAPASSO, F; FEDELE, M; IPPOLITO, P; CHIAPPETTA, G; BOTTI, G; FUSCO, A; PERSICO, MG			UP-REGULATION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) AND DOWN-REGULATION OF PLACENTA GROWTH-FACTOR (PIGF) ASSOCIATED WITH MALIGNANCY IN HUMAN THYROID-TUMORS AND CELL-LINES	ONCOGENE			English	Article						HUMAN THYROID; P1GF; VEGF; TUMOR; ANGIOGENESIS	PERMEABILITY FACTOR; TYROSINE KINASE; DEVELOPMENTAL EXPRESSION; NUCLEOTIDE-SEQUENCE; STROMA GENERATION; ANGIOGENIC FACTOR; RIBONUCLEIC-ACID; MESSENGER-RNA; FACTOR-ALPHA; FACTOR GENE	Vascular endothelial growth factor (VEGF) is a potent mitogen for endothelial cells in vitro, promotes neoangiogenesis in vivo and increases the permeability of the vascular endothelium. VEGF overexpression occurs in several cultured tumor cell lines and in certain human malignancies, Placenta growth factor (PIGF) is a recently identified growth factor for endothelial cells (EC); PIGF strongly potentiates both the proliferative and the permeabilization effects exerted by VEGF on the vascular endothelium, To uncover the molecular mechanisms underlying neoangiogenesis in human thyroid tumors, we have analysed VEGF and PIGF expression in a panel of thyroid carcinoma cell lines with different tumorigenic potential as well as in human primary thyroid tumors, We show that a high tumorigenic potential is associated with an elevated VEGF expression in human thyroid tumor cell lines, Furthermore, VEGF overexpression occurs in 5/5 highly malignant anaplastic carcinomas, Papillary and follicular carcinomas express intermediate levels of VEGF mRNA. In contrast, PIGF expression is severely down regulated in the majority of thyroid tumor cell lines and in tumors, Furthermore, we show that both the VEGF receptors, FLT-1 and flk/KDR, are expressed in endothelial cells that line tumor-embedded microvascular vessels, suggesting that VEGF but not PIGF, contributes to thyroid tumor development.	FAC MED & CHIRURG,CNR,CTR ONCOL SPERIMENTALE,DIPARTIMENTO BIOL CELLULARE & MOLEC,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,CATANZARO,ITALY; INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	VIGLIETTO, G (corresponding author), IST NAZL TUMORI,FDN SENATORE PASCALE,VIA M SEMMOLA,I-80131 NAPLES,ITALY.		Fedele, Monica/C-1417-2015; Cerutti, Janete M/E-9121-2014; Viglietto, Giuseppe/AAC-2852-2019; Cerutti, Janete/D-3513-2014	Fedele, Monica/0000-0002-9171-1312; Viglietto, Giuseppe/0000-0003-2327-7515; Botti, Gerardo/0000-0002-6287-733X; Fusco, Alfredo/0000-0003-3332-5197; Cerutti, Janete/0000-0003-0156-8274				BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BROWN LF, 1993, CANCER RES, V53, P4727; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; DVORAK HF, 1987, LAB INVEST, V57, P673; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; FABIEN N, 1993, CANCER, V73, P2206; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GASPARINI G, 1993, INT J CANCER, V55, P739, DOI 10.1002/ijc.2910550507; GITAYGOREN H, 1993, BIOCHEM BIOPH RES CO, V190, P702, DOI 10.1006/bbrc.1993.1106; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; KIESER A, 1994, ONCOGENE, V9, P963; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LADOUX A, 1993, BIOCHEM BIOPH RES CO, V195, P1005, DOI 10.1006/bbrc.1993.2144; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MONACCI WT, 1993, AM J PHYSIOL, V264, P995; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; NAKAMURA T, 1992, JPN J CANCER RES, V83, P1293, DOI 10.1111/j.1349-7006.1992.tb02761.x; OLSON TA, 1994, CANCER RES, V54, P276; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; PARK JE, 1994, J BIOL CHEM, V269, P25646; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHING Y, 1985, J CELL BIOCHEM, V29, P275, DOI 10.1002/jcb.240290402; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; TAKAHASHI A, 1994, CANCER RES, V54, P4233; TANAKA J, 1987, VIROLOGY, V161, P62, DOI 10.1016/0042-6822(87)90171-1; TERMAN BI, 1994, GROWTH FACTORS, V11, P187, DOI 10.3109/08977199409046916; TERMAN BI, 1991, ONCOGENE, V6, P1677; TISHER E, 1991, J BIOL CHEM, V266, P11974; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WILSON JD, 1989, TXB ENDOCRINOLOGY; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; ZEKI K, 1991, J CLIN ENDOCR METAB, V76, P125	70	204	210	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1569	1579						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478581				2022-12-28	WOS:A1995TC53500015
J	HUANG, Y; SAEZ, R; CHAO, L; SANTOS, E; AARONSON, SA; CHAN, AML				HUANG, Y; SAEZ, R; CHAO, L; SANTOS, E; AARONSON, SA; CHAN, AML			A NOVEL INSERTIONAL MUTATION IN THE TC21 GENE ACTIVATES ITS TRANSFORMING ACTIVITY IN A HUMAN LEIOMYOSARCOMA CELL-LINE	ONCOGENE			English	Article						RAS; TC21; ONCOGENE; SSCP; MUTATION; LEIOMYOSARCOMA	RAS-RELATED GENE; MOLECULAR SWITCH; DIRECT REPEATS; DELETIONS; ONCOGENES; PROTEIN	TC21 is the fourth member of the pas gene family to exhibit oncogenic activation in human tumor cells. To assess the prevalence of activated TC21 oncogenes in human tumors, we have developed sensitive single-strand conformational polymorphism (SSCP) conditions and immunological reagents for the detection of both single base alterations and/or overt overexpression in a wide spectrum of human tumor cell lines and surgical samples. In an initial examination of 33 human tumor specimens, we observed a novel nine basepair three amino acids insertion at TC21 codon 24 in one human uterine leiomyosarcoma cell line, SK-UT-1. This mutant allele when transfected into NIH3T3 cells, displayed high transforming activity comparable to that of the Leu72 oncogenic mutant identified by expression cDNA cloning from a human ovarian carcinoma cell line. Comparing the level of GTP-binding by the mutant and normal TC21 products revealed that this novel lesion increases the GTP-bound form of the TC21 molecule. These findings imply that the mechanism by which mutations activate the oncogenic properties of this ras-related molecule is analogous to that of previously known ras family members.	MT SINAI MED CTR,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464				ALBERTINI AM, 1982, CELL, V29, P319, DOI 10.1016/0092-8674(82)90148-9; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; COX AD, 1994, ONCOGENE, V9, P3281; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; GERNER RE, 1975, ANN SURG, V181, P803, DOI 10.1097/00000658-197506000-00007; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HIGINBOTHAM KG, 1994, ONCOGENE, V9, P2455; JEGO N, 1993, ONCOGENE, V8, P209; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PATTERSON H, 1994, BRIT J CANCER, V69, P1052, DOI 10.1038/bjc.1994.207; PORRAS A, 1992, J BIOL CHEM, V267, P21124; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; SAEZ R, 1994, ONCOGENE, V9, P2977; SATOH T, 1992, J BIOL CHEM, V267, P24149; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4648; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P	26	46	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1255	1260						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478545				2022-12-28	WOS:A1995RY96700005
J	PANAGOPOULOS, I; MANDAHL, N; MITELMAN, F; AMAN, P				PANAGOPOULOS, I; MANDAHL, N; MITELMAN, F; AMAN, P			2 DISTINCT FUS BREAKPOINT CLUSTERS IN MYXOID LIPOSARCOMA AND ACUTE MYELOID-LEUKEMIA WITH THE TRANSLOCATIONS T(12-16) AND T(16-21)	ONCOGENE			English	Article						MYXOID LIPOSARCOMA; ACUTE MYELOID LEUKEMIA; T(12-16); T(16-21); BREAKPOINT MAPPING; FUS GENE	GENE; CHOP; LOCALIZATION; ERG	The PUS gene, which maps to 16p11, is fused to the CHOP gene in the t(12;16) (q13;p11) that characterizes myxoid liposarcomas (MLS) and to the ERG gene in acute myeloid leukemia (AML) with t(16;21) (p11;q22). In the present study we have mapped the breakpoints within FUS in 13 MLS with t(12;16) and in one AML with t(16;21). This region of PUS is about 3.9 kb and contains four exons. The breakpoints clustered to two zones (1 and 2). A strong association was found between the two known types of PUS/CHOP transcripts and the genomic localization of the breakpoints. In all cases expressing only type I or both type I and II PUS/CHOP transcript the genomic breakpoints mapped to zone 1. In all cases expressing only the type II transcript the breakpoints occurred in zone 2. The breakpoint in the AML case was in zone 1, suggesting that in-frame fusion transcripts are selected by similar mechanisms in both MLS and AML.			PANAGOPOULOS, I (corresponding author), UNIV LUND HOSP,DEPT CLIN GENET,S-22185 LUND,SWEDEN.			Aman, Pierre/0000-0002-1482-8875; Panagopoulos, Ioannis/0000-0003-2159-5341				AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; ENEROTH M, 1990, CANCER GENET CYTOGEN, V48, P101, DOI 10.1016/0165-4608(90)90222-V; ICHIKAWA H, 1994, CANCER RES, V54, P2865; LADANYI M, 1994, CANCER RES, V54, P2837; MANDAHL N, 1994, INT J ONCOL, V4, P307; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; PONCE MR, 1992, NUCLEIC ACIDS RES, V29, P623; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; Sambrook J, 1989, MOL CLONING LABORATO; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	18	41	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1133	1137						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566973				2022-12-28	WOS:A1995RX18000016
J	KONDOH, G; HAYASAKA, N; LI, Q; NISHIMUNE, Y; HAKURA, A				KONDOH, G; HAYASAKA, N; LI, Q; NISHIMUNE, Y; HAKURA, A			AN IN-VIVO MODEL FOR RECEPTOR TYROSINE KINASE AUTOCRINE/PARACRINE ACTIVATION - AUTO-STIMULATED KIT RECEPTOR ACTS AS A TUMOR-PROMOTING FACTOR IN PAPILLOMAVIRUS-INDUCED TUMORIGENESIS	ONCOGENE			English	Article						HPV16 TRANSGENIC MOUSE; C-KIT SLF; AUTOSTIMULATION; TUMORIGENESIS	STEM-CELL FACTOR; AUTOCRINE GROWTH-FACTORS; C-KIT; W-LOCUS; LUNG-CANCER; TRANSMEMBRANE FORM; PROTO-ONCOGENE; SERTOLI CELLS; GENE-PRODUCT; MUTANT MICE	Constitutive overactivation of growth factor receptors through autocrinelparacrine mechanisms occurs frequently in cancer cells and are thought to play a critical role in carcinogenesis. In the present report, we propose a refined in vivo model which explains the significance of these mechanisms in tumour development. We have previously established transgenic mouse lines containing human papillomavirus type 16 (HPV16) E6E7 oncogenes, in male mice of which a Leydig cell tumor developes with a very high incidence, Not only HPV transgene but also the c-kit proto-oncogene receptor tyrosine kinase and its ligand Steel Factor (SLF) were coexpressed in all tumors analysed. This coexpression of c-kit/SLF was also found in two other Leydig cell tumor lines. Moreover, the proliferation of transgenic tumor cells was attenuated by treatment with a c-kit neutralizing antibody in vitro, strongly suggesting that tumorigenesis is closely related to stimulation of receptors through ligand induction, To confirm the significance of these findings, a defective mutation of the SLF gene in a laboratory mouse, the Steel-Dickey (Sld) mutation, was introduced into a line of transgenic mice showing 100% incidence of the tumor. In Sl(d)-E6E7 transgenic mice, tumorigenesis was initiated but numbers of tumor cells were markedly reduced compared with transgenic mice carrying both wild type SLP allele, showing that c-kit activation through the induction of SLF is essential for testicular tumorigenesis, especially in tumour promotion. This transgenic mice system should be a useful in vivo model for clarifying the implication of growth factor autostimulation in carcinogenesis.	OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN	Osaka University	KONDOH, G (corresponding author), OSAKA UNIV,GENOME INFORMAT RES CTR,SUITA,OSAKA 565,JAPAN.							ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BERDEL WE, 1992, CANCER RES, V52, P3498; BERNSTEIN SE, 1960, MOUSE NEWS LETT, V23, P33; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BROWDER TM, 1989, CANCER CELL-MON REV, V1, P9; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; CACERESCORTES JR, 1992, CANCER RES, V52, P5208; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V13, P2485; HIBI K, 1991, ONCOGENE, V6, P2291; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; INOUE M, 1994, CANCER RES, V54, P3049; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KONDOH G, 1991, J VIROL, V65, P3335, DOI 10.1128/JVI.65.6.3335-3339.1991; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; MANOVA K, 1993, DEV BIOL, V157, P85, DOI 10.1006/dbio.1993.1114; MANOVA K, 1990, DEVELOPMENT, V110, P1057; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MARZIALI G, 1993, DEV BIOL, V157, P182, DOI 10.1006/dbio.1993.1122; MOTRO B, 1991, DEVELOPMENT, V113, P1207; MUNGER K, 1989, J VIROL, V63, P4417; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; QIE F, 1988, EMBO J, V7, P1003; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, GENES PHENOTYPES GEN, V5, P105; RUSSELL NH, 1992, BLOOD REV, V6, P149, DOI 10.1016/0268-960X(92)90026-M; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; SATO B, 1987, ENDOCRINOLOGY, V120, P1112, DOI 10.1210/endo-120-3-1112; SEKIDO Y, 1991, CANCER RES, V51, P2416; SEKIDO Y, 1993, CANCER RES, V53, P1709; SHIN SI, 1967, ENDOCRINOLOGY, V81, P440, DOI 10.1210/endo-81-3-440; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STROHMEYER T, 1991, CANCER RES, V51, P1811; TAJIMA Y, 1991, DEVELOPMENT, V113, P1031; TOKSOZ D, 1992, P NATL ACAD SCI USA, V89, P7350, DOI 10.1073/pnas.89.16.7350; WILLIAMS DE, 1992, DEV BIOL, V151, P368, DOI 10.1016/0012-1606(92)90176-H; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	46	21	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					341	347						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7530826				2022-12-28	WOS:A1995QC62400013
J	FRYE, RA; BENZ, CC; LIU, E				FRYE, RA; BENZ, CC; LIU, E			DETECTION OF AMPLIFIED ONCOGENES BY DIFFERENTIAL POLYMERASE CHAIN-REACTION	ONCOGENE			English	Article									UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599; UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GENET,SAN FRANCISCO,CA 94143	University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina			Liu, Edison/C-4141-2008					ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0; KASHANISABET M, 1988, CANCER RES, V48, P5775; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEE MS, 1987, SCIENCE, V237, P175, DOI 10.1126/science.3110950; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	19	258	266	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1153	1157						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2780051				2022-12-28	WOS:A1989AM53100017
J	KODURU, PRK; OFFIT, K; FILIPPA, DA				KODURU, PRK; OFFIT, K; FILIPPA, DA			MOLECULAR ANALYSIS OF BREAKS IN BCL-1 PROTO-ONCOGENE IN B-CELL LYMPHOMAS WITH ABNORMALITIES OF 11Q13	ONCOGENE			English	Article									MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,CANC GENET & CYTOGENET LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,LEUKEMIA & LYMPHOMA SERV,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [R01CA034775] Funding Source: NIH RePORTER; NCI NIH HHS [CA34775] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKSHI A, 1987, P NATL ACAD SCI USA, V84, P2396; BAKSHI A, 1985, CELL, V41, P899; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CARE A, 1986, EMBO J, V5, P905, DOI 10.1002/j.1460-2075.1986.tb04302.x; CHAGANTI RSK, 1987, CYTOGENET CELL GENET, V45, P93, DOI 10.1159/000132436; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CROCE CM, 1986, COLD SPRING HARB SYM, V51, P891, DOI 10.1101/SQB.1986.051.01.102; HALUSKA FG, 1987, TRENDS GENET, V3, P11, DOI 10.1016/0168-9525(87)90155-7; HALUSKA FG, 1986, NATURE, V324, P158, DOI 10.1038/324158a0; INCE C, 1988, LEUKEMIA, V2, P343; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; KLEIN G, 1986, CANCER RES, V46, P3211; KODURU PRK, 1987, BLOOD, V69, P97; LEE MS, 1987, BLOOD, V70, P90; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; NOWELL P, 1981, BLOOD, V57, P444; OFFIT K, 1989, IN PRESS BR J HEMATO; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; RABBITTS PH, 1988, ONCOGENE, V3, P99; RABBITTS TH, 1986, COLD SPRING HARB SYM, V51, P923, DOI 10.1101/SQB.1986.051.01.105; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VANDENBERGHE H, 1984, CANCER GENET CYTOGEN, V11, P381, DOI 10.1016/0165-4608(84)90017-7; WEISENBURGER DD, 1987, BLOOD, V69, P1617; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; YUNIS JJ, 1984, CANCER GENET CYTOGEN, V13, P17, DOI 10.1016/0165-4608(84)90084-0; 1987, BLOOD, V70, P1554	33	57	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					929	934						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2787901				2022-12-28	WOS:A1989AE58400017
J	IGUCHIARIGA, SMM; OKAZAKI, T; ITANI, T; ARIGA, H				IGUCHIARIGA, SMM; OKAZAKI, T; ITANI, T; ARIGA, H			CLONING OF THE P53-DEPENDENT ORIGIN OF CELLULAR DNA-REPLICATION	ONCOGENE			English	Article									UNIV TOKYO,INST MED SCI,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN	University of Tokyo			Ariga, Hiroyoshi/B-5895-2013	Ariga, Hiroyoshi/0000-0001-7384-2143				ARIGA H, 1984, MOL CELL BIOL, V4, P1476, DOI 10.1128/MCB.4.8.1476; ARIGA H, 1987, MOL CELL BIOL, V7, P1; ARIGA H, 1983, J VIROL, V48, P481, DOI 10.1128/JVI.48.2.481-491.1983; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; FAVERA R D, 1982, Nature (London), V299, P61, DOI 10.1038/299061a0; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; ITANI T, 1987, GENE, V56, P267; KLEIN G, 1982, ADV VIRAL ONCOLOGY, V2; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MIYAMOTO C, 1985, P NATL ACAD SCI USA, V82, P7232, DOI 10.1073/pnas.82.21.7232; PAPABADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V394, P484; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SHOHAT O, 1987, ONCOGENE, V1, P277; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	25	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					509	515						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	2978868				2022-12-28	WOS:A1988R516300004
J	HEROLD, KM; ROTHBERG, PG				HEROLD, KM; ROTHBERG, PG			EVIDENCE FOR A LABILE INTERMEDIATE IN THE BUTYRATE INDUCED REDUCTION OF THE LEVEL OF C-MYC RNA IN SW837 RECTAL-CARCINOMA CELLS	ONCOGENE			English	Article									NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, DEPT HUMAN GENET, BUFFALO, NY 14263 USA	Roswell Park Cancer Institute					NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSHAVIT Z, 1986, ENDOCRINOLOGY, V118, P679, DOI 10.1210/endo-118-2-679; BERGER J, 1987, P NATL ACAD SCI USA, V84, P695, DOI 10.1073/pnas.84.3.695; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHUNG YS, 1985, CANCER RES, V45, P2976; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEBUSTROS A, 1985, J BIOL CHEM, V260, P98; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; GHOSH NK, 1977, BIOCHEM J, V166, P265, DOI 10.1042/bj1660265; GRIEP AE, 1986, P NATL ACAD SCI USA, V83, P5539, DOI 10.1073/pnas.83.15.5539; GUM JR, 1987, J BIOL CHEM, V262, P1092; HUBER BE, 1987, CANCER RES, V47, P3414; JOHNSON BE, 1986, J CLIN INVEST, V78, P525, DOI 10.1172/JCI112604; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIM YS, 1980, CANCER-AM CANCER SOC, V45, P1185, DOI 10.1002/1097-0142(19800315)45:5+<1185::AID-CNCR2820451324>3.0.CO;2-W; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MASON WS, 1982, P NATL ACAD SCI-BIOL, V79, P3997, DOI 10.1073/pnas.79.13.3997; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MULDER KM, 1988, INT J CANCER, V42, P64, DOI 10.1002/ijc.2910420113; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NATH P, 1987, EXP CELL RES, V169, P215, DOI 10.1016/0014-4827(87)90239-4; NISHIMURA S, 1987, BIOCHEM J, V243, P313, DOI 10.1042/bj2430313; PFEIFEROHLSSON S, 1985, P NATL ACAD SCI USA, V82, P5050, DOI 10.1073/pnas.82.15.5050; REED JC, 1985, P NATL ACAD SCI USA, V82, P4221, DOI 10.1073/pnas.82.12.4221; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; ROEDIGER WEW, 1982, GASTROENTEROLOGY, V83, P424; ROTHBERG PG, 1984, MOL CELL BIOL, V4, P1096, DOI 10.1128/MCB.4.6.1096; ROTHBERG PG, 1987, SEMIN SURG ONCOL, V3, P152, DOI 10.1002/ssu.2980030305; ROTHBERG PG, 1985, BRIT J CANCER, V52, P629, DOI 10.1038/bjc.1985.237; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; RUBINSTEIN R, 1969, CLIN SCI, V37, P549; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; STEWART J, 1986, BRIT J CANCER, V53, P1, DOI 10.1038/bjc.1986.1; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; TSAO D, 1983, CANCER RES, V43, P1217; TSAO D, 1982, CANCER RES, V42, P1052; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490	51	42	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1988	3	4					423	428						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3078950				2022-12-28	WOS:A1988Q773900010
J	SHAW, APW; POIRIER, V; TYLER, S; MOTT, M; BERRY, J; MAITLAND, NJ				SHAW, APW; POIRIER, V; TYLER, S; MOTT, M; BERRY, J; MAITLAND, NJ			EXPRESSION OF THE N-MYC ONCOGENE IN WILMS TUMOR AND RELATED-TISSUES	ONCOGENE			English	Article									UNIV BRISTOL,DEPT PATHOL,BRISTOL BS8 1TD,AVON,ENGLAND; UNIV BRISTOL,DEPT CHILD HLTH,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol; University of Bristol	SHAW, APW (corresponding author), UNIV BRISTOL,CANC & LEUKAEMIA CHILDHOOD TRUST RES UNIT,BRISTOL BS8 1TD,AVON,ENGLAND.							BERNARDS R, 1987, TRENDS GENET, V3, P298, DOI 10.1016/0168-9525(87)90272-1; Bolande R P, 1973, Perspect Pediatr Pathol, V1, P227; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRADY EF, 1987, CANCER RES, V47, P2931; GREENWOOD MF, 1984, WILMS TUMOUR CLIN BI; HOEFLER H, 1986, HISTOCHEM J, V18, P597, DOI 10.1007/BF01675295; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KNUDSON AG, 1985, CANCER RES, V45, P1435; KONECKI DS, 1982, NUCLEIC ACIDS RES, V10, P6763, DOI 10.1093/nar/10.21.6763; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; MACHIN GA, 1984, WILMS TUMOUR CLIN BI, P236; MAITLAND NJ, 1987, J ORAL PATHOL MED, V16, P199; MAITLAND NJ, 1981, J GEN VIROL, V55, P123, DOI 10.1099/0022-1317-55-1-123; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIERAU GW, 1987, ULTRASTRUCT PATHOL, V11, P313, DOI 10.3109/01913128709048329; NISEN PD, 1986, CANCER RES, V46, P6217; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SNYDER HM, 1981, J UROLOGY, V126, P513, DOI 10.1016/S0022-5347(17)54601-7; SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	28	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					143	149						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	2842712				2022-12-28	WOS:A1988Q053400003
J	PEAR, WS; NELSON, SF; AXELSON, H; WAHLSTROM, G; BAZIN, H; KLEIN, G; SUMEGI, J				PEAR, WS; NELSON, SF; AXELSON, H; WAHLSTROM, G; BAZIN, H; KLEIN, G; SUMEGI, J			ABERRANT CLASS SWITCHING JUXTAPOSES C-MYC WITH A MIDDLE REPETITIVE ELEMENT (LINE) AND AN IGH INTRON IN 2 SPONTANEOUSLY ARISING RAT IMMUNOCYTOMAS	ONCOGENE			English	Article									KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN; FREE UNIV BRUSSELS,EXPTL IMMUNOL UNIT,B-1050 BRUSSELS,BELGIUM	Karolinska Institutet; Universite Libre de Bruxelles; Vrije Universiteit Brussel			Nelson, Stanley F/D-4771-2009	Nelson, Stanley F/0000-0002-2082-3114	NCI NIH HHS [3R01CA4054] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; BAZIN H, 1972, INT J CANCER, V10, P568, DOI 10.1002/ijc.2910100316; BAZIN H, 1987, IN PRESS ADV CANCER; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BRUGGEMANN M, 1986, P NATL ACAD SCI USA, V83, P6075, DOI 10.1073/pnas.83.16.6075; CESARMAN E, 1987, IN PRESS SCIENCE; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CORY S, 1983, EMBO J, V2, P697, DOI 10.1002/j.1460-2075.1983.tb01487.x; Croce C M, 1986, Adv Immunol, V38, P245, DOI 10.1016/S0065-2776(08)60008-5; DAMBROSIO E, 1986, MOL CELL BIOL, V6, P411, DOI 10.1128/MCB.6.2.411; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUNNICK W, 1980, NATURE, V286, P669, DOI 10.1038/286669a0; DURDIK J, 1984, NATURE, V307, P749, DOI 10.1038/307749a0; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; ECONOMOUPACHNIS A, 1985, P NATL ACAD SCI USA, V82, P2857, DOI 10.1073/pnas.82.9.2857; FAWCETT DH, 1986, CELL, V47, P1007, DOI 10.1016/0092-8674(86)90815-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FURANO AV, 1986, NUCLEIC ACIDS RES, V14, P3717, DOI 10.1093/nar/14.9.3717; HALUSKA FG, 1987, TRENDS GENET, V3, P11, DOI 10.1016/0168-9525(87)90155-7; HALUSKA FG, 1986, NATURE, V324, P158, DOI 10.1038/324158a0; HAMMARSKJOLD ML, 1986, GENE, V43, P41, DOI 10.1016/0378-1119(86)90006-5; HARTL P, 1987, IN PRESS MOL CELL BI; HATTORI M, 1986, NATURE, V321, P625, DOI 10.1038/321625a0; HELLMAN L, 1982, P NATL ACAD SCI-BIOL, V79, P1264, DOI 10.1073/pnas.79.4.1264; HOCHTL J, 1983, NATURE, V302, P260, DOI 10.1038/302260a0; KATZIR N, 1985, P NATL ACAD SCI USA, V82, P1054, DOI 10.1073/pnas.82.4.1054; KIRSCH IR, 1981, NATURE, V293, P583; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; Klein G, 1981, NATURE, V294, P313, DOI 10.1038/294313a0; KLOBECK HG, 1987, NUCLEIC ACIDS RES, V15, P4877, DOI 10.1093/nar/15.12.4877; LOEB DD, 1986, MOL CELL BIOL, V6, P168, DOI 10.1128/MCB.6.1.168; LUEDERS KK, 1984, MOL CELL BIOL, V4, P2128, DOI 10.1128/MCB.4.10.2128; MANIATIS T, 1982, MOL CLONING LABORATO; MARTIN SL, 1984, P NATL ACAD SCI-BIOL, V81, P2308, DOI 10.1073/pnas.81.8.2308; Maxam A M, 1980, Methods Enzymol, V65, P499; NIKAIDO T, 1982, J BIOL CHEM, V257, P7322; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; PEAR WS, 1986, IMMUNOGENETICS, V23, P393, DOI 10.1007/BF00372672; PEAR WS, 1986, P NATL ACAD SCI USA, V83, P7376, DOI 10.1073/pnas.83.19.7376; PEAR WS, 1987, IN PRESS MOL CELL BI; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; PICOLLI SP, 1984, NATURE, V310, P327; RADBRUCH A, 1986, IMMUNOL REV, V89, P70; REMMERS EF, 1986, EMBO J, V5, P895; SAKANO H, 1980, NATURE, V286, P676, DOI 10.1038/286676a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SHIMIZU A, 1984, CELL, V36, P801, DOI 10.1016/0092-8674(84)90029-1; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SIMINOVITCH KA, 1985, NATURE, V316, P260, DOI 10.1038/316260a0; SINGER MF, 1985, TRENDS BIOCHEM SCI, V10, P119, DOI 10.1016/0968-0004(85)90271-3; SOARES MB, 1985, J MOL EVOL, V22, P117, DOI 10.1007/BF02101690; STADEN R, 1980, NUCLEIC ACIDS RES, V8, P3673, DOI 10.1093/nar/8.16.3673; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; STEEN ML, 1984, J MOL BIOL, V177, P19, DOI 10.1016/0022-2836(84)90055-X; SUMEGI J, 1983, NATURE, V306, P497, DOI 10.1038/306497a0; TAKAHASHI N, 1982, CELL, V29, P671, DOI 10.1016/0092-8674(82)90183-0; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; WIENER F, 1982, INT J CANCER, V29, P431, DOI 10.1002/ijc.2910290412; YANCOPOULOS GD, 1986, EMBO J, V5, P3259, DOI 10.1002/j.1460-2075.1986.tb04637.x; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x	65	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					499	507						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	3131719				2022-12-28	WOS:A1988N434800012
J	MAHADEVAN, LC; HEATH, JK; LEICHTFRIED, FE; CUMMING, DVE; HIRST, EMA; FOULKES, JG				MAHADEVAN, LC; HEATH, JK; LEICHTFRIED, FE; CUMMING, DVE; HIRST, EMA; FOULKES, JG			RAPID APPEARANCE OF NOVEL PHOSPHOPROTEINS IN THE NUCLEI OF MITOGEN-STIMULATED FIBROBLASTS	ONCOGENE			English	Article									NATL INST MED RES,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND; NATL INST MED RES,CELL SURFACE INTERACT LAB,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research; MRC National Institute for Medical Research								AARONSON RP, 1975, P NATL ACAD SCI USA, V72, P1007, DOI 10.1073/pnas.72.3.1007; BELL JC, 1987, NATURE, V235, P552; BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; BERRIDGE MJ, 1986, ONCOGENES GROWTH CON, P147; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; BRAVO R, 1986, ONCOGENES GROWTH CON, P253; CIRILLO DM, 1986, MOL CELL BIOL, V6, P4641, DOI 10.1128/MCB.6.12.4641; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DOWNES CP, 1985, MOL ASPECTS CELLULAR, V4, P3; EVERED D, 1986, CIBA F S; FOULKES JG, 1985, MOL ASPECTS CELL REG, V4, P217; GOSPODAROWICZ D, 1986, CELL DIFFER DEV, V19, P1, DOI 10.1016/0045-6039(86)90021-7; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HEATH JK, 1986, EMBO J, V5, P1809, DOI 10.1002/j.1460-2075.1986.tb04430.x; HEATH JK, 1984, EMBO J, V3, P2957, DOI 10.1002/j.1460-2075.1984.tb02240.x; HEATH JK, 1987, TERATOCARCINOMAS EMB; HUANG SS, 1986, J BIOL CHEM, V261, P9568; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1986, ONCOGENES GROWTH CON, P138; ISACKE CM, 1986, EMBO J, V5, P2889, DOI 10.1002/j.1460-2075.1986.tb04584.x; KAIBUCHI K, 1986, J BIOL CHEM, V261, P1187; KAUFMANN SH, 1981, EXP CELL RES, V132, P105, DOI 10.1016/0014-4827(81)90088-4; KAUFMANN SH, 1983, J BIOL CHEM, V258, P2710; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHADEVAN LC, 1987, EMBO J, V6, P921, DOI 10.1002/j.1460-2075.1987.tb04839.x; MCKEON FD, 1984, CELL, V36, P83, DOI 10.1016/0092-8674(84)90076-X; MOOLENAAR WH, 1986, ONCOGENES GROWTH CON, P170; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARKER PJ, 1986, ONCOGENES GROWTH CON, P154; POUYSSEGUR J, 1985, CANCER CELL, V3, P409; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SHIBANUMA M, 1987, EUR J BIOCHEM, V164, P15, DOI 10.1111/j.1432-1033.1987.tb10985.x; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; THOMAS G, 1986, ONCOGENES GROWTH CON, P177; TSUDA T, 1985, FEBS LETT, V191, P205, DOI 10.1016/0014-5793(85)80009-0; USHIRO H, 1980, J BIOL CHEM, V255, P8363	41	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					249	257						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3353115				2022-12-28	WOS:A1988M593100007
J	PROPST, F; ROSENBERG, MP; OSKARSSON, MK; RUSSELL, LB; NGUYENHUU, MC; NADEAU, J; JENKINS, NA; COPELAND, NG; VANDEWOUDE, GF				PROPST, F; ROSENBERG, MP; OSKARSSON, MK; RUSSELL, LB; NGUYENHUU, MC; NADEAU, J; JENKINS, NA; COPELAND, NG; VANDEWOUDE, GF			GENETIC-ANALYSIS AND DEVELOPMENTAL REGULATION OF TESTIS-SPECIFIC RNA EXPRESSION OF MOS, ABL, ACTIN AND HOX-1.4	ONCOGENE			English	Article									OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT UROL,NEW YORK,NY 10032; JACKSON LAB,BAR HARBOR,ME 04609	United States Department of Energy (DOE); Oak Ridge National Laboratory; Columbia University; Columbia University; Jackson Laboratory	PROPST, F (corresponding author), NCI,FREDERICK CANC RES FACIL,BRI BASIC RES PROGRAM,POB B,FREDERICK,MD 21701, USA.				OFFICE OF THE DIRECTOR, NCI [N01CO023909] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-23909] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; BENNETT D, 1975, CELL, V6, P441, DOI 10.1016/0092-8674(75)90033-1; BENNETT WI, 1971, BIOL REPROD, V5, P30, DOI 10.1093/biolreprod/5.1.30; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CATTANACH BM, 1971, CYTOGENETICS, V10, P318, DOI 10.1159/000130151; CATTANACH BM, 1977, NATURE, V269, P338, DOI 10.1038/269338a0; DUDLEY K, 1984, NUCLEIC ACIDS RES, V12, P4281, DOI 10.1093/nar/12.10.4281; EICHER EM, 1986, ANNU REV GENET, V20, P327, DOI 10.1146/annurev.ge.20.120186.001551; EICHER EM, 1982, SCIENCE, V217, P535, DOI 10.1126/science.7089579; ERICKSON RP, 1985, BIOSCIENCE REP, V5, P1087, DOI 10.1007/BF01119630; Favaloro J, 1980, Methods Enzymol, V65, P718; FUJIMOTO H, 1984, BIOSCIENCE REP, V4, P1037, DOI 10.1007/BF01116696; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HANDEL MA, 1987, J EXP ZOOL, V243, P81, DOI 10.1002/jez.1402430111; Hecht NB., 1986, EXPT APPROACHES MAMM, P151; JONES M, 1980, P NATL ACAD SCI-BIOL, V77, P2651, DOI 10.1073/pnas.77.5.2651; KESHET E, 1988, ONCOGENE, V2, P235; KLEENE KC, 1983, DEV BIOL, V98, P455, DOI 10.1016/0012-1606(83)90375-5; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; LYON MF, 1970, NATURE, V227, P1217, DOI 10.1038/2271217a0; MANIATIS T, 1982, MOL CLONING LABORATO; MINTZ B, 1955, ANAT REC, V122, P443; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OAKBERG EF, 1956, AM J ANAT, V99, P507, DOI 10.1002/aja.1000990307; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PETERS H, 1969, ACTA ENDOCRINOL-COP, V62, P98, DOI 10.1530/acta.0.0620098; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; RAPPOLD GA, 1987, EMBO J, V6, P1975, DOI 10.1002/j.1460-2075.1987.tb02460.x; RAVE N, 1979, NUCLEIC ACIDS RES, V6, P3559, DOI 10.1093/nar/6.11.3559; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RUBIN MR, 1986, SCIENCE, V233, P663, DOI 10.1126/science.3726554; RUSSELL LB, 1983, PROGR TOPICS CYTOG A, V3, P206; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; WATERS SH, 1985, MOL CELL BIOL, V5, P1649, DOI 10.1128/MCB.5.7.1649; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WIELAND SJ, 1979, CELL, V17, P781, DOI 10.1016/0092-8674(79)90318-0; WOLGEMUTH DJ, 1987, P NATL ACAD SCI USA, V84, P5813, DOI 10.1073/pnas.84.16.5813; WOLGEMUTH DJ, 1986, EMBO J, V5, P1229, DOI 10.1002/j.1460-2075.1986.tb04351.x; YELICK PC, 1987, MOL CELL BIOL, V7, P2173, DOI 10.1128/MCB.7.6.2173	49	40	41	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					227	233						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	2895445				2022-12-28	WOS:A1988M593100004
J	RONAI, ZA; OKIN, E; WEINSTEIN, IB				RONAI, ZA; OKIN, E; WEINSTEIN, IB			ULTRAVIOLET-LIGHT INDUCES THE EXPRESSION OF ONCOGENES IN RAT FIBROBLAST AND HUMAN KERATINOCYTE CELLS	ONCOGENE			English	Article									COLUMBIA UNIV, INST CANC RES, NEW YORK, NY 10032 USA	Columbia University	RONAI, ZA (corresponding author), COLUMBIA UNIV, CTR COMPREHENS CANC, NEW YORK, NY 10032 USA.			RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA 02656] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLER P, 1986, J CELL PHYSIOL, V128, P362, DOI 10.1002/jcp.1041280303; ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOWDEN GT, 1986, CHEM-BIOL INTERACT, V58, P333, DOI 10.1016/S0009-2797(86)80107-7; CHANG SE, 1985, BIOCHIM BIOPHYS ACTA, V823, P161; CHASS GL, 1982, J CELL PHYSL, V111, P309; CURRAN T, 1985, CANCER SURV, V4, P655; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DRAGANI TA, 1986, CANCER RES, V46, P1915; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FITZPATRICK TB, 1985, NEW ENGL J MED, V313, P818, DOI 10.1056/NEJM198509263131310; GEORGE DL, 1986, P NATL ACAD SCI USA, V83, P1651, DOI 10.1073/pnas.83.6.1651; GINZBURG I, 1980, NUCLEIC ACIDS RES, V8, P3553, DOI 10.1093/nar/8.16.3553; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GONDA MA, 1982, J VIROL, V44, P520, DOI 10.1128/JVI.44.2.520-529.1982; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HSIEH LL, 1987, CANCER RES, V47, P3421; KACZMAREK L, 1986, CELL BIOL INT REP, V10, P455, DOI 10.1016/0309-1651(86)90041-X; KARIN M, 1983, DNA CELL BIOL, V2, P329; KELLAND LR, 1983, PHOTOCHEM PHOTOBIOL, V37, P301, DOI 10.1111/j.1751-1097.1983.tb04477.x; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEINBERGER T, 1986, MOL CELL BIOL, V6, P1958, DOI 10.1128/MCB.6.6.1958; LAMBERT ME, 1983, CARCINOGENESIS, V4, P587, DOI 10.1093/carcin/4.5.587; LAMBERT ME, 1986, CARCINOGENESIS, V7, P1011, DOI 10.1093/carcin/7.6.1011; LAMBERT ME, 1986, ANTIMUTAGENESIS ANTI, P291; LAVI S, 1981, P NATL ACAD SCI-BIOL, V78, P6144, DOI 10.1073/pnas.78.10.6144; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; NOMURA S, 1984, MOL CELL BIOL, V4, P1159, DOI 10.1128/MCB.4.6.1159; OLSON EN, 1986, MOL CELL BIOL, V6, P2792, DOI 10.1128/MCB.6.8.2792; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; PEAK JG, 1985, PHOTOCHEM PHOTOBIOL, V41, P295, DOI 10.1111/j.1751-1097.1985.tb03488.x; RESENSTEIN BS, 1986, ENV MUT, V8, P335; RINGOLD GM, 1984, P NATL ACAD SCI-BIOL, V81, P3964, DOI 10.1073/pnas.81.13.3964; ROBERTS JJ, 1986, MUTAT RES, V165, P207, DOI 10.1016/0167-8817(86)90056-8; RONAI ZA, 1987, IN PRESS CANCER RES; ROTEM N, 1987, MOL CELL BIOL, V7, P622, DOI 10.1128/MCB.7.2.622; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SHUIN T, 1986, CANCER RES, V46, P5302; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STIMAC E, 1984, MOL CELL BIOL, V4, P2082, DOI 10.1128/MCB.4.10.2082; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; VANDERLUBBE JLM, 1986, MUTAT RES, V165, P47, DOI 10.1016/0167-8817(86)90059-3; VLEMINCKX C, 1986, CARCINOGENESIS, V7, P229, DOI 10.1093/carcin/7.2.229; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; [No title captured]	49	75	75	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1988	2	2					201	204						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	3285298				2022-12-28	WOS:A1988M086000015
J	PASTEAU, S; LOISEAU, L; AMAUD, L; TREMBLEAU, A; BRUN, G				PASTEAU, S; LOISEAU, L; AMAUD, L; TREMBLEAU, A; BRUN, G			ISOLATION AND CHARACTERIZATION OF A CHICKEN HOMOLOG OF THE E2F-1 TRANSCRIPTION FACTOR	ONCOGENE			English	Article						CHICKEN E2F-1; CELL CYCLE; TRANSCRIPTION FACTOR; NEURORETINA; ONCOGENIC PROPERTIES	DIHYDROFOLATE-REDUCTASE PROMOTER; RETINOBLASTOMA PROTEIN; EMBRYO FIBROBLASTS; BINDING PROTEIN; C-JUN; CLONING; ACTIVATION; EXPRESSION; GENE; MYC	In higher eukaryotes, the E2F-1 transcription factor is an essential and limiting component of cell cycle progression in late G1. E2F-1 heterodimerizes with members of the DP gene family and the resulting heterodimer regulates the expression of several protooncogenes and the genetic machinery of DNA replication. Cell cycle regulation of E2F activity is mediated through its association with the tumor suppressor Rb gene product. To examine the evolutionary conservation of the E2F-1 protein sequence and its developmental expression pattern we have isolated and sequenced the chick E2F-1 gene (chE2F-1) cDNA. The chicken protein is 34 amino acids (a.a) shorter than its human counterpart (403/437 a.a.) but has extremely web conserved bHLH and pRb binding domains, with respectively 94% and 83% identity. The position of the leucine zipper is also strictly conserved thereby accounting for ability of E2F-1 to form heterodimers with human and chicken DP-1. E2F-1 expression was analysed in synchronized cells as well as in embryonic or newborn chick tissues and appears to be closely correlated to the cell proliferation rate. In situ hybridization studies have shown very high expression levels in the neuroretina during the early stages of embryonic development when active nenroblast division occurs. Tn contrast, a sharp down-regulation is observed when cells become postmitotic. Overexpression of the chE2F-1 protein leads to oncogenic transformation only when a truncated version of the transgene lacking the pRb binding domain is used; the full length protein either has no effect or may be deleterious for cell survival.			PASTEAU, S (corresponding author), ECOLE NORMALE SUPER LYON,INRA,BIOL MOLEC & CELLULAIRE LAB,CNRS,ENS,UMR49,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE.			Trembleau, Alain/0000-0002-8290-0795				BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DOU QP, 1994, J BIOL CHEM, V269, P1306; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAYES TE, 1991, NEW BIOL, V3, P259; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOOSS K, 1995, ONCOGENE, V9, P1529; JORDAN KL, 1994, ONCOGENE, V9, P1177; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KITAGAWA M, 1995, ONCOGENE, V10, P229; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NEVINS JR, 1992, SCIENCE, V258, P424; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Sambrook J, 1989, MOL CLONING LABORATO; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU X, 1994, P NATL ACAD SCI USA, V91, P36602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357	48	9	10	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1475	1486						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478572				2022-12-28	WOS:A1995TC53500006
J	ALTOMARE, DA; GUO, K; CHENG, JQ; SONODA, G; WALSH, K; TESTA, JR				ALTOMARE, DA; GUO, K; CHENG, JQ; SONODA, G; WALSH, K; TESTA, JR			CLONING, CHROMOSOMAL LOCALIZATION AND EXPRESSION ANALYSIS OF THE MOUSE AKT2 ONCOGENE	ONCOGENE			English	Article						ONCOGENE; GENE MAPPING; DIFFERENTIATION; MUSCLE	FLUORESCENCE INSITU HYBRIDIZATION; MOLECULAR-CLONING; PROTEIN-KINASE; GENE; SUBFAMILY; HOMOLOGY; REGION	We isolated mouse cDNA clones containing the entire coding region of the putative oncogene Akt2, Sequence analysis revealed that, like its human homolog, Akt2 encodes a protein-serine/threonine kinase containing a pleckstrin homology domain at its amino terminus, Fluorescence in situ hybridization of the mouse cDNA to rodent metaphase spreads demonstrated that the Akt2 gene maps to mouse chromosome band 7B1 and rat chromosome 1q22. Expression levels of mouse Akt2 mRNA and Akt2 protein varied among tissues, with the highest levels in skeletal muscle, Akt2 expression was low in a multipotent fibroblast cell line, but it was upregulated when these cells were transformed with Myod and induced to differentiate into myocytes. These data demonstrate that Akt2 expression is activated during cellular differentiation and suggest that it functions in the signaling pathways of some adult tissues.	FOX CHASE CANC CTR,DEPT MED ONCOL,PHILADELPHIA,PA 19111; TUFTS UNIV,ST ELIZABETHS MED CTR,SCH MED,DEPT CARDIOVASC RES,BOSTON,MA 02135	Fox Chase Cancer Center; St. Elizabeth's Medical Center; Tufts University					NCI NIH HHS [P30 CA006927, R01 CA077429, CA 09035, CA-06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077429, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFER PJ, 1991, EUR J BIOCHEM, V210, P475; DATTA K, 1995, MOL CELL BIOL, V15, P2304; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FRANKE TF, 1994, ONCOGENE, V9, P141; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASLAM RJ, 1993, NATURE, V36, P309; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVAN G, 1991, GENOMICS, V10, P699, DOI 10.1016/0888-7543(91)90455-N; Maltais L. J., 1994, Mouse Genome, V92, P62; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; ROPERS HH, 1991, CYTOGENET CELL GENET, V58, P751, DOI 10.1159/000133179; Sambrook J, 1989, MOL CLONING LABORATO; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Staal SP, 1988, GENOMICS, V2, P96, DOI 10.1016/0888-7543(88)90114-0; TESTA JR, 1992, CYTOGENET CELL GENET, V60, P247, DOI 10.1159/000133350; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	30	79	84	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1055	1060						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566964				2022-12-28	WOS:A1995RX18000007
J	ROLLING, C; TRETON, D; BECKMANN, P; GALANAUD, P; RICHARD, Y				ROLLING, C; TRETON, D; BECKMANN, P; GALANAUD, P; RICHARD, Y			JAK3 ASSOCIATES WITH THE HUMAN INTERLEUKIN-4 RECEPTOR AND IS TYROSINE-PHOSPHORYLATED FOLLOWING RECEPTOR TRIGGERING	ONCOGENE			English	Article						JAK3; PTK; PTP; IL4R; HUMAN B-CELLS	SIGNAL-TRANSDUCTION; GAMMA-CHAIN; INTERFERON-ALPHA/BETA; FUNCTIONAL COMPONENT; IGE SYNTHESIS; B-CELLS; PROTEIN; KINASE; IL-4; IGG4	In human B cells, interleukin 4 (IL4) acts in regulating proliferation, antigen expression, isotype switching and differentiation. These different effects are mediated through the LL4R complex including the IL2R gamma chain (gamma c) and a specific p130/140 binding unit referred below as human Interleukin 4 Receptor (IL4-R). Here, we studied the signal transduction events following LT4R activation and leading to CD23 expression on resting B cells. We demonstrate that LL4R triggering induced the tyrosine phosphorylation of JAK3 and of a p170 protein. Coimmunoprecipitation of JAK3 with the IL4R suggests a physical association which exists prior to IL4R complex stimulation. Orthovanadate treatment, while having no effect on IL4-induced p130 phosphorylation, leads to the hyperphosphorylation of the p170 and inhibits IL4-induced CD23 expression. These suggest that two mandatory steps exist in early IL4 signaling: one controlled by JAK3 activation and the other by the p170 phosphoprotein.	INST PARIS SUD CYTOKINES,INSERM,U131,CLAMART,FRANCE; IMMUNEX CORP,SEATTLE,WA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Immunex Corporation			RICHARD, Yolande/B-7926-2008	RICHARD, Yolande/0000-0001-8560-9250				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; DELESPESSE G, 1992, IMMUNOL REV, V125, P77, DOI 10.1111/j.1600-065X.1992.tb00626.x; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KOETTNITZ K, 1993, EUR J IMMUNOL, V23, P988, DOI 10.1002/eji.1830230437; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; MIRESLUIS AR, 1991, J BIOL CHEM, V266, P18113; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PARK LS, 1987, J EXP MED, V166, P476, DOI 10.1084/jem.166.2.476; PAUL WE, 1991, BLOOD, V77, P1859; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RICHARD Y, 1986, EUR J IMMUNOL, V16, P1303, DOI 10.1002/eji.1830161019; ROLLING CH, 1994, IN PRESS LEUCOCYTE T, V5; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SEDIN DC, 1994, P NATL ACAD SCI USA, V91, P2140; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; VANDERKUUR JA, 1994, J BIOL CHEM, V34, P21709; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WALTING D, 1993, NATURE, V366, P166; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1992, P NATL ACAD SCI USA, V90, P4032; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	36	26	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1757	1761						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7538655				2022-12-28	WOS:A1995QX46900009
J	DAKSIS, JI; LU, RY; FACCHINI, LM; MARHIN, WW; PENN, LJZ				DAKSIS, JI; LU, RY; FACCHINI, LM; MARHIN, WW; PENN, LJZ			MYC INDUCES CYCLIN D1 EXPRESSION IN THE ABSENCE OF DE-NOVO PROTEIN-SYNTHESIS AND LINKS MITOGEN-STIMULATED SIGNAL-TRANSDUCTION TO THE CELL-CYCLE	ONCOGENE			English	Review							HUMAN C-MYC; DNA-BINDING; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; GROWTH-FACTOR; ORNITHINE DECARBOXYLASE; RETINOBLASTOMA PROTEIN; MESSENGER-RNA; NEGATIVE AUTOREGULATION; MAMMALIAN FIBROBLASTS	Mitogen-activated signal transduction frequently leads to the induction of the c-myc proto-oncogene, but the subsequent molecular events downstream of Myc protein expression which promote cell cycle progression remain unclear. To study Myc-specific effects, without the complexity of the broader proliferative response evoked by serum, we employed the MycER-inducible system in the non-transformed Rat-1 cell line. We demonstrate that activation of wild-type, but not mutant, MycER is sufficient to transiently induce cyclin D1 RNA as well as protein expression to physiological levels, and promote G0/G1 to S phase transition of the cell cycle. Stimulation of endogenous cyclin D1 RNA is rapid and clearly evident within 30 min of MycER-activation, reaching a peak at 3 h. Nuclear run-on analysis demonstrates that this induction occurs at the transcriptional level with a fivefold increase in the rate of transcription. Moreover, MycER induces cyclin D1 transcription with equal efficacy in the presence or absence of de novo protein synthesis. Our work shows that Myc and cyclin D1 lie consecutively in a major proliferation-control pathway, and together create a pivotal connection between signal transduction and cell cycle control.	UNIV TORONTO, TORONTO M5G 1X8, ON, CANADA; HOSP SICK CHILDREN, DEPT MICROBIOL, TORONTO M5G 1X8, ON, CANADA; HOSP SICK CHILDREN, DEPT IMMUNOL & CANC RES, TORONTO M5G 1X8, ON, CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; ASKEW DS, 1991, ONCOGENE, V6, P1915; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P71; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; COCKS BG, 1992, J BIOL CHEM, V267, P12307; CROUCH DH, 1993, ONCOGENE, V8, P1849; DAKSIS JI, 1992, VIROLOGY, V189, P196, DOI 10.1016/0042-6822(92)90695-L; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FACCHINI LM, 1994, CELL GROWTH DIFFER, V5, P637; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HERBER B, 1994, ONCOGENE, V9, P1295; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KARN J, 1989, ONCOGENE, V4, P773; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMIE GA, 1991, ONCOGENE, V6, P439; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOVEC H, 1994, ONCOGENE, V9, P323; LUKAS J, 1994, ONCOGENE, V9, P707; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NIKAIDO T, 1991, EXP CELL RES, V192, P102, DOI 10.1016/0014-4827(91)90163-O; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PALMERO I, 1993, ONCOGENE, V8, P1049; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PENA A, 1993, J BIOL CHEM, V268, P27277; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PENN LJZ, 1990, C MYC EVIDENCE MULTI, P69; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REDDY CD, 1992, ONCOGENE, V7, P2085; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG CL, 1993, ONCOGENE, V8, P519; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Sambrook J, 1989, MOL CLONING LABORATO; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WATERS CM, 1991, ONCOGENE, V6, P797; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	105	225	229	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3635	3645						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7526316				2022-12-28	WOS:A1994PT39200027
J	NADA, S; OKADA, M; AIZAWA, S; NAKAGAWA, H				NADA, S; OKADA, M; AIZAWA, S; NAKAGAWA, H			IDENTIFICATION OF MAJOR TYROSINE-PHOSPHORYLATED PROTEINS IN CSK-DEFICIENT CELLS	ONCOGENE			English	Article							SRC FAMILY; EMBRYO FIBROBLASTS; P53-DEFICIENT MICE; ANTIGEN RECEPTOR; CD4 RECEPTOR; KINASES; SUBSTRATE; GENE; ASSOCIATION; ADHESION	Csk is a non-receptor protein-tyrosine kinase that acts as a negative regulator of Src family tyrosine kinases. Csk-deficient mouse embryos exhibited developmental defects including inability to turn and impaired formation of neural tube. In these embryos, an accumulation of tyrosine phosphorylated proteins was observed as a consequence of constitutive activation of Src family kinases. In order to identify those tyrosine phosphorylated proteins, we established a Csk-deficient cell line from embryos lacking both Csk and the anti-oncogene product p53. On surveying several proteins known as Src substrates, we found that phosphorylation level of p80/85 (cortactin) was markedly elevated in the Csk-deficient cells. Enhancement of cortactin phosphorylation was also seen in Csk-deficient embryos. Furthermore, immunoprecipitated Src was able to directly phosphorylate cortactin in vitro. Thus, we suggest that cortactin is a good substrate of activated Src family kinases in vivo and may play important roles in signaling pathways mediated by Src family kinases.	KUMAMOTO UNIV, SCH MED, INST MOLEC EMBRYOL & GENET, DEPT MORPHOGENESIS, KUMAMOTO 860, JAPAN	Kumamoto University	NADA, S (corresponding author), OSAKA UNIV, INST PROT RES, DIV PROT METAB, 3-2 YAMADAOKA, SUITA, OSAKA 565, JAPAN.							BELL GM, 1992, MOL CELL BIOL, V12, P5548, DOI 10.1128/MCB.12.12.5548; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; EISEMAN E, 1992, NATURE, V355, P78; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HARVEY M, 1993, ONCOGENE, V8, P2457; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KOZMA LM, 1990, MOL CELL BIOL, V10, P837, DOI 10.1128/MCB.10.2.837; MAA MC, 1992, ONCOGENE, V7, P2429; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; SATO N, 1992, J CELL SCI, V103, P131; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; TSUKADA T, 1993, ONCOGENE, V8, P3313; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631	38	54	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3571	3578						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7526315				2022-12-28	WOS:A1994PT39200020
J	VARNUM, BC; LIM, RW; HERSCHMAN, HR				VARNUM, BC; LIM, RW; HERSCHMAN, HR			CHARACTERIZATION OF TIS7, A GENE INDUCED IN SWISS 3T3 CELLS BY THE TUMOR PROMOTER TETRADECANOYL PHORBOL ACETATE	ONCOGENE			English	Note									UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT BIOL CHEM,WARREN HALL,900 VET AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,BIOMED & ENVIRONM SCI LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM 24797, 2T32 GM07104] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007104, R01GM024797] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; ARENANDER AT, 1989, IN PRESS J NEUROSCI; BURD PR, 1987, J IMMUNOL, V139, P3126; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Curran T, 1988, ONCOGENE HDB, P307; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; KUJUBU DA, 1987, ONCOGENE, V1, P257; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; LIM RW, 1989, MOL CELL BIOL, V9, P1790, DOI 10.1128/MCB.9.4.1790; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; RYSECK RP, 1989, EXP CELL RES, V180, P266, DOI 10.1016/0014-4827(89)90230-9; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SKUP D, 1982, NUCLEIC ACIDS RES, V10, P3069, DOI 10.1093/nar/10.10.3069; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TIPPETTS MT, 1988, MOL CELL BIOL, V8, P4570, DOI 10.1128/MCB.8.10.4570; TIRONE F, 1989, P NATL ACAD SCI USA, V86, P2088, DOI 10.1073/pnas.86.6.2088; VARNUM BC, 1989, ONCOGENE, V4, P119; YAMAMOTO KR, 1976, ANNU REV BIOCHEM, V45, P721, DOI 10.1146/annurev.bi.45.070176.003445	21	41	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1989	4	10					1263	1265						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2797820				2022-12-28	WOS:A1989AU50800015
J	STARNAUD, R; CRAIG, J; MCBURNEY, MW; PAPKOFF, J				STARNAUD, R; CRAIG, J; MCBURNEY, MW; PAPKOFF, J			THE INT-1 PROTO-ONCOGENE IS TRANSCRIPTIONALLY ACTIVATED DURING NEUROECTODERMAL DIFFERENTIATION OF P19 MOUSE EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article									UNIV OTTAWA,DEPT MED,451 SMYTH RD,OTTAWA K1H 8M5,ONTARIO,CANADA; SYNTEX INC,CANC & DEV BIOL,PALO ALTO,CA 94304	University of Ottawa; Syntex Corporation								AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BELL JC, 1986, MOL CELL BIOL, V6, P617, DOI 10.1128/MCB.6.2.617; BENDER W, 1987, CELL, V50, P519, DOI 10.1016/0092-8674(87)90023-7; BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KEMLER R, 1981, J EMBRYOL EXP MORPH, V64, P45; LAZARUS P, 1988, ONCOGENE, V3, P517; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1987, ONCOGENE, V1, P243; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PAPKOFF J, 1989, IN PRESS MOL CELL BI; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PATERNO GD, 1989, UNPUB; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SCHUURING E, 1989, MOL CELL BIOL, V9, P1357, DOI 10.1128/MCB.9.3.1357; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; STAINES WA, 1987, NEUROSCIENCE, V23, P571, DOI 10.1016/0306-4522(87)90077-7; STARNAUD R, 1988, ONCOGENE, V3, P553; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; UZVOLGYI E, 1988, P NATL ACAD SCI USA, V85, P3034, DOI 10.1073/pnas.85.9.3034; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; ZAMBONI L, 1967, J CELL BIOL, V35, pA148	41	38	38	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1077	1080						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2674852				2022-12-28	WOS:A1989AM53100004
J	TONIN, PN; YEGER, H; STALLINGS, RL; SRINIVASAN, PR; LEWIS, WH				TONIN, PN; YEGER, H; STALLINGS, RL; SRINIVASAN, PR; LEWIS, WH			AMPLIFICATION OF N-MYC AND ORNITHINE DECARBOXYLASE GENES IN HUMAN NEURO-BLASTOMA AND HYDROXYUREA-RESISTANT HAMSTER-CELL LINES	ONCOGENE			English	Article									HOSP SICK CHILDREN,DEPT PATHOL,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV CALIF LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545; COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); United States Department of Energy (DOE); Los Alamos National Laboratory; Columbia University	TONIN, PN (corresponding author), UNIV TORONTO,DEPT MICROBIOL,150 COLL ST,TORONTO M5S 1A8,ONTARIO,CANADA.		Stallings, Raymond/A-7213-2008					ADAIR GM, 1983, SOMAT CELL GENET, V9, P477, DOI 10.1007/BF01543048; ALT FW, 1985, UCLA S MOL CELLULAR, V20, P233; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHAMPAGNE E, 1988, EUR J IMMUNOL, V18, P1033, DOI 10.1002/eji.1830180710; DEBATISSE M, 1986, MOL CELL BIOL, V6, P1776, DOI 10.1128/MCB.6.5.1776; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; HAMLIN JL, 1984, INT REV CYTOL, V90, P31, DOI 10.1016/S0074-7696(08)61487-4; KANDA N, 1987, CANCER RES, V47, P3291; KINZLER KW, 1986, P NATL ACAD SCI USA, V83, P1031, DOI 10.1073/pnas.83.4.1031; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; LEWIS WH, 1983, MOL CELL BIOL, V3, P1053, DOI 10.1128/MCB.3.6.1053; MICHALOPOULOS EE, 1985, HUM GENET, V70, P157, DOI 10.1007/BF00273074; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; RUSSELL DH, 1985, DRUG METAB REV, V16, P1, DOI 10.3109/03602538508991430; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P111; SHILOH Y, 1985, P NATL ACAD SCI USA, V82, P3761, DOI 10.1073/pnas.82.11.3761; SHILOH Y, 1986, CANCER RES, V46, P5297; SRINIVASAN PR, 1987, J BIOL CHEM, V262, P12871; STALLINGS RL, 1982, J HERED, V73, P399, DOI 10.1093/oxfordjournals.jhered.a109687; STALLINGS RL, 1981, SOMAT CELL GENET, V7, P683, DOI 10.1007/BF01538757; STARK GM, 1985, ANN REV BIOCH, V53, P447; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TONIN PN, 1987, CYTOGENET CELL GENET, V45, P102, DOI 10.1159/000132438; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; VANDERBLIEK AM, 1986, MOL CELL BIOL, V6, P1671, DOI 10.1128/MCB.6.5.1671; WAHL GM, 1983, MOL CELL BIOL, V3, P2066, DOI 10.1128/MCB.3.11.2066; WINQVIST R, 1986, CYTOGENET CELL GENET, V42, P133, DOI 10.1159/000132266; WRIGHT JA, 1987, SOMAT CELL MOLEC GEN, V13, P155, DOI 10.1007/BF01534695; YANG-FENG T L, 1987, Genomics, V1, P77, DOI 10.1016/0888-7543(87)90108-X	35	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1117	1121						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2780050				2022-12-28	WOS:A1989AM53100010
J	LIU, E; SANTOS, G; LEE, WMF; OSBORNE, CK; BENZ, CC				LIU, E; SANTOS, G; LEE, WMF; OSBORNE, CK; BENZ, CC			EFFECTS OF C-MYC OVEREXPRESSION ON THE GROWTH-CHARACTERISTICS OF MCF-7 HUMAN-BREAST CANCER-CELLS	ONCOGENE			English	Article									UNIV N CAROLINA,CURRICULUM GENET,CHAPEL HILL,NC 27599; UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143; UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DIV ONCOL,SAN ANTONIO,TX 78284	University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Francisco; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	LIU, E (corresponding author), UNIV N CAROLINA,LINEBERGER CANC RES CTR,DEPT MED,CB 7295,ROOM 227,CHAPEL HILL,NC 27599, USA.		Liu, Edison/C-4141-2008		NATIONAL CANCER INSTITUTE [K08CA001036, P01CA044768, R01CA036773] Funding Source: NIH RePORTER; NCI NIH HHS [CA-44768, 7-K08-CA01036-03, CA 36773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENZ C, 1986, CANCER RES, V46, P2276; BENZ C, 1987, MOL PHARMACOL, V32, P13; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARLONI G, 1988, FEBS LETT, V233, P269; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; EVANS GI, 1985, MOL CELL BIOL, V6, P3610; EVANS JL, 1987, J IMMUNOL, V139, P3497; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FRIEDMAN MA, 1981, CANCER, V47, P134, DOI 10.1002/1097-0142(19810101)47:1<134::AID-CNCR2820470122>3.0.CO;2-M; HOFFMAN PG, 1980, CANCER, V46, P2801, DOI 10.1002/1097-0142(19801215)46:12+<2801::AID-CNCR2820461412>3.0.CO;2-W; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAVIALLE C, 1988, ONCOGENE, V3, P335; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; LOKE SL, 1988, AM J PATHOL, V131, P29; Maniatis T., 1982, MOL CLONING; OSBORNE CK, 1985, CANCER RES, V45, P584; SCHWAB M, 1986, MOL CELL BIOL, V6, P2752, DOI 10.1128/MCB.6.7.2752; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAUB R, 1982, P NATL ACAD SCI USA, V79, P7824; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VARLEY JM, 1987, ONCOGENE, V1, P423; VARLEY JM, 1988, ONCOGENE, V3, P87; YOKOTA S, 1987, J IMMUNOL, V139, P2810; ZERLIN M, 1987, ONCOGENE, V1, P19	39	16	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					979	984						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2668848				2022-12-28	WOS:A1989AJ29700005
J	EICK, D; POLACK, A; KOFLER, E; BORNKAMM, GW				EICK, D; POLACK, A; KOFLER, E; BORNKAMM, GW			THE BLOCK OF ELONGATION IN C-MYC EXON-1 IS ABOLISHED IN BURKITTS-LYMPHOMA CELL-LINES WITH VARIANT TRANSLOCATION	ONCOGENE			English	Article											EICK, D (corresponding author), UNIV FREIBURG,INST MED MIKROBIOL & HYG,VIROL ABT,HERMANN HERDER STR 11,D-7800 FREIBURG,FED REP GER.							AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BORNKAMM GW, 1980, BLUT, V40, P167, DOI 10.1007/BF01008574; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; BOYM A, 1968, SCAND J CLIN LAB S97, V21, P77; BROOME HE, 1987, MOL CELL BIOL, V7, P2988, DOI 10.1128/MCB.7.8.2988; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DENNY CT, 1985, MOL CELL BIOL, V5, P3199, DOI 10.1128/MCB.5.11.3199; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRE F, 1987, ONCOGENE, V1, P387; FONATSCH C, 1982, INT J CANCER, V30, P321, DOI 10.1002/ijc.2910300311; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GAZIN C, 1986, EMBO J, V5, P2241, DOI 10.1002/j.1460-2075.1986.tb04491.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HALUSKA FG, 1986, NATURE, V324, P158, DOI 10.1038/324158a0; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; HOLLIS GF, 1984, NATURE, V307, P752, DOI 10.1038/307752a0; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; LACY J, 1987, P NATL ACAD SCI USA, V84, P5838, DOI 10.1073/pnas.84.16.5838; LENOIR GM, 1982, NATURE, V298, P474, DOI 10.1038/298474a0; LENOIR GM, 1985, IARC SCI PUBL, V60, P309; LEY TJ, 1982, P NATL ACAD SCI-BIOL, V79, P4775, DOI 10.1073/pnas.79.15.4775; MANIATIS T, 1982, MOL CLONING LABORATO; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1987, ONCOGENE, V1, P243; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; POLACK A, 1987, EMBO J, V6, P2959, DOI 10.1002/j.1460-2075.1987.tb02601.x; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RUPPERT C, 1986, EMBO J, V5, P1897, DOI 10.1002/j.1460-2075.1986.tb04442.x; SCHNEIDERSCHAULIES J, 1987, EUR J IMMUNOL, V17, P713, DOI 10.1002/eji.1830170521; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUN LK, 1986, NUCLEIC ACIDS RES, V14, P4037, DOI 10.1093/nar/14.10.4037; SZAJNERT MF, 1987, NUCLEIC ACIDS RES, V15, P4553, DOI 10.1093/nar/15.11.4553; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; WALDMANN TA, 1982, ADV IMMUNOL, V32, P1, DOI 10.1016/S0065-2776(08)60720-8; WIMAN KG, 1984, P NATL ACAD SCI-BIOL, V81, P6798, DOI 10.1073/pnas.81.21.6798; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x	52	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					397	403						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3078949				2022-12-28	WOS:A1988Q773900007
J	MORIKE, M; QUAISER, A; MULLER, D; MONTENARH, M				MORIKE, M; QUAISER, A; MULLER, D; MONTENARH, M			EARLY GENE-EXPRESSION AND CELLULAR DNA-SYNTHESIS AFTER STIMULATION OF QUIESCENT NIH3T3 CELLS WITH SERUM OR PURIFIED SIMIAN-VIRUS 40	ONCOGENE			English	Article									UNIV ULM,DEPT BIOCHEM,POB 4066,D-7900 ULM,FED REP GER	Ulm University			Montenarh, Mathias/AAB-6689-2020					Baserga R., 1976, MULTIPLICATION DIVIS; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; CAMPISI J, 1984, MOL CELL BIOL, V4, P1807, DOI 10.1128/MCB.4.9.1807; CHOU JY, 1975, J VIROL, V15, P145, DOI 10.1128/JVI.15.1.145-150.1975; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DENHARDT DT, 1986, BIOCH BIOPHYS ACTA, V865, P82; DEUEL TF, 1983, SCIENCE, V221, P1348, DOI 10.1126/science.6310754; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; GERSHON D, 1966, P NATL ACAD SCI USA, V56, P918, DOI 10.1073/pnas.56.3.918; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HELDIN CH, 1985, MOL CELL ENDOCRINOL, V39, P169, DOI 10.1016/0303-7207(85)90061-9; HENRY P, 1966, P NATL ACAD SCI USA, V56, P1170, DOI 10.1073/pnas.56.4.1170; HISCOTT JB, 1981, J VIROL, V37, P802, DOI 10.1128/JVI.37.2.802-812.1981; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; IDE T, 1977, P NATL ACAD SCI USA, V74, P3189, DOI 10.1073/pnas.74.8.3189; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KHANDJIAN EW, 1980, P NATL ACAD SCI-BIOL, V77, P1476, DOI 10.1073/pnas.77.3.1476; KIT S, 1966, VIROLOGY, V29, P69, DOI 10.1016/0042-6822(66)90197-8; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEOF EB, 1982, EXP CELL RES, V141, P107, DOI 10.1016/0014-4827(82)90073-8; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MONTENARH M, 1984, J VIROL, V49, P658, DOI 10.1128/JVI.49.3.658-664.1984; MOORE JP, 1986, J BIOL CHEM, V261, P8158; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; PLEDGER WJ, 1981, P NATL ACAD SCI-BIOL, V78, P4358, DOI 10.1073/pnas.78.7.4358; POCKL E, 1980, J VIROL, V35, P8; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; POSTEL EH, 1976, VIROLOGY, V73, P206, DOI 10.1016/0042-6822(76)90075-1; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; ROSENBERG BH, 1981, J VIROL METHODS, V3, P167, DOI 10.1016/0166-0934(81)90051-3; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SMITH HS, 1971, VIROLOGY, V44, P357; SOPRANO KJ, 1979, P NATL ACAD SCI US, V79, P3885; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; THOMAS G, 1981, P NATL ACAD SCI-BIOL, V78, P5712, DOI 10.1073/pnas.78.9.5712; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEIL R, 1978, BIOCHIM BIOPHYS ACTA, V516, P301, DOI 10.1016/0304-419X(78)90012-4; WINBERRY L, 1985, VIROLOGY, V147, P154, DOI 10.1016/0042-6822(85)90235-1; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210; [No title captured]	61	15	15	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					151	158						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	2842713				2022-12-28	WOS:A1988Q053400004
J	VANDERFELTZ, MJM; SHIVJI, MKK; GROSVELD, G; WIEDEMANN, LM				VANDERFELTZ, MJM; SHIVJI, MKK; GROSVELD, G; WIEDEMANN, LM			CHARACTERIZATION OF THE TRANSLOCATION BREAKPOINT IN A PATIENT WITH PHILADELPHIA POSITIVE, BCR NEGATIVE ACUTE LYMPHOBLASTIC-LEUKEMIA	ONCOGENE			English	Article									INST CANC RES,CHESTER BEATTY LABS,LEUKAEMIA RES FUND CTR,237 FULHAM RD,LONDON SW3 6JB,ENGLAND; ERASMUS UNIV,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Erasmus University Rotterdam			Wiedemann, Leanne/E-3316-2010	Wiedemann, Leanne/0000-0002-0964-4676				BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; DEKLEIN A, 1986, BLOOD, V68, P1369; ERIDANI S, 1987, LEUKEMIA RES, V11, P965, DOI 10.1016/0145-2126(87)90114-7; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORD AM, 1983, EMBO J, V2, P997, DOI 10.1002/j.1460-2075.1983.tb01533.x; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; KURZROCK R, 1987, BLOOD, V70, P1584; RIBEIRO RC, 1987, BLOOD, V70, P948; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUBIN CM, 1988, P NATL ACAD SCI USA, V85, P2795, DOI 10.1073/pnas.85.8.2795; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; VANKESSEL AHMG, 1981, SOMAT CELL GENET, V7, P645, DOI 10.1007/BF01538754; VANKESSEL AHMG, 1981, HUM GENET, V58, P162, DOI 10.1007/BF00278702; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; 1981, CANCER GENET CYTOGEN, V4, P101	28	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					215	219						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	3166123				2022-12-28	WOS:A1988Q053400013
J	BIGNAMI, M; ROSA, S; LAROCCA, SA; FALCONE, G; TATO, F				BIGNAMI, M; ROSA, S; LAROCCA, SA; FALCONE, G; TATO, F			DIFFERENTIAL INFLUENCE OF ADJACENT NORMAL-CELLS ON THE PROLIFERATION OF MAMMALIAN-CELLS TRANSFORMED BY THE VIRAL ONCOGENES MYC, RAS AND SRC	ONCOGENE			English	Article									UNIV ROME LA SAPIENZA,DIPARTIMENTO BIOL CELLULARE & SVILUPPO,VIA APULI,I-00185 ROME,ITALY; IST SUPER SANITA,TOSSICOL APPLICATA LAB,I-00161 ROME,ITALY	Sapienza University Rome; Istituto Superiore di Sanita (ISS)			Falcone, Germana/A-3735-2016; la rocca, severina anna/D-8028-2011	Falcone, Germana/0000-0002-3508-7623				ATKINSON MM, 1981, J CELL BIOL, V91, P573, DOI 10.1083/jcb.91.2.573; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P191, DOI 10.1007/BF01871629; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BERTRAM JS, 1979, CANCER RES, V39, P3502; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CHANG CC, 1985, P NATL ACAD SCI USA, V82, P5360, DOI 10.1073/pnas.82.16.5360; CONNAN G, 1985, NATURE, V314, P277, DOI 10.1038/314277a0; DAVIDSON JS, 1985, CARCINOGENESIS, V6, P1353, DOI 10.1093/carcin/6.9.1353; Diamond L, 1980, Adv Cancer Res, V32, P1, DOI 10.1016/S0065-230X(08)60360-7; DOTTO GP, 1985, NATURE, V318, P472; FALCONE G, 1987, EXP CELL RES, V168, P273, DOI 10.1016/0014-4827(87)90435-6; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HSIAO WLW, 1986, MOL CELL BIOL, V6, P1943, DOI 10.1128/MCB.6.6.1943; HSU YM, 1984, P NATL ACAD SCI-BIOL, V81, P2107, DOI 10.1073/pnas.81.7.2107; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEHTA PP, 1986, CELL, V44, P187, DOI 10.1016/0092-8674(86)90497-6; MONDAL S, 1976, NATURE, V260, P710, DOI 10.1038/260710a0; MONDAL S, 1976, CANCER RES, V36, P2254; MORDAN LJ, 1983, CANCER RES, V43, P4062; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PONTEN J, 1968, J CELL SCI, V3, P603; PONTEN J, 1971, SPONTANEOUS VIRUS IN; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; REZNIKOFF CA, 1973, CANCER RES, V33, P3239; SHAW J, 1985, J VIROL, V56, P943, DOI 10.1128/JVI.56.3.943-950.1985; STOKER MGP, 1966, J CELL SCI, V1, P297; STOKER MGP, 1967, J CELL SCI, V2, P293; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; WEISS RA, 1970, EXP CELL RES, V63, P1, DOI 10.1016/0014-4827(70)90326-5; WHITTENBERGER B, 1977, P NATL ACAD SCI USA, V74, P2251, DOI 10.1073/pnas.74.6.2251; WIESER RJ, 1985, EXP CELL RES, V158, P493, DOI 10.1016/0014-4827(85)90472-0	37	45	45	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					509	514						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	3287279				2022-12-28	WOS:A1988N434800013
J	KESHET, E; ROSENBERG, MP; MERCER, JA; PROPST, F; VANDEWOUDE, GF; JENKINS, NA; COPELAND, NG				KESHET, E; ROSENBERG, MP; MERCER, JA; PROPST, F; VANDEWOUDE, GF; JENKINS, NA; COPELAND, NG			DEVELOPMENTAL REGULATION OF OVARIAN-SPECIFIC MOS EXPRESSION	ONCOGENE			English	Article									NCI,FREDERICK CANC RES FACIL,BRI BASIC RES PROGRAM,POB B,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Keshet, Eli/GQR-0445-2022	Mercer, John/0000-0003-0307-4438	NCI NIH HHS [N01-CO-23909] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO023909] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachvarova R, 1985, Dev Biol (N Y 1985), V1, P453; BROWER PT, 1981, DEV BIOL, V86, P373, DOI 10.1016/0012-1606(81)90195-0; CASCIO SM, 1982, DEV BIOL, V89, P397, DOI 10.1016/0012-1606(82)90328-1; CLEGG KB, 1983, DEV BIOL, V95, P331, DOI 10.1016/0012-1606(83)90034-9; DEKEL N, 1979, BIOL REPROD, V20, P191, DOI 10.1095/biolreprod20.2.191; DELEON V, 1983, DEV BIOL, V98, P400, DOI 10.1016/0012-1606(83)90369-X; Eppig J J, 1985, Dev Biol (N Y 1985), V1, P313; EPPIG JJ, 1982, DEV BIOL, V89, P268, DOI 10.1016/0012-1606(82)90314-1; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HOGAN B, 1986, COLD SPRING HARBOUR; MALLER J, 1977, DEV BIOL, V58, P295, DOI 10.1016/0012-1606(77)90093-8; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; PEDERSEN T, 1969, ACTA ENDOCRINOL-COP, V62, P117, DOI 10.1530/acta.0.0620117; Pedersen T., 1972, Oogenesis., P361; PETERS H, 1969, ACTA ENDOCRINOL-COP, V62, P98, DOI 10.1530/acta.0.0620098; PHILPOTT CC, 1987, DEV BIOL, V121, P568, DOI 10.1016/0012-1606(87)90192-8; PIKO L, 1984, P NATL ACAD SCI-BIOL, V81, P488, DOI 10.1073/pnas.81.2.488; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, ONCOGENE, V2, P227; SETH A, 1987, P NATL ACAD SCI USA, V84, P3560, DOI 10.1073/pnas.84.11.3560; WOOD TG, 1983, J VIROL, V46, P726, DOI 10.1128/JVI.46.3.726-736.1983	24	61	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					235	240						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3353114				2022-12-28	WOS:A1988M593100005
J	FURUTA, Y; ILIC, D; KANAZAWA, S; TAKEDA, N; YAMAMOTO, T; AIZAWA, S				FURUTA, Y; ILIC, D; KANAZAWA, S; TAKEDA, N; YAMAMOTO, T; AIZAWA, S			MESODERMAL DEFECT IN LATE-PHASE OF GASTRULATION BY A TARGETED MUTATION OF FOCAL ADHESION KINASE, FAK	ONCOGENE			English	Article						MUTANT MOUSE; FAK; FOCAL ADHESION; CELL MOBILITY; MESODERM; CELL-EXTRACELLULAR MATRIX INTERACTION	PROTEIN-TYROSINE KINASE; EXTRACELLULAR-MATRIX; TUMOR-SUPPRESSOR; CELL-ADHESION; MOUSE EMBRYOS; GENE; EXPRESSION; FIBRONECTIN; BETA-1-INTEGRINS; PHOSPHORYLATION	FAK is a unique non-receptor protein tyrosine kinase that was found in cellular focal adhesions. An increasing number of in vitro observations has suggested that FAK mediates signaling through integrins brought about by interactions with extracellular matrix (ECM). It is highly tyrosine-phosphorylated in v-src-transformed cells and during embryogenesis. To clarify the function of FAK in cell-ECM interactions, embryonic phenotype of its mutant was analysed. FAK-deficient embryos could implant and initiate gastrulation normally, but showed abnormalities in. subsequent development. The abnormalities were characterized as a general deficiency in mesoderm, and the phenotype was quite similar to that caused by fibronectin-deficiency. The results suggest that FAK mediates fibronectin-integrin interactions uniquely at this stage of development, thereby playing an essential role in development of mesodermal cell lineages.	KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,DEPT MORPHOGENESIS,KUMAMOTO 860,JAPAN; UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN	Kumamoto University; University of Tokyo				ILIC, DUSKO/0000-0003-1647-0026				BARRY ST, 1994, J CELL SCI, V107, P2033; BOLEN JB, 1993, ONCOGENE, V8, P2025; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; CONLON RA, 1992, DEVELOPMENT, V116, P357; DAMSKY C, 1993, FASEB J, V7, P1320, DOI 10.1096/fasebj.7.14.8224605; DRAKE CJ, 1992, DEV DYNAM, V193, P83, DOI 10.1002/aja.1001930111; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GLUKHOVA MA, 1993, SEMIN CANCER BIOL, V4, P241; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ILIC D, 1995, BIOCHEM BIOPH RES CO, V209, P300, DOI 10.1006/bbrc.1995.1503; ILIC D, 1995, IN PRESS NATURE; KADOWAKI T, 1994, CANCER RES, V54, P291; KANAZAWA S, 1995, IN PRESS BIOCH BIOPH; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KOHMURA N, 1994, MOL CELL BIOL, V14, P6915, DOI 10.1128/MCB.14.10.6915; LINASK KK, 1988, DEV BIOL, V129, P315, DOI 10.1016/0012-1606(88)90378-8; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NAKAMURA N, 1993, J CELL SCI, V106, P1057; OCHIAI A, 1994, JPN J CANCER RES, V85, P266, DOI 10.1111/j.1349-7006.1994.tb02092.x; POLTE TR, 1994, J CELL BIOCHEM, V55, P106, DOI 10.1002/jcb.240550113; RISAU W, 1988, DEV BIOL, V125, P441, DOI 10.1016/0012-1606(88)90225-4; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; STEPHENS LE, 1993, J CELL BIOL, V123, P1607, DOI 10.1083/jcb.123.6.1607; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUTHERLAND AE, 1993, DEVELOPMENT, V119, P1175; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; YAGI T, 1994, ANAL BIOCHEM, V214, P70; YANG JT, 1993, DEVELOPMENT, V119, P1093; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	40	182	187	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					1989	1995						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478517				2022-12-28	WOS:A1995TF29700008
J	PAN, MG; WANG, YH; HIRSCH, DD; LABUDDA, K; STORK, PJS				PAN, MG; WANG, YH; HIRSCH, DD; LABUDDA, K; STORK, PJS			THE WNT-1 PROTOONCOGENE REGULATES MAP KINASE ACTIVATION BY MULTIPLE GROWTH-FACTORS IN PC12 CELLS	ONCOGENE			English	Article						WNT-1; GROWTH FACTORS; MAP KINASE; PC12 CELLS	DROSOPHILA HOMOLOG; XENOPUS EMBRYOS; PROTOONCOGENE; MESODERM; GENE; RAF; PHOSPHORYLATION; PLAKOGLOBIN; EXPRESSION; INHIBITION	PC12/Wnt-1 cells display morphological changes in response to stimulation by select growth factors but do not respond to NGF. Furthermore, stimulation by EGF can induce neuronal differentiation in these cells but not in wild type cells. We have found that in these cells, compared to wild type PC12 cells, FGF and EGF stimulation of MAP kinase activity is enhanced, while NGF stimulation of MAP kinase in diminished, Finally, in cells expressing Wnt-1, the effect of cyclic adenosine monophosphate (cAMP) on MAP kinase activation is reversed; cAMP stimulates MAP kinase in wild type PC12 cells but inhibits MAP kinase in PC12/Wnt-1 cells. These data suggest that Wnt-1 expression alters the specificity of growth factor signaling in neuronal cells.	OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DIV CARDIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V73, P215; Forrester LM, 1992, CURR OPIN GENET DEV, V2, P38, DOI 10.1016/S0959-437X(05)80319-3; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HO PL, 1992, J CELL PHYSIOL, V150, P647, DOI 10.1002/jcp.1041500326; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; ISONO F, 1994, J NEUROCHEM, V63, P1235; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KEIFER P, 1991, MOL CELL BIOL, V11, P5929; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MACHIDA CM, 1991, J CELL BIOL, V114, P1037, DOI 10.1083/jcb.114.5.1037; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RAMAKRISHNA NR, 1993, DEVELOPMENT S, V119, P95; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031	58	16	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2005	2012						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478519				2022-12-28	WOS:A1995TF29700010
J	PENG, ZY; CARTWRIGHT, CA				PENG, ZY; CARTWRIGHT, CA			REGULATION OF THE SRC TYROSINE KINASE AND SYP TYROSINE PHOSPHATASE BY THEIR CELLULAR-ASSOCIATION	ONCOGENE			English	Article						SRC; SYP; TYROSINE KINASE; TYROSINE PHOSPHATASE	HUMAN-COLON-CARCINOMA; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; PP60C-SRC PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; ACTIVATION; PHOSPHORYLATION; RECEPTOR; TRANSFORMATION; P60C-SRC; MITOSIS	The specific activity of the Src tyrosine kinase is elevated in human colon carcinoma cells. To identify Src-binding proteins that might upregulate Src activity in these cells, a human colon carcinoma lambda gt11 expression library was screened with purified, P-32-labeled Src. The SH-PTP2 (Syp) tyrosine phosphatase was isolated and shown to associate with Src. In vitro studies demonstrated that: (1) transforming F527 Src phosphorylates Syp, and (2) Syp dephosphorylates Src at Tyr 527. Both events are known to upregulate enzyme activity. Others have shown that overexpression of the receptor tyrosine phosphatase alpha in rat embryo fibroblasts results in Src activation by dephosphorylation of Tyr 527, cell transformation and tumorigenesis. Thus, transmembrane tyrosine phosphatases may be involved in cell transformation exerting at least some of their effects through activation of Src. To the best of our knowledge, this is the first identification of an intracellular tyrosine phosphatase which may activate Src by a similar mechanism.	STANFORD UNIV, SCH MED, DEPT MED, MED SCH LAB, STANFORD, CA 94305 USA	Stanford University					NIDDK NIH HHS [P30-DK38707, R29 DK43743] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707, R29DK043743] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BAGRODIA S, 1993, MOL CELL BIOL, V13, P1464, DOI 10.1128/MCB.13.3.1464; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DEMILIA JC, 1991, ONCOGENE, V6, P303; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; FANG KS, 1994, J BIOL CHEM, V269, P20194; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI RY, 1994, FEBS LETT, V343, P89, DOI 10.1016/0014-5793(94)80613-6; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; PARK J, 1995, MOL CELL BIOL, V15, P2374; PARK JS, 1993, ONCOGENE, V8, P2627; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STONE RL, 1994, J BIOL CHEM, V269, P31323; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	57	76	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	1995	11	10					1955	1962						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478513				2022-12-28	WOS:A1995TF29700004
J	BOYD, JM; GALLO, GJ; ELANGOVAN, B; HOUGHTON, AB; MALSTROM, S; AVERY, BJ; EBB, RG; SUBRAMANIAN, T; CHITTENDEN, T; LUTZ, RJ; CHINNADURAI, G				BOYD, JM; GALLO, GJ; ELANGOVAN, B; HOUGHTON, AB; MALSTROM, S; AVERY, BJ; EBB, RG; SUBRAMANIAN, T; CHITTENDEN, T; LUTZ, RJ; CHINNADURAI, G			BIK, A NOVEL DEATH-INDUCING PROTEIN SHARES A DISTINCT SEQUENCE MOTIF WITH BCL-2 FAMILY PROTEINS AND INTERACTS WITH VIRAL AND CELLULAR SURVIVAL-PROMOTING PROTEINS	ONCOGENE			English	Article						APOPTOSIS; BH3 DOMAIN; BCL-2 FAMILY; BIK; EBV BHRF1; E1B 19 KDA	FOLLICULAR LYMPHOMA; GENE; APOPTOSIS; HOMOLOG; SYSTEM; PURIFICATION; REGION; VIRUS	The survival-promoting activity of the Bcl-2 family of proteins appears to be modulated by interactions between various cellular proteins. We have identified a novel cellular protein, Bik, that interacts with the cellular survival-promoting proteins, Bcl-2 and Bcl-x(L), as well as the viral survival-promoting proteins, Epstein Barr virus-BHRF1 and adenovirus E1B-19 kDa, In transient transfection assays, Bik promotes cell death in a manner similar to the death-promoting members of the Bcl-2 family, Bar and Bah. This death-promoting activity of Bik can be suppressed by coexpression of Bcl-2, Bcl-x(L), EBV-BHRF1 and E1B-19 kDa proteins suggesting that Bik may be a common target for both cellular and viral anti-apoptotic proteins, While Bik does not show overt homology to the BH1 and BH2 conserved domains characteristic of the Bcl-2 family, it does share a 9 amino acid domain (BH3) with Bar and Bah which may be a critical determinant for the death-promoting activity of these proteins.	ST LOUIS UNIV,MED CTR,INST MOLEC VIROL,ST LOUIS,MO 63110; APOPTOSIS TECHNOL INC,CAMBRIDGE,MA 02139	Saint Louis University					NATIONAL CANCER INSTITUTE [R01CA033616, R01CA031719] Funding Source: NIH RePORTER; NCI NIH HHS [CA-33616, CA-31719] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BAKHSHI A, 1985, CELL, V41, P889; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, IN PRESS EMBO J; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FERNANDEZSARABI.MJ, 1993, NATURE, V366, P274; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KORSMEYER SJ, 1992, BLOOD, V80, P879; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; SUBRAMANIAN T, 1995, IN PRESS ONCOGENE; TARODI B, 1994, VIROLOGY, V201, P404, DOI 10.1006/viro.1994.1309; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WANG HG, 1994, ONCOGENE, V9, P2751; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	33	409	444	0	13	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1921	1928						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478623				2022-12-28	WOS:A1995TD09400030
J	CHOI, SS; PARK, IC; YUN, JW; SUNG, YC; HONG, SI; SHIN, HS				CHOI, SS; PARK, IC; YUN, JW; SUNG, YC; HONG, SI; SHIN, HS			A NOVEL BCL-2 RELATED GENE, BFL-1, IS OVEREXPRESSED IN STOMACH-CANCER AND PREFERENTIALLY EXPRESSED IN BONE-MARROW	ONCOGENE			English	Article						PROGRAMMED CELL DEATH (APOPTOSIS); BCL-2 RELATED GENES; CARCINOGENESIS	PROGRAMMED CELL-DEATH; SEQUENCE SIMILARITY; C-MYC; APOPTOSIS; PROTOONCOGENE; THYMOCYTES; SURVIVAL; PROTEIN; MICE	Programmed cell death (apoptosis) is an active process which is genetically encoded and plays an important role in several cellular activities such as embryonic development, deletion of autoreactive T-cells and homeostasis. Several genes regulating apoptosis have been reported, including p53, one of the tumor suppressor genes, c-myc, one of the proto-oncogenes, and various kinds of Bcl-2 related genes, A new cDNA clone which is homologous to Bcl-2, named as Bfl-1 were isolated from a human fetal liver at 22 week of gestation. This clone was identified by computer analysis of random cDNA sequences that were obtained in an effort to expand the expressed sequence tag (EST) databases to be used for human genome analysis. The homology was recognized by 72% amino acid identity to the murine Al gene, a member of the Bcl-2-related genes. The homology to the BH1 and BH2 domains of Bcl-2 was especially significant, suggesting that Bfl-1 is a new member of the Bcl-2-related genes. Bfl-1 is abundantly expressed in the bone marrow and at a low level in some other tissues. Interestingly, a correlation was noted between the expression level of Bh-l gene and the development of stomach cancer in eight sets of clinical samples. It is conceivable that Bfl-1 is involved in the promotion of the cell survival in the stomach cancer development or progression.	POHANG UNIV SCI & TECHNOL, DEPT LIFE SCI, POHANG 790784, SOUTH KOREA; KOREA CANC CTR HOSP, DEPT CLIN PATHOL, SEOUL 139240, SOUTH KOREA	Pohang University of Science & Technology (POSTECH); National Cancer Center - Korea (NCC)								BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CASTLE VP, 1993, AM J PATHOL, V143, P1543; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOI SS, 1995, IN PRESS MAMMALIAN G; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; HAGUE A, 1994, ONCOGENE, V9, P3367; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KANG HM, 1994, MOL CELLS, V4, P27; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LIN EY, 1993, J IMMUNOL, V151, P1979; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; McConkey David J., 1994, Trends in Cell Biology, V4, P370, DOI 10.1016/0962-8924(94)90087-6; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Osborne Barbara A., 1994, Trends in Cell Biology, V4, P394; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; Sambrook J., 1989, MOL CLONING, V1; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	49	134	150	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	1995	11	9					1693	1698						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478596				2022-12-28	WOS:A1995TD09400003
J	ORMONDROYD, E; DELALUNA, S; LATHANGUE, NB				ORMONDROYD, E; DELALUNA, S; LATHANGUE, NB			A NEW MEMBER OF THE DP FAMILY, DP-3, WITH DISTINCT PROTEIN PRODUCTS SUGGESTS A REGULATORY ROLE FOR ALTERNATIVE SPLICING IN THE CELL-CYCLE TRANSCRIPTION FACTOR DRTF1/E2F	ONCOGENE			English	Article						E2F; DP; TRANSCRIPTION FACTOR; CELL CYCLE; SPLICING	RETINOBLASTOMA GENE-PRODUCT; COMPLEX-FORMATION; BINDING PROTEIN; MESSENGER-RNA; FACTOR E2F; CLONING; P107; TRANSACTIVATION; PROLIFERATION; TRANSLATION	Integrating cell cycle progression with transcription provides an important level of control during proliferation, The cellular transcription factor DRTF1/E2F is implicated in this integration process by virtue of its physical interaction and control by key regulators of proliferation, such as retinoblastoma protein, cyclins and cyclin-dependent kinases and regulation of target genes required for cell cycle progression, Generic DRTF1/E2F DNA binding activity arises when a member of two distinct families of proteins, DP and E2F, interact as DP/E2F heterodimers, Here, we report the isolation and characterisation of a new member of the murine DP family, called DP-3 (also referred to as human DP-2), In contrast to previously characterised members of the DP and E2F families, processing of DP-3 RNA provides an important level of control by generating at least four distinct DP-3 proteins, of which three have been isolated, called alpha, beta and gamma, Processing events, which we show are both tissue- and cell-restricted, can occur either in the 5' region of DP-3 RNA and determine whether translation begins at one or two potential intiating codons, or within the coding sequence, producing variations in internal domains of the DP-3 proteins, The DP-3 proteins studied can co-operate with E2F-1 in DNA binding activity and trans activation of E2F site-dependent transcription, This analysis of DP-3, which has uncovered a hitherto unexpected and surprising level of complexity, documents a new member of the DP family and novel levels of control which may influence the activity DRTF1/E2F and hence cell cycle progression.	NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research			de la Luna, Susana/E-9553-2015	de la Luna, Susana/0000-0001-7765-916X; Ormondroyd, Elizabeth/0000-0002-9116-4064				ALTMANN M, 1993, TRENDS BIOCHEM SCI, V18, P429, DOI 10.1016/0968-0004(93)90143-B; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BUCK V, 1995, ONCOGENE, V11, P31; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GIRLING R, 1994, MOL BIOL CELL, V5, P1081, DOI 10.1091/mbc.5.10.1081; HEIBERT SW, 1992, GENE DEV, V6, P177; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HILL JR, 1993, J BIOL CHEM, V268, P726; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7032; NEVINS JR, 1992, SCIENCE, V258, P424; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; WU CL, 1995, MOL CELL BIOL, V15, P2536; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	44	59	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1437	1446						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478568				2022-12-28	WOS:A1995TC53500002
J	ELIOPOULOS, AG; KERR, DJ; HEROD, J; HODGKINS, L; KRAJEWSKI, S; REED, JC; YOUNG, LS				ELIOPOULOS, AG; KERR, DJ; HEROD, J; HODGKINS, L; KRAJEWSKI, S; REED, JC; YOUNG, LS			THE CONTROL OF APOPTOSIS AND DRUG-RESISTANCE IN OVARIAN-CANCER - INFLUENCE OF P53 AND BCL-2	ONCOGENE			English	Article						BCL-2; BAX; P53; OVARIAN; CISPLATIN; DRUG-RESISTANCE	PROGRAMMED CELL-DEATH; WILD-TYPE P53; B-CELLS; GENE AMPLIFICATION; ANTICANCER AGENTS; LEUKEMIC-CELLS; CYCLE CONTROL; C-MYC; PROTEIN; DNA	Modulation of apoptosis may influence resistance to chemotherapy and therefore affect the outcome of cancer treatment. Ovarian cancer, one of the most fatal malignancies in women, is often associated with drug resistance but the cellular pathways contributing to this effect remain obscure. We have found that Bcl-2 and p53, two proteins implicated in the control of apoptosis, are frequently expressed in fresh biopsies of primary ovarian carcinoma. Examination of Bcl-2 and p53 protein levels in pairs of cis-platin sensitive and resistant ovarian cell lines demonstrated that the resistant variants over-express Bcl-2 and/or p53, apparently due to progressive expansion of Bcl-2 and/or p53 positive subpopulations during the in vitro development of resistance. Exogenous expression of Bcl-2 or a temperature sensitive mutant p53 (ts p53) in the ovarian cell line A2780 resulted in protection from drug-induced apoptosis and a delay in drug-mediated S-phase arrest. Interestingly, p53 accumulation in response to DNA damage induced by different agents was significantly delayed and reduced in the Bcl-2 transfectants compared to the control A2780 line, suggesting that Bcl-2 may act upstream of the p53 pathway. Similarly, the induction of Bax mRNA and protein was also found to be delayed in the presence of Bcl-2. Overall, our data provide further evidence for cross-talk between Bcl-2, p53 and Bax and suggest that these genes are important determinants of drug-induced apoptosis thereby modulating resistance to chemotherapy.	UNIV BIRMINGHAM, SCH MED, CRC, INST CANC STUDIES, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA	University of Birmingham; Sanford Burnham Prebys Medical Discovery Institute			Young, Lawrence S/B-7213-2009; ELIOPOULOS, ARISTIDES/R-9449-2018; ELIOPOULOS, ARISTIDES/ABI-6632-2020	Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761	NCI NIH HHS [CA60138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA060138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEHRENS BC, 1987, CANCER RES, V47, P414; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; CAMPOS L, 1993, BLOOD, V81, P3091; CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEARY ML, 1987, CELL, V47, P2537; COLOMBEL M, 1993, AM J PATHOL, V143, P390; DAWSON CW, 1995, ONCOGENE, V10, P69; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; DIVE C, 1993, FRONTIERS PHARM CANC, P21; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; EASTMAN A, 1991, MOL CLIN ADV ANTICAN, P233; EASTMAN A, 1994, NEW MOL TARGETS CANC, P143; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FRITSCHE M, 1993, ONCOGENE, V8, P307; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGUE A, 1994, ONCOGENE, V9, P3367; HALDAR S, 1994, CANCER RES, V54, P2095; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KASTAN MB, 1991, CANCER RES, V51, P6304; KELLAND LR, 1992, CANCER RES, V52, P3857; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUPRYJANCZYK J, 1993, P NATL ACAD SCI USA, V90, P4961, DOI 10.1073/pnas.90.11.4961; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARKS JR, 1991, CANCER RES, V51, P2979; MASUDA H, 1990, CANCER RES, V50, P1863; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1992, CANCER RES, V52, P5407; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MONTENARH M, 1992, INT J ONCOL, V1, P37; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; SACHS L, 1993, BLOOD, V82, P15, DOI 10.1182/blood.V82.1.15.bloodjournal82115; Sambrook J, 1989, MOL CLONING LABORATO; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; SPANDIDOS DA, 1984, IN VITRO TRANSCRIPTI, P1; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TEYSSIER JR, 1989, CANCER GENET CYTOGEN, V39, P35, DOI 10.1016/0165-4608(89)90227-6; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605; ZHAN QM, 1994, ONCOGENE, V9, P3743	74	288	301	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1217	1228						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478541				2022-12-28	WOS:A1995RY96700001
J	NATOLI, G; IANNI, A; COSTANZO, A; DEPETRILLO, G; ILARI, I; CHIRILLO, P; BALSANO, C; LEVRERO, M				NATOLI, G; IANNI, A; COSTANZO, A; DEPETRILLO, G; ILARI, I; CHIRILLO, P; BALSANO, C; LEVRERO, M			RESISTANCE TO FAS-MEDIATED APOPTOSIS IN HUMAN HEPATOMA-CELLS	ONCOGENE			English	Article						FAS; SOLUBLE FAS; ALTERNATIVE SPLICING; APOPTOSIS; PROTEIN SYNTHESIS INHIBITORS	TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR SUPERFAMILY; MOLECULAR-CLONING; SURFACE ANTIGEN; MONOCLONAL-ANTIBODY; PROTEIN; DNA; EXPRESSION; INDUCTION; MEMBER	CTLs- and lymphokine-induced apoptosis of infected hepatocytes during the course of chronic viral hepatitis is thought to be important for both disease termination and prevention of hepatocellular transformation, We therefore studied apoptosis induced by Pas (APO-1 or CD95) - a widely expressed cell surface receptor whose ligand is involved in lymphocyte cytotoxicity - in a set of human hepatoma cell lines. As normal hepatocytes, all of the human hepatoma cell lines tested do express detectable amounts of Fas on their surface. Nevertheless, only PLC/PRF/5 cells undergo apoptosis following treatment with anti-Fas. Systematic cloning and sequence analysis of the Pas cDNA did not show mutations in the Pas gene in any of the cells lines tested, However, due to alternative splicing, 5 to 10% of the Fas cDNAs are deleted of 63 internal nucleotides corresponding to the transmembrane domain, thus encoding for a soluble and secreted form of Fas (Fas Delta TM), potentially able to neutralize anti-Fas or Fas-Ligand. Although we could not demonstrate a direct correlation between resistance of different hepatoma cell lines to Pas mediated death and endogenous expression of this transcript, we show that PLC/PRF 5 stable transfectants overexpressing Fas Delta TM are less sensitive to anti-Pas than control cells, Tn three different cell lines, resistance to anti-Pas was overcome by treatment with the protein synthesis inhibitor cyclohexymide, Although this could suggest the existence of short-lived repressors of the Fas-activated apoptotic signalling pathway(s), we show that translational inhibition is not required for the synergistic effect of cycloheximide to take place, and that resistant hepatoma cells can be sensitized to anti-Pas by subinhibitory concentrations of this protein synthesis inhibitor. Since cycloheximide is able to activate intracellular signalling independently on its effects on protein sysnthesis, we suggest that it might provide a costimulatory signal that cooperates with Fas in the induction of cell death and that, at least in the cells we tested, resistance to Fas is not an active process involving gene transciption and translation but only the consequence of an inadequate apoptotic stimulation.	UNIV ROMA LA SAPIENZA,POLICLIN UMBERTO 1,IST CLIN MED 1,I-00161 ROME,ITALY; UNIV LAQUILA,DIPARTIMENTO MED INTERNA,LAQUILA,ITALY; UNIV CAGLIARI,IST MED INTERNA,CAGLIARI,ITALY	Sapienza University Rome; University Hospital Sapienza Rome; University of L'Aquila; University of Cagliari	NATOLI, G (corresponding author), UNIV ROMA LA SAPIENZA,POLICLIN UMBERTO 1,FDN ANDREA CESALPINO,VIALE POLICLIN 155,I-00161 ROME,ITALY.		Natoli, gioacchino/ABB-8679-2020; Costanzo, Antonio/D-3896-2012; Natoli, gioacchino/J-2100-2018; Costanzo, Antonio/GZG-2433-2022; Balsano, Clara/AAK-9870-2020; Levrero, Massimo/G-5680-2016	Costanzo, Antonio/0000-0001-9697-2557; Balsano, Clara/0000-0002-9615-7031; Natoli, Gioacchino/0000-0003-0711-2411; Levrero, Massimo/0000-0002-4978-0875				ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; ALEXANDER JJ, 1976, S AFR MED J, V50, P2124; CASCINO I, 1995, J IMMUNOL, V154, P2706; CHANG C, 1983, MOL CELL BIOL, V3, P1133, DOI 10.1128/MCB.3.6.1133; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; CRISPE IN, 1994, IMMUNITY, V1, P347; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; FRITSCHE M, 1993, ONCOGENE, V8, P307; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KASTAN MB, 1991, CANCER RES, V51, P6304; KERR JFR, 1979, LANCET, V2, P827; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; MIZUHARA H, 1994, J EXP MED, V179, P1529, DOI 10.1084/jem.179.5.1529; MORIMOTO H, 1993, CANCER RES, V53, P2591; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OSAWA H, 1986, EUR J IMMUNOL, V16, P467, DOI 10.1002/eji.1830160426; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; Popper H., 1988, LIVER BIOL PATHOBIOL, P1087; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; SHALL TJ, 1990, CELL, V61, P361; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WALLACH D, 1984, J IMMUNOL, V132, P2464; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WONG GHW, 1994, J IMMUNOL, V152, P1751; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	38	147	151	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1157	1164						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566976				2022-12-28	WOS:A1995RX18000019
J	OUCHIDA, M; OHNO, T; FUJIMURA, Y; RAO, VN; REDDY, ESP				OUCHIDA, M; OHNO, T; FUJIMURA, Y; RAO, VN; REDDY, ESP			LOSS OF TUMORIGENICITY OF EWINGS-SARCOMA CELLS EXPRESSING ANTISENSE RNA TO EWS-FUSION TRANSCRIPTS	ONCOGENE			English	Article						EWINGS SARCOMA; THERAPY; RNA BINDING; ETS; EWS	ETS-RELATED GENE; CHROMOSOMAL TRANSLOCATIONS; DNA-BINDING; FLI-1; ERG; PROTEIN; ACTIVATION; FAMILY; LIPOSARCOMA; LEUKEMIA	Cytogenetic analysis of Ewing's sarcoma, primitive neuroectodermal tumors and Askin tumors revealed characteristic translocations t(11;22) or t(21;22). Molecular analysis of these translocations revealed S-region of EWS gene (from band 22q12) is fused to the 3'-region of either Fli-1 gene (from band 11q24) or erg gene (from band 21q22). Functional characterization of the EWS-Fli-1 and EWS-erg chimeric proteins suggested that they function as transcriptional activators. In order to develop therapeutic agents, it is essential to know whether expression of the EWS-fusion gene products is coupled to tumorigenicity of Ewing's sarcoma cells and if targeting the EWS-fusion products results in loss of tumorigenicity of Ewing's sarcoma cells. For this reason, we have made stable Ewing's sarcomas expressing antisense EWS-Fli-1 or EWS-erg transcripts by transfecting the antisense EWS-Fli-1 or EWS-erg expression plasmids. Expression of antisense EWS fusion transcripts resulted in a significant loss of endogenous EWS-Fli-1 and EWS-erg proteins in Ewing's sarcoma cells. These cells expressing antisense EWS fusion transcripts showed loss of anchorage independent growth and tumorigenicity in nude mice unlike the parental Ewing's sarcoma cells. These results demonstrate the necessity of a certain threshold level of expression of EWS-fusion products in the clonogenicity and tumorigenicity of Ewing's sarcoma cells and therefore emphasizes the importance of targeting the EWS-fusion products as a therapy for Ewing family of tumors.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL CANCER INSTITUTE [R01CA058642, R01CA057157, P01CA051083] Funding Source: NIH RePORTER; NCI NIH HHS [CA58642, CA51083, CA57157] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AURIAS A, 1983, NEW ENGL J MED, V309, P496; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOYD JA, 1994, MOL IMMUNOLOGIC APPR; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V369, P162; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; LADANYI M, 1994, CANCER RES, V54, P2837; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MITELMAN F, 1991, CATALOG CHROMOSOME A; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; PRASAD DDK, 1994, ONCOGENE, V9, P669; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	35	122	135	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1049	1054						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566963				2022-12-28	WOS:A1995RX18000006
J	HSU, B; MARIN, MC; ELNAGGAR, AK; STEPHENS, LC; BRISBAY, S; MCDONNELL, TJ				HSU, B; MARIN, MC; ELNAGGAR, AK; STEPHENS, LC; BRISBAY, S; MCDONNELL, TJ			EVIDENCE THAT C-MYC MEDIATED APOPTOSIS DOES NOT REQUIRE WILD-TYPE P53 DURING LYMPHOMAGENESIS	ONCOGENE			English	Article						APOPTOSIS; ONCOGENE; C-MYC; P53; LYMPHOMA	CELL-CYCLE ARREST; BURKITT-LYMPHOMA; PROTEIN; GENE; DEATH; MICE; FIBROBLASTS; EXPRESSION; INDUCTION; LINE	Deregulation of c-myc, frequently implicated in oncogenesis, is associated with increased cell proliferation and also cell death. Similarly, the p53 tumor suppressor gene commonly mutated in human tumors, is known to induce apoptosis or cell cycle arrest in its wild-type conformation. Genetically altered mice simultaneously overexpressing c-myc and possessing a disrupted p53 gene were used to investigate whether c-myc mediated apoptosis requires wild-type p53, The accelerated development of malignant lymphomas in these mice was found to be a consequence of enhanced proliferation and not reduced apoptosis resulting from the synergistic effect of c-myc overexpression and p53 inactivation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT VET MED & SURG,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Marín Vieira, María del Carmen/B-8108-2015; Marin, Maria C/G-1040-2010	Marín Vieira, María del Carmen/0000-0002-7149-287X; Marin, Maria C/0000-0002-7149-287X	NCI NIH HHS [CA09255, CA16672, CA62597] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062597, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELDIERY WS, 1994, CANCER RES, V54, P1169; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P4279; KASTAN MB, 1991, CANCER RES, V53, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MARIN MC, 1995, EXP CELL RES, V217, P240, DOI 10.1006/excr.1995.1083; MCDONNELL TJ, 1993, MOL CARCINOGEN, V8, P209, DOI 10.1002/mc.2940080402; MILNER AE, 1993, ONCOGENE, V8, P3385; OCONNOR PM, 1993, CANCER RES, V53, P4776; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; WAFIK S, 1994, CANCER RES, V54, P1169; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WATERS CM, 1991, ONCOGENE, V6, P797; XIONG Y, 1993, NATURE, V336, P701; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	32	96	100	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					175	179						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624125				2022-12-28	WOS:A1995RJ29500020
J	AVILA, MA; VELASCO, JA; CHO, C; LUPU, R; WEN, DZ; NOTARIO, V				AVILA, MA; VELASCO, JA; CHO, C; LUPU, R; WEN, DZ; NOTARIO, V			HYPERACTIVE AUTOCRINE LOOP MEDIATED BY A NDF-RELATED FACTOR IN NEOPLASTIC HAMSTER-EMBRYO FIBROBLASTS EXPRESSING AN ACTIVATED CPH ONCOGENE	ONCOGENE			English	Article						MITOGENIC FACTORS; ERBB-2 TYROSINE KINASE; NEOPLASTIC CONVERSION; CELL PROLIFERATION; CPH TRANSFORMATION	NEU DIFFERENTIATION FACTOR; HUMAN-BREAST-CANCER; GROWTH-FACTOR; PROTO-ONCOGENE; EGF RECEPTOR; SIGNAL TRANSDUCTION; TYROSINE KINASE; POINT MUTATION; LIGAND; CELLS	We described previously the characterization of a novel oncogene, cph, activated in primary Syrian hamster embryo fibroblasts by exposure to 3-methylcholanthrene (Velasco et al., Oncogene 9: 2065-2069, 1994). The present report describes the participation in the neoplastic conversion of cph-expressing (81C=39) hamster fibroblasts of a hyperactive autocrine loop involving a nea differentiation factor [NDF]-like protein, The tyrosine phosphorylation of the p185(erbB-2) receptor in the human breast carcinoma MDA-MB-453 cells was stimulated by conditioned medium from neoplastic 81C39 cells. The extent of this stimulatory effect was much greater than that induced by conditioned medium from normal 84-3 hamster cells. The p185(erbB-2) tyrosine phosphorylation-stimulating activity was partially blocked by the heparin analogue pentosan polysulfate [PPS], a known antagonist of p185(erbB-2) ligands, and was partially purified from 81C39 conditioned medium by heparin-Sepharose chromatography. The level of p185(erbB-2) tyrosine phosphorylation-stimulating activity in the heparin-Sepharose fractions correlated directly with their content in NDF-like protein as immunodetected with an anti-rat NDF antibody, Consistently, the steady-state level of NDF-related mRNA was found to be four times greater in neoplastic 81C39 cells than in normal 84-3 cells. However, the levels of erbB-2 mRNA were similar in both cell types, while the expression of erbB-4 mRNA was upregulated in the neoplastic fibroblasts. The ability of 81C39 conditioned medium to stimulate protein tyrosine phosphorylation and to induce other PPS-sensitive growth responses on 81C39 cells themselves suggested the involvement of an autocrine loop in their neoplastic conversion, The participation of a NDF-related factor in this autocrine loop was confirmed by the ability of an anti-NDF antibody to block the mitogenic activity present in their own conditioned medium. The involvement of the cpk oncogene in the upregulation of NDF-related expression was evidenced when cph-transformed NIH3T3 fibroblasts showed elevated levels of NDF-related mRNA, and their conditioned medium induced tyrosine phosphorylation on MDA-MB-453 cells, reproducing the effect of the medium from 81C39 hamster cells.	GEORGETOWN UNIV, MED CTR, DEPT RADIAT MED, DIV EXPTL CARCINOGENESIS, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC RES CTR, WASHINGTON, DC 20007 USA; AMGEN INC, THOUSAND OAKS, CA 91320 USA	Georgetown University; Georgetown University; Amgen			Avila, Matias A/Y-6342-2019; /AAB-6461-2022; /AFP-0764-2022	Avila, Matias A/0000-0001-6570-3557; 	NCI NIH HHS [CA49858] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA049858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BACUS SS, 1993, CANCER RES, V53, P5251; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3761, DOI 10.1073/pnas.75.8.3761; BERWALD Y, 1965, J NATL CANCER I, V35, P641; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIPAOLO JA, 1969, J NATL CANCER I, V42, P867; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HIRAKAWA T, 1991, ONCOGENE, V6, P289; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG SS, 1992, J BIOL CHEM, V267, P11508; KRAUS MH, 1988, ANN NY ACAD SCI, V551, P320, DOI 10.1111/j.1749-6632.1988.tb22358.x; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; NOTARIO V, 1990, ONCOGENE, V5, P1425; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; TARAKHOVSKY A, 1991, ONCOGENE, V6, P2187; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELASCO JA, 1994, ONCOGENE, V9, P2065; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WESTERMARK B, 1991, CANCER RES, V51, P5087; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569	51	25	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					963	971						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7534900				2022-12-28	WOS:A1995QL03800018
J	BOEUF, H; MURPHY, J; BIBBINS, KB; VARMUS, HE				BOEUF, H; MURPHY, J; BIBBINS, KB; VARMUS, HE			BINDING IN-VITRO OF PHOSPHOTYROSINE-CONTAINING PROTEINS TO PP60(C-SRC) SH2 DOMAIN DOES NOT CORRELATE WITH CEF CELL-TRANSFORMATION	ONCOGENE			English	Article						SH2; SH3; SRC; TRANSFORMATION; PHOSPHOTYROSINE	GTPASE-ACTIVATING PROTEIN; GROWTH-FACTOR RECEPTORS; SRC HOMOLOGY REGION-2; C-SRC; V-SRC; SIGNAL TRANSDUCTION; PP60(SRC) SUBSTRATE; DEPENDENT MANNER; TYROSINE KINASE; HIGH-AFFINITY	We have previously described pp60(c-src) SH2 mutants that are host-range-dependent for cell transformation; most of these mutants can transform CEF cells but not NIH3T3 cells, and others transform NM3T3 cells more efficiently than CEF (Hirai and Varmus, 1990c). In an attempt to understand the molecular basis of these phenotypes, we analysed the ability of mutant SH2 domains in GST fusion-proteins to bind to tyrosine phosphorylated proteins in lysates from CEF and NIH3T3 cells. The relative affinity of mutated versions of the SH2 domain for phosphotyrosine-containing proteins from CEF and NM3T3 cells was compared with the relative ability of the mutant Src proteins to transform the two cell types. While the affinity of the SH2 domain for phosphotyrosine-containing proteins was closely correlated with transformation in NIH3T3 cells, there was no correlation between phosphotyrosine binding and transformation of CEF cells, and none of the host range mutant SH2 domains showed significant differences in their ability to bind phosphotyrosine-containing proteins from lysates from either cell type. In addition, the SH3 domain was shown to augment the capacity of mutant SH2 domain to bind phosphotyrosine-containing proteins.	CU, STRASBOURG, FRANCE; CHIRON CORP, DEPT VIROL, EMERYVILLE, CA 94608 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; NIH, BETHESDA, MD 20892 USA	Novartis; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA	BOEUF, H (corresponding author), IGBMC, BP 163, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE.							ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIEBL EC, 1992, J VIROL, V66, P4315, DOI 10.1128/JVI.66.7.4315-4324.1992; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEELE RE, 1992, TRENDS BIOCHEM SCI, V17, P205, DOI 10.1016/0968-0004(92)90375-J; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VERDERAME MF, 1994, ONCOGENE, V9, P175; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	57	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					433	438						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7531318				2022-12-28	WOS:A1995QF64800003
J	DESEPULVEDA, P; PEYRIERAS, N; PANTHIER, JJ				DESEPULVEDA, P; PEYRIERAS, N; PANTHIER, JJ			INSTABILITY AT THE W/C-KIT LOCUS IN MICE - ANALYSIS OF MELANOCYTE CELL-LINES DERIVED FROM REVERSION SPOTS	ONCOGENE			English	Article							W-MUTANT MICE; C-KIT; MITOTIC RECOMBINATION; MOUSE MELANOCYTES; RECEPTOR KINASE; NEURAL CREST; HOUSE MOUSE; MUTATIONS; EXPRESSION; GENE	Mutations at the mouse W/c-kit locus have pleiotropic defects including impaired development of the melanocyte lineage. We have characterized the molecular basis of the W-ei mutation. We show here that W-ei is the result of a missense mutation in the ATP binding site domain of c-kit proto-oncogene which affects the tyrosine kinase function of the receptor. As a result, few melanoblasts survive during embryogenesis in heterozygous W-ei/+ foetuses. Therefore the adult skin is partly devoid of differentiated pigmented cells giving rise to a mottled coat colour phenotype. However, three per cent of W-ei/+mice exhibit spots of wild-type pigmentation on the coat which is otherwise of mutant phenotype. Such areas are known as phenotypic reversions. To dissect the molecular events responsible for the phenotypic instability of the W-ei mutation, we have isolated pure cultures of continuously proliferating melanocytes from two independent reversion spots. These melanocyte lines, designated W-ei-R1 and W-ei-R2, were shown to exhibit none of the characteristics associated with transformed melanocytes. We have used a polymorphic restriction site generated by the W-ei mutation to show that both melanocyte lines are still heterozygous at the W focus. Furthermore, W-ei-R1 and W-ei-R2 melanocytes express both the mutated and the wild-type c-kit RNA. These results indicate that the somatic mutation events responsible for reversion spots are not necessarily associated with loss of heterozygosity at the W/c-kit locus. Together with previous data, this points to the fact that several mechanisms account for the coat colour reversion phenotype.	ECOLE NATL VET, INRA, URA GENET MOLEC, F-94704 MAISONS ALFORT, FRANCE; CNRS MARSEILLE LUMINY, INSERM, CTR IMMUNOL, F-13288 MARSEILLE 9, FRANCE	Ecole Nationale Veterinaire d'Alfort (ENVA); INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			PANTHIER, Jean-Jacques/I-4366-2014; De sepulveda, paulo/K-6043-2015	PANTHIER, Jean-Jacques/0000-0002-7966-0663; De sepulveda, paulo/0000-0001-8295-5414; Peyrieras, Nadine/0000-0002-4905-6414				BENNETT DC, 1989, DEVELOPMENT, V105, P379; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; DUBREUIL P, 1990, ANN NY ACAD SCI, V599, P58; DUTTLINGER R, 1993, DEVELOPMENT, V118, P705; EICHE A, 1984, HEREDITAS, V101, P273; EICHE A, 1982, HEREDITAS, V97, P316; FLEISCHMAN RA, 1993, TRENDS GENET, V9, P285, DOI 10.1016/0168-9525(93)90015-A; GEISSLER EN, 1981, GENETICS, V97, P337; GOKKEL E, 1992, ONCOGENE, V7, P1423; Green MC., 1989, GENETIC VARIANTS STR, P12; GUENET JL, 1979, J HERED, V70, P9, DOI 10.1093/oxfordjournals.jhered.a109202; HALABAN R, 1984, IN VITRO CELL DEV B, V20, P447; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Herlyn M, 1990, Adv Cancer Res, V54, P213, DOI 10.1016/S0065-230X(08)60812-X; HUSZAR D, 1991, DEVELOPMENT, V112, P131; IWAMOTO T, 1992, EXP CELL RES, V200, P410, DOI 10.1016/0014-4827(92)90189-F; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; LARUE L, 1992, P NATL ACAD SCI USA, V89, P7816, DOI 10.1073/pnas.89.16.7816; LARUE L, 1993, ONCOGENE, V8, P523; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MINTZ B, 1974, ANNU REV GENET, V8, P411, DOI 10.1146/annurev.ge.08.120174.002211; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; MINTZ B, 1970, 25TH S INT SOC CELL, P15; MOTRO B, 1991, DEVELOPMENT, V113, P1207; MURPHY M, 1992, DEV BIOL, V153, P396, DOI 10.1016/0012-1606(92)90124-Y; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; PANTHIER JJ, 1990, GENETICS, V125, P175; PANTHIER JJ, 1991, BIOESSAYS, V13, P351, DOI 10.1002/bies.950130709; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; Sambrook J, 1989, MOL CLONING LABORATO; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SPANAKIS E, 1992, DEVELOPMENT, V114, P675; STEEL KP, 1992, DEVELOPMENT, V115, P1111; STERNBERG MJE, 1984, FEBS LETT, V175, P387, DOI 10.1016/0014-5793(84)80774-7; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TSUJIMURA T, 1993, BLOOD, V81, P2530; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	46	13	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2655	2661						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	7520149				2022-12-28	WOS:A1994PC05400026
J	FIELD, JK; SPANDIDOS, DA; STELL, PM; VAUGHAN, ED; EVAN, GI; MOORE, JP				FIELD, JK; SPANDIDOS, DA; STELL, PM; VAUGHAN, ED; EVAN, GI; MOORE, JP			ELEVATED EXPRESSION OF THE C-MYC ONCOPROTEIN CORRELATES WITH POOR PROGNOSIS IN HEAD AND NECK SQUAMOUS-CELL CARCINOMA	ONCOGENE			English	Article									UNIV LIVERPOOL, DEPT OTORHINOLARYNGOL, LIVERPOOL L69 3BX, ENGLAND; NATL HELLENIC RES FDN, BIOL RES CTR, GR-11635 ATHENS, GREECE; ST BARTHOLOMEWS HOSP, IMPERIAL CANC RES FUND, LONDON EC1A 7BE, ENGLAND; INST CANC RES, CHESTER BEATTY RES INST, SUTTON SM2 5PX, SURREY, ENGLAND; BEATSON INST CANC RES, GLASGOW G61 1BD, SCOTLAND; WALTON HOSP, DEPT MAXILLOFACIAL SURG, LIVERPOOL L9 1AE, MERSEYSIDE, ENGLAND	University of Liverpool; National Hellenic Research Foundation; Cancer Research UK; University of London; Queen Mary University London; University of London; Institute of Cancer Research - UK; Beatson Institute; Walton Centre	FIELD, JK (corresponding author), UNIV LIVERPOOL, DEPT CLIN DENT SCI, POB 147, LIVERPOOL L69 3BX, ENGLAND.		Field, John K./AAD-5674-2020	Field, John K./0000-0003-3951-6365; Spandidos, Demetrios/0000-0002-1146-931X				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1987, CANCER RES, V47, P4248; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; DAVIS RK, 1985, OTOLARYNG CLIN N AM, V18, P411; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; EISENMAN RN, 1986, CANCER SURV, V5, P309; ERISMAN MD, 1988, CANCER RES, V48, P1350; ERISMAN MD, 1988, ONCOGENE, V2, P367; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; EVAN GI, 1988, CURR TOP MICROBIOL, V141, P189; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD JK, 1987, J ORAL PATHOL MED, V16, P97, DOI 10.1111/j.1600-0714.1987.tb01474.x; FIELD JK, 1986, ANTICANCER RES, V6, P595; HARMER MN, 1978, UNION INT CANCER TNM; HOLM LE, 1983, LARYNGOSCOPE, V93, P792; JOHANSSON A, 1986, J IMMUNOL METHODS, V87, P7, DOI 10.1016/0022-1759(86)90337-6; JOHNSON BE, 1988, CANCER RES, V48, P5163; KALNINS IK, 1977, AM J SURG, V134, P450, DOI 10.1016/0002-9610(77)90376-2; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATZ AE, 1983, LARYNGOSCOPE, V93, P445; KOZBOR D, 1984, CANCER RES, V44, P438; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MOORE JP, 1987, ONCOGENE RES, V2, P65; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; RIOU G, 1987, LANCET, V1, P761; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SEEGER RC, 1987, P AM ASSOC CANC RES, V28, P23; SELF CH, 1985, J IMMUNOL METHODS, V76, P389, DOI 10.1016/0022-1759(85)90316-3; Siegel S., 1956, NONPARAMETRIC STAT B; SIKORA K, 1985, BRIT J CANCER, V52, P171, DOI 10.1038/bjc.1985.174; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SPANDIDOS DA, 1985, ANTICANCER RES, V5, P221; STANLEY CJ, 1985, J IMMUNOL METHODS, V83, P89, DOI 10.1016/0022-1759(85)90061-4; STELL PM, 1989, IN PRESS CLIN OTOL; STEWART J, 1986, BRIT J CANCER, V53, P1, DOI 10.1038/bjc.1986.1; VARLEY JM, 1987, ONCOGENE, V1, P423; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; 1978, MANUAL STAGING CANCE	45	144	146	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1989	4	12					1463	1468						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687767				2022-12-28	WOS:A1989CB65900007
J	MAY, E; MOURIESSE, H; MAYLEVIN, F; CONTESSO, G; DELARUE, JC				MAY, E; MOURIESSE, H; MAYLEVIN, F; CONTESSO, G; DELARUE, JC			A NEW APPROACH ALLOWING AN EARLY PROGNOSIS IN BREAST-CANCER - THE RATIO OF ESTROGEN-RECEPTOR (ER) LIGAND-BINDING ACTIVITY TO THE ER-SPECIFIC MESSENGER-RNA LEVEL	ONCOGENE			English	Article									INST GUSTAVE ROUSSY,DEPT MED STAT,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT MED,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT ANAT PATHOL C,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,HORMONAL BIOCHEM LAB,F-94805 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	MAY, E (corresponding author), INST RECH SCI CANC,MOLEC ONCOL LAB,7 RUE GOY MOCQUET,F-94802 VILLEJUIF,FRANCE.							AAMDAL S, 1984, CANCER-AM CANCER SOC, V53, P2525, DOI 10.1002/1097-0142(19840601)53:11<2525::AID-CNCR2820531126>3.0.CO;2-8; ADAMI HO, 1985, BREAST CANCER RES TR, V5, P293, DOI 10.1007/BF01806024; ALLEGRA JC, 1979, CANCER TREAT REP, V63, P1271; BARRETTLEE PJ, 1987, CANCER RES, V47, P6653; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CLARK GM, 1983, NEW ENGL J MED, V309, P1343, DOI 10.1056/NEJM198312013092240; CONTESSO G, 1987, J CLIN ONCOL, V5, P1378, DOI 10.1200/JCO.1987.5.9.1378; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; FISHER B, 1988, J CLIN ONCOL, V6, P1076, DOI 10.1200/JCO.1988.6.7.1076; GARCIA T, 1988, MOL ENDOCRINOL, V2, P785, DOI 10.1210/mend-2-9-785; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HAHNEL R, 1979, CANCER, V44, P671, DOI 10.1002/1097-0142(197908)44:2<671::AID-CNCR2820440238>3.0.CO;2-V; HENRY JA, 1988, BRIT J CANCER, V58, P600, DOI 10.1038/bjc.1988.267; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOWELL A, 1984, LANCET, V1, P588; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P107, DOI 10.1007/BF00364822; KNIGHT WA, 1977, CANCER RES, V37, P4669; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; MARTIN PM, 1981, EVALUATION MOYENS DI, P263; MCGUIRE WL, 1986, CANCER SURV, V5, P527; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PICHON MF, 1980, CANCER RES, V40, P3357; PIVA R, 1988, BIOCHEM BIOPH RES CO, V155, P943, DOI 10.1016/S0006-291X(88)80587-4; RIO MC, 1987, P NATL ACAD SCI USA, V84, P9243, DOI 10.1073/pnas.84.24.9243; SAMAAN NA, 1981, CANCER, V47, P554, DOI 10.1002/1097-0142(19810201)47:3<554::AID-CNCR2820470322>3.0.CO;2-W; STANFORD JL, 1986, EPIDEMIOL REV, V8, P42, DOI 10.1093/oxfordjournals.epirev.a036295; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889	29	33	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					1037	1042						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2761986				2022-12-28	WOS:A1989AJ29700014
J	NAKAJIMA, H; IKEDA, M; TSUCHIDA, N; NISHIMURA, S; TAYA, Y				NAKAJIMA, H; IKEDA, M; TSUCHIDA, N; NISHIMURA, S; TAYA, Y			INACTIVATION OF THE N-MYC GENE-PRODUCT BY SINGLE AMINO-ACID SUBSTITUTION OF LEUCINE RESIDUES LOCATED IN THE LEUCINE-ZIPPER REGION	ONCOGENE			English	Article									NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN; TOKYO MED & DENT UNIV,FAC DENT,INST STOMATOGNATH SCI,BUNKYO KU,TOKYO 113,JAPAN	National Cancer Center - Japan; Tokyo Medical & Dental University (TMDU)								BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; GARSON JA, 1986, LANCET, V1, P1496; GARSON JA, 1985, LANCET, V2, P718; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; IKEDA M, 1987, JPN J CANCER RES, V78, P428; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; MITANI K, 1986, JPN J CANCER RES, V77, P1062; MONTGOMERY KT, 1983, P NATL ACAD SCI-BIOL, V80, P5724, DOI 10.1073/pnas.80.18.5724; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; POLLACK R, 1974, P NATL ACAD SCI USA, V71, P4792, DOI 10.1073/pnas.71.12.4792; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; TAYA Y, 1986, EMBO J, V5, P1215, DOI 10.1002/j.1460-2075.1986.tb04349.x; TAYA Y, 1988, J CLIN EXP MED, V145, P410; UENO K, 1988, MOL CELL BIOL, V8, P4529, DOI 10.1128/MCB.8.10.4529; YAMASHITA T, 1986, Tumor Research, V21, P67; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	30	27	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					999	1002						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2668849				2022-12-28	WOS:A1989AJ29700008
J	CARLONI, G; PATERSON, H; MAREEL, M; AUGERYBOURGET, Y; SAHRAOUI, J; RUBINSTEIN, E; SUAREZ, H; AZZARONE, B				CARLONI, G; PATERSON, H; MAREEL, M; AUGERYBOURGET, Y; SAHRAOUI, J; RUBINSTEIN, E; SUAREZ, H; AZZARONE, B			N-RAS DEPENDENT REVERTANT PHENOTYPE IN HUMAN HT1080 FIBRO-SARCOMA CELLS IS ASSOCIATED WITH LOSS OF PROLIFERATION WITHIN NORMAL-TISSUES AND EXPRESSION OF AN ADULT MEMBRANE ANTIGENIC PHENOTYPE	ONCOGENE			English	Article									INST RECH SCI CANC,GENET MOLEC LAB,F-94802 VILLEJUIF,FRANCE; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND; DEPT RADIOTHERAPY & NUCL MED,EXPTL CANCEROL LAB,GHENT,BELGIUM; INSERM,U268,F-94824 VILLEJUIF,FRANCE	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Institut National de la Sante et de la Recherche Medicale (Inserm)			Rubinstein, Eric/B-4650-2019; Azzarone, Bruno/AAH-9251-2019	Rubinstein, Eric/0000-0001-7623-9665; Azzarone, Bruno/0000-0002-5962-3849				ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; AZZARONE B, 1984, J CELL BIOL, V98, P1133, DOI 10.1083/jcb.98.3.1133; AZZARONE B, 1984, INT J CANCER, V33, P759, DOI 10.1002/ijc.2910330608; AZZARONE B, 1985, EXP CELL RES, V159, P451, DOI 10.1016/S0014-4827(85)80018-5; AZZARONE B, 1986, INT J CANCER, V38, P177, DOI 10.1002/ijc.2910380206; AZZARONE B, 1987, J CELL SCI, V87, P155; AZZARONE B, 1988, MUTAT RES, V199, P313, DOI 10.1016/0027-5107(88)90211-4; AZZARONE B, 1985, RETROVIRUSES HUMAN P, P473; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; CARLONI G, 1988, FEBS LETT, V229, P333, DOI 10.1016/0014-5793(88)81151-7; CHO HY, 1976, SCIENCE, V194, P951, DOI 10.1126/science.62397; DUESBERG PH, 1983, NATURE, V304, P219, DOI 10.1038/304219a0; Favaloro J, 1980, Methods Enzymol, V65, P718; FRAZIERSCOTT K, 1988, J CLIN INVEST, V82, P1877; GAMBKE C, 1984, NATURE, V307, P476, DOI 10.1038/307476a0; GREENE WC, 1987, CANCER INVEST, V5, P369; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HAYNES BF, 1981, J IMMUNOL, V126, P1409; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; LEONARD WJ, 1984, NATURE, V311, P26; MAREEL M, 1979, VIRCHOWS ARCH B, V30, P197; Mareel M M, 1987, J Cell Sci Suppl, V8, P141; MAREEL M M, 1981, Invasion and Metastasis, V1, P195; MAREEL MM, 1986, ANTICANCER RES, V6, P419; MAREEL MM, 1982, MEMBRANES TUMOUR GRO, P223; MAREEL MMK, 1982, TUMOR INVASION METAS, P207; MARSHALL CJ, 1984, CANCER CELL, V2, P441; MICHALAK M, 1986, J BIOL CHEM, V261, P92; PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; RUBIN H, 1984, NATURE, V309, P518, DOI 10.1038/309518a0; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SARAGOVI H, 1987, J IMMUNOL, V139, P1918; SHARON M, 1988, J EXP MED, V167, P1265, DOI 10.1084/jem.167.3.1265; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; STORME G, 1981, ONCOLOGY, V38, P182, DOI 10.1159/000225547; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VARMUS HE, 1984, ANNU REV GENET, V18, P553; VOUSDEN KH, 1984, EMBO J, V3, P913, DOI 10.1002/j.1460-2075.1984.tb01905.x; WELTE K, 1984, J EXP MED, V160, P1390, DOI 10.1084/jem.160.5.1390; YAGITA H, 1986, CANCER RES, V46, P1478	43	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					873	880						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2666908				2022-12-28	WOS:A1989AE58400009
J	MOHAMED, AN; NAKEFF, A; MOHAMMAD, RM; KUKURUGA, M; ALKATIB, A				MOHAMED, AN; NAKEFF, A; MOHAMMAD, RM; KUKURUGA, M; ALKATIB, A			MODULATION OF C-MYC ONCOGENE EXPRESSION BY PHORBOL ESTER AND INTERFERON-GAMMA - APPRAISAL BY FLOW-CYTOMETRY	ONCOGENE			English	Article									WAYNE STATE UNIV, SCH MED, DEPT INTERNAL MED, DIV HEMATOL & ONCOL, DETROIT, MI 48201 USA	Wayne State University					NATIONAL CANCER INSTITUTE [P30CA022453] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005384] Funding Source: NIH RePORTER; NCI NIH HHS [T-32 CA-09532, CA22453] Funding Source: Medline; NCRR NIH HHS [SO7 RR-05384-25] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BAUER KD, 1986, CANCER RES, V46, P2428; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CELIS JE, 1984, LEUKEMIA RES, V8, P143, DOI 10.1016/0145-2126(84)90135-8; CLEVENGER CV, 1985, CYTOMETRY, V6, P208, DOI 10.1002/cyto.990060306; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1987, BLOOD, V70, P1233; DEAN PN, 1974, J CELL BIOL, V60, P523, DOI 10.1083/jcb.60.2.523; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P820, DOI 10.1073/pnas.80.3.820; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAVERA R D, 1982, Nature (London), V299, P61, DOI 10.1038/299061a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GEORGE DL, 1984, CANCER SURV, V3, P497; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYASHI K, 1984, GANN, V75, P475; JONAK GJ, 1984, P NATL ACAD SCI-BIOL, V81, P1747, DOI 10.1073/pnas.81.6.1747; KELLY JM, 1985, EUR J BIOCHEM, V153, P367, DOI 10.1111/j.1432-1033.1985.tb09312.x; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KELLY K, 1984, CURR TOP MICROBIOL, V113, P117; KLEIN E, 1968, CANCER RES, V28, P1300; KLEIN G, 1986, CANCER RES, V46, P3211; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; NAU MM, 1984, CURR TOP MICROBIOL, V113, P172; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; SATO H, 1987, SEMIN ONCOL, V14, P192; SUMEGI J, 1985, INT J CANCER, V36, P367; TARELLA C, 1982, CANCER RES, V42, P445; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; THORSBY E, 1970, HISTOCOMPATIBILITY T, P655; WATSON JV, 1985, J IMMUNOL METHODS, V83, P179, DOI 10.1016/0022-1759(85)90071-7; WATSON JV, 1986, CYTOMETRY, V7, P400, DOI 10.1002/cyto.990070503; WATSON JV, 1985, CYTOMETRY, V6, P310, DOI 10.1002/cyto.990060406	40	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1988	3	4					429	435						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3152600				2022-12-28	WOS:A1988Q773900011
J	RIOU, G; BARROIS, M; SHENG, ZM; DUVILLARD, P; LHOMME, C				RIOU, G; BARROIS, M; SHENG, ZM; DUVILLARD, P; LHOMME, C			SOMATIC DELETIONS AND MUTATIONS OF C-HA-RAS GENE IN HUMAN CERVICAL CANCERS	ONCOGENE			English	Article									INST GUSTAVE ROUSSY,SERV HISTOPATHOL B,F-94800 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,SERV GYNECOL,F-94800 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	RIOU, G (corresponding author), INST GUSTAVE ROUSSY,PHARMACOL CLIN & MOLEC LAB,RUE CAMILLE DESMOULINS,F-94800 VILLEJUIF,FRANCE.							ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CAMPION MJ, 1986, LANCET, V2, P237; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEINBERG AP, 1983, SCIENCE, V220, P1175, DOI 10.1126/science.6304875; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HALL SW, 1983, LANCET, V2, P731; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KNUDSON AG, 1987, ADV VIRAL ONCOL, V7, P1; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; KRONTIRIS TG, 1985, NATURE, V313, P369, DOI 10.1038/313369a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; MANIATIS T, 1982, MOL CLONING LABORATO; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PERUCHO M, 1981, CELL, V27, P185; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; RIOU G, 1984, CR ACAD SCI III-VIE, V299, P575; RIOU G, 1987, LANCET, V1, P761; RIOU G, 1985, PAPILLOMAVIRUSES MOL, P47; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SHENG ZM, 1988, ONCOGENE RES, V2, P245; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; SUAREZ HG, 1988, ONCOGENE, V2, P403; TERRIER P, 1988, BRIT J CANCER, V57, P43, DOI 10.1038/bjc.1988.6; THEILLET C, 1986, CANCER RES, V46, P4776; YANEZ L, 1987, ONCOGENE, V1, P315; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	41	128	129	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					329	333						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	3060795				2022-12-28	WOS:A1988Q436700012
J	KLEMPNAUER, KH				KLEMPNAUER, KH			INTERACTION OF MYB PROTEINS WITH NUCLEAR MATRIX INVITRO	ONCOGENE			English	Article											KLEMPNAUER, KH (corresponding author), UNIV HEIDELBERG,ZENTRUM MOLEC BIOL,IM NEUENHEIMER FELD 282,D-6900 HEIDELBERG,FED REP GER.							BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; CIEJEK EM, 1982, BIOCHEMISTRY-US, V21, P4945, DOI 10.1021/bi00263a018; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COOK PR, 1982, EMBO J, V1, P447, DOI 10.1002/j.1460-2075.1982.tb01189.x; CRAIG RW, 1984, CANCER RES, V44, P442; DIJKWEL PA, 1986, NUCLEIC ACIDS RES, V14, P3241, DOI 10.1093/nar/14.8.3241; DIJKWEL PA, 1979, NUCLEIC ACIDS RES, V6, P218; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; EVAN GI, 1984, MOL CELL BIOL, V4, P591; GONDA TJ, 1981, CELL, V23, P279, DOI 10.1016/0092-8674(81)90292-0; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; JACKSON DA, 1985, EMBO J, V4, P919, DOI 10.1002/j.1460-2075.1985.tb03719.x; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; MOSCOVICI MG, 1983, P NATL ACAD SCI-BIOL, V80, P1421, DOI 10.1073/pnas.80.5.1421; PARDOLL DM, 1980, CELL, V19, P527, DOI 10.1016/0092-8674(80)90527-9; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; ROBINSON SI, 1982, CELL, V28, P99, DOI 10.1016/0092-8674(82)90379-8; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SOUZA LM, 1980, P NATL ACAD SCI-BIOL, V77, P5177, DOI 10.1073/pnas.77.9.5177; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	34	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					545	551						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	3290804				2022-12-28	WOS:A1988N841500003
J	MAZZARELLI, JM; ATKINS, GB; GEISBERG, JV; RICCIARDI, RP				MAZZARELLI, JM; ATKINS, GB; GEISBERG, JV; RICCIARDI, RP			THE VIRAL ONCOPROTEINS AD5 E1A, HPV16 E7 AND SV40 TAG BIND A COMMON REGION OF THE TBP-ASSOCIATED FACTOR-110	ONCOGENE			English	Article						DTAF(II)110; HPV16 E7; SV40 TAG; AD5 E1A	TRANSCRIPTION FACTOR; ADENOVIRUS-E1A PROTEIN; DOMAIN BINDS; ACTIVATION; GENES	A function shared by the adenovirus E1A, papillomavirus E7 and SV40 TAg oncoproteins is their ability to interfere with normal cell growth by interacting with members of the retinoblastoma protein family, In this study, are show that each of these oncoproteins can also bind to the 921 amino acid TBP-associated factor-110 (TAF-110), The significance of the binding is underscored by the observation that each oncoprotein binds to the same 77 amino acid carboxyl region of TAF-110, In the case of E1A and TAg, this finding is consistent with their abilities to stimulate transcription initiation, in part, through their known interactions with TBP, While it is not clear whether E7 can also activate promoters through protein:protein interactions with components of the transcription initiation complex, our demonstration that E7 can bind to TAF-110, as well as TBP, suggests that E7 may modulate the expression of specific promoters which could contribute to the pathogenesis of human papillomavirus.	UNIV PENN, SCH DENT MED, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, GRAD GRP BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, MD PHD PROGRAM, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NCI NIH HHS [CA29797] Funding Source: Medline; NIAID NIH HHS [AI07324] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029797] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Broker T.R., 1986, CANCER CELL, V4, P17; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; GALLOWAY DA, 1989, ADV VIRUS RES, V37, P125; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; MONTELL C, 1982, NATURE, V295, P380, DOI 10.1038/295380a0; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MOROSOV A, 1994, J BIOL CHEM, V269, P18434; MUNGER K, 1993, BIOCHIM BIOPHYS ACTA, V1155, P111, DOI 10.1016/0304-419X(93)90025-8; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; Ricciardi R, 1995, DNA TUMOR VIRUSES ON, P195; RICCIARDI RP, 1981, P NATL ACAD SCI-BIOL, V78, P6121, DOI 10.1073/pnas.78.10.6121; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; ZUE J, 1991, J VIROL, V65, P2778	25	59	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	1995	11	9					1859	1864						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478615				2022-12-28	WOS:A1995TD09400022
J	ARTUSO, M; ESTEVE, A; BRESIL, H; VUILLAUME, M; HALL, J				ARTUSO, M; ESTEVE, A; BRESIL, H; VUILLAUME, M; HALL, J			THE ROLE OF THE ATAXIA-TELANGIECTASIA GENE IN THE P53, WAF1/CIP1(P21)- AND GADD45-MEDIATED RESPONSE TO DNA-DAMAGE PRODUCED BY IONIZING-RADIATION	ONCOGENE			English	Article						DNA DAMAGE; ATAXIA TELANGIECTASIA; P53 PROTEIN; WAF1/CIP1(P21); GADD45; CELL CYCLE	TUMOR-SUPPRESSOR PROTEIN; CYCLIN-DEPENDENT KINASES; IONIZING-RADIATION; GROWTH ARREST; HUMAN-CELLS; INDUCTION; SENSITIVITY; CANCER; ANTIGEN; UV	The inducible response of the tumour suppressor gene p53 has been examined following exposure to DNA-damaging agents in Ataxia telangiectasia (AT) cell lines, an autosomal recessive disorder with multiple clinical and biological abnormalities including sensitivity to ionising radiation. The p53 induction was significantly delayed and reduced in the 8 AT cell lines examined over the 6 h following irradiation with no dose response in p53 induction being observed compared to control cells, The increase of WAF1/CIP1(p21) and GADD45 mRNA, two genes transcriptionally activated by p53, was also reduced in the AT cell lines after such treatment. In contrast, the increase in p53 protein, WAF1/CIP1(p21) and GADD45 mRNA expression following exposure to the alkylating agent methylmethane sulphonate (25 and 100 mu g ml(-1)) was similar in both cell types, No alterations in the expression of EBNA-5, an EBV-encoded nuclear antigen which has been shown to bind p53 or mutations in the p53 gene (exons 4 to 8) were found in the AT cell lines studied, The AT gene product would thus appear to be involved upstream of p53, GADD45 and WAF1/CIP1 (p21) in the signalling of the presence of strand breaks produced by ionising radiation, with this defect in response contributing to the high cancer risk and radiosensitivity observed in this disorder.	INT AGCY RES CANC,MECH CARCINOGENESIS UNIT,F-69372 LYON 08,FRANCE	World Health Organization; International Agency for Research on Cancer (IARC)			hall, janet/G-1372-2013	hall, janet/0000-0002-4397-6295				BALALKIN G, 1994, P NATL ACAD SCI USA, V91, P413; CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V54, P1169; ELDEIRY WS, 1994, CANCER RES, V54, P1174; ESTEVE A, 1993, MOL CARCINOGEN, V8, P306, DOI 10.1002/mc.2940080414; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRITSCHE M, 1993, ONCOGENE, V8, P307; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1991, MOL CELL BIOL, V11, P3711, DOI 10.1128/MCB.11.7.3711; KEMP CJ, 1994, GENETICS, V8, P66; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LITTLE JB, 1968, NATURE, V218, P1064, DOI 10.1038/2181064a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACILWRATH AJ, 1994, CANCER RES, V54, P3718; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maniatis T., 1982, MOL CLONING; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MORRELL D, 1986, J NATL CANCER I, V77, P89; MURNANE JP, 1993, SEMIN CANCER BIOL, V4, P93; NAGASAWA H, 1985, MUTAT RES, V148, P71, DOI 10.1016/0027-5107(85)90209-X; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PIENTENPOL JA, 1993, NATURE, V211, P31; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SVITSKY K, 1995, SCIENCE, V268, P1749; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; TROELSTRA C, 1994, CURR BIOL, V4, P1149, DOI 10.1016/S0960-9822(00)00260-8; VOGELSTEIN B, 1992, NATURE, V355, P209, DOI 10.1038/355209a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755	61	83	83	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1427	1435						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478567				2022-12-28	WOS:A1995TC53500001
J	CHEN, CY; FALLER, DV				CHEN, CY; FALLER, DV			DIRECTION OF P21(RAS)-GENERATED SIGNALS TOWARDS CELL-GROWTH OR APOPTOSIS IS DETERMINED BY PROTEIN-KINASE-C AND BCL-2	ONCOGENE			English	Article						PROGRAMMED CELL DEATH; T LYMPHOCYTE; ONCOGENE; PHOSPHOPROTEIN; SIGNAL TRANSDUCTION; CELL CYCLE	ANTIGEN RECEPTOR; T-CELLS; REGULATED KINASE-2; DNA FRAGMENTATION; RAS ONCOGENES; LYMPHOCYTES-T; HA-RAS; ACTIVATION; DEATH; MYC	Normal and activated Ras proteins are known to act as signal transducers, mediating mitogenic responses. Interactions of p21(ras) and protein kinase C (PKC) are required in a number of mitogenic or activation signaling pathways. The constitutive expression of activated v-Ha-ras in Jurkat cells, a human T lymphoblastoid cell line, renders the cells susceptible to apoptosis during transient down-regulation or inhibition of PKC. Similarly, the expression of v-Ki-ras in murine fibroblasts induces apoptosis during suppression of PKC activity. This Ras-specific cell death is dependent upon suppression of cellular PKC activity, and can be blocked by the survival-promoting bcl-2 gene product. In vivo phosphorylation studies indicate that Bcl-2 is a phosphoprotein, and the phosphorylation state of Bcl-2 is modulated in the setting of activated p21(Ha-ras) in response to inhibition of PKC. These findings suggest an interactive regulation of growth or apoptosis in cells which involves at least three molecules: p21(ras), PKC and Bcl-2.	BOSTON UNIV,SCH MED,CANC RES CTR,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MICROBIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PATHOL & LAB MED,BOSTON,MA 02118	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University								ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BARBACID M, 1987, ANNU REV BIOCHEM, P779; BERRY N, 1990, EUR J BIOCHEM, V189, P204; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1990, NATURE, V348, P678, DOI 10.1038/348678a0; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; DEROSSI A, 1994, VIROLOGY, V198, P234, DOI 10.1006/viro.1994.1026; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DUKE RC, 1994, FASEB J, V8, P237, DOI 10.1096/fasebj.8.2.8119494; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FALLER DV, 1994, J BIOL CHEM, V269, P5022; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FERNANDEZSARABI.MJ, 1995, NATURE, V10, P768; FERNANDEZSARABI.MJ, 1993, NATURE, V366, P274; FU T, 1992, FEBS LETT, V307, P301, DOI 10.1016/0014-5793(92)80700-Q; FU T, 1991, EXP CELL RES, V203, P230; GRAVES JD, 1990, BIOCHEM J, V265, P407, DOI 10.1042/bj2650407; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOWE PH, 1993, J BIOL CHEM, V268, P21448; ILLERA VA, 1993, J IMMUNOL, V151, P2965; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOKA P, 1991, J IMMUNOL, V146, P2417; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOTEM J, 1994, CELL GROWTH DIFFER, V5, P321; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUCAS M, 1994, BIOCHEM PHARMACOL, V47, P667, DOI 10.1016/0006-2952(94)90129-5; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARVEL J, 1994, ONCOGENE, V9, P1117; MAUMOVSKI L, 1994, BLOOD, V83, P2261; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MCDONNELL TJ, 1993, RADIAT RES, V136, P307, DOI 10.2307/3578541; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1993, BLOOD, V81, P151; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MORRIS JDH, 1989, ONCOGENE, V4, P27; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; POLVERINO AJ, 1990, BIOCHEM J, V271, P309, DOI 10.1042/bj2710309; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; RAKE JB, 1991, J BIOL CHEM, V266, P5348; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; RODEN RBS, 1993, CELL GROWTH DIFFER, V4, P957; SCHER CD, 1982, J CELL PHYSIOL, V113, P211, DOI 10.1002/jcp.1041130205; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SUGIMOTO Y, 1992, EXP CELL RES, V203, P230, DOI 10.1016/0014-4827(92)90059-H; TAMM I, 1990, J CELL PHYSIOL, V143, P494, DOI 10.1002/jcp.1041430314; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WALTON MI, 1993, CANCER RES, V53, P1853; WANG HG, 1994, ONCOGENE, V9, P2751; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WIESMULLER L, 1994, CELL SIGNAL, V6, P247, DOI 10.1016/0898-6568(94)90030-2; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; WOODS NM, 1987, BIOCHEM J, V246, P619, DOI 10.1042/bj2460619; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; YOSHINO T, 1994, BLOOD, V83, P1856; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	95	120	121	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1487	1498						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478573				2022-12-28	WOS:A1995TC53500007
J	KIKUCHIYANOSHITA, R; TANAKA, K; MURAOKA, M; KONISHI, M; KAWASHIMA, I; TAKAMOTO, S; HIRAI, H; MIYAKI, M				KIKUCHIYANOSHITA, R; TANAKA, K; MURAOKA, M; KONISHI, M; KAWASHIMA, I; TAKAMOTO, S; HIRAI, H; MIYAKI, M			MALIGNANT TRANSFORMATION OF RAT EMBRYO FIBROBLASTS BY COTRANSFECTION WITH 11 HUMAN MUTANT P53 CDNAS AND ACTIVATED H-RAS GENE	ONCOGENE			English	Article						MUTANT P53 CDNAS; H-RAS GENE; REF; TRANSFORMATION; METASTASIS	FAMILIAL ADENOMATOUS POLYPOSIS; WILD-TYPE P53; TUMOR-ANTIGEN; CELLS; CARCINOMAS; ALLELES; DNA; IMMORTALIZATION; AMPLIFICATION; EXPRESSION	Eleven different missense and one nonsense mutant-type p53 cDNAs, which have been frequently detected in human colorectal carcinomas, were constructed and examined for their ability to cooperate with activated human H-ras genes, pSK2 and pHs49, in transfection of rat embryo fibroblasts (REF), Each missense mutant-type p53 cDNA with either of the two activated H-ras genes transformed REF with a different frequency of transformation depending on the different kind of mutation, whereas wild-type p53 (with ras), nonsense mutant-type p53 (with pas), as well as mutant-type p53 (alone) and ras (alone), did not transform REF, Six transformed REF cell lines were established from cotransfection with missense mutant-type p53 cDNA and ras gene; all of them exhibiting exogenous human p53 DNA, RNA, protein, and H-ras DNA and RNA, All six transformed cell lines showed both tumorigenicity and lung metastatic potential in nude mice, They also exhibited 92 kilodalton gelatinase activity, which was not detected in parental REF, These results suggest that missense mutations in p53 gene have a role in malignant transformation as well as metastatic potential.	TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT TUMOR IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN KOMAGOME HOSP,DEPT TRANSFUS MED,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; University of Tokyo								ADDISON C, 1990, ONCOGENE, V5, P423; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BERNHARD EJ, 1990, CANCER RES, V550, P3872; BRISTOW RG, 1994, ONCOGENE, V9, P1527; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HIDDEMANN W, 1984, CYTOMETRY, V5, P445, DOI 10.1002/cyto.990050502; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; IINO H, 1994, CANCER, V73, P1324, DOI 10.1002/1097-0142(19940301)73:5<1324::AID-CNCR2820730503>3.0.CO;2-W; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; KONISHI M, 1993, JPN J CANCER RES, V84, P893, DOI 10.1111/j.1349-7006.1993.tb02063.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; MIYAKI M, 1990, CANCER RES, V50, P7166; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; POLLACK R, 1974, P NATL ACAD SCI USA, V71, P4792, DOI 10.1073/pnas.71.12.4792; PONTA H, 1994, EUR J CANCER, V30A, P1995, DOI 10.1016/0959-8049(94)00393-J; ROVINSKI B, 1988, ONCOGENE, V2, P445; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLINGERLAND JM, 1991, J CELL PHYSIOL, V148, P391, DOI 10.1002/jcp.1041480309; TAKAMOTO S, 1991, CYTOMETRY RES, V1, P77; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHANG JY, 1992, CANCER RES, V52, P6682	35	12	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1339	1345						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478555				2022-12-28	WOS:A1995RY96700015
J	KATZAV, S; PACKHAM, G; SUTHERLAND, M; AROCA, P; SANTOS, E; CLEVELAND, JL				KATZAV, S; PACKHAM, G; SUTHERLAND, M; AROCA, P; SANTOS, E; CLEVELAND, JL			VAV AND RAS INDUCE FIBROBLAST TRANSFORMATION BY OVERLAPPING SIGNALING PATHWAYS, WHICH REQUIRE C-MYC FUNCTION	ONCOGENE			English	Article						VAV; VAS; C-MYC; SH2	TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; ORNITHINE DECARBOXYLASE; HEMATOPOIETIC-CELLS; TRANSCRIPTIONAL ACTIVATION; NEOPLASTIC TRANSFORMATION; SH2 DOMAIN; PROTEIN; EXPRESSION; KINASE	Recent evidence has suggested that the Vav oncoprotein may function as a hematopoietic-specific GTP exchange factor for the Ras superfamily of proteins, However, transformation of NIH3T3 fibroblast cells by Vav is morphologically distinct from that induced by activated Ras oncogenes, suggesting that the two oncoproteins induce separate signal transduction pathways which promote transformation, To address this issue, the effects of dominant negative mutants of H-ras and proto-Vav (proto-VavR695L, a mutation in the VavSH2 domain) were tested on Vav- and Ras-induced transformation, These mutants partially inhibited both Vav- and Ras-induced transformation, suggesting that they may induce a common downstream signaling pathway which potentiates transformation, As an independent measure of Vav function we also tested the ability of the purified protein encoded by VavSH2 to influence Germinal Vesicle Breakdown (GVBD) during Xenopus oocyte maturation, Microinjection of the VavSH2 protein alone, but not mutant VavR695L SH2 protein, was sufficient to induce GVBD and accelerated maturation induced by normal Ras, suggesting that in this system as well Vav and Ras signals overlap through a common effector, A key target of multiple signalling pathways is c-Myc. Dominant negative versions of c-Myc totally abolished morphologic transformation of NIH3T3 cells by both Vav and Ras oncogenes, These results suggest that distinct, but overlapping, signalling pathways are induced by Vav and Ras and that fibroblast cell transformation by either oncogene requires c-Myc functions.	MCGILL UNIV, DEPT ONCOL, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, DEPT MED, MONTREAL, PQ H3G 1Y6, CANADA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	McGill University; McGill University; St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Tennessee System; University of Tennessee Health Science Center	KATZAV, S (corresponding author), MCGILL UNIV, JEWISH GEN HOSP, LADY DAVIS INST MED RES, TERRY FOX MOLEC ONCOL GRP, MONTREAL, PQ H3T 1E2, CANADA.			Aroca, Pilar/0000-0002-7557-6931	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER; NCI NIH HHS [P0 CA21765] Funding Source: Medline; NIDDK NIH HHS [DK44158] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; ASKEW DS, 1993, BLOOD, V82, P2079; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENTINO M, 1991, SCIENCE, V253, P565; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; BUSTELO XR, 1992, NATURE, V356, P69; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALLAND F, 1992, ONCOGENE, V7, P585; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GULBINS E, 1994, J IMMUNOL, V152, P2123; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P2095, DOI 10.1021/bi00007a002; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MIN SY, 1994, CELL GROWTH DIFFER, V5, P563; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MURKHERJEE B, 1992, GENE DEV, V6, P1480; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P6661, DOI 10.1128/MCB.13.11.6661; NEBREDA AR, 1993, ONCOGENE, V8, P467; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PENA A, 1993, J BIOL CHEM, V268, P27277; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; PORRAS A, 1994, J BIOL CHEM, V269, P12741; PORRAS A, 1992, J BIOL CHEM, V267, P21124; PRENDERGAST GC, 1991, CELL, V65, P186; PUIL L, 1992, Current Biology, V2, P275, DOI 10.1016/0960-9822(92)90396-R; RESAR LMS, 1993, MOL CELL BIOL, V13, P1130, DOI 10.1128/MCB.13.2.1130; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAVIGIAN SV, 1994, MOL CELL BIOL WAGNJ, V5, P375; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629	84	35	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1079	1088						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566967				2022-12-28	WOS:A1995RX18000010
J	LAVAU, C; MARCHIO, A; FAGIOLI, M; JANSEN, J; FALINI, B; LEBON, P; GROSVELD, F; PANDOLFI, PP; PELICCI, PG; DEJEAN, A				LAVAU, C; MARCHIO, A; FAGIOLI, M; JANSEN, J; FALINI, B; LEBON, P; GROSVELD, F; PANDOLFI, PP; PELICCI, PG; DEJEAN, A			THE ACUTE PROMYELOCYTIC LEUKEMIA-ASSOCIATED PML GENE IS INDUCED BY INTERFERON	ONCOGENE			English	Article						ACUTE PROMYELOCYTIC LEUKEMIA; T(15-17) TRANSLOCATION; PML-RAR-ALPHA; NUCLEAR BODIES; INTERFERON	PRIMARY BILIARY-CIRRHOSIS; TRANS RETINOIC ACID; T(15-17) TRANSLOCATION; MONOCLONAL-ANTIBODY; NUCLEAR-BODIES; LEUKEMIA FUSES; RAR-ALPHA; EXPRESSION; RECEPTOR; CELLS	The PML protein concentrates within discrete nuclear structures known as nuclear bodies, also called NDs or PODs, which contain several proteins including the interferon (IFN)-inducible SP100 product, The function of these structures remains elusive, We and others have shown recently that they represent specific targets for adenovirus and herpes simplex virus. This prompted us to investigate whether PML, like SP100, might be induced by IFN and to explore the role of PML in viral infection, Here we report that PML mRNA levels increase rapidly in response to interferon treatment, This accumulation of. PML transcripts is a primary IFN response since it does not require de novo protein synthesis, The IFN-induced activation of the PML gene is accompanied by enhanced protein expression as revealed by immunolabelling, Both the intensity of the staining and the number of labelled structures increased upon interferon exposure, To probe the role of PML in IFN action, we compared the antiviral state established by alpha-interferon in embryonic fibroblasts (EFs) derived from null mutant mice for PML and from wild-type control mice, The resistance to viral infection conferred by IFN-alpha was identical in both PML(+/+) and PML(m/m) fibroblasts indicating that PML is not an essential mediator of the antiviral effect of interferon, We also noted that DNA-binding factors are normally activated by IFN in PML(m/m) cells.	UNIV PERUGIA,POLICLIN PERUGIA,IST CLIN MED 1,I-06100 PERUGIA,ITALY; HOP ST VINCENT DE PAUL,SERV BACTERIOL VIROL,F-75674 PARIS 14,FRANCE; NATL INST MED RES,GENE STRUCT & EXPRESS LAB,LONDON NW7 1AA,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,LONDON W12 0HS,ENGLAND; EUROPEAN INST ONCOL,I-20141 MILAN,ITALY	University of Perugia; Azienda Ospedaliera di Perugia; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; MRC National Institute for Medical Research; Imperial College London; IRCCS European Institute of Oncology (IEO)	LAVAU, C (corresponding author), INST PASTEUR,UNITE RECOMBINAISON & EXPRESS GENET,INSERM,U163,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		Dejean, Anne/L-5145-2018; Pelicci, Pier Giuseppe/AAL-6572-2020; Lavau, Catherine/Q-2928-2019; Jansen, J.H./H-8054-2014	Jansen, J.H./0000-0001-9459-568X; Lavau, Catherine/0000-0003-4800-1320; FALINI, Brunangelo/0000-0002-7198-5965				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ALLEN G, 1982, J GEN VIROL, V63, P207, DOI 10.1099/0022-1317-63-1-207; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BOUTEILLE M, 1974, CELL NUCLEUS, P5; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; BREITMAN TR, 1981, BLOOD, V57, P1000; CARVALHO T, 1995, IN PRESS J CELL BIOL; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; CHOMIENNE C, 1990, BLOOD, V76, P1710; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EPSTEIN AL, 1984, J VIROL, V50, P372, DOI 10.1128/JVI.50.2.372-379.1984; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1994, BLOOD, V83, P10; GULDNER HH, 1992, J IMMUNOL, V149, P4067; HORISBERGER MA, 1987, J GEN VIROL, V68, P945, DOI 10.1099/0022-1317-68-3-945; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JANSEN JH, 1995, IN PRESS P NATL ACAD; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LAVAU C, 1994, LEUKEMIA, V8, P1615; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; PADYKULA HA, 1981, CELL NUCLEUS, V9, P309; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; STUURMAN N, 1992, J CELL SCI, V101, P773; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TERRIS B, 1995, CANCER RES, V55, P1590; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; XIE KW, 1993, MOL CELL BIOL, V13, P6170, DOI 10.1128/MCB.13.10.6170	51	224	226	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					871	878						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7545807				2022-12-28	WOS:A1995RU79800007
J	MUTHUSWAMY, SK; MULLER, WJ				MUTHUSWAMY, SK; MULLER, WJ			DIRECT AND SPECIFIC INTERACTION OF C-SRC WITH NEU IS INVOLVED IN SIGNALING BY THE EPIDERMAL GROWTH-FACTOR RECEPTOR	ONCOGENE			English	Article						NEU; EGFR; C-SRC; SH2; RECEPTOR SIGNALING	TYROSINE KINASE-ACTIVITY; EGF RECEPTOR; AUTOPHOSPHORYLATION SITES; MITOGENIC RESPONSIVENESS; MAMMARY-TUMORS; BREAST-CANCER; ONCOGENE; FAMILY; PHOSPHORYLATION; PROTEIN	Transgenic mice expressing either the activated or wild type neu oncogene heritably develop metastatic mammary tumors. Tumor development in this transgenic mouse model correlates with activation of the Neu tyrosine kinase. Recently, we have shown that these Neu-induced mammary tumors possess elevated c-Src tyrosine kinase activity. Here, we demonstrate that c-Src requires tyrosine phosphorylated Neu for its ability to associate with Neu in vivo and this association is likely the result of a direct physical binding of c-Src SH2 domain to the tyrosine phosphorylated Neu. By contrast, the c-Src SH2 domain did not interact directly with tyrosine phosphorylated EGFR. Moreover, in established cell lines expressing elevated levels of EGFR, EGF stimulation results in transphosphorylation of Neu and formation of complexes between c-Src and tyrosine phosphorylated Neu. Taken together, these observations suggest that activation of c-Src by these two closely related EGFR family members results from a direct and specific interaction of c-Src with tyrosine phosphorylated Neu.	MCMASTER UNIV, INST MOLEC BIOL & BIOTECHNOL, DEPT BIOL, HAMILTON, ON, CANADA; MCMASTER UNIV, INST MOLEC BIOL & BIOTECHNOL, DEPT PATHOL, HAMILTON, ON, CANADA	McMaster University; McMaster University			Muthuswamy, Senthil K/AGY-2834-2022	Muthuswamy, Senthil K/0000-0001-6564-9634				BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; JANES PW, 1994, ONCOGENE, V9, P3601; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, ADV CANCER RES, V64, P111, DOI 10.1016/S0065-230X(08)60836-2; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PATERSON MC, 1991, CANCER RES, V51, P556; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROMANO A, 1994, ONCOGENE, V8, P2105; RON D, 1992, BIOTECHNIQUES, V13, P866; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SEGATTO O, 1993, ONCOGENE, V8, P2105; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SONGYANG Z, 1993, CELL, V77, P767; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536	56	105	109	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					271	279						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7542762				2022-12-28	WOS:A1995RK95700008
J	SOMMERS, CL; HUANG, K; SHORES, EW; GRINBERG, A; CHARLICK, DA; KOZAK, CA; LOVE, PE				SOMMERS, CL; HUANG, K; SHORES, EW; GRINBERG, A; CHARLICK, DA; KOZAK, CA; LOVE, PE			MURINE TXK - A PROTEIN-TYROSINE KINASE GENE REGULATED BY T-CELL ACTIVATION	ONCOGENE			English	Article						TXK; PROTEIN TYROSINE KINASE; THYMUS; T LYMPHOCYTES; SIGNAL TRANSDUCTION	X-LINKED AGAMMAGLOBULINEMIA; LYMPHOCYTES-T; ZETA-CHAIN; RECEPTOR; MOUSE; EXPRESSION; IDENTIFICATION; INTERLEUKIN-2; CLONING; FAMILY	To identify genes involved in signal transduction pathways that regulate T cell activation and development, murine fetal thymocytes were screened for expression of protein tyrosine kinase family members by the polymerase chain reaction, Using this approach, a nonreceptor protein tyrosine kinase, txk, was identified and cloned. Txk is expressed in thymocytes as early as fetal day 13.5 and its expression at the mRNA level continues throughout development, Txk transcripts are present in thymocytes, peripheral T cells and mast cell lines, but are not detectable in B cell macrophage/monocyte cell lines or in non-hematopoietic fetal or adult tissues, In both thymocytes and T cells, txk transcripts are down-regulated after activation with PMA and ionomycin, concanavalin A or T cell receptor cross-linking, Sequence analysis indicates that txk contains SH2, SH3 and kinase catalytic domains and belongs to the tec family of cytoplasmic protein tyrosine kinases which includes tec, itk and btk, Its unique N-terminus contains a proline-rich region, but unlike the other dec family members, does not contain a pleckstrin homology domain, The restricted expression pattern of txk and its regulation by T cell activation make it an excellent candidate for involvement in signal transduction during thymocyte development.	NIAID, MOLEC MICROBIOL LAB, BETHESDA, MD 20892 USA; US FDA, CTR BIOL EVALUAT & RES, DIV HEMATOL PROD, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); US Food & Drug Administration (FDA)	SOMMERS, CL (corresponding author), NICHHD, MAMMALIAN GENES & DEV LAB,BLDG 6B,ROOM 2B-210, 6 CTR DR, MSC 2780, BETHESDA, MD 20892 USA.							ADAMSON MC, 1991, VIROLOGY, V183, P778, DOI 10.1016/0042-6822(91)91010-E; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BROWN T, 1994, CURRENT PROTOCOLS; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DANCIGER M, 1993, GENOMICS, V16, P361, DOI 10.1006/geno.1993.1198; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207, DOI 10.1016/S0065-2776(08)60643-4; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GIBSON S, 1993, BLOOD, V82, P1561; GODFREY DI, 1992, J IMMUNOL, V149, P2281; Green EL, 1981, GENETICS PROBABILITY, P77; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HUANG HJS, 1987, P NATL ACAD SCI USA, V84, P204, DOI 10.1073/pnas.84.1.204; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; KOZAK CA, 1994, MAMM GENOME, V5, pS65; LEO O, 1987, J IMMUNOL, V139, P1214; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LOVE PE, 1994, J EXP MED, V179, P1485, DOI 10.1084/jem.179.5.1485; LUNDIN LG, 1993, GENOMICS, V16, P1, DOI 10.1006/geno.1993.1133; MANO H, 1994, ONCOGENE, V9, P3205; MANO H, 1993, ONCOGENE, V8, P417; MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x; MILLER J, 1985, J IMMUNOL, V134, P4212; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; PALACIOS R, 1992, DEVELOPMENT, V115, P1133; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; RAWLINGS DJ, 1994, IMMUNOL REV, V138, P105, DOI 10.1111/j.1600-065X.1994.tb00849.x; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SATO K, 1994, LEUKEMIA, V8, P1663; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SINGH G, 1991, P NATL ACAD SCI USA, V88, P10706, DOI 10.1073/pnas.88.23.10706; SMITH CIE, 1994, J IMMUNOL, V152, P557; TANAKA N, 1993, FEBS LETT, V324, P1, DOI 10.1016/0014-5793(93)81520-A; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VONBOEHMER H, 1992, BONE MARROW TRANSPL, V9, P46; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZUNIGAPFLUCKER JC, 1993, J EXP MED, V178, P1139, DOI 10.1084/jem.178.4.1139	52	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					245	251						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7542761				2022-12-28	WOS:A1995RK95700005
J	YAMATO, K; YAMAMOTO, M; HIRANO, Y; TSUCHIDA, N				YAMATO, K; YAMAMOTO, M; HIRANO, Y; TSUCHIDA, N			A HUMAN TEMPERATURE-SENSITIVE P53 MUTANT P53(VAL-138) - MODULATION OF THE CELL-CYCLE, VIABILITY AND EXPRESSION OF P53-RESPONSIVE GENES	ONCOGENE			English	Article						HUMAN TS P53 MUTANT; G1 ARREST; G2 ARREST; APOPTOSIS	WILD-TYPE P53; MAMMALIAN-CELLS; BINDING-SITE; IN-VIVO; PROTEIN; DNA; INHIBITION; APOPTOSIS; SEQUENCE; POTENT	A human p53 mutant, p53(Val-138) (amino acid 138, Alanine-->Valine), generated by in vitro mutagenesis was introduced into Saos-2 human osteosarcoma and Jurkat acute T-lymphoblastic leukemia cell lines, both lacking p53 protein expression. p53(Val-138) caused growth arrest in Saos-2 cell line and apoptosis in Jurkat cell line at 32.5 degrees C while it allowed both cell lines to grow continuously at 37.5 degrees C. p53(Val-138) activated expression of p53-responsive genes including MDM2, GADD45 and WAF1/CIP1/SDI1 in Saos-2 cell line upon the temperature shift-down from 37.5 degrees C to 32.5 degrees C. Thus, p53(Val-138) acted as a temperature-sensitive p53 mutant. Taking advantage of these human cell systems, we demonstrated that p53-mediated cell cycle arrest occurred in G1 and G2/M phases of Saos-2 cell line but not in Jurkat cell line. The induced level of WAF1/CIP1/SDI1 mRNA by p53 was extremely lower in Jurkat cell line than that of Saos-2 cell line. However, MDM2 mRNA accumulated to the similar levels in these two cell lines. These results suggest that a factor(s) other than p53 may be involved in differential expression of WAF1/CIP1/SDI1 and MDM2 mRNA	TOKYO MED & DENT UNIV,FAC DENT,DEPT MOLEC CELLULAR ONCOL & MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,FAC DENT,DEPT PERIODONTOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,FAC DENT,DEPT MAXILLOFACIAL SURG 2,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1995, GENE DEV, V8, P2939; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HASSAPOGLIDOU S, 1993, ONCOGENE, V8, P1501; HIRANO Y, ONCOGENE, V10, P1879; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KWON HJ, 1992, CANCER RES, V52, P6926; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MICHIELI P, 1994, CANCER RES, V54, P3391; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SEHGAL PB, 1993, ONCOGENE, V8, P3417; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SUGITO S, 1991, INT J CANCER, V49, P880, DOI 10.1002/ijc.2910490614; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	57	60	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					1	6						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624116				2022-12-28	WOS:A1995RJ29500001
J	GONZALEZCADAVID, NF; ZHOU, D; BATTIFORA, H; BARELI, M; CLINE, MJ				GONZALEZCADAVID, NF; ZHOU, D; BATTIFORA, H; BARELI, M; CLINE, MJ			DIRECT SEQUENCING ANALYSIS OF EXON-1 OF THE C-K-RAS GENE SHOWS A LOW-FREQUENCY OF MUTATIONS IN HUMAN PANCREATIC ADENOCARCINOMAS	ONCOGENE			English	Article											GONZALEZCADAVID, NF (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DIV HEMATOL ONCOL,FACTOR BLDG 11-151,LOS ANGELES,CA 90024, USA.							ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARELI M, 1989, BLOOD, V73, P281; BARELI M, 1989, IN PRESS BRIT J HAEM; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; PEDERSENBJERGAARD J, 1988, CANCER RES, V48, P1812; ROCHLITZ DF, 1988, DNA, V1, P515; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1988, CANCER RES, V48, P5738; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; VANTVEER LJ, 1988, ONCOGENE, V2, P157; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	19	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1137	1140						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2674856				2022-12-28	WOS:A1989AM53100013
J	KARN, J; WATSON, JV; LOWE, AD; GREEN, SM; VEDECKIS, W				KARN, J; WATSON, JV; LOWE, AD; GREEN, SM; VEDECKIS, W			REGULATION OF CELL-CYCLE DURATION BY C-MYC LEVELS	ONCOGENE			English	Article									MRC, CLIN ONCOL UNIT, CAMBRIDGE CB2 2QH, ENGLAND		KARN, J (corresponding author), MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND.							ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BRAUMBACH WR, 1986, J VIROL, V59, P276; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CAMPISI J, 1984, EXP CELL RES, V152, P459, DOI 10.1016/0014-4827(84)90647-5; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIERS W, 1978, NATURE, V273, P113, DOI 10.1038/273113a0; GAUTCHI W, 1964, APPLIED MATH SERIES, V55, P297; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; GREEN SM, 1989, ONCOGENE, V4, P737; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; GUTIERREZ C, 1987, MOL CELL BIOL, V7, P4594, DOI 10.1128/MCB.7.12.4594; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KENTER AL, 1987, J IMMUNOL METHODS, V97, P111, DOI 10.1016/0022-1759(87)90112-8; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MILLER AD, 1985, MOL CELL BIOL, V5, P431, DOI 10.1128/MCB.5.3.431; MILLER AD, 1984, J VIROL, V49, P214, DOI 10.1128/JVI.49.1.214-222.1984; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MORSE HC, 1986, P NATL ACAD SCI USA, V83, P6868, DOI 10.1073/pnas.83.18.6868; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SORRENTINO V, 1987, P NATL ACAD SCI USA, V84, P4131, DOI 10.1073/pnas.84.12.4131; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; SULLIVAN NF, 1986, COLD SPRING HARB SYM, V51, P943, DOI 10.1101/SQB.1986.051.01.107; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WATSON JV, 1988, J IMMUNOL METHODS, V113, P205, DOI 10.1016/0022-1759(88)90333-X; WATSON JV, 1985, J IMMUNOL METHODS, V83, P179, DOI 10.1016/0022-1759(85)90071-7; WATSON JV, 1987, NATURE, V325, P741, DOI 10.1038/325741a0; WATSON JV, 1985, BRIT J CANCER, V51, P433, DOI 10.1038/bjc.1985.60; WATSON JV, 1981, CYTOMETRY, V2, P14, DOI 10.1002/cyto.990020103; WATSON JV, 1980, CYTOMETRY, V1, P143, DOI 10.1002/cyto.990010209; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WHITE JG, 1987, J CELL BIOL, V105, P41, DOI 10.1083/jcb.105.1.41; WILTSHIRE CR, 1978, BRIT J CANCER, V37, P286; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	75	168	171	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1989	4	6					773	787						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2660073				2022-12-28	WOS:A1989AA66000014
J	PONZETTO, C; WADEWITZ, AG; PENDERGAST, AM; WITTE, ON; WOLGEMUTH, DJ				PONZETTO, C; WADEWITZ, AG; PENDERGAST, AM; WITTE, ON; WOLGEMUTH, DJ			P150C-ABL IS DETECTED IN MOUSE MALE GERM-CELLS BY AN INVITRO KINASE ASSAY AND IS ASSOCIATED WITH STAGE-SPECIFIC PHOSPHOPROTEINS IN HAPLOID CELLS	ONCOGENE			English	Article									COLUMBIA UNIV COLL PHYS & SURG, CTR REPROD SCI, 630 W 168TH ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT GENET & DEV, NEW YORK, NY 10032 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	Columbia University; Columbia University; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles				Pendergast, Ann Marie/0000-0002-1250-6880	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD005077] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA027507] Funding Source: NIH RePORTER; NCI NIH HHS [CA27507] Funding Source: Medline; NICHD NIH HHS [HD07093, P50 HD05077] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DUGGAL RN, 1987, BIOL TESTIS EPIDIDYM, P112; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER RA, 1972, P NATL ACAD SCI USA, V69, P2965, DOI 10.1073/pnas.69.10.2965; LIPSICH LA, 1982, MOL CELL BIOL, V2, P875, DOI 10.1128/MCB.2.7.875; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; NEBEL BR, 1961, SCIENCE, V134, P832, DOI 10.1126/science.134.3482.832; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PENDERGAST AM, 1987, MOL CELL BIOL, V7, P4280, DOI 10.1128/MCB.7.12.4280; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WITTE O, 1986, CANCER SURV, V5, P182; WOLGEMUTH DJ, 1985, GAMETE RES, V12, P1, DOI 10.1002/mrd.1120120102; ZAKERI ZF, 1988, DEV BIOL, V125, P417, DOI 10.1016/0012-1606(88)90222-9; ZIEMIECKI A, 1986, VIROLOGY, V151, P265, DOI 10.1016/0042-6822(86)90048-6	24	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1989	4	6					685	690						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2660070				2022-12-28	WOS:A1989AA66000003
J	LUBBERT, M; MILLER, CW; KAHAN, J; KOEFFLER, HP				LUBBERT, M; MILLER, CW; KAHAN, J; KOEFFLER, HP			EXPRESSION, METHYLATION AND CHROMATIN STRUCTURE OF THE P53-GENE IN UNTRANSFORMED AND HUMAN T-CELL LEUKEMIA-VIRUS TYPE-I-TRANSFORMED HUMAN LYMPHOCYTE-T	ONCOGENE			English	Article									UNIV CALIF LOS ANGELES,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles					NATIONAL CANCER INSTITUTE [R01CA033936, R01CA026038, U01CA043277] Funding Source: NIH RePORTER; NCI NIH HHS [CA33936, CA26038, CA43277] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBIERI R, 1987, BIOCHEM BIOPH RES CO, V145, P96, DOI 10.1016/0006-291X(87)91292-7; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P51; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN ISY, 1983, P NATL ACAD SCI-BIOL, V80, P7006, DOI 10.1073/pnas.80.22.7006; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EISSENBERG JC, 1985, ANNU REV GENET, V19, P485, DOI 10.1146/annurev.genet.19.1.485; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; Favaloro J, 1980, Methods Enzymol, V65, P718; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; Gluzman Y, 1980, Cold Spring Harb Symp Quant Biol, V44 Pt 1,, P293; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; HARDY KJ, 1985, P NATL ACAD SCI USA, V82, P8173, DOI 10.1073/pnas.82.23.8173; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; JAY G, 1981, P NATL ACAD SCI-BIOL, V78, P2932, DOI 10.1073/pnas.78.5.2932; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KOEFFLER HP, 1984, BLOOD, V64, P482; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; KOEFFLER HP, 1985, BLOOD, V65, P484; LAEMMLI UK, 1970, J MOL BIOL, V98, P680; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILLS FC, 1983, NATURE, V306, P809, DOI 10.1038/306809a0; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MIYOSHI I, 1981, NATURE, V294, P700; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; POPOVIC M, 1983, SCIENCE, V219, P856, DOI 10.1126/science.6600519; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROTTER V, 1981, J VIROL, V38, P336, DOI 10.1128/JVI.38.1.336-346.1981; ROTTER V, 1983, P NATL ACAD SCI-BIOL, V80, P2613, DOI 10.1073/pnas.80.9.2613; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHIMADA T, 1985, J BIOL CHEM, V260, P2468; SIDELL N, 1988, CANCER RES, V48, P2226; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; STORB U, 1983, P NATL ACAD SCI-BIOL, V80, P6642, DOI 10.1073/pnas.80.21.6642; TRATNER I, 1987, MOL CELL BIOL, V7, P1856, DOI 10.1128/MCB.7.5.1856; VANDERPLOEG LHT, 1980, CELL, V19, P947, DOI 10.1016/0092-8674(80)90086-0; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	60	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					643	651						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2657579				2022-12-28	WOS:A1989U768800016
J	OHARA, BM; BLAIR, DG				OHARA, BM; BLAIR, DG			A THRESHOLD EFFECT IN THE INDUCTION OF TUMORIGENICITY OF AN ESTABLISHED HUMAN CELL-LINE BY V-MOS	ONCOGENE			English	Article									NCI,FREDERICK CANC RES FACIL,MOLEC ONCOL LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BOREK C, 1982, ADV CANCER RES, V37, P159, DOI 10.1016/S0065-230X(08)60884-2; DIPAOLO JA, 1983, J NATL CANCER I, V70, P3; DONIGER J, 1983, SCIENCE, V222, P1144, DOI 10.1126/science.6648529; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FISCHINGER PJ, 1975, P NATL ACAD SCI USA, V72, P5150, DOI 10.1073/pnas.72.12.5150; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HAAPALA DK, 1985, J VIROL, V53, P827, DOI 10.1128/JVI.53.3.827-833.1985; KLINGER HP, 1986, CYTOGENET CELL GENET, V42, P225, DOI 10.1159/000132283; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OHARA BM, 1987, MOL CELL BIOL, V7, P2941, DOI 10.1128/MCB.7.8.2941; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; PAPKOFF J, 1984, J VIROL, V52, P420, DOI 10.1128/JVI.52.2.420-430.1984; ROBEY WG, 1977, CELL, V10, P79; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANBRIDGE EJ, 1981, SOMAT CELL GENET, V7, P699, DOI 10.1007/BF01538758; STEVENSON M, 1986, MOL CELL BIOL, V6, P3410, DOI 10.1128/MCB.6.10.3410; STILES CD, 1975, P NATL ACAD SCI USA, V72, P4971, DOI 10.1073/pnas.72.12.4971; TAINSKY MA, 1987, MOL CELL BIOL, V7, P1280, DOI 10.1128/MCB.7.3.1280; TODARO GJ, 1974, J NATL CANCER I, V52, P167, DOI 10.1093/jnci/52.1.167	30	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					295	299						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	2974527				2022-12-28	WOS:A1988Q436700008
J	WILLIAMS, BP; SHIPLEY, JP; SPURR, NK; SMITH, DR; HAYMAN, MJ; GOODFELLOW, PN				WILLIAMS, BP; SHIPLEY, JP; SPURR, NK; SMITH, DR; HAYMAN, MJ; GOODFELLOW, PN			A HUMAN SEQUENCE HOMOLOGOUS TO V-SEA MAPS TO CHROMOSOME-11, BAND-Q13	ONCOGENE			English	Note									IMPERIAL CANC RES FUND,HUMAN CYTOGENET LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,HUMAN GENET RESOURCE FACIL,S MIMMS,HERTS,ENGLAND; COLLABORAT RES INC,DEPT HUMAN GENET,WALTHAM,MA; SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794	Cancer Research UK; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	WILLIAMS, BP (corresponding author), IMPERIAL CANC RES FUND,HUMAN MOLEC GENET LAB,POB 123,LINCOLNS INN FIELD,LONDON WC2A 3PX,ENGLAND.			Williams, Brenda Patricia/0000-0003-4690-5932	NCI NIH HHS [CA42573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1981, SOMAT CELL GENET, V7, P435, DOI 10.1007/BF01542988; BENEDICT SH, 1985, VIROLOGY, V145, P154, DOI 10.1016/0042-6822(85)90210-7; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; CARRITT B, 1979, CYTOGENET CELL GENET, V23, P171, DOI 10.1159/000131323; CARRITT B, 1980, TISSUE CULTURE MED R, V2, P169; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHAN AML, 1987, ONCOGENE, V1, P229; DEAN M, 1985, NATURE, V318, P285; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EDWARDS YH, 1985, ANN HUM GENET, V49, P101, DOI 10.1111/j.1469-1809.1985.tb01681.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOODFELLOW PN, 1982, EUR J IMMUNOL, V12, P659, DOI 10.1002/eji.1830120807; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; HARRIS H, 1978, HUMAN GENETICS S; HARRIS H, 1977, HUMAN GENETICS S; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HOBART MJ, 1981, ANN HUM GENET, V45, P331, DOI 10.1111/j.1469-1809.1981.tb00346.x; JONES EA, 1976, SOMAT CELL GENET, V2, P483, DOI 10.1007/BF01542686; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; LARIZZA L, 1973, CELL BIOL INT REPORT, V7, P325; MANIATIS T, 1982, MOL CLONING LABORATO; NICKAMEYER WS, 1985, J VIROL, V53, P879; POVEY S, 1980, ANN HUM GENET, V43, P241, DOI 10.1111/j.1469-1809.1980.tb01557.x; SHEER D, 1982, SOMAT CELL GENET, V8, P1, DOI 10.1007/BF01538646; SMITH DR, 1988, UNPUB; SOLOMON E, 1976, SOMAT CELL GENET, V2, P125, DOI 10.1007/BF01542626; Stubbs EL, 1935, J EXP MED, V61, P593, DOI 10.1084/jem.61.5.593; SWALLOW DM, 1977, CYTOGENET CELL GENET, V18, P136, DOI 10.1159/000130758; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; TUNNACLIFFE A, 1984, GENETIC ANAL CELL SU, P57; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANHEYNINGEN V, 1975, ANN HUM GENET, V38, P295; VARMUS HE, 1982, CANCER SURV, V2, P309	35	35	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					345	348						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	3205567				2022-12-28	WOS:A1988Q436700015
J	PIZON, V; CHARDIN, P; LEROSEY, I; OLOFSSON, B; TAVITIAN, A				PIZON, V; CHARDIN, P; LEROSEY, I; OLOFSSON, B; TAVITIAN, A			HUMAN CDNAS RAP1 AND RAP2 HOMOLOGOUS TO THE DROSOPHILA GENE DRAS3 ENCODE PROTEINS CLOSELY RELATED TO RAS IN THE EFFECTOR REGION	ONCOGENE			English	Article											PIZON, V (corresponding author), INSERM, U248, FAC MED LARIBOISIERE ST LOUIS, 10 AVE VERDUN, F-75010 PARIS, FRANCE.		Pizon, Veronique/M-5590-2018	Pizon, Veronique/0000-0003-3596-8313				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DEVOS AM, 1988, IN PRESS SCIENCE; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FUJIYAMA A, 1986, P NATL ACAD SCI USA, V83, P1266, DOI 10.1073/pnas.83.5.1266; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; LEV Z, 1985, MOL CELL BIOL, V5, P1540, DOI 10.1128/MCB.5.6.1540; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; Maniatis T., 1982, MOL CLONING; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MESSING J, 1983, METHOD ENZYMOL, V101, P20; PAPAGEORGE A, 1982, J VIROL, V44, P509, DOI 10.1128/JVI.44.2.509-519.1982; PERRY RP, 1972, BIOCHIM BIOPHYS ACTA, V262, P220, DOI 10.1016/0005-2787(72)90236-5; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; SCHEJTER ED, 1985, EMBO J, V4, P407, DOI 10.1002/j.1460-2075.1985.tb03643.x; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P383, DOI 10.1073/pnas.80.2.383; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646	24	351	362	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1988	3	2					201	204						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	3045729				2022-12-28	WOS:A1988Q053400011
J	GREEN, PL; KAEHLER, DA; MCKEARN, J; RISSER, R				GREEN, PL; KAEHLER, DA; MCKEARN, J; RISSER, R			SUBSTITUTION OF THE LTR OF ABELSON MURINE LEUKEMIA-VIRUS DOES NOT ALTER THE CELL TYPE OF VIRALLY INDUCED-TUMORS	ONCOGENE			English	Article									UNIV WISCONSIN, MCARDLE LAB CANC RES, MADISON, WI 53706 USA; DUPONT CO, GLENOLDEN, PA 19036 USA	University of Wisconsin System; University of Wisconsin Madison; DuPont					NATIONAL CANCER INSTITUTE [T32CA009135, R01CA041302] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41302, CA-09135] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGOLD PJ, 1987, J VIROL, V61, P1193, DOI 10.1128/JVI.61.4.1193-1202.1987; BESMER P, 1983, NATURE, V303, P825, DOI 10.1038/303825a0; BOSZE Z, 1986, EMBO J, V5, P1615, DOI 10.1002/j.1460-2075.1986.tb04404.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATIS PA, 1984, J VIROL, V52, P248, DOI 10.1128/JVI.52.1.248-254.1984; CHATIS PA, 1983, P NATL ACAD SCI-BIOL, V80, P4408, DOI 10.1073/pnas.80.14.4408; COOK WD, 1985, MOL CELL BIOL, V5, P390, DOI 10.1128/MCB.5.2.390; COOK WD, 1982, P NATL ACAD SCI-BIOL, V79, P2917, DOI 10.1073/pnas.79.9.2917; DALE B, 1981, MOL CELL BIOL, V1, P731, DOI 10.1128/MCB.1.8.731; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DESGROSEILLERS L, 1984, J VIROL, V52, P945, DOI 10.1128/JVI.52.3.945-952.1984; DESGROSEILLERS L, 1983, P NATL ACAD SCI-BIOL, V80, P4203, DOI 10.1073/pnas.80.14.4203; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN PL, 1987, J VIROL, V61, P2192, DOI 10.1128/JVI.61.7.2192-2197.1987; GREEN PL, 1985, J IMMUNOL, V134, P1268; GREEN PL, 1987, P NATL ACAD SCI USA, V84, P5932, DOI 10.1073/pnas.84.16.5932; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLLAND CA, 1987, P NATL ACAD SCI USA, V84, P8662, DOI 10.1073/pnas.84.23.8662; HOPKINS N, 1981, P NATL ACAD SCI-BIOL, V78, P7555, DOI 10.1073/pnas.78.12.7555; HOROWITZ JM, 1987, J VIROL, V61, P701, DOI 10.1128/JVI.61.3.701-707.1987; HOROWITZ JM, 1982, J VIROL, V44, P950, DOI 10.1128/JVI.44.3.950-957.1982; ISHIMOTO A, 1985, VIROLOGY, V141, P30, DOI 10.1016/0042-6822(85)90180-1; JAHNER D, 1980, NATURE, V287, P456, DOI 10.1038/287456a0; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KIPREOS ET, 1987, P NATL ACAD SCI USA, V84, P1345, DOI 10.1073/pnas.84.5.1345; KOCH W, 1983, J VIROL, V45, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENZ J, 1984, NATURE, V308, P467, DOI 10.1038/308467a0; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MCKEARN JP, 1985, EUR J IMMUNOL, V15, P295, DOI 10.1002/eji.1830150316; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; OLIFF AI, 1980, J VIROL, V33, P475, DOI 10.1128/JVI.33.1.475-486.1980; POTTER M, 1973, SCIENCE, V182, P592, DOI 10.1126/science.182.4112.592; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; RISSER R, 1985, J VIROL, V55, P547, DOI 10.1128/JVI.55.3.547-553.1985; RISSER R, 1978, J EXP MED, V148, P714, DOI 10.1084/jem.148.3.714; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; ROSENBERG NE, 1980, J VIROL, V36, P766, DOI 10.1128/JVI.36.3.766-774.1980; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SHIELDS A, 1979, CELL, V18, P955, DOI 10.1016/0092-8674(79)90208-3; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SHORT MK, 1987, J VIROL, V61, P1067, DOI 10.1128/JVI.61.4.1067-1072.1987; SKLAR MD, 1975, NATURE, V253, P550, DOI 10.1038/253550a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPECK NA, 1987, MOL CELL BIOL, V7, P1101, DOI 10.1128/MCB.7.3.1101; STOCKING C, 1985, P NATL ACAD SCI USA, V82, P5746, DOI 10.1073/pnas.82.17.5746; WANG JYJ, 1982, J BIOL CHEM, V257, P13181; WANG JYJ, 1984, CELL, V36, P349; WEISS R, 1985, RNA TUMOR VIRUSES MO, P928; WHITLOCK CA, 1983, MOL CELL BIOL, V3, P596, DOI 10.1128/MCB.3.4.596; WHITLOCK CA, 1981, J VIROL, V40, P577, DOI 10.1128/JVI.40.2.577-584.1981; WITTE ON, 1981, J VIROL, V39, P870, DOI 10.1128/JVI.39.3.870-878.1981; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; YEN L, 1987, J VIROL, V61, P693, DOI 10.1128/JVI.61.3.693-700.1987	63	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1988	2	6					585	592						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	2838788				2022-12-28	WOS:A1988N841500009
J	ARRUSHDI, A; NEGRINI, M; KURZROCK, R; HUEBNER, K; CROCE, CM				ARRUSHDI, A; NEGRINI, M; KURZROCK, R; HUEBNER, K; CROCE, CM			FUSION OF THE BCR AND THE C-ABL GENES IN PH'-POSITIVE ACUTE LYMPHOCYTIC-LEUKEMIA WITH NO REARRANGEMENT IN THE BREAKPOINT CLUSTER REGION	ONCOGENE			English	Article									WISTAR INST ANAT & BIOL,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute			Negrini, Massimo/J-2377-2016; Young, Richard A/F-6495-2012	Negrini, Massimo/0000-0002-0007-1920; Young, Richard A/0000-0001-8855-8647	NCI NIH HHS [CA 39860] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039860] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRUSHDI A, 1982, SOMAT CELL GENET, V8, P151, DOI 10.1007/BF01538674; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERNARDS A, 1987, MOL CELL BIOL, V7, P3231, DOI 10.1128/MCB.7.9.3231; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; DEKLEIN A, 1986, BLOOD, V68, P1369; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; GRUBER LN, 1983, AM J CLIN HYPN, V25, P263; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, BRIT J HAEMATOL, V67, P55, DOI 10.1111/j.1365-2141.1987.tb02296.x; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LANGE B, 1987, BLOOD, V70, P192; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; NOWELL PC, 1960, SCIENCE, V132, P1497; RODENHUIS S, 1985, NEW ENGL J MED, V313, P51; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; ROWLEY JD, 1980, CLIN HAEMATOL, V9, P55; SANDBERG AA, 1980, CANCER GENET CYTOGEN, V2, P145, DOI 10.1016/0165-4608(80)90058-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201	30	20	20	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					353	357						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3283653				2022-12-28	WOS:A1988M947200007
J	TOBIAS, KE; SHOR, J; KAHANA, C				TOBIAS, KE; SHOR, J; KAHANA, C			C-MYC AND MAX TRANSREGULATE THE MOUSE ORNITHINE DECARBOXYLASE PROMOTER THROUGH INTERACTION WITH 2 DOWNSTREAM CACGTG MOTIFS	ONCOGENE			English	Article						TRANSCRIPTION; ORNITHINE DECARBOXYLASE; C-MYC; MAX; USF	HAMSTER OVARY CELLS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; LEUCINE ZIPPER; GENE; PROTEIN; SEQUENCE; EXPRESSION; DOMAINS; DIMERIZATION	Ornithine decarboxylase (ODC), the first enzyme in the biosynthesis of polyamines, is essential for the process of cellular proliferation. ODC is a typical delayed early gene, as its mitogenic activation requires ongoing protein synthesis in the stimulated cells. This study provides evidence that the immediate early c-Myc protein is a potential transactivator of the ODC gene. We demonstrate that overexpression of c-Myc results in efficient activation of the ODC promoter, whereas overexpression of Max exerts a repressive effect. Both effects depend on the presence of two evolutionary conserved CACGTG motifs found in the first intron of the ODC gene. Transactivation of the ODC promoter also requires the dimerization of c-Myc with Max. Interestingly, overexpression of USF, a member of the same family of proteins which efficiently binds these two CACGTG motifs, fails to transregulate the ODC promoter. Our data suggest that c-Myc and Max are potential transcriptional regulators of the ODC promoter.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; FITZGERALD MC, 1989, DNA-J MOLEC CELL BIO, V8, P623, DOI 10.1089/dna.1.1989.8.623; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KATZ A, 1988, J BIOL CHEM, V263, P7604; KATZ A, 1989, EMBO J, V8, P7604; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENA A, 1993, J BIOL CHEM, V268, P27277; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; POHJANPELTO P, 1985, MOL CELL BIOL, V5, P1385, DOI 10.1128/MCB.5.6.1385; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REDDY CD, 1992, ONCOGENE, V7, P2085; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; STEGLICH C, 1982, J BIOL CHEM, V257, P4603; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WEN L, 1989, J BIOL CHEM, V264, P9016; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	56	55	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1721	1727						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478599				2022-12-28	WOS:A1995TD09400006
J	BOWTELL, DDL; LANGDON, WY				BOWTELL, DDL; LANGDON, WY			THE PROTEIN PRODUCT OF THE C-CBL ONCOGENE RAPIDLY COMPLEXES WITH THE EGF RECEPTOR AND IS TYROSINE-PHOSPHORYLATED FOLLOWING EGF STIMULATION	ONCOGENE			English	Article						TYROSINE KINASE; SRC HOMOLOGY; CBL ONCOGENE; CELL TRANSFORMATION; GROWTH FACTOR SIGNAL TRANSDUCTION	V-CBL; VULVAR INDUCTION; DOMAIN; SH2; IDENTIFICATION; TRUNCATION; RETROVIRUS; PATHWAY; BINDING; KINASES	The cbl oncogene was first identified as part of a transforming retrovirus which arose in a mouse pre-B cell lymphoma. Its protein product, p120(cbl): is cytoplasmic and has several distinctive domains including a highly basic region, a RING finger motif and a large proline-rich domain, A mutation to cbl in the 70Z/3 pre-B cell lymphoma produces an oncogenic protein which exhibits a marked enhancement of tyrosine phosphorylation, Parallel studies have demonstrated that p120(cbl) is a substrate of protein tyrosine kinases activated by engagement of the T cell antigen receptor and that cbl is phosphorylated by oncogenic forms of the Abl tyrosine kinase, A genetic analysis of the Caenorhabditis elegans c61 homologue, sli-1, demonstrates that sli-1 negatively regulates the LET-23 tyrosine kinase receptor, Here we show that p120(cbl) is rapidly phosphorylated on tyrosine residues following EGF stimulation and that it forms an inducible complex with the receptor, Our results also show that the oncogenic 70Z/3 form of cbl has enhanced binding to the EGF receptor and that peptides spanning the proline-rich region bind a range SH3 domains. These findings are consistent with a conserved role for cbl/sli-1 proteins in mammals and nematodes.	PETER MACCALLUM CANC INST,TRESCOWTHICK RES LABS,MELBOURNE,VIC 3000,AUSTRALIA; UNIV WESTERN AUSTRALIA,DEPT BIOCHEM,NEDLANDS,WA 6009,AUSTRALIA	Peter Maccallum Cancer Center; University of Western Australia			Bowtell, David/H-1007-2016	Bowtell, David/0000-0001-9089-7525				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; GALISTEO ML, 1995, IN PRESS J BIOL CHEM; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARCILA A, 1995, J BIOL CHEM, V5270, P9115; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YOON CH, 1995, IN PRESS SCIENCE; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	27	88	91	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1561	1567						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478580				2022-12-28	WOS:A1995TC53500014
J	OKAN, I; WANG, YS; CHEN, F; HU, LF; IMREH, S; KLEIN, G; WIMAN, KG				OKAN, I; WANG, YS; CHEN, F; HU, LF; IMREH, S; KLEIN, G; WIMAN, KG			THE EBV-ENCODED LMP1 PROTEIN INHIBITS P53-TRIGGERED APOPTOSIS BUT NOT GROWTH ARREST	ONCOGENE			English	Article						LMP1; P53; APOPTOSIS	WILD-TYPE P53; PROGRAMMED CELL-DEATH; CHROMOSOMAL BREAKPOINT; LYMPHOMA LINE; CYCLE CONTROL; EXPRESSION; BCL-2; SUPPRESSION; P53-PROTEIN; INDUCTION	We have previously shown that exogenous wild type p53 induces apoptosis in the Burkitt lymphoma line BL41 that carries endogenous mutant p53, using a temperature sensitive p53 construct expressed as mutant p53 at 37 degrees C and wild type p53 at 32 degrees C (Ramqvist et al., Oncogene, 8, 1495-1500, 1993). We also found that wild type p53-induced apoptosis is blocked by bcl-2 in a mouse T lymphoma line (Wang et al., Oncogene, 8, 3427-3431, 1993) The Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) can protect Burkitt lymphoma cells from apoptosis induced by low serum, In order to test if LMP1 can block p53-triggered apoptosis, we infected BL41 cells expressing the ts p53 construct with an LMP1-carrying retrovirus, The LMP1-expressing BL41-ts p53 cells were arrested in G1 upon induction of wild type p53 expression at 32 degrees C, but did not enter apoptosis as shown by the absence of positive TUNEL staining, WAF1/p21 mRNA was induced at 32 degrees C in both the ts p53-expressing and ts p53/LMP1-expressing BL41 cells, Thus, LMP1 prevents p53-induced apoptosis but does not interfere induction of WAF1/p21, The LMP1-infected expressed elevated bcl-2 protein levels, Therefore, our data suggest that LMP1 blocks p53-triggered apoptosis but not G1 arrest by upregulating bcl-2 expression.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet			Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X				BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DELDEIRY WS, 1994, CANCER, V54, P1; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GAVRIELI Y, 1993, J CELL BIOL, V119, P493; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Masucci Maria G., 1994, Trends in Microbiology, V2, P125, DOI 10.1016/0966-842X(94)90599-1; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NIYASHITA T, 1995, CELL, V80, P293; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAMQVIST T, 1993, ONCOGENE, V8, P1495; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; TOWBIN H, 1979, P NATL ACAD SCI USA, V88, P4350; TRIVEDI P, 1991, INT J CANCER, V48, P794, DOI 10.1002/ijc.2910480527; WANG YS, 1993, ONCOGENE, V8, P3427; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WILLIAMS C A, 1989, Methods in Molecular and Cellular Biology, V1, P35; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	35	81	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1027	1031						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566960				2022-12-28	WOS:A1995RX18000003
J	RICHARDSON, PM; ZON, LI				RICHARDSON, PM; ZON, LI			MOLECULAR-CLONING OF A CDNA WITH A NOVEL DOMAIN PRESENT IN THE TRE-2 ONCOGENE AND THE YEAST-CELL CYCLE REGULATORS BUB2 AND CDC16	ONCOGENE			English	Article						HEMATOPORESIS; MAST CELLS; CELL CYCLE; CDNA; GERM CELLS	BINDING TRANSCRIPTION FACTORS; MAST-CELLS; CARBOXYPEPTIDASE-A; PROTEIN CDNA; GENE; IDENTIFICATION; SEQUENCES; CYTOKINESIS; ENCODES; MITOSIS	Tn an effort to identify genes that are differentially regulated during mast cell development, subtracted cDNA prepared from wild-type murine P815 mastocytoma cells and a P815 subline that exhibits properties of mast cell differentiation was used to screen mast cell cDNA libraries. Several known mast cell-specific cDNAs were isolated including mast cell carboxypeptidase A (MC-CPA), murine mast cell protease-5 (MMCP-5), and gp49. A novel cDNA, designated Tbc1, was identified that showed differential expression in the two mast cell lines. The amino acid sequence predicted from the cDNA contains a 200 amino acid domain that is homologous to regions in the tre-2 oncogene and the yeast regulators of mitosis, BUB2 and cdc16. The N-terminal region contains a number of cysteine and histidine residues, potentially encoding a zinc finger domain. Tbc1 is a nuclear protein and is expressed in highest levels in hematopoietic cells, testis and kidney. Within these tissues, expression of Tbc1 is cell- and stage-specific. Based on sequence similarity, pattern of expression and subcellular localization, Tbc1 may play a role in the cell cycle and differentiation of various tissues.	CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST,DANA FARBER CANC INST,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute					NHLBI NIH HHS [P10 HL32262, R01 HL46668] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262, R01HL046668] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARM JP, 1991, J BIOL CHEM, V266, P15966; AVRAHAM S, 1989, P NATL ACAD SCI USA, V86, P3763, DOI 10.1073/pnas.86.10.3763; CHANG F, 1993, TRENDS GENET, V9, P333, DOI 10.1016/0168-9525(93)90022-A; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; FANKHAUSER C, 1993, EMBO J, V12, P2697, DOI 10.1002/j.1460-2075.1993.tb05931.x; FANKHAUSER C, 1994, EMBO J, V13, P3011, DOI 10.1002/j.1460-2075.1994.tb06600.x; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GURISH MF, 1991, J IMMUNOL, V146, P1527; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HUANG RY, 1991, EUR J IMMUNOL, V21, P39; HUEBNER K, 1988, ONCOGENE, V3, P449; ITO E, 1993, NATURE, V3623, P466; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; LOCHT C, 1986, P NATL ACAD SCI USA, V83, P6372, DOI 10.1073/pnas.83.17.6372; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1990, DNA CELL BIOL, V9, P697, DOI 10.1089/dna.1990.9.697; ONNO M, 1993, DNA CELL BIOL, V12, P107, DOI 10.1089/dna.1993.12.107; ONNO M, 1992, ONCOGENE, V7, P2519; ORKIN SH, 1992, BLOOD, V80, P575; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PEVNY L, DEVELOPMENT, V121, P163; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, J CELL BIOL, V110, P1033; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SERAFIN WE, 1987, J IMMUNOL, V139, P3771; STEPHENSON DA, 1994, MAMM GENOME, V5, P342, DOI 10.1007/BF00356552; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; TRANSY C, 1987, J EXP MED, V166, P341, DOI 10.1084/jem.166.2.341; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759; ZON LI, 1991, J BIOL CHEM, V266, P22948	33	60	66	1	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1139	1148						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566974				2022-12-28	WOS:A1995RX18000017
J	MURRELL, AM; BOCKAMP, EO; GOTTGENS, B; CHAN, YS; CROSS, MA; HEYWORTH, CM; GREEN, AR				MURRELL, AM; BOCKAMP, EO; GOTTGENS, B; CHAN, YS; CROSS, MA; HEYWORTH, CM; GREEN, AR			DISCORDANT REGULATION OF SCL/TAL-1 MESSENGER-RNA AND PROTEIN DURING ERYTHROID-DIFFERENTIATION	ONCOGENE			English	Article						SCL/TAL-1; ERYTHROID DIFFERENTIATION	SCL GENE-PRODUCT; LOOP-HELIX GENE; T-CELL LEUKEMIA; SELF-RENEWAL; TRANSLOCATION; EXPRESSION; HEMATOPOIESIS; ENCODES; TAL-1; LINES	SCL/TAL1 gene was originally identified by virtue of its rearrangement and transcriptional activation in patients with T cell acute lymphoblastic leukaemia, It encodes a helix-loop-helix transcription factor, is not normally expressed in T cells, but is expressed in erythroid, mast, megakaryocytic and progenitor cells, Over-expression of sense and antisense constructs have implicated SCL as a positive regulator of erythroid differentiation, In addition we have previously shown that SCL mRNA levels undergo biphasic modulation during induced erythroid differentiation of murine erythroleukaemia (MEL) cells with a transient early fall followed by a late rise, In this paper we have studied expression of the SCL protein during erythroid differentiation and also the molecular basis for the raised SCL mRNA levels that accompany erythroid differentiation, We have generated an anti-SCL antiserum and used it to demonstrate that an early transient fall in SCL protein does not occur during induced differentiation of MEL cells, Furthermore SCL protein levels underwent a late fall in three different models of erythroid differentiation and in two models of myeloid differentiation, The fall in SCL protein levels during induced erythroid differentiation contrasted with the concomitant marked rise in SCL mRNA levels. These observations have significant implications for the mechanism by which SCL may regulate erythropoiesis. In addition we have demonstrated that the stability of SCL mRNA was only marginally enhanced during erythroid differentiation of MEL cells, whereas the activity of a luciferase reporter construct driven by the SCL promoter was increased 11- to 17-fold, Up-regulation of transcription therefore accounted for most of the increase in SCL mRNA levels during erythroid differentiation.	UNIV CAMBRIDGE,CTR MRC,DEPT HAEMATOL,CAMBRIDGE CB2 2QH,ENGLAND; CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,CRC,DEPT EXPTL HAEMATOL,MANCHESTER M20 9BX,LANCS,ENGLAND	University of Cambridge; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research				Cross, Michael/0000-0002-8815-7621; Gottgens, Berthold/0000-0001-6302-5705; Bockamp, Ernesto/0000-0002-6181-1734; Green, Anthony/0000-0002-9795-0218	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEGLEY CG, 1994, GENE, V138, P93, DOI 10.1016/0378-1119(94)90787-0; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1991, ONCOGENE, V6, P1477; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CHENG JT, 1993, ONCOGENE, V8, P677; CROSS MA, 1994, ONCOGENE, V9, P3013; ELWOOD NJ, 1994, LEUKEMIA, V8, P106; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GOLDFARB AN, 1992, BLOOD, V80, P2858; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; GREEN AR, 1993, EXP HEMATOL, V21, P525; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HWANG LY, 1993, ONCOGENE, V8, P3043; KAIHO SI, 1985, ANAL BIOCHEM, V149, P117, DOI 10.1016/0003-2697(85)90483-X; KAN O, 1993, HAEMOPOIEISIS PRACTI; KIM KJ, 1979, J IMMUNOL, V122, P549; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; MITSUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322; MOUTHON MA, 1993, BLOOD, V81, P647; MURRELL AM, 1995, ONCOGENE, V10, P631; PROUD CG, 1994, NATURE, V371, P747, DOI 10.1038/371747a0; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VISVADER J, 1991, ONCOGENE, V6, P195; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x	41	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					131	139						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624120				2022-12-28	WOS:A1995RJ29500016
J	BROWNELL, E; MITTEREDER, N; RICE, NR				BROWNELL, E; MITTEREDER, N; RICE, NR			A HUMAN REL PROTO-ONCOGENE CDNA CONTAINING AN ALU FRAGMENT AS A POTENTIAL CODING EXON	ONCOGENE			English	Article									NCI,FREDERICK CANC RES FACIL,MOLEC VIROL & CARCINOGENESIS,BRI BASIC RES PROGRAM,POB B,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; BROWNELL E, 1988, ONCOGENE, V3, P93; BROWNELL E, 1986, AM J HUM GENET, V39, P194; BROWNELL E, 1985, MOL CELL BIOL, V5, P2826, DOI 10.1128/MCB.5.10.2826; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARAS IW, 1987, NATURE, V325, P545, DOI 10.1038/325545a0; CHEN ISY, 1983, J VIROL, V45, P104, DOI 10.1128/JVI.45.1.104-113.1983; DEININGER PL, 1988, MOL CELL BIOL, V8, P4566, DOI 10.1128/MCB.8.10.4566; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HERZOG NK, 1986, J VIROL, V57, P371, DOI 10.1128/JVI.57.1.371-375.1986; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1988, MOL CELL BIOL, V8, P2737, DOI 10.1128/MCB.8.7.2737; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LUNDWALL AB, 1985, J BIOL CHEM, V260, P2108; Maxam A M, 1980, Methods Enzymol, V65, P499; MILES JS, 1988, NUCLEIC ACIDS RES, V16, P5783, DOI 10.1093/nar/16.13.5783; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NICHOLLS RD, 1987, CELL, V49, P369, DOI 10.1016/0092-8674(87)90289-3; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; RICE NR, 1987, J VIROL, V61, P1577, DOI 10.1128/JVI.61.5.1577-1585.1987; RICE NR, 1988, ONCOGENE HDB, P495; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHARMA S, 1987, SCIENCE, V235, P1489, DOI 10.1126/science.3547651; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMEK S, 1988, ONCOGENE RES, V2, P103; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; SRIVASTAVA R, 1987, P NATL ACAD SCI USA, V84, P4224, DOI 10.1073/pnas.84.12.4224; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; WALRO DS, 1987, VIROLOGY, V160, P433, DOI 10.1016/0042-6822(87)90015-8; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WILLARD C, 1987, J MOL EVOL, V26, P180, DOI 10.1007/BF02099850	40	178	179	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					935	942						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2666912				2022-12-28	WOS:A1989AE58400018
J	POPESCU, NC; MARK, GE				POPESCU, NC; MARK, GE			LOCALIZATION OF THE PKS GENE, A RAF RELATED SEQUENCE ON HUMAN CHROMOSOME-X AND CHROMOSOME-7	ONCOGENE			English	Note									MERCK SHARP & DOHME RES LABS,RAHWAY,NJ 07065	Merck & Company	POPESCU, NC (corresponding author), NCI,DIV CANC ETIOL,BIOL LAB,BETHESDA,MD 20892, USA.							BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLEEKERWAGEMAKERS LM, 1985, HUM GENET, V71, P211, DOI 10.1007/BF00284575; BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; CROCE CM, 1985, BLOOD, V65, P1; DEGROUCHY J, 1985, ANN GENET-PARIS, V28, P86; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; GAL A, 1985, CLIN GENET, V27, P282; GILGENKRANTZ S, 1985, ANN GENET-PARIS, V28, P90; GRIFFIN CA, 1987, CANCER GENET CYTOGEN, V26, P181, DOI 10.1016/0165-4608(87)90148-8; HAMEISTER H, 1986, HUM GENET, V72, P241, DOI 10.1007/BF00291886; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; HUEBNER K, 1986, AM J HUM GENET, V38, P819; LYON MF, 1970, NATURE, V227, P1217, DOI 10.1038/2271217a0; MARK GE, 1986, P NATL ACAD SCI USA, V83, P6312, DOI 10.1073/pnas.83.17.6312; MENKES JH, 1962, PEDIATRICS, V29, P764; MIGEON BR, 1981, P NATL ACAD SCI-BIOL, V78, P6339, DOI 10.1073/pnas.78.10.6339; MITCHELL G, 1986, American Journal of Human Genetics, V39, pA163; NOGUCHI T, 1987, EMBO J, V6, P1301, DOI 10.1002/j.1460-2075.1987.tb02368.x; PEACOCKE M, 1987, P NATL ACAD SCI USA, V84, P3430, DOI 10.1073/pnas.84.10.3430; POPESCU NC, 1985, CYTOGENET CELL GENET, V39, P73, DOI 10.1159/000132107; POPESCU NC, 1987, CYTOGENET CELL GENET, V44, P58, DOI 10.1159/000132342; RAMESH V, 1987, HUM GENET, V76, P121, DOI 10.1007/BF00284906; ROWLEY JD, 1984, CANCER RES, V44, P3159; SANDBERG AA, 1980, CHROMOSOMES HUMAN CA; SMITH S, 1987, CANCER GENET CYTOGEN, V26, P179, DOI 10.1016/0165-4608(87)90147-6; SPURR NK, 1987, ANN HUM GENET, V51, P189, DOI 10.1111/j.1469-1809.1987.tb00870.x; TEMIN HM, 1986, GENETIC REARRANGEMEN, P136; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WIEACKER P, 1987, HUM GENET, V76, P248; YANGFENG TL, 1986, P NATL ACAD SCI USA, V83, P8679, DOI 10.1073/pnas.83.22.8679	31	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					517	519						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2717185				2022-12-28	WOS:A1989U567700018
J	GAO, CL; WANG, LC; VASS, WC; SETH, A; CHANG, KSS				GAO, CL; WANG, LC; VASS, WC; SETH, A; CHANG, KSS			THE ROLE OF V-MOS IN TRANSFORMATION, ONCOGENICITY, AND METASTATIC POTENTIAL OF MINK LUNG-CELLS	ONCOGENE			English	Article									NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; NCI,MOLEC ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ATTIA MA, 1965, CANCER RES, V25, P451; BASSIN RH, 1984, CANCER CELL, V2, P463; BOONE LR, 1983, J VIROL, V45, P484, DOI 10.1128/JVI.45.1.484-488.1983; BRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277, DOI 10.1073/pnas.83.14.5277; CHANG KSS, 1982, J GEN VIROL, V58, P115, DOI 10.1099/0022-1317-58-1-115; CHATTOPADHYAY SK, 1980, P NATL ACAD SCI-BIOL, V77, P5774, DOI 10.1073/pnas.77.10.5774; CHATTOPADHYAY SK, 1982, NATURE, V295, P25, DOI 10.1038/295025a0; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FISCHINGER PJ, 1974, VIROLOGY, V59, P217, DOI 10.1016/0042-6822(74)90217-7; FISCHINGER PJ, 1981, CANCER RES, V41, P958; FRANKEL AE, 1977, J VIROL, V23, P492, DOI 10.1128/JVI.23.3.492-502.1977; GEISER AG, 1986, P NATL ACAD SCI USA, V83, P5209, DOI 10.1073/pnas.83.14.5209; GORER PA, 1950, BRIT J CANCER, V4, P372, DOI 10.1038/bjc.1950.36; GREIG RG, 1985, P NATL ACAD SCI USA, V82, P3698, DOI 10.1073/pnas.82.11.3698; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KRZYZEK RA, 1979, J VIROL, V29, P507, DOI 10.1128/JVI.29.2.507-516.1979; LANDER MR, 1984, J VIROL, V52, P695, DOI 10.1128/JVI.52.2.695-698.1984; LIOTTA LA, 1986, CANCER RES, V46, P1; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; MEROMSKY L, 1986, CANCER RES, V46, P5270; NICOLSON GL, 1987, CANCER RES, V47, P1473; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OSTERTAG W, 1987, ADV CANCER RES, V48, P193, DOI 10.1016/S0065-230X(08)60693-4; PAPKOFF J, 1984, J VIROL, V52, P420, DOI 10.1128/JVI.52.2.420-430.1984; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PEEBLES PT, 1976, SCIENCE, V192, P1143, DOI 10.1126/science.179144; PEEBLES PT, 1975, VIROLOGY, V67, P288, DOI 10.1016/0042-6822(75)90427-4; PINCUS T, 1971, J EXP MED, V133, P1219, DOI 10.1084/jem.133.6.1219; PORZIG KJ, 1979, CELL, V16, P875, DOI 10.1016/0092-8674(79)90102-8; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; RADINSKY R, 1987, P NATL ACAD SCI USA, V84, P5143, DOI 10.1073/pnas.84.15.5143; SELIGER B, 1987, J VIROL, V61, P2567, DOI 10.1128/JVI.61.8.2567-2572.1987; SERGIESCU D, 1986, P NATL ACAD SCI USA, V83, P5764, DOI 10.1073/pnas.83.16.5764; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEWOUDE GF, 1979, P NATL ACAD SCI USA, V76, P4464; WANG LC, 1987, CANCER RES, V47, P4192	37	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					267	273						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	2849740				2022-12-28	WOS:A1988Q436700004
J	LIU, E; DOLLBAUM, C; SCOTT, G; ROCHLITZ, C; BENZ, C; SMITH, HS				LIU, E; DOLLBAUM, C; SCOTT, G; ROCHLITZ, C; BENZ, C; SMITH, HS			MOLECULAR LESIONS INVOLVED IN THE PROGRESSION OF A HUMAN-BREAST CANCER	ONCOGENE			English	Article									UNIV CALIF SAN FRANCISCO, CANC RES INST, SAN FRANCISCO, CA 94143 USA; PERALTA CANC RES INST, OAKLAND, CA USA	University of California System; University of California San Francisco	LIU, E (corresponding author), UNIV N CAROLINA, LINEBERGER CANC RES CTR, DEPT MED, CB 7297, CHAPEL HILL, NC 27599 USA.		Liu, Edison/C-4141-2008		NATIONAL CANCER INSTITUTE [P01CA044768, R01CA012705] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA44768, CA28739, CA12705] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AAPRO MS, 1987, J CLIN ONCOL, V5, P890, DOI 10.1200/JCO.1987.5.6.890; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CHANG SE, 1982, CANCER RES, V42, P2040; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CLINE MJ, 1987, J CLIN ONCOL, V5, P999, DOI 10.1200/JCO.1987.5.7.999; ENGEL LW, 1978, CANCER RES, V38, P4327; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH HS, 1987, JNCI-J NATL CANCER I, V78, P611; SMITH HS, 1983, BIOCHIM BIOPHYS ACTA, V738, P103, DOI 10.1016/0304-419X(84)90009-X; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; THEILLET C, 1986, CANCER RES, V46, P4776; TRENT JM, 1985, BREAST CANCER RES TR, V5, P221, DOI 10.1007/BF01806017; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0; 1984, NATURE, V309, P111	34	30	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1988	3	3					323	327						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	2849743				2022-12-28	WOS:A1988Q436700011
J	HANCOCK, JF; MARSHALL, CJ; MCKAY, IA; GARDNER, S; HOUSLAY, MD; HALL, A; WAKELAM, MJO				HANCOCK, JF; MARSHALL, CJ; MCKAY, IA; GARDNER, S; HOUSLAY, MD; HALL, A; WAKELAM, MJO			MUTANT BUT NOT NORMAL P21-RAS ELEVATES INOSITOL PHOSPHOLIPID BREAKDOWN IN 2 DIFFERENT CELL SYSTEMS	ONCOGENE			English	Article									UNIV GLASGOW,DEPT BIOCHEM,MOLEC PHARMACOL GRP,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow	HANCOCK, JF (corresponding author), ROYAL CANC HOSP,INST CANC RES,CHESTER BEATTY LABS,CELL & MOLEC BIOL SECT,FULHAM RD,LONDON SW3 6JB,ENGLAND.		Houslay, Miles/AAM-5281-2020; Houslay, Miles D/A-6825-2011	Hancock, John/0000-0003-0542-4710; Houslay, Miles/0000-0002-3826-8091; Wakelam, Michael/0000-0003-4059-9276				BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GARRETT JS, 1984, P NATL ACAD SCI-BIOL, V81, P7466, DOI 10.1073/pnas.81.23.7466; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HALL A, 1986, J BIOL CHEM, V261, P963; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; MARSHALL CJ, 1982, NATURE, V299, P171, DOI 10.1038/299171a0; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; TABIN C, 1982, NATURE, V300, P762; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WILLINGHAM MC, 1983, EXP CELL RES, V149, P141, DOI 10.1016/0014-4827(83)90387-7; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILLUMSEN BM, 1985, EMBO J, V4, P2893, DOI 10.1002/j.1460-2075.1985.tb04019.x	29	55	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					187	193						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	2842715				2022-12-28	WOS:A1988Q053400009
J	CHEN, HM; RAYGALLET, D; ZHANG, P; HETHERINGTON, CJ; GONZALEZ, DA; ZHANG, DE; MOREAUGACHELIN, F; TENEN, DG				CHEN, HM; RAYGALLET, D; ZHANG, P; HETHERINGTON, CJ; GONZALEZ, DA; ZHANG, DE; MOREAUGACHELIN, F; TENEN, DG			PU.1 (SPI-1) AUTOREGULATES ITS EXPRESSION IN MYELOID CELLS	ONCOGENE			English	Article						PU.1 (SPI-1); SPI-B; PROMOTER; AUTOREGULATION; MYELOID CELL; IN VIVO FOOTPRINT	TRANSCRIPTION FACTOR GATA-1; MUSCLE-SPECIFIC ENHANCER; AUTO-REGULATION; CD11B PROMOTER; CHROMOSOMAL LOCALIZATION; FUNCTIONAL-ANALYSIS; PUTATIVE ONCOGENE; BINDING PROTEIN; ETS ONCOGENE; HEAVY-CHAIN	PU.1 (Spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid (granulocytes, monocytes and macrophages) and B cells. PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34(+) progenitors prior to this upregulation blocks myeloid colony formation. Since PU.1 expression appears to play a role in hematopoietic development, we characterized the PU.1 promoter. Here we report that the murine PU.1 promoter, as well as the human promoter, demonstrate tissue-specific reporter gene expression in myeloid cell lines but not in T cells and HeLa (non-hematopoietic cells) cells. Deletion analysis of the PU.1 promoter indicates that tissue-specific functional elements are encoded in the -61 to -39 bp and -7 to +34 bp regions. The first region contains a functional octamer (Oct) site at -54 bp and an Spl site at -39 bp. The second contains a binding site at +20 bp for both PU.1 itself and the related ets family member Spi-B. In vivo footprinting assays demonstrate that a hypersensitive band was detected at the PU.1 site in myeloid cells but not in HeLa. A mutation of the PU.1 site which abolished PU.1 binding caused a significant decrease in promoter activity., Mutation of the Oct and/or Spl site results in a lesser decrease of promoter activity in myeloid cells. Cotransfection of PU.1 or Spi-B in cells lacking PU.1 and Spi-B specifically transactivated a minimal promoter containing the PU.1 binding site, indicating that PU.1 can activate its own promoter elements in an autoregulatory loop. Positive autoregulation of the PU.1 promoter may play an important role in the function of PU.1 in myeloid cells.	HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA; FAC MED LARIBOISIERE, INSERM, U248, F-75010 PARIS, FRANCE	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Ray-Gallet, Dominique/A-9224-2019	Tenen, Daniel/0000-0002-6423-3888	NCI NIH HHS [CA59589, CA41456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA059589, R01CA041456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHNE B, 1994, J BIOL CHEM, V269, P17794; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BURN TC, 1992, BLOOD, V80, P3051; CARVALHO M, 1993, J VIROL, V67, P3885, DOI 10.1128/JVI.67.7.3885-3890.1993; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELGADO MD, 1994, ONCOGENE, V9, P1723; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; FLEMING JC, 1993, J IMMUNOL, V150, P480; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HEHLGANS T, 1995, J IMMUNOL, V154, P5181; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; HROMAS R, 1993, BLOOD, V82, P2998; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; LEE ME, 1991, J BIOL CHEM, V266, P16188; MAURY W, 1994, J VIROL, V68, P6270, DOI 10.1128/JVI.68.10.6270-6279.1994; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; OKA T, 1991, ONCOGENE, V6, P2077; OMORI SA, 1993, P NATL ACAD SCI USA, V90, P11723, DOI 10.1073/pnas.90.24.11723; PAHL HL, 1992, BLOOD, V79, P865; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; RAY D, 1990, ONCOGENE, V5, P663; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RAYGALLET D, 1995, ONCOGENE, V11, P303; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SMITH LT, 1994, BLOOD, V84, pA372; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TOOTHAKER LE, 1991, BLOOD, V78, P1826; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; VOSO MT, 1994, P NATL ACAD SCI USA, V91, P7932, DOI 10.1073/pnas.91.17.7932; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	69	174	176	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1549	1560						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478579				2022-12-28	WOS:A1995TC53500013
J	FUKUDA, T; MIKI, T; YOSHIDA, T; HATANO, M; OHASHI, K; HIROSAWA, S; TOKUHISA, T				FUKUDA, T; MIKI, T; YOSHIDA, T; HATANO, M; OHASHI, K; HIROSAWA, S; TOKUHISA, T			THE MURINE BCL6 GENE IS INDUCED IN ACTIVATED LYMPHOCYTES AS AN IMMEDIATE-EARLY GENE	ONCOGENE			English	Article						BCL6; LYMPHOCYTES; IMMEDIATE EARLY GENE	NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; B-CELL LYMPHOMAS; CHROMOSOME-TRANSLOCATION; MOLECULAR-CLONING; PROTO-ONCOGENE; REGION; BREAKPOINT; SEQUENCE; FOS	The chromosomal translocation involving 3q27 is often detected in human B-cell lymphomas, especially diffuse lymphomas with a large-cell component, The BCL6 gene has been isolated from the chromosomal breakpoint in these lymphomas. Here we cloned the murine BCL6 (mBCL6) cDNA from the muscle cDNA library using the human BCL6 (hBCL6) cDNA as a probe, The predicted amino acid sequence was 95% identical to that of hBCL6. It contains six repeats of the Kruppel-like zinc-finger motif that are completely identical to those of hBCL6, indicating that the BCL6 gene is well conserved between humans and mice, Expression of the mBCL6 gene was ubiquitously detected in adult mouse tissues including lymphatic organs, Furthermore, it was induced in lymphocytes activated with phorbol ester and Ca2+ ionophore within 30 min after stimulation, This induction was not inhibited by treatment of the cells with a protein synthesis inhibitor, cycloheximide. These results suggest that BCL6 plays a role in activated lymphocytes as an immediate early gene.	TOKYO MED & DENT UNIV,DEPT INTERNAL MED 1,TOKYO 113,JAPAN; CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV DEV GENET,CHIBA 260,JAPAN	Tokyo Medical & Dental University (TMDU); Chiba University								ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BAKHSHI A, 1985, CELL, V41, P889; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BASTARD C, 1992, BLOOD, V79, P2527; BASTARD C, 1994, BLOOD, V83, P2423; CHARDIN P, 1991, NUCLEIC ACIDS RES, V19, P1431, DOI 10.1093/nar/19.7.1431; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; HARRIS NL, 1994, BLOOD, V84, P1361; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LO CF, 1994, BLOOD, V83, P1757; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MIKI T, 1994, BLOOD, V83, P217; MIKI T, 1994, BLOOD, V83, P26; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OFFIT K, 1989, BLOOD, V74, P1876; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; TAKAO S, 1991, INT IMMUNOL, V3, P369, DOI 10.1093/intimm/3.4.369; TRAUB R, 1982, P NATL ACAD SCI USA, V79, P7837; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YE BHH, 1993, CANCER RES, V53, P2732	33	54	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1657	1663						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478591				2022-12-28	WOS:A1995TC53500025
J	LUCA, M; XIE, SH; GUTMAN, M; HUANG, SY; BARELI, M				LUCA, M; XIE, SH; GUTMAN, M; HUANG, SY; BARELI, M			ABNORMALITIES IN THE CDKN2 (P16(INK4)/MTS-1) GENE IN HUMAN-MELANOMA CELLS - RELEVANCE TO TUMOR-GROWTH AND METASTASIS	ONCOGENE			English	Note						CDKN2 (P16(INK4)/MTS-1); HUMAN MELANOMA; METASTASIS	P53 MUTATIONS	The inhibitor of cyclin-dependent kinase 4, CDKN2 (also known as p16(INK4) Or MTS-1, multiple tumor suppressor gene 1), has been mapped to 9p21, The gene has been shown to be deleted or mutated in high frequency in human melanoma cell lines and familial melanoma patients, suggesting that it could be a melanoma suppressor gene. How these observations are related to tumorigenicity and metastasis of human melanoma is not clear however, To test the role of CDW2 in human melanoma metastasis, 14 human melanoma cell lines with different metastatic abilities in nude mice were analysed for possible abnormalities in the CDKN2 gene, Homozygous deletions that resulted in a lack of gene expression were found in six of 14 cell lines tested. SSCP-direct sequencing revealed point mutations in three other cell lines, One cell line displayed CC to TT transitions which constitute a hallmark of ultraviolet-induced DNA damage, Overall, abnormalities in the CDKN2 gene were found in nine of 14 (64%) cell lines tested, Homozygous deletion and lack of gene expression were found in several low tumorigenic and nonmetastatic melanoma lines, whereas other metastatic cells did not exhibit abnormalities in the CDKN2 gene, These data suggest that the absence of normal CDKN2 does not confer growth advantage to melanoma cells in vivo and that the production of metastasis by human melanoma cells can occur in the absence of CDKN2 gene abnormalities.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA041525] Funding Source: NIH RePORTER; NCI NIH HHS [CA 41525] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; FIDLER IJ, 1991, CANCER METAST REV, V10, P229, DOI 10.1007/BF00050794; GUTMAN M, 1994, ANTICANCER RES, V14, P1759; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LEEJACKSON D, 1993, BIOTECHNIQUES, V15, P363; LIU Q, 1995, ONCOGENE, V10, P1061; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; LUCA M, 1993, INT J ONCOL, V3, P19; NOBORI T, 1994, NATURE, V363, P753; OHTA M, 1994, CANCER RES, V54, P5269; RADINSKY R, 1994, ONCOGENE, V9, P1877; ROSTAD EK, 1994, BRIT J CANCER, V70, P804; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211	17	56	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1399	1402						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478563				2022-12-28	WOS:A1995RY96700023
J	HERBST, R; MUNEMITSU, S; ULLRICH, A				HERBST, R; MUNEMITSU, S; ULLRICH, A			ONCOGENIC ACTIVATION OF V-KIT INVOLVES DELETION OF A PUTATIVE TYROSINE-SUBSTRATE INTERACTION SITE	ONCOGENE			English	Article						RECEPTOR TYROSINE KINASE; ONCOGENIC MUTATION; V-KIT; SIGNAL TRANSDUCTION	EPIDERMAL GROWTH-FACTOR; FMS PROTO-ONCOGENE; STEM-CELL FACTOR; MALIGNANT HUMAN HEMATOPOIESIS; ACUTE MYELOBLASTIC-LEUKEMIA; C-KIT; KINASE RECEPTOR; SIGNAL TRANSDUCTION; NEU ONCOGENE; SRC FAMILY	The transforming gene of the Hardy-Zuckerman-4 strain of feline sarcoma virus, v-kit, arose by transduction of the cellular c-kit gene, which encodes the receptor tyrosine kinase (RTK) p145(c-kit). To gain insight into the molecular basis of the v-kit transforming potential, we characterized the feline c-kit by cDNA cloning. Comparison of the feline v-kit and c-kit sequences revealed, in addition to deletions of the extracellular and transmembrane domains, three additional mutations in the v-kit oncogene product: deletion of tyrosine-569 and valine-570, the exchange of aspartate at position 761 to glycine, and replacement of the C-terminal 50 amino acids by five unrelated residues, Examinations of individual v-kit mutations in the context of chimeric receptors yielded inhibitory effects for some mutants on both autophosphorylation and substrate phosphorylation functions. In contrast, deletion of tyrosine-569 and valine-570 significantly enhanced transforming and mitogenic activities of p145(c-kit), while the other mutations had no significant effects. Conservation in subclass III RTKs and the identification of the corresponding residue in beta PDGF-R, Y579, as a binding site for src family tyrosine kinases suggests an important role for Y568 in kit signal regulation and the definition of its oncogenic potential, Repositioning of Y571 by an in-frame two codon deletion may be the crucial alteration resulting in enhancement of v-kit oncogenic activity.	MAX PLANCK INST BIOCHEM,DEPT BIOL MOLEC,D-82152 MARTINSRIED,GERMANY	Max Planck Society								ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERRETI A, 1991, BLOOD S, V78, pA373; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BROWNING PJ, 1986, P NATL ACAD SCI USA, V83, P7800, DOI 10.1073/pnas.83.20.7800; BUHRING HJ, 1993, CANCER RES, V53, P4424; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FENDLY BM, 1990, CANCER RES, V50, P1550; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HERBST R, 1991, J BIOL CHEM, V266, P19908; HERBST R, 1992, J BIOL CHEM, V267, P13210; HIBI K, 1991, ONCOGENE, V6, P2291; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HUANG E, 1990, CELL, V63, P223; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LASSAM N, 1992, ONCOGENE, V7, P51; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; MAJUMDER S, 1990, ONCOGENE RES, V5, P329; Maniatis T., 1982, MOL CLONING; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MILLER AD, 1985, MOL CELL BIOL, V5, P431, DOI 10.1128/MCB.5.3.431; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MOSTOV KE, 1984, NATURE, V318, P37; NATALI PG, 1992, INT J CANCER, V52, P713, DOI 10.1002/ijc.2910520508; NATALI PG, 1992, INT J CANCER, V52, P197, DOI 10.1002/ijc.2910520207; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P1710, DOI 10.1073/pnas.89.5.1710; RATAJCZAK MZ, 1992, INT J CELL CLONING, V10, P205; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1990, ONCOGENE, V5, P25; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SACCA R, 1986, P NATL ACAD SCI USA, V83, P3331, DOI 10.1073/pnas.83.10.3331; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKIDO Y, 1991, CANCER RES, V51, P2416; SHERR CJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P225, DOI 10.1016/0304-419X(88)90011-X; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG C, 1989, LEUKEMIA, V3, P699; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	67	37	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					369	379						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7530827				2022-12-28	WOS:A1995QC62400016
J	LEGROS, Y; MEYER, A; ORY, K; SOUSSI, T				LEGROS, Y; MEYER, A; ORY, K; SOUSSI, T			MUTATIONS IN P53 PRODUCE A COMMON CONFORMATIONAL EFFECT THAT CAN BE DETECTED WITH A PANEL OF MONOCLONAL-ANTIBODIES DIRECTED TOWARD THE CENTRAL PART OF THE P53 PROTEIN	ONCOGENE			English	Note							LARGE T-ANTIGEN; BREAST-CANCER; SUPPRESSOR; EPITOPES; CELLS; GENE	Human p53 displays two immunodominant regions localized in the amino and carboxy termini of the protein. Using a truncated p53 (residues 66 to 361), we selected eight new monoclonal antibodies directed to the central part of the protein. We identified the epitopes recognized by seven out of eight antibodies with a set of overlapping peptides. One of these antibodies had an epitope similar to PAb240, whereas the others recognized novel and diverse antigenic determinants. Using a series of 19 p53 mutants, we show that the behavior of several of the new monoclonal antibodies is similar to that of PAb240 despite their various epitope localizations. This suggests that different mutations in the p53 protein induce an overall conformational change that can be detected by various monoclonal antibodies directed toward the central part of the protein.	INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE; ESTBA,F-75020 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)				soussi, thierry/0000-0001-8184-3293				BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1994, ONCOGENE, V9, P299; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LANE DP, 1994, MOL BIOL REP, V19, P23, DOI 10.1007/BF00987319; LEBROS Y, 1994, ONCOGENE, V9, P2071; LEGROS Y, 1993, B CANCER, V80, P102; LUBIN R, 1993, CANCER RES, V53, P5872; MEDCALF EA, 1992, ONCOGENE, V7, P71; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1987, ONCOGENE, V1, P453; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; SCHLICHTHOLZ B, 1994, BRIT J CANCER, V69, P809, DOI 10.1038/bjc.1994.159; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	22	81	86	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3689	3694						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7526318				2022-12-28	WOS:A1994PT39200033
J	KRAUZEWICZ, N; ELLIOTT, J; GRIFFIN, BE				KRAUZEWICZ, N; ELLIOTT, J; GRIFFIN, BE			CELL FRACTIONATION IN NONIONIC DETERGENT DISTINGUISHES SUBPOPULATIONS OF POLYOMA-VIRUS MIDDLE T-ANTIGEN AND REVEALS A NOVEL FORM	ONCOGENE			English	Article							TUMOR-ANTIGEN; MONOCLONAL-ANTIBODIES; KINASE-ACTIVITY; EARLY REGION; PROTEIN; PP60C-SRC; TRANSFORMATION; ASSOCIATION; COMPLEX; BINDING	The transforming function of polyoma virus, middle T antigen (MT), interacts with several cellular enzymes, essential to its oncogenic activity. We have used cell fractionation to study the various MT/cellular protein complexes. We demonstrate that MT can be separated into three sub-species, dependent upon extraction in two buffers that we designate A and B: Antigen extracted from whole cells by both buffers (called MT(1)) is associated with most of the phosphorylated phosphatidylinositol kinase 85 kD subunit, pp85, and protein phosphatase 2A. Antigen (MT(2)), associated with the greater portion of pp60c-src, is extracted by buffer B, but not buffer A. A third population (MT(3)), resistant to extraction by either buffer, is not detectably associated with protein phosphatase 2A or pp85. It is, however, associated with a low level kinase activity. The interaction between pp60c-src and MT appears to influence the formation of both MT(2) and MT(3). MT(2) fractionates with the cellular microtubule network, but does not appear to be directly associated with it. MT(3), a previously undescribed population, comprises about one third of MT in wild type antigen-containing cells. It is missing in mutants incapable of interacting with pp60c-src, but exists in the absence of an interaction with pp85. We suggest that MT(3) may be an intermediate in, or product of, one of the MT/pp60c-src signalling pathways, distinct from that involving pp85.	ROYAL POSTGRAD MED SCH,DEPT VIROL,LONDON W12 0NN,ENGLAND	Imperial College London								ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; BOLEN JB, 1985, J VIROL, V53, P114, DOI 10.1128/JVI.53.1.114-119.1985; BOLEN JB, 1987, J VIROL, V61, P3299, DOI 10.1128/JVI.61.10.3299-3305.1987; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHENG SH, 1986, EMBO J, V5, P325, DOI 10.1002/j.1460-2075.1986.tb04216.x; CHENG SH, 1990, MOL CELL BIOL, V10, P5569, DOI 10.1128/MCB.10.10.5569; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DILWORTH SM, 1982, P NATL ACAD SCI-BIOL, V79, P1059, DOI 10.1073/pnas.79.4.1059; DILWORTH SM, 1986, EMBO J, V5, P491, DOI 10.1002/j.1460-2075.1986.tb04238.x; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; GRIFFIN BE, 1979, J VIROL, V31, P645, DOI 10.1128/JVI.31.3.645-656.1979; GRIFFIN BE, 1983, ADV CANCER RES, V39, P183, DOI 10.1016/S0065-230X(08)61036-2; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GRUSSENMEYER T, 1987, J VIROL, V61, P3902, DOI 10.1128/JVI.61.12.3902-3909.1987; HOFER KB, 1988, ONCOGENE, V3, P365; KAPLAN DR, 1989, BIOCHIM BIOPHYS ACTA, V948, P345, DOI 10.1016/0304-419X(89)90006-1; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KRAUZEWICZ J, 1992, THESIS LONDON U; KRAUZEWICZ N, 1993, ELECTROPHORESIS, V15, P491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENSTRA JA, 1983, EUR J BIOCHEM, V135, P413, DOI 10.1111/j.1432-1033.1983.tb07668.x; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MAGNUSSON G, 1979, J VIROL, V32, P523, DOI 10.1128/JVI.32.2.523-529.1979; MARKLAND W, 1986, J VIROL, V59, P82, DOI 10.1128/JVI.59.1.82-89.1986; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; OSBORN M, 1977, EXP CELL RES, V106, P339, DOI 10.1016/0014-4827(77)90179-3; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; PONTEN J, 1971, VIROL MONOGR, P45; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; SCHAFFHAUSEN BS, 1982, MOL CELL BIOL, V2, P1187, DOI 10.1128/MCB.2.10.1187; SEGAWA K, 1982, P NATL ACAD SCI-BIOL, V79, P6812, DOI 10.1073/pnas.79.22.6812; SMITH AE, 1979, CELL, V18, P915, DOI 10.1016/0092-8674(79)90204-6; SMITH AE, 1980, COLD SPRING HARB SYM, V1, P141; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STRAUSS M, 1986, GENE, V49, P331, DOI 10.1016/0378-1119(86)90369-0; STREULI CH, 1990, J VIROL, V64, P3570, DOI 10.1128/JVI.64.8.3570-3580.1990; TALMAGE DA, 1988, MOL CELL BIOL, V8, P2309, DOI 10.1128/MCB.8.6.2309; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; WALTER G, 1982, P NATL ACAD SCI-BIOL, V79, P4025, DOI 10.1073/pnas.79.13.4025; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WYSS A, 1990, J VIROL, V64, P5163, DOI 10.1128/JVI.64.10.5163-5166.1990; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	49	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2283	2291						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7518577				2022-12-28	WOS:A1994NX62900021
J	SETH, A; ROBINSON, L; PANAYIOTAKIS, A; THOMPSON, DM; HODGE, DR; ZHANG, XK; WATSON, DK; OZATO, K; PAPAS, TS				SETH, A; ROBINSON, L; PANAYIOTAKIS, A; THOMPSON, DM; HODGE, DR; ZHANG, XK; WATSON, DK; OZATO, K; PAPAS, TS			THE ENDOA ENHANCER CONTAINS MULTIPLE ETS BINDING-SITE REPEATS AND IS REGULATED BY ETS PROTEINS	ONCOGENE			English	Article							GENE FAMILY; C-FOS; TRANSCRIPTIONAL ACTIVATION; C-ETS-1 PROTOONCOGENE; ONCOGENIC ACTIVITY; EXPRESSION; MEMBER; MOUSE; PHOSPHORYLATION; IDENTIFICATION	EndoA is a type II keratin and with EndoB (type T keratin), constitutes intermediate filaments in various simple epithelial tissues. EndoA is developmentally regulated and has an enhancer that is located at the 3' - end of the gene. This enhancer contains two single and five dual Ets binding sites. Thus far, no other promoter or enhancer has been shown to contain as many potential clustered Ets binding sites. To study the transcriptional regulation of EndoA by the ETS family proteins, we amplified the EndoA enhancer fragment from mouse genomic DNA by PCR, and cloned it into the pBLCAT2 vector upstream from the CAT reporter gene. Several pBLCAT-ENDOA clones were squenced to verify the presence of all the ETS binding sites. Clones that did not show any point mutations in the ETS binding sites were chosen to study the transcription regulation by ETS1, ETS2 and ERGB/FLI-1 gene products. EMSA results indicated that the ETS1, ETS2 and ERGB/FLI-1 proteins bind to the enhancer sequence, and DNase I protection data demonstrated that the ETS proteins protect all seven EBS core sequences. Cotransfection of the COS cells with the pBLCAT-ENDOA construct, along with increasing amounts of different ETS expression vectors, resulted in a significant induction of CAT reporter gene expression. Previously, we have shown that the overexpression of the ETS1 gene transforms NIH3T3, and these transformed cells (7AQS2.1) produce high levels of ETS1 protein (Seth and Papas, 1990). In this report, we show that the undifferentiated P19 EC cells do not express detectable levels of ETS1; however, an elevated level of ETS1 is expressed in differentiated derivatives of these cells. We therefore used these two cell lines to examine the activity of the EndoA enhancer with the ETS1 product. Transfection of the pBLCAT-ENDOA construct alone in undifferentiated P19 EC cells results in very low CAT gene expression; however, upon differentiation with retinoic acid the level of CAT gene activity increases dramatically. Similarly, an increase in CAT expression from the same construct (pBLCAT-ENDOA) was also observed in 7AQS2.1 cells. Our results therefore indicate that the EndoA enhancer is regulated by ETS proteins via interaction with multiple ETS-binding site sequences.	PROGRAM RESOURCES INC,DYNCORP,FREDERICK,MD 21702									ASCIONE R, 1992, INT J ONCOL, V1, P631; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FISHER RJ, 1991, ONCOGENE, V6, P1001; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; HASHIDO K, 1991, EXP CELL RES, V192, P203, DOI 10.1016/0014-4827(91)90177-V; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HODGE DR, 1993, IN PRESS METHODS MOL; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; MCLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OSHIMA RG, 1985, CELL PROLIFERAT, V10, P51; PANAYIOTAKIS A, 1993, J VIRAL DISEASES, V1, P53; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; SAMBROOK J, 1989, MOL CLONING LABORATO, P542; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1989, ONCOGENE RES, V5, P61; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SETH A, 1993, INT J ONCOL, V2, P739; SETH A, 1993, CANCER PRINCIPLES PR, P23; TAKEMOTO Y, 1991, NUCLEIC ACIDS RES, V19, P2761, DOI 10.1093/nar/19.10.2761; TOPOL LZ, 1992, CANCER LETT, V67, P71, DOI 10.1016/0304-3835(92)90010-S; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	39	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					469	477						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	7507230				2022-12-28	WOS:A1994MW24800014
J	APPLEBY, MW; GREENFIELD, IM; CROOK, T; PARKINSON, EK; STANLEY, MA				APPLEBY, MW; GREENFIELD, IM; CROOK, T; PARKINSON, EK; STANLEY, MA			INVIVO AND INVITRO EFFECTS OF V-FOS AND EJ-HA-RAS ONCOGENE EXPRESSION IN MURINE EPIDERMAL-KERATINOCYTES	ONCOGENE			English	Article									UNIV CAMBRIDGE,DEPT PATHOL,IMPERIAL CANC RES FUND,TUMOUR VIRUS GRP,CAMBRIDGE CB2 1QP,ENGLAND; BEATSON INST CANC RES,GLASGOW G61 1BD,SCOTLAND	University of Cambridge; Beatson Institute								ASSELINEAU D, 1985, EXP CELL RES, V159, P536, DOI 10.1016/S0014-4827(85)80027-6; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BRAVO R, 1982, J MOL BIOL, V154, P121, DOI 10.1016/0022-2836(82)90421-1; BREITKREUTZ D, 1984, DIFFERENTIATION, V26, P154, DOI 10.1111/j.1432-0436.1984.tb01389.x; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BUICK RN, 1984, CANCER RES, V44, P4909; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1986, P NATL ACAD SCI USA, V83, P8521, DOI 10.1073/pnas.83.22.8521; CURRAN T, 1988, ONCOGENE HDB; DORAN TI, 1980, CELL, V22, P17, DOI 10.1016/0092-8674(80)90150-6; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GREEN H, 1977, CELL, V11, P405, DOI 10.1016/0092-8674(77)90058-7; GREENHALGH DA, 1988, MOL CARCINOGEN, V1, P134, DOI 10.1002/mc.2940010209; HAMMOND EJ, 1987, TRANSPLANTATION, V44, P106, DOI 10.1097/00007890-198707000-00022; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; JANOSSY G, 1987, LYMPHOCYTES PRACTICA, P67; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; MACKENZIE IC, 1983, J INVEST DERMATOL, V81, pS189, DOI 10.1111/1523-1747.ep12541093; Maniatis T., 1982, MOL CLONING; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NELSON KG, 1982, CANCER RES, V42, P4176; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARKINSON EK, 1987, CARCINOGENESIS, V8, P907, DOI 10.1093/carcin/8.7.907; PERA MF, 1984, CARCINOGENESIS, V5, P671, DOI 10.1093/carcin/5.5.671; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; ROOP DR, 1983, P NATL ACAD SCI-BIOL, V80, P716, DOI 10.1073/pnas.80.3.716; ROSEJOHN S, 1982, CELL, V29, P161; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STANLEY MA, 1979, INT J CANCER, V24, P407, DOI 10.1002/ijc.2910240406; STRICKLAND JE, 1988, CANCER RES, V48, P165; SUN TT, 1977, NATURE, V269, P489, DOI 10.1038/269489a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YUSPA SH, 1983, CANCER RES, V43, P6021; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0; YUSPA SH, 1981, J INVEST DERMATOL, V76, P144, DOI 10.1111/1523-1747.ep12525490	43	7	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1323	1330						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2682460				2022-12-28	WOS:A1989AX65900008
J	SIMPSON, SC; BOLEN, JB; VEILLETTE, A				SIMPSON, SC; BOLEN, JB; VEILLETTE, A			CD4 AND P56LCK CAN STABLY ASSOCIATE WHEN CO-EXPRESSED IN NIH3T3 CELLS	ONCOGENE			English	Note									MCGILL UNIV,MCGILL CANC CTR,ROOM 701,MCINTYRE BLDG,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA; NCI,TUMOR VIRUS BIOL LAB,BETHESDA,MD 20892	McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ANDERSON P, 1988, J IMMUNOL, V140, P1732; BALLHAUSEN WG, 1988, J EXP MED, V167, P1493, DOI 10.1084/jem.167.4.1493; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RIVAS A, 1988, J IMMUNOL, V140, P2912; ROJO JM, 1989, P NATL ACAD SCI USA, V86, P3311, DOI 10.1073/pnas.86.9.3311; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SLECKMAN BP, 1988, J IMMUNOL, V141, P49; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VEILLETTE A, IN PRESS ONCOGENES; WILDE DB, 1983, J IMMUNOL, V131, P2178	20	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1141	1143						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2789360				2022-12-28	WOS:A1989AM53100014
J	GREEN, SM; LOWE, AD; PARRINGTON, J; KARN, J				GREEN, SM; LOWE, AD; PARRINGTON, J; KARN, J			TRANSFORMATION OF GROWTH FACTOR-DEPENDENT MYELOID STEM-CELLS WITH RETROVIRAL VECTORS CARRYING C-MYC	ONCOGENE			English	Article									MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology								ALLEN TD, 1984, EXP HEMATOL, V12, P517; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BAZILL GW, 1983, BIOCHEM J, V210, P747, DOI 10.1042/bj2100747; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; CROCKER PR, 1985, J EXP MED, V162, P993, DOI 10.1084/jem.162.3.993; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; DZIERZAK EA, 1988, NATURE, V331, P35, DOI 10.1038/331035a0; FUNG MC, 1984, NATURE, V307, P233, DOI 10.1038/307233a0; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GRUBER HE, 1985, SCIENCE, V230, P1057, DOI 10.1126/science.3864246; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; HUNT P, 1987, CELL, V48, P997, DOI 10.1016/0092-8674(87)90708-2; IHLE JN, 1983, J IMMUNOL, V131, P282; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KELLER G, 1986, COLD SPRING HARB SYM, V51, P1052; KINCADE PW, 1981, J IMMUNOL, V127, P2262; KKARN J, 1989, ONCOGENE, V4, P773; KUNG JT, 1981, J IMMUNOL, V127, P873; LAHER C, 1987, P NATL ACAD SCI USA, V84, P8458; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; LY IA, 1974, J IMMUNOL METHODS, V5, P239, DOI 10.1016/0022-1759(74)90108-2; MAGLI MC, 1987, P NATL ACAD SCI USA, V84, P789, DOI 10.1073/pnas.84.3.789; MARSHAKROTHSTEIN A, 1979, J IMMUNOL, V122, P2491; METCALF D, 1980, BLOOD, V55, P138; MOCHIZUKI DY, 1987, P NATL ACAD SCI USA, V84, P5267, DOI 10.1073/pnas.84.15.5267; MORSE HC, 1986, P NATL ACAD SCI USA, V83, P6868, DOI 10.1073/pnas.83.18.6868; MULLERSIEBURG CE, 1986, CELL, V44, P653, DOI 10.1016/0092-8674(86)90274-6; NICOLA NA, 1983, J BIOL CHEM, V258, P9017; NUSSENZWEIG MC, 1981, J EXP MED, V154, P168, DOI 10.1084/jem.154.1.168; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; ROSEN H, 1987, J EXP MED, V166, P1685, DOI 10.1084/jem.166.6.1685; SANCHEZMADRID F, 1983, J EXP MED, V158, P586, DOI 10.1084/jem.158.2.586; SNODGRASS R, 1987, EMBO J, V6, P3955, DOI 10.1002/j.1460-2075.1987.tb02737.x; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SPRINGER TA, 1981, J BIOL CHEM, V256, P3833; STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022-1759(81)90156-3; STANLEY ER, 1986, CELL, V45, P667, DOI 10.1016/0092-8674(86)90781-6; STEINMAN RM, 1983, J EXP MED, V157, P613, DOI 10.1084/jem.157.2.613; STEINMAN RM, 1980, J EXP MED, V152, P1248, DOI 10.1084/jem.152.5.1248; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; WHITE JG, 1987, J CELL BIOL, V105, P41, DOI 10.1083/jcb.105.1.41; WHITLOCK CA, 1987, CELL, V48, P1009, DOI 10.1016/0092-8674(87)90709-4; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0	54	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					737	751						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2660072				2022-12-28	WOS:A1989AA66000010
J	PARK, RE; HASELTINE, WA; ROSEN, CA				PARK, RE; HASELTINE, WA; ROSEN, CA			A NUCLEAR FACTOR IS REQUIRED FOR TRANSACTIVATION OF HTLV-I GENE-EXPRESSION	ONCOGENE			English	Article									ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT MOLEC ONCOL,NUTLEY,NJ 07110; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PATHOL,BOSTON,MA 02115	Roche Holding; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School								BLATTNER WA, 1982, INT J CANCER, V30, P257, DOI 10.1002/ijc.2910300302; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CHEN ISY, 1983, P NATL ACAD SCI-BIOL, V80, P7006, DOI 10.1073/pnas.80.22.7006; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; FUJISAWA J, 1985, P NATL ACAD SCI US, V82, P2276; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; INOUE J, 1986, EMBO J, V5, P2882; JOSEPHS SF, 1984, VIROLOGY, V1139, P340; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE TH, 1984, SCIENCE, V226, P57, DOI 10.1126/science.6089350; Maxam A M, 1980, Methods Enzymol, V65, P499; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; PASHKALIS H, 1986, P NATL ACAD SCI US, V83, P6558; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPOVIC M, 1983, SCIENCE, V219, P856, DOI 10.1126/science.6600519; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; RUBEN S, IN PRESS SCIENCE; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXON A, 1978, J IMMUNOL, V120, P777; SAXON A, 1978, ANN INTERN MED, V88, P323, DOI 10.7326/0003-4819-88-3-323; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; WEINBERGER J, 1986, NATURE, V322, P846, DOI 10.1038/322846a0; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467	39	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					275	279						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	2849741				2022-12-28	WOS:A1988Q436700005
J	GUBITS, RM; FAIRHURST, JL				GUBITS, RM; FAIRHURST, JL			C-FOS MESSENGER-RNA LEVELS ARE INCREASED BY THE CELLULAR STRESSORS, HEAT-SHOCK AND SODIUM ARSENITE	ONCOGENE			English	Article									NATHAN S KLINE INST,DIV MOLEC BIOL,ORANGEBURG,NY 10962	Nathan Kline Institute for Psychiatric Research					NIGMS NIH HHS [GM38202] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038202] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; AXELROD J, 1984, SCIENCE, V224, P452, DOI 10.1126/science.6143403; BARKA T, 1986, MOL CELL BIOL, V6, P2984, DOI 10.1128/MCB.6.8.2984; BARKA T, 1987, ONCOGENE, V1, P297; BESTERMAN JM, 1985, J BIOL CHEM, V260, P1155; BURDON RH, 1986, BIOCHEM J, V240, P313, DOI 10.1042/bj2400313; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1984, CELL, V36, P259; DAVIS RJ, 1985, J BIOL CHEM, V260, P2543; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GUBITS RM, 1986, ENDOCRINOLOGY, V119, P1382, DOI 10.1210/endo-119-3-1382; GUBITS RM, 1984, J BIOL CHEM, V259, P2803; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HIGHTOWER LE, 1981, J CELL PHYSIOL, V108, P261, DOI 10.1002/jcp.1041080216; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; HUNT SP, 1987, NATURE, V328, P631; INGOLIA TD, 1980, CELL, V21, P669, DOI 10.1016/0092-8674(80)90430-4; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LI GC, 1983, J CELL PHYSIOL, V115, P116, DOI 10.1002/jcp.1041150203; LI GC, 1985, CHANGES EUKARYOTIC G, P227; LIN CY, 1984, PLANT PHYSIOL, V74, P152, DOI 10.1104/pp.74.1.152; LOWE DG, 1986, J BIOL CHEM, V261, P2102; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; PELHAM H, 1985, TRENDS GENET, V1, P31, DOI 10.1016/0168-9525(85)90012-5; RENAN MJ, 1986, BIOSCIENCE REP, V6, P819, DOI 10.1007/BF01117105; RENAN MJ, 1985, BIOSCIENCE REP, V5, P739, DOI 10.1007/BF01119872; RENZ M, 1987, NUCLEIC ACIDS RES, V15, P277, DOI 10.1093/nar/15.1.277; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SCHARF KD, 1982, CELL, V30, P427, DOI 10.1016/0092-8674(82)90240-9; SCHLESINGER MJ, 1985, CHANGES EUKARYOTIC G, P183; SIMCOX AA, 1985, MOL CELL BIOL, V5, P3397, DOI 10.1128/MCB.5.12.3397; THEODORAKIS NG, 1987, MOL CELL BIOL, V7, P4357, DOI 10.1128/MCB.7.12.4357; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; WU BJ, 1985, P NATL ACAD SCI USA, V82, P6070, DOI 10.1073/pnas.82.18.6070; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629	52	75	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					163	168						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	3412774				2022-12-28	WOS:A1988Q053400006
J	MARCH, PE; LERNER, CG; AHNN, J; CUI, X; INOUYE, M				MARCH, PE; LERNER, CG; AHNN, J; CUI, X; INOUYE, M			THE ESCHERICHIA-COLI RAS-LIKE PROTEIN (ERA) HAS GTPASE ACTIVITY AND IS ESSENTIAL FOR CELL-GROWTH	ONCOGENE			English	Article											MARCH, PE (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH RUTGERS,DEPT BIOCHEM,675 HOES LANE,PISCATAWAY,NJ 08854, USA.				NIGMS NIH HHS [GM19043] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019043, R01GM019043] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHNN J, 1986, P NATL ACAD SCI USA, V83, P8849, DOI 10.1073/pnas.83.23.8849; ARMSTRONG KA, 1984, J MOL BIOL, V175, P331, DOI 10.1016/0022-2836(84)90352-8; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CHEN ZQ, 1985, J VIROL, V56, P607, DOI 10.1128/JVI.56.2.607-612.1985; CULLEN SE, 1976, J IMMUNOL, V117, P136; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; DUFFAUD GD, 1987, METHOD ENZYMOL, V153, P492; FUMIYAMA A, 1986, P NATL ACAD SCI US, V83, P1266; GOLDMARK PJ, 1972, J BIOL CHEM, V247, P1849; INOUYE S, 1976, J BACTERIOL, V127, P555, DOI 10.1128/JB.127.1.555-563.1976; INOUYE S, 1985, NUCLEIC ACIDS RES, V13, P3101, DOI 10.1093/nar/13.9.3101; JASIN M, 1984, J BACTERIOL, V159, P783, DOI 10.1128/JB.159.2.783-786.1984; KUSHNER SR, 1971, P NATL ACAD SCI USA, V68, P824, DOI 10.1073/pnas.68.4.824; LUNN CA, 1987, J BIOL CHEM, V262, P8318; MANIATIS T, 1984, MOL CLONING LABORATO; MARCH PE, 1985, J BIOL CHEM, V260, P7206; Miller D L, 1974, Methods Enzymol, V30, P219; NAKAMURA K, 1982, Journal of Molecular and Applied Genetics, V1, P289; OISHI M, 1972, BIOCHEM BIOPH RES CO, V49, P1568, DOI 10.1016/0006-291X(72)90520-7; SHIH TY, 1982, J VIROL, V42, P253, DOI 10.1128/JVI.42.1.253-261.1982; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; UNO I, 1985, P NATL ACAD SCI USA, V82, P7855, DOI 10.1073/pnas.82.23.7855; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WACHERNAGEL W, 1973, BIOCHEM BIOPH RES CO, V51, P306; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; WURTZEL ET, 1982, J BIOL CHEM, V257, P13685; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	31	79	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					539	544						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	2838786				2022-12-28	WOS:A1988N841500002
J	BROWNELL, E; FELL, HP; TUCKER, PW; VANKESSEL, AHMG; HAGEMEIJER, A; RICE, NR				BROWNELL, E; FELL, HP; TUCKER, PW; VANKESSEL, AHMG; HAGEMEIJER, A; RICE, NR			REGIONAL LOCALIZATION OF THE HUMAN C-REL LOCUS USING TRANSLOCATION CHROMOSOME ANALYSIS	ONCOGENE			English	Article									ONCOGEN,SEATTLE,WA 98121; UNIV TEXAS,HLTH SCI CTR,SW MED SCH,GRAD PROGRAM IMMUNOL,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,SW MED SCH,DEPT MICROBIOL,DALLAS,TX 75235; ERASMUS UNIV,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Erasmus University Rotterdam	BROWNELL, E (corresponding author), NCI,FREDERICK CANC RES FACIL,BRI BASIC RES PROGRAM,FREDERICK,MD 21701, USA.		van Kessel, Ad Geurts/A-2810-2010		NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AURIAS A, 1986, HUM GENET, V72, P210, DOI 10.1007/BF00291879; BROWNELL E, 1986, AM J HUM GENET, V39, P194; BROWNELL E, 1985, MOL CELL BIOL, V5, P2826, DOI 10.1128/MCB.5.10.2826; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; BUCHBERG AM, 1988, ONCOGENE RES, V2, P149; CLAFLIN JL, 1978, IMMUNOGENETICS, V6, P379, DOI 10.1007/BF01563929; Davis MM, 1985, ATAXIA TELANGIECTASI, P197; DENDUNNEN JT, 1985, HUM GENET, V70, P217, DOI 10.1007/BF00273445; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P7581, DOI 10.1073/pnas.80.24.7581; FELL HP, 1986, SCIENCE, V232, P491, DOI 10.1126/science.3961491; GIBSON DM, 1978, J IMMUNOL, V121, P1585; GOTTLIEB PD, 1974, J EXP MED, V140, P1432, DOI 10.1084/jem.140.5.1432; HERZOG NK, 1986, J VIROL, V57, P371, DOI 10.1128/JVI.57.1.371-375.1986; ITAKURA K, 1972, TRANSPLANTATION, V13, P239, DOI 10.1097/00007890-197203000-00007; LARSON RA, 1987, P NATL ACAD SCI US, V84, P2970; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; PETTENATI MJ, 1987, P NATL ACAD SCI USA, V84, P2970, DOI 10.1073/pnas.84.9.2970; SUKHATME VP, 1985, J EXP MED, V161, P429, DOI 10.1084/jem.161.2.429; YUNIS JJ, 1987, ONCOGENE, V1, P59; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	20	28	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					527	529						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	3287280				2022-12-28	WOS:A1988N434800016
J	BERNARD, O; LARSEN, CJ; HAMPE, A; MAUCHAUFFE, M; BERGER, R; MATHIEUMAHUL, D				BERNARD, O; LARSEN, CJ; HAMPE, A; MAUCHAUFFE, M; BERGER, R; MATHIEUMAHUL, D			MOLECULAR MECHANISMS OF A T(8-14)(Q24-Q11) TRANSLOCATION JUXTAPOSING C-MYC AND TCR-ALPHA GENES IN A T-CELL LEUKEMIA - INVOLVEMENT OF A V-ALPHA INTERNAL HEPTAMER	ONCOGENE			English	Article									HOP ST LOUIS,CTR HAYEM,INSERM,UNITE 301,F-75475 PARIS 10,FRANCE; HOP ST LOUIS,CTR HAYEM,HEMATOL EXPTL LAB,F-75475 PARIS 10,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			Mathieu, Daniele/G-6092-2012; Bernard, Olivier A./E-5721-2016					BERGER R, 1986, CHROMOSOMES HEMATOLO, P104; CAUBET JF, 1985, CR ACAD SCI III-VIE, V300, P171; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; EARLY P, 1982, MOL CELL BIOL, V2, P829, DOI 10.1128/MCB.2.7.829; ERIKSON J, 1986, SCIENCE, V232, P884, DOI 10.1126/science.3486470; ERIKSON J, 1985, SCIENCE, V229, P784, DOI 10.1126/science.3875152; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; FUJIMOTO S, 1987, NATURE, V327, P242, DOI 10.1038/327242a0; HAYASHI Y, 1986, NEW ENGL J MED, V314, P650, DOI 10.1056/NEJM198603063141018; HOPE TJ, 1986, SCIENCE, V231, P1141, DOI 10.1126/science.3003919; KATAOKA T, 1984, NUCLEIC ACIDS RES, V12, P5995, DOI 10.1093/nar/12.15.5995; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LEBEAU MM, 1986, P NATL ACAD SCI USA, V83, P9744; MALISSEN M, 1986, NATURE, V319, P28, DOI 10.1038/319028a0; MATHIEUMAHUL D, 1986, J EXP MED, V163, P1308, DOI 10.1084/jem.163.5.1308; MATHIEUMAHUL D, 1986, INT J CANCER, V38, P835, DOI 10.1002/ijc.2910380609; MATHIEUMAHUL D, 1985, EMBO J, V4, P3427, DOI 10.1002/j.1460-2075.1985.tb04100.x; MCKEITHAN TW, 1986, P NATL ACAD SCI USA, V83, P6636, DOI 10.1073/pnas.83.17.6636; RETH M, 1986, NATURE, V322, P840, DOI 10.1038/322840a0; RIVIERE D, 1983, NOUV REV FR HEMATOL, V25, P175; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHIMA EA, 1986, P NATL ACAD SCI USA, V83, P3439, DOI 10.1073/pnas.83.10.3439; YANCOPOULOS GD, 1986, ANNU REV IMMUNOL, V4, P339, DOI 10.1146/annurev.iy.04.040186.002011; YOSHIKAI Y, 1986, J EXP MED, V164, P90, DOI 10.1084/jem.164.1.90	25	53	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					195	200						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	2966921				2022-12-28	WOS:A1988M086000014
J	FAVOT, P; YUE, X; HUME, DA				FAVOT, P; YUE, X; HUME, DA			REGULATION OF THE C-FMS PROMOTER IN MURINE TUMOR-CELL LINES	ONCOGENE			English	Article						MACROPHAGE; C-FMS; TRANSCRIPTION; CSF-1; TUMOR PROGRESSION	COLONY-STIMULATING FACTOR; MACROPHAGE GROWTH-FACTOR; CSF RECEPTOR EXPRESSION; FACTOR-I RECEPTOR; PLASMINOGEN-ACTIVATOR; CARCINOMAS INVIVO; PROTO-ONCOGENE; BONE-MARROW; MOUSE; GENE	Macrophage colony-stimulating factor (CSF-1) mRNA was detected in a wide range of murine tumour cell lines. Stable transfection with a CSF-1 receptor (c-fms) expression plasmid increased the number and size of colonies formed in soft agar by tumour cell lines that were already clonogenic, but did not induce transformation in non-clonogenic lines. To identify mechanisms that might lead to ectopic expression of c-fms, the regulation of the exon 2 promoter of the gene, which flanks the transcription start sites in macrophages, was examined. In transient and stable transfections this promoter was as active in non-macrophage tumour cell lines as it was in RAW264 macrophages. Promoter activity in non-macrophage lines was serum-dependent and was activated further in lines stably transfected with c-fms. Cis-acting elements required for serum-dependent activity lay outside the 300 bp proximal promoter that was sufficient for maximal activity in RAW264 macrophages, but the c-fms-responsive elements were retained in the proximal promoter. Exon 2 promoter activity was selectively suppressed in non-macrophage fines inclusion of intron 2, which has been implicated transcription attenuation. Lewis lung carcinoma cells were able to partly bypass this block and expressed c-fms mRNA when grown in limiting serum. The finding that c-fms promoter activity and c-fms mRNA levels are responsive to growth factor signalling pathways provides an insight into mechanisms that may lead to ectopic c-fms expression in tumour cells.	UNIV QUEENSLAND, CTR CELLULAR & MOLEC BIOL, ST LUCIA, QLD 4072, AUSTRALIA	University of Queensland			Hume, David A/C-7695-2013	Hume, David/0000-0002-2615-1478				AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; BAIOCCHI G, 1991, CANCER, V67, P990, DOI 10.1002/1097-0142(19910215)67:4<990::AID-CNCR2820670422>3.0.CO;2-8; BAUKNECHT T, 1994, CANCER DETECT PREV, V18, P231; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BERTRAM JS, 1980, CANCER LETT, V11, P63, DOI 10.1016/0304-3835(80)90130-5; BRUCKNER A, 1992, CANCER RES, V52, P3043; BURTHEM J, 1994, BLOOD, V83, P1381, DOI 10.1182/blood.V83.5.1381.bloodjournal8351381; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; EVANS R, 1990, BIOTECHNIQUES, V8, P357; FILDERMAN AE, 1992, CANCER RES, V52, P3661; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANKS LM, 1978, J PATHOL, V124, P35, DOI 10.1002/path.1711240108; GLINIAK BC, 1992, MOL BIOL CELL, V3, P535, DOI 10.1091/mbc.3.5.535; HUME DA, 1983, J CELL PHYSIOL, V117, P189, DOI 10.1002/jcp.1041170209; JIN DI, 1995, MOL CELL BIOL, V15, P693; KACINSKI BM, 1990, INT J RADIAT ONCOL, V19, P619, DOI 10.1016/0360-3016(90)90488-6; KACINSKI BM, 1991, ONCOGENE, V6, P941; KACINSKI BM, 1990, AM J PATHOL, V137, P135; KAUMA SW, 1991, J CLIN ENDOCR METAB, V73, P746, DOI 10.1210/jcem-73-4-746; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LADNER MB, 1988, P NATL ACAD SCI USA, V85, P6706, DOI 10.1073/pnas.85.18.6706; LANGER SJ, 1988, MOL CELL BIOL, V8, P3872, DOI 10.1128/MCB.8.9.3872; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEISEROWITZ GS, 1993, GYNECOL ONCOL, V49, P190, DOI 10.1006/gyno.1993.1106; PAIETTA E, 1990, CANCER RES, V50, P2049; PATEK PQ, 1978, NATURE, V276, P510, DOI 10.1038/276510a0; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; RAMBALDI A, 1988, J CLIN INVEST, V81, P1030, DOI 10.1172/JCI113413; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; ROBERTS WM, 1992, BLOOD, V79, P586; ROSS IL, 1994, ONCOGENE, V9, P121; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SANFORD KK, 1948, J NATL CANCER I, V9, P229; SARIBAN E, 1989, BLOOD, V74, P123; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SHERR CJ, 1990, BLOOD, V75, P1; STACEY KJ, 1993, IMMUNOL CELL BIOL, V71, P75, DOI 10.1038/icb.1993.8; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; STORGA D, 1992, INT J EXP PATHOL, V73, P527; TANG RP, 1992, J CELL BIOCHEM, V50, P350, DOI 10.1002/jcb.240500403; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TILL KJ, 1993, BRIT J HAEMATOL, V83, P223, DOI 10.1111/j.1365-2141.1993.tb08276.x; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; YUE X, 1993, MOL CELL BIOL, V13, P3191, DOI 10.1128/MCB.13.6.3191; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	54	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1371	1381						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478559				2022-12-28	WOS:A1995RY96700019
J	AGARWAL, S; CORBLEY, MJ; ROBERTS, TM				AGARWAL, S; CORBLEY, MJ; ROBERTS, TM			RECONSTITUTION OF SIGNAL-TRANSDUCTION FROM THE MEMBRANE TO THE NUCLEUS IN A BACULOVIRUS EXPRESSION SYSTEM - ACTIVATION OF RAF-1 LEADS TO HYPERMODIFICATION OF C-JUN AND C-FOS VIA MULTIPLE PATHWAYS	ONCOGENE			English	Article						SIGNALING PATHWAYS; KINASES; RAF-1; ERK-1; NUCLEAR ONCOGENES; C-FOS; C-JUN; POSTTRANSLATIONAL MODIFICATIONS	GLYCOGEN-SYNTHASE KINASE-3; DEPENDENT PROTEIN-KINASE; DNA-BINDING ACTIVITY; MAP KINASE; HA-RAS; COMPLEX-FORMATION; GROWTH-FACTORS; INSECT CELLS; S6 KINASE; 3T3 CELLS	We have attempted to dissect signaling pathways involved in transmitting activating signals from the cell surface to the nucleus by reconstituting them in the baculovirus/Sf9 cell system. We have used this system to coexpress different combinations of the critical signaling proteins pp60(v-src), p21(v-ras), Raf-1 and ERK-1 and assayed the effects of resulting signaling cascades on the modifications of coexpressed transcription factors c-jun or c-fos. We observe that activation of ERK-1 via Raf-1 and p21(ras) dependent signals can result in the hyperphosphorylation of c-jun. In contrast, c-fos appears to be the target of two Raf-1 activated modifying signals: one independent of ERK-1 and the other dependent on ERK-1 stimulation. Thus, coexpression of c-fos with pp60(v-src), p21(v-ras) or constitutively active forms of Raf-1 results in a dramatic reduction of its electrophoretic mobility in the absence of coexpressed ERK-1. Activation of this ERK-1-independent pathway together with the ERK-1 dependent pathway that modifies c-jun results in additional modification of c-fos. Our observation of a Raf-1 activated, ERK-independent signaling pathway is consistent with previous reports that constitutively active Raf-1 can, in some cell types, result in transformation or differentiation without activation of ERKs. Our data indicate the presence of multiple Raf-1 activated pathways that lead to modification of transcription factors.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NCI NIH HHS [CA43803] Funding Source: Medline; NICHD NIH HHS [HD24926] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, ONCOGENE, V6, P2179; ADLER V, 1992, J BIOL CHEM, V267, P17001; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; AHN NG, 1992, CIBA F SYMP, V164, P113; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHUNG J, 1991, P NATL ACAD SCI USA, V58, P4981; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CURRAN T, 1986, P NATL ACAD SCI USA, V83, P8521, DOI 10.1073/pnas.83.22.8521; CURRAN T, 1984, CELL, V36, P259; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEGROOT RP, 1993, ONCOGENE, V8, P841; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Distel R J, 1990, Adv Cancer Res, V55, P37, DOI 10.1016/S0065-230X(08)60467-4; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HERRERA R, 1990, CELL GROWTH DIFFER, V1, P483; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MEEK DW, 1992, BIOCHEM J, V287, P1; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHULTZ AM, 1988, ONCOGENE, V2, P187; SETH A, 1992, J BIOL CHEM, V267, P24796; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Summers MD, 1987, MANUAL METHODS BACUL; TAYLOR LK, 1994, J BIOL CHEM, V269, P308; TAYLOR LK, 1993, P NATL ACAD SCI USA, V90, P368, DOI 10.1073/pnas.90.2.368; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VIK TA, 1990, P NATL ACAD SCI USA, V87, P2685, DOI 10.1073/pnas.87.7.2685; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOSATKA RJ, 1989, J CELL PHYSIOL, V138, P493, DOI 10.1002/jcp.1041380308; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAN MH, 1994, NATURE, V372, P798; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	92	22	23	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					427	438						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7543194				2022-12-28	WOS:A1995RN53000002
J	EYCHENE, A; DUSANTERFOURT, I; BARNIER, JV; PAPIN, C; CHARON, M; GISSELBRECHT, S; CALOTHY, G				EYCHENE, A; DUSANTERFOURT, I; BARNIER, JV; PAPIN, C; CHARON, M; GISSELBRECHT, S; CALOTHY, G			EXPRESSION AND ACTIVATION OF B-RAF KINASE ISOFORMS IN HUMAN AND MURINE LEUKEMIA-CELL LINES	ONCOGENE			English	Article						B-RAF; C-RMIL; RAF-1; SERINE THREONINE KINASE; HEMATOPOIETIC CELLS	COLONY-STIMULATING FACTOR; SERINE-THREONINE KINASE; PROTEIN-KINASE; GROWTH-FACTOR; RAPID PHOSPHORYLATION; C-RAF; SIGNAL TRANSDUCTION; PROTOONCOGENE; ERYTHROPOIETIN; INTERLEUKIN-3	The B-raf/c-Rmil proto-oncogene belongs to the raf/mil family of serine/threonine protein kinases. It encodes multiple protein isoforms previously shown to be expressed predominantly in neural tissues. We report here that B-Raf proteins of 95 and 72 kDa are also expressed in various human and murine hematopoietic cell lines. Their relative level of expression is variable depending on the cell line examined. The highest level of expression of p95(B-raf) was found in UT-7 cells, a human pluripotent cell line established from a patient with a megakaryoblastic leukemia. These cells are able to differentiate toward erythroid or myeloid lineage phenotypes in presence of erythropoietin (EPO) or granulocyte-macrophage colony-stimulating factor (GM-CSF) respectively. We show that treatment of UT-7 cells with EPO, GM-CSF or stem cell factor (SCF) rapidly induces phosphorylation of p95(B-raf) as indicated by a shift of electrophoretic mobility. This increase in phosphorylation is correlated with a three-fold increase of B-Raf kinase activity. B-Raf activation also increases in a dose-dependent manner in response to EPO and GM-CSF. We also show that both p95(B-raf) and p72(B-raf) can be activated by IL-3 in murine BAF-3 pro-B cells and by anti-CD3 in human Jurkat cells, respectively. These observations provide the first evidence that the B-Raf kinase is involved in signal transduction pathways regulating proliferation and differentiation of hematopoietic cells of both myeloid and lymphoid lineages.	HOP COCHIN,ICGM,INSERM,U363,F-75674 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	EYCHENE, A (corresponding author), CTR UNIV ORSAY,INST CURIE,LAB 110,CNRS,URA 1443,F-91405 ORSAY,FRANCE.		Eychene, Alain/M-8838-2017; Dusanter-Fourt, Isabelle/P-4558-2017	Dusanter-Fourt, Isabelle/0000-0002-9286-1021; EYCHENE, Alain/0000-0002-6818-7225				BRENNSCHEIDT U, 1994, CELL GROWTH DIFFER, V5, P367; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUSCHER D, 1993, ONCOGENE, V8, P3323; CALOGERAKI I, 1993, BIOCHEM BIOPH RES CO, V193, P1324, DOI 10.1006/bbrc.1993.1770; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; EYCHENE A, 1992, ONCOGENE, V7, P1657; EYCHENE A, 1992, ONCOGENE, V7, P1315; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FELDER MP, 1991, J VIROL, V65, P3633, DOI 10.1128/JVI.65.7.3633-3640.1991; HEIDECKER G, 1991, ADV CANCER RES, V58, P53; HERMINE O, 1992, BLOOD, V80, P3060; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; KANAKURA Y, 1991, BLOOD, V77, P243; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOMATSU N, 1991, CANCER RES, V51, P341; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; MIHALY A, 1993, BRAIN RES, V627, P225, DOI 10.1016/0006-8993(93)90325-H; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; RAMOSMORALES F, 1994, IN PRESS ONCOGENE, V9; RAPP UR, 1991, ONCOGENE, V6, P495; RIEDEL D, 1993, EUR J IMMUNOL, V23, P3146, DOI 10.1002/eji.1830231216; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SOZERI O, 1992, ONCOGENE, V7, P2259; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; STORM SM, 1990, ONCOGENE, V5, P345; TAMAKI T, 1992, CANCER RES, V52, P566; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6934, DOI 10.1073/pnas.85.18.6934; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	47	47	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1159	1165						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7535416				2022-12-28	WOS:A1995QN35300017
J	BRIZZI, MF; BLECHMAN, JM; CAVALLONI, G; GIVOL, D; YARDEN, Y; PEGORARO, L				BRIZZI, MF; BLECHMAN, JM; CAVALLONI, G; GIVOL, D; YARDEN, Y; PEGORARO, L			PROTEIN-KINASE C-DEPENDENT RELEASE OF A FUNCTIONAL WHOLE EXTRACELLULAR DOMAIN OF THE MAST-CELL GROWTH-FACTOR (MGF) RECEPTOR BY MGF-DEPENDENT HUMAN MYELOID CELLS	ONCOGENE			English	Article							TYROSINE KINASE; SIGNAL TRANSDUCTION; KIT PROTOONCOGENE; PHORBOL ESTERS; SI-LOCUS; LIGAND; BINDING; MOUSE; INHIBITION; FORM	The mast cell growth factor (MGF) affects migration, proliferation and differentiation of erythroid and myeloid progenitor cells by binding to a transmembrane receptor tyrosine kinase encoded by the c-Kit proto-oncogene. By using MGF-dependent human myeloid cell lines (M-07e and TF-1), here we show that a Kit-related 100 kDa protein is associated with the cell but it undergoes release into the medium upon treatment with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA), an activator of protein kinase C. Immunological analysis with a series of antibodies to Kit indicated that the released protein (p100(Kit)) contains the whole glycosylated extracellular portion of the transmembrane Kit protein (p145(Kit)). The secreted protein retained the ability to specifically bind MGF. Moreover, p100(Kit) was able to block the mitogenic effect of MGF on cultured M-07e cells, suggesting that the soluble protein may function as a physiological antagonist of MGF.	UNIV TURIN,DIPARTIMENTO SCI BIOMED & ONCOL UMANA,SEZ CLIN,I-10149 TURIN,ITALY; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	University of Turin; Weizmann Institute of Science			YARDEN, YOSEF/K-1467-2012; Brizzi, Maria Felice/J-7882-2016	Cavalloni, Giuliana/0000-0002-9965-3436				ABKOWITZ JL, 1992, BLOOD, V79, P25, DOI 10.1182/blood.V79.1.25.bloodjournal79125; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; BUDEL LM, 1993, LEUKEMIA, V7, P426; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LEE LS, 1979, P NATL ACAD SCI USA, V10, P5178; LEV S, 1992, J BIOL CHEM, V267, P10866; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCCAFFREY PG, 1984, J BIOL CHEM, V259, P2502; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P1710, DOI 10.1073/pnas.89.5.1710; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SIBLEY DR, 1988, ENDOCR REV, V9, P38, DOI 10.1210/edrv-9-1-38; THOMOPOULOS P, 1982, EUR J BIOCHEM, V129, P389, DOI 10.1111/j.1432-1033.1982.tb07062.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VU TH, 1989, MOL CELL BIOL, V9, P4563, DOI 10.1128/MCB.9.10.4563; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YEE NS, 1993, J BIOL CHEM, V268, P14189; ZINI MG, 1993, COMMUNICATION; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	37	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1583	1589						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	7514283				2022-12-28	WOS:A1994NL81500008
J	WOLLERSHEIM, M; DEBELKA, U; HOFSCHNEIDER, PH				WOLLERSHEIM, M; DEBELKA, U; HOFSCHNEIDER, PH			A TRANSACTIVATING FUNCTION ENCODED IN THE HEPATITIS-B VIRUS-X GENE IS CONSERVED IN THE INTEGRATED STATE	ONCOGENE			English	Article									MAX PLANCK INST BIOCHEM,D-8033 MARTINSRIED,FED REP GER	Max Planck Society								Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHANG CM, 1987, EMBO J, V6, P675, DOI 10.1002/j.1460-2075.1987.tb04807.x; CHANG RSM, 1954, P SOC EXP BIOL MED, V87, P440; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; Favaloro J, 1980, Methods Enzymol, V65, P718; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HASELTINE WA, 1984, SCIENCE, V225, P419, DOI 10.1126/science.6330894; HUNT T, 1985, NATURE, V316, P580, DOI 10.1038/316580a0; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MILLER RH, 1986, P NATL ACAD SCI USA, V83, P2531, DOI 10.1073/pnas.83.8.2531; MIYAKI M, 1986, J GEN VIROL, V67, P1449, DOI 10.1099/0022-1317-67-7-1449; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; NELSONREES WA, 1981, SCIENCE, V212, P446, DOI 10.1126/science.6451928; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; SUREAU C, 1986, CELL, V47, P37, DOI 10.1016/0092-8674(86)90364-8; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TREININ M, 1987, MOL CELL BIOL, V7, P545, DOI 10.1128/MCB.7.1.545; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VONLORINGHOVEN AF, 1985, EMBO J, V4, P249, DOI 10.1002/j.1460-2075.1985.tb02343.x; WILL H, 1985, P NATL ACAD SCI USA, V82, P891, DOI 10.1073/pnas.82.3.891; WOLLERSHEIM M, 1988, VIRAL HEPATITIS LIVE, P334; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAHM P, 1988, IN PRESS ONCOGENE	34	187	189	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					545	552						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	2856254				2022-12-28	WOS:A1988R516300010
J	YOKOTA, J; AKIYAMA, T; FUNG, YKT; BENEDICT, WF; NAMBA, Y; HANAOKA, M; WADA, M; TERASAKI, T; SHIMOSATO, Y; SUGIMURA, T; TERADA, M				YOKOTA, J; AKIYAMA, T; FUNG, YKT; BENEDICT, WF; NAMBA, Y; HANAOKA, M; WADA, M; TERASAKI, T; SHIMOSATO, Y; SUGIMURA, T; TERADA, M			ALTERED EXPRESSION OF THE RETINOBLASTOMA (RB) GENE IN SMALL-CELL CARCINOMA OF THE LUNG	ONCOGENE			English	Article									KYOTO UNIV,INST VIRUS RES,KYOTO 606,JAPAN; UNIV SO CALIF,SCH MED,DEPT PEDIAT & MICROBIOL,LOS ANGELES,CA 90033; CHILDRENS HOSP LOS ANGELES,DIV OPHTHALMOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT OPHTHALMOL & PEDIAT,LOS ANGELES,CA 90033; CHILDRENS HOSP LOS ANGELES,DIV HEMATOL ONCOL,LOS ANGELES,CA 90027	Kyoto University; University of Southern California; Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles	YOKOTA, J (corresponding author), NATL CANC CTR,RES INST,STUDIES METASTASIS SECT,1-1 TSUKIJI 5 CHOME,CHUO KU,TOKYO 104,JAPAN.				NEI NIH HHS [EY-02715] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002715] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKIYAMA T, 1984, BIOCHEM BIOPH RES CO, V123, P797, DOI 10.1016/0006-291X(84)90300-0; AKIYAMA T, 1986, ARCH BIOCHEM BIOPHYS, V245, P531, DOI 10.1016/0003-9861(86)90246-8; CAVENEE W, 1984, AM J HUM GENET, V36, P10; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GAMOU S, 1987, CANCER RES, V47, P2668; GODDARD AD, 1988, MOL CELL BIOL, V8, P2082, DOI 10.1128/MCB.8.5.2082; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; TERASAKI T, 1986, JPN J CLIN ONCOL, V16, P203; WILLARD HF, 1985, CYTOGENET CELL GENET, V40, P360, DOI 10.1159/000132180; YAMADA T, 1985, JPN J CANCER RES, V76, P967; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	20	311	347	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					471	475						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	2856251				2022-12-28	WOS:A1988Q773900017
J	SCALES, JB; WINNING, RS; RENAUD, CS; SHEA, LJ; SARGENT, TD				SCALES, JB; WINNING, RS; RENAUD, CS; SHEA, LJ; SARGENT, TD			NOVEL MEMBERS OF THE EPH RECEPTOR TYROSINE KINASE SUBFAMILY EXPRESSED DURING XENOPUS DEVELOPMENT	ONCOGENE			English	Article						EPH; RECEPTOR TYROSINE KINASE; XENOPUS; CEMENT GLAND	DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; PROTEIN; FAMILY; CLONING; LAEVIS; ELK; IDENTIFICATION; DROSOPHILA; HINDBRAIN	Three cDNAs encoding receptor tyrosine kinases (RTKs) of the eph-subfamily have been identified based on their homology to Pagliaccio (Winning and Sargent, 1994, Mech. Dev. 46:219-229). These have been named TCK, Xelk (Xenopus homologue of elk), and PL7a (pag-like clone 7a). Each of these genes is expressed in a distinctive, tissue specific manner during early development. TCR is expressed in pre-semitic mesoderm, caudal somites, midbrain and cement gland, Xelk is expressed in the brain and spinal cord and in the first and fourth visceral arches. PL7a cDNA is expressed throughout the head and in the tip of the tab. All of the genes are represented in maternal mRNA, and are expressed in adult tissues. The Xelk cDNA encodes a protein which is 94% identical to rat elk and therefore is likely to represent the Xenopus homologue of this gene. TCK and PL7a are less related to previously identified eph-subfamily RTKs. The inability to unambiguously assign TCK and PL7a as Xenopus homologues of any previously identified eph RTK leads us to conclude that these cDNAs represent novel members of this family.	NICHHD,MOLEC GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDRES AC, 1994, ONCOGENE, V9, P1461; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BLITZ IL, 1995, DEVELOPMENT, V121, P993; BOHME B, 1993, ONCOGENE, V8, P2857; CHAN J, 1991, ONCOGENE, V6, P1057; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; FOX GM, 1995, ONCOGENE, V10, P897; GILARDIHEBENSTREIT, 1992, ONCOGENE, V7, P2499; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; JAMRICH M, 1989, DEVELOPMENT, V105, P779; JONES TL, 1995, ONCOGENE, V11, P1111; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATHERS PH, 1995, IN PRESS DEV BIOL; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; PANNESE M, 1995, DEVELOPMENT, V121, P707; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SCALES JB, 1991, CELL GROWTH DIFFER, V2, P619; TUZI NL, 1994, BRIT J CANCER, V19, P417; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WINNING RS, 1994, MECH DEVELOP, V46, P219, DOI 10.1016/0925-4773(94)90072-8; 1994, WISCONSIN GCG PACKAG	41	35	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1745	1752						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478602				2022-12-28	WOS:A1995TD09400009
J	CHAOUCHI, N; ARVANITAKIS, L; AUFFREDOU, MT; BLANCHARD, DA; VAZQUEZ, A; SHARMA, S				CHAOUCHI, N; ARVANITAKIS, L; AUFFREDOU, MT; BLANCHARD, DA; VAZQUEZ, A; SHARMA, S			CHARACTERIZATION OF TRANSFORMING GROWTH-FACTOR-BETA-1 INDUCED APOPTOSIS IN NORMAL HUMAN B-CELLS AND LYMPHOMA B-CELL LINES	ONCOGENE			English	Article						TGF-BETA; APOPTOSIS; CELL CYCLE; BURKITT; BCL-2; C-MYC	FACTOR-BETA; C-MYC; BCL-2 EXPRESSION; LYMPHOCYTES-B; DEATH; INDUCTION; PROTEIN; INHIBITION; SURVIVAL; GENE	Transforming growth factor beta 1 (TGF beta 1) has been shown to inhibit growth stimulation in normal human B cells as well as in Epstein Barr virus (EBV)-negative Burbitt's lymphoma (BL) cell lines. The mechanisms for this potent growth inhibition are not completely defined. Here me show that a number of EBV-negative lymphoma B cell lines (BL-41, Ramos and CAPA-2), when exposed in vitro to TGF beta 1, undergo apoptosis. Maximum apoptosis was observed at 48 h following TGF beta 1 treatment, with no apparent effect on the expression of c-myc and bcl-2 proteins. Similar induction of apoptosis was observed when these lymphoma cell lines were treated with aphidicolin, a DNA synthesis inhibitor. In contrast, various preparations (14 out of 17) of normal human tonsilar B cells showed no significant apoptosis, although both TGF beta 1 and aphidicolin inhibited anti-mu/IL-4 induced DNA synthesis in all preparations. Furthermore, another TGF beta 1 sensitive EBV-negative BL cell line, CA46, exhibited no apoptosis in response to TGF beta 1 and aphidicolin, corroborating the findings in normal human B cells. Taken together, these data support the hypothesis that exposure to TGF beta 1, which results in cell cycle arrest and DNA synthesis inhibition, may not be obligatory or sufficient for the induction of apoptosis. Rather, induction of apoptosis or lack of-it may be intrinsically determined by an interplay between extracellular and intracellular regulators of cellular growth.	INSERM,U131,F-92140 CLAMART,FRANCE; BROWN UNIV,ROGER WILLIAMS MED CTR,DEPT PATHOL,EXPTL PATHOL SECT,PROVIDENCE,RI 02908	Institut National de la Sante et de la Recherche Medicale (Inserm); Brown University; Roger Williams Medical Center					NCI NIH HHS [CA 55910, CA 54763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055910, R01CA054763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKBAR AN, 1993, J EXP MED, V178, P427, DOI 10.1084/jem.178.2.427; ARVANITAKIS L, 1995, IN PRESS J IMMUNOL; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHAOUCHI N, 1994, CLIN IMMUNOL IMMUNOP, V73, P197, DOI 10.1006/clin.1994.1188; DANCESCU M, 1992, J EXP MED, V176, P1319, DOI 10.1084/jem.176.5.1319; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P7581, DOI 10.1073/pnas.80.24.7581; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FERNANDEZRUIZ E, 1989, J IMMUNOL, V143, P4146; FINKE J, 1992, BLOOD, V80, P459; FISCHER G, 1994, J EXP MED, V179, P221, DOI 10.1084/jem.179.1.221; FRIED J, 1978, J HISTOCHEM CYTOCHEM, V26, P921, DOI 10.1177/26.11.82573; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HANNON GJ, 1994, NATURE, V371, P534; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOLDER MJ, 1992, EUR J IMMUNOL, V22, P2725, DOI 10.1002/eji.1830221037; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KEHRL JH, 1986, J IMMUNOL, V137, P3855; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KUMAR A, 1991, J IMMUNOL, V147, P998; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LEE G, 1987, J EXP MED, V166, P1290, DOI 10.1084/jem.166.5.1290; LI L, 1990, J BIOL CHEM, V265, P1556; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LOMO J, 1995, J IMMUNOL, V154, P1634; LOTZ M, 1994, J EXP MED, V179, P999, DOI 10.1084/jem.179.3.999; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; ROUACH EY, 1991, NATURE, V352, P345; Sambrook J, 1989, MOL CLONING LABORATO; SMELAND EB, 1987, EXP CELL RES, V171, P213, DOI 10.1016/0014-4827(87)90264-3; TAIEB J, 1994, EUR J IMMUNOL, V24, P480, DOI 10.1002/eji.1830240233; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VAZQUEZ A, 1991, EUR J IMMUNOL, V21, P2311, DOI 10.1002/eji.1830211004; WELLER M, 1994, EUR J IMMUNOL, V24, P1293, DOI 10.1002/eji.1830240608; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILLIE AH, 1980, NATURE, V284, P555; WILLY AH, 1987, INT REV CYTOL S, V17, P755	57	81	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1615	1622						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478586				2022-12-28	WOS:A1995TC53500020
J	MAHER, J; BAKER, DA; MANNING, M; DIBB, NJ; ROBERTS, IAG				MAHER, J; BAKER, DA; MANNING, M; DIBB, NJ; ROBERTS, IAG			EVIDENCE FOR CELL-SPECIFIC DIFFERENCES IN TRANSFORMATION BY N-RAS, H-RAS AND K-RAS	ONCOGENE			English	Article						N-RAS; H-RAS; K-RAS; TRANSFORMATION	MURINE SARCOMA-VIRUS; GENE FAMILY; PROTO-ONCOGENE; HARVEY-RAS; LINE; P21; EXPRESSION; DIFFERENTIATION; INDEPENDENCE; PROTEINS	Although Ras plays a fundamental role in cellular proliferation, differentiation and transformation, clear functional differences between the three major Ras proteins (N-, H- and K-Ras) have not as yet been demonstrated. In this study, chimeric constructs were used to compare directly transformation by N-, H- and E-vas oncogenes. In Rat-2 and MH3T3 fibroblasts, transformation assays (anchorage independence, focus-formation and growth in 1% FCS) showed that H-12-Ras was more transforming than N-12-Ras or K-12-Ras. By contrast, in the human multipotent haemopoietic cell line, TF-1, N-12-Ras exhibited greater biological activity. Northern blotting and protein analyses indicated that these findings were not the result of differences in expression or stability of p21Ras. Using further H-ras/N-ras chimeric constructs, we found that the greater transforming activity of H-12-Ras in fibroblasts was not due to the hypervariable-CAAX region, but rather to unique sequences between amino acids 84 and 143. These data demonstrate cell specific differences in the intrinsic transforming potential of N-ras, H-ras and K-ras oncogenes.	HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT HAEMATOL, LONDON W12 0NN, ENGLAND; HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT OBSTET & GYNAECOL, LONDON W12 0NN, ENGLAND	Imperial College London; Imperial College London				Maher, John/0000-0001-8275-8488				ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; BAKER DA, 1994, LEUKEMIA, V8, P1970; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; BOSWELL HS, 1990, EXP HEMATOL, V18, P452; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CARBONE A, 1991, ONCOGENE, V6, P731; CHANG EH, 1982, P NATL ACAD SCI-BIOL, V79, P4848, DOI 10.1073/pnas.79.16.4848; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; DEFEOJONES D, 1985, SCIENCE, V228, P179, DOI 10.1126/science.3883495; DELGADO MD, 1992, CANCER RES, V52, P5979; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Dibb NJ, 1990, GROWTH FACTORS, V2, P301, DOI 10.3109/08977199009078018; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FIORUCCI G, 1988, BIOCHIM BIOPHYS ACTA, V950, P81, DOI 10.1016/0167-4781(88)90076-0; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MAHER J, 1994, EXP HEMATOL, V22, P8; MAHER J, 1994, IN PRESS LEUKEMIA, V84; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sambrook J, 1989, MOL CLONING LABORATO; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P383, DOI 10.1073/pnas.80.2.383; TOKSOZ D, 1989, BRIT J HAEMATOL, V71, P1, DOI 10.1111/j.1365-2141.1989.tb06265.x; UEMURA N, 1992, BLOOD, V80, P3198; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0	45	73	73	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1639	1647						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478589				2022-12-28	WOS:A1995TC53500023
J	GANDARILLAS, A; WATT, FM				GANDARILLAS, A; WATT, FM			CHANGES IN EXPRESSION OF MEMBERS OF THE FOS AND JUN FAMILIES AND MYC NETWORK DURING TERMINAL DIFFERENTIATION OF HUMAN KERATINOCYTES	ONCOGENE			English	Note						AP-1; NDK; SQUAMOUS CELL CARCINOMA; SUSPENSION CULTURE	HUMAN INVOLUCRIN GENE; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; PROTEIN; GROWTH; MAX; PROLIFERATION; PROMOTER; CELL; PROTOONCOGENE	Normal human epidermal keratinocytes are induced to undergo terminal differentiation when disaggregated and placed in suspension: commitment occurs at about 5 h and overt differentiation by 24 h. In contrast, the squamous cell carcinoma line SCC12B2 does not initiate terminal differentiation until 75 h in suspension and the ndk strain of keratinocytes undergoes growth arrest but does not differentiate at all. In order to identify genes that may regulate terminal differentiation we have examined mRNA levels of members of the fos and jun gene families and myc gene network in suspension cultures of normal keratinocytes, SCC12B2 and ndk. The major changes observed were an up-regulation of c-Fos and Fra-1 and a decrease in c-Myc at the time of commitment, followed by an increase in Mad, Mxi1, Fra-2 and JunB expression at the onset of differentiation. The sequence of events shows a striking similarity to that which occurs during myeloid differentiation and suggests a role for AP-1 complexes and Myc and Mad complexes in regulating keratinocyte differentiation.	IMPERIAL CANC RES FUND,KERATINOCYTE LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Watt, Fiona/AHB-0226-2022	Watt, Fiona/0000-0001-9151-5154				ADAMS JC, 1988, J CELL BIOL, V107, P1927, DOI 10.1083/jcb.107.5.1927; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; ADAMS JC, 1991, J CELL BIOL, V115, P8829; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FISHER C, 1991, DEVELOPMENT, V111, P253; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; GANDARILLAS A, 1995, IN PRESS MAMMALIAN G; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; HASHIRO M, 1991, BIOCHEM BIOPH RES CO, V174, P287, DOI 10.1016/0006-291X(91)90518-C; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HOTCHIN NA, 1993, J CELL SCI, V106, P1131; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LARSSON LG, 1994, ONCOGENE, V9, P1247; MATSUI M, 1990, ONCOGENE, V5, P249; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; READ J, 1988, J INVEST DERMATOL, V90, P739, DOI 10.1111/1523-1747.ep12560940; RHEINWALD JG, 1983, HUMAN CARCINOGENESIS, P85; Sambrook J, 1989, MOL CLONING LABORATO; SONOBE MH, 1995, ONCOGENE, V10, P689; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; YAAR M, 1993, CLIN RES, V41, pA486, DOI 10.1006/excr.1993.1143; YONEDA K, 1992, J BIOL CHEM, V267, P18060; YOUNUS J, 1992, J CELL PHYSIOL, V152, P232, DOI 10.1002/jcp.1041520203; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	41	76	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1403	1407						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478564				2022-12-28	WOS:A1995RY96700024
J	LEVIN, WJ; PRESS, MF; GAYNOR, RB; SUKHATME, VP; BOONE, TC; REISSMANN, PT; FIGLIN, RA; HOLMES, EC; SOUZA, LM; SLAMON, DJ				LEVIN, WJ; PRESS, MF; GAYNOR, RB; SUKHATME, VP; BOONE, TC; REISSMANN, PT; FIGLIN, RA; HOLMES, EC; SOUZA, LM; SLAMON, DJ			EXPRESSION PATTERNS OF IMMEDIATE-EARLY TRANSCRIPTION FACTORS IN HUMAN NONSMALL CELL LUNG-CANCER	ONCOGENE			English	Article						C-JUN; C-FOS; EGR1; NON-SMALL CELL LUNG; CANCER	C-FOS GENE; DNA-BINDING; PROTO-ONCOGENE; FACTOR EGR-1; RESPONSE ELEMENT; JUN ENCODES; 3T3 CELLS; GROWTH; DIFFERENTIATION; AP-1	In 1995, there will be 172 000 new cases of lung cancer diagnosed and 153 000 deaths from this disease in the United States. While the pathogenesis of the disease profess is poorly understood, a growing body of evidence suggests that abnormalities in cellular regulatory genes may play an important role in the induction, maintenance and/or progression of some tumor types. These genes include both growth promoting oncogenes as well as growth inhibitory or suppressor genes. Included among these genetic sequences are several cellular transcription factor. A group of these factors including c-jun, c-fos and EGR1 are members of a class of genes known as immediate early genes whose expression are inducible by a variety of stimuli including mitogenic and differentiation inducing growth factors, indicating a potential important role for these genes in normal growth processes. Since these genes are involved in early regulation of cellular growth properties and at least two (c-jun and c-fos) can act as oncogenes, we wished to determine whether their expression levels were altered in human non-small cell lung cancers (NSCLC) compared to normal lung tissue. To address this, Northern blot analyses were performed using c-fos, c-jun and EGR1 probes on RNA extracted from 101 NSCLC tumor specimens and adjacent uninvolved lung tissue. Analysis of this cohort revealed that 72% of the normal tissues demonstrate significantly greater expression of these transcription factors as compared to adjacent malignant tissue. Moreover, this expression pattern appeared to be coordinate for all three genes in the majority of cases. This differential expression pattern was confirmed at the protein level using an immunohistochemical approach with antibodies directed against the c-jun, c-fos and EGR1 gene products. Southern blot analyses demonstrated no gross alterations of these sequences at the DNA level, indicating that the observed differential expression pattern was not due to gross structural changes in the genes. These data suggest that downregulation of these genes may be involved in the pathogenesis of lung cancer.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT SURG, LOS ANGELES, CA 90024 USA; UNIV SO CALIF, SCH MED, DEPT PATHOL, LOS ANGELES, CA 90033 USA; UNIV TEXAS, SW MED CTR, DEPT MED, DALLAS, TX 75235 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; AMGEN INC, THOUSAND OAKS, CA 91320 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Southern California; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Amgen			Sukhatme, Vikas/W-2776-2019		NCI NIH HHS [R01 CA36827] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036827] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAICHWAL VR, 1990, CELL, V59, P979; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELD SJ, 1992, P NATL ACAD SCI USA, V89, P9306, DOI 10.1073/pnas.89.19.9306; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GINSBERG RJ, 1993, CHEST S4, V104, pS356; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HILBERG F, 1992, ONCOGENE, V7, P2371; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IP YT, 1990, MOL CELL BIOL, V10, P3782, DOI 10.1128/MCB.10.7.3782; JOISHY SK, 1977, ANN INTERN MED, V87, P447, DOI 10.7326/0003-4819-87-4-447; KORNUC M, 1990, J VIROL, V64, P2004, DOI 10.1128/JVI.64.5.2004-2013.1990; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KUJUBU DA, 1987, ONCOGENE, V1, P257; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MINNA JD, 1989, INT J CANCER, P32; MOLINARRODE R, 1993, MOL CELL BIOL, V13, P3213, DOI 10.1128/MCB.13.6.3213; MOOLGAVKAR SH, 1989, J NATL CANCER I, V81, P415, DOI 10.1093/jnci/81.6.415; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; PRESS MF, 1990, ONCOGENE, V5, P953; REISSMANN PT, 1993, ONCOGENE, V8, P1913; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VOLM M, 1992, ANTICANCER RES, V12, P11; VOLM M, 1993, CLIN EXP METASTAS, V11, P325, DOI 10.1007/BF00058052; WATSON WL, 1966, CANCER, V19, P776, DOI 10.1002/1097-0142(196606)19:6<776::AID-CNCR2820190606>3.0.CO;2-J; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	67	118	125	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1261	1269						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478546				2022-12-28	WOS:A1995RY96700006
J	SALVATI, PD; RANFORD, PR; FORD, J; KEES, UR				SALVATI, PD; RANFORD, PR; FORD, J; KEES, UR			HOX11 EXPRESSION IN PEDIATRIC ACUTE LYMPHOBLASTIC-LEUKEMIA IS ASSOCIATED WITH T-CELL PHENOTYPE	ONCOGENE			English	Article						HOX11; 10Q24; T-ALL; PEDIATRIC ALL	DNA-BINDING MOTIF; HOMEOBOX GENE; CHROMOSOMAL TRANSLOCATION; MYELOID-LEUKEMIA; PRE-B; PROTEIN; CHILDHOOD; ONCOGENE; ENCODES; DIFFERENTIATION	Based on cytogenetic analysis, chromosomal translocations involving band 10q24 occur in 4-7% of T-cell acute lymphoblastic leukemia (T-ALL). The HOX11 gene is located in this chromosomal band and is activated by translocations t(10;14) (q24;q11) and t(7;10) (q35;q24). Ectopic expression of the HOX11 gene appears to be involved in the development of T-cell tumors. The aim of this study was to determine the frequency of HOX11 activation in pediatric ALL patients and to correlate gene expression with ALL immunophenotype. None of 53 B-lineage ALLs was positive for HOX11 expression, however, Northern blot and RT-PCR analysis revealed that four out of 12 T-ALLs (33%) showed expression of the gene. In order to assess whether HOX11 expression is present in other pediatric malignancies we examined a panel of 20 tumor cell lines established from solid tumors and leukemias, but none of them showed expression of HOX11. Using our RT-PCR method we confirmed that HOX11 expression is not detectable in normal T-cells. These findings indicate that HOX11 expression in pediatric ALL is exclusive to T-ALL and does not occur in B-lineage ALL. The frequency detected by molecular techniques was significantly higher than the frequency reported in the literature based on cytogenetic analysis. These results support the notion that ectopic expression of the HOX11 homeobox gene is a crucial step in T-cell tumorigenesis.	TVW TELETHON INST CHILD HLTH RES, DIV CHILDRENS LEUKAEMIA & CANC RES, PERTH, WA 6872, AUSTRALIA	Telethon Kids Institute; University of Western Australia								ADAMS JM, 1992, CANCER SURV, V15, P119; BASH RO, 1993, BLOOD, V81, P2110; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1991, ONCOGENE, V6, P695; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DUBE ID, 1991, BLOOD, V78, P2996; EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAWLEY RG, 1994, ONCOGENE, V9, P1; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAGAN J, 1994, CANCER RES, V54, P226; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KEES UR, 1989, BLOOD, V74, P369; KEES UR, 1987, LEUKEMIA RES, V11, P489, DOI 10.1016/0145-2126(87)90082-8; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; LARSON RC, 1994, ONCOGENE, V9, P3675; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MING L, 1992, ONCOGENE, V7, P1325; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; RAIMONDI SC, 1993, BLOOD, V81, P2237; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SCHNEIDER EL, 1975, IN VITRO CELL DEV B, V11, P20; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	38	46	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1333	1338						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478554				2022-12-28	WOS:A1995RY96700014
J	AVANTAGGIATO, V; TORINO, A; WONG, WT; DIFIORE, PP; SIMEONE, A				AVANTAGGIATO, V; TORINO, A; WONG, WT; DIFIORE, PP; SIMEONE, A			EXPRESSION OF THE RECEPTOR TYROSINE KINASE SUBSTRATE GENES EPS8 AND EPS15 DURING MOUSE DEVELOPMENT	ONCOGENE			English	Article						EPS8; EPS15; DEVELOPMENT; EXPRESSION	GROWTH-FACTOR RECEPTOR; DROSOPHILA-TRITHORAX; INT-1 PROTOONCOGENE; SIGNAL TRANSDUCTION; ACUTE LEUKEMIAS; ONCOGENE INT-1; EGF RECEPTOR; CELLS; DOMAINS; WNT-1	Receptor tyrosine kinases (RTKs) control proliferation and differentiation through their ability to bind and/or phosphorylate intracellular substrates, The repertoire of substrates recruited by different RTK is largely overlapping, It is not clear, therefore, how a cell distinguishes among signals originating from different RTKs. One possibility is that selective availability of substrates participates in the regulation of this process, To gain insight into this issue, we studied the expression pattern, embryogenesis, of the eps8 and eps15 encode two recently identified RTK substrates, Both genes are expressed from E 10 in a restricted fashion, eps8 is first expressed in frontonasal neural crest-derived cells, in the mesenchyme of branchial arches and in the liver primordium. At E 12.5-E 14, eps8 is additionally expressed in the central nervous system (CNS) in a regional restricted pattern at the met-mesencephalic transition area and in the developing submandibular salivary glands, eps15 is expressed at E 10 in the liver primordium, in the spinal ganglia and in the encephalic ganglia derived from the hindbrain neural crest, In addition, at E 12.5-E 14, eps15 is expressed, along all the CNS, in the ventricular zone where undifferentiated neuroblasts are located. The regional pattern of developmental expression of these two substrates sharply contrasts with their ubiquitous expression in adults, raising the possibility that their expression during embryogenesis is linked to selective proliferative and/or differentiative responses of specific neuroectodermal regions and body organs.	CNR,INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; EUROPEAN INST ONCOL,IEO,I-20132 MILAN,ITALY; UNIV BARI,IST MICROBIOL,I-70100 BARI,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); IRCCS European Institute of Oncology (IEO); Universita degli Studi di Bari Aldo Moro			Simeone, Antonio/ABG-5269-2020; Di Fiore, Pier Paolo/K-2130-2012	Simeone, Antonio/0000-0003-2693-9836; Di Fiore, Pier Paolo/0000-0002-2252-0950				BALLYCUIF L, 1992, DEVELOPMENT, V115, P999; BERNARD OA, 1994, ONCOGENE, V9, P1039; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; Kuhlenbeck H., 1973, CENTRAL NERVOUS SYST; MATOSKOVA B, 1995, IN PRESS MOL CELL BI; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SCHUMACHER C, 1995, IN PRESS J BIOL CHEM; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WONG WT, 1994, ONCOGENE, V9, P3057; WONG WT, 1994, ONCOGENE, V9, P1591; ZERLIN M, 1993, ONCOGENE, V8, P2731	31	11	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1191	1198						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566980				2022-12-28	WOS:A1995RX18000023
J	KISTLER, B; PFISTERER, P; WIRTH, T				KISTLER, B; PFISTERER, P; WIRTH, T			LYMPHOID-AND MYELOID-SPECIFIC ACTIVITY OF THE PU.1 PROMOTER IS DETERMINED BY THE COMBINATORIAL ACTION OF OCTAMER AND ETS TRANSCRIPTION FACTORS	ONCOGENE			English	Article						GENE REGULATION; CELL-TYPE-SPECIFIC TRANSCRIPTION; ETS-TRANSCRIPTION FACTORS; POU-DOMAIN PROTEINS	PUTATIVE ONCOGENE SPI-1; CHAIN GENE ENHANCER; DNA-BINDING MOTIF; REGULATES EXPRESSION; CD11B PROMOTER; DOMAIN; ACTIVATION; ERYTHROLEUKEMIAS; COMPONENT; PROTEINS	The putative oncogene PU.1/Spi-1 is a member of the ets-family of transcription factors normally expressed in a subset of hematopoietic cell types. Here we have characterized the role of the PU.1 promoter region for the eel-type specific expression. The proximal 120 bp are sufficient to mediate a high level of activity specifically in B cells and macrophages. Three important motifs could be identified within this region. Two of them, an ets binding site (EBS) and a variant octamer motif were most important for cell-type-specific promoter activity in B cells and macrophages, An additional Spl motif stimulates basal activity of this promoter element. The relative contribution to overall activity of octamer motif and EBS differs in B cells and macrophages. In B cells, both octamer motif and EBS combine to mediate high level activity, whereas in macrophages the EBS predominantly confers promoter activity. Both the Oct1 and Oct2 transcription factors, presumably in combination with a B-cell-restricted coactivator, are responsible for the activity of the variant octamer motif in B cells. Interestingly, the PU.1 transcription factor can functionally interact with the EBS in its own promoter, suggesting a positive feedback regulation.	UNIV HEIDELBERG,ZMBH,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg			Wirth, Thomas/X-7172-2019					ANNWEILER A, 1993, J BIOL CHEM, V268, P2525; ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; JOANNSEN E, 1995, J VIROL, V69, P253; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; LU Y, 1972, CELL, V71, P231; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PETTERSSON M, 1987, GENE DEV, V1, P962, DOI 10.1101/gad.1.9.962; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; PFISTERER P, 1995, UNPUB; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RADOMSKA HS, 1994, IMMUNITY, V1, P623, DOI 10.1016/1074-7613(94)90034-5; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; WIRTH T, 1995, IN PRESS IMMUNOBIOLO; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X	43	42	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1095	1106						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566969				2022-12-28	WOS:A1995RX18000012
J	MYERS, RL; CHEDID, M; TRONICK, SR; CHIU, IM				MYERS, RL; CHEDID, M; TRONICK, SR; CHIU, IM			DIFFERENT FIBROBLAST-GROWTH-FACTOR-1 (FGF-1) TRANSCRIPTS IN NEURAL TISSUES, GLIOBLASTOMAS AND KIDNEY CARCINOMA CELL-LINES	ONCOGENE			English	Note						AFGF; ALTERNATIVE SPLICING; GLIOBLASTOMA; RETINA; DIABETIC RETINOPATHY; ALTERNATIVE PROMOTER USAGE	FACTOR MESSENGER-RNA; SMOOTH-MUSCLE CELLS; FACTOR-I; EPITHELIAL-CELLS; GENE-EXPRESSION; HUMAN GLIOMA; ACIDIC FGF; CLONING; FAMILY; SEQUENCE	We have previously reported the tissue specific distribution of four different FGF-1 transcripts containing alternative 5' untranslated exons Spliced to the first protein coding exon. The predominant transcript in brain is FGF-1.B and in kidney FGF-1.A. Others have shown, by in situ hybridization and immunohistochemical analysis, that expression of FGF-1 in the brain is exclusively in neural cells but not in glial cells. Here we have examined the distribution of FGF-1.B and FGF-1.A transcripts in glioblastoma and retinal tissues and in kidney carcinoma cell lines. Our results show that FGF-1.B is the predominant transcript in neural derived tissues including both the diabetic retina and normal retina tissues. Surprisingly, FGF-1.B transcript is highly expressed in glioblastoma tissues. In contrast, a normal brain glial cell line, CHII, expresses very low levels of FGF-1 mRNA. These results strongly implicate the role of FGF-1 in the etiology of glioblastoma. We also examined several kidney carcinoma derived cell lines for the expression of FGF-1 mRNA. Most of these kidney cell lines do not express any FGF-1 transcripts. An interpretation by deduction is that kidney adenocarcinomas are derived from cortex but medulla has been reported as the site of FGF-I synthesis. Of the kidney derived cell lines which are positive for FGF-1 message, only one expressed FGF-1.A transcript. The data may suggest that the establishment of kidney cell lines results in a switch of promoter usage from the 1.A seen in kidney tissue. Similarly, culturing of glioma cell lines may result in a snitch from FGF-1.B seen in glioma tissues to FGF-1.D seen in most glioma cell lines. Continued studies of the FGF-1 transcripts, their functional promoters and their tissues distribution will provide insight into the potential role of FGF-1 in cell growth, tissue differentiation and malignant transformation.	OHIO STATE UNIV, DEPT INTERNAL MED, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, CTR COMPREHENS CANC, COLUMBUS, OH 43210 USA; NCI, MOLEC & CELLULAR BIOL LAB, BETHESDA, MD 20892 USA; SANTA CRUZ BIOTECHNOL INC, SANTA CRUZ, CA 95060 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chiu, Ing-Ming/B-1534-2008		NCI NIH HHS [T32 CA09338, R01 CA45611] Funding Source: Medline; NINDS NIH HHS [P20 NS31087] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045611, T32CA009338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS031087] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ALTERIO J, 1990, BIOCHEM BIOPH RES CO, V166, P1205, DOI 10.1016/0006-291X(90)90994-X; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BAUDOUIN C, 1990, OPHTHALMIC RES, V22, P73, DOI 10.1159/000267004; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BUNNAG P, 1991, IN VITRO CELL DEV B, V27, P89; BURGESS WH, ANN REV BIOCH, V58, P575; CHIU IM, 1990, ONCOGENE, V5, P755; CHOTANI MA, 1995, NUCLEIC ACIDS RES, V23, P434, DOI 10.1093/nar/23.3.434; COOK PW, 1990, MOL ENDOCRINOL, V4, P1377, DOI 10.1210/mend-4-9-1377; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; ECKENSTEIN FP, 1994, BIOCHEM PHARMACOL, V47, P103, DOI 10.1016/0006-2952(94)90442-1; ELDE R, 1991, NEURON, V7, P349, DOI 10.1016/0896-6273(91)90288-B; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FREDJREYGROBELLET D, 1991, OPHTHALMIC RES, V23, P154, DOI 10.1159/000267115; GOSPODAROWICZ D, 1987, METHOD ENZYMOL, V147, P106; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; MARICS I, 1989, ONCOGENE, V4, P335; MILNER RJ, 1983, NUCLEIC ACIDS RES, V11, P5497, DOI 10.1093/nar/11.16.5497; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MYERS RL, 1995, J BIOL CHEM, V270, P8257, DOI 10.1074/jbc.270.14.8257; MYERS RL, 1993, ONCOGENE, V8, P341; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; NISHIGUCHI DJ, 1985, J NEUROPATH EXP NEUR, V44, P254, DOI 10.1097/00005072-198505000-00004; PAYSON RA, 1993, NUCLEIC ACIDS RES, V21, P489, DOI 10.1093/nar/21.3.489; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; STOCK A, 1992, J NEUROSCI, V12, P4688; SULLIVAN DE, 1991, BIOCHIM BIOPHYS ACTA, V1090, P17, DOI 10.1016/0167-4781(91)90031-G; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WANG WP, 1991, DNA CELL BIOL, V10, P771, DOI 10.1089/dna.1991.10.771; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; Weich HA, 1990, GROWTH FACTORS, V2, P313, DOI 10.3109/08977199009078019; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; WINKLES JA, 1987, P NATL ACAD SCI USA, V84, P7124, DOI 10.1073/pnas.84.20.7124; WINKLES JA, 1991, CELL GROWTH DIFFER, V2, P531; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZHANG GH, 1993, J BIOL CHEM, V268, P11542	40	30	31	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					785	789						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7544453				2022-12-28	WOS:A1995RQ46900022
J	WILLIAMS, AC; MILLER, JC; COLLARD, TJ; BRACEY, TS; COSULICH, S; PARASKEVA, C				WILLIAMS, AC; MILLER, JC; COLLARD, TJ; BRACEY, TS; COSULICH, S; PARASKEVA, C			MUTANT P53 IS NOT FULLY DOMINANT OVER ENDOGENOUS WILD-TYPE P53 IN A COLORECTAL ADENOMA CELL-LINE AS DEMONSTRATED BY INDUCTION OF MDM2 PROTEIN AND RETENTION OF A P53 DEPENDENT G1 ARREST AFTER GAMMA-IRRADIATION	ONCOGENE			English	Article						P53; COLON; ADENOMA; MDM2; G1 ARREST; GAMMA IRRADIATION; TGF-BETA	AUTOREGULATORY FEEDBACK LOOP; TUMOR-SUPPRESSOR GENE; BINDING-SITE; CANCER CELLS; MUTATIONS; GROWTH; DNA; TRANSFORMATION; EXPRESSION; APOPTOSIS	To determine whether a single mutational event in one p53 gene is sufficient to confer a significant growth advantage on a colonic epithelial cell, the 143(Ala) p53 mutation was previously expressed in the human colonic adenoma derived cell line AA/C1 (which is wild type for p53) and shown to have no effect on it's in vitro or in vivo growth characteristics. In this investigation, by expressing the 175(His), 248(Trp) or 273(His) mutations in the same AA/C1 cell line, we have shown that this failure to affect the growth of the cells was not mutant specific. We have also demonstrated, using induction of MDM2 protein and the ability of the cells to undergo a p53 dependent G1 arrest, that the 143(Ala), 175(His) or 248(Trp) transfected cells retain functional endogenous wild type p53 activity, and suggest that these p53 mutations would not have a fully dominant negative mode of action in vivo. In contrast, one of the two AA/C1 cell lines transfected with the 273(His) mutation did fail to cell cycle arrest after gamma irradiation, indicating that this mutation can act as a dominant negative. However even loss of wild type p53 function in this fell line was insufficient to directly effect the growth rate of the AA/C1 cells, suggesting that acquisition of the 273(His) mutation may contribute to malignant progression through genomic instability (by inhibiting the G1 arrest) and that other mutations are required before outgrowth of the cell population containing the p53 mutation.	UNIV YORK,DEPT BIOL,JACK BIRCH UNIT ENVIRONM CARCINOGENESIS,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK	WILLIAMS, AC (corresponding author), UNIV BRISTOL,DEPT PATHOL & MICROBIOL,CRC,COLORECTAL TUMOUR BIOL RES GRP,UNIV WALK,BRISTOL BS8 1TD,AVON,ENGLAND.			Williams, Ann/0000-0002-6009-7137				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BOND JA, 1994, ONCOGENE, V9, P281; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FREBOURG T, 1994, CANCER RES, V54, P878; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISAACS WB, 1991, CANCER RES, V51, P4716; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1992, NEW ENGL J MED, V326, P1350, DOI 10.1056/NEJM199205143262008; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI Y, 1994, ONCOGENE, V9, P2261; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAITY A, 1994, ONCOL, V31, P1; MANNING AM, 1991, ONCOGENE, V6, P1471; MATOZAKI T, 1992, CANCER RES, V52, P4335; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARK DJ, 1994, ONCOGENE, V9, P1899; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; WILLIAMS AC, 1994, ONCOGENE, V9, P1479; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	61	35	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					141	149						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624121				2022-12-28	WOS:A1995RJ29500017
J	SHOR, J; BENASHER, E; ALONI, Y				SHOR, J; BENASHER, E; ALONI, Y			TRANSCRIPTION ELONGATION OF THE MURINE ORNITHINE DECARBOXYLASE (ODC) GENE IS REGULATED IN-VITRO AT 2 DOWNSTREAM ELEMENTS BY DIFFERENT ATTENUATION MECHANISMS	ONCOGENE			English	Article						ELONGATION FACTORS; IN VITRO TRANSCRIPTION; NUCLEAR EXTRACT; ODC TRANSCRIPTION; TRANSCRIPTION ELONGATION	RNA POLYMERASE-II; HAMSTER OVARY CELLS; C-MYC GENE; CALF THYMUS; MESSENGER-RNA; FACTOR-SII; TERMINATION; DNA; PURIFICATION; SEQUENCE	Ornithine decarboxylase (ODC) plays an important role in cell proliferation. Its expression is tightly regulated at the mRNA and protein levels and is found to be deregulated in various malignancies. The rapid acid dramatic induction of cellular ODC mRNA upon serum addition raised the possibility that a transcriptional attenuation mechanism may be involved in the regulation of ODC gene expression, Using transcription in HeLa nuclear extract acid isolated transcription complexes, we have identified two sites of transcription arrest downstream to the transcription start site: Attenuator 1 (Att.1) located at +220, near two repeats of a USF/ Myc-Max binding consensus sequence and attenuator 2 (Att.2) located at +1590 near a long stretch of T-residues, The two attenuators exhibit distinct properties as revealed by elongation of briefly initiated and partially purified transcription complexes: Att.l serves as transient pause site while arrest at Att,2 is more prolonged. The arrest at both attenuators is modulated by the general elongation factor TFIIS. In a promoter independent transcription system, using partially purified RNA polymerase II, only Att.2 was recognized efficiently. This suggests that the recognition of Att.2 is an intrinsic property of the polymerase while Att.1 recognition has to be facilitated by an auxiliary factor/s.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science					NCI NIH HHS [CA 14995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BAEK KH, 1986, P NATL ACAD SCI USA, V83, P7623, DOI 10.1073/pnas.83.20.7623; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENGAL E, 1989, J BIOL CHEM, V264, P18926; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BENGAL E, 1989, J BIOL CHEM, V264, P9791; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; CHEN Z, 1990, MOL CELL BIOL, V10, P4555, DOI 10.1128/MCB.10.9.4555; CONNELLY S, 1989, MOL CELL BIOL, V9, P5254, DOI 10.1128/MCB.9.11.5254; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLORES O, 1990, J BIOL CHEM, V265, P5629; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; Janne J, 1983, Spec Top Endocrinol Metab, V5, P227; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KATZ A, 1988, J BIOL CHEM, V263, P7604; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KESSLER M, 1991, J BIOL CHEM, V266, P13019; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUK GD, 1984, NEW ENGL J MED, V311, P80, DOI 10.1056/NEJM198407123110202; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, CANCER RES, V48, P759; POHJANPELTO P, 1985, MOL CELL BIOL, V5, P1385, DOI 10.1128/MCB.5.6.1385; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REINES D, 1989, J BIOL CHEM, V264, P10799; RESNEKOV O, 1988, GENE, V72, P91, DOI 10.1016/0378-1119(88)90130-8; RESNEKOV O, 1989, P NATL ACAD SCI USA, V86, P12, DOI 10.1073/pnas.86.1.12; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SPENCER CA, 1990, ONCOGENE, V5, P777; STEGLICH C, 1982, J BIOL CHEM, V257, P4603; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TONIN PN, 1989, ONCOGENE, V4, P1117; UNEO A, 1992, P NATL ACAD SCI USA, V89, P3676; WIEST DK, 1992, J BIOL CHEM, V267, P7733; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; YANOFSKY C, 1988, J BIOL CHEM, V263, P609	47	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1587	1596						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7537363				2022-12-28	WOS:A1995QU68100015
J	WOLKOWICZ, R; ELKIND, NB; RONEN, D; ROTTER, V				WOLKOWICZ, R; ELKIND, NB; RONEN, D; ROTTER, V			THE DNA-BINDING ACTIVITY OF WILD-TYPE P53 IS MODULATED BY BLOCKING ITS VARIOUS ANTIGENIC EPITOPES	ONCOGENE			English	Article						DNA-BINDING; P53; ANTIGENIC EPITOPES	CELL-CYCLE CONTROL; A MOUSE CELLS; MUTANT P53; MONOCLONAL-ANTIBODY; GROWTH SUPPRESSION; CONTROL PROTEIN; TUMOR-ANTIGEN; NORMAL 3T3; EXPRESSION; GENE	Interaction of wild type p53 with specific DNA target sequences, which is dictated by several structural domains, can be modified by blocking the different antigenic epitopes of the protein. Comparison of p53 protein expressed by recombinant bacteria (wtp53-Bac) to that produced in an eukaryotic system by a vaccinia expression vector (wtp53-Vac), indicated that only the later exhibited spontaneous DNA-binding activity. Furthermore, DNA-binding patterns of these wild type p53 proteins were affected differently by their interactions with monoclonal anti-p53 antibodies recognizing individual antigenic epitopes of the molecule. While the vaccinia derived p53 that spontaneously bound DNA is supershifted by the N'-terminal specific antibodies PAb-248, the bacterial derived p53 protein that retains this antigenic epitope but does not bind DNA spontaneously, is not affected. The C'-terminal specific PAb-421 antibodies accelerated binding of the bacterial p53 protein and modified the pattern of the interaction of the vaccinia derived p53 DNA. DNA-binding patterns generated by PAb-421 and PAb-248, suggest that either interaction of wild type p53 is dependent on modification of the p53 protein or that it interacts with cellular factors which their activity can be mimicked by PAb-421. Saturation of both types of wild type p53 with several anti-p53 monoclonal antibodies directed against the wild type p53 specific epitope that maps to the N'-terminal border of the DNA-binding region, blocked specific DNA-binding. The fact that most p53 mutants have lost the wild type p53 conformation specific epitope coupled with the observation that blocking of this site by binding specific antibodies, prevents the interaction of wild type p53 with DNA, suggests that maintaining the correct structural conformation of this site is central for DNA-binding activity. The wild type specific epitope which maps to the N'-terminal border of the DNA-binding region is neighboring the first P-strand detected by the recent crystallographic analysis.	WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DEPPERT W, 1990, ONCOGENE, V5, P1701; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1474; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRISON SC, 1991, NATURE, V353; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KELMAN Z, 1989, BLOOD, V74, P2318; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MICHALOVITZ D, 1989, P NATL ACAD SCI USA, V86, P8763; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; RONEN D, 1992, NUCLEIC ACIDS RES, V20, P3435, DOI 10.1093/nar/20.13.3435; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; Rotter Varda, 1993, Trends in Cell Biology, V3, P46, DOI 10.1016/0962-8924(93)90151-P; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TARUNINA M, 1993, ONCOGENE, V8, P3165; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, J IMMUNOL METHODS, V151, P237; WADEHARPER J, 1993, CELL, V75, P805; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	73	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1167	1174						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7535417				2022-12-28	WOS:A1995QN35300018
J	VOJTESEK, B; DOLEZALOVA, H; LAUEROVA, L; SVITAKOVA, M; HAVLIS, P; KOVARIK, J; MIDGLEY, CA; LANE, DP				VOJTESEK, B; DOLEZALOVA, H; LAUEROVA, L; SVITAKOVA, M; HAVLIS, P; KOVARIK, J; MIDGLEY, CA; LANE, DP			CONFORMATIONAL-CHANGES IN P53 ANALYZED USING NEW ANTIBODIES TO THE CORE DNA-BINDING DOMAIN OF THE PROTEIN	ONCOGENE			English	Note						P53; DNA BINDING; CONFORMATION; ANTIBODIES; MUTANTS	MONOCLONAL-ANTIBODIES; IMMUNOCHEMICAL ANALYSIS; CANCER; MUTATIONS; EXPRESSION; SUPPRESSOR; APOPTOSIS; FORM	The p53 protein contains a protease resistant core section that binds to DNA in a sequence specific manner and whose crystal structure has been determined. This core is flanked at the N-terminus by the transcriptional transactivation domain and at the C-terminus by sequences involved in the oligomerisation of the protein. Extensive immunochemical analysis of p53 has shown that dominant antigenic sites lie within these N- and C-terminal domains while few antibodies to the central core have been identified; One of these, PAb240, has been extensively characterised as its epitope is cryptic in the native DNA binding core structure but is exposed by denaturation. This epitope is also exposed on many p53 proteins that contain point mutations in the core domain suggesting that these mutations may have a common affect on the structure of the core. To investigate this further we have generated several new antibodies to novel sites on p53 and mapped their epitopes using synthetic peptides. We find that antibodies to two other discrete sites in the core can also, like PAb240, recognize cryptic epitopes and distinguish mutant from wild-type conformations implying that the point mutations found in p53 in human tumours have widespread effects on the folding pattern of the DNA binding domain.	MASARYK MEM CANC INST,DEPT CELLULAR & MOLEC ONCOL,CR-65653 BRNO,CZECH REPUBLIC; UNIV DUNDEE,CANC RES CAMPAIGN LABS,DUNDEE DD1 4HN,SCOTLAND	Masaryk Memorial Cancer Institute; University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1993, J PATHOL, V169, P27, DOI 10.1002/path.1711690106; BARTEK J, 1990, ONCOGENE, V5, P893; CHO Y, 1994, SCIENCE, V256, P346; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLMAN PM, 1987, IMMUNOL TODAY, V8, P44; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LEGROS Y, 1994, ONCOGENE, V9, P2071; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1993, ONCOGENE, V8, P2001; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x	24	82	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					389	393						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7530828				2022-12-28	WOS:A1995QC62400018
J	STEWART, N; HICKS, GG; PARASKEVAS, F; MOWAT, M				STEWART, N; HICKS, GG; PARASKEVAS, F; MOWAT, M			EVIDENCE FOR A 2ND CELL-CYCLE BLOCK AT G2/M BY P53	ONCOGENE			English	Article						P53; RAS; CELL CYCLE	WILD-TYPE P53; TUMOR SUPPRESSOR PROTEIN; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; GROWTH ARREST; BINDING PROTEIN; DNA-BINDING; ERYTHROLEUKEMIA-CELLS; NUCLEAR-LOCALIZATION; DEPENDENT KINASES	Wild type p53 can induce cell cycle arrest at specific points in the cell cycle, in particular G1/S, an ability lost by most p53 mutants. We have previously reported that p53 mutant genes can rescue REF52 cells from ras-induced growth arrest and that over expression of wild type p53 inhibits cell growth in these cells. In this paper we examined whether p53 can also induce cell cycle arrest at the G2/M boundary of the cell cycle. To accomplish this we used the REF52 cell line and the temperature sensitive p53val(135) mutant allele. Cells were enriched in the late G1 and early S phases before the temperature shift. REF52 cells expressing mutant-p53val(135) alone with an activated H-vas gene arrest primarily at the G1/S and G2/M parts of the cell cycle at the restrictive temperature, as determined by flow cytometry analysis. These results suggest that the antiproliferative activity of p53 may be involved in regulation of the cell cycle at the G2/M restriction point as well as transit through G1/S and initiation of DNA synthesis.	MANITOBA CANC TREATMENT & RES FDN,MANITOBA INST CELL BIOL,WINNIPEG,MB R3E 0V9,CANADA; UNIV MANITOBA,DEPT PHYSIOL,WINNIPEG,MB R3E 0V9,CANADA; UNIV MANITOBA,DEPT HUMAN GENET,WINNIPEG,MB R3E 0V9,CANADA	University of Manitoba; University of Manitoba				Hicks, Geoffrey/0000-0003-4688-2312				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BASERGA R, 1985, BIOL CELL REPRODUCTI; BEISKER W, 1987, CYTOMETRY, V8, P235, DOI 10.1002/cyto.990080218; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1993, BIOL CHEM H-S, V374, P227; LI Y, 1994, ONCOGENE, V9, P2261; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, ONCOGENE, V5, P1683; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; Rotter Varda, 1993, Trends in Cell Biology, V3, P46, DOI 10.1016/0962-8924(93)90151-P; ROUACH EY, 1991, NATURE, V353, P345; ROVINSKI B, 1988, ONCOGENE, V2, P445; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1987, ONCOGENE, V1, P201; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WOLF D, 1984, P NATL ACAD SCI USA, V82, P790; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	79	347	349	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					109	115						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7529916				2022-12-28	WOS:A1995QA98000013
J	STACEY, SN; EKLUND, C; JORDAN, D; SMITH, NK; STERN, PL; DILLNER, J; ARRAND, JR				STACEY, SN; EKLUND, C; JORDAN, D; SMITH, NK; STERN, PL; DILLNER, J; ARRAND, JR			SCANNING THE STRUCTURE AND ANTIGENICITY OF HPV-16 E6 AND E7 ONCOPROTEINS USING ANTIPEPTIDE ANTIBODIES	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; SEQUENCE-ANALYSIS PROGRAMS; ANTI-PEPTIDE ANTIBODIES; AMINO-ACID-SEQUENCE; OPEN READING FRAMES; CERVICAL-CANCER; GENE-PRODUCTS; SYNTHETIC PEPTIDES; ESCHERICHIA-COLI; ATOMIC MOBILITY	The structure and antigenicity of the HPV-16 E6 and E7 oncoproteins was studied using a set of antisera against overlapping synthetic peptides. We report that antigenic, mobile regions of the native proteins, as defined by reactivity with antipepide antisera, occur at the N-termini of both E6 and E7 proteins, corresponding to regions of known or suspected protein-protein interactions. The putative zinc finger domains were consistently non-reactive, despite computer predictions of relatively high antigenicity, suggesting that the proposed zinc finger regions are held in stable secondary structures that the peptides were not able to mimic. In E6, the linker region between the two zinc fingers was antigenic, indicating that the two zinc finger structures might be able to articulate relative to one another by a flexible linker region. The highly antigenic N-terminal region of HPV-16 E7 was also found to be antigenic in E7 of both HPV-11 and HPV-18, indicating that the E7 proteins of different HPV types have similar antigenic structures. The identification of antigenic regions of the E6 and E7 proteins should be therefore be useful in the design of site-directed antibodies against E6 and E7 for numerous HPV types.	CHRISTIE HOSP, PATERSON INST CANC RES, CANC RES CAMPAIGN, DEPT IMMUNOL, MANCHESTER M20 9BX, LANCS, ENGLAND; KAROLINSKA INST, DEPT VIROL, STOCKHOLM, SWEDEN	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Karolinska Institutet	STACEY, SN (corresponding author), CHRISTIE HOSP, PATERSON INST CANC RES, CANC RES CAMPAIGN, DEPT MOLEC BIOL, MANCHESTER M20 9BX, LANCS, ENGLAND.							ARMSTRONG DJ, 1992, J GEN VIROL, V73, P1275, DOI 10.1099/0022-1317-73-5-1275; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BERZOFSKY JA, 1985, SCIENCE, V229, P932, DOI 10.1126/science.2410982; BURNETT TS, 1983, J GEN VIROL, V64, P1509, DOI 10.1099/0022-1317-64-7-1509; CHAMBERS MA, 1994, J GEN VIROL, V75, P165, DOI 10.1099/0022-1317-75-1-165; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; COMERFORD SA, 1991, J VIROL, V65, P4681, DOI 10.1128/JVI.65.9.4681-4690.1991; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DARMANN K, 1986, VIROLOGY, V151, P124, DOI 10.1016/0042-6822(86)90110-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DILLNER J, 1990, INT J CANCER, V46, P703, DOI 10.1002/ijc.2910460426; DIMAIO D, 1991, ADV CANCER RES, V56, P133; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GAUTHIER JM, 1991, NUCLEIC ACIDS RES, V19, P7073, DOI 10.1093/nar/19.25.7073; GEYSEN HM, 1987, SCIENCE, V235, P1184, DOI 10.1126/science.3823878; GHOSH AK, 1993, INT J CANCER, V53, P591, DOI 10.1002/ijc.2910530411; GROSSMAN SR, 1989, J VIROL, V63, P366, DOI 10.1128/JVI.63.1.366-374.1989; GROSSMAN SR, 1989, ONCOGENE, V4, P1089; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P673; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; JEMMERSON R, 1987, P NATL ACAD SCI USA, V84, P9180, DOI 10.1073/pnas.84.24.9180; JENISON SA, 1991, J VIROL, V65, P1208, DOI 10.1128/JVI.65.3.1208-1218.1991; JENSON AB, 1990, PAPILLOMAVIRUSES HUM; JOCHMUSKUDIELKA I, 1989, J NATL CANCER I, V81, P1698, DOI 10.1093/jnci/81.22.1698; JONES RE, 1990, J BIOL CHEM, V265, P12782; KANDA T, 1991, VIROLOGY, V182, P723, DOI 10.1016/0042-6822(91)90613-G; KOCHEL HG, 1991, INT J CANCER, V48, P682, DOI 10.1002/ijc.2910480509; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRCHNAK V, 1990, J GEN VIROL, V71, P2719, DOI 10.1099/0022-1317-71-11-2719; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; MACKETT M, 1985, DNA CLONING PRACTICA, V11, P191; MALLON RG, 1987, J VIROL, V61, P1655, DOI 10.1128/JVI.61.5.1655-1660.1987; MANN VM, 1990, CANCER RES, V50, P7815; MATLASHEWSKI G, 1989, ANTICANCER RES, V9, P1447; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MULLER M, 1990, J GEN VIROL, V71, P2709, DOI 10.1099/0022-1317-71-11-2709; MULLER M, 1992, VIROLOGY, V187, P508; MUNGER K, 1992, CANCER SURV, V12, P197; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Munoz N, 1992, IARC SCI PUBLICATION; NIEDOBITEK G, 1991, CANCER J - FRANCE, V4, P163; PAGE MJ, 1989, NUCLEIC ACIDS RES, V17, P454, DOI 10.1093/nar/17.1.454; PATRICK DR, 1992, J BIOL CHEM, V267, P6910; RHODES D, 1988, NUCLEIC ACIDS MOL BI, V2; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SECKLER R, 1986, BIOCHEMISTRY-US, V25, P2403, DOI 10.1021/bi00357a016; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STACEY SN, 1993, J MED VIROL, V40, P14, DOI 10.1002/jmv.1890400105; STACEY SN, 1992, J GEN VIROL, V73, P2337, DOI 10.1099/0022-1317-73-9-2337; SUTCLIFFE JG, 1983, SCIENCE, V219, P660, DOI 10.1126/science.6186024; TAINER JA, 1985, ANNU REV IMMUNOL, V3, P501, DOI 10.1146/annurev.iy.03.040185.002441; TAINER JA, 1984, NATURE, V312, P127, DOI 10.1038/312127a0; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; TINDLE RW, 1990, J GEN VIROL, V71, P1347, DOI 10.1099/0022-1317-71-6-1347; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WESTHOF E, 1984, NATURE, V311, P123, DOI 10.1038/311123a0; WOLF H, 1988, COMPUT APPL BIOSCI, V4, P187	62	19	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					635	645						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	7507231				2022-12-28	WOS:A1994MW24800032
J	ITOH, M; INOUE, J; TOYOSHIMA, H; AKIZAWA, T; HIGASHI, M; YOSHIDA, M				ITOH, M; INOUE, J; TOYOSHIMA, H; AKIZAWA, T; HIGASHI, M; YOSHIDA, M			HTLV-1-REX AND HIV-1-REV ACT THROUGH SIMILAR MECHANISMS TO RELIEVE SUPPRESSION OF UNSPLICED RNA EXPRESSION	ONCOGENE			English	Article									JAPANESE FDN CANC RES,INST CANC,DEPT VIRAL ONCOL,KAMI IKEBUKURO,TOSHIMA KU,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research								CULLEN BR, 1988, J VIROL, V62, P2498, DOI 10.1128/JVI.62.7.2498-2501.1988; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265, DOI 10.1128/JVI.63.3.1265-1274.1989; HAHN BH, 1984, NATURE, V312, P166, DOI 10.1038/312166a0; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3653, DOI 10.1073/pnas.84.11.3653; INOUE JI, 1986, FEBS LETT, V209, P187, DOI 10.1016/0014-5793(86)81108-5; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KNIGHT DM, 1987, SCIENCE, V236, P837, DOI 10.1126/science.3033827; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; OHTA M, 1988, J VIROL, V62, P4445, DOI 10.1128/JVI.62.12.4445-4451.1988; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; ROSENBLATT JD, 1988, SCIENCE, V240, P916, DOI 10.1126/science.2834826; SADAIE MR, 1988, SCIENCE, V239, P910, DOI 10.1126/science.3277284; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; STINSKI MF, 1983, J VIROL, V46, P1; TERWILLIGER E, 1988, J VIROL, V62, P655, DOI 10.1128/JVI.62.2.655-658.1988; YOSHIDA M, 1988, CONTROL OF HUMAN RETROVIRUS GENE EXPRESSION, P251	27	31	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1275	1279						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2682457				2022-12-28	WOS:A1989AX65900001
J	KRAUSS, RS; HOUSEY, GM; JOHNSON, MD; WEINSTEIN, IB				KRAUSS, RS; HOUSEY, GM; JOHNSON, MD; WEINSTEIN, IB			DISTURBANCES IN GROWTH-CONTROL AND GENE-EXPRESSION IN A C3H/10T 1/2 CELL-LINE THAT STABLY OVERPRODUCES PROTEIN KINASE-C	ONCOGENE			English	Article									COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR COMPREHENS CANC,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INST CANC RES,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University					NCI NIH HHS [CA08346, CA02656] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHENDEL CL, 1983, CANCER RES, V43, P4333; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Berenblum I, 1941, CANCER RES, V1, P44; BLUMBERG PM, 1980, CRC CR REV TOXICOL, V8, P153, DOI 10.3109/10408448009037493; BOREIKO C, 1980, CANCER RES, V40, P4709; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; BOUTWELL RK, 1964, PROG EXP TUMOR RES, V4, P207; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COULOMBE B, 1988, MOL CELL BIOL, V8, P3227, DOI 10.1128/MCB.8.8.3227; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DIAMOND L, 1984, PHARMACOL THERAPEUT, V26, P89, DOI 10.1016/0163-7258(84)90052-4; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DORMAN BH, 1983, CARCINOGENESIS, V4, P1109, DOI 10.1093/carcin/4.9.1109; EDWARDS DR, 1986, NUCLEIC ACIDS RES, V14, P8863, DOI 10.1093/nar/14.22.8863; FRAZELLE JH, 1983, CARCINOGENESIS, V4, P709, DOI 10.1093/carcin/4.6.709; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GEWERT DR, 1987, EMBO J, V6, P651, DOI 10.1002/j.1460-2075.1987.tb04804.x; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; JOHNSON MD, 1987, MOL CELL BIOL, V7, P2821, DOI 10.1128/MCB.7.8.2821; KIKKAWA U, 1987, FEBS LETT, V223, P212, DOI 10.1016/0014-5793(87)80291-0; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; LANKAS GR, 1977, MUTAT RES, V45, P153, DOI 10.1016/0027-5107(77)90053-7; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; LOWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEHTA PP, 1986, CELL, V44, P187, DOI 10.1016/0092-8674(86)90497-6; MILOSZEWSKA J, 1986, FEBS LETT, V206, P283, DOI 10.1016/0014-5793(86)80997-8; MONDAL S, 1976, CANCER RES, V36, P2254; MORDAN LJ, 1988, CARCINOGENESIS, V9, P1129, DOI 10.1093/carcin/9.7.1129; Mottram JC, 1944, J PATHOL BACTERIOL, V56, P181, DOI 10.1002/path.1700560207; MURPHY G, 1985, J BIOL CHEM, V260, P3079; NEIDEL JE, 1983, P NATL ACAD SCI USA, V80, P36; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PARKER PJ, 1984, EMBO J, V3, P953, DOI 10.1002/j.1460-2075.1984.tb01913.x; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; REZNIKOFF CA, 1973, CANCER RES, V33, P3239; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; Rous P, 1941, J EXP MED, V73, P365, DOI 10.1084/jem.73.3.365; SLAGA TJ, 1984, MECHANISMS TUMOR PRO, V2, P189; SLAGA TJ, 1984, MECHANISMS TUMOR PRO, V2, P1; SOPER CJ, 1977, CANCER RES, V37, P2487; TROSKO JE, 1977, CANCER RES, V37, P188; TROSKO JE, 1984, MECHANISMS TUMOR PRO, V4, P119; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WEINSTEIN IB, 1981, J SUPRAMOL STR CELL, V17, P99, DOI 10.1002/jsscb.380170202; WEINSTEIN IB, 1987, J CELL BIOCHEM, V33, P213, DOI 10.1002/jcb.240330308; YOTTI LP, 1979, SCIENCE, V206, P1089, DOI 10.1126/science.493994	57	74	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					991	998						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2761987				2022-12-28	WOS:A1989AJ29700007
J	ROVERA, G; REICHARD, BA; HUDSON, S; BITTENBENDER, S; YAMADA, M; TOURNAY, O; PREISLER, HD				ROVERA, G; REICHARD, BA; HUDSON, S; BITTENBENDER, S; YAMADA, M; TOURNAY, O; PREISLER, HD			POINT MUTATIONS IN BOTH TRANSFORMING AND NON-TRANSFORMING CODONS OF THE N-RAS PROTO-ONCOGENE OF PH+ LEUKEMIAS	ONCOGENE			English	Article									UNIV CINCINNATI,BARRETT CANC CTR,CINCINNATI,OH 45221; UNIV CINCINNATI,DIV HEMATOL ONCOL,CINCINNATI,OH 45221	University of Cincinnati; University of Cincinnati	ROVERA, G (corresponding author), WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104, USA.				NCI NIH HHS [CA 10816, CA 41285, CA 47983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA047983, P01CA041285] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMOGUERA C, 1988, CELL, V53, P548; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; COLLINS SJ, 1989, BLOOD, V73, P1028; EVA A, 1983, P NATL ACAD SCI-BIOL, V80, P4926, DOI 10.1073/pnas.80.16.4926; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; GAMBKE C, 1984, NATURE, V307, P476, DOI 10.1038/307476a0; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HIRAI H, 1987, BIOCHEM BIOPH RES CO, V147, P108, DOI 10.1016/S0006-291X(87)80093-1; HIRAI H, 1985, BLOOD, V66, P1371; JANSSEN JVG, 1987, P NATL ACAD SCI USA, V86, P9228; JANSSEN JWG, 1987, NUCLEIC ACIDS RES, V15, P5669, DOI 10.1093/nar/15.14.5669; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEMAISTRE A, 1989, BLOOD, V73, P889; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; Maniatis T., 1982, MOL CLONING; MAVILIO F, 1988, ONCOGENE, V4, P301; MURRAY M, 1987, CELL, V33, P749; NEEDLEMAN SW, 1986, BLOOD, V67, P753; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; NOWELL P, 1983, NATURE, V306, P494, DOI 10.1038/306494a0; PREISLER HD, 1988, CANCER GENET CYTOGEN, V32, P133, DOI 10.1016/0165-4608(88)90320-2; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SELIGER H, 1986, CHEM SCRIPTA, V26, P569; SHIH TY, 1979, P NATL ACAD SCI USA, V176, P5714	29	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					867	872						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2666907				2022-12-28	WOS:A1989AE58400008
J	STRANGE, R; AGUILARCORDOVA, E; YOUNG, LJT; BILLY, HT; DANDEKAR, S; CARDIFF, RD				STRANGE, R; AGUILARCORDOVA, E; YOUNG, LJT; BILLY, HT; DANDEKAR, S; CARDIFF, RD			HARVEY-RAS MEDIATED NEOPLASTIC DEVELOPMENT IN THE MOUSE MAMMARY-GLAND	ONCOGENE			English	Article											STRANGE, R (corresponding author), UNIV CALIF DAVIS,SCH MED,DEPT PATHOL,DAVIS,CA 95616, USA.							ASCH BB, 1981, P NATL ACAD SCI-BIOL, V78, P5643, DOI 10.1073/pnas.78.9.5643; ASHLEY RL, 1980, CANCER RES, V40, P4232; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1986, CARCINOGENESIS, V7, P1037, DOI 10.1093/carcin/7.7.1037; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CARDIFF RD, 1988, ONCOGENE, V3, P205; CARDIFF RD, 1984, ADV CANCER RES, V42, P167, DOI 10.1016/S0065-230X(08)60458-3; CHAN R, 1986, CANCER RES, V46, P6353; CLAIR T, 1987, CANCER RES, V47, P5290; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; EDWARDS PAW, 1988, ONCOGENE, V2, P402; EHMANN UK, 1987, JNCI-J NATL CANCER I, V78, P751; EHMANN UK, 1984, J CELL BIOL, V98, P1026, DOI 10.1083/jcb.98.3.1026; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; ETHIER SP, 1984, CANCER RES, V44, P4517; FOULDS L, 1969, NEOPLASTIC DEV, V1; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HAGER GL, 1979, J VIROL, V31, P795, DOI 10.1128/JVI.31.3.795-809.1979; HAND PH, 1987, J NATL CANCER I, V79, P59; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEDINA D, 1986, J NATL CANCER I, V76, P1143; Medina D., 1982, MOUSE BIOMEDICAL RES, VIV, P373; Morris D. W., 1987, ADV VIRAL ONCOL, V7, P123; ODONNELL PV, 1985, J VIROL, V55, P500, DOI 10.1128/JVI.55.2.500-503.1985; OWEN RD, 1987, MOL CELL BIOL, V7, P2512, DOI 10.1128/MCB.7.7.2512; PATHAK VK, 1987, J NATL CANCER I, V78, P327; POIRIER Y, 1988, J VIROL, V62, P3985, DOI 10.1128/JVI.62.11.3985-3992.1988; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REDMOND SMS, 1988, ONCOGENE, V2, P259; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SATO Y, 1986, AM J PATHOL, V125, P431; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; TANAKA T, 1986, CANCER RES, V46, P1465; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WONG G, 1986, CANCER RES, V46, P6029; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	45	33	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1989	4	3					309	315						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2784851				2022-12-28	WOS:A1989U567600006
J	BALLMERHOFER, K; ZIEGLER, A; BURGER, MM				BALLMERHOFER, K; ZIEGLER, A; BURGER, MM			ASSOCIATION OF POLYOMA-VIRUS MIDDLE T-ANTIGEN AND PP60SRC WITH CYTOSKELETAL ELEMENTS	ONCOGENE			English	Article											BALLMERHOFER, K (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.			Ballmer-Hofer, Kurt/0000-0002-3800-9129; Ziegler, Annemarie/0000-0003-0018-7031				ABERCROMBIE M, 1975, EXP CELL RES, V92, P57, DOI 10.1016/0014-4827(75)90636-9; ASH JF, 1976, P NATL ACAD SCI USA, V73, P3603, DOI 10.1073/pnas.73.10.3603; BALLMERHOFER K, 1985, EMBO J, V4, P2321, DOI 10.1002/j.1460-2075.1985.tb03933.x; BENDIG MM, 1980, J VIROL, V33, P1215, DOI 10.1128/JVI.33.3.1215-1220.1980; BENZEEV A, 1985, BIOCHIM BIOPHYS ACTA, V780, P197; Bishop J, 1982, MOL BIOL TUMOR VIRUS, P999; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BROWN DJ, 1984, J BIOL CHEM, V259, P9580; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; COLLETT MS, 1984, MOL CELL BIOL, V4, P1213, DOI 10.1128/MCB.4.7.1213; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DILWORTH SM, 1986, EMBO J, V5, P491, DOI 10.1002/j.1460-2075.1986.tb04238.x; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GEIGER B, 1981, COLD SPRING HARBOR S, V2, P671; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; ITO S, 1983, J BIOL CHEM, V258, P4626; KORNBLUTH S, 1986, MOL CELL BIOL, V6, P1545, DOI 10.1128/MCB.6.5.1545; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; NIGG EA, 1982, P NATL ACAD SCI-BIOL, V79, P5322, DOI 10.1073/pnas.79.17.5322; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; POLLACK R, 1975, P NATL ACAD SCI USA, V72, P994, DOI 10.1073/pnas.72.3.994; Rohrschneider L, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 2, P953; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; SCHAFFHAUSEN B, 1981, J VIROL, V40, P184, DOI 10.1128/JVI.40.1.184-196.1981; SCHAFFHAUSEN B, 1981, COLD SPRING HARBOR C, V8, P1281; SCHLEGEL R, 1978, CELL, V14, P587, DOI 10.1016/0092-8674(78)90244-1; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SEGAWA K, 1982, P NATL ACAD SCI-BIOL, V79, P6812, DOI 10.1073/pnas.79.22.6812; SHRIVER K, 1981, J CELL BIOL, V89, P525, DOI 10.1083/jcb.89.3.525; SHRIVER K, 1981, COLD SPRING HARBOR C, V8, P1247; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WITTELSBERGER SC, 1981, CELL, V24, P859, DOI 10.1016/0092-8674(81)90111-2; YONEMOTO W, 1987, MOL CELL BIOL, V7, P905, DOI 10.1128/MCB.7.2.905	37	7	7	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					365	371						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	2856248				2022-12-28	WOS:A1988Q773900003
J	WILKS, AF; KURBAN, RR				WILKS, AF; KURBAN, RR			ISOLATION AND STRUCTURAL-ANALYSIS OF MURINE C-FES CDNA CLONES	ONCOGENE			English	Article											WILKS, AF (corresponding author), ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,PARKVILLE,VIC 3050,AUSTRALIA.		Wilks, Andrew F/R-5542-2019	Wilks, Andrew F/0000-0002-8554-2399				BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DIAMOND B, 1978, J IMMUNOL, V121, P1329; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FELDMAN RA, 1987, ONCOGENE RES, V1, P441; FELDMAN RA, 1986, MOL CELL BIOL, V6, P1065, DOI 10.1128/MCB.6.4.1065; FOSTER DA, 1986, MOL CELL BIOL, V6, P325, DOI 10.1128/MCB.6.1.325; FOSTER DA, 1985, CELL, V42, P105, DOI 10.1016/S0092-8674(85)80106-9; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HAMPE A, 1982, CELL, V30, P775, DOI 10.1016/0092-8674(82)90282-3; HANAFUSA T, 1980, P NATL ACAD SCI-BIOL, V77, P3009, DOI 10.1073/pnas.77.5.3009; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; HUANG CC, 1984, J VIROL, V50, P125, DOI 10.1128/JVI.50.1.125-131.1984; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MATHEYPREVOT B, 1982, CELL, V28, P897, DOI 10.1016/0092-8674(82)90069-1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; METCALF D, 1982, INT J CANCER, V30, P773, DOI 10.1002/ijc.2910300616; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROEBROEK AJM, 1987, J VIROL, V61, P2009, DOI 10.1128/JVI.61.6.2009-2016.1987; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA M, 1982, CELL, V30, P787, DOI 10.1016/0092-8674(82)90283-5; SODROSKI JG, 1984, P NATL ACAD SCI-BIOL, V81, P3039, DOI 10.1073/pnas.81.10.3039; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; ULLRICH A, 1984, NATURE, V289, P258; WARNER NL, 1969, J NATL CANCER I, V43, P963; WARNER NL, 1979, IMMUNOBIOLOGY IMNUNO, P223; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; YOUNG JC, 1984, J VIROL, V52, P913, DOI 10.1128/JVI.52.3.913-918.1984	40	47	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					289	294						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	3060793				2022-12-28	WOS:A1988Q436700007
J	CHAN, AML; KING, HWS; DEAKIN, EA; TEMPEST, PR; HILKENS, J; KROEZEN, V; EDWARDS, DR; WILLS, AJ; BROOKES, P; COOPER, CS				CHAN, AML; KING, HWS; DEAKIN, EA; TEMPEST, PR; HILKENS, J; KROEZEN, V; EDWARDS, DR; WILLS, AJ; BROOKES, P; COOPER, CS			CHARACTERIZATION OF THE MOUSE MET PROTO-ONCOGENE	ONCOGENE			English	Article									NETHERLANDS CANC INST,ANTONI VANLEEUWENHOEK HUIS,DEPT TUMOUR BIOL,1066 CX AMSTERDAM,NETHERLANDS; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	Netherlands Cancer Institute; University of Oxford	CHAN, AML (corresponding author), INST CANC RES,CHESTER BEATTY LABS,CHEM CARCINOGENESIS SECT,FULHAM RD,LONDON SW3 6JB,ENGLAND.		Edwards, Dylan R/B-4734-2009; Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020	Edwards, Dylan R/0000-0002-3292-2064; Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464; Hilkens, John/0000-0002-0932-7793				BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; CACCIA N, 1984, CELL, V37, P1091, DOI 10.1016/0092-8674(84)90443-4; CHAN AML, 1987, ONCOGENE, V1, P229; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, CANCER RES, V44, P1; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEAN M, 1985, NATURE, V311, P29; Favaloro J, 1980, Methods Enzymol, V65, P718; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; HAYATA I, 1983, CANCER RES, V43, P367; HILKENS J, 1986, SOMAT CELL MOLEC GEN, V12, P81, DOI 10.1007/BF01560730; HOHN B, 1977, P NATL ACAD SCI USA, V74, P3259, DOI 10.1073/pnas.74.8.3259; HONEY NK, 1984, SOMAT CELL MOLEC GEN, V10, P377, DOI 10.1007/BF01535633; HONEY NK, 1984, SOMAT CELL MOLEC GEN, V10, P369, DOI 10.1007/BF01535632; HONEY NK, 1986, HUM GENET, V72, P27, DOI 10.1007/BF00278813; KIENY MP, 1983, GENE, V26, P91, DOI 10.1016/0378-1119(83)90039-2; LEBEAU MM, 1985, CELL, V41, P335, DOI 10.1016/0092-8674(85)90086-8; MANIATIS T, 1982, MOL CLONING LABORATO; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; SAKAGUCHI AY, 1984, P NATL ACAD SCI-BIOL, V81, P525, DOI 10.1073/pnas.81.2.525; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TEMPEST PR, 1986, CARCINOGENESIS, V7, P2051, DOI 10.1093/carcin/7.12.2051; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; 1988, J CELL BIOL, V106, P441	38	140	146	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					593	599						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	2838789				2022-12-28	WOS:A1988N841500010
J	KING, HWS; TEMPEST, PR; MERRIFIELD, KR; RANCE, AJ				KING, HWS; TEMPEST, PR; MERRIFIELD, KR; RANCE, AJ			TPR HOMOLOGS ACTIVATE MET AND RAF	ONCOGENE			English	Article									UNIV ABERDEEN,SCOTGEN LTD,DEPT GENET,ABERDEEN AB9 2TN,SCOTLAND	University of Aberdeen	KING, HWS (corresponding author), INST CANC RES,CHESTER BEATTY LABS,FULHAM RD,LONDON SW3 6JB,ENGLAND.							BISHOP M, 1984, NUCLEIC ACIDS RES, V12, P5471, DOI 10.1093/nar/12.13.5471; Chan A. H. Y., UNPUB; CHAN AML, 1987, ONCOGENE, V1, P229; COOPER CS, 1984, CANCER RES, V44, P1; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343; ISHIKAWA F, 1985, BIOCHEM BIOPH RES CO, V132, P186, DOI 10.1016/0006-291X(85)91005-8; ISHIKAWA F, 1986, P NATL ACAD SCI USA, V83, P3209, DOI 10.1073/pnas.83.10.3209; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; KIENY MP, 1983, GENE, V26, P91, DOI 10.1016/0378-1119(83)90039-2; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; TEMPEST PR, 1986, CARCINOGENESIS, V7, P2051, DOI 10.1093/carcin/7.12.2051; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5	21	18	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					617	619						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	3387099				2022-12-28	WOS:A1988N841500014
J	MUNROE, DG; ROVINSKI, B; BERNSTEIN, A; BENCHIMOL, S				MUNROE, DG; ROVINSKI, B; BERNSTEIN, A; BENCHIMOL, S			LOSS OF A HIGHLY CONSERVED DOMAIN ON P53 AS A RESULT OF GENE DELETION DURING FRIEND VIRUS-INDUCED ERYTHROLEUKEMIA	ONCOGENE			English	Article									UNIV TORONTO,ONTARIO CANC INST,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA; MT SINAI HOSP,RES INST,TORONTO M5G 1X5,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute				Benchimol, Samuel/0000-0003-3433-890X				BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	20	76	78	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					621	624						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	3290808				2022-12-28	WOS:A1988N841500015
J	BAICHWAL, VR; SUGDEN, B				BAICHWAL, VR; SUGDEN, B			TRANSFORMATION OF BALB 3T3 CELLS BY THE BNLF-1 GENE OF EPSTEIN-BARR VIRUS	ONCOGENE			English	Article									UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NCI NIH HHS [CA-22443, CA07175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022443, P30CA007175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; AUERBACH R, 1978, CANCER RES, V38, P1739; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; Bankier A T, 1983, Mol Biol Med, V1, P425; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; DAMBAUGH T, 1986, J VIROL, V59, P453, DOI 10.1128/JVI.59.2.453-462.1986; DAMBAUGH T, 1986, EPSTEINBARR VIRUS RE, P13; HENNESSY K, 1984, P NATL ACAD SCI-BIOL, V81, P7207, DOI 10.1073/pnas.81.22.7207; HEPPEL LA, 1955, METHOD ENZYMOL, V2, P546, DOI 10.1016/S0076-6879(55)02249-0; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; KNUTSON JC, 1987, ANAL BIOCHEM, V164, P44, DOI 10.1016/0003-2697(87)90365-4; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LANE MA, 1982, CELL, V28, P873, DOI 10.1016/0092-8674(82)90066-6; LIEBOWITZ D, 1986, J VIROL, V58, P223; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MILLER G, 1985, VIROLOGY, P563; NILSSON K, 1977, INT J CANCER, V19, P337, DOI 10.1002/ijc.2910190309; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUGDEN B, 1977, J VIROL, V23, P503, DOI 10.1128/JVI.23.3.503-508.1977; Sugden B, 1979, Adv Cancer Res, V30, P239, DOI 10.1016/S0065-230X(08)60898-2; TOPP WC, 1980, DNA TUMOR VIRUSES, P205; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; ZERLIN M, 1987, ONCOGENE, V1, P19	26	268	274	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					461	467						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	2836780				2022-12-28	WOS:A1988N434800007
J	SHIOZAWA, M; OCHIYA, T; HATADA, I; IMAMURA, T; OKUDAIRA, Y; HIRAOKA, H; MATSUBARA, K				SHIOZAWA, M; OCHIYA, T; HATADA, I; IMAMURA, T; OKUDAIRA, Y; HIRAOKA, H; MATSUBARA, K			THE LCA AS AN ONCO-FETAL GENE - ITS EXPRESSION IN HUMAN-FETAL LIVER	ONCOGENE			English	Article									OSAKA UNIV,INST MOLEC & CELLULAR BIOL,YAMADA OKA,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,HOSP ATTACHED RES INST MICROBIAL DIS,SUITA,OSAKA 565,JAPAN; HANWA HOSP,DEPT GYNECOL & OBSTET,SUMIYOSHI,OSAKA 558,JAPAN	Osaka University; Osaka University			Ochiya, Takahiro/AAH-7585-2019					AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; GITLIN D, 1970, NATURE, V228, P995, DOI 10.1038/228995a0; HAN JH, 1986, P NATL ACAD SCI USA, V83, P110, DOI 10.1073/pnas.83.1.110; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LEFFERT H, 1978, P NATL ACAD SCI USA, V75, P1834, DOI 10.1073/pnas.75.4.1834; LEFFERT HL, 1972, J CELL BIOL, V52, P559, DOI 10.1083/jcb.52.3.559; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MANIATIS T, 1982, MOL CLONING LABORATO; MATSUBARA K, 1987, ONCOGENES CANCER; MOORE KL, 1977, DEV HUMAN; MORINAGA T, 1983, P NATL ACAD SCI-BIOL, V80, P4604, DOI 10.1073/pnas.80.15.4604; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; OCHIYA T, 1986, P NATL ACAD SCI USA, V83, P4993, DOI 10.1073/pnas.83.14.4993; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SLAMON DJ, 1984, P NATL ACAD SCI-BIOL, V81, P7141, DOI 10.1073/pnas.81.22.7141; Van Furth R, 1969, Nature, V222, P1296, DOI 10.1038/2221296a0; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WIDDOWSON EM, 1972, ARCH DIS CHILD, V47, P652, DOI 10.1136/adc.47.254.652; ZHANG XK, 1987, BIOCHEM BIOPH RES CO, V142, P932, DOI 10.1016/0006-291X(87)91503-8	27	2	2	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					523	526						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	2836781				2022-12-28	WOS:A1988N434800015
J	REDMOND, SMS; REICHMANN, E; MULLER, RG; FRIIS, RR; GRONER, B; HYNES, NE				REDMOND, SMS; REICHMANN, E; MULLER, RG; FRIIS, RR; GRONER, B; HYNES, NE			THE TRANSFORMATION OF PRIMARY AND ESTABLISHED MOUSE MAMMARY EPITHELIAL-CELLS BY P21-RAS IS CONCENTRATION DEPENDENT	ONCOGENE			English	Article											REDMOND, SMS (corresponding author), INSELSPITAL,LUDWIG INST CANC RES,CH-3010 BERN,SWITZERLAND.							ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1984, MED BIOL, V62, P304; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BRAWERMAN G, 1972, BIOCHEMISTRY-US, V11, P637, DOI 10.1021/bi00754a027; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FOULDS L, 1969, NEOPLASTIC DEV, V1; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GARCIA I, 1986, MOL CELL BIOL, V6, P1974, DOI 10.1128/MCB.6.6.1974; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAND PH, 1984, P NATL ACAD SCI-BIOL, V81, P5227, DOI 10.1073/pnas.81.16.5227; HARPER JR, 1986, MOL CELL BIOL, V6, P3144, DOI 10.1128/MCB.6.9.3144; HYNES NE, 1985, MOL CELL BIOL, V5, P268, DOI 10.1128/MCB.5.1.268; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; MANIATIS T, 1982, MOL CLONING LABORATO; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OWENS RB, 1974, J NATL CANCER I, V53, P261, DOI 10.1093/jnci/53.1.261; Peto R, 1977, ORIGINS HUMAN CANC C, P1403; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SISTONEN L, 1987, EXP CELL RES, V168, P518, DOI 10.1016/0014-4827(87)90024-3; SONNENBERG A, 1986, J IMMUNOL, V137, P1264; SONNENBERG A, 1986, J HISTOCHEM CYTOCHEM, V34, P1037, DOI 10.1177/34.8.2426332; SONNENBERG A, 1986, CANCER RES, V46, P5913; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; VANDERHOORN FA, 1985, MOL CELL BIOL, V5, P2204, DOI 10.1128/MCB.5.9.2204; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	45	76	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					259	265						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3127778				2022-12-28	WOS:A1988M593100008
J	SUBRAMANIAN, T; KUPPUSWAMY, M; NASR, RJ; CHINNADURAI, G				SUBRAMANIAN, T; KUPPUSWAMY, M; NASR, RJ; CHINNADURAI, G			AN N-TERMINAL REGION OF ADENOVIRUS-E1A ESSENTIAL FOR CELL-TRANSFORMATION AND INDUCTION OF AN EPITHELIAL-CELL GROWTH-FACTOR	ONCOGENE			English	Article									ST LOUIS UNIV,MED CTR,INST MOLEC VIROL,3681 PARK AVE,ST LOUIS,MO 63110	Saint Louis University					NATIONAL CANCER INSTITUTE [R01CA031719] Funding Source: NIH RePORTER; NCI NIH HHS [CA-31719] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORELLI E, 1984, NATURE, V312, P608; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; CHINNADURAI G, 1979, J VIROL, V32, P623, DOI 10.1128/JVI.32.2.623-628.1979; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GARCIA JV, 1986, NATURE, V322, P383, DOI 10.1038/322383a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1984, ADENOVIRUSES, P339; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LAIMINS LA, 1982, P NATL ACAD SCI US, V76, P3665; LATHE R, 1984, DNA-J MOLEC CELL BIO, V3, P173, DOI 10.1089/dna.1984.3.173; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; MANIATIS T, 1982, MOL CLONING LABORATO; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; QUEEN C, 1984, MOL CELL BIOL, V4, P1042, DOI 10.1128/MCB.4.6.1042; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1987, P NATL ACAD SCI USA, V84, P3283, DOI 10.1073/pnas.84.10.3283; QUINLAN MP, 1986, CANCER CELL, V4, P327; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; SUSSENBACH JS, 1984, ADENOVIRUSES, P35; SVENSSON C, 1983, J MOL BIOL, V165, P475, DOI 10.1016/S0022-2836(83)80214-9; TAUB M, 1984, METHODS SERUM FREE C, P3; ULFENDAHL PJ, 1987, EMBO J, V6, P2037, DOI 10.1002/j.1460-2075.1987.tb02468.x; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; YEE SP, 1985, VIROLOGY, V146, P315, DOI 10.1016/0042-6822(85)90015-7; YOSHIDA K, 1987, GENE DEV, V1, P645, DOI 10.1101/gad.1.7.645; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	42	88	89	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					105	112						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	2966920				2022-12-28	WOS:A1988M086000002
J	ASKER, CE; MAGNUSSON, KP; PICCOLI, SP; ANDERSSON, K; KLEIN, G; COLE, MD; WIMAN, KG				ASKER, CE; MAGNUSSON, KP; PICCOLI, SP; ANDERSSON, K; KLEIN, G; COLE, MD; WIMAN, KG			MOUSE AND RAT B-MYC SHARE AMINO-ACID-SEQUENCE HOMOLOGY WITH THE C-MYC TRANSCRIPTIONAL ACTIVATOR DOMAIN AND CONTAIN A B-MYC SPECIFIC CARBOXY-TERMINAL REGION	ONCOGENE			English	Article						B-MYC; SEQUENCE; MOUSE; RAT; NUCLEAR PROTEIN	MURINE ERYTHROLEUKEMIA-CELLS; DNA-BINDING PROTEINS; N-MYC; NUCLEOTIDE-SEQUENCE; TRANSGENIC MICE; LEUCINE ZIPPER; NEOPLASTIC TRANSFORMATION; DIFFERENTIATION; EXPRESSION; GENE	B-myc is a member of the myc gene family. Previous studies indicate that the rat B-myc gene contains a single exon which shows 77% nucleotide homology to the second exon of the rat c-myc gene. Its open reading frame (ORF) encodes a polypeptide with a predicted molecular weight of 20 kD. We have isolated a new, larger rat B-myc genomic clone. Sequence analysis of this clone confirmed the presence of one single coding exon. Furthermore, a genomic mouse B-myc clone was identified and compared to the rat homolog. Nucleotide analysis of B-myc coding and non-coding sequences suggests that it may be a functional gene evolved by selective duplication of part of the second c-myc exon. Analysis of the rodent B-myc open reading frames revealed two in-frame amino acid duplications in mouse B-myc and a 96% conservation at the amino acid level. Both rat and mouse B-myc proteins contain an identical and unique stretch of 14 carboxy terminal amino acid residues not found in other myc proteins. In vitro translation of rat and mouse B-myc ORF's yielded proteins that migrated as 26 kD bands in SDS-PAGE and could be immunoprecipitated by a polyclonal panmyc antiserum. Immunostaining of human lymphoma cells transiently transfected with a B-myc expression vector showed that the protein was mainly localized to the nucleus.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA; IMMUNOCOM, HUNTINGDON VALLEY, PA 19006 USA	Princeton University	ASKER, CE (corresponding author), KAROLINSKA INST, CTR MICROBIOL & TUMOR BIOL, S-17177 STOCKHOLM, SWEDEN.		Wiman, Klas/AAB-8399-2021; Magnusson, Kristinn P Pétur/X-4907-2019; Magnusson, Kristinn/A-6479-2011	Wiman, Klas/0000-0002-7113-524X; Magnusson, Kristinn P Pétur/0000-0003-4528-6826; Magnusson, Kristinn/0000-0003-4528-6826	NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER; NCI NIH HHS [5RO1 CA 14054-15] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ASKER C, 1989, ONCOGENE, V4, P1523; BARNER M, 1992, CELL GROWTH DIFFER, V3, P183; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BIRRER MJ, 1989, MOL CELL BIOL, V9, P2734, DOI 10.1128/MCB.9.6.2734; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CLASSON M, 1993, GENE, V133, P153, DOI 10.1016/0378-1119(93)90633-E; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DEPINHO R, 1987, J CELL BIOCHEM, V33, P257, DOI 10.1002/jcb.240330404; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; DOOLITTLE RF, 1992, PROTEIN SCI, V1, P191; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; INGVARSSON S, 1988, ONCOGENE, V3, P679; INGVARSSON S, 1988, MOL CELL BIOL, V8, P3168, DOI 10.1128/MCB.8.8.3168; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOROY T, 1991, ONCOGENE, V6, P1941; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RESAR LMS, 1993, MOL CELL BIOL, V13, P1130, DOI 10.1128/MCB.13.2.1130; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455	48	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	1995	11	10					1963	1969						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478514				2022-12-28	WOS:A1995TF29700005
J	KAGAN, J; STEIN, J; BABAIAN, RJ; JOE, YS; PISTERS, LL; GLASSMAN, AB; VONESCHENBACH, AC; TRONCOSO, P				KAGAN, J; STEIN, J; BABAIAN, RJ; JOE, YS; PISTERS, LL; GLASSMAN, AB; VONESCHENBACH, AC; TRONCOSO, P			HOMOZYGOUS DELETIONS AT 8P22 AND 8P21 IN PROSTATE-CANCER IMPLICATE THESE REGIONS AS THE SITES FOR CANDIDATE TUMOR-SUPPRESSOR GENES	ONCOGENE			English	Article						CHROMOSOME 8P; LOH; MICROSATELLITE; PROSTATE CANCER; TUMOR SUPPRESSOR GENE (TSG)	DINUCLEOTIDE REPEAT POLYMORPHISM; ALLELIC LOSS; CHROMOSOME REARRANGEMENTS; ADENOCARCINOMA; LOCALIZATION; CARCINOMA; LOCUS	Frequent loss of an allele at specific chromosomal regions implicates these regions as sites of tumor suppressor genes (TSG) that become inactivated during tumor progression. We have studied chromosome 8p allele losses in 32 primary human prostate carcinomas with 16 polymorphic microsatellite sequences. Overall, 22 of 32 (69%) informative specimens showed loss of allele in at least one locus. The most frequent losses of heterozygosity (LOH) occurred at the LPL locus (46%) on chromosome 8p22 and at the DSS360 (45%) and NEFL (43%) loci on chromosome 8p21. Homozygous deletions were detected at the LPL and NEFL loci at 8p22 and 8p21, respectively. The minimal region with frequent LOH and homozygous deletion, around the LPL locus, was restricted between the MSR locus and the D8S258 marker, separated by less than 9 cM. The second region was restricted between markers D8S1128 and D8S131 separated by 12 cM. The results suggest the existence of two chromosome 8p sites for candidate TSGs in prostate cancer.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT UROL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	KAGAN, J (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DIV LAB MED,HEMATOPATHOL PROGRAM,BOX 72,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							ARPS S, 1993, CANCER GENET CYTOGEN, V66, P93, DOI 10.1016/0165-4608(93)90234-D; ATKIN NB, 1985, HUM GENET, V70, P359, DOI 10.1007/BF00295378; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BOOKSTEIN R, 1994, GENOMICS, V24, P317, DOI 10.1006/geno.1994.1622; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BOVA GS, 1993, CANCER RES, V53, P3869; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHANG M, 1994, AM J PATHOL, V144, P1; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; FUJIWARA Y, 1995, ONCOGENE, V10, P891; GIBAS Z, 1985, CANCER GENET CYTOGEN, V16, P301, DOI 10.1016/0165-4608(85)90237-7; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; ICHIKAWA T, 1994, CANCER RES, V54, P2299; KAGAN J, 1994, INT J ONCOL, V5, P921; KAMINO K, 1993, HUM MOL GENET, V2, P1751, DOI 10.1093/hmg/2.10.1751; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; LUNDGREN R, 1988, CANCER GENET CYTOGEN, V35, P103, DOI 10.1016/0165-4608(88)90128-8; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MURRAY JE, 1993, COMMUNICATION; PYKETT MJ, 1994, CANCER GENET CYTOGEN, V76, P23, DOI 10.1016/0165-4608(94)90064-7; Rogaev E., 1992, Human Molecular Genetics, V1, P781, DOI 10.1093/hmg/1.9.781; SADLER LA, 1991, NUCLEIC ACIDS RES, V19, P6058, DOI 10.1093/nar/19.21.6058-a; THOMFOHRDE J, 1992, GENOMICS, V14, P144; TRAPMAN J, 1994, CANCER RES, V54, P6061; WAGNER MJ, 1991, GENOMICS, V10, P114, DOI 10.1016/0888-7543(91)90491-V; WEBBER JL, 1990, NUCLEIC ACIDS RES, V18, P4038; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Wood S, 1993, Cytogenet Cell Genet, V64, P134; WOOD S, 1992, GENOMICS, V13, P232, DOI 10.1016/0888-7543(92)90230-P; YU CE, 1994, HUM MOL GENET, V3, P211; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370	40	105	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2121	2126						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478532				2022-12-28	WOS:A1995TF29700023
J	KORTENJANN, M; SHAW, PE				KORTENJANN, M; SHAW, PE			RAF-1 KINASE AND ERK2 UNCOUPLED FROM MITOGENIC SIGNALS IN RAT FIBROBLASTS	ONCOGENE			English	Article						C-FOS; CELL PROLIFERATION; SIGNAL CASCADE; MAP KINASES	ACTIVATED PROTEIN-KINASE; SERUM RESPONSE ELEMENT; MAP KINASE; C-FOS; GROWTH-FACTOR; TRANSDUCTION PATHWAY; IN-VITRO; V-RAF; CELLS; PHOSPHORYLATION	The MAP kinase pathway impinging on ERK2 has been shown to be integrally associated with mitogenic signalling in many cell types. Previously, we and others have demonstrated that oncogenic forms of Raf-1 kinase, when expressed in fibroblasts, lead to the constitutive activation of ERK2, the de-regulation of c-fos expression and increased cell proliferation. Here we describe an exception to this scenario. In Rat6 cells, although both ERK1 and ERK2 are activated in response to mitogens that induce c-fos expression, such as Epidermal Growth Factor (EGF), lysophosphatidic acid (LPA) or serum, expression of v-Raf fails to induce c-fos expression and increase proliferation. However, ERK2 is activated by v-Raf expression. The co-transfection of an interfering mutant of ERK2 has no effect on the level of c-fos reporter expression in Rat6 cells whereas the analogous ERK1 mutant reduces its expression. Furthermore, the spontaneous focus formation observed in Rat6 cells is susceptible to the interfering mutant of ERK1 but resistant to that of ERK2. Thus, not only do mitogenic signals appear to by-pass both Raf-1 kinase and ERK2, the Raf-1-ERK2 pathway seems to be functionally compromised in Rat6 cells as its activation leads neither to c-fos expression nor to increased proliferation.	MAX PLANCK INST IMMUNBIOL,SPEMANN LABS,D-79108 FREIBURG,GERMANY	Max Planck Society				SHAW, Peter/0000-0002-2598-4283				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BURGERING BMT, 1993, BIOCHEM SOC T, V21, P888, DOI 10.1042/bst0210888; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CHOI KY, 1994, CELL, V78, P499; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GILLE H, 1995, UNPUB; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JAGGI R, 1986, EMBO J, V55, P2609; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; OTSU M, 1993, FEBS LETT, V320, P246, DOI 10.1016/0014-5793(93)80596-M; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V113, P3003; PAPIN C, 1995, ONCOGENE, V10, P1647; PERKINS LM, 1994, NUCLEIC ACIDS RES, V22, P450, DOI 10.1093/nar/22.3.450; PHAM CD, 1995, ONCOGENE, V10, P1683; PRINTEN JA, 1994, GENETICS, V138, P609; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROZAKISADOCK M, 1992, NATURE, V260, P689; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WU J, 1993, ADV SEC MESS PHOSPH, V28, P219; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	71	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2105	2112						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478530				2022-12-28	WOS:A1995TF29700021
J	RAMSAY, RG; MORRICE, N; VANEEDEN, P; KANAGASUNDARAM, V; NOMURA, T; DEBLAQUIERE, J; ISHII, S; WETTENHALL, R				RAMSAY, RG; MORRICE, N; VANEEDEN, P; KANAGASUNDARAM, V; NOMURA, T; DEBLAQUIERE, J; ISHII, S; WETTENHALL, R			REGULATION OF C-MYB THROUGH PROTEIN-PHOSPHORYLATION AND LEUCINE-ZIPPER INTERACTIONS	ONCOGENE			English	Article						C-MYB; CASEIN KINASE II; LEUCINE ZIPPERS; DNA BINDING	DNA-BINDING; IN-VITRO; ACTIVATION; TRUNCATION; PROTOONCOGENE; ONCOPROTEINS; KINASES	c-Myb function is modulated in part by a negative regulation domain which encompasses a leucine zipper (LZ). When E. coli-expressed c-Myb with wild type or mutated LZ proteins are assessed for DNA binding activity, the mutant form is substantially better at DNA binding than the wild type (WT) form. In contrast, the DNA binding activity of the WT protein is increased to an equivalent level of activity of the LZ-mutant when both are expressed in rabbit reticulocyte lysates (RRL) or insect cells. The possibility that phosphorylation overcomes the negative influence of the LZ was investigated. E. coli-expressed mutant, but not wild type c-Myb proteins, were shown to be substrates for Casein Kinase II (CKII) and cAMP-dependent Protein Kinase (PKA). The phosphorylation sites for CKII and PKA were serines 11 and 12, and 8 and 116, respectively. Serines 11 and 12 were found to be phosphorylated in recombinant wild type and mutant c-Myb expressed in insect cells and DNA binding was markedly reduced following phosphatase treatment. Substitution of serines 11 and 12 with glutamic acid and alanine in E. coli-expressed Myb demonstrated that these amino terminal residues influence the negative effect on DNA binding exerted by the LZ. Collectively, these observations support the notion that phosphorylation of serines 11 and 12 positively modulate DNA binding.	LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, PARKVILLE, VIC 3050, AUSTRALIA; UNIV MELBOURNE, DEPT BIOCHEM, PARKVILLE, VIC 3050, AUSTRALIA; LA TROBE UNIV, CTR PROT & ENZYME TECHNOL, BUNDOORA, VIC 3083, AUSTRALIA; RIKEN, TSUKUBA LIFE SCI CTR, TSUKUBA, IBARAKI, JAPAN	Ludwig Institute for Cancer Research; University of Melbourne; La Trobe University; RIKEN			van Eeden, Pauline/O-8713-2014; Ishii, Shunsuke/A-5271-2016; van Eeden, Pauline/H-4952-2014; Ramsay, Robert G/C-3291-2015	Ishii, Shunsuke/0000-0002-6530-2478; Ramsay, Robert G/0000-0001-5003-0433				AZIZ N, 1993, ONCOGENE, V8, P2259; BADING H, 1989, ONCOGENE, V4, P33; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; FAVIER D, 1994, ONCOGENE, V9, P305; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HUNTER T, 1988, COLD SPRING HARB SYM, V53, P131, DOI 10.1101/SQB.1988.053.01.019; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KARIN M, 1994, ONCOGENE, V9, P305; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; NOMURA T, 1993, J BIOL CHEM, V268, P21914; Ramsay R G, 1995, Methods Mol Biol, V37, P369; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAMSAY RG, 1992, CELL GROWTH DIFFER, V3, P723; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; Weston K M, 1990, Semin Cancer Biol, V1, P371; WETTENHALL REH, 1984, J BIOL CHEM, V259, P2084; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186	25	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	1995	11	10					2113	2120						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478531				2022-12-28	WOS:A1995TF29700022
J	FELIX, CA; WASSERMAN, R; CESANO, A; NOWELL, PC; HOSLER, MR; MASTERSON, M; POPLACK, DG; SANTOLI, D				FELIX, CA; WASSERMAN, R; CESANO, A; NOWELL, PC; HOSLER, MR; MASTERSON, M; POPLACK, DG; SANTOLI, D			CLONAL EXPANSION OF GERMLINE B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA IN SEVERE COMBINED IMMUNODEFICIENT MICE	ONCOGENE			English	Article						CDR3; POLYMERASE CHAIN REACTION; SOUTHERN BLOT ANALYSIS; DIFFERENTIATION; SUBCLONE	IMMUNOGLOBULIN HEAVY-CHAIN; T-CELL; GENE REARRANGEMENT; RESIDUAL DISEASE; ALL-1 GENE; CHILDHOOD; DIFFERENTIATION; EXPRESSION; PATTERNS; ORIGIN	CD19(+) B lineage acute lymphoblastic leukemias (ALLs) with unrearranged Ig and TCR genes are designated germline B lineage ALLS. We used CDR3 PCR to determine whether pediatric germline B lineage ALLs contain minor subclones with rearranged Ig H V genes. In six of seven cases there were no PCR detectable CDR3 rearrangements. One case with a smear pattern on CDR3 PCR contained multiple unique CDR3 sequences at frequencies of 1-2 per 2 600, suggesting that polyclonal B cells were present at low frequency. To verify that the germline patterns were from leukemic cells and evaluate in vivo subclone differentiation, a germline B lineage ALL with the t(4;11) translocation was propagated in severe combined immunodeficient (SCID) mice. The Ig and TCR genes in the leukemic cells recovered from mouse tissues were germline by Southern blot analysis except for single rearrangements that suggested subclone evolution at the Ig H and lambda loci in addition to the germline population. No CDR3 sequences were detected, indicating that the observed Ig H gene rearrangement most likely was a DJ joining. This study suggests that the transformed cell ingermline B lineage ALL represents an early pro-B cell with limited tendency to further differentiate.	UNIV PENN,SCH MED,WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV CINCINNATI,CHILDRENS HOSP,MED CTR,DEPT PEDIAT,CINCINNATI,OH 45229; TEXAS CHILDRENS HOSP,BAYLOR COLL MED,HEMATOL ONCOL SERV,HOUSTON,TX 77030	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Baylor College of Medicine	FELIX, CA (corresponding author), UNIV PENN,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,DIV ONCOL,PHILADELPHIA,PA 19104, USA.				NCI NIH HHS [CA-42232] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042232] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANVRET M, 1984, NUCLEIC ACIDS RES, V12, P1149, DOI 10.1093/nar/12.2.1149; BEISHUIZEN A, 1994, BLOOD, V83, P2238, DOI 10.1182/blood.V83.8.2238.bloodjournal8382238; BEISHUIZEN A, 1991, LEUKEMIA, V5, P657; BEISHUIZEN A, 1992, LEUKEMIA, V6, P60; BIONDI A, 1989, BLOOD, V73, P2133; BIRD J, 1988, J EXP MED, V168, P229, DOI 10.1084/jem.168.1.229; BORIES JC, 1991, BLOOD, V78, P2053, DOI 10.1182/blood.V78.8.2053.bloodjournal7882053; CESANO A, 1991, BLOOD, V77, P2463; CESANO A, 1992, ONCOGENE, V7, P827; DAVEY MP, 1986, P NATL ACAD SCI USA, V83, P8759, DOI 10.1073/pnas.83.22.8759; DEANE M, 1991, LEUKEMIA, V5, P832; EHRLICH A, 1993, CELL, V72, P695; FELIX CA, 1993, CANCER RES, V53, P2954; FELIX CA, 1987, J CLIN INVEST, V80, P545, DOI 10.1172/JCI113103; FELIX CA, 1987, BLOOD, V70, P536; FELIX CA, 1990, J CLIN ONCOL, V8, P431, DOI 10.1200/JCO.1990.8.3.431; FELIX CA, 1994, LEUKEMIA, V8, P963; FOA R, 1984, J CLIN INVEST, V74, P1756, DOI 10.1172/JCI111594; GREENBERG JM, 1986, J IMMUNOL, V137, P2043; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HARA J, 1988, J CLIN INVEST, V82, P1974, DOI 10.1172/JCI113817; HUNGER SP, 1993, BLOOD, V81, P3197; JANSEN B, 1992, CANCER RES, V52, P406; KAMELREID S, 1989, SCIENCE, V246, P1597, DOI 10.1126/science.2595371; KITCHINGMAN GR, 1986, BLOOD, V67, P698; KITCHINGMAN GR, 1993, BLOOD, V81, P775; KIYOI H, 1992, J CLIN INVEST, V89, P739, DOI 10.1172/JCI115650; KORSMEYER SJ, 1983, J CLIN INVEST, V71, P301, DOI 10.1172/JCI110770; LEBIEN TW, 1990, HEMATOL ONCOL CLIN N, V4, P835, DOI 10.1016/S0889-8588(18)30470-2; MIRRO J, 1986, BLOOD, V67, P689; NADLER LM, 1984, J CLIN INVEST, V74, P332, DOI 10.1172/JCI111428; RAIMONDI SC, 1993, BLOOD, V81, P2237; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; STEENBERGEN EJ, 1993, BLOOD, V82, P581, DOI 10.1182/blood.V82.2.581.bloodjournal822581; TYCKO B, 1992, BLOOD, V79, P481; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1988, BLOOD, V71, P13; VANDONGEN JJM, 1987, J IMMUNOL, V138, P1260; WASSERMAN R, 1992, BLOOD, V79, P223; YAMADA M, 1989, P NATL ACAD SCI USA, V86, P5123, DOI 10.1073/pnas.86.13.5123; YAMADA M, 1991, J EXP MED, V173, P395, DOI 10.1084/jem.173.2.395; YAMADA M, 1990, NEW ENGL J MED, V323, P448, DOI 10.1056/NEJM199008163230705; YONEDA N, 1993, BLOOD, V82, P207, DOI 10.1182/blood.V82.1.207.bloodjournal821207	43	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1753	1759						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478603				2022-12-28	WOS:A1995TD09400010
J	MIRZAYANS, R; FAMULSKI, KS; ENNS, L; FRASER, M; PATERSON, MC				MIRZAYANS, R; FAMULSKI, KS; ENNS, L; FRASER, M; PATERSON, MC			CHARACTERIZATION OF THE SIGNAL-TRANSDUCTION PATHWAY MEDIATING GAMMA-RAY-INDUCED INHIBITION OF DNA-SYNTHESIS IN HUMAN-CELLS - INDIRECT EVIDENCE FOR INVOLVEMENT OF CALMODULIN BUT NOT PROTEIN-KINASE-C NOR P53	ONCOGENE			English	Article						RADIORESISTANT DNA SYNTHESIS; ATAXIA-TELANGIECTASIA; LI-FRAUMENI SYNDROME; CALMODULIN; PROTEIN KINASE C; P53	ATAXIA-TELANGIECTASIA CELLS; LI-FRAUMENI SYNDROME; WILD-TYPE P53; IONIZING-RADIATION; 4-NITROQUINOLINE 1-OXIDE; MUTANT P53; STAUROSPORINE; HYPERSENSITIVITY; COMPLEMENTATION; REPLICATION	Cultured cells from patients inheriting the rare cancer-prone and radiotherapy-sensitive disorder ataxia-telangiectasia (A-T) exhibit anomalies in cell. cycle control and protein kinase C (PKC)-mediated upregulation of p53 protein following exposure to ionizing radiation. It remains unclear, however, as to whether this irregularity in a p53-dependent signal transduction pathway controlling the G(1)/S checkpoint is causally linked to the most consistent molecular hallmark. of A-T - namely, marked attenuation in the inhibition of replicative DNA synthesis at early times (less than or equal to 2 h) after irradiation [radioresistant DNA synthesis (RDS)]. We report here that treatment of normal human fibroblast strains with inhibitors of calmodulin (CaM) (i.e. W7 and W13) and CaM-dependent protein kinases II and IV (i.e. KN62) prior to radiation exposure elicits an 'A-T-like' RDS phenotype, whereas treatment with PKC inhibitors (e.g. staurosporine) does not produce this response. Moreover, at 1 h post-gamma irradiation A-T fibroblasts undergo normal induction of p53 protein while exhibiting the RDS trait. At later times (e.g. 4 h) following irradiation, however, these A-T cells contain abnormally low levels of p53 protein, as do their lymphoblastoid cell line counterparts during the entire post-gamma ray incubation period. On the other hand, human cells which either lack the p53 gene completely (i.e. HL60 leukemia cells) or harbor a germline mutation in the gene (i.e. Li-Frauneni syndrome cells) shut down their DNA replication machinery normally upon sustaining radiation damage. We thus conclude that the transitory delay in DNA; synthesis routinely experienced by human cells in the face of radiation injury is mediated through a CaM-dependent regulatory cascade which involves neither PKC nor p53 protein. Accordingly, A-T cells appear to be malfunctional in at least two distinct radiation-responsive signalling pathways, one regulating the G(1)/S checkpoint and governed by p53 and PKC and another controlling passage through S phase and requiring CaM.	CROSS CANC INST,ONCOL MOLEC PROGRAM,EDMONTON,AB T6G 1Z2,CANADA; UNIV ALBERTA,DEPT ONCOL,EDMONTON,AB T6G 1Z2,CANADA	University of Alberta; University of Alberta			Famulski, Konrad/J-8685-2012					BACHS O, 1994, CELL CALCIUM, V16, P289, DOI 10.1016/0143-4160(94)90092-2; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; CHAFOULEAS JG, 1984, SCIENCE, V224, P1346, DOI 10.1126/science.6203171; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; CLEAVER JE, 1990, RADIAT RES, V124, P294, DOI 10.2307/3577842; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; GANGULY A, 1992, BIOCHEM BIOPH RES CO, V182, P254, DOI 10.1016/S0006-291X(05)80138-X; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; HANAWALT P, 1985, ATAXIA TELANGIECTASI, P67; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIDAKA H, 1979, MOL PHARMACOL, V15, P49; HIDAKA H, 1984, P NATL ACAD SCI USA, V78, P4354; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAMB JR, 1989, INT J RADIAT BIOL, V56, P125, DOI 10.1080/09553008914551271; LAVIN MF, 1993, NATO ASI SERIES H, V77, P235; LEHMANN AR, 1979, CANCER RES, V39, P4237; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARX J, 1994, SCIENCE, V266, P1321, DOI 10.1126/science.7973719; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MIRZAYANS R, 1989, CANCER RES, V49, P5523; MIRZAYANS R, 1991, CARCINOGENESIS, V12, P19, DOI 10.1093/carcin/12.1.19; MIRZAYANS R, 1995, 86TH ANN M AM ASS CA, P172; MURNANE JP, 1982, P NATL ACAD SCI-BIOL, V79, P1960, DOI 10.1073/pnas.79.6.1960; Murray A, 1993, CELL CYCLE INTRO; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OBRIAN CA, 1990, J NATL CANCER I, V82, P1734, DOI 10.1093/jnci/82.22.1734; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1986, INT J RADIAT BIOL, V49, P771; PALCIC B, 1990, BIOINSTRUMENTATION D, P923; PATERSON MC, 1994, 3RD MCGILL U C REG E; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SCHNEIDE.EL, 1974, EXP CELL RES, V84, P311, DOI 10.1016/0014-4827(74)90411-X; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SHUNG B, 1994, MUTAT RES, V307, P43, DOI 10.1016/0027-5107(94)90276-3; SRIVASTAVA S, 1993, ONCOGENE, V8, P2449; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; WANG Y, 1993, CANCER RES, V53, P1213; WRIGHT CD, 1986, BIOCHEM BIOPH RES CO, V135, P749, DOI 10.1016/0006-291X(86)90992-7; YOUNG BR, 1989, HUM GENET, V82, P113, DOI 10.1007/BF00284040; ZHUKOVSKAYA N, 1994, CARCINOGENESIS, V15, P2189, DOI 10.1093/carcin/15.10.2189	50	32	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1597	1605						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478584				2022-12-28	WOS:A1995TC53500018
J	JIANG, HP; LIN, J; YOUNG, SM; GOLDSTEIN, NI; WAXMAN, S; DAVILA, V; CHELLAPPAN, SP; FISHER, PB				JIANG, HP; LIN, J; YOUNG, SM; GOLDSTEIN, NI; WAXMAN, S; DAVILA, V; CHELLAPPAN, SP; FISHER, PB			CELL-CYCLE GENE-EXPRESSION AND E2F TRANSCRIPTION FACTOR COMPLEXES IN HUMAN-MELANOMA CELLS INDUCED TO TERMINALLY DIFFERENTIATE	ONCOGENE			English	Review						TERMINAL CELL DIFFERENTIATION; REVERSIBLE DIFFERENTIATION; HUMAN MELANOMA; E2F GROWTH ARREST COMPLEX; E2F TERMINAL DIFFERENTIATION COMPLEX	DNA POLYMERASE-DELTA; WILD-TYPE P53; PROTEIN-KINASE-C; MESSENGER-RNA; AUXILIARY PROTEIN; NUCLEAR ANTIGEN; S-PHASE; RETINOBLASTOMA PROTEIN; DOWN-REGULATION; F9 CELLS	Defects in cellular differentiation are a common occurrence in human cancers, The combination of recombinant human fibroblast interferon (IFN-beta) and the antileukemic compound mezerein (MEZ) results in an irreversible loss of proliferative capacity and terminal cell differentiation in H0-1 human melanoma cells, In contrast, either agent alone induces reversible growth arrest and/or specific components of the differentiation process without inducing terminal differentiation, The current study investigates changes in cell cycle, cell cycle gene expression and E2F transcription factor complex formation during the processes of reversible and irreversible (terminal) differentiation, Induction of both terminal differentiation and reversible differentiation (MEZ treatment) results in a temporal decrease in DNA synthesis and the percentage of cells in S phase and a decrease in the expression of cell cycle and growth regulated genes, including cdc2, cyclin A, cyclin B, histone H1, histone H4, nm23-H1, p53 and c-myc, Persistent gene expression changes occur in terminally differentiated cells, but not in reversibly differentiated cells, H0-1 cells contain several E2F binding activities, including uncomplexed E2F, an E2F-p107-cyclin A-cdk2 kinase complex and an Rb-E2F complex, Induction of growth arrest by MEZ results in a slow migrating gel-shift band that contains E2F associated with the pRb2/p130 protein. There is also a loss of the Rb-E2F complex. Induction of terminal differentiation after treatment with IFN-beta+MEZ generates a second pRb2/p130-E2F complex that migrates considerably faster than the pRb2/p130-E2F complex resulting from growth arrest, The slower migrating complex may contribute to growth arrest, whereas the faster migrating complex may play a role in terminal differentiation. Our results demonstrate that terminal cell differentiation involves a co-ordinate and continuous suppression of a number of cell cycle and growth related genes and results in the development of a novel E2F transcription factor complex not apparent in growth arrested and reversibly differentiated human melanoma cells.	COLUMBIA UNIV, COLL PHYS & SURG,CTR COMPREHENS CANC, INST CANC RES,DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG,CTR COMPREHENS CANC, INST CANC RES,DEPT UROL, NEW YORK, NY 10032 USA; IMCLONE SYST INC, DEPT IMMUNOL MONOCLONAL ANTIBODIES, NEW YORK, NY 10014 USA; MT SINAI MED CTR, DEPT MED, DIV MED ONCOL, NEW YORK, NY 10029 USA	Columbia University; Columbia University; Eli Lilly; Icahn School of Medicine at Mount Sinai					NATIONAL CANCER INSTITUTE [R01CA063136, R01CA035675] Funding Source: NIH RePORTER; NCI NIH HHS [CA63136, CA35675] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKHURST RJ, 1989, DIFFERENTIATION, V40, P36, DOI 10.1111/j.1432-0436.1989.tb00811.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BRAVO R, 1980, J CELL BIOL, V84, P795, DOI 10.1083/jcb.84.3.795; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CAROZZI N, 1984, SCIENCE, V224, P1115, DOI 10.1126/science.6719136; CELIS JE, 1987, FEBS LETT, V220, P1, DOI 10.1016/0014-5793(87)80865-7; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHELLAPPAN SP, 1994, MOL CELL DIFFER, V22, P201; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COLLART DG, 1988, J BIOL CHEM, V263, P15860; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143, DOI 10.1016/0163-7258(85)90067-1; FISHER PB, 1991, SERONO SYM, V82, P201; FISHER PB, 1988, PHARM EFFECTS LIPIDS, V3, P69; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAETANO C, 1991, CELL GROWTH DIFFER, V2, P487; GIOVANELLA BC, 1976, J NATL CANCER I, V56, P1131, DOI 10.1093/jnci/56.6.1131; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAHAM GM, 1991, CANCER IMMUNOL IMMUN, V32, P382, DOI 10.1007/BF01741333; GUARINI L, 1992, PIGM CELL RES, P123; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARPER JW, 1993, CELL, V75, P805; HASS R, 1993, CELL GROWTH DIFFER, V4, P159; HAYES TE, 1991, NEW BIOL, V3, P259; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1995, ONCOGENE, V10, P1855; JIANG HP, 1992, INT J ONCOL, V1, P227; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KEIM DR, 1993, CLIN EXP METASTAS, V11, P83, DOI 10.1007/BF00880069; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KIYOKAWA H, 1992, CELL GROWTH DIFFER, V3, P377; KIYOKAWA H, 1993, P NATL ACAD SCI USA, V90, P6746, DOI 10.1073/pnas.90.14.6746; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAYOL X, 1993, ONCOGENE, V8, P2561; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1992, SCIENCE, V258, P424; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; RICHON VM, 1989, ONCOGENE, V4, P165; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; Sang Nianli, 1995, Molecular and Cellular Differentiation, V3, P1; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHEN DW, 1993, P NATL ACAD SCI USA, V80, P5919; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEIN G S, 1992, Current Opinion in Cell Biology, V4, P166, DOI 10.1016/0955-0674(92)90028-B; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SU ZZ, 1991, MOL CARCINOGEN, V4, P231, DOI 10.1002/mc.2940040310; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; WHITMAN MM, 1990, CANCER RES, V50, P3193; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMASHIRO S, 1994, ONCOGENE, V9, P2461; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	102	55	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	1995	11	6					1179	1189						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566979				2022-12-28	WOS:A1995RX18000022
J	BEUG, H; DAHL, R; STEINLEIN, P; MEYER, S; DEINER, EM; HAYMAN, MJ				BEUG, H; DAHL, R; STEINLEIN, P; MEYER, S; DEINER, EM; HAYMAN, MJ			IN-VITRO GROWTH OF FACTOR-DEPENDENT MULTIPOTENTIAL HEMATOPOIETIC-CELLS IS INDUCED BY THE NUCLEAR ONCOPROTEIN V-SKI	ONCOGENE			English	Article						SKI; C-KIT; MULTIPOTENT PROGENITORS; HEMATOPOIESIS; CYTOKINES; STEROID HORMONES	AVIAN ERYTHROBLASTOSIS VIRUS; CHICKEN-EMBRYO FIBROBLASTS; PROGENITOR CELLS; STEM-CELLS; MONOCLONAL-ANTIBODIES; SELF-RENEWAL; ERYTHROID-DIFFERENTIATION; ONCOGENE; INVITRO; TRANSFORMATION	Understanding how self renewal, commitment and differentiation are regulated in normal, multipotent hematopoietic progenitors is important for our understanding of underlying mechanisms involved in leukemogenesis, In addition, knowledge of progenitor cell biology is critical if these cells are to be used far gene therapy, In this communication, we demonstrate that the oncogenic transcription factor v-Ski, together with the ligand activated receptor tyrosine kinase c-Kit, induces the continuous in vitro self renewal of primary avian multipotent progenitors, These cells have an in vitro life span of >100 generations, In addition they spontaneously differentiate into cells of the erythroid, monocytic and granulocytic lineages, If clonal strains of these multipotent progenitors are exposed to specific mixtures of growth factors and hormones, they develop into committed cells of either the erythroid or myeloid Lineages, These committed cells underwent efficient terminal differentiation when they were treated with the relevant lineage-specific growth/differentiation factors, but underwent apoptosis when exposed to the incorrect factors for the respective lineage, While the committed tells coexpress marker proteins from different lineages, expression of the 'wrong' lineage marker is repressed during terminal differentiation, Our results indicate that a combination of v-Ski and activated c-Kit induces long-term self renewal in primary multipotent progenitors, which can be induced to commit and differentiate along specific lineages under different, defined conditions, Our data also suggest that growth factors and steroid hormones control terminal differentiation by a combined induction of commitment, growth and apoptosis, a process likely to be affected in stem cell leukemias.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Dahl, Richard/0000-0002-6341-5604				BARKA T, 1962, J HISTOCHEM CYTOCHEM, V10, P741, DOI 10.1177/10.6.741; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1977, EXP CELL RES, V107, P417, DOI 10.1016/0014-4827(77)90363-9; BEUG H, 1994, IN PRESS METHODS ENZ; BROXMEYER HE, 1991, BLOOD, V77, P2142; CROWE AJ, 1991, J VIROL, V65, P2533, DOI 10.1128/JVI.65.5.2533-2538.1991; DALYOT N, 1993, NUCLEIC ACIDS RES, V21, P4031, DOI 10.1093/nar/21.17.4031; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GRAF T, 1978, NATURE, V275, P496, DOI 10.1038/275496a0; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HAYMAN MJ, 1982, J CELL BIOCHEM, V18, P351, DOI 10.1002/jcb.1982.240180308; HEBERLEIN C, 1992, MOL CELL BIOL, V12, P1815, DOI 10.1128/MCB.12.4.1815; KAMPS MP, 1988, ONCOGENE, V2, P305; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; KRAUT N, 1994, GENE DEV, V8, P33, DOI 10.1101/gad.8.1.33; LARSEN J, 1992, ONCOGENE, V7, P1903; LARSEN J, 1993, ONCOGENE, V8, P3221; LEUTZ A, 1989, EMBO J, V8, P175, DOI 10.1002/j.1460-2075.1989.tb03362.x; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; NAMCIU S, 1994, ONCOGENE, V9, P1407; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPANGRUDE GJ, 1991, BLOOD, V78, P1395; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; SPOONCER E, 1984, NATURE, V310, P228, DOI 10.1038/310228a0; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	40	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					59	72						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624132				2022-12-28	WOS:A1995RJ29500008
J	JAATTELA, M; BENEDICT, M; TEWARI, M; SHAYMAN, JA; DIXIT, VM				JAATTELA, M; BENEDICT, M; TEWARI, M; SHAYMAN, JA; DIXIT, VM			BCL-X AND BCL-2 INHIBIT TNF AND FAS-INDUCED APOPTOSIS AND ACTIVATION OF PHOSPHOLIPASE A(2) IN BREAST-CARCINOMA CELLS	ONCOGENE			English	Article						CELL DEATH; CERAMIDE; FAS; TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION	TUMOR-NECROSIS-FACTOR; FACTOR-MEDIATED CYTOTOXICITY; MOLECULAR-CLONING; FACTOR-ALPHA; MONOCLONAL-ANTIBODY; CYTO-TOXICITY; EXPRESSION; RECEPTOR; PROTEIN; DEATH	Tumor necrosis factor (TNF) induces cell death in several tumor cell lines by undefined mechanisms. Using a cDNA expression cloning strategy we identified two cDNAs that completely inhibit the TNF-induced death pathway in MCF7 breast carcinoma cells. These cDNAs encoded for Bcl-2 and Bcl-x. To compare the cytotoxic signal transduction pathway induced by the TNF receptor versus that induced by Fas, we transfected MCF7 cells with a Fas expression construct. The resulting cell line, MCF-Fas, was highly sensitive to cytotoxicity induced by TNF or anti-Fas. Expression of either bcl-2 or bcl-x in these cells rendered them completely resistant to lysis induced by either TNF or Pas. Interestingly, exposure of MCF-Pas cells to anti-Fas or TNF induced activation of phospholipase A(2) (PLA(2)), while only TNF activated NF-kappa B. Activation of PLA(2) was completely blocked whereas activation of NF-kappa B was unaffected by overexpression of either bcl-x or bcl-2. Moreover, PLA(2)-inhibitors, quinacrine and dexamethasone, partially inhibited cytotoxicity induced by either TNF or anti-Pas. These data suggest an involvement of PLA(2) in both TNF- and Fas-mediated cytotoxicity and a novel mechanism of action for bcl-2 and bcl-x, i.e. inhibition of arachidonic acid metabolism, by which they may, in addition of apoptosis, modulate inflammation.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	JAATTELA, M (corresponding author), DANISH CANC SOC,RES CTR,DEPT TUMOR CELL BIOL,DK-2100 COPENHAGEN,DENMARK.		Jäättelä, Marja/AAT-7932-2021; dixit, vishva m/A-4496-2012	Jäättelä, Marja/0000-0001-5950-7111; dixit, vishva m/0000-0001-6983-0326				BETTS JC, 1994, J BIOL CHEM, V269, P8455; BOISE LH, 1993, CELL, V744, P597; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CIFONE MG, 1993, J EXP MED, V177, P1547; EICHEN CM, 1994, J IMMUNOL, V153, P1947; HASHIZUME T, 1991, ARCH BIOCHEM BIOPHYS, V289, P47, DOI 10.1016/0003-9861(91)90440-T; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HENNET T, 1993, CANCER RES, V53, P1456; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAATTELA M, 1991, LAB INVEST, V64, P724; JAATTELA M, 1991, LYMPHOKINE CYTOK RES, V10, P119; JAATTELA M, 1989, EUR J IMMUNOL, V19, P1413, DOI 10.1002/eji.1830190810; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; JAATTELA M, 1993, J IMMUNOL, V151, P4286; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KNAUER MF, 1990, J CELL PHYSIOL, V142, P469, DOI 10.1002/jcp.1041420305; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; KRASNOW SW, 1991, CYTOKINE, V3, P372, DOI 10.1016/1043-4666(91)90040-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASTER SM, 1988, J IMMUNOL, V141, P2629; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NEALE ML, 1988, IMMUNOLOGY, V64, P81; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; PREISS J, 1986, J BIOL CHEM, V261, P8597; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; SALGO MG, 1993, ARCH BIOCHEM BIOPHYS, V304, P123, DOI 10.1006/abbi.1993.1330; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	60	299	307	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2297	2305						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7540278				2022-12-28	WOS:A1995RE54300004
J	BURGAYA, F; GARCIAFERNANDEZ, J; RIUTORT, M; BAGUNA, J; SALO, E				BURGAYA, F; GARCIAFERNANDEZ, J; RIUTORT, M; BAGUNA, J; SALO, E			STRUCTURE AND EXPRESSION OF SPK-1, AN SRC-RELATED GENE-PRODUCT FOUND IN THE PLANARIAN DUGESIA-(G)-TIGRINA	ONCOGENE			English	Note							PROTEIN-TYROSINE KINASE; SIGNAL TRANSDUCTION; PATTERN-FORMATION; SEQUENCE-ANALYSIS; FAMILY; DOMAIN; REGENERATION; NEOBLASTS; PHYLOGENY; RNAS	A cDNA clone encoding a 497 amino acid protein 75% similar to most Src proteins has been isolated from the planarian Dugesia (Girardia) tigrina (Platyhelminthes; Turbellaria) by PCR followed by screening procedures. This gene product has been designated Spk-1 as it is the first Src-related kinase isolated in a planarian. The predicted amino acid sequence of Spk-1 suggest that it is anchored to the plasma membrane and that it interacts with other phosphotyrosine proteins. Spk-1 is expressed in both intact and regenerating organisms as an mRNA transcript of about 1.9 kb. Planarians, which conserve most features of the common ancestor to protostomian and deuterostomian phyla, are the most primitive triploblastic organisms from which a protein tyrosine kinase gene product has been isolated. The presence of this gene product in such a primitive organism, and its presumed role, are discussed.	UNIV BARCELONA,FAC BIOL,DEPT GENET,DIAGONAL 645,E-08028 BARCELONA,SPAIN	University of Barcelona			Salo, Emili/M-3928-2014; Garcia-Fernandez, Jordi/B-3839-2013; Riutort, Marta/B-6441-2009	Salo, Emili/0000-0001-5460-9223; Garcia-Fernandez, Jordi/0000-0001-5677-5970; Riutort, Marta/0000-0002-2134-7674				BAGUNA J, 1981, NATURE, V290, P14, DOI 10.1038/290014b0; BAGUNA J, 1989, DEVELOPMENT, V107, P77; BAGUNA J, 1990, EXPT EMBRYOLOGY AQUA, P129; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BERGSTROM L, 1987, MOL PHARMACOL, V32, P764; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; BUSS JE, 1988, MOL CELL BIOL, V8, P3960, DOI 10.1128/MCB.8.9.3960; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GALLIOT B, 1993, TRENDS GENET, V9, P3, DOI 10.1016/0168-9525(93)90051-I; GARCIAFERNANDEZ J, 1993, DEVELOPMENT, V118, P241; GARCIAFERNANDEZ J, 1991, P NATL ACAD SCI USA, V88, P7338, DOI 10.1073/pnas.88.16.7338; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; Karlstedt K.A., 1990, Acta Academiae Aboensis Ser B Mathematica et Physica Matematik Naturvetenskaper Teknik, V50, P59; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OTTILIE S, 1992, ONCOGENE, V7, P1625; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1992, NATURE, V356, P285, DOI 10.1038/356285a0; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RIDLEY AJ, 1992, NATURE, V355, P497, DOI 10.1038/355497a0; RIUTORT M, 1992, CAN J ZOOL, V70, P1425, DOI 10.1139/z92-199; SALO E, 1984, J EMBRYOL EXP MORPH, V83, P63; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; STERNBERG PW, 1991, TRENDS GENET, V7, P366, DOI 10.1016/0168-9525(91)90257-Q; Willmer P., 1990, INVERTEBRATE RELATIO	36	7	10	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1267	1272						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	7510865				2022-12-28	WOS:A1994NC04800033
J	MAISONPIERRE, PC; BARREZUETA, NX; YANCOPOULOS, GD				MAISONPIERRE, PC; BARREZUETA, NX; YANCOPOULOS, GD			EHK-1 AND EHK-2 - 2 NOVEL MEMBERS OF THE EPH RECEPTOR-LIKE TYROSINE KINASE FAMILY WITH DISTINCTIVE STRUCTURES AND NEURONAL EXPRESSION	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; CENTRAL-NERVOUS-SYSTEM; CONSERVED FEATURES; MOLECULAR-CLONING; PROTEIN-KINASES; TRK FAMILY; C-KIT; GENE; IDENTIFICATION; CELLS	We have identified two novel members of the Eph RTK family, termed Ehk (eph homology kinase) -1 and -2. Compared to the amino acid sequences of various Eph family members, Ehk-1 and Ehk-2 are closest to the Sek and Cek-4/Mek-4/Hek kinases, and both are more similar to the Elk kinase than they are to the Eck or Eph kinases. Analysis of Ehk-1 cDNAs from various brain libraries reveals alternatively spliced transcripts: that can encode five different forms of Ehk-1 transmembrane proteins. By contrast, Ehk-2 cDNAs revealed only a single form of protein coding region. However, the structure of Ehk-2 differs from all known members of the Eph family based on a 42 amino acid insert positioned between homology regions IV and V in the kinase domain. Ehk-1 and Ehk-2 are almost exclusively expressed in the nervous system. RNA in situ hybridization analyses on adult brain show that the Ehks are predominantly expressed in neurons and display overlapping, but distinct patterns of expression in various neuronal populations.			MAISONPIERRE, PC (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOYD AW, 1992, J BIOL CHEM, V267, P3262; Brownstein MJ, 1984, HDB CHEM NEUROANAT 1, P23; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHAN J, 1991, ONCOGENE, V6, P1057; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAUB O, 1990, P NATL ACAD SCI USA, V87, P8022, DOI 10.1073/pnas.87.20.8022; Hefti F., 1993, NEUROTROPHIC FACTORS, P25; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUGHES RA, 1993, NEURON, V10, P369, DOI 10.1016/0896-6273(93)90327-N; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LINDSAY RM, 1993, NEUROTROPHIC FACTORS, P257; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOTRO B, 1991, DEVELOPMENT, V113, P1207; Nei M., 1987, MOL EVOLUTIONARY GEN; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; SAJJADI FG, 1991, NEW BIOL, V3, P769; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	101	118	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3277	3288						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	7504232				2022-12-28	WOS:A1993MG78200011
J	BIRCHENALLROBERTS, MC; ENGELMANN, GL; KELLER, JR; LOHREY, N; RUSCETTI, FW				BIRCHENALLROBERTS, MC; ENGELMANN, GL; KELLER, JR; LOHREY, N; RUSCETTI, FW			RETROVIRAL V-MYC INFECTION OF PRIMARY FETAL LIVER-CELLS - TRANSFORMATION OF MONOCYTES INVITRO	ONCOGENE			English	Article									CLEVELAND CLIN FDN,RES INST,DEPT HEART & HYPERTENS,CLEVELAND,OH 44195; NCI,FREDERICK CANC RES FACIL,PROGRAM RESOURCES INC,BIOL CARCINOGENESIS DEV PROGRAM,FREDERICK,MD 21701	Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	BIRCHENALLROBERTS, MC (corresponding author), NCI,FREDERICK CANC RES FACIL,DIV CANC TREATMENT,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21701, USA.		Keller, Jonathan R./O-6677-2018		OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DALLAFAVERA R, 1982, NATURE, V299, P61; FALTYNEK CR, 1988, J BIOL CHEM, V263, P7112; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MINNA JD, 1986, COLD SPRING HARB SYM, V51, P843, DOI 10.1101/SQB.1986.051.01.098; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MULLER R, 1984, EMBO J, V3, P1887, DOI 10.1002/j.1460-2075.1984.tb02063.x; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; REIN A, 1985, MOL CELL BIOL, V5, P2257, DOI 10.1128/MCB.5.9.2257; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUSCETTI FW, 1986, J IMMUNOL, V136, P3619; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	25	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					731	735						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2786619				2022-12-28	WOS:A1989AA66000009
J	ZEILLINGER, R; KURY, F; CZERWENKA, K; KUBISTA, E; SLIUTZ, G; KNOGLER, W; HUBER, J; ZIELINSKI, C; REINER, G; JAKESZ, R; STAFFEN, A; REINER, A; WRBA, F; SPONA, J				ZEILLINGER, R; KURY, F; CZERWENKA, K; KUBISTA, E; SLIUTZ, G; KNOGLER, W; HUBER, J; ZIELINSKI, C; REINER, G; JAKESZ, R; STAFFEN, A; REINER, A; WRBA, F; SPONA, J			HER-2 AMPLIFICATION, STEROID-RECEPTORS AND EPIDERMAL GROWTH-FACTOR RECEPTOR IN PRIMARY BREAST-CANCER	ONCOGENE			English	Article									VIENNA UNIV,DEPT OBSTET & GYNECOL 1,A-1090 VIENNA,AUSTRIA; VIENNA UNIV,DEPT SURG 2,A-1090 VIENNA,AUSTRIA; VIENNA UNIV,LUDWIG BOLTZMANN INST PRENATAL & EXPTL GENOME ANAL,A-1090 VIENNA,AUSTRIA; VIENNA UNIV,DEPT SURG 1,A-1090 VIENNA,AUSTRIA; VIENNA UNIV,DEPT PATHOL,A-1090 VIENNA,AUSTRIA; VIENNA UNIV,DEPT INTERNAL MED 2,A-1090 VIENNA,AUSTRIA	University of Vienna; University of Vienna; Ludwig Boltzmann Institute; University of Vienna; University of Vienna; University of Vienna; University of Vienna				Zeillinger, Robert/0000-0001-6771-4591				ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BERGER MS, 1988, CANCER RES, V48, P1238; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK GM, 1983, NEW ENGL J MED, V309, P1343, DOI 10.1056/NEJM198312013092240; CLINE MJ, 1987, J CLIN ONCOL, V5, P999, DOI 10.1200/JCO.1987.5.7.999; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIZIKES GJ, 1986, BIOCHEM BIOPH RES CO, V141, P53, DOI 10.1016/S0006-291X(86)80333-3; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; GRILL HJ, 1984, ONCOLOGY, V41, P25, DOI 10.1159/000225785; HAHNEL R, 1979, CANCER, V44, P671, DOI 10.1002/1097-0142(197908)44:2<671::AID-CNCR2820440238>3.0.CO;2-V; HILF R, 1980, CANCER-AM CANCER SOC, V45, P1993, DOI 10.1002/1097-0142(19800415)45:8<1993::AID-CNCR2820450802>3.0.CO;2-2; JAKESZ R, 1979, CANCER TREAT REP, V63, P1191; JAKESZ R, 1981, 17TH P ANN M AM SOC, V22, P150; KIANG DT, 1978, NEW ENGL J MED, V299, P1330, DOI 10.1056/NEJM197812142992403; KNIGHT WA, 1977, CANCER RES, V37, P4669; MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428; REINER A, 1986, AM J PATHOL, V125, P443; REINER A, 1987, J CANCER RES CLIN, V113, P285, DOI 10.1007/BF00396387; REINER G, 1988, DEUT MED WOCHENSCHR, V113, P892, DOI 10.1055/s-2008-1067739; SAINSBURY JRC, 1987, LANCET, V1, P1398; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPONA J, 1983, CANCER DETECT PREV, V6, P227; STULLER I, 1987, ONKOLOGIE, V10, P302, DOI 10.1159/000216427; VARLEY JM, 1988, ONCOGENE, V3, P87; VIJVER M, 1987, MOL CELL BIOL, V7, P2019; VIJVER M, 1988, EUR J SURG ONCOL, V14, P111; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WRBA F, 1988, PATHOL RES PRACT, V183, P277, DOI 10.1016/S0344-0338(88)80122-5; YAMOMOTO T, 1986, NATURE, V319, P230; ZHOU DJ, 1988, ONCOGENE, V2, P279; ZIELINSKI CC, 1985, WIEN KLIN WOCHENSCHR, V97, P493; ZIELINSKI CC, 1986, LANCET, V1, P1164	41	172	174	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					109	114						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2915900				2022-12-28	WOS:A1989U567400017
J	FALCO, JP; TAYLOR, WG; DIFIORE, PP; WEISSMAN, BE; AARONSON, SA				FALCO, JP; TAYLOR, WG; DIFIORE, PP; WEISSMAN, BE; AARONSON, SA			INTERACTIONS OF GROWTH-FACTORS AND RETROVIRAL ONCOGENES WITH MITOGENIC SIGNAL TRANSDUCTION PATHWAYS OF BALB/MK KERATINOCYTES	ONCOGENE			English	Article									NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1E24,BETHESDA,MD 20892; CHILDRENS HOSP LOS ANGELES,LOS ANGELES,CA 90027	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Children's Hospital Los Angeles			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950	NCI NIH HHS [R01 CA36936, R01 CA39602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036936, R01CA039602] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1970, VIROLOGY, V42, P9, DOI 10.1016/0042-6822(70)90233-3; AARONSON SA, 1978, J VIROL, V27, P366, DOI 10.1128/JVI.27.2.366-373.1978; AKIYAMA SK, 1987, ADV ENZYMOL RAMB, V59, P1; ANDERSEN PR, 1981, CELL, V26, P129, DOI 10.1016/0092-8674(81)90041-6; BARNES D, 1980, CELL, V22, P649, DOI 10.1016/0092-8674(80)90540-1; BERTOLERO F, 1984, EXP CELL RES, V155, P64, DOI 10.1016/0014-4827(84)90768-7; BOTTENSTEIN JE, 1980, EXP CELL RES, V129, P361, DOI 10.1016/0014-4827(80)90504-2; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DIFIORE PP, 1988, MOL CELL BIOL, V8, P557, DOI 10.1128/MCB.8.2.557; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; ETHIER SP, 1987, CANCER RES, V47, P5316; GAZIT A, 1986, J VIROL, V60, P19, DOI 10.1128/JVI.60.1.19-28.1986; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HILL DJ, 1985, PEDIATR RES, V19, P879, DOI 10.1203/00006450-198509000-00001; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIRSTEN WH, 1967, J NATL CANCER I, V39, P311; KOHN CR, 1985, ANNU REV MED, V36, P429; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MCKEEHAN WL, 1976, J CELL BIOL, V71, P727, DOI 10.1083/jcb.71.3.727; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; Pledger W. J., 1984, MAMMALIAN CELL CULTU, P1, DOI 10.1007/978-1-4615-9361-4_1; PORZIG KJ, 1979, VIROLOGY, V92, P91, DOI 10.1016/0042-6822(79)90217-4; RISS TL, 1987, CANCER RES, V47, P3776; ROVERA G, 1987, ONCOGENE, V1, P29; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SMITH HS, 1971, VIROLOGY, V44, P359, DOI 10.1016/0042-6822(71)90267-4; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; TEMIN HOWARD M., 1967, WISTAR INST SYMP MONOGR, V7., P103; UHLRICH S, 1986, BIOCHEM BIOPH RES CO, V137, P1205, DOI 10.1016/0006-291X(86)90353-0; UNDERWOOD LE, 1986, CLIN ENDOCRINOL META, V15, P59, DOI 10.1016/S0300-595X(86)80042-1; WANG LH, 1987, P NATL ACAD SCI USA, V84, P5725, DOI 10.1073/pnas.84.16.5725; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	51	60	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					573	578						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	3290805				2022-12-28	WOS:A1988N841500007
J	JUNG, JM; BRUNER, JM; RUAN, SB; LANGFORD, LA; KYRITSIS, AP; KOBAYASHI, T; LEVIN, VA; ZHANG, W				JUNG, JM; BRUNER, JM; RUAN, SB; LANGFORD, LA; KYRITSIS, AP; KOBAYASHI, T; LEVIN, VA; ZHANG, W			INCREASED LEVELS OF P21(WAF1/CIP1) IN HUMAN BRAIN-TUMORS	ONCOGENE			English	Article						GLIOMA; P21(WAF1/CIP1); CELL CYCLE; IMMUNOHISTOCHEMISTRY	HUMAN GLIOMAS; AMPLIFICATION; GENE; EXPRESSION; RECEPTORS	The cdk inhibitor p21(WAF1/Cip1) (p21), which can be transcriptionally activated by p53, functions to block cell cycle progression. In this study, we analysed the expression of p21 in normal and reactive brain and in gliomas of various malignancy grades. Southern blotting showed no p21 gene deletion. Western blotting and immunohistochemical assay showed that the levels of p21 protein in normal and reactive brain tissue were very low; however, p21 was elevated in a majority of gliomas tested, regardless of their malignancy grades. In glioblastoma multiforme, marked elevation of p21 was observed in samples harboring either wild-type or mutant p53. But, in anaplastic astrocytomas, the level of p21 was not elevated in samples harboring mutant-type p53. Immunohistochemical staining of paraffin-embedded astrocytomas and glioblastomas showed that tumor cells and not contaminating normal cells were positive for p21. Therefore, overexpression of p21 appears to be an early event in the development of glial neoplasms and p53-dependent p21 expression appears to be tumor grade specific.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [P01CA055261] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 55261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLO MJ, 1994, GENE CHROMOSOME CANC, V9, P33; CHOZICK BS, 1994, CANCER, V73, P406, DOI 10.1002/1097-0142(19940115)73:2<406::AID-CNCR2820730228>3.0.CO;2-S; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FLEMING TP, 1992, CANCER RES, V52, P4550; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; JEN J, 1994, CANCER RES, V54, P6353; JUNG JM, 1995, CELL GROWTH DIFFER, V6, P909; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KORNBLAU SM, 1994, BLOOD, V84, P256; KUN LE, 1994, MOSS RAD ONCOLOGY RA, P737; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LI YJ, 1995, ONCOGENE, V10, P599; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LOUIS DN, 1994, J NEUROPATH EXP NEUR, V53, P11, DOI 10.1097/00005072-199401000-00002; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; MORRISON RS, 1990, CANCER RES, V50, P2524; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PATCHELL RA, 1992, CHEMOTHERAPY SOURCE, P908; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; Russell D., 1989, PATHOLOGY TUMORS NER; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; VAN MEIR EG, 1994, CANCER RES, V54, P649; VANMEYEL DJ, 1994, JNCI-J NATL CANCER I, V86, P1011, DOI 10.1093/jnci/86.13.1011; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WRANN M, 1987, EMBO J, V6, P1633, DOI 10.1002/j.1460-2075.1987.tb02411.x; YUNG WKA, 1990, CANCER COMMUN, V2, P201, DOI 10.3727/095535490820874416; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, LEUKEMIA LYMPHOMA, V16, P191, DOI 10.3109/10428199509049757; Zhang W, 1995, CLIN CANCER RES, V1, P1051; ZHANG W, 1995, CANCER RES, V55, P668	41	162	166	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2021	2028						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478521				2022-12-28	WOS:A1995TF29700012
J	SHEIKH, MS; ROCHEFORT, H; GARCIA, M				SHEIKH, MS; ROCHEFORT, H; GARCIA, M			OVEREXPRESSION OF P21(WAF1/CIP1) INDUCES GROWTH ARREST, GIANT-CELL FORMATION AND APOPTOSIS IN HUMAN BREAST-CARCINOMA CELL-LINES	ONCOGENE			English	Note						TRANSFECTION; APOPTOSIS; GROWTH SUPPRESSION; BREAST CARCINOMA	SUPPRESSION; KINASES	The p21(WAF1/CIP1) protein was shown to be a critical downstream effector of p53 and a potent inhibitor of cyclin-dependent kinases. We investigated the effects of exogenous p21(WAF1/CIP1) in two different human breast carcinoma (HBC) cell lines MCF-7 and T47D, p21(WAF1/CIP1) transfected cells formed significantly reduced number of drug-resistant colonies than their mock-transfected counterparts, The majority of the p21(WAF1/CIP1) transfected MCF-7 cells acquired 50-100-fold increase in their sizes and persisted as single giant cells for several days without cell division, while the remainder underwent nuclear division (multiple nuclei) but were unable to complete cytokinesis, and finally all succumbed to apoptosis, Only few p21(WAF1/CIP1) transfected T47D cells displayed increase in their sizes while a number of them formed small sized drug-resistant colonies which diminished in size due to cell death, The cells in these shrinking colonies exhibited characteristic signs of apoptosis such as chromatin condensation and fragmented nuclei while their membrane integrity was preserved, Thus in HBC cell lines the growth suppression due to enforced overexpression of p21(WAF1/CIP1) is associated with giant cell formation and apoptosis.	UNIV MONTPELLIER 1, FAC MED, F-34090 MONTPELLIER, FRANCE	Universite de Montpellier	SHEIKH, MS (corresponding author), INSERM, U148, 60 RUE NAVACELLES, F-34090 MONTPELLIER, FRANCE.							CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CASEY G, 1991, ONCOGENE, V6, P1791; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; Isaacs John T., 1994, Current Opinion in Oncology, V6, P82, DOI 10.1097/00001622-199401000-00012; MIYASHITA T, 1994, ONCOGENE, V9, P1799; REED SI, 1994, J CELL SCI, P69; SHAO ZM, 1995, ONCOGENE, V11, P493; SHEIKH MS, 1994, ONCOGENE, V9, P3407; STEINMAN RA, 1994, ONCOGENE, V9, P3389; VOJTESEK B, 1993, J CELL SCI, V105, P607; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668	18	182	187	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	1995	11	9					1899	1905						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478620				2022-12-28	WOS:A1995TD09400027
J	STUART, AD; STEWART, JP; ARRAND, JR; MACKETT, M				STUART, AD; STEWART, JP; ARRAND, JR; MACKETT, M			THE EPSTEIN-BARR-VIRUS ENCODED CYTOKINE VIRAL INTERLEUKIN-10 ENHANCES TRANSFORMATION OF HUMAN B-LYMPHOCYTES	ONCOGENE			English	Article						EPSTEIN-BARR VIRUS; TRANSFORMATION; VIRAL INTERLEUKIN-10 VIABILITY; INTERFERON-GAMMA	INTERFERON-GAMMA; IN-VITRO; T-CELL; INFECTION; EXPRESSION; BLOOD; LEUKOCYTES; REGION	In vitro infection of human B lymphocytes with Epstein-Barr virus (EBV) results in their growth transformation and establishment of immortalised lymphoblastoid cell lines, The virus was recently found to encode homologue of the pleitropic cytokine interleukin-10 (IL-10), which has wide ranging effects on the immune system, We have investigated the effect of this virally encoded growth factor on the ability of EBV to immortalize B lymphocytes from tonsils and from adult and neonatal blood, Recombinant viral interleukin-10 (vIL-10) was found to increase dramatically the growth transformation of B cells from all three populations infected with either the highly transforming type 1 strain B95-8 or the less efficient type 2 strain BL16, This striking enhancement of transforming ability in the presence of viral ILIO may be in part due to increased viability of the B cells during infection and decreased levels of interferon-gamma, a cytokine known to inhibit EBV transformation, Thus viral 1L-10 influences a number of cell types of the immune system to allow the enhanced outgrowth of EBV transformed cells.	UNIV EDINBURGH,ROYAL DICK SCH VET STUDIES,DEPT VET PATHOL,EDINBURGH EH9 1QH,MIDLOTHIAN,SCOTLAND	University of Edinburgh	STUART, AD (corresponding author), CHRISTIE HOSP NATL HLTH SERV TRUST,PATERSON INST CANC RES,DEPT MOLEC BIOL,WILMSLOW RD,MANCHESTER M20 9BX,LANCS,ENGLAND.		Stewart, James/A-6034-2012	Stewart, James/0000-0002-8928-2037				ADLDINGER HK, 1985, VIROLOGY, V14, P221; ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; ARRAND JR, 1989, J VIROL, V63, P983, DOI 10.1128/JVI.63.2.983-986.1989; BURDIN N, 1993, J EXP MED, V177, P295, DOI 10.1084/jem.177.2.295; CAYROL C, 1995, J VIROL, V69, P4206, DOI 10.1128/JVI.69.7.4206-4212.1995; De The G, 1980, VIRAL ONCOLOGY, P769; Geser A., 1983, EUR J CANCER CLIN ON, V19, P1394; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; GOSSELIN J, 1991, EUR J IMMUNOL, V21, P203, DOI 10.1002/eji.1830210130; HENLE G, 1979, EPSTEIN BARR VIRUS, P257; HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142; HUDSON GS, 1985, VIROLOGY, V147, P81, DOI 10.1016/0042-6822(85)90229-6; KIEFF E, 1990, VIROLOGY, P1889; KRUSE A, 1993, J INTERFERON RES, V13, P221, DOI 10.1089/jir.1993.13.221; LENOIR GM, 1985, IARC SCI PUBL, V60, P309; LOTZ M, 1985, EUR J IMMUNOL, V15, P520, DOI 10.1002/eji.1830150518; MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383; MIYAZAKI I, 1993, J EXP MED, V178, P439, DOI 10.1084/jem.178.2.439; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOSS DJ, 1972, J GEN VIROL, V17, P233, DOI 10.1099/0022-1317-17-2-233; MUELLER N, 1989, NEW ENGL J MED, V320, P689, DOI 10.1056/NEJM198903163201103; NAKAGOMI H, 1994, INT J CANCER, V57, P240, DOI 10.1002/ijc.2910570218; POPE JH, 1968, INT J CANCER, V3, P857, DOI 10.1002/ijc.2910030619; PURTILO DT, 1981, CANCER RES, V41, P4226; RICKINSON AB, 1975, NATURE, V258, P236, DOI 10.1038/258236a0; RICKINSON AB, 1987, J VIROL, V61, P1310, DOI 10.1128/JVI.61.5.1310-1317.1987; RONCAROLO MG, 1994, BLOOD CELLS, V20, P573; ROWE M, 1989, J VIROL, V63, P1031, DOI 10.1128/JVI.63.3.1031-1039.1989; Sambrook J, 1989, MOL CLONING LABORATO; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; STEWART JP, 1992, VIROLOGY, V191, P773, DOI 10.1016/0042-6822(92)90253-L; STEWART JP, 1994, VIROLOGY, V200, P724, DOI 10.1006/viro.1994.1236; SWAMINATHAN S, 1993, J VIROL, V97, P7406; TAGA K, 1993, INT IMMUNOL, V5, P1599, DOI 10.1093/intimm/5.12.1599; THORLEYLAWSON DA, 1981, J IMMUNOL, V126, P829; TIERNEY RJ, 1994, J VIROL, V68, P7374, DOI 10.1128/JVI.68.11.7374-7385.1994; WALLS EV, 1987, LYMPHOCYTES PRACTICA, P149; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; WHITTINGHAM S, 1993, IMMUNOL CELL BIOL, V71, P259, DOI 10.1038/icb.1993.30; WIENER MS, 1973, BLOOD, V42, P939; WRIGHTHAM MN, 1995, IN PRESS VIROLOGY	42	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1711	1719						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478598				2022-12-28	WOS:A1995TD09400005
J	MALIK, KTA; WALLACE, JI; IVINS, SM; BROWN, KW				MALIK, KTA; WALLACE, JI; IVINS, SM; BROWN, KW			IDENTIFICATION OF AN ANTISENSE WT1 PROMOTER IN INTRON-1 - IMPLICATIONS FOR WT1 GENE-REGULATION	ONCOGENE			English	Article						WT1 AUTOREGULATION; ANTISENSE PROMOTER	WILMS-TUMOR GENE; FACTOR-A-CHAIN; GROWTH-FACTOR; GENITOURINARY DEVELOPMENT; TRANSCRIPTION FACTORS; GENOMIC ORGANIZATION; UROGENITAL SYSTEM; SUPPRESSOR WT1; EXPRESSION; DELETION	Expression of the Wilms' tumour suppressor gene, WT1, is tightly regulated during nephrogenesis, and loss of function of its gene product correlates with malignancy. By using luciferase reporter gene constructs containing DNA sequences from the first intron of the WT1 gene, we have identified an antisense WT1 promoter operational in the opposite direction relative to the 5' promoter. Transcription directed by the promoter is negatively regulated by upstream elements, but is activated by expression of WT1. This effect of WT1 is reciprocal to that observed on the 5' promoter, suggesting that antisense promoter activity is involved in WT1 gene regulation. By mimicking expression of the transcript regulated by the antisense promoter, we demonstrate that cellular levels of WT1 can be effectively down-regulated by antisense mRNA complementary to sequences in the first exon of WT1.			MALIK, KTA (corresponding author), UNIV BRISTOL, SCH MED SCI, DEPT PATHOL & MICROBIOL, CLIC RES UNIT, UNIV WALK, BRISTOL BS8 1TD, AVON, ENGLAND.		Brown, Keith/C-3355-2009	Brown, Keith/0000-0002-4258-5129; Malik, Karim/0000-0002-8965-200X				BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BENNINGTON JL, 1975, ATLAS TUMOR PATHOLOG; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; BRENNER B, 1992, ONCOGENE, V7, P1431; BROWN KW, 1992, ONCOGENE, V7, P763; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAMPBELL CE, 1994, ONCOGENE, V9, P583; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; COWELL JK, 1991, ONCOGENE, V6, P595; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ECCLES MR, 1994, ONCOGENE, V9, P2059; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P277, DOI 10.1093/nar/23.2.277; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; Hastie Nicholas D., 1992, Human Molecular Genetics, V1, P293; HILDEBRANDT M, 1992, CELL, V69, P197, DOI 10.1016/0092-8674(92)90130-5; HOFMANN W, 1993, ONCOGENE, V8, P3123; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, AM J HUM GENET, V48, P997; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; MALIK KTA, 1994, FEBS LETT, V349, P75, DOI 10.1016/0014-5793(94)00642-3; MATSUNAGA E, 1981, HUM GENET, V57, P231; MIWA H, 1992, LEUKEMIA, V6, P405; MIYAGI T, 1993, LEUKEMIA, V7, P970; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROYERPOKORA B, 1991, GENE CHROMOSOME CANC, V3, P89, DOI 10.1002/gcc.2870030203; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; Sambrook J., 1989, MOL CLONING, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA PM, 1992, CANCER RES, V52, P6407; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; TADOKORO K, 1992, JPN J CANCER RES, V83, P1198, DOI 10.1111/j.1349-7006.1992.tb02745.x; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1995, ONCOGENE, V10, P1243; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709; WOODRUFF KA, 1995, ONCOGENE, V10, P1335; YEGER H, 1992, CELL GROWTH DIFFER, V3, P855	56	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1589	1595						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478583				2022-12-28	WOS:A1995TC53500017
J	GAO, X; ZACHAREK, A; GRIGNON, DJ; SAKR, W; POWELL, IJ; PORTER, AT; HONN, KV				GAO, X; ZACHAREK, A; GRIGNON, DJ; SAKR, W; POWELL, IJ; PORTER, AT; HONN, KV			LOCALIZATION OF POTENTIAL TUMOR-SUPPRESSOR LOCI TO A LESS-THAN-2 MB REGION ON CHROMOSOME 17Q IN HUMAN PROSTATE-CANCER	ONCOGENE			English	Article						LOSS OF HETEROZYGOSITY; DELETION MAPPING; TUMOR SUPPRESSOR GENE; POLYMERASE CHAIN REACTION; PROSTATIC CARCINOMA	BREAST-OVARIAN-CANCER; FAMILIAL BREAST; REPEAT POLYMORPHISM; ESOPHAGEAL CANCERS; LINKAGE ANALYSIS; ALLELIC LOSS; GENES; P53; CARCINOMA; DELETION	We recently demonstrated a high frequency of loss of heterozygosity (LOH) at the D17S856 and D17S855 (within the BRCA1 gene) loci in primary prostate cancer, suggesting that the BRCA1, gene and/or other tumor suppressor gene(s) located within the interval of the D17S856 and D17S855 loci and/or within the vicinity of this interval may be important in prostate cancer (Cancer Res., 55: 1002-1005, 1995). To further define the exact boundary of the deleted region (i.e., D17S856/D17S855) and to detect other possible LOH regions on the long arm of chromosome 17, we analysed 23 matched normal and tumor DNAs with 15 polymorphic microsatellite markers spanning chromosome 17q12-21. Eleven of 22 (50%) informative tumors showed allelic deletion at one or more of the loci studied. A minimal area of LOH was identified to extend from the proximal boundary at the D17S776 locus to the distal boundary at the D17S855 locus, spanning an estimated <2 Mb segment on chromosome 17q21. Our results suggest that a potential tumor suppressor gene(s) may reside in the <2 Mb region centromeric (inclusive) to the BRCA1 gene and that this tumor suppressor gene(s) may be involved in the formation of prostate cancer.	WAYNE STATE UNIV,SCH MED,DEPT RADIAT ONCOL,DIV CANC BIOL,DETROIT,MI 48202; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48202; WAYNE STATE UNIV,SCH MED,DEPT UROL,DETROIT,MI 48202	Wayne State University; Wayne State University; Wayne State University								ANDERSON LA, 1993, GENOMICS, V17, P618, DOI 10.1006/geno.1993.1381; ARASON A, 1993, AM J HUM GENET, V52, P711; BAQUET CR, 1991, J NATL CANCER I, V83, P551, DOI 10.1093/jnci/83.8.551; BERGERHEIM USR, 1993, GENE CHROMOSOME CANC, V3, P215; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOVA GS, 1993, CANCER RES, V53, P3869; BRAWN PN, 1993, CANCER, V71, P2569, DOI 10.1002/1097-0142(19930415)71:8<2569::AID-CNCR2820710822>3.0.CO;2-R; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367; CARTER BS, 1993, J UROLOGY, V150, P797, DOI 10.1016/S0022-5347(17)35617-3; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CHEN YQ, 1994, CANCER MOL BIOL, V1, P357; CHIARODO A, 1991, CANCER RES, V51, P2498; CROPP CS, 1993, CANCER RES, V53, P5617; CROPP CS, 1994, CANCER RES, V54, P2548; DEINARD AS, 1992, NUCLEIC ACIDS RES, V20, P1171, DOI 10.1093/nar/20.5.1171-a; EASTON DF, 1993, AM J HUM GENET, V52, P678; EFFERT PJ, 1993, J UROLOGY, V150, P257, DOI 10.1016/S0022-5347(17)35458-7; FLEJTER WL, 1993, HUM MOL GENET, V2, P1080, DOI 10.1093/hmg/2.7.1080; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, CANCER RES, V54, P6374; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAO X, 1995, CANCER RES, V55, P1002; GAO X, 1995, INT J ONCOL, V6, P111; GAO X, 1993, CANCER RES, V53, P2723; GAO X, 1995, IN PRESS PATHOL ONCO; GAO X, 1995, CANCER MOL BIOL, V2, P475; GAO X, 1995, IN PRESS UROL; GAO X, 1994, CANCER MOL BIOL, V1, P297; GAO X, 1995, IN PRESS ONCOGENE; GAO XA, 1994, ONCOGENE, V9, P2999; GOLDGAR DE, 1994, J NATL CANCER I, V86, P200, DOI 10.1093/jnci/86.3.200; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOLLAND EA, 1994, ONCOGENE, V9, P1361; HUANG Y, 1992, CANCER RES, V52, P6525; ILES DE, 1993, HUM MOL GENET, V2, P863; ISAACS WB, 1991, CANCER RES, V51, P4716; ISSHIKI K, 1994, ONCOGENE, V9, P1649; JACOBS IJ, 1993, CANCER RES, V53, P1218; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V26, P436; KEEN AJ, 1994, ONCOGENE, V9, P2083; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUYAMA H, 1994, ONCOGENE, V9, P3071; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MORI T, 1994, CANCER RES, V54, P3396; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; NEUHAUSEN SL, 1994, HUM MOL GENET, V3, P1919, DOI 10.1093/hmg/3.11.1919; PEEHL DM, 1993, CANCER, V71, P1159, DOI 10.1002/1097-0142(19930201)71:3+<1159::AID-CNCR2820711439>3.0.CO;2-U; PHILLIPS SMA, 1994, BRIT J UROL, V73, P390, DOI 10.1111/j.1464-410X.1994.tb07602.x; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V20, P1961; REIS A, 1994, NAT GENET, V6, P174, DOI 10.1038/ng0294-174; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; ROACH M, 1992, INT J RADIAT ONCOL, V24, P441, DOI 10.1016/0360-3016(92)91058-U; SAITO H, 1993, CANCER RES, V53, P3382; SIMARD J, 1994, NAT GENET, V8, P393; TARMIN L, 1994, CANCER RES, V54, P6094; TRAPMAN J, 1994, CANCER RES, V54, P6061; UCHIDA T, 1995, ONCOGENE, V10, P1019; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370	71	52	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1241	1247						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478543				2022-12-28	WOS:A1995RY96700003
J	PRICE, BD; HUGHESDAVIES, L; PARK, SJ				PRICE, BD; HUGHESDAVIES, L; PARK, SJ			CDK2 KINASE PHOSPHORYLATES SERINE-315 OF HUMAN P53 IN-VITRO	ONCOGENE			English	Article						P53; CDK2; PHOSPHORYLATION; DNA DAMAGE; TRANSCRIPTION	CELL-CYCLE CONTROL; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; MAMMALIAN-CELLS; GENE; INHIBITION; P34CDC2	DNA damage increases p53 protein levels and activates transcription of the p21 gene. The p21 protein binds to and inhibits cdk2 kinase, causing G1 arrest. Here, we have investigated if a p53 fusion protein is a substrate for cdk2 kinase in vitro. Cdk2 kinase was immunoprecipitated from NIH3T3 cells and allowed to phosphorylate a human p53-GST (glutathione-s-transferase) fusion protein. Cdk2 and cyclin E-cdk2 efficiently phosphorylated both wild-type (wt) and mutant p53-GST. Cdk2 immunoprecipitated from cells in Go and early G1 exhibited minimal p53 kinase activity, whereas cells in S-phase displayed high levels of p53 kinase activity. If NIH3T3 cells were X-ray irradiated to induce DNA damage, cdk2 p53 kinase activity was rapidly inhibited within 1 h, but had recovered by 4 h post irradiation. Mutation of serine 315 of p53 to alanine (p53-S315A) abolished phosphorylation by cdk2 kinase. However, wtp53 and p53-S315A were equally effective at activating transcription when cotransfected with a p53 reporter construct. The results demonstrate that ser 315 of p53 is phosphorylated by cdk2 in vitro. However, ser 315 of wtp53 is not required for transcriptional activity in vivo, suggesting that cdk2 phosphorylation of p53 may be involved in regulating other cellular functions of wtp53.			PRICE, BD (corresponding author), DANA FARBER CANC INST,JOINT CTR RADIAT THERAPY,STRESS PROT GRP,44 BINNEY ST,BOSTON,MA 02115, USA.				NCI NIH HHS [CA64585] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064585] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BADER SB, 1992, J CELL PHYSIOL, V151, P56, DOI 10.1002/jcp.1041510110; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHO Y, 1994, NATURE, V265, P346; CROOK T, 1994, EMBO J, V79, P817; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUERBITZ SJ, 1991, SCIENCE, V252, P1708; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LIN X, 1993, MOL CELL BIOL, V13, P3291; LOCK RB, 1990, CANCER RES, V50, P3761; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRICE BD, 1994, CANCER RES, V54, P896; PRICE BD, 1993, ONCOGENE, V8, P3055; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STEVENSON MA, 1994, CANCER RES, V54, P12; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TARUNINA M, 1993, ONCOGENE, V8, P3165; TISHLER RB, 1993, CANCER RES, V53, P2212; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHANG W, 1994, CELL GROWTH DIFFER, V5, P705	55	53	54	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					73	80						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624134				2022-12-28	WOS:A1995RJ29500009
J	MCGEADY, ML; KERBY, S; SHANKAR, V; CIARDIELLO, F; SALOMON, D; SEIDMAN, M				MCGEADY, ML; KERBY, S; SHANKAR, V; CIARDIELLO, F; SALOMON, D; SEIDMAN, M			INFECTION WITH A TGF-ALPHA RETROVIRAL VECTOR TRANSFORMS NORMAL MOUSE MAMMARY EPITHELIAL-CELLS BUT NOT NORMAL RAT FIBROBLASTS	ONCOGENE			English	Article									OTSUKA PHARMACEUT CO LTD,MARYLAND RES LABS,ROCKVILLE,MD 20851	Otsuka Pharmaceutical	MCGEADY, ML (corresponding author), NCI,TUMOR IMMUNOL & BIOL,BETHESDA,MD 20892, USA.		Cutler, Mary L/G-5735-2017	Cutler, Mary L/0000-0001-9727-4320; Ciardiello, Fortunato/0000-0002-3369-4841				ANZANO MA, 1982, CANCER RES, V42, P4776; ASSOIAN RK, 1984, CELL, V36, P35, DOI 10.1016/0092-8674(84)90071-0; ASSOIAN RK, 1985, J BIOL CHEM, V260, P9613; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIARDIELLO F, 1988, MOL ENDOCRINOL, V2, P1202, DOI 10.1210/mend-2-12-1202; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DEAN M, 1987, ONCOGENE RES, V1, P279; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DELARCO JE, 1985, P NATL ACAD SCI USA, V82, P5015; DELARUE JC, 1988, BREAST CANCER RES TR, V11, P173, DOI 10.1007/BF01805841; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1987, CANCER RES, V47, P707; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FINZI E, 1987, P NATL ACAD SCI USA, V84, P3733, DOI 10.1073/pnas.84.11.3733; GENTRY LE, 1987, MOL CELL BIOL, V7, P1585, DOI 10.1128/MCB.7.5.1585; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; HYNES NE, 1985, MOL CELL BIOL, V5, P268, DOI 10.1128/MCB.5.1.268; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; JHAPPAN C, 1986, J VIROL, V60, P750, DOI 10.1128/JVI.60.2.750-753.1986; KAPLAN PL, 1981, VIROLOGY, V108, P484, DOI 10.1016/0042-6822(81)90455-4; KAPLAN PL, 1982, VIROLOGY, V123, P372, DOI 10.1016/0042-6822(82)90270-7; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARQUARDT H, 1983, P NATL ACAD SCI-BIOL, V80, P4684; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PERROTEAU I, 1986, BREAST CANCER RES TR, V7, P201, DOI 10.1007/BF01806251; PIKE LJ, 1982, J BIOL CHEM, V257, P4628; REDMOND SMS, 1988, ONCOGENE, V2, P259; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; RIOS MA, 1988, ANTICANCER RES, V8, P173; RIZZINO A, 1984, IN VITRO CELL DEV B, V20, P815, DOI 10.1007/BF02618298; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SAINSBURY JRC, 1987, LANCET, V1, P1398; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SHANKAR V, 1989, IN PRESS MOL CARCINO; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; TEIXIDO J, 1987, NATURE, V326, P83; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; VALVERIUS EM, 1989, MOL ENDOCRINOL, V3, P203, DOI 10.1210/mend-3-1-203; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WATANABE S, 1987, P NATL ACAD SCI USA, V84, P1258, DOI 10.1073/pnas.84.5.1258; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZAJCHOWSKI D, 1988, CANCER RES, V48, P7041	61	89	89	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1375	1382						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2812779				2022-12-28	WOS:A1989AX65900015
J	REISMAN, D; ROTTER, V				REISMAN, D; ROTTER, V			2 PROMOTERS THAT MAP TO 5'-SEQUENCES OF THE HUMAN P53 GENE ARE DIFFERENTIALLY REGULATED DURING TERMINAL DIFFERENTIATION OF HUMAN MYELOID LEUKEMIC-CELLS	ONCOGENE			English	Article											REISMAN, D (corresponding author), WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL.				NCI NIH HHS [IR01 CA4003] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTON NK, 1979, NATURE, V282, P861; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; BENDORI R, 1987, VIROLOGY, V161, P607, DOI 10.1016/0042-6822(87)90159-0; BENYAJATI C, 1983, CELL, V33, P125, DOI 10.1016/0092-8674(83)90341-0; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHEN CN, 1987, NATURE, V329, P721, DOI 10.1038/329721a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; COLLINS SJ, 1987, BLOOD, V70, P1233; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PROKOCIMER M, 1986, BLOOD, V68, P113; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REISMAN D, 1988, P NATL ACAD SCI USA, V85, P5146, DOI 10.1073/pnas.85.14.5146; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; ROTTER V, 1983, P NATL ACAD SCI-BIOL, V80, P2613, DOI 10.1073/pnas.80.9.2613; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SHEN DW, 1983, P NATL ACAD SCI-BIOL, V80, P5919, DOI 10.1073/pnas.80.19.5919; SHOHAT O, 1987, ONCOGENE, V1, P277; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; THOMPSON NL, 1986, CANCER RES, V46, P3111; TODARO GJ, 1966, SCIENCE, V153, P1252, DOI 10.1126/science.153.3741.1252; WOLF D, 1985, MOL CELL BIOL, V5, P1887, DOI 10.1128/MCB.5.8.1887; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YEN A, 1985, EXP CELL RES, V156, P198, DOI 10.1016/0014-4827(85)90274-5	57	24	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					945	953						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2668845				2022-12-28	WOS:A1989AJ29700001
J	TIMMONS, MS; WITTE, ON				TIMMONS, MS; WITTE, ON			STRUCTURAL CHARACTERIZATION OF THE BCR-GENE PRODUCT	ONCOGENE			English	Article									UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MICROBIOL,LOS ANGELES,CA 90024	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; CROCE CM, 1987, P NATL ACAD SCI USA, V84, P7174, DOI 10.1073/pnas.84.20.7174; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; FIALKOW PJ, 1981, BLOOD, V58, P158, DOI 10.1182/blood.V58.1.158.158; FROST E, 1978, VIROLOGY, V91, P39, DOI 10.1016/0042-6822(78)90353-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LIFSHITZ B, 1988, ONCOGENE, V2, P113; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; Maniatis T., 1982, MOL CLONING LABORATO, P86; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; PRIEST JR, 1980, BLOOD, V56, P15; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SANDBERG AA, 1980, CANCER GENET CYTOGEN, V2, P145, DOI 10.1016/0165-4608(80)90058-8; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0	42	33	35	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					559	567						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2657572				2022-12-28	WOS:A1989U768800005
J	SHORE, SK; HARD, GC; MAGEE, PN				SHORE, SK; HARD, GC; MAGEE, PN			DEREGULATION AND OVEREXPRESSION OF C-FOS PROTO-ONCOGENE IN RAT RENAL CELL-LINES AND PRIMARY TUMORS INDUCED BY DIMETHYLNITROSAMINE	ONCOGENE			English	Article									TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS RES INST,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL CANCER INSTITUTE [T32CA009214] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09214] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARR FG, 1986, MOL CELL BIOL, V6, P3023, DOI 10.1128/MCB.6.9.3023; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CALABRETTA B, 1987, BIOCHEM BIOPH RES CO, V147, P716, DOI 10.1016/0006-291X(87)90989-2; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORRAL M, 1985, EXP CELL RES, V160, P427, DOI 10.1016/0014-4827(85)90190-9; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARD GC, 1977, J NATL CANCER I, V58, P1377, DOI 10.1093/jnci/58.5.1377; HARD GC, 1975, JNCI-J NATL CANCER I, V54, P1085, DOI 10.1093/jnci/54.5.1085; HARD GC, 1970, CANCER RES, V30, P2796; HARD GC, 1974, ONCOLOGY, V30, P485, DOI 10.1159/000224992; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; Maniatis T., 1982, MOL CLONING; MCLEAN AEM, 1970, BRIT J EXP PATHOL, V51, P587; MILLER AD, 1984, CELL, V36, P51; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NICOLL JW, 1975, NATURE, V254, P261, DOI 10.1038/254261a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHIZAWA M, 1987, J VIROL, V61, P3733, DOI 10.1128/JVI.61.12.3733-3740.1987; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P2391, DOI 10.1093/nar/11.8.2391; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SUKUMAR S, 1986, MOL CELL BIOL, V6, P2716, DOI 10.1128/MCB.6.7.2716; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VERMA IM, 1987, ADV CANCER RES, V49, P29, DOI 10.1016/S0065-230X(08)60793-9; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x	29	4	4	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					567	570						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3152601				2022-12-28	WOS:A1988R516300013
J	GELINAS, C; TEMIN, HM				GELINAS, C; TEMIN, HM			THE V-REL ONCOGENE ENCODES A CELL-SPECIFIC TRANSCRIPTIONAL ACTIVATOR OF CERTAIN PROMOTERS	ONCOGENE			English	Article									UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [P01CA022443, P30CA007175] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22443, CA-07175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ASSELIN C, 1986, J VIROL, V57, P165, DOI 10.1128/JVI.57.1.165-172.1986; BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; EMBRETSON JE, 1986, J VIROL, V60, P662, DOI 10.1128/JVI.60.2.662-668.1986; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; GARSON K, 1986, BIOCHEM BIOPH RES CO, V134, P716, DOI 10.1016/S0006-291X(86)80479-X; GELINAS C, 1985, VIROLOGY, V146, P233, DOI 10.1016/0042-6822(85)90007-8; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; NEVINS JR, 1986, ADV CANCER RES, V47, P283, DOI 10.1016/S0065-230X(08)60202-X; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; ROSS J, 1976, J MOL BIOL, V106, P403, DOI 10.1016/0022-2836(76)90093-0; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SHIBUYA T, 1982, CANCER RES, V42, P2722; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; THEILEN GH, 1966, J NATL CANCER I, V37, P731; TOOZE J, 1980, MOL BIOL TUMOR VIRUS, V2; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WEAVER RF, 1979, NUCLEIC ACIDS RES, V7, P1175, DOI 10.1093/nar/7.5.1175	38	97	98	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					349	355						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	2856247				2022-12-28	WOS:A1988Q773900001
J	OHLSSON, RI; SCHWARZE, P; RUUD, E; PFEIFEROHLSSON, S				OHLSSON, RI; SCHWARZE, P; RUUD, E; PFEIFEROHLSSON, S			POTENTIAL MULTIPLE FUNCTIONS OF THE V-MYC ONCOGENE WITHIN A SINGLE CELL CLONE OF OK10 RETROVIRUS-TRANSFORMED QUAIL FIBROBLASTS	ONCOGENE			English	Article									NORWEGIAN RADIUMHOSP,DEPT TISSUE CULTURE,N-0310 OSLO 3,NORWAY; NORWEGIAN RADIUMHOSP,IMMUNOL LAB,N-0310 OSLO 3,NORWAY	University of Oslo; University of Oslo	OHLSSON, RI (corresponding author), KAROLINSKA INST,HUDDINGE HOSP,CTR BIOTECHNOL,F82,S-14186 HUDDINGE,SWEDEN.		Schwarze, Per/I-2080-2016					ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BISHOP JM, 1983, ANNU REV BIOCHEM, V47, P310; BROOME S, 1985, CELL, V40, P537, DOI 10.1016/0092-8674(85)90202-8; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CONNAN G, 1985, NATURE, V314, P277, DOI 10.1038/314277a0; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CRISSMAN HA, 1974, SCIENCE, V184, P1297, DOI 10.1126/science.184.4143.1297; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; GOUSTIN AS, 1985, CELL, V41, P301, DOI 10.1016/0092-8674(85)90083-2; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GREENBERG ME, 1984, NATURE, V290, P475; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; JOHNSON BE, 1986, J CLIN INVEST, V78, P525, DOI 10.1172/JCI112604; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; NISHIKURA K, 1984, SCIENCE, V224, P399, DOI 10.1126/science.6424234; OHLSSON RI, 1987, EXP CELL RES, V173, P1, DOI 10.1016/0014-4827(87)90327-2; OKERBLOM N, 1978, J GEN VIROL, V40, P623, DOI 10.1099/0022-1317-40-3-623; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PFEIFER S, 1983, J VIROL, V46, P347, DOI 10.1128/JVI.46.2.347-354.1983; PFEIFEROHLSSON S, 1984, INTERVIROLOGY, V21, P121, DOI 10.1159/000149510; PFEIFEROHLSSON S, 1984, CELL, V38, P585, DOI 10.1016/0092-8674(84)90513-0; PFEIFEROHLSSON S, 1985, P NATL ACAD SCI USA, V82, P5050, DOI 10.1073/pnas.82.15.5050; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SAGER R, 1984, CANCER SURV, V3, P321; SMELAND E, 1985, P NATL ACAD SCI USA, V82, P6255, DOI 10.1073/pnas.82.18.6255; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448	38	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					457	461						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3078953				2022-12-28	WOS:A1988Q773900015
J	PATSCHINSKY, T; BISTER, K				PATSCHINSKY, T; BISTER, K			STRUCTURAL-ANALYSIS OF NORMAL AND TRANSFORMING MIL(RAF) PROTEINS - EFFECT OF 5'-TRUNCATION ON PHOSPHORYLATION INVIVO OR INVITRO	ONCOGENE			English	Article									MAX PLANCK INST MOLEC GENET,OTTO WARBURG LAB,D-1000 BERLIN 33,FED REP GER	Max Planck Society			Bister, Klaus/AFA-9400-2022	Bister, Klaus/0000-0001-6545-5653				BECHADE C, 1988, J VIROL, V62, P1211; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BIEGALKE B, 1987, J VIROL, V61, P1949, DOI 10.1128/JVI.61.6.1949-1956.1987; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BISTER K, 1987, ONCOGENE, V1, P97; BISTER K, 1987, ADV VIRAL ONCOL, V6, P45; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; DOZIER C, 1987, MOL CELL BIOL, V7, P1995, DOI 10.1128/MCB.7.5.1995; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FUKUI M, 1987, MOL CELL BIOL, V7, P1776, DOI 10.1128/MCB.7.5.1776; GALIBERT F, 1984, EMBO J, V3, P1333, DOI 10.1002/j.1460-2075.1984.tb01972.x; HU SSF, 1978, VIROLOGY, V89, P162, DOI 10.1016/0042-6822(78)90049-1; HUANG KP, 1986, J BIOL CHEM, V261, P2134; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; INOUE M, 1977, J BIOL CHEM, V252, P7610; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; JANSEN HW, 1985, VIROLOGY, V142, P248, DOI 10.1016/0042-6822(85)90333-2; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; JANSEN HW, 1985, VIROLOGY, V143, P359, DOI 10.1016/0042-6822(85)90376-9; JANSEN HW, 1985, MODERN TRENDS HUMAN, V6, P280; KAN NC, 1984, SCIENCE, V223, P813, DOI 10.1126/science.6320371; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KOENEN M, 1988, ONCOGENE, V2, P179; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOLDERS H, 1985, EMBO J, V4, P693, DOI 10.1002/j.1460-2075.1985.tb03685.x; PALMIERI S, 1987, J VIROL, V61, P1717, DOI 10.1128/JVI.61.5.1717-1721.1987; PATSCHINSKY T, 1986, J VIROL, V59, P341, DOI 10.1128/JVI.59.2.341-353.1986; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PATSCHINSKY T, 1986, MOL CELL BIOL, V6, P739, DOI 10.1128/MCB.6.2.739; PATSCHINSKY T, 1984, VIROLOGY, V136, P348, DOI 10.1016/0042-6822(84)90171-5; RAMSAY G, 1982, EMBO J, V1, P1111, DOI 10.1002/j.1460-2075.1982.tb01305.x; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1983, J VIROL, V45, P914, DOI 10.1128/JVI.45.3.914-924.1983; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; SCHULTZ AM, 1988, ONCOGENE, V2, P187; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; VANBEVEREN C, 1986, CURR TOP MICROBIOL, V123, P73; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198	44	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					357	364						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3274084				2022-12-28	WOS:A1988Q773900002
J	DAVID, YB; PRIDEAUX, VR; CHOW, V; BENCHIMOL, S; BERNSTEIN, A				DAVID, YB; PRIDEAUX, VR; CHOW, V; BENCHIMOL, S; BERNSTEIN, A			INACTIVATION OF THE P53-ONCOGENE BY INTERNAL DELETION OR RETROVIRAL INTEGRATION IN ERYTHROLEUKEMIC CELL-LINES INDUCED BY FRIEND-LEUKEMIA VIRUS	ONCOGENE			English	Article									MT SINAI HOSP, RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA; ONTARIO CANC INST, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, DEPT MED GENET & MED BIOPHYS, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto				Benchimol, Samuel/0000-0003-3433-890X				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BECKER A, 1975, P NATL ACAD SCI USA, V72, P581, DOI 10.1073/pnas.72.2.581; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; CLARK SP, 1983, P NATL ACAD SCI-BIOL, V80, P5037, DOI 10.1073/pnas.80.16.5037; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HOHN B, 1975, J MOL BIOL, V98, P93, DOI 10.1016/S0022-2836(75)80103-3; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MOWAT M, 1983, J VIROL, V47, P471, DOI 10.1128/JVI.47.3.471-477.1983; MUNROE DG, 1988, ONCOGENE, V2, P621; OLIFF A, 1983, J VIROL, V46, P718, DOI 10.1128/JVI.46.3.718-725.1983; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARDEE AB, 1981, BIOL NORMAL HUMAN GR, P59; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROTTER V, 1983, J IMMUNOL, V181, P329; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO JA, 1979, P NATL ACAD SCI USA, V76, P1933, DOI 10.1073/pnas.76.4.1933; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SHOHAT O, 1987, ONCOGENE, V1, P277; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEPHENSON JR, 1971, P NATL ACAD SCI USA, V68, P1542, DOI 10.1073/pnas.68.7.1542; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WENDLING F, 1981, P NATL ACAD SCI-BIOL, V78, P3614, DOI 10.1073/pnas.78.6.3614; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILLIAMS B, 1979, J VIROL, V24, P555; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	48	126	128	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1988	3	2					179	185						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	2842714				2022-12-28	WOS:A1988Q053400008
J	CARROLL, RB; SAMAD, A; MANN, A; HARPER, J; ANDERSON, CW				CARROLL, RB; SAMAD, A; MANN, A; HARPER, J; ANDERSON, CW			RNA IS COVALENTLY LINKED TO SV40 LARGE T-ANTIGEN	ONCOGENE			English	Article									NYU, RITA & STANLEY H KAPLAN CANC CTR, SCH MED, NEW YORK, NY 10016 USA; BROOKHAVEN NATL LAB, DEPT BIOL, UPTON, NY 11973 USA	New York University; United States Department of Energy (DOE); Brookhaven National Laboratory	CARROLL, RB (corresponding author), NYU, SCH MED, DEPT PATHOL, 550 1ST AVE, NEW YORK, NY 10016 USA.				NATIONAL CANCER INSTITUTE [R01CA020802, P01CA016239] Funding Source: NIH RePORTER; NCI NIH HHS [CA9161, CA20802, CA16239] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON CW, 1986, CANCER CELL, V1, P395; ANDERSON KP, 1984, P NATL ACAD SCI-BIOL, V81, P4023, DOI 10.1073/pnas.81.13.4023; BOCK RM, 1967, METHODS ENZYMOLOGY A, V12, P638; CARROLL RB, 1982, J VIROL, V44, P565, DOI 10.1128/JVI.44.2.565-573.1982; CHALLBERG MD, 1980, P NATL ACAD SCI-BIOL, V77, P5105, DOI 10.1073/pnas.77.9.5105; CRAWFORD LV, 1979, COLD SPRING HARB SYM, V44, P179; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P961, DOI 10.1073/pnas.74.3.961; GLUZMAN Y, 1982, VIROLOGY, V123, P78, DOI 10.1016/0042-6822(82)90296-3; GREENSPAN DS, 1981, P NATL ACAD SCI-BIOL, V78, P105, DOI 10.1073/pnas.78.1.105; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; JEKEL PA, 1983, ANAL BIOCHEM, V134, P347, DOI 10.1016/0003-2697(83)90308-1; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KHANDJIAN EW, 1982, P NATL ACAD SCI-BIOL, V79, P1139, DOI 10.1073/pnas.79.4.1139; KLEIN G, 1982, ADV VIRAL ONCOL, V2, P53; KLEIN H, 1979, J BIOL CHEM, V254, P1051; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE YF, 1977, P NATL ACAD SCI USA, V74, P59, DOI 10.1073/pnas.74.1.59; MANOS MM, 1985, J VIROL, V53, P120, DOI 10.1128/JVI.53.1.120-127.1985; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; PAUCHA E, 1986, J VIROL, V57, P50, DOI 10.1128/JVI.57.1.50-64.1986; ROTHBERG PG, 1978, P NATL ACAD SCI USA, V75, P4868, DOI 10.1073/pnas.75.10.4868; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1981, J VIROL, V38, P59, DOI 10.1128/JVI.38.1.59-69.1981; Tooze J., 1981, COLD SPRING HARB MON, Vsecond; TORNOW J, 1983, J VIROL, V47, P487, DOI 10.1128/JVI.47.3.487-494.1983	27	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1988	2	5					437	444						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	2836778				2022-12-28	WOS:A1988N434800004
J	LENNY, N; MEYERS, S; HIEBERT, SW				LENNY, N; MEYERS, S; HIEBERT, SW			FUNCTIONAL DOMAINS OF THE T(8-21) FUSION PROTEIN, AML-1/ETO	ONCOGENE			English	Article						AML-1; TRANSCRIPTION; REPRESSION; TRANSLOCATION	ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; E2F TRANSCRIPTION FACTOR; DNA-BINDING; AML1 GENE; SECONDARY-STRUCTURE; TRANSLOCATION; RUNT; IDENTIFICATION; EXPRESSION	The AML-1/ETO fusion protein is created by the (8;21) translocation, the second most frequent chromosomal abnormality associated with acute myeloid leukemia. In the fusion protein the AML-1 rant homology domain, which is responsible for DNA binding and CBF beta interaction, is linked to ETO, a gene of unknown function. The primary sequences of the rant homology domain indicates no known DNA binding motifs, but is predicted to contain six beta-strands, two alpha-helices and a nucleotide binding motif, Mutagenesis of AML-1/ETO was performed to delimit the functional domains of the chimeric protein. Most mutations in the runt homology domain that resulted in reduced CBF beta binding also inhibited DNA binding, indicating that the DNA and CBF beta binding sequences are tightly linked. However, these activities were separated by a point mutation of residue 144, within the putative ATP binding motif, which nearly eliminated DNA binding, but did not affect CBF beta binding, Random mutagenesis identified the hydrophobic face of the amphipathic fifth beta-strand, adjacent to the putative ATP binding motif, as critical for both DNA and CBF beta binding. C-terminal deletion mutants of AML-1/ETO indicated that ETO sequences are essential for interference with AML-1B-mediated transcriptional activation, and that residue 540 defines the C-terminal boundary of a potential repression domain. Thus, these mutational analyses define the regions of AML-1/ETO which regulate its function and that may be important in promoting leukemia.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital			Hiebert, Scott W/C-9979-2010		NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA 21765] Funding Source: Medline; PHS HHS [R01-64140] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DOWNING JR, 1993, BLOOD, V81, P2860; ERICKSON P, 1992, BLOOD, V80, P1825; FRANK R, 1995, IN PRESS ONCOGENE; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Leung DW, 1989, TECHNIQUE, V1, P11; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MADDEN SL, 1993, ONCOGENE, V8, P1713; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; WANG S, 1993, EMBO J, V13, P3324; WOLIN M, 1993, ONCOGENE, V8, P1905; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	39	99	104	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1761	1769						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478604				2022-12-28	WOS:A1995TD09400011
J	BARLAT, I; HENGLEIN, B; PLET, A; LAMB, N; FERNANDEZ, A; MCKENZIE, F; POUYSSEGUR, J				BARLAT, I; HENGLEIN, B; PLET, A; LAMB, N; FERNANDEZ, A; MCKENZIE, F; POUYSSEGUR, J			TGF-BETA-1 AND CAMP ATTENUATE CYCLIN-A GENE-TRANSCRIPTION VIA A CAMP-RESPONSIVE ELEMENT THROUGH INDEPENDENT PATHWAYS	ONCOGENE			English	Article						TGF-BETA; CYCLIN-A; CAMP; INHIBITION OF PROLIFERATION	GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; TGF-BETA; SIGNAL TRANSDUCTION; NEGATIVE REGULATION; CATALYTIC SUBUNIT; DNA-REPLICATION; A EXPRESSION; CROSS-TALK; PHOSPHORYLATION	Transforming growth factor beta (TGF-beta) is a potent inhibitor of the proliferation of many cell lines. The expression of Cyclin A is down-regulated by TGF-beta 1 in Chinese hamster lung fibroblasts and most of this effect is mediated at the transcriptional level through a cAMP-reponsive element (CRE), but does not require a functional cAMP-dependent protein kinase. However, activation of the cAMP pathway in these cells gives rise to a strong inhibition of proliferation, paralleled by a down-regulation of Cyclin A promoter activity. This effect requires the integrity of the CRE, suggesting a role for CRE-binding proteins in late G1/S controls.	CNRS,CTR GENET MOLEC,UPR 2420,F-91198 GIF SUR YVETTE,FRANCE; CNRS,INSERM,CRBM,CELL BIOL UNIT,F-34033 MONTPELLIER 1,FRANCE; UNIV NICE,CTR BIOCHIM,CNRS,UMR 134,F-06108 NICE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	BARLAT, I (corresponding author), INST GENET MOLEC MONTPELLIER,CNRS,UMR 9942,BP 5051,1919 ROUTE MENDE,F-34033 MONTPELLIER 1,FRANCE.							ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHAMBARD JC, 1988, J CELL PHYSIOL, V135, P101, DOI 10.1002/jcp.1041350114; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; DARBON JM, 1994, ONCOGENE, V9, P3127; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FERNANDEZPOL JA, 1987, BIOCHEM BIOPH RES CO, V144, P1197, DOI 10.1016/0006-291X(87)91438-0; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HOPPESEYLER F, 1991, NUCLEIC ACIDS RES, V19, P5080, DOI 10.1093/nar/19.18.5080; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KRAMER IM, 1991, EMBO J, V10, P1083, DOI 10.1002/j.1460-2075.1991.tb08048.x; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; Lew D J, 1992, Trends Cell Biol, V2, P77, DOI 10.1016/0962-8924(92)90076-Y; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P2355, DOI 10.1073/pnas.79.7.2355; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; MCCORMICK F, 1993, CURRENT OP GENET DEV, V4, P71; MECHTA F, 1989, New Biologist, V1, P297; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PINES J, 1993, BIOCHEM SOC T, V18, P921; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROGERS KV, 1990, P NATL ACAD SCI USA, V87, P8975, DOI 10.1073/pnas.87.22.8975; ROSKOSKI R, 1993, METHOD ENZYMOL, V99, P3; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCOTTO L, 1990, J BIOL CHEM, V265, P2203; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	79	55	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1309	1318						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478551				2022-12-28	WOS:A1995RY96700011
J	COFFER, PJ; BURGERING, BMT; PEPPELENBOSCH, MP; BOS, JL; KRUIJER, W				COFFER, PJ; BURGERING, BMT; PEPPELENBOSCH, MP; BOS, JL; KRUIJER, W			UV ACTIVATION OF RECEPTOR TYROSINE KINASE-ACTIVITY	ONCOGENE			English	Article						UV; GROWTH FACTOR; RECEPTORS; EGF; INSULIN; SIGNAL TRANSDUCTION	ARACHIDONIC-ACID; EGF RECEPTOR; DNA-BINDING; NF-KAPPA; PROTEIN; INSULIN; CELLS; PHOSPHORYLATION; EXPRESSION; SIGNAL	The exposure of mammalian cells to ultraviolet radiation (UV) may lead to DNA damage resulting in mutation and thus possibly cancer, while irradiation can further act as a potent tumour promoter. In addition UV induces p21ras-mediated signalling leading to activation of transcription factors such as AP-1 and NF-kappa B, as well as activation of the Src tyrosine kinase. This 'UV-response' has been well studied in mammalian cells and furthermore is conserved in yeast, however the most upstream components of this signal transduction pathway have remained elusive. Here we show that UV rapidly activates both the EGF receptor and insulin receptor, as shown by tyrosine phosphorylation of these receptors. We demonstrate that this activation is due to autophosphorylation as it only occurs in cells containing receptors with a functional kinase domain. We have further analysed the propagation of the UV-induced signal to downstream events such as, IRS-1 and Shc tyrosine phosphorylation, phosphatidylinositol 3-kinase activation, leukotriene synthesis, MAP kinase activation and gene induction all of which are activated by UV irradiation. Importantly, we demonstrate that in cells expressing a 'kinase-dead' receptor mutant the UV-response is inhibited, blocking leukotriene synthesis, MAP kinase activation and transcriptional induction. Furthermore, prior-stimulation of cells with UV appears to reduce further responsiveness to addition of growth factor suggesting a common signaling pathway. These data demonstrate a critical role for receptor-mediated events in regulating the response of mammalian cells to UV exposure.	UNIV UTRECHT,3508 TA UTRECHT,NETHERLANDS; UNIV GRONINGEN,CTR BIOL,DEPT GENET,9750 AA HAREN,NETHERLANDS	Utrecht University; University of Groningen	COFFER, PJ (corresponding author), NETHERLANDS INST DEV BIOL,HUBRECHT LAB,UPPSALALAAN 8,3584 CT UTRECHT,NETHERLANDS.		Coffer, Paul J/A-5769-2009; Coffer, Paul/AAF-7970-2020	Peppelenbosch, Maikel/0000-0001-9112-6028				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; [Anonymous], 1985, DNA REPAIR; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGERING BMT, 1993, BIOCHEM SOC T, V21, P888, DOI 10.1042/bst0210888; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CALDENHOVEN E, 1994, J BIOL CHE3M, V269, P22146; CLARK S, 1991, BIOCHEM J, V274, P715, DOI 10.1042/bj2740715; COFFER P, 1994, ONCOGENE, V9, P911; COHEN D, 1993, PHOTOCHEM PHOTOBIOL, V57, P383, DOI 10.1111/j.1751-1097.1993.tb02306.x; DEEG HJ, 1989, BLOOD, V73, P369; DEFIZE LHK, 1986, EMBO J, V5, P1187, DOI 10.1002/j.1460-2075.1986.tb04345.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FISHER SM, 1989, PROGR CLIN BIOL RES, V298, P249; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Fursin G. I., 1990, Engineering Information in Data Bases and Knowledge Based Systems. Techno-Data '90. Proceedings of the International Conference Techno-Data '90, P107; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; HAWK JLM, 1983, J INVEST DERMATOL, V80, P496, DOI 10.1111/1523-1747.ep12535038; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HURZA LL, 1993, J INVEST DERMATOL, V100, P35; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KRAMER M, 1993, J BIOL CHEM, V257, P13193; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEVINE L, 1981, ADV CANCER RES, V35, P49, DOI 10.1016/S0065-230X(08)60908-2; MAHER VM, 1988, DNA REPLICATION MUTA, P465; MATSUI MS, 1989, J INVEST DERMATOL, V93, P617; MATSUI MS, 1991, CANCER CELLS, V31, P8; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NAKADATE T, 1990, EICOSANOIDS SKIN, P185; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QIAN XL, 1994, ONCOGENE, V9, P1507; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Romerdahl C A, 1989, Cancer Commun, V1, P209; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; WARMUTH I, 1994, CANCER RES, V54, P374; WHITMAN M, 1990, BIOCHEM J, V247, P165; YAMAMOTO S, 1992, CANCER CHEMOPREVENTION, P141; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	50	147	150	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					561	569						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7543196				2022-12-28	WOS:A1995RN53000017
J	WELLBROCK, C; LAMMERS, R; ULLRICH, A; SCHARTL, M				WELLBROCK, C; LAMMERS, R; ULLRICH, A; SCHARTL, M			ASSOCIATION BETWEEN THE MELANOMA-INDUCING RECEPTOR TYROSINE KINASE XMRK AND SRC FAMILY TYROSINE KINASES IN XIPHOPHORUS	ONCOGENE			English	Article						GROWTH FACTOR RECEPTOR; MELANOMA; PLC-GAMMA; SIGNAL TRANSDUCTION; SH2 DOMAIN; TYROSINE KINASES	GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; FAINT-LITTLE-BALL; EGF RECEPTOR; ELEVATED EXPRESSION; SIGNAL-TRANSDUCTION; MALIGNANT-MELANOMA; SH2 DOMAINS; PROTEIN; GENE	Melanoma formation in the fish Xiphophorus is an in vivo model for the function of receptor tyrosine kinases (RTKs) in tumor development. The overexpression and high activity of the RTK Xmrk (Xiphophorus melanoma receptor kinase) is responsible for the formation of hereditary malignant melanoma in this fish, but the mechanism by which Xmrk signals cell proliferation has not been elucidated. Remarkably, in earlier experiments an elevated level of a pp60(c-src) related kinase activity was found in the melanomas. In order to evaluate the significance of src family SH2 domain interactions in the intracellular signalling of Xmrk, we determined its relative binding affinity to the ubiquitous general RTK substrate, PLC gamma, and to the Xiphophorus cytoplasmic kinases Xsrc, Xfyn and Xyes. Recombinant Xmrk purified from baculovirus infected Sf9 cells bound with high affinity to the SH2 domains of PLC gamma and Xfyn in vitro. The affinity of Xmrk to Xsrc and Xyes SH2 domains was 5- to 10-fold lower. Coprecipitation experiments revealed that the Xmrk/Xfyn interaction occurred also in melanoma cells. Moreover, stimulation of the Xmrk kinase activity was paralleled by an increase in Xfyn activity. These results suggest that in malignant melanoma of Xiphophorus the highly activated Xmrk may enhance the activity of Xfyn through direct interaction and that both kinases are linked in a signal transduction pathway.	UNIV WURZBURG, THEODOR BOVERI INST, BIOCTR, DEPT PHYSIOL CHEM 1, D-97074 WURZBURG, GERMANY; MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, D-82152 MARTINSRIED, GERMANY	University of Wurzburg; Max Planck Society				Wellbrock, Claudia/0000-0002-3825-6381; Schartl, Manfred/0000-0001-9882-5948				ADAM D, 1993, SCIENCE, V259, P816, DOI 10.1126/science.8430335; ADAM D, 1991, ONCOGENE, V6, P73; ALTSCHMIED J, 1994, LEGACY CELL FUSION, P199; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARNEKOW A, 1982, CANCER RES, V42, P2429; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; FENDLY BM, 1990, CANCER RES, V50, P1550; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANNIG G, 1991, ONCOGENE, V6, P361; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LOGANZO F, 1993, ONCOGENE, V8, P2637; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MALITSCHEK B, 1994, J BIOL CHEM, V269, P10423; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MAUELER W, 1988, ONCOGENE, V3, P113; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; PAWSON T, 1994, CURR OPIN GENET DEV, V4, P1, DOI 10.1016/0959-437X(94)90084-1; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RATH HM, 1990, J BIOL CHEM, V265, P3080; ROTIN D, 1992, J BIOL CHEM, V267, P9678; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SCHARTL M, 1985, INT J CANCER, V36, P199, DOI 10.1002/ijc.2910360212; SCHARTL M, 1982, CANCER RES, V42, P4222; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIERKE SL, 1983, BIOL BIOPHYS RES COM, V191, P45; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V73, P321; WAKAMATSU Y, 1981, CANCER RES, V41, P679; WINKLER C, 1994, ONCOGENE, V9, P1517; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU GC, 1993, J BIOL CHEM, V268, P1775; ZHU GC, 1994, ONCOGENE, V9, P1379	41	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2135	2143						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7540277				2022-12-28	WOS:A1995RB70300008
J	KARLSSON, T; ZHOU, SY; LANDGREN, E; LAVERGNE, C; DIFIORE, PP; ANAFI, M; PAWSON, T; CANTLEY, LC; CLAESSONWELSH, L; WELSH, M				KARLSSON, T; ZHOU, SY; LANDGREN, E; LAVERGNE, C; DIFIORE, PP; ANAFI, M; PAWSON, T; CANTLEY, LC; CLAESSONWELSH, L; WELSH, M			MOLECULAR-INTERACTIONS OF THE SRC HOMOLOGY-2 DOMAIN PROTEIN SHB WITH PHOSPHOTYROSINE RESIDUES, TYROSINE KINASE RECEPTORS AND SRC HOMOLOGY-3 DOMAIN PROTEINS	ONCOGENE			English	Article						SRC HOMOLOGY 2 (SH2) DOMAIN; SRC HOMOLOGY 3 (SH3) DOMAIN; TYROSINE KINASE RECEPTORS; PROLINE-RICH MOTIFS; MITOGENIC SIGNAL TRANSDUCTION; ADAPTER SH2 DOMAIN PROTEIN	GROWTH-FACTOR RECEPTOR; PDGF BETA-RECEPTOR; SIGNAL TRANSDUCTION; AUTOPHOSPHORYLATION SITES; POINT MUTATION; C-SRC; RAS; IDENTIFICATION; GRB2; ASSOCIATION	The molecular interactions of the Src homology 2 (SH2) domain and the N-terminal proline-rich sequence motifs (pro-1 to pro-5) of the SH2 protein Shb with other components were presently characterised, Using a degenerate phosphopeptide library the preferred binding site for the Shb SH2 domain was determined to pTyr-Thr/Val/Ile-X-Leu at positions +1 to +3 relative the phosphotyrosine residue, Experiments with competing peptides and platelet-derived growth factor (PDGF) beta-receptor mutants with Y to F substitutions in autophosphorylation sites revealed multiple binding sites for the Shb SH2 domain in the receptor, The Shb SH2 domain also binds to in vitro phosphorylated fibroblast growth factor receptor-1 (FGFR-1) mainly through position Y776, The receptor experiments suggest that other residues besides the +1 to +3 positions may also be of significance for Shb binding, The pro-4/pro-5 motif of Shb binds in vitro particularly well to the Src, p85 alpha PI3-kinase and Eps8 SH3 domains expressed as GST fusion proteins, However, the GST-SH3 domain fusion proteins tested bind in vitro to peptides corresponding to the pro-1 to pro-5 motifs of Shb with low affinity and selectivity, suggesting that sequences outside the core proline motif may also be important for Shb-SH3 domain interactions, In vivo association between Shb-SH3 domain proteins v-Src and Eps8 was detected by coimmunoprecipitation. PDGF treatment did not affect the association between Eps8 and Shb. The data suggest that Shb is an adaptor protein linking SH3 domain proteins to tyrosine kinases or other tyrosine phosphorylated proteins.	UNIV UPPSALA, DEPT MED CELL BIOL, UPPSALA, SWEDEN; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV SIGNAL TRANSDUCT, BOSTON, MA USA; UPPSALA UNIV, LUDWIG INST CANC RES, UPPSALA, SWEDEN; HOP ROBERT DEBRE, INSERM, CJF 93-13, F-75019 PARIS, FRANCE; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA	Uppsala University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Ludwig Institute for Cancer Research; Uppsala University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Di Fiore, Pier Paolo/K-2130-2012; Cantley, Lewis C/D-1800-2014; Pawson, Tony J/E-4578-2013	Di Fiore, Pier Paolo/0000-0002-2252-0950; Cantley, Lewis C/0000-0002-1298-7653; Welsh, Michael/0000-0002-5467-9755				ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASTAGNINO P, 1995, IN PRESS ONCOGENE; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; MELLSTROM K, 1987, MOL CELL BIOL, V7, P4178, DOI 10.1128/MCB.7.12.4178; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SORKIN A, 1993, J CELL PHYSIOL, V156, P373, DOI 10.1002/jcp.1041560221; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WELSH M, 1994, ONCOGENE, V9, P19; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; WENNSTROM S, 1994, ONCOGENE, V9, P651; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	57	61	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1475	1483						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7537362				2022-12-28	WOS:A1995QU68100002
J	CASTAGNINO, P; BIESOVA, Z; WONG, WT; FAZIOLI, F; GILL, GN; DIFIORE, PP				CASTAGNINO, P; BIESOVA, Z; WONG, WT; FAZIOLI, F; GILL, GN; DIFIORE, PP			DIRECT BINDING OF EPS8 TO THE JUXTAMEMBRANE DOMAIN OF EGFR IS PHOSPHOTYROSINE-INDEPENDENT AND SH2-INDEPENDENT	ONCOGENE			English	Article						EPS8; EGFR; JUXTAMEMBRANE; BINDING	GROWTH-FACTOR RECEPTOR; SIGNALING PROTEINS; TYROSINE KINASES; SH3 DOMAINS; PHOSPHORYLATION; SPECIFICITY; THREONINE; ERBB-2	Several signal transducers bind through their SH2 domains to phosphotyrosine-containing motifs present in receptor tyrosine kinases (RTKs). However, the juxtamembrane regions of the epidermal growth factor receptor (EGFR) and of the related erbB-2 protein, while important in mitogenic signaling, lack demonstrable tyrosine phosphorylation sites, suggesting that other modalities of receptor-transducer interactions exist. A candidate for investigating this type of association is p97(eps8), a recently described substrate for RTKs. p97(eps8) is phosphorylated by several RTKs, associates with EGFR in vivo and, upon overexpression, enhances the transduction of EGFR-mediated mitogenic signals. Here we report that eps8 binds directly to the juxtamembrane region of EGFR through a domain that does not bear resemblance to SH2 domains and by a mechanism that does not require the presence of phosphotyrosine residues. Thus, the physical association between EGFR and eps8 represents a novel interaction between RTKs and their substrates.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; FAC MED & CHIRURG BARI, IST MICROBIOL, BARI, ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Diego; Universita degli Studi di Bari Aldo Moro			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013149, R01DK013149] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 13149] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COCHET C, 1991, J BIOL CHEM, V266, P637; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; DOUGALL WC, 1993, J CELL BIOCHEM, V53, P61, DOI 10.1002/jcb.240530108; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHLESSINGER J, 1992, COLD SPRING HARB SYM, V57, P67, DOI 10.1101/SQB.1992.057.01.009; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WONG WT, 1994, ONCOGENE, V9, P3057; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	53	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					723	729						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7532293				2022-12-28	WOS:A1995QH61200012
J	JIANG, W; KAHN, SM; GUILLEM, JG; LU, SH; WEINSTEIN, IB				JIANG, W; KAHN, SM; GUILLEM, JG; LU, SH; WEINSTEIN, IB			RAPID DETECTION OF RAS ONCOGENES IN HUMAN-TUMORS - APPLICATIONS TO COLON, ESOPHAGEAL, AND GASTRIC-CANCER	ONCOGENE			English	Article									COLUMBIA UNIV COLL PHYS & SURG,CTR COMPREHENS CANC,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INST CANC RES,NEW YORK,NY 10032; CHINESE ACAD MED SCI,INST CANC,BEIJING,PEOPLES R CHINA	Columbia University; Columbia University; Chinese Academy of Medical Sciences - Peking Union Medical College				Jiang, Wei/0000-0002-2309-9571				ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ANDERSON MLM, 1988, ANTICANCER RES, V8, P873; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1986, NUCLEIC ACIDS RES, V14, P1209, DOI 10.1093/nar/14.3.1209; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1984, NUCLEIC ACIDS RES, V12, P9155, DOI 10.1093/nar/12.23.9155; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; DENG G, 1988, NUCLEIC ACIDS RES, V16, P6231, DOI 10.1093/nar/16.13.6231; DENG G, 1987, CANCER RES, V47, P3195; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUJITA K, 1987, GASTROENTEROLOGY, V93, P1339, DOI 10.1016/0016-5085(87)90264-2; HIGUCHI R, 1988, NATURE, V332, P543, DOI 10.1038/332543a0; HOLLSTEIN MC, 1988, CANCER RES, V48, P5119; KNUDSON AG, 1985, CANCER RES, V45, P1437; KOZMA SC, 1987, NUCLEIC ACIDS RES, V15, P5963; KUMAR R, 1988, ONCOGENE, V3, P647; LU SH, 1988, INT J CANCER, V42, P502, DOI 10.1002/ijc.2910420406; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; NISHIDA J, 1987, BIOCHEM BIOPH RES CO, V146, P247, DOI 10.1016/0006-291X(87)90717-0; OHARA BM, 1986, CANCER RES, V46, P4695; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VRIES V, 1986, GENE, V50, P313; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WEINSTEIN IB, 1987, J CELL BIOCHEM, V33, P213, DOI 10.1002/jcb.240330308; WINTER E, 1985, P NATL ACAD SCI USA, V82, P7575, DOI 10.1073/pnas.82.22.7575	33	298	315	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					923	928						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2666911				2022-12-28	WOS:A1989AE58400016
J	ROMERO, P; BERAN, M; SHTALRID, M; ANDERSSON, B; TALPAZ, M; BLICK, M				ROMERO, P; BERAN, M; SHTALRID, M; ANDERSSON, B; TALPAZ, M; BLICK, M			ALTERNATIVE 5' END OF THE BCR-ABL TRANSCRIPT IN CHRONIC MYELOGENOUS LEUKEMIA	ONCOGENE			English	Article									UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT CLIN IMMUNOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT BIOL THERAPY,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT HEMATOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center				Talpaz, Moshe/0000-0003-3361-3981				ARRUSHDI A, 1988, ONCOGENE, V2, P353; BERSTEIN R, 1988, SEMIN HEMATOL, V25, P20; BLICK M, 1987, CANCER GENET CYTOGEN, V27, P349, DOI 10.1016/0165-4608(87)90018-5; BLICK MB, 1986, LEUKEMIA RES, V10, P1401, DOI 10.1016/0145-2126(86)90006-8; CATOVSKY D, 1979, AM J CLIN PATHOL, V72, P736; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; COLLINS S, 1987, MOL CELL BIOL, V7, P2870, DOI 10.1128/MCB.7.8.2870; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DREAZEN O, 1988, SEMIN HEMATOL, V25, P35; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, BLOOD, V70, P233; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LIFSHITZ B, 1988, ONCOGENE, V2, P113; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAXWELL SA, 1987, CANCER RES, V47, P1731; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; MESSING J, 1983, METHOD ENZYMOL, V101, P20; NOWELL PC, 1960, SCIENCE, V132, P1497; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUBIN CM, 1988, P NATL ACAD SCI USA, V85, P2795, DOI 10.1073/pnas.85.8.2795; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1987, BLOOD, V69, P971; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; 1978, BRIT J HAEMATOL, V39, P311	40	18	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					93	98						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2915904				2022-12-28	WOS:A1989U567400014
J	LAZARUS, P; PARKIN, N; SONENBERG, N				LAZARUS, P; PARKIN, N; SONENBERG, N			DEVELOPMENTAL REGULATION OF TRANSLATION BY THE 5' NONCODING REGION OF MURINE C-MYC MESSENGER-RNA IN XENOPUS-LAEVIS	ONCOGENE			English	Article									MCGILL UNIV,DEPT BIOCHEM,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA; MCGILL UNIV,CTR CANC,MONTREAL H3G 1Y6,QUEBEC,CANADA	McGill University; McGill University			Parkin, Neil/P-2724-2019					BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; Colman A., 1984, TRANSCRIPTION TRANSL, P49; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; Maxam A.M., 1980, METHODS ENZYMOL, V65, P449; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PARKIN NT, 1988, EMBO J, V7, P2831, DOI 10.1002/j.1460-2075.1988.tb03139.x; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PELLETIER J, 1988, J VIROL, V62, P2219, DOI 10.1128/JVI.62.7.2219-2227.1988; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RICHTER JD, 1982, DEV BIOL, V89, P152; RIVERA VM, 1988, IN PRESS VIROLOGY; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; WASSERMAN WJ, 1986, GAMETOGENESIS EARLY, P111; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	38	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					517	521						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3078957				2022-12-28	WOS:A1988R516300005
J	BIZUB, D; BLAIR, D; ALVORD, G; SKALKA, AM				BIZUB, D; BLAIR, D; ALVORD, G; SKALKA, AM			CORRELATION BETWEEN H-RAS P21TLEU61 PROTEIN-CONTENT AND TUMORIGENICITY OF NIH3T3 CELLS	ONCOGENE			English	Article									FOX CHASE CANC CTR, INST CANC RES, PHILADELPHIA, PA 19111 USA; NCI, FREDERICK CANC RES FACIL, DIV CANC ETIOL, FREDERICK, MD 21701 USA; NCI, FREDERICK CANC RES FACIL, DATA MANAGEMENT SERV, FREDERICK, MD 21701 USA	Fox Chase Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [N01-CO-74103, CA-06927] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074103] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BOS JL, 1986, NUCLEIC ACIDS RES, V14, P1209, DOI 10.1093/nar/14.3.1209; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; DENHARDT DT, 1987, ONCOGENE, V2, P55; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GREIG RG, 1985, P NATL ACAD SCI USA, V82, P3698, DOI 10.1073/pnas.82.11.3698; HERBERMAN RB, 1975, INT J CANCER, V16, P216, DOI 10.1002/ijc.2910160204; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOVITS I, 1977, 2ND P INT WORKSH NUD, P557; OHARA BM, 1986, CANCER RES, V46, P4695; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REDMOND SMS, 1988, ONCOGENE, V2, P259; REYNOLDS VL, 1987, ONCOGENE, V1, P323; SISTONEN L, 1987, EXP CELL RES, V168, P518, DOI 10.1016/0014-4827(87)90024-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	24	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1988	3	4					443	448						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3078952				2022-12-28	WOS:A1988Q773900013
J	BADING, H; GERDES, J; SCHWARTING, R; STEIN, H; MOELLING, K				BADING, H; GERDES, J; SCHWARTING, R; STEIN, H; MOELLING, K			NUCLEAR AND CYTOPLASMIC DISTRIBUTION OF CELLULAR MYB PROTEIN IN HUMAN HEMATOPOIETIC-CELLS EVIDENCED BY MONOCLONAL-ANTIBODY	ONCOGENE			English	Article									MAX PLANCK INST MOLEC GENET,ABT SCHUSTER,IHNESTR 73,D-1000 BERLIN 33,FED REP GER; FREE UNIV BERLIN,KLINIKUM STEGLITZ,INST PATHOL,D-1000 BERLIN 45,FED REP GER	Max Planck Society; Free University of Berlin								ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BADING H, 1987, ONCOGENE, V1, P395; BADING H, 1987, MODERN TRENDS HUMAN, V7, P488; BEIMLING P, 1985, BIOCHEMISTRY-US, V24, P6349, DOI 10.1021/bi00344a005; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; CRAIG RW, 1984, CANCER RES, V44, P442; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; ENGLEMAN EG, 1981, J IMMUNOL, V127, P2124; GERDES J, 1984, J IMMUNOL, V133, P1710; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GROSSO LE, 1984, BIOCHEM BIOPH RES CO, V119, P473, DOI 10.1016/S0006-291X(84)80273-9; HABESHAW JA, 1983, LANCET, V1, P498; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; KADIN ME, 1986, BLOOD, V68, P1042; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLINMAN DM, 1986, J EXP MED, V163, P1292, DOI 10.1084/jem.163.5.1292; MAVILIO F, 1986, P NATL ACAD SCI USA, V83, P4394, DOI 10.1073/pnas.83.12.4394; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; PENMAN S, 1969, FUNDAMENTAL TECHNIQU, P35; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; STEIN H, 1984, ADV CANCER RES, V42, P67, DOI 10.1016/S0065-230X(08)60456-X; STEIN H, 1982, INT J CANCER, V30, P445, DOI 10.1002/ijc.2910300411; STEIN H, 1985, LAB INVEST, V52, P676; STEIN H, 1985, BLOOD, V66, P848; Stein H, 1986, Verh Dtsch Ges Pathol, V70, P127; STEIN H, 1985, RECENT ADV HAEMATOLO, V4, P127; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	48	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					257	265						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	3060791				2022-12-28	WOS:A1988Q436700003
J	BEREBBI, M; DANDOLO, L; HASSOUN, J; BERNARD, AM; BLANGY, D				BEREBBI, M; DANDOLO, L; HASSOUN, J; BERNARD, AM; BLANGY, D			SPECIFIC TISSUE TARGETING OF POLYOMA-VIRUS ONCOGENICITY IN ATHYMIC NUDE-MICE	ONCOGENE			English	Article									UNIV PIERRE & MARIE CURIE,INST RECH SCI CANC,VIRUS ONCOGENES LAB,EQUIPE RECH 272,BP 8,F-94802 VILLEJUIF,FRANCE; INST J PAOLI I CALMETTES,ANAT PATHOL LAB,F-13009 MARSEILLE,FRANCE; CNRS,JE,F-13009 MARSEILLE,FRANCE	UDICE-French Research Universities; Sorbonne Universite; UNICANCER; Institut Paoli-Calmette (IPC); Centre National de la Recherche Scientifique (CNRS)								ALLISON AC, 1974, NATURE, V252, P746, DOI 10.1038/252746a0; AMATI P, 1985, CELL, V43, P561, DOI 10.1016/0092-8674(85)90225-9; ARYA SK, 1982, J GEN VIROL, V63, P405, DOI 10.1099/0022-1317-63-2-405; ARYA SK, 1982, J GEN VIROL, V58, P107, DOI 10.1099/0022-1317-58-1-107; ASSELIN C, 1983, MOL CELL BIOL, V3, P1451, DOI 10.1128/MCB.3.8.1451; Azzopardi JG., 1979, PROBLEMS BREAST PATH, V1st edn; DANDOLO L, 1983, J VIROL, V47, P55, DOI 10.1128/JVI.47.1.55-64.1983; DANDOLO L, 1984, MOL CELL BIOL, V4, P317, DOI 10.1128/MCB.4.2.317; DAWE CJ, 1987, AM J PATHOL, V127, P243; DAWE CJ, 1959, J NATL CANCER I, V23, P717; DAWE CLYDE J., 1960, NATL CANCER INST MONOGR, V4, P67; EDDY BE, 1969, VIROL MONOGR, V7, P1; FLANAGAN SP, 1966, GENET RES, V8, P295, DOI 10.1017/S0016672300010168; FREUND R, 1987, J VIROL, V61, P2232, DOI 10.1128/JVI.61.7.2232-2239.1987; Fried M, 1975, Cold Spring Harb Symp Quant Biol, V39 Pt 1, P45; GIOVANELLA BC, 1985, ADV CANCER RES, V44, P69, DOI 10.1016/S0065-230X(08)60026-3; Herberman R B, 1978, Adv Cancer Res, V27, P305; HERBERMAN RB, 1975, INT J CANCER, V16, P216, DOI 10.1002/ijc.2910160204; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERRINGGILLAM E, 1985, VIRUS RES, V4, P1, DOI 10.1016/0168-1702(85)90016-4; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; ISRAEL MA, 1980, J BIOL CHEM, V255, P3798; KATINKA M, 1980, CELL, V20, P393, DOI 10.1016/0092-8674(80)90625-X; KATINKA M, 1981, NATURE, V290, P720, DOI 10.1038/290720a0; MELIN F, 1985, EMBO J, V4, P1799, DOI 10.1002/j.1460-2075.1985.tb03853.x; MELIN F, 1985, J VIROL, V53, P862, DOI 10.1128/JVI.53.3.862-866.1985; Morris D. W., 1987, ADV VIRAL ONCOL, V7, P123; Pantelouris E M, 1973, Differentiation, V1, P437, DOI 10.1111/j.1432-0436.1973.tb00143.x; PANTELOURIS EM, 1968, NATURE, V217, P370, DOI 10.1038/217370a0; RABSON AS, 1963, J NATL CANCER I, V30, P367; RICHIE JP, 1981, J NATL CANCER I, V62, P761; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART SE, 1957, VIROLOGY, V3, P380, DOI 10.1016/0042-6822(57)90100-9; STUTMAN O, 1975, J IMMUNOL, V114, P1213; VANDEPUTTE M, 1974, INT J CANCER, V14, P445, DOI 10.1002/ijc.2910140404; VASSEUR M, 1980, P NATL ACAD SCI-BIOL, V77, P1068, DOI 10.1073/pnas.77.2.1068; VASSEUR M, 1982, J VIROL, V43, P800, DOI 10.1128/JVI.43.3.800-808.1982	38	32	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					149	156						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	2835724				2022-12-28	WOS:A1988M086000008
J	DHANWADA, KR; DICKENS, M; NEADES, R; DAVIS, R; PELLING, JC				DHANWADA, KR; DICKENS, M; NEADES, R; DAVIS, R; PELLING, JC			DIFFERENTIAL-EFFECTS OF UV-B AND UV-C COMPONENTS OF SOLAR-RADIATION ON MAP KINASE SIGNAL-TRANSDUCTION PATHWAYS IN EPIDERMAL-KERATINOCYTES	ONCOGENE			English	Article						UV-B/C RADIATION; MAP KINASE; KERATINOCYTES; JUN NH2-TERMINAL KINASE (JNK); ERK KINASE	HUMAN-SKIN; ACTIVATION DOMAIN; PROTEIN-KINASE; PHORBOL ESTER; JUN ACTIVITY; PHOSPHORYLATION; RAS; CANCER; GENE; CARCINOGENESIS	Exposure to solar ultraviolet (UV) light is a major cause of skin cancer, the most common human neoplasm. The earth's upper atmosphere absorbs the high energy UV-C wavelengths (100-280 mm), while allowing transmission of UV-B (280-320 nm) and UV-A (320-400 nm). It is therefore UV-B and to some extent UV-A, that contributes to most human skin malignancies. We report that the exposure of cultured keratinocytes or skin to UV-C radiation causes activation of MAP kinases (ERK and JNK). In contrast, the solar radiation associated with skin cancer (UV-B) was an ineffective activator of the ERK and JNK signal transduction pathways. Therefore, while exposure of epidermal cells to UV-C radiation under laboratory conditions causes marked activation of MAP kinase signal transduction pathways, only a low level of MAP kinase signaling is involved in the response of skin to biologically relevant solar radiation.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC,OMAHA,NE; UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,WORCESTER,MA	University of Nebraska System; University of Nebraska Medical Center; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester			Dickens, Martin/B-2001-2012		NCI NIH HHS [CA58396, CA65861, CA40847] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396, R01CA040847, R01CA065861] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, IN PRESS CELL GROWTH; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; BETZ NA, 1995, MOL CARCINOGEN, V12, P66, DOI 10.1002/mc.2940120203; BETZ NA, 1992, MOL CARCINOGEN, V6, P10, DOI 10.1002/mc.2940060104; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK HS, 1985, CANCER RES, V45, P6254; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BUSCHER M, 1988, ONCOGENE, V3, P301; BUZZELL RA, 1993, OTOLARYNG CLIN N AM, V26, P1; CAMPBELL C, 1993, CANCER RES, V53, P2697; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; COWLEY S, 1994, CELL, V11, P841; DARR DJ, 1988, CUTANEOUS AGING, P415; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; HALL PA, 1993, ONCOGENE, V8, P203; HERRLICH P, 1984, ADV ENZYME REGUL, V25, P485; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMBERT WC, 1995, SKIN CANC MECH HUMAN, P39; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LIU M, 1995, ONCOGENE, V10, P1955; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6940; RONAI ZA, 1990, CELL BIOL TOXICOL, V6, P105, DOI 10.1007/BF00135030; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, P910; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STRICKLAND JE, 1988, CANCER RES, V48, P165; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; YAN MH, 1994, NATURE, V372, P798; YUSPA SH, 1991, PHYSL BIOCH MOL BIOL, P1365	58	59	59	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					1947	1953						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478512				2022-12-28	WOS:A1995TF29700003
J	MYERS, SM; ENG, C; PONDER, BAJ; MULLIGAN, LM				MYERS, SM; ENG, C; PONDER, BAJ; MULLIGAN, LM			CHARACTERIZATION OF RET PROTOONCOGENE 3'-SPLICING VARIANTS AND POLYADENYLATION SITES - A NOVEL C-TERMINUS FOR RET	ONCOGENE			English	Article						RET; 3' SPLICING; UTR; POLYADENYLATION	NEUROBLASTOMA CELL-LINES; MYOTONIC-DYSTROPHY; MESSENGER-RNA; TYROSINE KINASE; EXPRESSION; PROTOONCOGENE; GENE; MUTATIONS; ISOFORMS; SEQUENCE	The RET proto-oncogene, which encodes a receptor tyrosine kinase, displays multiple alternative splicing variants. Splicing of sequences 3' of exon 19 to generate several coding and untranslated region (UTR) sequences has been previously reported. We have sequenced the full length RET coding region and characterized the transcripts and 3' UTRs generated by alternative splicing of the RET 3' terminus. These analyses were performed using both RET cDNA cloned from a pheochromocytoma library and reverse transcriptase PCR products generated using RNA from a neuroblastoma cell line (LA-N-2). Three different carboxyl termini were identified. In addition to the nine and 51 terminal amino acid forms already known, we identified a third with 43 terminal amino acids predicted to encode a novel RET protein isoform. A total of 3621 base pairs of DNA 3' of exon 19, which spans the alternatively spliced exons and RET UTRs, was sequenced. Four polyadenylation sites were identified. The observed combinations of polyadenylation sites and 3' coding sequence suggest that RET transcripts with up to 10 different 3' sequences and up to 40 different full length RET transcripts may exist.	QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT PAEDIAT,KINGSTON,ON K7L 3N6,CANADA; UNIV CAMBRIDGE,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115	Queens University - Canada; Queens University - Canada; University of Cambridge; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Eng, Charis/0000-0002-3693-5145				ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; ANGRIST M, 1995, HUM MOL GENET, V4, P821, DOI 10.1093/hmg/4.5.821; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3583; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Borson N D, 1992, PCR Methods Appl, V2, P144; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CECCHERINI I, 1994, ONCOGENE, V9, P3025; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; GARDNER E, 1994, HUM MOL GENET, V3, P1771, DOI 10.1093/hmg/3.10.1771; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HOPPENER J, 1994, 5TH INT WORKSH MULT, P70; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; JHIANG SM, 1991, NUCLEIC ACIDS RES, V19, P4303, DOI 10.1093/nar/19.15.4303; KWOK JBJ, 1993, ONCOGENE, V8, P2575; LORENZO MJ, 1995, ONCOGENE, V10, P1377; MOQADAM F, 1994, CLONTECHNIQUES, V9, P6; MULLIGAN L, 1995, IN PRESS J INT MED; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PESOLE G, 1994, GENE, V140, P219, DOI 10.1016/0378-1119(94)90547-9; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; ROMANO A, 1994, ONCOGENE, V9, P2923; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; Sambrook J, 1989, MOL CLONING LABORATO; SCHUCHARDT A, 1995, ONCOGENE, V10, P641; SINGH IN, 1990, J NEUROSCI RES, V25, P476, DOI 10.1002/jnr.490250405; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WEST GJ, 1977, CANCER RES, V37, P1372	50	132	135	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2039	2045						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478523				2022-12-28	WOS:A1995TF29700014
J	DARVILLE, MI; ANTOINE, IV; MERTENSSTRIJTHAGEN, JR; DUPRIEZ, VJ; ROUSSEAU, GG				DARVILLE, MI; ANTOINE, IV; MERTENSSTRIJTHAGEN, JR; DUPRIEZ, VJ; ROUSSEAU, GG			AN E2F-DEPENDENT LATE-SERUM-RESPONSE PROMOTER IN A GENE THAT CONTROLS GLYCOLYSIS	ONCOGENE			English	Article						CELL CYCLE; E2F; FRUCTOSE-2,6-BISPHOSPHATE; GLYCOLYSIS; SRC; ETS	TRANSCRIPTION FACTOR E2F; EPIDERMAL GROWTH-FACTOR; THYMIDINE KINASE; MESSENGER-RNA; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; CELL-PROLIFERATION; BINDING-SITE; STIMULATION; ASSOCIATION; FIBROBLASTS	The F-type mRNA of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase is found in proliferating, but not in quiescent, cells. This bifunctional enzyme catalyses the synthesis and degradation of fructose-2,6-bisphosphate, a potent stimulator of glycolysis. F-type mRNA concentration decreased upon differentiation of rat rhabdomyosarcoma cells; it increased in Rat-1. fibroblasts stimulated to proliferate by serum, by epidermal growth factor, or by the v-src oncogene product. This increase resulted, at least in part, from a stimulation of F promoter activity. The stimulation occurred at the G(1)/S transition of the cell cycle. It depended on a binding site for the oncogenic transcription factor E2F located in the first exon of F-type mRNA, This effect was inhibited by agents that increase cAMP concentration. The data provide the first evidence that a gene involved in the control of glycolysis can be regulated by a late-serum-response promoter in an E2F-dependent way.	UNIV LOUVAIN,SCH MED,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; INT INST CELLULAR & MOLEC PATHOL,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel								BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DARVILLE MI, 1989, P NATL ACAD SCI USA, V86, P6543, DOI 10.1073/pnas.86.17.6543; DARVILLE MI, 1992, NUCLEIC ACIDS RES, V20, P3575, DOI 10.1093/nar/20.14.3575; DIAMOND I, 1978, J BIOL CHEM, V253, P866; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; DUPRIEZ VJ, 1993, P NATL ACAD SCI USA, V90, P8224, DOI 10.1073/pnas.90.17.8224; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EIGENBRODT E, 1985, REGULATION CARBOHYDR, V2, P141; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GAUTRON S, 1991, NUCLEIC ACIDS RES, V19, P767, DOI 10.1093/nar/19.4.767; GERHARZ CD, 1989, CANCER RES, V49, P7132; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUE L, 1993, ADV ENZYME REGUL, V33, P97; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; MARCHAND MJ, 1992, BIOCHEM J, V285, P413, DOI 10.1042/bj2850413; MATRISIAN LM, 1985, NUCLEIC ACIDS RES, V13, P711, DOI 10.1093/nar/13.3.711; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MEIENHOFER MC, 1983, BIOCHEM J, V214, P195, DOI 10.1042/bj2140195; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PEPPEL K, 1990, BIOTECHNIQUES, V9, P711; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; REICHEL R, 1987, CELL, V48, P501, DOI 10.1016/0092-8674(87)90200-5; ROUSSEAU GG, 1993, PROG NUCLEIC ACID RE, V45, P99, DOI 10.1016/S0079-6603(08)60868-5; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; WEINHOUSE S, 1976, Z KREBSFORSCH KLIN O, V87, P115; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357	47	39	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1509	1517						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478575				2022-12-28	WOS:A1995TC53500009
J	PROSCHEL, C; BLOUIN, MJ; GUTOWSKI, NJ; LUDWIG, R; NOBLE, M				PROSCHEL, C; BLOUIN, MJ; GUTOWSKI, NJ; LUDWIG, R; NOBLE, M			LIMK1 IS PREDOMINANTLY EXPRESSED IN NEURAL TISSUES AND PHOSPHORYLATES SERINE, THREONINE AND TYROSINE RESIDUES IN-VITRO	ONCOGENE			English	Article						LIMK1; LIM-DOMAIN; PROTEIN KINASE; CHROMOSOME 5; MOUSE	CYSTEINE-RICH PROTEIN; POLYMERASE CHAIN-REACTION; ZINC-FINGER MOTIF; T-CELL ONCOGENE; KINASE FAMILY; DEVELOPMENTAL REGULATION; CONSERVED FEATURES; POINT MUTATIONS; INSULIN GENE; KIT RECEPTOR	We have isolated the murine Limk1 gene, which is a single copy gene located at the distal end of mouse chromosome 5. Limk1 exhibits a 95% homology to the human homologue, LIMK, which contains two LIM domains and a putative protein kinase domain. Although Limk1 and LIMK contain all motifs found in catalytic kinase domains, amino acids previously described to be diagnostic of either serine/threonine- or tyrosine-kinases are not present. It is demonstrated that GST-Limk1-fusion protein can autophosphorylate on serine, tyrosine and threonine residues in vitro and that mutation of residue D460 within the IHRDL motif abolishes kinase activity. Northern blot showed preferential expression of a 3.5 kb message in adult spinal cord and brain. In situ hybridisation confirmed high expression levels in the nervous system, particularly in the spinal cord and the cranial nerve and dorsal root ganglia. Limk1 also contains two tandem LIM-domains. These zinc-finger like domains can mediate protein-protein interactions and have been described in nuclear and cytoskeletal proteins. The combination of LIM- and kinase domains may provide a novel route by which intracellular signalling can be integrated.			PROSCHEL, C (corresponding author), LUDWIG INST CANC RES, 91 RIDING HOUSE ST, LONDON W1P 8BT, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; ARCHER VEV, 1994, P NATL ACAD SCI USA, V91, P316, DOI 10.1073/pnas.91.1.316; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; DAVIES AH, 1993, BIO-TECHNOL, V11, P933, DOI 10.1038/nbt0893-933; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONG JL, 1991, MOL ENDOCRINOL, V5, P1633, DOI 10.1210/mend-5-11-1633; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FISCH P, 1992, ONCOGENE, V7, P2389; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEVIN DE, 1987, P NATL ACAD SCI USA, V84, P6035, DOI 10.1073/pnas.84.17.6035; LI PM, 1991, P NATL ACAD SCI USA, V88, P9210, DOI 10.1073/pnas.88.20.9210; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; MIZUNO K, 1994, ONCOGENE, V9, P1605; MORAN MF, 1988, ONCOGENE, V3, P665; NADEAU JH, 1984, P NATL ACAD SCI-BIOL, V81, P814, DOI 10.1073/pnas.81.3.814; NORNES HO, 1974, BRAIN RES, V73, P121, DOI 10.1016/0006-8993(74)91011-7; OKANO I, 1993, FEBS LETT, V333, P51, DOI 10.1016/0014-5793(93)80373-3; ORKIN SH, 1992, BLOOD, V80, P575; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; PEREZALVARADO GC, 1994, STRUCT BIOL, V1, P388; PLACZEK M, 1991, DEVELOPMENT, P105; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REITH AD, 1993, ONCOGENE, V8, P45; ROWE LB, 1994, MAMMALIAN GENOME, V5; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SAMBROOK KJ, 1989, MOL CLONING LABORATO; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Scott J D, 1992, Curr Opin Neurobiol, V2, P289, DOI 10.1016/0959-4388(92)90117-4; TAIRA M, 1993, DEV BIOL, V159, P245, DOI 10.1006/dbio.1993.1237; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; TAYLOR SS, 1992, CURR OPIN STRUC BIOL, V2, P743; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; TURNER CE, 1994, J CELL SCI, V107, P1583; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; WILKINSON DG, 1992, IN SITU HYBRIDSATION; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WOODGETT JR, 1989, RECEPTORS PRACTICAL, P133; WU RY, 1994, J BIOL CHEM, V269, P25085; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	82	97	99	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1271	1281						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478547				2022-12-28	WOS:A1995RY96700007
J	HAWLEY, RG; FONG, AZC; NGAN, BY; HAWLEY, TS				HAWLEY, RG; FONG, AZC; NGAN, BY; HAWLEY, TS			HEMATOPOIETIC TRANSFORMING POTENTIAL OF ACTIVATED RAS IN CHIMERIC MICE	ONCOGENE			English	Article						RAS ONCOGENE; LEUKEMOGENESIS; MSCV RETROVIRAL VECTOR	ACUTE MYELOID-LEUKEMIA; MURINE SARCOMA-VIRUS; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CELL ANTIGEN RECEPTOR; MODIFIED BONE-MARROW; V-HA-RAS; NUCLEOTIDE-SEQUENCE; GENE-TRANSFER; MYELOPROLIFERATIVE DISEASE	Although activating mutations in ras genes are the most common genetic abnormality in human hematologic malignancies, the role of ras mutations as an initiating event in leukemogenesis remains unclear, To assess the consequences of ectopic expression of an activated ras gene in normal hematopoietic cells in vivo, lethally irradiated mice were reconstituted with bone marrow cells infected with a mutant ras-containing retrovirus [murine stem cell virus (MSCV)-v-H-ras] based on the MSCV retroviral vector which efficiently transduces functional genes into hematopoietic stem/progenitor cells, Despite a marked myeloid leukocytosis detectable in the peripheral blood within 4 weeks of engraftment, none of 22 primary or secondary transplant recipients studied for longer periods of time presented with myeloid neoplasms, Instead, 18 of the MSCV-v-H-ras mice developed pre-T-celI thymic lymphomas and/or pre-B-cell lymphoblastic leukemia/lymphomas between 7 and 12 weeks post-transplantation. The pre-B and pre-T lymphoid tumors that arose in one animal were shown to harbor a; common MSCV-v-H-ras provirus, indicating that the target cell for transformation was a bipotential lymphoid precursor. To more precisely examine the effects of activated ras expression on the behavior of hematopoietic progenitors, infected bone marrow cells were assayed in methylcellulose cultures under conditions favorable for growth of multilineage myeloid colonies or were passaged as bulk suspension cultures in the presence of various hematopoietic growth factors, including interleukin (IL)-3, IL-4, IL-6 and IL-7. MSCV-directed expression of v-H-ras selectively promoted the formation of large dense colonies comprised of monocyte-macrophages in methylcellulose cultures. When transferred to liquid cultures, the vast majority of the cells underwent terminal macrophage differentiation, By comparison, tumorigenic B-lymphoid and mixed lymphoid/myeloid cell lines were routinely established from the bulk suspension cultures, with cell lines of predominantly myeloid phenotype emerging only in IL-6-supplemented cultures/ These results, considered together with previous findings, suggest that activating ras mutations could be an initiating genetic alteration in human acute lymphoblastic leukemia but are more Likely to be a postinitiation change in human acute myeloid leukemia.	UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT MED BIOPHYS, TORONTO, ON M4N 3M5, CANADA; UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT PATHOL, TORONTO, ON M4N 3M5, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	HAWLEY, RG (corresponding author), UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DIV CANC BIOL, 2075 BAYVIEW AVE, TORONTO, ON M4N 3M5, CANADA.			Hawley, Robert/0000-0003-3512-5818				ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; AHUJA HG, 1990, BLOOD, V75, P1684; ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; ANTICA M, 1994, BLOOD, V84, P111; BASHEY A, 1992, BLOOD, V79, P981; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BERGER LC, 1994, BIOCHEM BIOPH RES CO, V202, P596, DOI 10.1006/bbrc.1994.1970; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CARDIFF RD, 1993, AM J PATHOL, V142, P1199; COGSWELL PC, 1989, BLOOD, V74, P2629; CUMANO A, 1992, EMBO J, V11, P593, DOI 10.1002/j.1460-2075.1992.tb05091.x; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; DIBIRDIK I, 1991, BLOOD, V78, P564, DOI 10.1182/blood.V78.3.564.bloodjournal783564; DUNBAR CE, 1991, ONCOGENE RES, V6, P39; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; FRANZ T, 1985, NATURE, V315, P149, DOI 10.1038/315149a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GOODWIN RG, 1991, CYTOKINE HDB, P191; HAGAG N, 1990, ONCOGENE, V5, P1481; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HARRIS JF, 1992, J IMMUNOL METHODS, V148, P199, DOI 10.1016/0022-1759(92)90173-Q; HAUPT Y, 1992, ONCOGENE, V7, P981; HAWLEY RG, 1994, ONCOGENE, V9, P1; HAWLEY RG, 1994, GENE THER, V1, P136; HAWLEY RG, 1994, STEM CELLS, V12, P155; HAWLEY RG, 1993, J EXP MED, V178, P1175, DOI 10.1084/jem.178.4.1175; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; Hawley RG, 1995, ANN NY ACAD SCI, V762, P294; HAWLEY TS, 1991, LEUKEMIA RES, V15, P659, DOI 10.1016/0145-2126(91)90068-5; HAWLEY TS, 1991, CYTOKINE, V3, P60, DOI 10.1016/1043-4666(91)90011-2; HIBI S, 1993, BLOOD, V81, P1841; HIRSCHGINSBERG C, 1990, BLOOD, V76, P1214; HOANG T, 1988, BLOOD, V72, P823; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P6687, DOI 10.1073/pnas.82.19.6687; HOLMES KL, 1986, J EXP MED, V164, P443, DOI 10.1084/jem.164.2.443; IWAMOTO A, 1987, J EXP MED, V165, P591, DOI 10.1084/jem.165.3.591; JACOBSON DR, 1994, ONCOGENE, V9, P553; KALEKO M, 1990, BLOOD, V75, P1733; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAWAKAMI T, 1980, NUCLEIC ACIDS RES, V8, P3933, DOI 10.1093/nar/8.17.3933; KELLER G, 1989, GENE DEV, V3, P827, DOI 10.1101/gad.3.6.827; KISHNER MB, 1994, P NATL ACAD SCI USA, V76, P253; LEONARD EJ, 1990, BIOTECHNIQUES, V9, P684; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUBBERT M, 1992, ONCOGENE, V7, P263; LUBBERT M, 1990, BLOOD, V75, P1163; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATSUZAKI Y, 1993, J EXP MED, V178, P1283, DOI 10.1084/jem.178.4.1283; MAYER A, 1982, NATURE, V295, P253; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; NAOE T, 1993, BLOOD, V82, P2260, DOI 10.1182/blood.V82.7.2260.bloodjournal8272260; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; NEUBAUER A, 1994, BLOOD, V83, P1603; OVERELL RW, 1989, ONCOGENE, V4, P1425; PAQUETTE RL, 1993, BLOOD, V82, P590, DOI 10.1182/blood.V82.2.590.bloodjournal822590; PATTENGALE PK, 1983, AM J PATHOL, V113, P235; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PIERCE JH, 1982, J EXP MED, V156, P873, DOI 10.1084/jem.156.3.873; PIERCE JH, 1985, MOL CELL BIOL, V5, P667, DOI 10.1128/MCB.5.4.667; PRICE CM, 1994, BRIT J HAEMATOL, V88, P338, DOI 10.1111/j.1365-2141.1994.tb05028.x; RADICH JP, 1990, BLOOD, V76, P801; Sambrook J, 1989, MOL CLONING LABORATO; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SIRINIAN MI, 1993, ONCOGENE, V8, P157; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; WILLIAMS DA, 1990, HUM GENE THER, V1, P229, DOI 10.1089/hum.1990.1.3-229; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617	78	43	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	1995	11	6					1113	1123						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566971				2022-12-28	WOS:A1995RX18000014
J	OBEYESEKERE, MN; HERBERT, JR; ZIMMERMAN, SO				OBEYESEKERE, MN; HERBERT, JR; ZIMMERMAN, SO			A MODEL OF THE G1 PHASE OF THE CELL-CYCLE INCORPORATING CYCLIN E/CDK2 COMPLEX AND RETINOBLASTOMA PROTEIN	ONCOGENE			English	Article						CYCLIN E; CDK2; RB; G1; CELL CYCLE; MATHEMATICAL MODELS	SUSCEPTIBILITY GENE-PRODUCT; MAMMALIAN FIBROBLASTS; DNA-REPLICATION; DEPHOSPHORYLATION; PHOSPHORYLATION; BINDING; GROWTH; IDENTIFICATION; PROGRESSION; EXPRESSION	A mathematical model of cyclin E, cdk2 and retinoblastoma protein control of the G1 phase of the human cell cycle is proposed. The model includes retinoblastoma (Rb) protein phosphorylation by a cyclin E/cdk2 complex and its subsequent dephosphorylation at the end of the cell cycle. The numerical solutions to this model demonstrates the cyclic behavior of the cyclin E/cdk2 complex, with and without Rb function, cell cycle. This model suggests an inhibition of cyclin E/cdk2 complex formation (or its activation) by hypophosphorylated retinoblastoma protein. The experimental results of cell cycle arrest upon injection of transforming growth factor-beta, alpha-interferon or D-erythro-sphingosine during G1 phase are reproduced. Cell cycle behavior predicted by this model for increasing the concentration of hypophosphorylated retinoblastoma protein during the G1 phase is discussed. Additional results are obtained by numerical simulation.	UNIV TEXAS,SCH MED,HOUSTON,TX	University of Texas System	OBEYESEKERE, MN (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOMATH,BOX 237,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BYBEE A, 1993, CELL CYCLE 93 REGULA; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHAO R, 1992, J BIOL CHEM, V267, P23459; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, CELL CYCLE 93 REGULA; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; NOREL R, 1991, SCIENCE, V251, P1076, DOI 10.1126/science.1825521; OBEYESEKERE MN, 1994, CELL PROLIFERAT, V27, P105, DOI 10.1111/j.1365-2184.1994.tb01409.x; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; REED SI, 1991, COLD SH Q B, V56, P61; REED SI, 1992, P AM ASSOC CANC RES, V33, pA574; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1993, CELL CYCLE 93 REGULA; TYSON JJ, 1991, P NATL ACAD SCI USA, V88, P7328, DOI 10.1073/pnas.88.16.7328; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	32	43	44	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1199	1205						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566981				2022-12-28	WOS:A1995RX18000024
J	KIRCHHOFF, S; KOROMILAS, AE; SCHAPER, F; GRASHOFF, M; SONENBERG, N; HAUSER, H				KIRCHHOFF, S; KOROMILAS, AE; SCHAPER, F; GRASHOFF, M; SONENBERG, N; HAUSER, H			IRF-1 INDUCED CELL-GROWTH INHIBITION AND INTERFERON INDUCTION REQUIRES THE ACTIVITY OF THE PROTEIN-KINASE PKR	ONCOGENE			English	Article						IRF-1; INTERFERON-BETA; PROLIFERATION; PROTEIN KINASE PKR; TUMOR SUPPRESSOR	REGULATORY FACTOR-I; IFN-INDUCIBLE GENES; CONSTITUTIVE EXPRESSION; TRANSCRIPTION FACTOR; BETA PROMOTERS; P68 KINASE; RESISTANCE; ELEMENTS; ACTIVATION; VIRUS	Expression of the tumor suppressor IRF-1 results in the inhibition of cell growth and transcriptional activation of the IFN-beta gene. IFN production is not responsible for the IRF-1 mediated cell growth inhibition. It is shown here that activation of IRF-1 causes induction of PKR expression, PKR is a serine/threonine kinase with tumor suppressor activity. IRF-1 mediated cell growth inhibition and IFN induction correlates with PKR expression. A catalytically inactive dominant negative PKR mutant abolishes both activities of IRF-1. These data demonstrate that the tumor suppressor activity of IRF-1 is mediated, at least in part, by PKR.	GESELL BIOTECHNOL FORSCH MBH,GENET EUKARYOTES,D-38124 BRAUNSCHWEIG,GERMANY; MCGILL UNIV,JEWISH GEN HOSP,LADY DAVIS INST MED RES,DEPT ONCOL & EXPTL MED,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA	Gesellschaft fur Biotechnologische Forschung mbH; Lady Davis Institute; McGill University; McGill University; McGill University			Schaper, Fred/F-1403-2013	Schaper, Fred/0000-0002-8899-5414				BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOULTWOOD J, 1993, BLOOD, V82, P2611; CHANG CH, 1992, IMMUNOGENETICS, V35, P378; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; DAIGNEAULT L, 1992, NUCLEIC ACIDS RES, V20, P2749, DOI 10.1093/nar/20.11.2749; DINTER H, 1987, EMBO J, V6, P599, DOI 10.1002/j.1460-2075.1987.tb04796.x; DIRKS W, 1989, J INTERFERON RES, V9, P125, DOI 10.1089/jir.1989.9.125; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HISCOTT J, 1989, J VIROL, V63, P2504; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; ICELY PL, 1991, J BIOL CHEM, V266, P16073; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LACOSTE J, 1990, J VIROL, V64, P4726, DOI 10.1128/JVI.64.10.4726-4734.1990; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; Sambrook J, 1989, MOL CLONING LABORATO; SEN GC, 1992, J BIOL CHEM, V267, P5017; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMADA G, 1991, P NATL ACAD SCI USA, V88, P532, DOI 10.1073/pnas.88.2.532; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	44	107	111	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					439	445						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7543195				2022-12-28	WOS:A1995RN53000003
J	ELSON, A; DENG, CX; CAMPOSTORRES, J; DONEHOWER, LA; LEDER, P				ELSON, A; DENG, CX; CAMPOSTORRES, J; DONEHOWER, LA; LEDER, P			THE MMTV/C-MYC TRANSGENE AND P53 NULL ALLELES COLLABORATE TO INDUCE T-CELL LYMPHOMAS, BUT NOT MAMMARY CARCINOMAS IN TRANSGENIC MICE	ONCOGENE			English	Article						C-MYC; P53; COLLABORATION; T-CELL LYMPHOMA; MAMMARY CARCINOMA	C-MYC; P53-DEFICIENT MICE; BREAST-CANCER; GROWTH-FACTOR; N-MYC; TUMORS; GENE; ONCOGENE; MUTATION; CARCINOGENESIS	A number of properties of the cancer-related genes c-myc and p53 suggest that they might collaborate to induce tumorigenesis, To test this notion, we produced doubly heterozygotic mice bearing disrupted p53 alleles and a fusion transgene consisting of the mouse mammary tumor virus (MMTV) I;TR and the oncogene c-myc. Mice bearing both the MMTV/c-myc transgene and a single p53(-) allele develop very aggressive pre-T- and T-cell lymphomas with a significantly shorter latency than mice carrying either the p53- allele or the c-myc transgene alone, Moreover, every lymphoma occurring in these animals has lost or suffers an inactivation of its wild type p53 allele indicating that loss of p53 activity is necessary for this c-myc-accelerated lymphomagenesis. Nonetheless, p53 inactivation and expression of the MMTV/c-myc transgene are not sufficient for lymphoid transformation, Tumors that arise in homozygous p53(-) mice carrying the c-myc transgene are monoclonal, suggesting that at least one additional event is necessary for their transformation, Moreover, since mice bearing only the MMTV/c-myc transgene predominantly develop mammary carcinomas, it was surprising that the p53(-) allele failed to accelerate the incidence of mammary carcinomas, Further, in contrast to the lymphomas, only one in four mammary tumors that arose in the double heterozygotic mice had lost its wild type p53 allele, Apparently cell context influences the ability of c-myc and p53(-) to cooperate in inducing oncogenesis.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115; BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Baylor College of Medicine				Elson, Ari/0000-0001-9808-9135				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BERNS A, 1991, J CELL BIOCHEM, V47, P130, DOI 10.1002/jcb.240470206; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; EELES RA, 1993, CANCER SURV, V18, P57; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; GUTIERREZ MI, 1992, CANCER RES, V52, P1032; HARPER JW, 1993, CELL, V75, P805; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU B, 1995, ONCOGENE, V11, P175; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IMAMURA J, 1993, CANCER RES, V53, P4053; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KREIPE H, 1993, CANCER RES, V53, P1956; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, BRIT J CANCER, V69, P409; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MOROY T, 1991, ONCOGENE, V6, P1941; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PURDIE CA, 1994, ONCOGENE, V9, P603; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOLZENBERG MC, 1994, ONCOGENE, V9, P2799; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRANGE R, 1992, DEVELOPMENT, V115, P49; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUBURA A, 1988, CANCER RES, V48, P6555; VARLEY JM, 1991, ONCOGENE, V6, P413; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	48	76	79	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					181	190						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624126				2022-12-28	WOS:A1995RJ29500021
J	MIYASHIRO, I; SENDA, T; MATSUMINE, A; BAEG, GH; KURODA, T; SHIMANO, T; MIURA, S; NODA, T; KOBAYASHI, S; MONDEN, M; TOYOSHIMA, K; AKIYAMA, T				MIYASHIRO, I; SENDA, T; MATSUMINE, A; BAEG, GH; KURODA, T; SHIMANO, T; MIURA, S; NODA, T; KOBAYASHI, S; MONDEN, M; TOYOSHIMA, K; AKIYAMA, T			SUBCELLULAR-LOCALIZATION OF THE APC PROTEIN - IMMUNOELECTRON MICROSCOPIC STUDY OF THE ASSOCIATION OF THE APC PROTEIN WITH CATENIN	ONCOGENE			English	Article						TUMOR SUPPRESSOR GENE; APC; FAP; CATENIN; COLORECTAL TUMOR	FAMILIAL ADENOMATOUS POLYPOSIS; MULTIPLE INTESTINAL NEOPLASIA; CANCER CELL-LINE; GENE-PRODUCT; MUTATIONS; CHROMOSOME-5Q21; IDENTIFICATION; EXPRESSION; FAP	Mutations in the APC gene are linked to the development of sporadic colorectal tumors as well as to familial adenomatous polyposis, Recently, the APC protein was reported to associate with catenins, proteins that bind to the cell adhesion molecule E-cadherin, In the present study, we examined the distribution and localization of the APC protein and alpha-catenin in the normal mouse intestine by light and immunoelectron microscopy using specific antibodies, The APC protein was found to be localized in microvilli and in the apical and lateral cytoplasm of the epithelial cells, whereas alpha-catenin was detected only in the lateral cytoplasm. Double-labeling immunoelectron microscopy showed colocalization of the APC protein with alpha-catenin in the lateral cytoplasm, especially along the lateral plasma membrane, although a certain portion of the APC protein in this region was distributed independently of alpha-catenin. These results suggest that a portion of the APC protein localized in the lateral cytoplasm of intestinal epithelial cells functions in cooperation with catenins, whereas the APC protein in microvilli and in the apical cytoplasm has other functions independent of catenins.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT ONCOGENSE RES,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT SURG 2,SUITA,OSAKA 565,JAPAN; NAGOYA UNIV,SCH MED,DEPT ANAT 1,SHOWA KU,NAGOYA,AICHI 466,JAPAN; UNIV TOKYO,INST MED SCI,DEPT PATHOL,MINATO KU,TOKYO 108,JAPAN; JAPANESE FDN CANC RES,INST CANC,DEPT CELL BIOL,TOSHIMA KU,TOKYO 170,JAPAN	Osaka University; Osaka University; Nagoya University; University of Tokyo; Japanese Foundation for Cancer Research			Baeg, Gyeong-Hun/A-2951-2008; Noda, Tetsuo/B-1667-2016	Kuroda, Toshihiko/0000-0001-6660-8930				BHAT RV, 1994, J NEUROSCI, V14, P3059; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; GARDNER EJ, 1953, AM J HUM GENET, V5, P139; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MUNEMITSU S, 1994, CANCER RES, V54, P3676; NAGAFUCHI A, 1994, DEV GROWTH DIFFER, V36, P59; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; ODA T, 1993, BIOCHEM BIOPH RES CO, V193, P897, DOI 10.1006/bbrc.1993.1710; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SENDA T, 1991, HISTOCHEMISTRY, V96, P25, DOI 10.1007/BF00266757; SHIBATA T, 1994, BIOCHEM BIOPH RES CO, V203, P519, DOI 10.1006/bbrc.1994.2213; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SMITH KJ, 1994, CANCER RES, V54, P3672; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1993, CANCER RES, V53, P2728; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z	30	95	96	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					89	96						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624136				2022-12-28	WOS:A1995RJ29500011
J	TAKAISHI, K; SASAKI, T; KAMEYAMA, T; TSUKITA, S; TSUKITA, S; TAKAI, Y				TAKAISHI, K; SASAKI, T; KAMEYAMA, T; TSUKITA, S; TSUKITA, S; TAKAI, Y			TRANSLOCATION OF ACTIVATED RHO FROM THE CYTOPLASM TO MEMBRANE RUFFLING AREA, CELL-CELL ADHESION SITES AND CLEAVAGE FURROWS	ONCOGENE			English	Article						SMALL GTP-BINDING PROTEIN; RHOA; ERM FAMILY; CD44; MEMBRANE RUFFLING; CELL-CELL ADHESION; CYTOKINESIS	GTP-BINDING-PROTEIN; BOTULINUM ADP-RIBOSYLTRANSFERASE; SWISS 3T3 CELLS; GENE-PRODUCT; CLOSTRIDIUM-BOTULINUM; FOCAL ADHESIONS; BRAIN CYTOSOL; RIBOSYLATION; PURIFICATION; GDI	Rho small GTP-binding protein regulates various cell functions, such as formation of stress fibers and focal adhesions, cell motility, membrane ruffling, cytokinesis and smooth muscle contraction in mammalian cells and bud formation in the yeast Saccharomyces cerevisiae. As to the functioning sites of Rho in Saccharomyces cerevisiae, we have recently shown that RHO1 protein, a homologue of mammalian RhoA, is concentrated to the growth region of the cells where cortical actin patches are clustered. However, in mammalian cells, the functioning sites of Rho have not yet been studied. In the present study, MDCK cell lines stably expressing myc-tagged RhoA (myc-RhoA) were prepared and localization of myc-RhoA was first immunohistochemically examined using an anti-myc antibody. In the resting cells, almost all of myc-RhoA was observed in the cytosol. When the cells were stimulated with phorbol ester or hepatocyte growth factor, membrane rufflings were induced and myc-RhoA was translocated to the membrane ruffling area. Moreover, myc-RhoA was translocated from the cytosol to the cell-cell adhesion sites when the cells were transferred from a low to normal Ca2+ medium. RhoA was also concentrated to the cleavage furrows during cytokinesis in Swiss 3T3 cells. Translocation of myc-RhoA to the membrane ruffling area was inhibited by prior microinjection into the cells of Rho GDI, a negative regulator of Rho which inhibits activation of Rho, or of C3, an exoenzyme of Clostridium botulinum which ADP-ribosylates Rho and inhibits its functions, indicating that both activation and functioning of Rho are essential for the translocation of Rho. The ERM (Ezrin, Radixin, Moesin) family members were colocalized with RhoA at all of these sites. However, RhoA was not apparently observed at the focal adhesion plaque where vinculin was localized. These results suggest that at least one of the functioning sites of Rho is the ERM family-controlled actin filament/plasma membrane association sites.	OSAKA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,SUITA,OSAKA 565,JAPAN; KYOTO UNIV,COLL MED TECHNOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT CELL BIOL,KYOTO 606,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Osaka University; Kyoto University; Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)								ABERCROMBIE M, 1970, EXP CELL RES, V60, P437, DOI 10.1016/0014-4827(70)90537-9; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; DIPASQUALE A, 1975, EXP CELL RES, V94, P191, DOI 10.1016/0014-4827(75)90545-5; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HIRATA K, 1992, J BIOL CHEM, V267, P8719; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LANG P, 1992, J BIOL CHEM, V267, P11677; LANKES W, 1988, BIOCHEM J, V251, P831, DOI 10.1042/bj2510831; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MIURA Y, 1993, J BIOL CHEM, V268, P510; MORII N, 1992, J BIOL CHEM, V267, P20921; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; PAKKANEN R, 1987, J HISTOCHEM CYTOCHEM, V135, P809; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SATO N, 1992, J CELL SCI, V103, P131; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SELF AJ, 1993, ONCOGENE, V8, P655; SHIMIZU K, 1991, BIOCHEM BIOPH RES CO, V175, P199, DOI 10.1016/S0006-291X(05)81220-3; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZHANG J, 1993, J BIOL CHEM, V268, P22251	50	193	196	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					39	48						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624130				2022-12-28	WOS:A1995RJ29500006
J	HARRISONFINDIK, D; SUSA, M; VARTICOVSKI, L				HARRISONFINDIK, D; SUSA, M; VARTICOVSKI, L			ASSOCIATION OF PHOSPHATIDYLINOSITOL 3-KINASE WITH SHC IN CHRONIC MYELOGENEOUS LEUKEMIA-CELLS	ONCOGENE			English	Article						BCR/ABL; SHC; SH2; SH3; PI 3-KINASE; TYROSINE PHOSPHORYLATION	SIGNAL TRANSDUCTION; TYROSINE KINASES; PHOSPHOINOSITIDE 3-KINASE; PHILADELPHIA-CHROMOSOME; MITOGENIC SIGNAL; ADAPTER PROTEIN; PI 3-KINASE; RAS; DOMAIN; TRANSFORMATION	Expression of p210 BCR/abl oncoprotein transforms hematopoietic cells. P210 BCR/abl tyrosine kinase induces tyrosine phosphorylation of Shc, and activation of p21(ras) and PI 3-Kinase. Here we show that PI 3-Kinase associates with She in cells transformed by BCR/abl oncoprotein. Immunoprecipitation of Shc from cells expressing p210 BCR/abl had 7.5-fold increase in PI 3-Kinase activity compared to parental cells. Tyrosine phosphorylated She specifically bound to the C-SH2 domain of the p85 subunit of PI 3-Kinase. The p85 SH3 domain also interacted with She in cell lysates from parental and transformed cells. The binding of p85 SH3 domain to She was substantially higher in BCR/abl transformed than in parental cells. Phenylphosphate blocked p85 SH2 mediated association with She but enhanced the binding of the p85 SH3 domain to She. The N-terminal proline-rich region of She between A263 and N273 specifically blocked the interaction of p85 SH3 domain with She. Our results indicate that PI 3-Kinase interacts with She directly in hematopoietic cells which express p210 BCR/abl oncoprotein.	TUFTS UNIV, SCH MED, ST ELIZABETHS MED CTR, DEPT MED, BOSTON, MA 02135 USA; TUFTS UNIV, SCH MED, ST ELIZABETHS MED CTR, DEPT BIOMED RES, BOSTON, MA 02135 USA	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University				Varticovski, Lyuba/0000-0002-5105-9008	NCI NIH HHS [R29CA530094] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1993, SCIENCE, V260, P737; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANDANAS RA, 1993, BLOOD, V82, P1838; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MINAMI Y, 1991, J BIOL CHEM, V266, P9222; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RREN R, 1993, SCIENCE, V259, P1157; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUSA M, 1992, J BIOL CHEM, V267, P22951; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992	53	68	68	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1385	1391						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7537361				2022-12-28	WOS:A1995QR65100016
J	DENNIS, JW; KOSH, K; BRYCE, DM; BREITMAN, ML				DENNIS, JW; KOSH, K; BRYCE, DM; BREITMAN, ML			ONCOGENES CONFERRING METASTATIC POTENTIAL INDUCE INCREASED BRANCHING OF ASN-LINKED OLIGOSACCHARIDES IN RAT2 FIBROBLASTS	ONCOGENE			English	Article									UNIV TORONTO, DEPT MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto	DENNIS, JW (corresponding author), MT SINAI HOSP, RES INST, DIV CANC & CELL BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA.		Dennis, James/E-7268-2013	Bryce, Dawn/0000-0002-7403-2940				AUERSPERG N, 1987, CANCER RES, V47, P6341; BRILES EB, 1982, INT REV CYTOL, V75, P101, DOI 10.1016/S0074-7696(08)61003-7; BROCKHAUSEN I, 1988, BIOCHEM CELL BIOL, V66, P1134, DOI 10.1139/o88-131; CHEN JW, 1988, J BIOL CHEM, V263, P8754; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DEKORTE D, 1987, CANCER RES, V47, P1841; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1986, CANCER RES, V46, P5131; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMMARSTROM S, 1982, P NATL ACAD SCI-BIOL, V79, P1611, DOI 10.1073/pnas.79.5.1611; HUMPHRIES MJ, 1986, CANCER RES, V46, P5215; KERBEL RS, 1979, AM J PATHOL, V97, P609; LAFERTE S, 1989, BIOCHEM J, V259, P569, DOI 10.1042/bj2590569; LAFERTE S, 1988, CANCER RES, V48, P4743; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAUNTENBERG JA, 1981, P NATL ACAD SCI USA, V78, P1518; MCGUIRE WL, 1987, SCIENCE, V235, P177; MUSCHEL RJ, 1985, AJP, V21, P1; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PIERCE M, 1986, J BIOL CHEM, V261, P772; SANTER UV, 1984, CANCER RES, V44, P3730; SANTER UV, 1979, BIOCHEMISTRY-US, V18, P2533, DOI 10.1021/bi00579a016; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMETS LA, 1983, BIOCHIM BIOPHYS ACTA, V738, P237, DOI 10.1016/0304-419X(83)90006-9; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; TAKASAKI S, 1980, BIOCHEM BIOPH RES CO, V92, P735, DOI 10.1016/0006-291X(80)90765-2; TRIMBLE WS, 1986, NATURE, V321, P782, DOI 10.1038/321782a0; VOUSDEN KH, 1986, INT J CANCER, V37, P425, DOI 10.1002/ijc.2910370315; WAGHORNE C, 1987, ONCOGENE, V1, P149; WARREN L, 1972, P NATL ACAD SCI USA, V69, P1838, DOI 10.1073/pnas.69.7.1838; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WEINMASTER G, 1986, J BIOL CHEM, V261, P328; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834	36	100	100	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1989	4	7					853	860						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2666906				2022-12-28	WOS:A1989AE58400006
J	VECCHIO, G; CAVAZZANA, AO; TRICHE, TJ; RON, D; REYNOLDS, CP; EVA, A				VECCHIO, G; CAVAZZANA, AO; TRICHE, TJ; RON, D; REYNOLDS, CP; EVA, A			EXPRESSION OF THE DBL PROTO-ONCOGENE IN EWINGS SARCOMAS	ONCOGENE			English	Article									NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1E24,BETHESDA,MD 20892; NCI,PATHOL LAB,BETHESDA,MD 20892; CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Consiglio Nazionale delle Ricerche (CNR); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Eva, Alessandra/J-8268-2016	Eva, Alessandra/0000-0003-2949-078X; Reynolds, C. Patrick/0000-0002-2827-8536				ASKIN FB, 1979, CANCER, V43, P2438, DOI 10.1002/1097-0142(197906)43:6<2438::AID-CNCR2820430640>3.0.CO;2-9; AURIAS A, 1984, CANCER GENET CYTOGEN, V12, P21, DOI 10.1016/0165-4608(84)90003-7; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; CAILLAUD JM, 1984, CANCER RES, V44, P4432; CAVAZZANA AO, 1987, AM J PATHOL, V127, P507; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; DONNER L, 1985, ADV NEUROBLASTOMA RE, P347; EMANUEL BS, 1986, CANCER GENET CYTOGEN, V19, P81, DOI 10.1016/0165-4608(86)90375-4; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1987, ONCOGENE, V1, P355; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; Ewing, 1921, P NEW YORK PATHOL S, V21, P17; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; HARTMAN KR, IN PRESS CANCER; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MISER JS, 1988, J CLIN ONCOL, V6, P484, DOI 10.1200/JCO.1988.6.3.484; PADUA RA, 1984, NATURE, V311, P671, DOI 10.1038/311671a0; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PEREZATAYDE A, 1985, P SIOP, V18, P61; REYNOLDS CP, 1981, CANCER, V48, P2088, DOI 10.1002/1097-0142(19811101)48:9<2088::AID-CNCR2820480929>3.0.CO;2-U; REYNOLDS CP, 1988, ADV NEUROBLASTOMA RE, P291; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1318; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; TRICHE TJ, 1983, HUM PATHOL, V14, P569; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P4; WHANGPENG J, 1986, CANCER GENET CYTOGEN, V21, P185, DOI 10.1016/0165-4608(86)90001-4; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	37	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					897	900						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2666909				2022-12-28	WOS:A1989AE58400012
J	POGNONEC, P; BOULUKOS, KE; GHYSDAEL, J				POGNONEC, P; BOULUKOS, KE; GHYSDAEL, J			THE C-ETS-1 PROTEIN IS CHROMATIN ASSOCIATED AND BINDS TO DNA INVITRO	ONCOGENE			English	Article											POGNONEC, P (corresponding author), INST PASTEUR,CNRS,UA 041160,INSERM,U186,F-59019 LILLE,FRANCE.		GHYSDAEL, Jacques/F-3377-2013					BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JH, 1988, ONCOGENE RES, V2, P371; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; ELGIN SCR, 1984, NATURE, V309, P213, DOI 10.1038/309213a0; FUJIWARA S, 1988, ONCOGENE, V2, P99; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GHYSDAEL J, 1986, EMBO J, V5, P2251, DOI 10.1002/j.1460-2075.1986.tb04492.x; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KAUFMANN Y, 1987, J EXP MED, V166, P810, DOI 10.1084/jem.166.3.810; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MULLER R, 1987, ONCOGENE RES, V2, P19; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; RENZ M, 1987, NUCLEIC ACIDS RES, V15, P277, DOI 10.1093/nar/15.1.277; ROUSSEL M, 1979, NATURE, V281, P453; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0	35	84	84	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					691	697						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2660071				2022-12-28	WOS:A1989AA66000004
J	HALEY, JD; HSUAN, JJ; WATERFIELD, MD				HALEY, JD; HSUAN, JJ; WATERFIELD, MD			ANALYSIS OF MAMMALIAN FIBROBLAST TRANSFORMATION BY NORMAL AND MUTATED HUMAN EGF RECEPTORS	ONCOGENE			English	Article									LUDWIG INST CANC RES,LONDON W1 8PT,ENGLAND	Ludwig Institute for Cancer Research			Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564				BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BASSIRI M, 1986, J VIROL, V59, P525, DOI 10.1128/JVI.59.2.525-530.1986; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BEUG H, 1986, ONCOGENES GROWTH CON, P85; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRUGGE JS, 1986, CELL, V46, P149, DOI 10.1016/0092-8674(86)90729-4; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CLARK S, 1988, J CELL PHYSIOL, V134, P421, DOI 10.1002/jcp.1041340313; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIS RJ, 1988, J BIOL CHEM, V263, P5373; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GAMETT DC, 1986, P NATL ACAD SCI USA, V83, P6053, DOI 10.1073/pnas.83.16.6053; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; GILMORE T, 1985, CELL, V40, P609, DOI 10.1016/0092-8674(85)90209-0; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; HALEY J, 1987, ONCOGENE RES, V1, P375; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; HUNTER T, 1984, NATURE, V311, P414, DOI 10.1038/311414a0; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1985, EMBO J, V4, P3179, DOI 10.1002/j.1460-2075.1985.tb04062.x; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; NG M, 1986, J VIROL, V58, P542, DOI 10.1128/JVI.58.2.542-553.1986; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; OZANNE B, 1986, J PATHOL, V149, P9, DOI 10.1002/path.1711490104; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; REISS N, 1986, BIOCHEM J, V239, P691, DOI 10.1042/bj2390691; RIEDEL H, 1987, SCIENCE, V236, P197, DOI 10.1126/science.3494307; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; ROYERPOKORA B, 1978, CELL, V13, P751, DOI 10.1016/0092-8674(78)90225-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT JA, 1985, EMBO J, V4, P105, DOI 10.1002/j.1460-2075.1985.tb02323.x; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WANG LH, 1987, P NATL ACAD SCI USA, V84, P5725, DOI 10.1073/pnas.84.16.5725; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	63	54	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1989	4	3					273	283						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2784850				2022-12-28	WOS:A1989U567600002
J	SIEGFRIED, Z; ZIFF, EB				SIEGFRIED, Z; ZIFF, EB			TRANSCRIPTION ACTIVATION BY SERUM, PDGF, AND TPA THROUGH THE C-FOS DSE - CELL TYPE SPECIFIC REQUIREMENTS FOR INDUCTION	ONCOGENE			English	Article									NYU MED CTR,DEPT BIOCHEM,550 1ST AVE,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University				Ziff, Edward/0000-0001-7389-8649	NATIONAL CANCER INSTITUTE [R01CA044042, P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007827] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44042, P30 CA 16087] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07827] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AVIV H, 1976, CELL, V8, P495, DOI 10.1016/0092-8674(76)90217-8; BIENZ M, 1986, CELL, V45, P753, DOI 10.1016/0092-8674(86)90789-0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; BROWN KD, 1984, BIOCHEM BIOPH RES CO, V123, P377, DOI 10.1016/0006-291X(84)90424-8; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; COOPER JA, 1982, CELL, V31, P263, DOI 10.1016/0092-8674(82)90426-3; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EK B, 1982, J BIOL CHEM, V257, P486; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOWENHAUPT K, 1978, CELL, V14, P337, DOI 10.1016/0092-8674(78)90119-8; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; METZ R, 1988, IN PRESS COND SPRING, V52; MILLER AD, 1984, CELL, V36, P51; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIMURA J, 1982, P NATL ACAD SCI-BIOL, V79, P4303, DOI 10.1073/pnas.79.14.4303; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VOLLOCH V, 1981, CELL, V23, P509, DOI 10.1016/0092-8674(81)90146-X; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YEE CL, 1985, AM J PATHOL, V119, P3261	53	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					3	11						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2915902				2022-12-28	WOS:A1989U567400001
J	LYMAN, SD; PARK, L; ROHRSCHNEIDER, LR				LYMAN, SD; PARK, L; ROHRSCHNEIDER, LR			COLONY STIMULATING FACTOR-I INDUCED GROWTH-STIMULATION OF V-FMS TRANSFORMED FIBROBLASTS	ONCOGENE			English	Article									IMMUNEX CORP,SEATTLE,WA 98101	Immunex Corporation	LYMAN, SD (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.				NATIONAL CANCER INSTITUTE [R01CA020551, R01CA040987, T32CA009229] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40987, CA 20551, CA 09229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTOCCI A, 1986, J EXP MED, V164, P956, DOI 10.1084/jem.164.3.956; CERRETTI DP, 1988, MOL IMMUNOL, V25, P761, DOI 10.1016/0161-5890(88)90112-5; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; HOPP TP, 1988, ICSU SHORT REP, V8, P138; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KOURY MJ, 1982, NATURE, V299, P638, DOI 10.1038/299638a0; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LYMAN SD, 1987, MOL CELL BIOL, V7, P3287, DOI 10.1128/MCB.7.9.3287; MCDONOUGH SK, 1971, CANCER RES, V31, P953; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; PARK LS, 1986, J BIOL CHEM, V261, P4177; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; SACCA R, 1986, P NATL ACAD SCI USA, V83, P3331, DOI 10.1073/pnas.83.10.3331; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SKLAR MD, 1985, MACROPHAGE BIOL, P673; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STANLEY ER, 1985, METHOD ENZYMOL, V116, P564; STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022-1759(81)90156-3; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; WHEELER EF, 1986, NATURE, V324, P377, DOI 10.1038/324377a0	33	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					391	395						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	2856249				2022-12-28	WOS:A1988Q773900006
J	ROVINSKI, B; BENCHIMOL, S				ROVINSKI, B; BENCHIMOL, S			IMMORTALIZATION OF RAT EMBRYO FIBROBLASTS BY THE CELLULAR P53 ONCOGENE	ONCOGENE			English	Article									ONTARIO CANC INST,DIV BIOL RES,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto				Benchimol, Samuel/0000-0003-3433-890X				BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KACZMAREK L, 1986, EXP CELL RES, V162, P268, DOI 10.1016/0014-4827(86)90445-3; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PELLEGRINI S, 1986, J CELL PHYSIOL, V126, P107, DOI 10.1002/jcp.1041260115; PINHASI O, 1984, MOL CELL BIOL, V4, P2180, DOI 10.1128/MCB.4.10.2180; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; ROVINSKI B, 1987, UCLA S MOL CELLULAR, V61, P31; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SHIROKI K, 1986, MOL CELL BIOL, V6, P4379, DOI 10.1128/MCB.6.12.4379; SHOHAT O, 1987, ONCOGENE, V1, P277; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; WATANABE SM, 1983, J VIROL, V45, P1028, DOI 10.1128/JVI.45.3.1028-1036.1983; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZERLIN M, 1987, ONCOGENE, V1, P19	50	193	196	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					445	452						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	3287278				2022-12-28	WOS:A1988N434800005
J	HUANG, LW; TURCK, CW; RAO, P; PETERS, KG				HUANG, LW; TURCK, CW; RAO, P; PETERS, KG			GRB2 AND SH-PTP2 - POTENTIALLY IMPORTANT ENDOTHELIAL SIGNALING MOLECULES DOWNSTREAM OF THE TEK/TIE2 RECEPTOR TYROSINE KINASE	ONCOGENE			English	Article						ENDOTHELIUM; GRB2; SH-PTP2; RECEPTOR TYROSINE KINASE	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; EPIDERMAL GROWTH-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; ADAPTER PROTEIN; EXPRESSION CLONING; VASCULAR ENDOTHELIUM; SH3 DOMAINS; RAS; IDENTIFICATION; MORPHOGENESIS	TEK is a newly cloned receptor tyrosine kinase that is expressed predominantly in the endothelium of actively growing blood vessels. Disruption of TEK function in transgenic mice results in a profound defect in vascular development leading to embryonic lethality. These studies show that TEK signaling is indispensable for the development of the embryonic vasculature and suggest that TEK, signaling may also be required for the development of the tumor vasculature. Because the ligand for TEPC has not been identified, it has been difficult to study signal transduction by this important endothelial receptor. To circumvent this problem, a soluble TEK kinase domain (GTEKH) was developed which could be easily purified, autophosphorylated, and radiolabeled, Using the autophosphorylated, radiolabeled GTEKH to probe a mouse embryo expression library only two candidate signaling molecules were isolated, SH-PTP2 and GRB2. Autophosphorylated GTEKH associated with GRB2 and SH-PTP2 from endothelial lysates and not with PI3 kinase or PLC gamma. The association of GRB2 and SH-PTP2 with TEK was highly dependent on specific tyrosine residues in the TEK c-tail. These studies identify GRB2 and SH-PTP2 as potentially important mediators of TEK signaling that may trigger crucial endothelial responses during embryonic vascular development and during pathologic vascular growth.	DUKE UNIV, MED CTR, DEPT MED, DIV CARDIOVASC, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	Duke University; Duke University; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BANNWARTH W, 1992, HELV CHIM ACTA, V75, P707, DOI 10.1002/hlca.19920750305; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CASE RD, 1994, J BIOL CHEM, V269, P10467; COFFIN JD, 1988, DEVELOPMENT, V102, P735; COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENG FS, 1994, TIG, V10, P54; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PARDANAUD L, 1987, DEVELOPMENT, V100, P339; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PETERS KG, 1992, COLD SPRING HARB SYM, V57, P63, DOI 10.1101/SQB.1992.057.01.008; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SCHWARTZ SM, 1993, J CARDIOVASC PHARM, V21, pS31, DOI 10.1097/00005344-199321001-00007; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TURCK CW, 1992, PEPTIDE RES, V5, P156; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; WAGNER RC, 1980, ADV MICROCIRCULAT, V9, P45; WELLBROCK C, 1995, ONCOGENE, V10, P2135; XIAO S, 1994, J BIOL CHEM, V269, P21244; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIEGLER SF, 1993, ONCOGENE, V8, P663	62	73	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	1995	11	10					2097	2103						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478529				2022-12-28	WOS:A1995TF29700020
J	ZORNIG, M; BUSCH, G; BENEKE, R; GULBINS, E; LANG, F; MA, A; KORSMEYER, S; MOROY, T				ZORNIG, M; BUSCH, G; BENEKE, R; GULBINS, E; LANG, F; MA, A; KORSMEYER, S; MOROY, T			SURVIVAL AND DEATH OF PRELYMPHOMATOUS B-CELLS FROM N-MYC/BCL-2 DOUBLE TRANSGENIC MICE CORRELATES WITH THE REGULATION OF INTRACELLULAR CA2+ FLUXES	ONCOGENE			English	Article						B-CELLS; N-MYC; BCL-2; TRANSGENIC MICE; APOPTOSIS; CALCIUM FLUX	HUMAN FOLLICULAR LYMPHOMA; C-MYC; PRE-B; BCL-2 GENE; N-MYC; FLOW-CYTOMETRY; APOPTOSIS; EXPRESSION; GENERATION; GROWTH	Coexpression of the proto-oncogenes c-myc and bcl-2 under the control of the immunoglobulin enhancer E mu provokes the rapid development of primitive lymphoid tumors in transgenic mice, In the present study we show that the myc family members N-myc and L-myc also cooperate with bcl-2 in oncogenesis and can provoke the development of more mature pre-B, B and T cell type lymphomas. The analysis of prelymphomatous B-cells from single E mu N-myc and bcl-2-Ig transgenic animals and from young, tumor free, double transgenic E mu N-myc/bcl-2-Ig mice revealed that E mu directed expression of N-myc leads to very rapid apoptosis after explantation and culturing compared to B-cells from normal mice. As expected, B-cells from bcl-2-Ig transgenics were protected to a certain degree from apoptosis, Strikingly however, B-cells from E mu N-myc/bcl-2-Ig double transgenic animals were found to be almost completely resistant towards a number of different apoptotic stimuli. Furthermore, after treatment with H2O2, which can trigger apoptosis, B-cells from E mu N-myc animals reach levels of intracellular free Ca2+ concentrations that are comparable to B-cells from normal mice, whereas B-cells from bcl-2-Ig or E mu N-myc/bcl-2-Ig double transgenic mice show no increase in intracellular Ca2+ concentrations after stimulation with H2O2. These findings suggest that the prevention of apoptosis conferred by bcl-2 correlates with the inhibition of intracellular Ca2+ fluxes whereas induction of apoptosis mediated by N-myc requires normal Ca2+ levels. We hypothesize therefore that the regulation of intracellular Ca2+ concentrations represent one important parameter in the oncogenic cooperation between bcl-2 and N-myc.	UNIV MARBURG,IMT,INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY; UNIV TUBINGEN,INST PHYSIOL 1,D-72076 TUBINGEN,GERMANY; HARVARD UNIV,CHILDRENS HOSP,SCH MED,CTR BLOOD RES,HOWARD HUGHES MED INST,BOSTON,MA 02115; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PATHOL,ST LOUIS,MO 63110	Philipps University Marburg; Eberhard Karls University of Tubingen; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)			Moroy, Tarik/D-9923-2011; Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342				BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; CHEN U, 1992, IMMUNOBIOLOGY, V185, P366, DOI 10.1016/S0171-2985(11)80653-4; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; DOWD DR, 1992, MOL ENDOCRINOL, V6, P1843, DOI 10.1210/me.6.11.1843; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; GOUGH NM, 1981, P NATL ACAD SCI-BIOL, V78, P509, DOI 10.1073/pnas.78.1.509; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOGAN B, 1986, MANIPULATION MOUSE E; ISEKI R, 1993, J IMMUNOL, V151, P5198; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LANGDON WY, 1988, ONCOGENE RES, V3, P271; LEWIS S, 1982, CELL, V30, P807, DOI 10.1016/0092-8674(82)90285-9; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MOROY T, 1991, ONCOGENE, V6, P1941; NOWELL PC, 1987, DEV RECOGNITION TRAN; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; PERRY RP, 1980, P NATL ACAD SCI-BIOL, V77, P1937, DOI 10.1073/pnas.77.4.1937; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7202; Sambrook J, 1989, MOL CLONING LABORATO; SENTMAN CL, 1992, CELL, V67, P879; SEYSCHAB H, 1989, EUR J IMMUNOL, V19, P1605, DOI 10.1002/eji.1830190913; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; YANCOPOULOS GD, 1984, NATURE, V311, P727, DOI 10.1038/311727a0; ZHING LT, 1993, P0 NATL ACAD SCI US, V90, P4533; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	45	33	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2165	2174						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478538				2022-12-28	WOS:A1995TF29700029
J	KEARSEY, JM; COATES, PJ; PRESCOTT, AR; WARBRICK, E; HALL, PA				KEARSEY, JM; COATES, PJ; PRESCOTT, AR; WARBRICK, E; HALL, PA			GADD45 IS A NUCLEAR-CELL CYCLE-REGULATED PROTEIN WHICH INTERACTS WITH P21(CIP1)	ONCOGENE			English	Article						GADD45; P21(CIP1); PCNA; P53; CELL CYCLE	IONIZING-RADIATION; P53 PROTEIN; DNA-BINDING; ANTIGEN; EXPRESSION; INDUCTION; SEQUENCE; REPAIR; GENE; IDENTIFICATION	GADD45 was originally identified as a cDNA clone induced by growth arrest and DNA damage. We show that Gadd45 is a nuclear protein, widely expressed in normal tissues, particularly in quiescent cellular populations. Using cell synchronisation methods we show that Gadd45 levels are highest in the G1 phase of the cell cycle, and are greatly reduced during S phase. Immunoprecipitation of Gadd45 from mammalian cells reveals that it is tightly associated with a protein which reacts with antibodies to the cyclin dependent kinase inhibitor p21(Cip1). Binding of recombinant Gadd45 protein to overlapping p21(Cip1) peptides in ELISA assays and use of the yeast two hybrid assay show that Gadd45 directly interacts with this cell cycle inhibitor. These data suggest that Gadd45 may act in the regulation of the cell cycle. It is postulated that the interactions of Gadd45 with both p21(Cip1) and PCNA are important for the modulation of cell cycles, and for the inhibition of DNA replication.	UNIV DUNDEE,DEPT PATHOL,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,DEPT ANAT & PHYSIOL,DUNDEE DD1 9SY,SCOTLAND	University of Dundee; University of Dundee; University of Dundee			Prescott, Alan/Y-5956-2018; Coates, Philip J/H-6854-2019; Warbrick, Emma/C-6424-2008	Prescott, Alan/0000-0002-0747-7317; Coates, Philip J/0000-0003-1518-6306; 				ABDOLLAHI A, 1991, ONCOGENE, V6, P165; BAE IS, 1995, CANCER RES, V55, P2387; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CHALUT C, 1994, BIOESSAYS, V16, P651, DOI 10.1002/bies.950160910; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FREDERSDORF S, 1995, IN PRESS AM J PATHOL; FRIEDBERG EC, 1995, DNA REPAIR; GERDES J, 1984, J IMMUNOL, V133, P1710; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOUBIN F, 1995, ONCOGENE, V10, P2281; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HALL PA, 1995, ONCOGENE, V10, P2427; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HALL PA, 1993, ONCOGENE, V8, P203; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; JONES CJ, 1992, NUCLEIC ACIDS RES, V20, P991, DOI 10.1093/nar/20.5.991; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, IN PRESS SCI; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI Y, 1994, ONCOGENE, V9, P2261; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIURA M, 1992, J CELL PHYSIOL, V150, P370, DOI 10.1002/jcp.1041500221; MIYASHITA T, 1995, CELL, V80, P293; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PRICE BD, 1992, CANCER RES, V52, P3814; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEIN GS, 1972, J CELL BIOL, V52, P292, DOI 10.1083/jcb.52.2.292; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAHN Q, 1995, INT J ONCOL, V6, P937; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	67	239	249	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1675	1683						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478594				2022-12-28	WOS:A1995TD09400001
J	NAYERI, S; DANIELSSON, C; KAHLEN, JP; SCHRADER, M; MATHIASEN, IS; BINDERUP, L; CARLBERG, C				NAYERI, S; DANIELSSON, C; KAHLEN, JP; SCHRADER, M; MATHIASEN, IS; BINDERUP, L; CARLBERG, C			THE ANTIPROLIFERATIVE EFFECT OF VITAMIN-D-3 ANALOGS IS NOT MEDIATED BY INHIBITION OF THE AP-1 PATHWAY, BUT MAY BE RELATED TO PROMOTER SELECTIVITY	ONCOGENE			English	Article						REGULATION OF TRANSCRIPTION; CONTROL OF PROLIFERATION; MCF-7 BREAST CANCER CELLS; RETINOID-X-RECEPTOR VITAMIN-D-3 RECEPTOR HETERODIMERS; VITAMIN-D-3 RESPONSE ELEMENTS	CANCER CELL-PROLIFERATION; RETINOIC ACID RECEPTORS; HUMAN OSTEOCALCIN GENE; GLUCOCORTICOID RECEPTOR; REGULATORY ELEMENTS; SIGNALING PATHWAYS; THYROID-HORMONE; C-JUN; DIFFERENTIATION; INVIVO	The hormone 1,25-dihydroxyvitamin D-3 (VD) is able to induce cellular differentiation and to inhibit cellular proliferation, which provides it with an interesting therapeutic potential in cancer. However, side effects of VD on homeostasis (eg hypercalcemia) had made the need for the development of VD analogues with low calcemic effect. On the human breast cancer cell line MCF-7 we obtained with the VD analogue EB1089 an about 100-fold higher anti-proliferative effect than with VD. We found that this difference in biological activity is neither related to increased functional affinity to the VD receptor nor to repression of AP-1 activity. The physiologically most prominent complex of the VD receptor is a heterodimer with the retinoid X receptor that binds VD response elements formed two hexameric core binding motifs being arranged either as direct repeats spaced by 3 nucleotides (DR3s) or as inverted palindromes spaced by 9 nucleotides (IP9s). We observed that EB1089 stimulates transcriptional activation from IP9-type elements at clearly lower concentrations than from DR3-type elements. It is possible that IP9-type response elements play an important role in or contribute to the control of cell proliferation, so that promoter-selectivity may explain the high anti-proliferative effect of EB1089.	HOP CANTONAL GENEVA,DERMATOL CLIN,CH-1211 GENEVA 14,SWITZERLAND; LEO PHARMACEUT PROD,BIOL RES & DEV,DK-2750 BALLERUP,DENMARK	University of Geneva			Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				BERG JP, 1994, J STEROID BIOCHEM, V50, P145, DOI 10.1016/0960-0760(94)90021-3; BIKLE DD, 1993, ENDOCR REV, V14, P3, DOI 10.1210/er.14.1.3; BINDERUP L, 1992, BIOCHEM PHARMACOL, V43, P1885, DOI 10.1016/0006-2952(92)90630-2; BINDERUP L, 1992, REV CONTEMP PHARMACO, V3, P357; CARLBERG C, 1994, J STEROID BIOCHEM, V51, P137, DOI 10.1016/0960-0760(94)90086-8; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; CARLBERG C, 1993, BIOCHEM BIOPH RES CO, V195, P1345, DOI 10.1006/bbrc.1993.2191; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P2273, DOI 10.1016/0006-2952(92)90669-A; COLSTON KW, 1989, LANCET, V1, P188; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P693, DOI 10.1016/0006-2952(92)90405-8; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; HAQ M, 1993, J CLIN INVEST, V91, P2416, DOI 10.1172/JCI116475; JAMES SY, 1994, J ENDOCRINOL, V141, P555, DOI 10.1677/joe.0.1410555; JIANG HP, 1994, ONCOGENE, V9, P3397; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KISSMEYER AM, 1995, ENDOCRINE, V3, P263, DOI 10.1007/BF03021403; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1984, J CELL BIOL, V98, P391, DOI 10.1083/jcb.98.2.391; MATHIASEN IS, 1993, J STEROID BIOCHEM, V46, P365, DOI 10.1016/0960-0760(93)90226-M; McElwain Mariann C., 1995, Molecular and Cellular Differentiation, V3, P31; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; QUELO I, 1994, DNA CELL BIOL, V13, P1181, DOI 10.1089/dna.1994.13.1181; SCHRADER M, 1995, MOL CELL BIOL, V15, P1154; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SCHRADER M, 1993, NUCLEIC ACIDS RES, V21, P1231, DOI 10.1093/nar/21.5.1231; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SCHRADER M, 1994, J MOL ENDOCRINOL, V12, P327, DOI 10.1677/jme.0.0120327; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STERN PH, 1981, CALCIFIED TISSUE INT, V33, P1, DOI 10.1007/BF02409404; VIETH R, 1990, BONE MINER, V11, P267, DOI 10.1016/0169-6009(90)90023-9; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; ZHANG Q, 1992, EUR J BIOCHEM, V207, P649, DOI 10.1111/j.1432-1033.1992.tb17092.x	49	61	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1853	1858						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478614				2022-12-28	WOS:A1995TD09400021
J	HABUCHI, T; DEVLIN, J; ELDER, PA; KNOWLES, MA				HABUCHI, T; DEVLIN, J; ELDER, PA; KNOWLES, MA			DETAILED DELETION MAPPING OF CHROMOSOME-9Q IN BLADDER-CANCER - EVIDENCE FOR 2 TUMOR-SUPPRESSOR LOCI	ONCOGENE			English	Note						BLADDER CANCER; CHROMOSOME 9; LOSS OF HETEROZYGOSITY; TUMOR SUPPRESSOR GENE	TRANSITIONAL-CELL CARCINOMA; GORLIN SYNDROME; GENE	Loss of heterozygosity (LOH) at loci on chromosome 9p and/or 9q is the most frequent genetic alteration in transitional cell carcinoma (TCC) of the bladder. However, localisation of the tumour suppressor locus or loci on 9q has been hampered by the relative infrequency of tumours with subchromosomal deletions. We have used 24 microsatellite markers to examine LOH in 70 new cases of TCC of the bladder and upper urinary tract. Forty tumours (57%) showed LOH at one or more loci on 9q and partial deletions were detected in five tumoms (7%). Combined data from the five cases with partial deletions place one tumour suppressor locus at 9q34 between D9S61 and D9S66 (an estimated distance of 13-14 cM). This region is frequently deleted in other sporadic tumours and encompasses one of the loci for tuberous sclerosis(TSC1). One tumour contained a distinct deletion between D9S153 and D9S109 (9q13-q31), which encompasses the locus for the familial nevoid basal cell carcinoma syndrome (Gorlin syndrome). This may indicate the presence of another tumour suppressor locus on 9q for TCC. Our findings significantly reduce the regions of 90 within which suppressor genes for TCC may reside. The possible involvement of two deletion targets on 90 in addition to the locus at 9p21 implicated in TCC may explain why LOH at all loci on chromosome 9 is frequent in TCC.	MARIE CURIE RES INST,MOLEC GENET LAB,OXTED RH8 0TL,SURREY,ENGLAND									AHSEE KW, 1994, CANCER RES, V54, P1617; BERNUES M, 1993, CANCER GENET CYTOGEN, V69, P76, DOI 10.1016/0165-4608(93)90120-B; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1995, CANCER RES, V55, P224; CAIRNS P, 1993, CANCER RES, V53, P1230; CARBONARA C, 1994, HUM MOL GENET, V3, P1829, DOI 10.1093/hmg/3.10.1829; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; DEVLIN J, 1994, ONCOGENE, V9, P2757; FARNDON PA, 1992, LANCET, V339, P581, DOI 10.1016/0140-6736(92)90868-4; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; GOUDIE DR, 1993, NAT GENET, V3, P165, DOI 10.1038/ng0293-165; GREEN AJ, 1994, HUM MOL GENET, V3, P1833, DOI 10.1093/hmg/3.10.1833; HABUCHI T, 1993, INT J CANCER, V53, P579, DOI 10.1002/ijc.2910530409; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAO CH, 1993, GENE CHROMOSOME CANC, V8, P155, DOI 10.1002/gcc.2870080304; KEEN AJ, 1994, ONCOGENE, V9, P2083; KNOWLES MA, 1994, CANCER RES, V54, P531; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; LOUGHRAN O, 1994, CANCER RES, V54, P5045; MERLO A, 1994, CANCER RES, V54, P2322; MIURA K, 1995, CANCER RES, V55, P1828; MIYAO N, 1993, CANCER RES, V53, P4066; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLUMI AF, 1990, CANCER RES, V50, P7081; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; POVEY S, 1994, ANN HUM GENET, V58, P177, DOI 10.1111/j.1469-1809.1994.tb01887.x; QUINN AG, 1994, GENE CHROMOSOME CANC, V11, P222, DOI 10.1002/gcc.2870110404; RUPPERT JM, 1993, CANCER RES, V53, P5093; SCHULTZ DC, 1995, CANCER RES, V55, P2150; SHANLEY SM, 1995, HUM MOL GENET, V4, P129; SMEETS W, 1987, CANCER GENET CYTOGEN, V29, P29, DOI 10.1016/0165-4608(87)90028-8; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STADLER WM, 1994, CANCER RES, V54, P2060; VANDERRIET P, 1994, CANCER RES, V54, P25; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8	37	106	115	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1671	1674						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478593				2022-12-28	WOS:A1995TC53500027
J	REZZONICO, R; LOUBAT, A; LALLEMAND, D; PFARR, CM; FAR, DF; PROUDFOOT, A; ROSSI, B; PONZIO, G				REZZONICO, R; LOUBAT, A; LALLEMAND, D; PFARR, CM; FAR, DF; PROUDFOOT, A; ROSSI, B; PONZIO, G			CYCLIC-AMP STIMULATES A JUND/FRA-2 AP-1 COMPLEX AND INHIBITS THE PROLIFERATION OF INTERLEUKIN-6-DEPENDENT CELL-LINES	ONCOGENE			English	Article						ANTIPROLIFERATIVE EFFECT; AP-1; CYCLIC AMP; FRA-2; JUN D; INTERLEUKIN-6	TRANSCRIPTION FACTOR AP-1; DNA-BINDING ACTIVITY; C-JUN; MACROPHAGE DIFFERENTIATION; GENE-TRANSCRIPTION; ENHANCER ACTIVITY; GROWTH-HORMONE; NUCLEAR FACTOR; PHORBOL ESTER; FOS	Interleukin-6 (IL-6) is a proinflammatory cytokine which also acts as a growth factor for some murine hybridomas (7TD1) or human myelomas (U266). We demonstrate that elevation of cAMP cellular content inhibits IL-6-stimulated cell growth, by blocking cells mainly in G1 phase. This inhibition is associated with increased expression of the Fos family protein Fra-2. Treatment of cells with 8Br-cAMP results in increased DNA-binding activity of two distinct AP-1 complexes; JunD/Fra-2 and JunB/Fra-2, and also in elevated AP-1 transactivation. When 8Br-cAMP is withdrawn from the medium, cells enter S phase and Fra-2 protein levels and AP-1 DNA-binding activity decrease to their basal value indicating that a temporally correlation exists between the 8Br-cAMP-mediated induction of JunD/Fra-2 AP-1 complex and the 7TD1 and U266 cell growth inhibition.	FAC MED NICE,INSERM,U364,F-06107 NICE 02,FRANCE; INST PASTEUR,DEPT BIOTECHNOL,ONCOGEN VIRUSES UNIT,F-75724 PARIS 15,FRANCE; GLAXO INST MOLEC BIOL SA,GENEVA,SWITZERLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; GlaxoSmithKline			Ponzio, Gilles/Q-1256-2016; Pfarr, Curt/HHD-1410-2022; lallemand, dominique/O-7445-2017; REZZONICO, Roger/N-9626-2016	Ponzio, Gilles/0000-0003-2741-0248; lallemand, dominique/0000-0002-0212-7342; REZZONICO, Roger/0000-0002-8460-1641				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V129, P1072; BETTS JC, 1993, J BIOL CHEM, V268, P25624; BLOMHOFF HK, 1987, J CELL PHYSIOL, V131, P426, DOI 10.1002/jcp.1041310315; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Distel R J, 1990, Adv Cancer Res, V55, P37, DOI 10.1016/S0065-230X(08)60467-4; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; DOGLIO A, 1986, BIOCHEM J, V238, P123, DOI 10.1042/bj2380123; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; GRUDA MC, 1994, ONCOGENE, V9, P2537; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIRAI S-I, 1989, New Biologist, V1, P181; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIMURA E, 1993, MOL ENDOCRINOL, V7, P1463, DOI 10.1210/me.7.11.1463; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KUMAR G, 1994, J IMMUNOL, V153, P4436; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MATSUI M, 1990, ONCOGENE, V5, P249; MELAMED D, 1993, CELL GROWTH DIFFER, V4, P689; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NATSUKA S, 1992, BLOOD, V79, P460; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PROUDFOOT AEI, 1993, J PROTEIN CHEM, V12, P489, DOI 10.1007/BF01025050; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; REZZONICO R, 1995, J BIOL CHEM, V270, P1261, DOI 10.1074/jbc.270.3.1261; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHWAB G, 1991, BLOOD, V77, P587; STANKOVA J, 1992, BIOCHEM J, V282, P625; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAMIR A, 1994, J IMMUNOL, V152, P3391; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; VAIRO G, 1990, J BIOL CHEM, V265, P2692; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9676; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEGENKA UM, 1994, MOL CELL BIOL, V14, P1386; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; WOLLBERG P, 1994, J BIOL CHEM, V269, P19719; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	70	35	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1069	1078						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566966				2022-12-28	WOS:A1995RX18000009
J	SALGIA, R; BRUNKHORST, B; PISICK, E; LI, JL; LO, SH; CHEN, LB; GRIFFIN, JD				SALGIA, R; BRUNKHORST, B; PISICK, E; LI, JL; LO, SH; CHEN, LB; GRIFFIN, JD			INCREASED TYROSINE PHOSPHORYLATION OF FOCAL ADHESION PROTEINS IN MYELOID CELL-LINES EXPRESSING P210(BCR/ABL)	ONCOGENE			English	Article						P210(BCR/AB1); ACTIN; TYROSINE PHOSPHORYLATION; CYTOSKELETAL PROTEINS	CHRONIC MYELOGENOUS LEUKEMIA; PHILADELPHIA-CHROMOSOME; KINASE; PAXILLIN; BINDING; ABL; BCR; TRANSFORMATION; FIBROBLASTS; FIBRONECTIN	The BCR/ABL oncogene causes chronic myelogenous leukemia (CML) in humans and induces growth factor independence of hematopoietic cell lines in tissue culture. p210(BCR/ABL) is localized at least in part to the cytoskeleton, and has been shown to interact directly with actin filaments through an actin binding domain located in the C-terminus of ABL. CML cells have reduced adhesion to some extracellular matrix components but the mechanism of this phenomenon is unknown. In this study we examined tyrosine phosphorylation of focal adhesion proteins in cells expressing p210(BCR/ABL) An interleukin-3 (IL-3)-dependent cell line, 32Dc13, was transformed with a BCR/ABL cDNA, and the patterns of localization, expression, and tyrosine phosphorylation of focal adhesion proteins were compared among untransformed 32Dc13 cells with and without IL-3 stimulation and BCR/ABL-transformed 32Dc13 cells. Of the focal adhesion proteins examined, only paxillin exhibited tyrosine phosphorylation in response to IL-3; while in cells transformed by p210(BCR/ABL), paxillin, vinculin, p125(FAK), talin and tensin were constitutively tyrosine phosphorylated. IL-3 induced a transient association between paxillin and vinculin, while in BCR/ABL-transformed cells, several proteins coimmunoprecipitated with paxillin, including vinculin, p125(FAK), talin and tensin. Pseudopodia enriched in focal adhesion proteins were transiently detected in 32Dc13 cells in response to IL-3, but constitutively detected in cells expressing p210(BCR/ABL). P210(BCR/ABL) protein was also found concentrated in punctate structures adjacent to the cell membrane in myeloid cell lines, which often contained vinculin and paxillin. Since the focal adhesion is where the interaction between integrins and actin filaments is believed to occur, the observed effect of p210(BCR/ABL) on food adhesion protein interactions in myeloid cell lines could contribute to the adhesion defects in CML cells.	DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA; DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School			Li, Jian-Liang/AAE-9315-2019	Li, Jian-Liang/0000-0002-6487-081X; Lo, Su Hao/0000-0002-2675-9387				AMBROS VR, 1975, P NATL ACAD SCI USA, V72, P3144, DOI 10.1073/pnas.72.8.3144; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DRUKER B, 1992, BLOOD, V79, P2215; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SANCHEZGARCIA I, 1993, SEMIN CANCER BIOL, V4, P349; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	35	144	147	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	1995	11	6					1149	1155						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566975				2022-12-28	WOS:A1995RX18000018
J	XIAO, GH; JIN, F; YEUNG, RS				XIAO, GH; JIN, F; YEUNG, RS			GERM-LINE TSC2 MUTATION IN A DOMINANTLY INHERITED CANCER MODEL DEFINES A NOVEL FAMILY OF RAT INTRACISTERNAL-A PARTICLE ELEMENTS	ONCOGENE			English	Article						TUMOR SUPPRESSOR GENE; ANIMAL MODEL; IAP ELEMENT; TUBEROUS SCLEROSIS; EKER RAT	LONG TERMINAL REPEATS; RENAL-CELL CARCINOMA; EKER RAT; SUSCEPTIBILITY GENE; DNA REARRANGEMENT; SEQUENCE; PROMOTER; INSERTION; CHROMOSOME-10; GENOME	A spontaneous hereditary cancer syndrome in the Eker rat serves as a useful model for studying tissue-specific tumorigenesis. The genetic basis of this germline mutation was found to involve the tuberous sclerosis 2 (Tsc2) gene. In this study, we have identified and characterized a full-length rat intracisternal A-particle (IAP) element that has undergone an intronic transposition as the mechanism of inactivating the Tsc2 gene. The insertion of this 6253 basepair element disrupted the transcription of the gene to give rise to multiple abnormal mRNA. Genomic organization of this novel IAP element is similar to a typical retroviral structure including the gag, pol and env domains with flanking LTRs. This Eker rat associated CERA) IAP sequence was found to contain multiple termination codons rendering it non-functional with respect to its endogenous genes. The element is conserved among different rat strains and the distribution of the estimated similar to 580 copies throughout the rat genome would support their random integration. The net effect of the mutation causes the expression of abnormal predicted proteins devoid of the rap1GAP-like catalytic domain that lies 3' to the insertion. These results provide evidence that cancer predisposition can be the direct consequence of germ-like insertional mutation by retrotransposition targeting a tumor suppressor gene.	FOX CHASE CANC CTR,DIV MED SCI,PHILADELPHIA,PA 19111	Fox Chase Cancer Center								BLANKENSTEIN T, 1990, J EXP MED, V171, P965, DOI 10.1084/jem.171.3.965; CHRISTY RJ, 1988, MOL CELL BIOL, V8, P1093, DOI 10.1128/MCB.8.3.1093; DONEHOWER LA, 1981, J VIROL, V37, P226, DOI 10.1128/JVI.37.1.226-238.1981; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; EKER R, 1954, ACTA PATHOL MIC SC, V34, P554; EKER R, 1981, DIAGN HISTOPATHOL, V4, P99; FURTER CS, 1989, J BIOL CHEM, V264, P18276; FURTER CS, 1992, BIOCHIM BIOPHYS ACTA, V1130, P213, DOI 10.1016/0167-4781(92)90531-4; GOFF SP, 1990, CANCER CELL-MON REV, V2, P172; HINO O, 1993, P NATL ACAD SCI USA, V90, P327, DOI 10.1073/pnas.90.1.327; HINO O, 1993, JPN J CANCER RES, V84, P1106, DOI 10.1111/j.1349-7006.1993.tb02808.x; KAZAZIAN HH, 1988, NATURE, V322, P164; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; LUEDERS KK, 1983, NUCLEIC ACIDS RES, V11, P4391, DOI 10.1093/nar/11.13.4391; LUEDERS KK, 1984, MOL CELL BIOL, V4, P2128, DOI 10.1128/MCB.4.10.2128; MIETZ JA, 1987, J VIROL, V61, P3020, DOI 10.1128/JVI.61.10.3020-3029.1987; MIKI Y, 1992, CANCER RES, V52, P643; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NARITA N, 1993, J CLIN INVEST, V91, P1862, DOI 10.1172/JCI116402; RECHAVI G, 1982, NATURE, V300, P607, DOI 10.1038/300607a0; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SONG CS, 1990, BIOCHEMISTRY-US, V29, P542, DOI 10.1021/bi00454a031; WALKER C, 1992, SCIENCE, V255, P1693, DOI 10.1126/science.1553556; YEUNG RS, 1993, P NATL ACAD SCI USA, V90, P8038, DOI 10.1073/pnas.90.17.8038; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; YEUNG RS, 1993, CYTOGENET CELL GENET, V62, P149, DOI 10.1159/000133459; YEUNG RS, 1995, IN PRESS MOL CARCINO; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	31	36	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					81	87						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624135				2022-12-28	WOS:A1995RJ29500010
J	ISHIZAKA, Y; ITOH, F; TAHIRA, T; IKEDA, I; SUGIMURA, T; TUCKER, J; FERTITTA, A; CARRANO, AV; NAGAO, M				ISHIZAKA, Y; ITOH, F; TAHIRA, T; IKEDA, I; SUGIMURA, T; TUCKER, J; FERTITTA, A; CARRANO, AV; NAGAO, M			HUMAN RET PROTO-ONCOGENE MAPPED TO CHROMOSOME 10Q11.2	ONCOGENE			English	Note									UNIV CALIF LAWRENCE LIVERMORE NATL LAB,DIV BIOMED SCI,LIVERMORE,CA 94550	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	ISHIZAKA, Y (corresponding author), NATL CANC CTR,RES INST,DIV CARCINOGENESIS,1-1 TSUKIJI 5,CHUO KU,TOKYO 104,JAPAN.							DONGHI R, 1989, ONCOGENE, V4, P521; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; HARPER ME, 1981, P NATL ACAD SCI-BIOL, V78, P4458, DOI 10.1073/pnas.78.7.4458; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; JELINEK WR, 1980, P NATL ACAD SCI-BIOL, V77, P1398, DOI 10.1073/pnas.77.3.1398; LANDEGENT JE, 1987, HUM GENET, V77, P366, DOI 10.1007/BF00291428; LIOU GI, 1987, NUCLEIC ACIDS RES, V15, P3196, DOI 10.1093/nar/15.7.3196; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; Pearse A G, 1974, Pathol Annu, V9, P27; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAHIRA T, IN PRESS ONCOGENE; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TUCKER JD, 1988, CYTOGENET CELL GENET, V48, P103, DOI 10.1159/000132600	18	178	192	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1519	1521						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687772				2022-12-28	WOS:A1989CB65900016
J	RHIM, JS; PARK, JB; JAY, G				RHIM, JS; PARK, JB; JAY, G			NEOPLASTIC TRANSFORMATION OF HUMAN KERATINOCYTES BY POLYBRENE-INDUCED DNA-MEDIATED TRANSFER OF AN ACTIVATED ONCOGENE	ONCOGENE			English	Article									AMER RED CROSS, JEROME H HOLLAND LAB, VIROL LAB, ROCKVILLE, MD 20855 USA	American Red Cross	RHIM, JS (corresponding author), NCI, CELLULAR & MOLEC BIOL, BETHESDA, MD 20892 USA.		Jay, Gregory/C-6346-2013					AUTRUP HN, 1983, HUMAN CARCINOGENESIS; BANKSSCHLEGEL SP, 1983, J CELL BIOL, V96, P330, DOI 10.1083/jcb.96.2.330; BOREK C, 1980, NATURE, V283, P776, DOI 10.1038/283776a0; BRASH DE, 1987, MOL CELL BIOL, V7, P2031, DOI 10.1128/MCB.7.5.2031; CROCE CM, 1975, P NATL ACAD SCI USA, V72, P1397, DOI 10.1073/pnas.72.4.1397; DIPAOLO JA, 1983, J NATL CANCER I, V70, P3; GANTT R, 1987, CANCER RES, V47, P1390; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; KAKUNAGA T, 1980, ADV MOD TOXICOL, V1, P355; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MCCORMICK JJ, 1988, CARCINOGENESIS, V9, P2073, DOI 10.1093/carcin/9.11.2073; MILO GE, 1978, NATURE, V275, P130, DOI 10.1038/275130a0; MORGAN TL, 1986, IN VITRO CELL DEV B, V22, P317, DOI 10.1007/BF02623404; OBRIEN W, 1986, P NATL ACAD SCI USA, V83, P8659; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; REYNOLDS RK, 1988, P NATL ACAD SCI USA, V85, P3135, DOI 10.1073/pnas.85.9.3135; REYNOLDS RK, 1976, P NATL ACAD SCI USA, V2, P1337; RHIM JS, 1988, LEUKEMIA, V2, pS151; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RHIM JS, 1976, PREVENTION DETECTION, V2, P1337; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SAGER R, 1984, CANCER CELL, V2, P487; SAWAI S, 1984, MOL CELL BIOL, V4, P1172; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEINBERG ML, 1979, P NATL ACAD SCI USA, V76, P801, DOI 10.1073/pnas.76.2.801; SUTHERLAND BM, 1984, CANCER RES, V44, P2769	31	26	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1989	4	11					1403	1409						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2682464				2022-12-28	WOS:A1989AX65900019
J	DASGUPTA, P; LINNENBACH, AJ; GIACCIA, AJ; STAMATO, TD; REDDY, EP				DASGUPTA, P; LINNENBACH, AJ; GIACCIA, AJ; STAMATO, TD; REDDY, EP			MOLECULAR-CLONING OF THE BREAKPOINT REGION ON CHROMOSOME-6 IN CUTANEOUS MALIGNANT-MELANOMA - EVIDENCE FOR DELETION IN THE C-MYB LOCUS AND TRANSLOCATION OF A SEGMENT OF CHROMOSOME-12	ONCOGENE			English	Article									WISTAR INST, 36TH ST SPRUCE, PHILADELPHIA, PA 19104 USA	The Wistar Institute			Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [CA 44463, CA 25875] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044463, P01CA025875] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANSUBEL FM, 1987, CURRENT PROTOCOLS MO, P221; BALABAN G, 1984, CANCER GENET CYTOGEN, V11, P429, DOI 10.1016/0165-4608(84)90024-4; BALABAN GB, 1986, CANCER GENET CYTOGEN, V19, P113, DOI 10.1016/0165-4608(86)90378-X; BECHER R, 1983, CANCER RES, V43, P5010; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629; FRANCHINI G, 1983, P NATL ACAD SCI-BIOL, V80, P7385, DOI 10.1073/pnas.80.24.7385; GIACCIA AJ, 1989, UNPUB; GROFFEN J, 1989, PROG NUCLEIC ACID RE, V36, P281; HALUSKA FG, 1989, PROG NUCLEIC ACID RE, V36, P269; HARPER ME, 1983, NATURE, V304, P169, DOI 10.1038/304169a0; HERLYN M, 1987, LAB INVEST, V56, P461; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; LINNENBACH AJ, 1988, P NATL ACAD SCI USA, V85, P74, DOI 10.1073/pnas.85.1.74; LIOTTA LA, 1987, PIGM CELL RES, V1, P5, DOI 10.1111/j.1600-0749.1987.tb00528.x; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MANIATIS T, 1982, MOL CLONING LABORATO, P109; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; PATHAK S, 1983, CYTOGENET CELL GENET, V36, P573, DOI 10.1159/000131975; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SMITH HO, 1976, NUCLEIC ACIDS RES, V3, P2387, DOI 10.1093/nar/3.9.2387; TRENT JM, 1989, CANCER RES, V49, P420	23	28	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1989	4	10					1201	1205						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2677917				2022-12-28	WOS:A1989AU50800006
J	HUBER, BE; CORDINGLEY, MG				HUBER, BE; CORDINGLEY, MG			EXPRESSION AND PHENOTYPIC ALTERATIONS CAUSED BY AN INDUCIBLE TRANSFORMING RAS ONCOGENE INTRODUCED INTO RAT-LIVER EPITHELIAL-CELLS	ONCOGENE			English	Article									NCI,HORMONE ACT & ONCOGENESIS SECT,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HUBER, BE (corresponding author), WELLCOME RES LABS,3030 CORNWALLIS RD,RES TRIANGLE PK,NC 27709, USA.							ALTMAN S, 1970, J MOL BIOL, V50, P235, DOI 10.1016/0022-2836(70)90190-7; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; DAMANTE G, 1987, P NATL ACAD SCI USA, V84, P774, DOI 10.1073/pnas.84.3.774; DARNELL J, 1986, MOL CELL BIOL, P1046; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; EMERMAN M, 1984, J VIROL, V50, P42, DOI 10.1128/JVI.50.1.42-49.1984; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; FASEL N, 1982, EMBO J, V1, P3, DOI 10.1002/j.1460-2075.1982.tb01115.x; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; FURMAN PA, 1979, J VIROL, V32, P72, DOI 10.1128/JVI.32.1.72-77.1979; GEORGE DL, 1986, P NATL ACAD SCI USA, V83, P1651, DOI 10.1073/pnas.83.6.1651; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; GRUSS P, 1981, NATURE, V293, P486, DOI 10.1038/293486a0; HAGER GL, 1983, PROG NUCLEIC ACID RE, V29, P193, DOI 10.1016/S0079-6603(08)60447-X; HAGER GL, 1985, MAMMALIAN VIRAL VECT; HSIEH LL, 1987, CANCER RES, V47, P3421; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; HUBER BE, 1987, CANCER RES, V47, P3414; HUBER BE, 1985, CANCER RES, V45, P4322; HUBER BE, 1986, J BIOL CHEM, V261, P2400; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARDER B, 1987, EMBO J, V6, P3133, DOI 10.1002/j.1460-2075.1987.tb02623.x; LEVINSON AD, 1986, TRENDS GENET, V2, P81, DOI 10.1016/0168-9525(86)90184-8; Lizardi PM, 1984, GENE ANAL TECH, V1, P33; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MCLAREN C, 1983, ANTIVIR RES, V3, P223, DOI 10.1016/0166-3542(83)90001-3; MCMAHON G, 1986, P NATL ACAD SCI USA, V83, P9418, DOI 10.1073/pnas.83.24.9418; MCMAHON JB, 1986, CANCER RES, V46, P4665; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILLER AD, 1984, SCIENCE, V225, P993, DOI 10.1126/science.6089340; NOTARIO V, 1984, CANCER CELLS, V2; OSTROWSKI MC, 1981, P NATL ACAD SCI-BIOL, V78, P4485, DOI 10.1073/pnas.78.7.4485; OSTROWSKI MC, 1984, EMBO J, V3, P1891, DOI 10.1002/j.1460-2075.1984.tb02064.x; OWEN RD, 1987, MOL CELL BIOL, V7, P2512, DOI 10.1128/MCB.7.7.2512; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; REYNOLDS SH, 1986, P NATL ACAD SCI USA, V83, P33, DOI 10.1073/pnas.83.1.33; RUTA M, 1986, MOL CELL BIOL, V6, P1706, DOI 10.1128/MCB.6.5.1706; SCHWEIZER J, 1980, EUR J BIOCHEM, V112, P243, DOI 10.1111/j.1432-1033.1980.tb07200.x; SCOLNICK EM, 1976, J VIROL, V18, P559, DOI 10.1128/JVI.18.2.559-566.1976; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; SVEC J, 1977, NEOPLASMA, V24, P601; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARMUS HE, 1982, SCIENCE, V216, P812, DOI 10.1126/science.6177038; WEBER MJ, 1984, FED PROC, V43, P2246; WISEMAN RW, 1986, P NATL ACAD SCI USA, V83, P5825, DOI 10.1073/pnas.83.16.5825; WONG G, 1986, CANCER RES, V46, P6029; YASWEN P, 1985, MOL CELL BIOL, V5, P780, DOI 10.1128/MCB.5.4.780	58	34	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					245	256						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	3060790				2022-12-28	WOS:A1988Q436700002
J	BLAM, SB; MITCHELL, R; TISCHER, E; RUBIN, JS; SILVA, M; SILVER, S; FIDDES, JC; ABRAHAM, JA; AARONSON, SA				BLAM, SB; MITCHELL, R; TISCHER, E; RUBIN, JS; SILVA, M; SILVER, S; FIDDES, JC; ABRAHAM, JA; AARONSON, SA			ADDITION OF GROWTH-HORMONE SECRETION SIGNAL TO BASIC FIBROBLAST GROWTH-FACTOR RESULTS IN CELL-TRANSFORMATION AND SECRETION OF ABERRANT FORMS OF THE PROTEIN	ONCOGENE			English	Article									CALIF BIOTECHNOL INC,MT VIEW,CA 94043		BLAM, SB (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1E24,BETHESDA,MD 20892, USA.				NATIONAL CANCER INSTITUTE [F32CA007843] Funding Source: NIH RePORTER; NCI NIH HHS [CA 07843-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ADELMAN JP, 1983, DNA-J MOLEC CELL BIO, V2, P183, DOI 10.1089/dna.1983.2.183; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CRABB JW, 1986, BIOCHEM BIOPH RES CO, V136, P1155, DOI 10.1016/0006-291X(86)90455-9; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOTTO GP, 1985, NATURE, V318, P472; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V127, P121, DOI 10.1002/jcp.1041270116; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KARIN M, 1984, CELL, V36, P371, DOI 10.1016/0092-8674(84)90230-7; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARTIAL JA, 1979, SCIENCE, V205, P602, DOI 10.1126/science.377496; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOSCATELLI D, 1987, P NATL ACAD SCI USA, V84, P5778, DOI 10.1073/pnas.84.16.5778; MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; PRESTA M, 1986, MOL CELL BIOL, V6, P4060, DOI 10.1128/MCB.6.11.4060; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SCHAEFFER WI, 1976, CANCER LETT, V1, P259; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SHARMA S, 1985, EMBO J, V4, P1479, DOI 10.1002/j.1460-2075.1985.tb03806.x; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SOMMER A, 1987, BIOCHEM BIOPH RES CO, V144, P543, DOI 10.1016/S0006-291X(87)80001-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STORY MT, 1987, BIOCHEM BIOPH RES CO, V142, P702, DOI 10.1016/0006-291X(87)91471-9; SUNG WL, 1986, P NATL ACAD SCI USA, V83, P561, DOI 10.1073/pnas.83.3.561; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; Tooze J, 1980, DNA TUMOR VIRUSES; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UENO N, 1986, BIOCHEM BIOPH RES CO, V138, P580, DOI 10.1016/S0006-291X(86)80536-8; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	55	100	104	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					129	136						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	3412772				2022-12-28	WOS:A1988Q053400001
J	HIGUCHI, Y; SETOGUCHI, M; YOSHIDA, S; AKIZUKI, S; YAMAMOTO, S				HIGUCHI, Y; SETOGUCHI, M; YOSHIDA, S; AKIZUKI, S; YAMAMOTO, S			ENHANCEMENT OF C-FOS EXPRESSION IS ASSOCIATED WITH ACTIVATED MACROPHAGES	ONCOGENE			English	Article											HIGUCHI, Y (corresponding author), MED COLL OITA,DEPT PATHOL,OITA 87956,JAPAN.							AKAGAWA KS, 1981, MICROBIOL IMMUNOL, V25, P1215, DOI 10.1111/j.1348-0421.1981.tb00130.x; AKAGAWA KS, 1982, MICROBIOL IMMUNOL, V26, P831, DOI 10.1111/j.1348-0421.1982.tb00229.x; ANDREW PW, 1984, EUR J IMMUNOL, V14, P962, DOI 10.1002/eji.1830141018; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; GEMSA D, 1983, J IMMUNOL, V131, P833; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HIGUCHI Y, 1984, IMMUNOGENETICS, V20, P95, DOI 10.1007/BF00364481; HOMMA Y, 1982, J IMMUNOL, V129, P1619; INTRONA M, 1986, J IMMUNOL, V137, P2711; JONES CM, 1986, J IMMUNOL, V137, P571; KLEINSCHMIDT WJ, 1982, J INTERFERON RES, V2, P291, DOI 10.1089/jir.1982.2.291; KOHLER G, 1976, EUR J IMMUNOL, V6, P292, DOI 10.1002/eji.1830060411; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LE JM, 1983, J IMMUNOL, V131, P2821; LEE JC, 1986, J IMMUNOL, V136, P1322; MANIATIS T, 1982, MOL CLONING LABORATO; MECHAM JO, 1985, J IMMUNOL, V134, P3516; MELTZER MS, 1982, J IMMUNOL, V129, P2802; MELTZER MS, 1981, J IMMUNOL, V127, P197; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; ONOZAKI K, 1983, CELL IMMUNOL, V75, P242, DOI 10.1016/0008-8749(83)90323-4; PACE JL, 1983, P NATL ACAD SCI-BIOL, V80, P3782, DOI 10.1073/pnas.80.12.3782; ROBERTS WK, 1982, J INTERFERON RES, V2, P519, DOI 10.1089/jir.1982.2.519; Schiffmann E, 1979, Curr Top Cell Regul, V15, P203; SCHREIBER RD, 1983, J IMMUNOL, V131, P826; STEARNE PA, 1985, J IMMUNOL, V134, P443; TAKAHASHI T, 1970, J EXP MED, V131, P1325, DOI 10.1084/jem.131.6.1325; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WEIEL JE, 1985, J IMMUNOL, V134, P293; YAMAMOTO S, 1984, BIOMED RES-TOKYO, V5, P91, DOI 10.2220/biomedres.5.91; YAMAMOTO S, 1984, IMMUNOGENETICS, V19, P519, DOI 10.1007/BF00403443; YAMAMOTO S, 1971, IMMUNOLOGY, V20, P803	43	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					515	521						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	3131720				2022-12-28	WOS:A1988N434800014
J	STORER, RD; ALLEN, HL; KRAYNAK, AR; BRADLEY, MO				STORER, RD; ALLEN, HL; KRAYNAK, AR; BRADLEY, MO			RAPID INDUCTION OF AN EXPERIMENTAL METASTATIC PHENOTYPE IN 1ST PASSAGE RAT EMBRYO CELLS BY COTRANSFECTION OF EJ C-HA-RAS AND C-MYC ONCOGENES	ONCOGENE			English	Article											STORER, RD (corresponding author), MERCK SHARP & DOHME RES LABS,W POINT,PA 19486, USA.							BRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277, DOI 10.1073/pnas.83.14.5277; FOULDS L, 1964, CELLULAR CONTROL MEC, P242; Kuhn T.S., 1970, STRUCTURE SCI REVOLU, P174; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; MANIATIS T, 1983, MOL CLONING LABORATO; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STORER RD, 1986, CANCER RES, V46, P1458; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455	18	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					141	147						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	3285293				2022-12-28	WOS:A1988M086000007
J	FUJITA, M; SHIKU, H				FUJITA, M; SHIKU, H			DIFFERENCES IN SENSITIVITY TO INDUCTION OF APOPTOSIS AMONG RAT FIBROBLAST CELLS TRANSFORMED BY HTLV-I TAX GENE OR CELLULAR NUCLEAR ONCOGENES	ONCOGENE			English	Article						HTLV-I; TAX; C-MYC; C-FOS; APOPTOSIS; RAT-1	VIRUS TYPE-I; LONG TERMINAL REPEAT; NF-KAPPA-B; LEUKEMIA-VIRUS; C-FOS; TRANSCRIPTIONAL ACTIVATOR; NEOPLASTIC TRANSFORMATION; EXPRESSION; PROTEIN; MYC	The tax gene of human T lymphotropic virus type I has been implicated in the genesis of adult T cell leukemia (ATL), It has been reported that expression of tax induces neoplastic transformation in the rat fibroblast cell line Rat-1, and that co-expression with the ras gene can transform rat embryo fibroblasts. Possible activation of cellular oncogenes including c-myc and c-fos by tax has been implicated in these tax functions, In this study, comparative analysis of biological properties of tax and cellular nuclear oncogenes c-myc and c-fos was performed in Rat-1 cells, While all three oncogenes could transform Rat-1 cells, significant differences in the sensitivity to induction of apoptosis were observed between cells transformed with each oncogene, Induction of apoptosis by serum starvation was observed in tax-transfected Rat-1 cells but to a lesser extent than that in those transfected with c-myc or c-fos, In contrast, exposure to a DNA-damaging agent, etoposide, resulted in enhanced apoptotic death only in c-myc-transfected Rat-1 cells, Our findings indicate that the pathways for apoptosis induction may not be identical among these three oncogenes, and that the relatively low apoptosis-inducing activity and sufficient transforming capacity of tax might be associated with transformation of T cells and the low susceptibility of the transformed T cells (ATL cells) to chemotherapeutic agents.	NAGASAKI UNIV,SCH MED,DEPT ONCOL,NAGASAKI 852,JAPAN	Nagasaki University				Fujita, Masatoshi/0000-0001-6617-2452				BHALLA K, 1993, BLOOD, V82, P3133; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJITA M, 1994, BLOOD, V84, P2591, DOI 10.1182/blood.V84.8.2591.bloodjournal8482591; FUJITA M, 1993, FEBS LETT, V322, P15, DOI 10.1016/0014-5793(93)81101-5; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MILLER AD, 1984, CELL, V36, P51; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NAKAMURA M, 1989, J BIOL CHEM, V264, P20189; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; SAKURAI M, 1992, INT J CANCER, V52, P323, DOI 10.1002/ijc.2910520228; Sambrook J., 1989, MOL CLONING; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TSUDA H, 1993, JPN J CANCER RES, V84, P431, DOI 10.1111/j.1349-7006.1993.tb00154.x; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; 1991, LEUKEMIA RES, V15, P81	45	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					15	20						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624122				2022-12-28	WOS:A1995RJ29500003
J	HAAPAJARVI, T; KIVINEN, L; PITKANEN, K; LAIHO, M				HAAPAJARVI, T; KIVINEN, L; PITKANEN, K; LAIHO, M			CELL-CYCLE DEPENDENT EFFECTS OF UV-RADIATION ON P53 EXPRESSION AND RETINOBLASTOMA PROTEIN-PHOSPHORYLATION	ONCOGENE			English	Article						P53; PRB; GROWTH ARREST; CELL CYCLE; UV RADIATION	WILD-TYPE P53; SUSCEPTIBILITY GENE-PRODUCT; TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGING AGENTS; IONIZING-RADIATION; APOPTOSIS; INDUCTION; PROLIFERATION; CHECKPOINT; GROWTH	Control of fate of cells encountered with DNA damaging agents is pivotal for normal cellular homeostasis. DNA damage leads in many cases to growth arrest of the cells ensuring sufficient time for damage repair. Growth arrest can be mediated by p53 tumor suppressor protein and loss pf its function leads to inability of the cells to both growth arrest and undergo apoptosis. We show here that followed by genotoxic stress, the retinoblastoma gene product, pRB, is associated with growth arrest of cells in a p53 independent manner. In u.v.-treated human and mouse fibroblasts, pRB is rapidly dephosphorylated. pRB dephosphorylation occurs concomitant with growth arrest of cells including cells with p53 mutations (SW 480 colon carcinoma cells), cells expressing SV40 T antigen and rat-transformed cells (T-24 bladder carcinoma cells) unresponsive in regard to p53 stimulation. Furthermore, how cytometry analysis of u.v.-radiated synchronized G1 cells indicates that the cells transiently arrest in G1 for 10-12 h with pRB dominating in its underphosphorylated form, whereas p53 accumulation occurs only after the cells have entered into S-phase. In addition, u.v.-radiation of late S- and G2/M-phase cells leads to p53 accumulation and cell cycle arrest. The results indicate that p53 accumulation upon u.v.-radiation occurs during DNA replication and is thus not involved in G1 arrest. We suggest that the events that lead to pRB dephosphorylation upon u.v.-radiation provide the cell an efficient G1 arrest which occurs prior and independently of p53.	HELSINKI UNIV,DEPT VIROL,SF-00014 HELSINKI,FINLAND	University of Helsinki								BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRITSCHE M, 1993, ONCOGENE, V8, P307; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HALL PA, 1993, ONCOGENE, V8, P203; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO J, 1993, GENE DEV, V7, P331; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEVINS JR, 1992, SCIENCE, V258, P424; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PITKANEN K, 1993, EXP CELL RES, V207, P99, DOI 10.1006/excr.1993.1167; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RON D, 1994, P NATL ACAD SCI USA, V91, P1985, DOI 10.1073/pnas.91.6.1985; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; STEWART N, 1995, ONCOGENE, V10, P109; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	49	43	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					151	159						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624123				2022-12-28	WOS:A1995RJ29500018
J	HATADA, I; TOKINO, T; OCHIYA, T; MATSUBARA, K				HATADA, I; TOKINO, T; OCHIYA, T; MATSUBARA, K			CO-AMPLIFICATION OF INTEGRATED HEPATITIS-B VIRUS-DNA AND TRANSFORMING GENE HST-1 IN A HEPATOCELLULAR-CARCINOMA	ONCOGENE			English	Article									OSAKA UNIV,INST MOLEC & CELLULAR BIOL,1-3 YAMADA OKA,SUITA,OSAKA 565,JAPAN	Osaka University			Ochiya, Takahiro/AAH-7585-2019; Tokino, Takashi/AAI-9887-2021					ADELAIDE J, 1988, IN PRESS ONCOGENE; BRESLOW JL, 1982, P NATL ACAD SCI-BIOL, V79, P6861, DOI 10.1073/pnas.79.22.6861; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; FORD M, 1986, CELL, V45, P425, DOI 10.1016/0092-8674(86)90328-4; FORD M, 1985, P NATL ACAD SCI USA, V82, P3370, DOI 10.1073/pnas.82.10.3370; HYRIEN O, 1988, EMBO J, V7, P407, DOI 10.1002/j.1460-2075.1988.tb02828.x; IMAZEKI F, 1988, J VIROL, V62, P861, DOI 10.1128/JVI.62.3.861-865.1988; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; LOONEY JE, 1987, MOL CELL BIOL, V7, P569, DOI 10.1128/MCB.7.2.569; MIZUSAWA H, 1985, P NATL ACAD SCI USA, V82, P208, DOI 10.1073/pnas.82.1.208; NAKAGAMA H, 1987, JPN J CANCER RES, V78, P651; NALBANTOGLU J, 1986, NUCLEIC ACIDS RES, V14, P8361, DOI 10.1093/nar/14.21.8361; OCHIYA T, 1986, P NATL ACAD SCI USA, V83, P4993, DOI 10.1073/pnas.83.14.4993; PASSANANTI C, 1987, EMBO J, V6, P1697, DOI 10.1002/j.1460-2075.1987.tb02420.x; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; SAITO I, 1986, P NATL ACAD SCI USA, V83, P8664, DOI 10.1073/pnas.83.22.8664; SAKAMOTO H, 1988, BIOCHEM BIOPH RES CO, V151, P965, DOI 10.1016/S0006-291X(88)80460-1; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SAWADA R, 1988, MOL CELL BIOL, V8, P588; SEKI T, 1985, P NATL ACAD SCI USA, V82, P6657, DOI 10.1073/pnas.82.19.6657; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TOKINO T, 1987, J VIROL, V61, P3848, DOI 10.1128/JVI.61.12.3848-3854.1987; TSUTSUMI M, 1988, JPN J CANCER RES, V79, P428, DOI 10.1111/j.1349-7006.1988.tb01609.x; YOSHIDA MC, 1985, JPN J CANCER RES, V76, P559; YOSHIDA MC, 1988, IN PRESS P NATL ACAD; YUASA Y, 1987, JPN J CANCER RES, V78, P1036	29	74	73	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					537	540						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	2856253				2022-12-28	WOS:A1988R516300008
J	GANGULY, S				GANGULY, S			DESCRIPTION OF A HUMAN PLACENTAL ANTI-INSULIN RECEPTOR POLYCLONAL ANTIBODY THAT ACTIVATES INSULIN BINDING TO THE RECEPTOR INVITRO	ONCOGENE			English	Article									YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine								CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P318, DOI 10.1073/pnas.69.2.318; DAS M, 1984, EUR J BIOCHEM, V141, P429, DOI 10.1111/j.1432-1033.1984.tb08209.x; DEUTSCH PJ, 1983, P NATL ACAD SCI-BIOL, V80, P133, DOI 10.1073/pnas.80.1.133; FREDMAN P, 1983, J BIOL CHEM, V258, P1206; GANGULY S, 1987, FEBS LETT, V224, P198, DOI 10.1016/0014-5793(87)80447-7; GANGULY S, 1985, CURR TOP CELL REGUL, V27, P83; HEDO JA, 1981, P NATL ACAD SCI-BIOL, V78, P4791, DOI 10.1073/pnas.78.8.4791; IKEDA Y, 1976, J BIOL CHEM, V251, P6135; JACOBS S, 1978, SCIENCE, V200, P1283, DOI 10.1126/science.663609; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KASUGA M, 1981, DIABETES, V30, P354, DOI 10.2337/diabetes.30.4.354; KHAN CR, 1976, NEW ENGL J MED, V294, P739; KULL FC, 1982, BIOCHEM BIOPH RES CO, V106, P1019, DOI 10.1016/0006-291X(82)91813-7; MORGAN D, 1986, BIOCHEMISTRY, V25, P1371; PETRUZZELLI LM, 1982, P NATL ACAD SCI-BIOL, V79, P6792, DOI 10.1073/pnas.79.22.6792; PONZIO G, 1987, EMBO J, V6, P333, DOI 10.1002/j.1460-2075.1987.tb04759.x; ROTH RA, 1982, P NATL ACAD SCI-BIOL, V79, P7312, DOI 10.1073/pnas.79.23.7312; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; SIEGEL TW, 1981, J BIOL CHEM, V256, P9266; ZICK Y, 1984, J BIOL CHEM, V259, P4396	20	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					341	344						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	3144692				2022-12-28	WOS:A1988Q436700014
J	MAUELER, W; RAULF, F; SCHARTL, M				MAUELER, W; RAULF, F; SCHARTL, M			EXPRESSION OF PROTO-ONCOGENES IN EMBRYONIC, ADULT, AND TRANSFORMED TISSUE OF XIPHOPHORUS (TELEOSTEI-POECILIIDAE)	ONCOGENE			English	Article											MAUELER, W (corresponding author), MAX PLANCK INST BIOCHEM,GENTECHNOL ARBEITSGRP MOLEK EMBRYOL,KLOPFERSPITZ 18A,D-8033 MARTINSRIED,FED REP GER.			Schartl, Manfred/0000-0001-9882-5948				ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; ANDERS A, 1978, BIOCHIM BIOPHYS ACTA, V516, P61, DOI 10.1016/0304-419X(78)90004-5; Anders A., 1973, P33; ANDERS F, 1984, ADV CANCER RES, V42, P191, DOI 10.1016/S0065-230X(08)60459-5; BARNEKOW A, 1987, CANCER RES, V47, P235; BARNEKOW A, 1982, CANCER RES, V42, P2429; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BISHOP JM, 1986, J CELL PHYSIOL, V4, P1; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; COLLINS T, 1985, NATURE, V316, P748, DOI 10.1038/316748a0; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FRIEND SF, 1987, IN PRESS P NATL ACAD; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; FURTH ME, 1987, ONCOGENE, V1, P47; GELMANN EP, 1981, P NATL ACAD SCI-BIOL, V78, P3373, DOI 10.1073/pnas.78.6.3373; GESSLER M, 1984, BIOSCIENCE REP, V4, P757, DOI 10.1007/BF01128817; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GOUSTIN AS, 1985, CELL, V41, P301, DOI 10.1016/0092-8674(85)90083-2; GUSTERSON B, 1984, CELL BIOL INT REP, V8, P649, DOI 10.1016/0309-1651(84)90045-6; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; IGARASHI H, 1987, ONCOGENE, V1, P79; JACOB L, 1987, CELL, V50, P215, DOI 10.1016/0092-8674(87)90217-0; JANSEN HW, 1983, EMBO J, V2, P1969, DOI 10.1002/j.1460-2075.1983.tb01686.x; Kallman K.D., 1975, P81; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P105; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KNUDSON AG, 1985, CANCER RES, V45, P1437; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KUHN C, 1979, IN VITRO CELL DEV B, V15, P537, DOI 10.1007/BF02618156; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEMEUR M, 1981, CELL, V23, P561, DOI 10.1016/0092-8674(81)90152-5; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; LEV Z, 1985, MOL CELL BIOL, V5, P1540, DOI 10.1128/MCB.5.6.1540; LEV Z, 1986, BIOCHIM BIOPHYS ACTA, V867, P144, DOI 10.1016/0167-4781(86)90074-6; LYNCH HT, 1985, PIGMENT CELL, P691; MANIATIS T, 1982, MOL CLONING LABORATO; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLER R, 1986, TRENDS BIOCHEM SCI, V11, P129, DOI 10.1016/0968-0004(86)90066-6; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1984, CURR TOP MICROBIOL, V112, P73; MULLER R, 1983, COLD SPRING HARBOR C, V10, P451; NEMOTO N, 1987, J CANCER RES CLIN, V113, P56, DOI 10.1007/BF00389967; OHARA B, 1986, CYTOGENET CELL GENET, V43, P97, DOI 10.1159/000132303; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; PAWSON T, 1985, MOL CELL BIOL, V5, P33, DOI 10.1128/MCB.5.1.33; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RHODES AR, 1983, J AM ACAD DERMATOL, V9, P563, DOI 10.1016/S0190-9622(83)70171-4; SCHARTL M, 1985, INT J CANCER, V36, P199, DOI 10.1002/ijc.2910360212; SCHARTL M, 1984, DEV BIOL, V105, P415, DOI 10.1016/0012-1606(84)90298-7; SCHARTL M, 1982, CANCER RES, V42, P4222; SCHARTL M, 1988, IN PRESS PIGMENT CEL, V8; SCHARTL M, 1988, IN PRESS GENETICS; SEFTON BM, 1985, TRENDS GENET, V1, P306, DOI 10.1016/0168-9525(85)90120-9; SEJERSEN T, 1986, P NATL ACAD SCI USA, V83, P6844, DOI 10.1073/pnas.83.18.6844; SEKIYA T, 1985, JPN J CANCER RES, V76, P555; SHEINESS DK, 1980, VIROLOGY, V105, P415, DOI 10.1016/0042-6822(80)90042-2; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SLAMON DJ, 1984, P NATL ACAD SCI-BIOL, V81, P7141, DOI 10.1073/pnas.81.22.7141; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPANDIDOS DA, 1985, ANTICANCER RES, V5, P221; TATOSYAN AG, 1985, INT J CANCER, V35, P731, DOI 10.1002/ijc.2910350606; TAVOLGA WN, 1949, B AM MUS NAT HIST, V164, P161; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VARDIMON L, 1986, MOL CELL BIOL, V6, P4109, DOI 10.1128/MCB.6.11.4109; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VENNSTROM B, 1980, J VIROL, V36, P375; WAKAMATSU Y, 1984, DEV GROWTH DIFFER, V26, P503; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WEINBERG RA, 1986, J CLIN ONCOL, V4, P1293, DOI 10.1200/JCO.1986.4.9.1293; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	80	32	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					421	430						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	3374960				2022-12-28	WOS:A1988N434800002
J	TAVASSOLI, M; SHALL, S				TAVASSOLI, M; SHALL, S			TRANSCRIPTION OF THE C-MYC ONCOGENE IS ALTERED IN SPONTANEOUSLY IMMORTALIZED RODENT FIBROBLASTS	ONCOGENE			English	Article											TAVASSOLI, M (corresponding author), UNIV SUSSEX, CELL & MOLEC BIOL LAB, BIOL BLDG, BRIGHTON BN1 9QG, E SUSSEX, ENGLAND.							ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; DUESBERG PH, 1977, P NATL ACAD SCI USA, V74, P4320, DOI 10.1073/pnas.74.10.4320; EISENMAN RN, 1986, CANCER SURV, V5, P309; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; KARATZA C, 1984, J CELL SCI, V65, P163; KARATZA C, 1984, J CELL SCI, V66, P401; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; LEY TJ, 1982, P NATL ACAD SCI-BIOL, V79, P4775, DOI 10.1073/pnas.79.15.4775; MANIATIS T, 1982, MOL CLONING LABORATO; MILES MF, 1981, J BIOL CHEM, V256, P2545; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; NEUBERGER MS, 1983, NATURE, V305, P240, DOI 10.1038/305240a0; NICOLAIEW N, 1986, EXP CELL RES, V166, P357, DOI 10.1016/0014-4827(86)90482-9; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PONTEN J, 1983, J CELL PHYSIOL, V117, P342, DOI 10.1002/jcp.1041170309; PONTEN J, 1971, SPONTANEOUS VIRUS IN; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RABBITTS TH, 1985, TRENDS GENET, V1, P327, DOI 10.1016/0168-9525(85)90127-1; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SHALL S, 1979, J THEOR BIOL, V76, P219, DOI 10.1016/0022-5193(79)90371-0; SHALL S, 1987, PERSPECTIVES MAMMALI, P184; SMITH JR, 1984, P NATL ACAD SCI USA, V83, P8167; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STEIN WD, 1978, CELL REPRODUCTION, P147; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917	52	17	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1988	2	4					337	345						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3283652				2022-12-28	WOS:A1988M947200005
J	BASTIEN, C; FEUNTEUN, J				BASTIEN, C; FEUNTEUN, J			THE HAMSTER POLYOMAVIRUS TRANSFORMING PROPERTIES	ONCOGENE			English	Article									INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,F-94805 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy			Feunteun, Jean/AAZ-1267-2020	Feunteun, Jean/0000-0003-1212-9189				ACHESON NH, 1978, P NATL ACAD SCI USA, V75, P4754, DOI 10.1073/pnas.75.10.4754; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DELMAS V, 1985, EMBO J, V4, P1279, DOI 10.1002/j.1460-2075.1985.tb03773.x; GRAFFI A, 1970, COMP LEUK RES BIBLIO, V36, P293; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; MENEGUZZI G, 1984, EMBO J, V3, P365, DOI 10.1002/j.1460-2075.1984.tb01813.x; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZOUZIAS D, 1977, J VIROL, V24, P142, DOI 10.1128/JVI.24.1.142-150.1977	14	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					129	135						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	3285292				2022-12-28	WOS:A1988M086000005
J	LIFSHITZ, B; FAINSTEIN, E; MARCELLE, C; SHTIVELMAN, E; AMSON, R; GALE, RP; CANAANI, E				LIFSHITZ, B; FAINSTEIN, E; MARCELLE, C; SHTIVELMAN, E; AMSON, R; GALE, RP; CANAANI, E			BCR GENES AND TRANSCRIPTS	ONCOGENE			English	Article									WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024	Weizmann Institute of Science; University of California System; University of California Los Angeles					NCI NIH HHS [CA-38569] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038569] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CANAANI E, 1984, LANCET, V1, P593; CHAMPLIN RE, 1985, BLOOD, V65, P1039; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; FINK GR, 1986, CELL, V45, P155, DOI 10.1016/0092-8674(86)90378-8; FROMM M, 1983, Journal of Molecular and Applied Genetics, V2, P127; GALE RP, 1984, P NATL ACAD SCI US, V81, P5548; GREENBERG ME, 1983, CELL, V33, P767, DOI 10.1016/0092-8674(83)90019-3; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1985, BIOCHIM BIOPHYS ACTA, V823, P1, DOI 10.1016/0304-419X(85)90012-5; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; NOWELL PC, 1960, SCIENCE, V132, P1197; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984	27	85	87	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					113	117						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	3285291				2022-12-28	WOS:A1988M086000003
J	GAO, X; CHEN, YQ; WU, N; GRIGNON, DJ; SAKR, W; PORTER, AT; HONN, KV				GAO, X; CHEN, YQ; WU, N; GRIGNON, DJ; SAKR, W; PORTER, AT; HONN, KV			SOMATIC MUTATIONS OF THE WAF1/CIP1 GENE IN PRIMARY PROSTATE-CANCER	ONCOGENE			English	Note						TUMOR SUPPRESSOR GENE; WAF1/CIP1; PROSTATIC ADENOCARCINOMA; MUTATION; POLYMERASE CHAIN REACTION	TUMOR; INHIBITOR; KINASES; P21	The WAF1/CIP1 gene, a potential tumor suppressor gene, has recently been cloned and identified as a p53 mediator and an inhibitor for G1 cyclin-dependent kinases (CDKs). We undertook this study to investigate the possible role of the WAF1/CIP1 gene in human prostatic carcinoma. Matched normal and cancer tissues from 18 patients with prostate cancer were screened for WAF1/CIP1 mutation by nested reverse transcription-polymerase chain reaction/single strand conformational polymorphism (RT-PCR/SSCP) and DNA sequencing. Shifted bands from three tumor, but not the matched normal specimens, were observed. Subsequent direct DNA sequencing of the PCR fragments identified four sequence alterations including a cytosine (C) to adenine (A) transversion and a guanine (G) to A transition and two A insertions. Our results demonstrated that mutations of the WAF1/CTP1 gene occur and may be important during the pathogenesis of human prostate cancer. This is the first report of WAF1/CIP1 mutation in a primary human cancer.	WAYNE STATE UNIV,SCH MED,DEPT RADIAT ONCOL,DIV CANC BIOL,DETROIT,MI 48202; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48202	Wayne State University; Wayne State University			Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708				BHATIA K, 1995, CANCER RES, V55, P1431; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CHEDID M, 1994, ONCOGENE, V9, P3021; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHEN YQ, 1992, J BIOL CHEM, V267, P17314; CHEN YQ, 1994, CANCER RES, V54, P1574; CHEN YQ, 1994, CANCER MOL BIOL, V1, P357; CHI SG, 1994, J NATL CANCER I, V86, P926, DOI 10.1093/jnci/86.12.926; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GAO X, 1995, CANCER RES, V55, P1002; GAO X, 1995, INT J ONCOL, V6, P111; GAO X, 1993, CANCER RES, V53, P2723; GAO X, 1995, IN PRESS PATHOL ONCO; GAO X, 1995, CANCER MOL BIOL, V2, P475; GAO X, 1995, IN PRESS UROL; GAO X, 1994, CANCER MOL BIOL, V1, P297; GAO XA, 1994, ONCOGENE, V9, P2999; HAGMANN W, 1995, PROSTAGLANDINS, V49, P49, DOI 10.1016/0090-6980(94)00005-H; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; JIANG HP, 1994, ONCOGENE, V9, P3397; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LI YJ, 1995, ONCOGENE, V10, P599; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; STEINMAN RA, 1994, ONCOGENE, V9, P3389; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG W, 1995, CANCER RES, V55, P668; ZHOU XL, 1994, ONCOGENE, V9, P3737	39	109	116	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1395	1398						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478562				2022-12-28	WOS:A1995RY96700022
J	SCHOTT, AF; APEL, IJ; NUNEZ, G; CLARKE, MF				SCHOTT, AF; APEL, IJ; NUNEZ, G; CLARKE, MF			BCL-X(L) PROTECTS CANCER-CELLS FROM P53-MEDIATED APOPTOSIS	ONCOGENE			English	Article						BCL-X(L); P53; BREAST CANCER	BCL-2 PROTEIN; DEATH; GENE; MYC; P53; EXPRESSION; SURVIVAL; LINE	Oncogenesis is a process resulting from genetic events which cause loss of growth control or inhibition of appropriate cell death. The Bcl-x(L) protein is a recently discovered member of the bcl-2 family which has been shown to protect cells from some forms of programmed cell death, but has not yet been implicated in the genesis of human carcinomas. In this report we explore the role of Bcl-x(L) overexpression in protecting cancer cells from p53-mediated apoptosis. Increased levels of Bcl-x(L) were found in a subset of primary human breast carcinomas, as well as in the breast cancer line, T47D. T47D cells were then transfected with a temperature-sensitive mutant of the tumor suppressor p53 (p53ts). Although many tumor cell lines undergo apoptosis when p53 is expressed, the T47D transfectants remained viable at temperatures permitting wild-type p53 phenotype. This suggested that endogenous Bcl-x(L) could protect cancer cells from p53-mediated apoptosis. To test this hypothesis, murine erythroleukemia cells were transfected with bcl-x(L) and p53ts. While cell lines expressing p53 alone rapidly died, those cells co-expressing Bcl-x(L) survived. These results demonstrate that Bcl-x(L) is capable of protecting cells from p53-mediated apoptosis, and suggest a possible mechanism by which tumors expressing Bcl-x(L) are able to partly overcome the tumor suppressor functions of p53.	UNIV MICHIGAN,DEPT HEMATOL ONCOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Nuñez, Gabriel/A-7160-2014; Schott, Anne/AAD-1902-2019		NCI NIH HHS [CA-46657] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046657] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; BHARGAVA V, 1994, AM J PATHOL, V145, P535; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CASTLE VP, 1993, AM J PATHOL, V143, P1543; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; COLOMBEL M, 1993, AM J PATHOL, V143, P390; DOGLIONI C, 1994, VIRCHOWS ARCH, V424, P47; FUKUNAGAJOHNSON N, 1995, IN PRESS CARCINOGENE; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; HALDAR S, 1994, CANCER RES, V54, P2095; IKEGAKI N, 1994, CANCER RES, V54, P6; JOENSUU H, 1994, AM J PATHOL, V145, P1191; KORSMEYER SJ, 1992, BLOOD, V880, P879; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; PIENTENPOL JA, 1993, NATURE, V365, P17; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG YS, 1993, ONCOGENE, V8, P3427; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZUTTER M, 1991, BLOOD, V78, P1062	34	114	117	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1389	1394						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478561				2022-12-28	WOS:A1995RY96700021
J	YU, DH; MATIN, A; XIA, WY; SORGI, F; HUANG, L; HUNG, MC				YU, DH; MATIN, A; XIA, WY; SORGI, F; HUANG, L; HUNG, MC			LIPOSOME-MEDIATED IN-VIVO E1A GENE-TRANSFER SUPPRESSED DISSEMINATION OF OVARIAN-CANCER CELLS THAT OVEREXPRESS HER-2/NEU	ONCOGENE			English	Note						C-ERBB-2; CATIONIC LIPOSOME; TUMOR SUPPRESSION; ADENOVIRUS-5 E1A; ONCOGENE	NATURAL-KILLER CELLS; BREAST-CANCER; NEU GENE; EXPRESSION; ADENOVIRUS; ONCOGENE; PROTOONCOGENE; PRODUCTS; AMPLIFICATION; METASTASIS	The HER-2/neu proto-oncogene is frequently amplified or overexpressed in many different types of human cancers, a phenomenon that has been shown to correlate with shorter survival time and lower survival rate in ovarian cancer patients, We previously reported that increased HER-2/neu expression led to more severe malignancy and increased metastatic potential in animal models and that the adenovirus 5 E1A gene repressed HER-2/nue gene expression at transcriptional level and was able to suppress tumor growth when stably transfected into human ovarian cancer SKOV-3 cells which overexpress HER-2/neu. To investigate whether the E1A gene may be used as a therapeutic agent for HER-2/neu-overexpressing human cancers in living hosts, we first developed tumor-bearing mice by injecting SKOV-3 cells that overexpress HER-2/neu intraperitonealy into female nu/nu mice, Five days later, rye used cationic liposomes to directly deliver the E1A gene into adenocarcinomas that developed in the peritoneal cavity and an the mesentery of the mice that received the SKOV-3 cell injection, We found that liposome-mediated E1A gene transfer significantly inhibited growth and dissemination of ovarian cancer cells that overexpress HER-2/neu in the treated mice; about 70% of these mice survived at least 365 days, whereas all the control mice that did not receive the gene therapy developed severe tumor symptoms and died within 160 days, The results suggest that liposome-mediated E1A gene transfer may serve as an effective therapy for human ovarian cancers that overexpress HER-2/neu by directly targeting the HER-2/neu oncogene.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT SURG ONCOL,HOUSTON,TX 77030; UNIV PITTSBURGH,DEPT PHARMACOL,PITTSBURGH,PA 15261	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NCI NIH HHS [CA64654, CA59327, CA60488] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060488, R01CA064654, R29CA060488, P01CA059327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEAHRS OH, 1992, MANUAL STAGING CANCE; BERCHUCK A, 1990, CANCER RES, V50, P4087; BERGMANN CI, 1986, NATURE, V319, P226; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; COOK JL, 1984, SCIENCE, V224, P612, DOI 10.1126/science.6710160; COOK JL, 1989, J IMMUNOL, V142, P4527; CREASMAN WT, 1991, AM J OBSTET GYNECOL, V165, P7, DOI 10.1016/0002-9378(91)90213-B; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HSU SM, 1982, J HISTOCHEM CYTOCHEM, V29, P577; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PIVER MS, 1991, SEMIN ONCOL, V18, P177; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SAWADA Y, 1985, VIROLOGY, V147, P413, DOI 10.1016/0042-6822(85)90143-6; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEEG PS, 1988, CANCER RES, V48, P6550; TOIKKANEN S, 1992, J CLIN ONCOL, V10, P1044, DOI 10.1200/JCO.1992.10.7.1044; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEINER DB, 1990, CANCER RES, V50, P421; YAN DH, 1991, ONCOGENE, V6, P343; YU D, 1995, MOL BASIS ONCOLOGY, P131; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; ZHANG X, 1989, ONCOGENE, V4, P985	36	98	118	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1383	1388						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478560				2022-12-28	WOS:A1995RY96700020
J	VANETTEN, RA; DEBNATH, J; ZHOU, H; CASASNOVAS, JM				VANETTEN, RA; DEBNATH, J; ZHOU, H; CASASNOVAS, JM			INTRODUCTION OF A LOSS-OF-FUNCTION POINT MUTATION FROM THE SH3 REGION OF THE CAENORHABDITIS-ELEGANS SEM-5 GENE ACTIVATES THE TRANSFORMING ABILITY OF C-ABL IN-VIVO AND ABOLISHES BINDING OF PROLINE-RICH LIGANDS IN-VITRO	ONCOGENE			English	Article						ONCOGENES; ABELSON MURINE LEUKEMIA VIRUS; TYROSINE KINASE; CELL TRANSFORMATION; SRC HOMOLOGY REGION	TYROSINE-PHOSPHORYLATED PEPTIDES; GUANINE-NUCLEOTIDE EXCHANGE; ONCOGENIC ACTIVATION; CRYSTAL-STRUCTURE; ADAPTER PROTEIN; KINASE-ACTIVITY; DOMAIN; GRB2; SRC; RAS	We have introduced two loss-of-function point mutations from highly conserved regions of the src homology 3 (SH3) domains of the Caenorhabditis elegans sem-5 gene into the SH3 domain of the murine type IV c-abl tyrosine kinase proto-oncogene. One of the mutations, P131L, activated abl to transform fibroblasts while tbe other, G128R, did not. When combined with independent activating mutations in the c-abl kinase domain or NH,terminus, the G128R mutation blocked transformation by the double mutant, suggesting that the G128R mutant was unable to transform cells for trivial reasons. The c-Abl G128R mutant, like wild type c-Abi protein, was localized to the nucleus and actin cytoskeleton and had normal tyrosine kinase activity in vitro, while the transforming c-Abl P131L protein was localized exclusively to the cytoplasm and exhibited decreased in vitro kinase activity. By real-time biospecific interaction analysis, the wild type Abl SH3 domain bound to two proteins containing proline-rich motifs with dissociation constants of 0.2 and 17 mu M; the G128R mutant bound with 50-fold lower affinity, and no binding was detected by the P131L mutant. Both mutations completely abolished binding of the Abl SH3 domain to proline-rich target proteins in a filter-binding assay, These results suggest that the transforming activity of Abl is regulated in vivo by an inhibitor protein which associates with the SH3 domain via a proline-rich sequence.	HARVARD UNIV, SCH MED, CTR BLOOD RES, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	VANETTEN, RA (corresponding author), HARVARD UNIV, SCH MED, CTR BLOOD RES, DEPT GENET, 200 LONGWOOD AVE, BOSTON, MA 02115 USA.			Debnath, Jayanta/0000-0002-8745-4069	NIAID NIH HHS [AI 39121] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; BORCHERT TV, 1994, FEBS LETT, V341, P79, DOI 10.1016/0014-5793(94)80244-0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DRUKER BJ, 1992, NEW ENGL J MED, V321, P1383; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MULLER AJ, 1993, P NATL ACAD SCI USA, V90, P3457, DOI 10.1073/pnas.90.8.3457; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; Potts W M, 1988, Oncogene Res, V3, P343; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SASISEKHARAN V, 1959, ACTA CRYSTALLOGR, V12, P897, DOI 10.1107/S0365110X59002535; SAWYERSMAKER L, 1986, J VIROL, V57, P1182; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	70	48	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					1977	1988						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7539119				2022-12-28	WOS:A1995QZ92600012
J	ALIMANDI, M; ROMANO, A; CURIA, MC; MURARO, R; FEDI, P; AARONSON, SA; DIFIORE, PP; KRAUS, MH				ALIMANDI, M; ROMANO, A; CURIA, MC; MURARO, R; FEDI, P; AARONSON, SA; DIFIORE, PP; KRAUS, MH			COOPERATIVE SIGNALING OF ERBB3 AND ERBB2 IN NEOPLASTIC TRANSFORMATION AND HUMAN MAMMARY CARCINOMAS	ONCOGENE			English	Article						ERBB RECEPTOR FAMILY; ONCOGENES; TYROSINE PHOSPHORYLATION; HETERODIMERIZATION; PI3-KINASE	TYROSINE KINASE-ACTIVITY; HUMAN-BREAST-CARCINOMA; FACTOR RECEPTOR FAMILY; HER-2 NEU ONCOGENE; EGF RECEPTOR; PROTO-ONCOGENE; C-ERBB-2 ONCOGENE; POINT MUTATION; BETA-ACTIN; CELLS	In the present study we demonstrate that erbB-3 and erbB-2 cooperate in neoplastic transformation. Under conditions in which neither gene alone induced transformation, they readily transformed NIH3T3 cells if coexpressed. Furthermore, at high expression levels of ErbB2 which cause transformation, ErbB3 enhanced focus formation by one order of magnitude. Synergy required an intact ErbB2 extracellular domain and tyrosine kinase activity. Cooperation between ErbB3 and ErbB2 involved heterodimerization and increased tyrosine phosphorylation of ErbB3. Signaling by the heterodimer resulted in increased PI 3-kinase recruitment as web as quantitative and qualitative differences in substrate phosphorylation. Evidence for signaling by an active ErbB3-ErbB2 heterodimer in four mammary tumor cell lines indicated relevance of this mechanism for human neoplasia. Our detection of the NDF/heregulin transcript in NIH3T3 cells implicates an autocrine loop involving this ligand in signaling by the ErbB3-ErbB2 heterodimer in the model system, whereas heregalin-independent mechanisms likely exist for cooperative signaling by ErbB3 and ErhB2 chronically activated in some human mammary carcinomas.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NCI, EXPTL CARCINOGENESIS LAB, BETHESDA, MD 20892 USA; UNIV G DANNUNZIO, IST PATOL UMANA & MED SOCIALE, I-66013 CHIETI, ITALY; MT SINAI MED CTR, DERALD H RUTTENBERG CANC CTR, NEW YORK, NY 10029 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); G d'Annunzio University of Chieti-Pescara; Icahn School of Medicine at Mount Sinai			Di Fiore, Pier Paolo/K-2130-2012; Mieszkowska, Magdalena/O-6753-2017; curia, maria cristina/AAA-3118-2019; Alimandi, Maurizio/AAG-9246-2019	Di Fiore, Pier Paolo/0000-0002-2252-0950; Alimandi, Maurizio/0000-0002-1409-6803				BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BERGER MS, 1988, CANCER RES, V48, P1238; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HALEY JD, 1989, ONCOGENE, V4, P273; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KRAUS MH, 1991, METHOD ENZYMOL, V200, P546; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PATERSON MC, 1991, CANCER RES, V51, P556; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROMANO A, 1994, ONCOGENE, V9, P2923; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YOKOTA J, 1986, LANCET, V1, P765	51	500	544	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1813	1821						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7538656				2022-12-28	WOS:A1995QX46900014
J	MUCA, C; VALLAR, L				MUCA, C; VALLAR, L			EXPRESSION OF MUTATIONALLY ACTIVATED G-ALPHA(S) STIMULATES GROWTH AND DIFFERENTIATION OF THYROID FRTL5 CELLS	ONCOGENE			English	Article							ADENYLATE-CYCLASE ACTIVITY; HUMAN PITUITARY-TUMORS; G-PROTEIN; THYROTROPIN RECEPTOR; IODIDE EFFLUX; GSP ONCOGENE; TSH RECEPTOR; CAMP; INHIBITION; ALPHA	The alpha subunit of the GTP-binding protein G(s) mediates hormonal stimulation of adenylyl cyclase. Human pituitary and thyroid tumours harbour mutations of G alpha(s) that constitutively activate the protein by inhibiting its intrinsic GTPase activity. We have investigated the mitogenic action of mutationally activated alpha(s) in thyroid FRTL5 cells, a cell line dependent upon thyroid-stimulating hormone (TSH) for both growth and differentiation. Introduction of alpha(s) carrying the substitution of glutamine-227 with leucine (Q227L alpha(s)) by retroviral infection of FRTL5 cells resulted in the expected stimulation of membrane adenylyl cyclase activity and in increased intracellular accumulation of cAMP. Measurements of cytosolic Ca2+ levels did not detect any concomitant effect on the polyphosphoinositide-Ca2+ signalling pathway. Expression of Q227L alpha(s) conferred to FRTL5 cells the ability to synthesize DNA in the absence of TSH, as revealed by [H-3]thymidine incorporation experiments, and to proliferate independently of the mitogenic hormone, although with a rate of growth slower than that observed with TSH stimulation. The effect of Q227L alpha(s) on cell proliferation was associated with the constitutive activation of iodide the constitutive uptake. The results indicate that expression of mutationally activated G alpha(s) is sufficient to bypass the requirement for TSH and promotes autonomous growth and activation of thyroid-specific differentiated functions in FRTL5 cells.	UNIV MILAN,DIBIT,SCI INST SAN RAFFAELE,I-20132 MILAN,ITALY; UNIV MILAN,CNR,CTR CYTOPHARMACOL,DEPT PHARMACOL,I-20132 MILAN,ITALY	University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); University of Milan								AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; BENDER JL, 1983, J BIOL CHEM, V258, P2432; BONE EA, 1986, ENDOCRINOLOGY, V119, P2193, DOI 10.1210/endo-119-5-2193; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; CLEMENTI E, 1990, ONCOGENE, V5, P1059; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CORDA D, 1985, J BIOL CHEM, V260, P9230; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FAURE M, 1994, J BIOL CHEM, V269, P7851; FRODIN M, 1994, J BIOL CHEM, V269, P6207; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HEN R, 1989, P NATL ACAD SCI USA, V86, P4785, DOI 10.1073/pnas.86.12.4785; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MA YH, 1994, ENDOCRINOLOGY, V134, P42, DOI 10.1210/en.134.1.42; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; OKAJIMA F, 1988, ENDOCRINOLOGY, V123, P1035, DOI 10.1210/endo-123-2-1035; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; SPADA A, 1990, J CLIN ENDOCR METAB, V71, P1421, DOI 10.1210/jcem-71-6-1421; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; SUAREZ HG, 1991, ONCOGENE, V6, P677; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; VALENTE WA, 1983, ENDOCRINOLOGY, V112, P71, DOI 10.1210/endo-112-1-71; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; VALLAR L, 1990, J BIOL CHEM, V265, P10320; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YATANI A, 1988, J BIOL CHEM, V263, P9887; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K	43	44	44	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3647	3653						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7526317				2022-12-28	WOS:A1994PT39200028
J	AMARAVADI, L; KING, MW				AMARAVADI, L; KING, MW			CHARACTERIZATION AND EXPRESSION OF THE XENOPUS C-MYB HOMOLOG	ONCOGENE			English	Note							PROTO-ONCOGENE; HEMATOPOIETIC-CELLS; NUCLEOTIDE-SEQUENCE; DNA; GENE; PROLIFERATION; TRANSCRIPTION; ORGANIZATION; ACTIVATION; PROTEINS	The c-Myb protein is a sequence specific DNA-binding transcriptional regulator that is critically involved in the regulation of hematopoietic differentiation. Its role in these processes suggests that the function of c-Myb may be important early in the establishment of the hematopoietic lineage. We have isolated cDNA and partial genomic clones representing the Xenopus c-Myb homolog (Xc-Myb) in order to examine the role this gene plays in early mesodermal patterning in the frog embryo. The establishment of these clones as c-Myb homologs, as opposed to Myb-related sequences, is based upon both predicted amino acid sequences and the location of the exon-intron boundaries within the Xc-Myb gene. Maternally derived Xc-Myb RNA is degraded following fertilization then, beginning at midblastula, re-accumulates throughout early development. Xc-Myb RNA is localized to the animal cap region of the early blastula. Following the onset of gastrulation expression predominates in the ventral half of the embryo. During neurulation expression of Xc-Myb is observed in both the anterior dorsal and ventral vegetal regions of the embryo. Expression of Xc-Myb occurs in several adult tissues, the highest levels of which are in the intestine, heart, liver, lung and ovary. Xc-Myb encodes a protein of 624 amino acids and exhibits a mobility in SDS-PAGE of approximately 75 kDa, identical with that of the murine c-Myb protein. Xc-Myb protein exhibits 70% identity with avian and 67% identity with mammalian c-Myb proteins.	INDIANA UNIV,SCH MED,TERRE HAUTE CTR MED SCI,DEPT BIOCHEM & MOLEC BIOL,TERRE HAUTE,IN 47809; INDIANA STATE UNIV,DEPT LIFE SCI,TERRE HAUTE,IN 47809	Indiana University System; Indiana State University								ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BANKER DE, 1991, MOL CELL BIOL, V11, P5079, DOI 10.1128/MCB.11.10.5079; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DESBIENS X, 1991, DEVELOPMENT, V111, P699; DUPASQUIER L, 1989, ANNU REV IMMUNOL, V7, P251, DOI 10.1146/annurev.immunol.7.1.251; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GREEN N, 1979, Cellular Immunology, V48, P59, DOI 10.1016/0008-8749(79)90099-6; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; KATAGIRI C, 1986, CURR TOP DEV BIOL, V98, P315; KING MW, 1993, CELL GROWTH DIFFER, V4, P85; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NIEUWKOOP PD, 1967, NORMAL TABLE XENOPUS, P162; REILLY CF, 1989, J BIOL CHEM, V264, P6990; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SLACK JMW, 1993, MECH DEVELOP, V41, P91, DOI 10.1016/0925-4773(93)90040-5; THEILE CJ, 1988, MOL CELL BIOL, V8, P1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043	30	18	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					971	974						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	7509053				2022-12-28	WOS:A1994MW55100036
J	LISCIA, DS; MERLO, GR; GARRETT, C; FRENCH, D; MARIANICOSTANTINI, R; CALLAHAN, R				LISCIA, DS; MERLO, GR; GARRETT, C; FRENCH, D; MARIANICOSTANTINI, R; CALLAHAN, R			EXPRESSION OF INT-2 MESSENGER-RNA IN HUMAN-TUMORS AMPLIFIED AT THE INT-2 LOCUS	ONCOGENE			English	Article									NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892; GEORGE WASHINGTON UNIV,MED CTR,DEPT PATHOL,WASHINGTON,DC 20037; GD ANNUNZIO UNIV,CHIETI,ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); George Washington University; G d'Annunzio University of Chieti-Pescara			Mariani-Costantini, Renato/B-6637-2012	Mariani-Costantini, Renato/0000-0002-4440-1848				ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ADELAIDE J, 1988, ONCOGENE, V2, P413; ALI IU, 1989, ONCOGENE, V4, P89; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CARROLL SM, 1988, MOL CELL BIOL, V8, P1525, DOI 10.1128/MCB.8.4.1525; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; FOLKMAN J, 1986, CANCER RES, V46, P467; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GOSPODAROWICZ D, 1986, CELL DIFFER DEV, V19, P1, DOI 10.1016/0045-6039(86)90021-7; HALABAN R, 1988, ONCOGENE RES, V3, P177; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; Maniatis T., 1982, MOL CLONING; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; RAMM P, 1985, MICROCOMPUTER CELL N, P311; REDMOND SMS, 1988, ONCOGENE, V2, P259; SIERRA F, 1982, P NATL ACAD SCI-BIOL, V79, P1795, DOI 10.1073/pnas.79.6.1795; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; VARLEY JM, 1988, ONCOGENE, V3, P87; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHOU DJ, 1988, ONCOGENE, V2, P279	31	78	78	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1989	4	10					1219	1224						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2677918				2022-12-28	WOS:A1989AU50800009
J	REEVES, BR; SMITH, S; FISHER, C; WARREN, W; KNIGHT, J; MARTIN, C; CHAN, AML; GUSTERSON, BA; WESTBURY, G; COOPER, CS				REEVES, BR; SMITH, S; FISHER, C; WARREN, W; KNIGHT, J; MARTIN, C; CHAN, AML; GUSTERSON, BA; WESTBURY, G; COOPER, CS			CHARACTERIZATION OF THE TRANSLOCATION BETWEEN CHROMOSOME-X AND CHROMOSOME-18 IN HUMAN SYNOVIAL SARCOMAS	ONCOGENE			English	Article									INST CANC RES, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND; ROYAL MARSDEN HOSP, LONDON SW3 6JJ, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	REEVES, BR (corresponding author), INST CANC RES, HADDOW LABS, 15 COTSWOLD RD, SUTTON SM2 5NG, SURREY, ENGLAND.		Chan, Andrew Man-Lok/J-9497-2013; gusterson, barry a/D-3752-2009	Chan, Andrew Man-Lok/0000-0001-9923-5464; 				ALHADEFF B, 1977, CYTOGENET CELL GENET, V19, P236, DOI 10.1159/000130814; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BRIDGE JA, 1988, CANCER, V62, P935, DOI 10.1002/1097-0142(19880901)62:5<935::AID-CNCR2820620514>3.0.CO;2-E; CORSON JM, 1984, HUM PATHOL, V15, P615, DOI 10.1016/S0046-8177(84)80284-1; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER C, 1986, HUM PATHOL, V17, P996, DOI 10.1016/S0046-8177(86)80083-1; FRIEND KK, 1976, SOMAT CELL GENET, V2, P183, DOI 10.1007/BF01542631; FUKUI M, 1985, P NATL ACAD SCI USA, V82, P5954, DOI 10.1073/pnas.82.17.5954; GALLIMORE PH, 1973, CHROMOSOMA, V41, P259, DOI 10.1007/BF00344020; GRIFFIN CA, 1987, CANCER GENET CYTOGEN, V26, P181, DOI 10.1016/0165-4608(87)90148-8; GUSTERSON B, 1985, INT J CANCER, V36, P689; Harnden DG, 1985, INT SYSTEM HUMAN CYT; HEIM S, 1987, CANCER CYTOGENETICS; HEYDERMAN E, 1979, J CLIN PATHOL, V32, P35, DOI 10.1136/jcp.32.1.35; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; ISHIKAWA F, 1986, P NATL ACAD SCI USA, V83, P3209, DOI 10.1073/pnas.83.10.3209; KLEBE RJ, 1970, J CELL BIOL, V45, P74, DOI 10.1083/jcb.45.1.74; LIMON J, 1986, CANCER GENET CYTOGEN, V23, P87, DOI 10.1016/0165-4608(86)90152-4; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; MANDAHL N, 1988, CANCER GENET CYTOGEN, V30, P323, DOI 10.1016/0165-4608(88)90202-6; MIETTINEN M, 1983, VIRCHOWS ARCH B, V44, P187, DOI 10.1007/BF02890169; MIETTINEN M, 1984, AM J PATHOL, V117, P18; NOGUERA R, 1988, CANCER GENET CYTOGEN, V33, P311, DOI 10.1016/0165-4608(88)90040-4; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SHENG WW, 1987, CANCER GENET CYTOGEN, V29, P179, DOI 10.1016/0165-4608(87)90048-3; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; SMITH S, 1987, CANCER GENET CYTOGEN, V26, P179, DOI 10.1016/0165-4608(87)90147-6; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; UEDA T, 1988, CANCER GENET CYTOGEN, V30, P183, DOI 10.1016/0165-4608(88)90111-2; WITTE ON, 1986, CANCER SURV, V5, P183; 1988, CYTOGENT CELL GENET, V46, P1	36	48	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1989	4	3					373	378						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2704557				2022-12-28	WOS:A1989U567600014
J	COHEN, N; SALZBERG, A; LEV, Z				COHEN, N; SALZBERG, A; LEV, Z			A BIDIRECTIONAL PROMOTER IS REGULATING THE DROSOPHILA-RAS2 GENE	ONCOGENE			English	Article									TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL	Technion Israel Institute of Technology			Salzberg, Adi/A-9986-2014; Salzberg, Adi/O-1198-2019	Salzberg, Adi/0000-0002-0427-9809; Salzberg, Adi/0000-0002-0427-9809				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROCK HW, 1987, GENE, V51, P129, DOI 10.1016/0378-1119(87)90301-5; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Elgin S.C.R., 1978, P112; FARNHAM PJ, 1985, P NATL ACAD SCI USA, V82, P3978, DOI 10.1073/pnas.82.12.3978; FURTH ME, 1987, ONCOGENE, V1, P47; GARABEDIAN MJ, 1985, P NATL ACAD SCI USA, V82, P1396, DOI 10.1073/pnas.82.5.1396; GARFINKEL MD, 1983, J MOL BIOL, V168, P765, DOI 10.1016/S0022-2836(83)80074-6; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; HONKAWA H, 1987, MOL CELL BIOL, V7, P2933, DOI 10.1128/MCB.7.8.2933; HU MCT, 1986, GENE, V42, P21; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; IATROU K, 1983, EMBO J, V2, P1431, DOI 10.1002/j.1460-2075.1983.tb01604.x; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; LEV Z, 1985, MOL CELL BIOL, V5, P1540, DOI 10.1128/MCB.5.6.1540; LEV Z, 1987, ANAL BIOCHEM, V160, P332, DOI 10.1016/0003-2697(87)90055-8; LEV Z, 1986, BIOCHIM BIOPHYS ACTA, V867, P144, DOI 10.1016/0167-4781(86)90074-6; LEVANON D, 1985, EMBO J, V4, P77, DOI 10.1002/j.1460-2075.1985.tb02320.x; LEVINSON AD, 1986, TRENDS GENET, V2, P81, DOI 10.1016/0168-9525(86)90184-8; LIN HC, 1985, ANAL BIOCHEM, V147, P114, DOI 10.1016/0003-2697(85)90016-8; MANIATIS T, 1982, LABORATORY MANUAL; MASTERS JN, 1985, MOL CELL BIOL, V5, P493, DOI 10.1128/MCB.5.3.493; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MCGROGAN M, 1985, J BIOL CHEM, V260, P2307; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOZER B, 1985, MOL CELL BIOL, V5, P885, DOI 10.1128/MCB.5.4.885; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; NEUMANSILBERBERG FS, 1984, CELL, V37, P1027; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NOTHIGER R, 1980, DROS INFOR SERVICE, V55, P162; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; PAPAGEORGE AG, 1984, MOL CELL BIOL, V4, P23, DOI 10.1128/MCB.4.1.23; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEJTER ED, 1985, EMBO J, V4, P407, DOI 10.1002/j.1460-2075.1985.tb03643.x; SEGAL D, 1986, MOL CELL BIOL, V6, P2241, DOI 10.1128/MCB.6.6.2241; SEGEV O, 1988, IN PRESS ONCOGENE; SPANDIDOS DA, 1986, FEBS LETT, V203, P169, DOI 10.1016/0014-5793(86)80736-0; STELLER H, 1984, EMBO J, V3, P165, DOI 10.1002/j.1460-2075.1984.tb01778.x; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SWAROOP A, 1986, MOL CELL BIOL, V6, P833, DOI 10.1128/MCB.6.3.833; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WILLIAMS TJ, 1986, MOL CELL BIOL, V6, P4558, DOI 10.1128/MCB.6.12.4558	55	20	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					137	142						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	3412773				2022-12-28	WOS:A1988Q053400002
J	BATTISTA, S; MARTELLI, ML; FEDELE, M; CHIAPPETTA, G; TRAPASSO, F; DEVITA, G; BATTAGLIA, C; SANTORO, M; VIGLIETTO, G; FAGIN, JA; FUSCO, A				BATTISTA, S; MARTELLI, ML; FEDELE, M; CHIAPPETTA, G; TRAPASSO, F; DEVITA, G; BATTAGLIA, C; SANTORO, M; VIGLIETTO, G; FAGIN, JA; FUSCO, A			A MUTATED P53 GENE ALTERS THYROID-CELL DIFFERENTIATION	ONCOGENE			English	Article						P53; THYROID; DIFFERENTIATION	WILD-TYPE P53; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; THYROGLOBULIN PROMOTER; THYROTROPIN RECEPTOR; MAMMALIAN-CELLS; MESSENGER-RNA; DNA-BINDING; EXPRESSION; MUTATIONS	p53 is the gene most frequently found mutated in human neoplasias. In the majority of tumors, p53 mutations contribute to the progression towards stages of increasing malignancy with the appearance of an undifferentiated phenotype. Also in thyroid cancerogenesis, p53 mutations correlate with the loss of the differentiated phenotype. The results presented here, suggest a direct involvement of p53 in the molecular mechanisms regulating cellular differentiation in thyroid since a mutated p53 gene markedly affects the growth potential and differentiated functions of the rat thyroid cell line PC Cl 3. Blockage in the expression of the PAX-8 transcription factor seems to be a key event in the loss of thyroid differentiated functions induced by the mutated p53 gene. Thyroid cells carrying a mutated p53 gene did not form colonies in soft agar or tumors in athymic mice, suggesting that a mutation of the p53 gene is not sufficient for the induction of the malignant phenotype and probably a cooperation with other oncogenes is necessary to accomplish full malignancy. No effect on either growth or differentiation of thyroid cells was exerted either by overexpression of the wild-type p53 gene, or by the vector alone.	UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; FDN PASCALE,IST NAZL TUMORI,I-80131 NAPLES,ITALY; UNIV NAPLES,FAC MED & CHIRURG NAPOLI,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80131 NAPLES,ITALY; UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DIV ENDOCRINOL,LOS ANGELES,CA 90048	Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; IRCCS Fondazione Pascale; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Battista, Sabrina/AAY-2981-2020; De Vita, Gabriella/H-4422-2011; Viglietto, Giuseppe/AAC-2852-2019; Fedele, Monica/C-1417-2015	Battista, Sabrina/0000-0001-5899-9759; De Vita, Gabriella/0000-0002-7302-1174; Viglietto, Giuseppe/0000-0003-2327-7515; Fedele, Monica/0000-0002-9171-1312; Fusco, Alfredo/0000-0003-3332-5197				AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AVVEDIMENTO EV, 1989, CELL, V58, P1135, DOI 10.1016/0092-8674(89)90511-4; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; AVVEDIMENTO VE, 1988, P NATL ACAD SCI USA, V85, P1744, DOI 10.1073/pnas.85.6.1744; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTEK J, 1990, ONCOGENE, V5, P893; BERLINGIERI MT, 1990, BIOCHEM BIOPH RES CO, V173, P172, DOI 10.1016/S0006-291X(05)81037-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DILAURO R, 1982, GENE, V19, P117, DOI 10.1016/0378-1119(82)90196-2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DOBASHI Y, 1993, AM J SURG PATHOL, V14, P375; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; FUSCO A, 1981, CANCER RES, V42, P618; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ITO T, 1992, CANCER RES, V52, P1369; KERN SE, 1991, ONCOGENE, V6, P131; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LI FP, 1988, CANCER RES, V48, P5358; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MUSTI AM, 1987, NUCLEIC ACIDS RES, V15, P8149, DOI 10.1093/nar/15.20.8149; NAKAMURA T, 1992, JPN J CANCER RES, V83, P1293, DOI 10.1111/j.1349-7006.1992.tb02761.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Sambrook J, 1989, MOL CLONING LABORATO; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SODDU S, 1994, BLOOD, V83, P2230, DOI 10.1182/blood.V83.8.2230.bloodjournal8382230; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WRIGHT PA, 1991, ONCOGENE, V6, P1693; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZARRILLI R, 1990, MOL ENDOCRINOL, V4, P39, DOI 10.1210/mend-4-1-39; ZHANG W, 1993, ONCOGENE, V8, P2555	55	39	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2029	2037						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478522				2022-12-28	WOS:A1995TF29700013
J	SHINTO, Y; MORIMOTO, M; KATSUMATA, M; UCHIDA, A; AOZASA, K; OKAMOTO, M; KUROSAWA, T; OCHI, T; GREENE, MI; TSUJIMOTO, Y				SHINTO, Y; MORIMOTO, M; KATSUMATA, M; UCHIDA, A; AOZASA, K; OKAMOTO, M; KUROSAWA, T; OCHI, T; GREENE, MI; TSUJIMOTO, Y			MOLONEY MURINE LEUKEMIA-VIRUS INFECTION ACCELERATES LYMPHOMAGENESIS IN E-MU-BCL-2 TRANSGENIC MICE	ONCOGENE			English	Article							C-MYC; PRE-B; CHROMOSOMAL BREAKPOINT; FOLLICULAR LYMPHOMA; CELL LYMPHOMAS; T-CELLS; N-MYC; BCL-2; GENE; ACTIVATION	E mu-bcl-2 transgenic mice bearing the bcl-2 proto-oncogene linked to the immunoglobulin enhancer (E mu) sporadically develop B or T cell lymphomas after a long latent period. To identify genes that play important roles in development of lymphoid malignancies, proviral insertional mutagenesis with Moloney murine leukemia virus (MMuLV) was carried out in two lines of transgenic mice expressing the bcl-2 gene primarily in B or T cells. MMuLV infection of non-transgenic mice induced primarily mature T cell lymphomas. By contrast, infection of newborn E mu-blc-2 mice with the virus accelerated lymphomagenesis, and nearly all of the mice eventually succumbed to clonal pre-B, B, or mainly immature T cell lymphoma, indicating the active contribution of the bcl-2 gene in lymphomagenesis. Southern blot analysis of tumor DNA from MMuLV-infected transgenic mice revealed a proviral insertion at the c-myc gene in 26% (9/35) of tumors, at the pim-l gene in 6% (2/35) and at the pim-2 (recently renamed tic-1) gene in 23% (8/35). Some tumors carried two activated oncogenes. No insertion was detected at the bmi-l gene. These data suggest the usefulness of this transgenic system for analysis of lymphomagenesis involving the activated bcl-2 gene.	OSAKA UNIV, SCH MED, BIOMED RES CTR, DEPT MED GENET, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT ORTHOPAED SURG, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT MOLEC PATHOL, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, INST EXPTL ANIM SCI, SUITA, OSAKA 565, JAPAN; UNIV PENN, SCH MED, DEPT PATHOL, PHILADELPHIA, PA 19104 USA	Osaka University; Osaka University; Osaka University; Osaka University; University of Pennsylvania								Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ARMITAGE JO, 1988, J NATL CANCER I, V80, P576, DOI 10.1093/jnci/80.8.576; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BERNS A, 1991, J CELL BIOCHEM, V47, P130, DOI 10.1002/jcb.240470206; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BREUER ML, 1989, EMBO J, V8, P743, DOI 10.1002/j.1460-2075.1989.tb03434.x; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COMPERE SJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P129, DOI 10.1016/0304-419X(88)90008-X; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; CUYPERS HT, 1984, CELL, V37, P141; DAVIS B, 1985, NATURE, V314, P550, DOI 10.1038/314550a0; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HARRIS AW, 1988, CURR TOP MICROBIOL, V141, P82; HAUPT Y, 1992, ONCOGENE, V7, P981; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; ISHIMOTO A, 1987, J VIROL, V61, P1861, DOI 10.1128/JVI.61.6.1861-1866.1987; KATSUMATA M, 1992, P NATL ACAD SCI USA, V89, P11376, DOI 10.1073/pnas.89.23.11376; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MOLONEY JB, 1960, J NATL CANCER I, V24, P933; NUNEZ G, 1990, J IMMUNOL, V144, P3602; REDDY E P, 1980, Cell, V19, P663, DOI 10.1016/S0092-8674(80)80043-2; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; SAWAI S, 1991, NEW BIOL, V3, P861; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WEINBERG RA, 1989, CANCER RES, V49, P3713; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	53	25	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	1995	11	9					1729	1736						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478600				2022-12-28	WOS:A1995TD09400007
J	SOROKIN, A				SOROKIN, A			ACTIVATION OF THE EGF RECEPTOR BY INSERTIONAL MUTATIONS IN ITS JUXTAMEMBRANE REGIONS	ONCOGENE			English	Article						EGF RECEPTOR; DIMERIZATION; TRANSFORMATION	EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; TRANSMEMBRANE DOMAIN; EXTRACELLULAR DOMAIN; LIGAND-BINDING; SIGNAL TRANSDUCTION; NEU ONCOGENE; SURFACE-RECEPTORS; CARCINOMA-CELLS; POINT MUTATION	Ligand dependent activation of receptor tyrosine kinases is mediated by an allosteric dimerization process that is responsible for the stimulation of protein tyrosine kinase activity and receptor autophosphorylation. In order to gain further insight into the processes which control this process, we have generated EGF receptor mutants that contain inserts of 20-40 amino acids in their juxtamembrane regions, on each side of the receptor's single transmembrane domain. An EGF receptor mutant with an insertion on the cytoplasmic side of the transmembrane domain exhibited typical EGF binding characteristics, ligand-dependent tyrosine autophosphorylation, as web as ligand-induced DNA synthesis. However, an EGF receptor mutant with an insertion on both sides of the transmembrane domain was found to be constitutively activated. This mutant also exhibited dramatically reduced EGF binding, but dimerized and had enhanced tyrosine kinase activity even in the absence of ligand. Moreover, NIH3T3 cells expressing this mutant receptor formed colonies in soft agar in the absence of EGF. This represents a novel example of a constitutively activated receptor, and provides further support for receptor dimerization as a mechanism for activation of EGFR and other receptor tyrosine kinases.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University				Sorokin, Andrey/0000-0002-5660-0190				BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; BORMANN BJ, 1992, ANNU REV BIOPH BIOM, V21, P223, DOI 10.1146/annurev.bb.21.060192.001255; CAO HN, 1992, J BIOL CHEM, V267, P20489; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CARPENTER G, 1989, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1993, J BIOL CHEM, V268, P23860; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COCHET C, 1988, J BIOL CHEM, V263, P3290; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; HAIGLER HT, 1979, J CELL BIOL, V83, P82, DOI 10.1083/jcb.83.1.82; HALEY JD, 1989, ONCOGENE, V4, P273; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; HAZAN R, 1995, J CELL PHYSIOL, V162, P74, DOI 10.1002/jcp.1041620110; HILLMAN GM, 1982, BIOCHEMISTRY-US, V21, P1667, DOI 10.1021/bi00536a030; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOHDA D, 1993, J BIOL CHEM, V268, P1976; KOLAND JG, 1988, J BIOL CHEM, V263, P2230; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LAX I, 1990, CELL REGUL, V1, P173, DOI 10.1091/mbc.1.2.173; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; NORTHWOOD IC, 1988, J BIOL CHEM, V263, P7450; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; RIZZINO A, 1987, METHOD ENZYMOL, V146, P341; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHREIBER AB, 1981, P NATL ACAD SCI-BIOL, V78, P7535, DOI 10.1073/pnas.78.12.7535; SOROKIN AB, 1988, DOKL AKAD NAUK SSSR+, V300, P974; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAIMUN L, 1990, P NATL ACAD SCI USA, V87, P7270; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; ZIDOVETZKI R, 1981, P NATL ACAD SCI-BIOL, V78, P6981, DOI 10.1073/pnas.78.11.6981	54	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1531	1540						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478577				2022-12-28	WOS:A1995TC53500011
J	WU, LW; HACKETT, PB				WU, LW; HACKETT, PB			DEVELOPMENT OF CELLULAR-RESISTANCE TO PP60(V-SRC) KINASE-INDUCED CELL-DEATH	ONCOGENE			English	Article						CYTOTOXICITY; PP60(V-SRC) OVEREXPRESSION; TYROSINE KINASE	ROUS-SARCOMA VIRUS; PROTEIN-TYROSINE PHOSPHATASES; HEAT-SHOCK; V-SRC; GENE-EXPRESSION; C-SRC; TRANSFORMING GENE; MAMMALIAN-CELLS; PHOSPHORYLATION; FIBROBLASTS	The v-src gene of Rous sarcoma virus (RSV) encodes pp60(v-src) a tyrosine kinase that can initiate cellular transformation. High levels of v-src gene expression can either be cytotoxic or the cause of altered expression of cellular genes, Examination of cytotoxic thresholds is difficult because cells expressing high levels of a cytotoxic oncogene will die. To evaluate quantitatively the cytotoxicity of pp60(v-src) on growth, we amplified two different v-src genes, under the control of the human hsp70B heat shock promoter to establish cell clones with varying copy numbers of the heat-inducible v-src gene. The viability of cell lines over a prolonged period of time depended on the particular src gene, the expression of v-src mRNA, synthesis of the pp60(v-src) protein and, most importantly, the tyrosine kinase activity of the pp60(v-src) protein. We found a relatively sharp threshold in v-src-encoded tyrosine kinase activity above which cell viability rapidly declines. However, over time, tyrosine kinase activity was exponentially suppressed at about a 10-fold higher rate than pp60(v-src) protein during passage. Our results indicate that homeostasis: of tyrosine phosphorylation is important for cell viability, that perturbation of this balance results in cell mortality, and that cells can evolve to accommodate overexpression of oncogene by downregulating the level of tyrosine kinase activity.	UNIV MINNESOTA, DEPT GENET & CELL BIOL, ST PAUL, MN 55108 USA; UNIV MINNESOTA, INST HUMAN GENET, ST PAUL, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NCI NIH HHS [R01 CA 1983881] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELGHANY M, 1990, P NATL ACAD SCI USA, V87, P7061, DOI 10.1073/pnas.87.18.7061; ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; ASHBURNER M, 1979, CELL, V17, P241, DOI 10.1016/0092-8674(79)90150-8; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BISHOP JM, 1982, RNA TUMOR VIRUS MOL, P1001; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BRUGGE JS, 1987, MOL CELL BIOL, V7, P2180, DOI 10.1128/MCB.7.6.2180; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DEWEY WC, 1971, INT J RADIAT BIOL RE, V20, P505, DOI 10.1080/09553007114551421; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FORNACE AJ, 1989, EXP CELL RES, V182, P61, DOI 10.1016/0014-4827(89)90279-6; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HOSKINS JM, 1956, EXP CELL RES, V11, P297, DOI 10.1016/0014-4827(56)90105-7; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JACKS CM, 1988, NUCLEIC ACIDS RES, V16, P10751, DOI 10.1093/nar/16.22.10751; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; JOHNSTON RN, 1988, SCIENCE, V242, P1551, DOI 10.1126/science.3201244; KAMMANN M, 1989, NUCLEIC ACIDS RES, V17, P5404, DOI 10.1093/nar/17.13.5404; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; KAUFMAN RJ, 1987, EMBO J, V6, P187, DOI 10.1002/j.1460-2075.1987.tb04737.x; KAUFMAN RJ, 1985, MOL CELL BIOL, V5, P1750, DOI 10.1128/MCB.5.7.1750; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; LI GC, 1983, J CELL PHYSIOL, V115, P116, DOI 10.1002/jcp.1041150203; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIU ZJ, 1989, NUCLEIC ACIDS RES, V17, P3986, DOI 10.1093/nar/17.10.3986; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MOUSTAKAS A, 1993, J VIROL, V67, P4337, DOI 10.1128/JVI.67.7.4337-4349.1993; NELSON RL, 1984, MOL CELL BIOL, V4, P1003, DOI 10.1128/MCB.4.6.1003; OZAKI T, 1993, P NATL ACAD SCI USA, V90, P2593, DOI 10.1073/pnas.90.7.2593; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PETERSEN RB, 1989, J VIROL, V63, P4787, DOI 10.1128/JVI.63.11.4787-4796.1989; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SCHLESINGER MJ, 1989, STRESS INDUCED PROTE, P137; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STOLTZFUS CM, 1987, J VIROL, V61, P3401, DOI 10.1128/JVI.61.11.3401-3409.1987; TARPLEY WG, 1984, MOL CELL BIOL, V4, P2653, DOI 10.1128/MCB.4.12.2653; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VOELLMY R, 1985, P NATL ACAD SCI USA, V82, P4949, DOI 10.1073/pnas.82.15.4949; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WARREN SL, 1988, MOL CELL BIOL, V8, P632, DOI 10.1128/MCB.8.2.632; WASILENKO WJ, 1990, MOL CELL BIOL, V10, P1254, DOI 10.1128/MCB.10.3.1254; WATANABE SM, 1983, J VIROL, V45, P1028, DOI 10.1128/JVI.45.3.1028-1036.1983; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cellbio.6.1.679; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; WU LW, 1993, THESIS U MINNESOTA; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	69	5	5	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1459	1468						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478570				2022-12-28	WOS:A1995TC53500004
J	OTTERSON, GA; KHLEIF, SN; CHEN, WD; COXON, AB; KAYE, FJ				OTTERSON, GA; KHLEIF, SN; CHEN, WD; COXON, AB; KAYE, FJ			CDKN2 GENE SILENCING IN LUNG-CANCER BY DNA HYPERMETHYLATION AND KINETICS OF P16(INK4) PROTEIN INDUCTION BY 5-AZA 2'DEOXYCYTIDINE	ONCOGENE			English	Article						P16(INK4); CDKN2; METHYLATION; 5-AZA 2'DEOXYCYTIDINE; LUNG CANCER	RETINOBLASTOMA GENE; MUTATION	Absent expression of the cyclin dependent kinase-inhibitor, p16(INK4), is observed in a wide range of primary human cancers. Although homozygous deletions and point mutations have been reported in a subset of these tumors, the molecular basis for absent p16(INK4) in other samples is unknown. We have examined 33 tumor cell lines and have shown that hypermethylation of a G:C-rich region within exon 1 of the CDKN2 gene was present in 100% of samples with wildtype RE expression and no detectable CDKN2 mutations. Treatment for at least 4 hours with the demethylating agent 5-aza 2'deoxycytidine, but not 5-azacytidine or 6-azacytidine, induces the prolonged expression of p16(INK4) protein each of these samples following a discrete 24-48 hour lag period, Consistent with the hypothesis that hypermethylation of the CDKN2 gene is a tumor-specific mechanism for gene inactivation, we observed hypomethylation at the exon 1 site exclusively in tumor lines that expressed p16(INK4) or that had sustained inactivating point mutations within the CDKN2 open reading frame, These findings demonstrate a link between DNA methylation and the p16(INK4):RB tumor suppressor pathway.	NCI,USN HOSP,ONCOL BRANCH,BETHESDA,MD 20889; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20889	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Uniformed Services University of the Health Sciences - USA			kaye, frederic/E-2437-2011; CHEN, WEI-DONG/F-4521-2014	CHEN, WEI-DONG/0000-0003-2264-5515				FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LAIRD PW, 1994, HUM MOL GENET, P1487; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, COLD SPRING HARB SYM, V58, P297, DOI 10.1101/SQB.1993.058.01.035; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; NAKAGAWA K, 1995, IN PRESS ONCOGENE; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Rideout W M 3rd, 1991, Princess Takamatsu Symp, V22, P207; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHIMIZU E, 1994, ONCOGENE, V9, P2441; TAM SW, 1994, CANCER RES, V54, P5816; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WASHIMI O, 1995, CANCER RES, V55, P514; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	28	214	233	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1211	1216						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566983				2022-12-28	WOS:A1995RX18000026
J	ROUQUET, N; ALLEMAND, I; MOLINA, T; BENNOUN, M; BRIAND, P; JOULIN, V				ROUQUET, N; ALLEMAND, I; MOLINA, T; BENNOUN, M; BRIAND, P; JOULIN, V			FAS-DEPENDENT APOPTOSIS IS IMPAIRED BY SV40 T-ANTIGEN IN TRANSGENIC LIVER	ONCOGENE			English	Article						T-ANTIGEN; APOPTOSIS; FAS-RECEPTOR; CARCINOGENESIS	GROWTH-FACTOR RECEPTOR; TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; MICE; ANTIBODY; GENE; PHOSPHORYLATION; EXPRESSION; DOMAIN; LENS	A transgenic mouse model for hepatocarcinoma has been previously produced by targeting SV40 T-antigen expression to the liver. To evaluate the perturbation of cell death occurring during hepatocarcinogenesis, we examined the Fas-induced apoptosis on hepatocytes expressing T-antigen. Whereas anti-Fas antibody induced apoptosis in primary cultured normal hepatocytes, they imparted a weak cytotoxicity on primary cultured hepatocytes expressing T-antigen. This resistance of hepatic Fas-mediated apoptosis appears to result in an enhancement of a protective mechanism involving the protein kinase C signaling pathway rather than in a down-regulation of Fas-antigen expression. We further demonstrated that anti-Fas antibody does not have as efficient a lethal effect in T-antigen transgenic mice as in wild-type mice, The livers of transgenic mice injected with anti-Fas mAbs showed large intact regions with a few scattered apoptotic bodies: these regions strictly corresponded with carcinoma nodules, expressing high level of T-antigen. Our results describe a novel function for SV40 T-antigen which could contribute to viral pathogenesis by protecting infected cells against the host apoptotic defense mechanism.	INST COCHIN GENET MOLEC, INSERM, U380, F-75014 PARIS, FRANCE; UNIV PARIS, RECH & HISTOPATHOL LAB, F-75006 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Molina, Thierry/ABA-5214-2020	Molina, Thierry/0000-0002-3929-9754; allemand, isabelle/0000-0002-8861-7632; JOULIN, Virginie/0000-0003-1091-7819				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ANTOINE B, 1992, EXP CELL RES, V200, P175, DOI 10.1016/S0014-4827(05)80086-2; CHEN JD, 1992, ONCOGENE, V7, P1167; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; DEBATIN KM, 1990, LANCET, V335, P497, DOI 10.1016/0140-6736(90)90735-N; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DUBOIS N, 1991, J HEPATOL, V13, P227, DOI 10.1016/0168-8278(91)90819-W; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GILL BM, 1994, IMMUNOL REV, V142, P113, DOI 10.1111/j.1600-065X.1994.tb00885.x; GRELL M, 1994, EUR J IMMUNOL, V24, P2563, DOI 10.1002/eji.1830241045; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; GRIEP AE, 1989, GENE DEV, V3, P1075, DOI 10.1101/gad.3.7.1075; GUO MW, 1994, BIOCHEM BIOPH RES CO, V203, P1438, DOI 10.1006/bbrc.1994.2346; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; LEIST M, 1995, J IMMUNOL, V154, P1307; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MEEK DW, 1992, BIOCHEM J, V287, P1; MITA E, 1994, BIOCHEM BIOPH RES CO, V204, P468, DOI 10.1006/bbrc.1994.2483; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; SAMBROOK J, 1989, MOL CLONIGN LABORATO; SAYAMA K, 1994, J INVEST DERMATOL, V103, P330, DOI 10.1111/1523-1747.ep12394858; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; WONG GHW, 1994, J IMMUNOL, V152, P1751	39	28	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	1995	11	6					1061	1067						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566965				2022-12-28	WOS:A1995RX18000008
J	KUPRASH, DV; UDALOVA, IA; TURETSKAYA, RL; RICE, NR; NEDOSPASOV, SA				KUPRASH, DV; UDALOVA, IA; TURETSKAYA, RL; RICE, NR; NEDOSPASOV, SA			CONSERVED KAPPA-B ELEMENT LOCATED DOWNSTREAM OF THE TUMOR-NECROSIS-FACTOR-ALPHA GENE - DISTINCT NF-KAPPA-B BINDING PATTERN AND ENHANCER ACTIVITY IN LPS ACTIVATED MURINE MACROPHAGES	ONCOGENE			English	Article						NF-KAPPA-B; TUMOR NECROSIS FACTOR; TRANSCRIPTION	C-REL; NUCLEAR FACTOR; DNA-BINDING; V-REL; TRANSCRIPTIONAL ACTIVATION; P65 SUBUNIT; TNF LOCUS; PREFERENTIALLY INTERACTS; PROTEIN; MOTIFS	Transcriptional activation of various genes by lipopolysaccharide (LPS) is known to be mediated, at least in part, by the NF-kappa B/Rel family of transcription factors. We have identified a novel kappa B element located immediately downstream of the TNF-alpha gene that is conserved together with its flanking sequences across species lines and can act as an LPS-responsive enhancer for reporter gene constructs driven by the minimal TNF promoter. In extracts from activated murine macrophages and macrophage cell lines this element binds several non-canonical NF-kappa B/Rel complexes, in addition to p50 (NFKB1) homodimer and p50-p65 (NKFB1-RelA) heterodimer. Combination of high-resolution electrophoretic mobility shift assays (EMSA) with monospecific antibodies and u.v.-cross-linking indicates that the prominent slow migrating complex III contain p65 homodimer and c-Rel. The appearance of complex III in EMSA parallels the translocation of p65 and c-Rel into the nucleus and occurs shortly after LPS induction. Transfection experiments with reporter constructs driven by this kappa B element indicate strong inducibility by LPS and p65, moderate inducibility by c-Rel and repression by p50. Functional activity of sandwich TNF-CAT-TNF constructs further suggests that LPS-inducible transcriptional activation of the TNF gene in murine macrophages may be partly mediated by a downstream enhancer.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21702; RUSSIAN ACAD SCI,VA ENGELHARDT MOLEC BIOL INST,CYTOKINE MOLEC BIOL LAB,MOSCOW,RUSSIA; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Nedospasov, Sergei/J-5936-2013; Nedospasov, Sergei/C-3043-2018; Nedospasov, Sergei/L-1990-2015; Kuprash, Dmitry/O-4899-2015; Nedospasov, Sergei/Q-7319-2016	Kuprash, Dmitry/0000-0002-1488-4148; Udalova, Irina/0000-0002-6716-2528	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEUTLER B, 1992, TUMOR NECROSIS FACTO, P561; BIRAGYN A, 1995, IN PRESS J IMMUNOL, V155; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; COX GW, 1989, J NATL CANCER I, V81, P1492, DOI 10.1093/jnci/81.19.1492; DROUET C, 1991, J IMMUNOL, V147, P1694; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FRANZOSO G, 1994, J EXP MED, V180, P1445, DOI 10.1084/jem.180.4.1445; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GIROIR BP, 1992, P NATL ACAD SCI USA, V89, P4864, DOI 10.1073/pnas.89.11.4864; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GRILLI M, 1993, INT REV CYTOL, V143, P1; HAN J, 1991, J IMMUNOL, V146, P1843; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; JONGENEEL CV, 1989, EUR J IMMUNOL, V19, P549; JONGENEEL CV, 1992, TUMOR NECROSIS FACTO, P561; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KOCHEL T, 1992, ONCOGENE, V7, P567; KUHNERT P, 1991, GENE, V102, P171, DOI 10.1016/0378-1119(91)90075-M; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUPRASH D, 1993, TUMOR NECROSIS FACTOR : MOLECULAR AND CELLULAR BIOLOGY AND CLINICAL RELEVANCE, P19; KUPRASH DV, 1994, P ACAD SCI USSR DOKL, V337, P658; LATTION AL, 1992, MOL CELL BIOL, V12, P5217, DOI 10.1128/MCB.12.11.5217; LAWTON P, 1995, J IMMUNOL, V154, P239; LAYBOURN PJ, 1994, SCIENCE, V257, P1682; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NABEL GJ, 1993, GENE DEV, V7, P2063, DOI 10.1101/gad.7.11.2063; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NEDOSPASOV SA, 1986, COLD SPRING HARB SYM, V51, P611, DOI 10.1101/SQB.1986.051.01.073; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; OHMORI Y, 1994, J BIOL CHEM, V269, P17684; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; POKHOLOK DK, 1995, P NATL ACAD SCI USA, V92, P674, DOI 10.1073/pnas.92.3.674; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEMON D, 1987, NUCLEIC ACIDS RES, V15, P9083, DOI 10.1093/nar/15.21.9083; SHAKHOV AN, 1990, GENE, V95, P215, DOI 10.1016/0378-1119(90)90364-W; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TURETSKAYA RL, 1992, TUMOR NECROSIS FACTO, P35; WIRTH T, 1988, EMBO J, V7, P3109, DOI 10.1002/j.1460-2075.1988.tb03177.x	67	111	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					97	106						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624137				2022-12-28	WOS:A1995RJ29500012
J	OKAMURA, H; RESH, MD				OKAMURA, H; RESH, MD			DIFFERENTIAL BINDING OF PP60(C-SRC) AND PP60(V-SRC) TO CYTOSKELETON IS MEDIATED BY SH2 AND CATALYTIC DOMAINS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; PHOSPHOTYROSINE-CONTAINING PROTEINS; GTPASE-ACTIVATING PROTEIN; INSOLUBLE CELLULAR MATRIX; GROWTH-FACTOR RECEPTORS; TYROSINE KINASE; SIGNAL TRANSDUCTION; SRC GENE; MORPHOLOGICAL TRANSFORMATION; PP60C-SRC	The transforming protein of Rous sarcoma virus, pp60(v-src), and its normal cellular homolog, pp60(c-src), differ not only in oncogenic potential but also in their subcellular localization and cytoskeletal binding ability. pp60(v-src) has been shown to stably associate with a detergent-insoluble cytoskeletal matrix, whereas pp60(c-src) does not. We have generated a series of precise deletion and truncations of the Src homology domains within pp60(v-src) and pp60(c-src), based on the crystal and solution structures of these regions, to determine not only the region responsible for cytoskeletal association but also the mechanism accounting for the differential binding observed. Here we show that the SH2 domain, but not the SH3 domain, mediates cytoskeletal association of pp60(v-src) through a phosphotyrosine-dependent interaction. The ability to interact with the cytoskeletal matrix is regulated by the catalytic (SH1) domain. Truncation of the pp60(v-src) catalytic domain results in lower binding while removal of the catalytic domain of pp60(c-src) results in the acquisition of cytoskeletal binding similar to that of the analogous v-src construct. These results indicate that the SH2 and catalytic domains function coordinately to regulate the cytoskeletal association of pp60(v-src) and pp60(c-src).	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Memorial Sloan Kettering Cancer Center; Princeton University				Resh, Marilyn/0000-0001-6118-9466	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [NCI-P30-CA-08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HAMAGUCHI M, 1989, ONCOGENE RES, V4, P29; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KLAPPER A, 1992, BIOTECHNIQUES, V12, P651; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU XQ, 1993, ONCOGENE, V8, P1119; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SILVERMAN L, 1992, J CELL BIOL, V119, P415, DOI 10.1083/jcb.119.2.415; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	50	46	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2293	2303						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7518578				2022-12-28	WOS:A1994NX62900022
J	LANDESMAN, Y; BRINGOLD, F; KIMCHI, A				LANDESMAN, Y; BRINGOLD, F; KIMCHI, A			P53 UNDERGOES EPITOPIC CHANGES IN-VITRO BY SODIUM-VANADATE	ONCOGENE			English	Note							TUMOR-SUPPRESSOR PROTEIN; KERATINOCYTE CELL-LINE; VIRUS-40 T-ANTIGEN; BINDING-SITE; WILD-TYPE; MUTANT; KINASE; GENE; PHOSPHORYLATION; SEQUENCE	p53 has at least two conformations that differ in their immunoreactivity. They consist of the functional tumor suppressor form, characteristic of the wild type p53 and the mutant form, generated by changes in the primary amino acid sequence of the protein. It has been previously shown that the wild type p53 protein also acquires the mutant conformation upon certain changes in growth conditions. Here we report that similar epitopic changes can be induced in crude cell lysate by addition of vanadate anions at 1 mm final concentration. A panel of anti p53 antibodies was used to discriminate between the different immunoreactive forms of wild type p53 in SV80 fibroblasts. It was found that addition of sodium vanadate to the lysis buffer converted part of p53 molecules into a mutant conformation that is recognized by the PAb 240 monoclonal antibodies. The effect of vanadate on p53 conformation was prominent even if it was added to the cell lysates after 15 min of preincubation at 37-degrees-C. This further excluded its possible role as phosphatase inhibitor in the system and suggested a direct interaction with the p53 protein itself. Based on these data we recommend to avoid using sodium vanadate as a phosphatase inhibitor in experiments where in vivo conformational changes of wild type p53 are studied.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL; GERMAN CANC RES CTR,DIV DIFFERENTIAT & CARCINOGENESIS IN VITRO 0240,D-69120 HEIDELBERG,GERMANY	Weizmann Institute of Science; Helmholtz Association; German Cancer Research Center (DKFZ)								BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOUKAMP P, 1993, P53 GROWTH CONTROL N; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HIRATSUKA T, 1990, J BIOL CHEM, V265, P18791; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1988, ONCOGENE HDB, P403; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANDESMAN Y, 1992, ONCOGENE, V7, P1661; LANE PD, 1991, CURR OPIN CELL BIOL, V2, P581; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER W E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P251; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1990, ONCOGENE, V5, P1683; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MONTENARH M, 1992, Critical Reviews in Oncogenesis, V3, P233; NECHAY BR, 1986, FASEB J, V45, P123; OREN M, 1991, BIOCH MOL ASPECTS SE, P373; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; TAKAHASHI K, 1992, JPN J CANCER RES, V83, P358, DOI 10.1111/j.1349-7006.1992.tb00115.x; TOMINAGA O, 1992, Critical Reviews in Oncogenesis, V3, P257; TRACEY AS, 1986, P NATL ACAD SCI USA, V83, P609, DOI 10.1073/pnas.83.3.609; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	40	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1241	1245						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	7510864				2022-12-28	WOS:A1994NC04800029
J	MULDER, MP; KEIJZER, W; VERKERK, A; BOOT, AJM; PRINS, MEF; SPLINTER, TAW; BOS, JL				MULDER, MP; KEIJZER, W; VERKERK, A; BOOT, AJM; PRINS, MEF; SPLINTER, TAW; BOS, JL			ACTIVATED RAS GENES IN HUMAN SEMINOMA - EVIDENCE FOR TUMOR HETEROGENEITY	ONCOGENE			English	Article									SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,2300 RA LEIDEN,NETHERLANDS; UNIV HOSP DIJKZIGT,DEPT MED ONCOL,ROTTERDAM,NETHERLANDS; ERASMUS UNIV,DEPT PATHOL,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam	MULDER, MP (corresponding author), ERASMUS UNIV,DEPT CELL BIOL & GENET,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.							ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ATKIN NB, 1983, CANCER GENET CYTOGEN, V10, P199, DOI 10.1016/0165-4608(83)90125-5; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; CHESA PG, 1987, P NATL ACAD SCI USA, V84, P3234, DOI 10.1073/pnas.84.10.3234; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; FURTH ME, 1987, ONCOGENE, V1, P47; GIBAS Z, 1986, CANCER GENET CYTOGEN, V19, P245, DOI 10.1016/0165-4608(86)90053-1; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRAI H, 1988, BLOOD, V71, P256; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; JANSSEN JWG, 1987, NUCLEIC ACIDS RES, V15, P5669, DOI 10.1093/nar/15.14.5669; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LEVINSON AD, 1986, TRENDS GENET, V2, P81, DOI 10.1016/0168-9525(86)90184-8; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; MALONE PR, 1985, BRIT J UROL, V57, P664, DOI 10.1111/j.1464-410X.1985.tb07028.x; Maniatis T., 1982, MOL CLONING; MARSHALL CJ, 1986, ONCOGENES GROWTH CON, P192; MCCOY MS, 1983, NATURE, V302, P79, DOI 10.1038/302079a0; MOSTOFI FK, 1980, CANCER, V45, P1735, DOI 10.1002/cncr.1980.45.s7.1735; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PADUA RA, 1988, LEUKEMIA, V2, P503; PECKHAM MJ, 1979, LANCET, V2, P267; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1988, CANCER RES, V48, P5738; SHEN WPV, 1987, ONCOGENE, V1, P157; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; SUAREZ HG, 1988, ONCOGENE, V2, P403; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TOKSOZ D, 1987, ONCOGENE, V1, P409; VARMUS HE, 1984, ANNU REV GENET, V18, P553; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VERWEIJ CL, 1985, NUCLEIC ACIDS RES, V13, P4699, DOI 10.1093/nar/13.13.4699; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; VISVANATHAN KV, 1988, ONCOGENE RES, V3, P77; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YUNIS JJ, 1989, ONCOGENE, V4, P609; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	51	57	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1345	1351						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2682461				2022-12-28	WOS:A1989AX65900011
J	STRAWHECKER, JM; BETZ, NA; NEADES, RY; HOUSER, W; PELLING, JC				STRAWHECKER, JM; BETZ, NA; NEADES, RY; HOUSER, W; PELLING, JC			BINDING OF THE 97KDA GLUCOCORTICOID RECEPTOR TO THE 5' UPSTREAM FLANKING REGION OF THE MOUSE C-HA-RAS ONCOGENE	ONCOGENE			English	Article									UNIV NEBRASKA,MED CTR,DEPT BIOCHEM,OMAHA,NE 68105	University of Nebraska System; University of Nebraska Medical Center	STRAWHECKER, JM (corresponding author), UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,42ND & DEWEY AVE,OMAHA,NE 68105, USA.				NATIONAL CANCER INSTITUTE [K04CA001382, P30CA036727, R01CA040847] Funding Source: NIH RePORTER; NCI NIH HHS [K04-CA 01382, CA40847, CA36727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BROWN K, 1988, MOL CARCINOGEN, V1, P161, DOI 10.1002/mc.2940010304; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUERTIN M, 1983, BIOCHEMISTRY-US, V22, P4296, DOI 10.1021/bi00287a021; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KO MSH, 1989, DNA-J MOLEC CELL BIO, V8, P127, DOI 10.1089/dna.1.1989.8.127; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIMINS LA, 1982, P NATL ACAD SCI-BIOL, V79, P6453, DOI 10.1073/pnas.79.21.6453; MATHIS JM, 1989, ARCH BIOCHEM BIOPHYS, V269, P93, DOI 10.1016/0003-9861(89)90090-8; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; OIKARINEN J, 1981, BIOCHEM J, V198, P519, DOI 10.1042/bj1980519; OSTROWSKI MC, 1984, EMBO J, V3, P1891, DOI 10.1002/j.1460-2075.1984.tb02064.x; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PELLING JC, 1987, CARCINOGENESIS, V8, P1481, DOI 10.1093/carcin/8.10.1481; POTTER E, 1981, P NATL ACAD SCI-BIOL, V78, P6662, DOI 10.1073/pnas.78.11.6662; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SILVA CM, 1987, P NATL ACAD SCI USA, V84, P1744, DOI 10.1073/pnas.84.7.1744; Slaga T J, 1980, Carcinog Compr Surv, V5, P111; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P6992; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3	28	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1317	1322						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2682459				2022-12-28	WOS:A1989AX65900007
J	RAY, R; THOMAS, S; MILLER, DM				RAY, R; THOMAS, S; MILLER, DM			MOUSE FIBROBLASTS TRANSFORMED WITH THE HUMAN C-MYC GENE EXPRESS A HIGH-LEVEL OF MESSENGER-RNA BUT A LOW-LEVEL OF C-MYC PROTEIN AND ARE NON-TUMORIGENIC IN NUDE-MICE	ONCOGENE			English	Article									UNIV ALABAMA,CTR COMPREHENS CANC,DEPT INTERNAL MED,288 BHSB,BIRMINGHAM,AL 35294; UNIV ALABAMA,CTR COMPREHENS CANC,DEPT BIOCHEM,BIRMINGHAM,AL 35294; VET ADM MED CTR,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NCI NIH HHS [R01 CA42337, R01 CA42664] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042337, R01CA042664] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPELAND NG, 1980, J VIROL, V33, P1199, DOI 10.1128/JVI.33.3.1199-1202.1980; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIALLONGO A, 1983, SCIENCE, V222, P430, DOI 10.1126/science.6604943; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; JOHNSON BE, 1986, J CLIN INVEST, V78, P525, DOI 10.1172/JCI112604; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; KOLLER CA, 1985, J CLIN INVEST, V76, P365, DOI 10.1172/JCI111970; KOLLER CA, 1986, NEW ENGL J MED, V315, P1433, DOI 10.1056/NEJM198612043152301; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAUTENBERGER JA, 1981, P NATL ACAD SCI-BIOL, V78, P1518, DOI 10.1073/pnas.78.3.1518; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; Maniatis T., 1982, MOL CLONING; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MORSE B, 1989, MOL CELL BIOL, V9, P74, DOI 10.1128/MCB.9.1.74; NEPVEU A, 1985, NATURE, V317, P440, DOI 10.1038/317440a0; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PERRY RP, 1983, CELL, V33, P647, DOI 10.1016/0092-8674(83)90006-5; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; SCHAWB M, 1984, CANCER CELLS, V2, P215; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPECTOR DL, 1987, ONCOGENE, V1, P5; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; SULLIVAN N, 1986, CURR TOP MICROBIOL, V132, P355; VANBENEDEN RJ, 1986, P NATL ACAD SCI USA, V83, P3698; VENNSTROM B, 1987, ONCOGENE, V1, P271; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363	53	24	24	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					593	600						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2657574				2022-12-28	WOS:A1989U768800009
J	YUNIS, JJ; BOOT, AJM; MAYER, MG; BOS, JL				YUNIS, JJ; BOOT, AJM; MAYER, MG; BOS, JL			MECHANISMS OF RAS MUTATION IN MYELODYSPLASTIC SYNDROME	ONCOGENE			English	Article									SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,POB 9503,2300 RA LEIDEN,NETHERLANDS; UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities					NCI NIH HHS [CA23124] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; ECONOMOPOULOS T, 1987, EUR J HAEMATOL, V38, P338; Elandt-Johnson R C, 1980, SURVIVAL MODELS DATA; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; HIRAI H, 1988, BLOOD, V71, P256; HIRAI H, 1987, NATURE, V327, P430, DOI 10.1038/327430a0; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; JUNEJA SK, 1983, J CLIN PATHOL, V36, P1129, DOI 10.1136/jcp.36.10.1129; KAPLAN ME, 1976, IN VITRO METHODS CEL; KERKHOFS H, 1987, BRIT J HAEMATOL, V65, P73, DOI 10.1111/j.1365-2141.1987.tb06138.x; LEMOINE NR, 1989, IN PRESS ONCOGENE; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; LYONS J, 1988, BLOOD, V71, P1707; Maniatis T., 1982, MOL CLONING; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; PADUA RA, 1988, LEUKEMIA, V2, P503; RASKIND WH, 1984, BLOOD, V63, P1318; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; SENNHP, 1988, BLOOD, V72, P931; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; TOKSOZ D, 1987, ONCOGENE, V1, P409; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YUNIS JJ, 1986, BLOOD, V67, P1721; YUNIS JJ, 1988, BRIT J HAEMATOL, V68, P189, DOI 10.1111/j.1365-2141.1988.tb06188.x; 1984, CANCER GENET CYTOGEN, V11, P249; [No title captured]	31	128	134	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					609	614						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2657575				2022-12-28	WOS:A1989U768800011
J	HUME, CR; NOCKA, KH; SORRENTINO, V; LEE, JS; FLEISSNER, E				HUME, CR; NOCKA, KH; SORRENTINO, V; LEE, JS; FLEISSNER, E			CONSTITUTIVE C-MYC EXPRESSION ENHANCES THE RESPONSE OF MURINE MAST-CELLS TO IL-3, BUT DOES NOT ELIMINATE THEIR REQUIREMENT FOR GROWTH-FACTORS	ONCOGENE			English	Article									CORNELL UNIV,GRAD SCH MED SCI,SLOAN KETTERING DIV,NEW YORK,NY 10021	Cornell University; Memorial Sloan Kettering Cancer Center			Sorrentino, Vincenzo/A-4793-2014	Sorrentino, Vincenzo/0000-0002-8573-8631				ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; CONSCIENCE JF, 1986, EMBO J, V5, P317, DOI 10.1002/j.1460-2075.1986.tb04215.x; CORY S, 1987, ONCOGENE RES, V1, P61; DEAN M, 1987, ONCOGENE RES, V1, P279; DUNNICK W, 1983, P NATL ACAD SCI-BIOL, V80, P7269, DOI 10.1073/pnas.80.23.7269; Favaloro J, 1980, Methods Enzymol, V65, P718; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAHN SR, 1985, NATURE, V314, P366; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; METCALF D, 1985, BLOOD, V65, P357; RALPH P, 1976, J EXP MED, V143, P1528, DOI 10.1084/jem.143.6.1528; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; SORRENTINO V, IN PRESS ANN NY ACAD; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; YUNG YP, 1981, J IMMUNOL, V127, P794; ZERLIN M, 1987, ONCOGENE, V1, P19	26	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					223	226						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3281092				2022-12-28	WOS:A1988M593100003
J	EISEN, T; EASTY, DJ; BENNETT, DC; GODING, CR				EISEN, T; EASTY, DJ; BENNETT, DC; GODING, CR			THE POU DOMAIN TRANSCRIPTION FACTOR BRN-2 - ELEVATED EXPRESSION IN MALIGNANT-MELANOMA AND REGULATION OF MELANOCYTE-SPECIFIC GENE-EXPRESSION	ONCOGENE			English	Article						MELANOCYTES; MELANOMA; TRANSCRIPTION; POU DOMAIN; BRN-2; N-OCT3	OCTAMER-BINDING-PROTEIN; DNA-BINDING; CELLS; PIGMENTATION; DISTINCT; PROMOTER; BRAIN; OCT-1	Previous work has shown that melanoma cell lines express a distinct octamer binding protein. Given the role of octamer-binding proteins in cell differentiation and development, the role this factor is a key issue in understanding melanocyte differentiation and transformation. Using a proteolytic clipping assay, we show that the melanoma-specific octamer factor is Brn-2/N-Oct3, a POU domain protein previously known to be expressed in adult brain and in the developing nervous system. N-Oct3 mRNA was detected in a range of human melanoma cell lines and was around 10-fold elevated compared to normal human melanocytes while mRNA for Brn-2 was also detected in a mouse melanoblast cell line. Expression of Brn-2/N-Oct3, in melanoma cells in cotransfection assays activated the expression of the MHC class II DR alpha promoter but repressed the activity of the melanocyte-specific tyrosinase promoter. Repression correlated with Brn-2/N-Oct3 binding in a mutually exclusive fashion with basic-helix-loop-helix-leucine-zipper (bHLH-LZ) transcription factor USF in vitro and with Brn-2 expression preventing activation of the tyrosinase promoter by the bHLH-LZ factor Microphthalmia in vivo. The potential role of Brn-2/N-Oct3 in melanocyte differentiation and gene expression is discussed.	MARIE CURIE RES INST, EUKARYOT TRANSCRIPT LAB, OXTED RH8 0TL, SURREY, ENGLAND; UNIV LONDON ST GEORGES HOSP, SCH MED, LONDON SW17 0RE, ENGLAND	St Georges University London			Bennett, Dorothy C/C-2418-2008	Bennett, Dorothy C/0000-0002-3639-7527; Goding, Colin/0000-0002-1614-3909				ANGUS J, 1995, ONCOGENE, V11, P691; BENNETT DC, 1985, J CELL SCI, V77, P167; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COX PM, 1988, NUCLEIC ACIDS RES, V16, P11047, DOI 10.1093/nar/16.23.11047; COX PM, 1994, TRANSCRIPTIONAL REGU; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; EASTY DJ, 1993, J INVEST DERMATOL, V101, P679, DOI 10.1111/1523-1747.ep12371675; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FITZPATRICK TB, 1979, BIOL MELANIN PIGMENT; FUJII H, 1993, NEURON, V11, P1197, DOI 10.1016/0896-6273(93)90231-F; GODING CR, 1987, NUCLEIC ACIDS RES, V15, P7761, DOI 10.1093/nar/15.19.7761; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SCHREIBER E, 1990, NUCLEIC ACIDS RES, V18, P5495, DOI 10.1093/nar/18.18.5495; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SCHREIBER E, 1992, CANCER RES, V52, P6121; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; STURM RA, 1991, CELL GROWTH DIFFER, V2, P519; STURM RA, 1994, PIGM CELL RES, V7, P235, DOI 10.1111/j.1600-0749.1994.tb00055.x; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; THOMSON JAF, 1993, PIGM CELL RES, V6, P13, DOI 10.1111/j.1600-0749.1993.tb00576.x; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YAVUZER U, 1994, MOL CELL BIOL, V14, P3494, DOI 10.1128/MCB.14.5.3494; YAVUZER U, 1995, ONCOGENE, V10, P123	29	63	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	1995	11	10					2157	2164						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478537				2022-12-28	WOS:A1995TF29700028
J	RICCI, A; LANFRANCONE, L; CHIARI, R; BELARDO, G; PERTICA, C; NATALI, PG; PELICCI, PG; SEGATTO, O				RICCI, A; LANFRANCONE, L; CHIARI, R; BELARDO, G; PERTICA, C; NATALI, PG; PELICCI, PG; SEGATTO, O			ANALYSIS OF PROTEIN-PROTEIN INTERACTIONS INVOLVED IN THE ACTIVATION OF THE SHC/GRB-2 PATHWAY BY THE ERBB-2 KINASE	ONCOGENE			English	Article						ERBB-2; SHC; GRBB-2; SIGNAL TRANSDUCTION	RECEPTOR TYROSINE KINASES; SH3 DOMAINS; SIGNAL TRANSDUCTION; EGF RECEPTOR; NEU ONCOGENE; RAS; GRB2; GENE; AUTOPHOSPHORYLATION; PHOSPHORYLATION	In murine fibroblasts activation of the Shc/Grb-2 pathway by the ErbB-2 kinase involves tyrosine phosphorylation of She products and the formation of Shc/ErbB-2, Shc/Grb-2 and Grb-2/ErbB-2 complexes. Tyr 1139 of ErbB-2 bound to the Grb-2 SH2 domain in vitro as well as in intact cells. Tyr 1221 and 1248 are binding sites of gp185(ErbB-2) for Shc SH2 domain in vitro whereas Tyr 1196 and 1248 are major binding sites of ErbB-2 for She PTB domain. Inhibition of Shc/ErbB-2 complex formation in intact cells was obtained by simultaneous mutational inactivation of She SH2 and She PTB binding sites of gp185(Erb-2). Shc/ErbB-2 complexes are formed upon activation of the ErbB-2 kinase and tyrosine phosphorylation of She proteins; they are located in both cytosol and cellular membranes. ErbB-2 activation induces also translocation of Grb-2 from cytosol to membranes. This network of protein-protein interactions may reflect the ability of the Shc/Grb-2 pathway to act as a molecular snitch controlling different cellular functions regulated by RTK activation. In fact the Ras GDP exchanger mSOS was recruited in Grb-2/ErbB-2 complexes; furthermore besides mSOS, other polypeptides present in either cytosolic or membrane preparations were able to complex in vitro with Grb-2 SH3 domains.	REGINA ELENA INST CANC RES, IMMUNOL LAB, I-00156 ROME, ITALY; UNIV PERUGIA, IST CLIN MED, MOLEC BIOL LAB, I-06100 PERUGIA, ITALY	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Perugia			Lanfrancone, Luisa/AAC-8671-2019; Pelicci, Pier Giuseppe/AAL-6572-2020	Lanfrancone, Luisa/0000-0002-4523-3815; Segatto, Oreste/0000-0003-2561-1142; chiari, rita/0000-0002-7649-273X				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V73, P611; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIGIESI G, 1992, HYBRIDOMA, V11, P519, DOI 10.1089/hyb.1992.11.519; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HARLOW E, 1988, ANTIBODIES LABORATOR; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JANES PW, 1994, ONCOGENE, V9, P3601; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; LONARDO F, 1990, New Biologist, V2, P992; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SEGATTO O, 1992, ONCOGENE, V7, P1339; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	60	62	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1519	1529						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478576				2022-12-28	WOS:A1995TC53500010
J	GAJEWSKI, KM; SCHULZ, RA				GAJEWSKI, KM; SCHULZ, RA			REQUIREMENT OF THE ETS DOMAIN TRANSCRIPTION FACTOR D-ELG FOR EGG CHAMBER PATTERNING AND DEVELOPMENT DURING DROSOPHILA OOGENESIS	ONCOGENE			English	Article						CELL MIGRATION; DROSOPHILA OOGENESIS; MUTANT PHENOTYPE; TRANSCRIPTION FACTOR	BINDING-PROTEIN; GENE; RNA; LOCALIZATION; EMBRYO; DIFFERENTIATION; EMBRYOGENESIS; MELANOGASTER; CHROMOSOME; POLARITY	The D-elg gene encodes an ETS domain transcription factor that functions in Drosophila oogenesis. D-elg belongs to a small group of genes that are required for the formation of both the anteroposterior and dorsoventral axes of the egg chamber. During oogenesis in D-elg mutant females, the spatial localization of oskar and gurken mRNAs in the oocyte is disrupted and a follicle cell enhancer trap marker identifies dorsoventral polarity defects. Also, specialized follicle cells, called border cells, fail to migrate from their anterior location to a position adjacent to the developing oocyte. Consistent with these phenotypes, D-elg shows genetic interactions with two genes required for normal egg chamber differentiation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NICHD NIH HHS [T32 HD 07324] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007324] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BROWN T, 1992, GENE DEV, V6, P502; CHRISTERSON LB, 1994, GENE DEV, V8, P614, DOI 10.1101/gad.8.5.614; CUPP MB, 1962, MOUSE NEWS LETT, V26, P51; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FORLANI S, 1993, MECH DEVELOP, V41, P109, DOI 10.1016/0925-4773(93)90041-U; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KIMBLE M, 1990, GENETICS, V126, P991; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; LANTZ V, 1994, GENE DEV, V8, P598, DOI 10.1101/gad.8.5.598; LEPTIN M, 1989, CELL, V56, P401, DOI 10.1016/0092-8674(89)90243-2; LU XY, 1993, DEVELOPMENT, P47; MANSEAU L, 1994, 35TH ANN DROS RES C; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; NEUMANSILBERBER.FS, 1993, CELL, V75, P165; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PEIFER M, 1993, DEVELOPMENT, V118, P1191; ROTH S, 1994, DEVELOPMENT, V120, P2245; SCHULZ RA, 1993, P NATL ACAD SCI USA, V90, P10076, DOI 10.1073/pnas.90.21.10076; SCHULZ RA, 1993, ONCOGENE, V8, P3369; SCHUPBACH T, 1991, GENETICS, V129, P1119; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; SPRADLING A, 1909, DEV DROSOPHILA MELAN, P1; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; SPRENGER F, 1993, MOL CELL BIOL, V13, P1163, DOI 10.1128/MCB.13.2.1163; STJOHNSTON D, 1989, CELL, P13; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEURKAUF WE, 1994, SCIENCE, V265, P2093, DOI 10.1126/science.8091233; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644	36	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1033	1040						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566961				2022-12-28	WOS:A1995RX18000004
J	LARSON, RC; OSADA, H; LARSON, TA; LAVENIR, I; RABBITTS, TH				LARSON, RC; OSADA, H; LARSON, TA; LAVENIR, I; RABBITTS, TH			THE ONCOGENIC LIM-PROTEIN RBTN2 CAUSES THYMIC DEVELOPMENTAL ABERRATIONS THAT PRECEDE MALIGNANCY IN TRANSGENIC MICE	ONCOGENE			English	Article						RBTN2; LEUKEMIA; THYMUS; HEMATOPOIESIS; TRANSLOCATION	T-CELL ONCOGENE; HUMAN CD2 GENE; THY-1 GENE; BURKITT-LYMPHOMA; EXPRESSION; TRANSLOCATION; LEUKEMIA; TTG-1; RECEPTOR; ANTIGEN	RBTN2 is activated by the chromosomal translocation t(11;14) (P13;p11) in some T cell leukaemias. Histologically similar T cell. tumours develop with long latency in transgenic mice when either CD2 or thy1.1 promoters control rbtn2 expression, During the asymptomatic period, perturbation of T cell differentiation occurs in the thymus. The major anomalies present during this phase are an increase in the percentage of large thymocytes lacking CD4 and CD8 markers and also of small thymocytes express both the T cell marker CD3 and the B cell-specific form of CD45. These abnormal T cell populations can be clonal and thus a primary result of aberrant expression of the LIM-protein Rbtn2 is alteration of T cell differentiation preceding overt malignancy, These data provide a biological explanation for the role of Rbtn2 in tumorigenesis and presumably RBTN2 expression in T cells after the translocation t(11;14) in children has the same effect.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	MRC Laboratory Molecular Biology; Aichi Cancer Center			Osada, Hiroyuki/AAY-6254-2020; Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CHEN SH, 1987, CELL, V51, P7, DOI 10.1016/0092-8674(87)90005-5; CLARK SS, 1993, J VIROL, V67, P6033, DOI 10.1128/JVI.67.10.6033-6046.1993; Coffman R L, 1982, Immunol Rev, V69, P5; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; FEINBERG AP, 1993, ANAL BIOCHEM, V132, P6; FISCH P, 1992, ONCOGENE, V7, P2389; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; GORDON JW, 1987, CELL, V50, P445, DOI 10.1016/0092-8674(87)90498-3; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; KAMOUN M, 1991, J EXP MED, V1553, P207; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KOLLIAS G, 1987, P NATL ACAD SCI USA, V84, P1492, DOI 10.1073/pnas.84.6.1492; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LARSON RC, 1994, ONCOGENE, V9, P3675; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; NISHIMURA H, 1992, CELL IMMUNOL, V140, P423; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Sperling A I, 1989, Int Immunol, V1, P434, DOI 10.1093/intimm/1.4.434; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VIDAL M, 1990, EMBO J, V9, P833, DOI 10.1002/j.1460-2075.1990.tb08180.x; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Yagita H, 1989, INT IMMUNOL, V1, P94, DOI 10.1093/intimm/1.1.94	39	80	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					853	862						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7545805				2022-12-28	WOS:A1995RU79800005
J	BENNICELLI, JL; FREDERICKS, WJ; WILSON, RB; RAUSCHER, FJ; BARR, FG				BENNICELLI, JL; FREDERICKS, WJ; WILSON, RB; RAUSCHER, FJ; BARR, FG			WILD-TYPE PAX3 PROTEIN AND THE PAX3-FKHR FUSION PROTEIN OF ALVEOLAR RHABDOMYOSARCOMA CONTAIN POTENT, STRUCTURALLY DISTINCT TRANSCRIPTIONAL ACTIVATION DOMAINS	ONCOGENE			English	Article						PAX3; FKHR; FUSION PROTEIN; TRANSCRIPTION FACTOR; CHROMOSOMAL TRANSLOCATION	DNA-BINDING DOMAIN; MAMMALIAN-CELLS; GENE-EXPRESSION; EWINGS-SARCOMA; PRE-B; TRANSLOCATION; VIRUS; RNA; LIPOSARCOMA; E2A-PBX1	Alveolar rhabdomyosarcoma (ARMS) is characterized cytogenetically by a t(2;13)(q35;q14) chromosomal translocation involving two transcription factor genes: PAX3 and FKHR. ARMS cells express a PAX3-FKHR fusion protein containing the complete N-terminal, DNA-binding domain of PAX3 and the C-terminus of FKHR. Recently we demonstrated that PAX3-FKHR is a more potent transcriptional activator than PAX3 despite impaired binding to canonical PAX3 binding sites. Therefore, we propose that the gene fusion results in snitching of PAX3 and FKHR transactivation domains with distinct structure, potency or function. To compare the PAX3 and putative PAX3-FKHR transactivation domains, we fused C-terminal test fragments to the heterologous GAL4 DNA-binding domain and tested activation of a reporter gene co-transfected into four cell types. GAL4-PAX3 and GAL4-PAX3-FKHR were found to be potent activators exhibiting different concentration-dependent transactivation profiles and distinct structural motifs. Deletion mapping demonstrated essential acidic and/or serine/threonine-rich domains in the extreme 3' ends of their respective coding regions and positive modifying elements in adjacent 5' sequences. These data demonstrate that PAX3 and PAX3-FKHR contain structurally distinct transcriptional activation domains and suggest that a consequent difference in function is important for oncogenesis.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania; The Wistar Institute					NATIONAL CANCER INSTITUTE [P01CA047983, R01CA064202] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002871] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64202, CA 47983] Funding Source: Medline; NHLBI NIH HHS [K08 HL02871] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DAVIS RJ, 1994, CANCER RES, V54, P2869; DENECKE B, 1993, J BIOL CHEM, V268, P18076; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Manet Evelyne, 1993, Gene Expression, V3, P49; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OHNO T, 1993, CANCER RES, V53, P5859; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; TASSABEHJI M, 1994, HUM MOL GENET, V3, P1069, DOI 10.1093/hmg/3.7.1069; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; VANDIJK MA, 1989, P NATL ACAD SCI USA, V90, P6061; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	39	77	77	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					119	130						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624119				2022-12-28	WOS:A1995RJ29500015
J	CALIFANO, D; MONACO, C; DEVITA, G; DALESSIO, A; DATHAN, NA; POSSENTI, R; VECCHIO, G; FUSCO, A; SANTORO, M; DEFRANCISCIS, V				CALIFANO, D; MONACO, C; DEVITA, G; DALESSIO, A; DATHAN, NA; POSSENTI, R; VECCHIO, G; FUSCO, A; SANTORO, M; DEFRANCISCIS, V			ACTIVATED RET/PTC ONCOGENE ELICITS IMMEDIATE-EARLY AND DELAYED-RESPONSE GENES IN PC12 CELLS	ONCOGENE			English	Article						RET; PHEOCHROMOCYTOMA; TYROSINE KINASE; ONCOGENE; PC12	NERVE GROWTH-FACTOR; NEURON-SPECIFIC ENOLASE; RET PROTO-ONCOGENE; PHEOCHROMOCYTOMA CELLS; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; TYROSINE KINASE; VGF GENE; EXPRESSION; RAS	The expression of the receptor-like tyrosine kinase RET is associated with tumors, tissues or cell lines of neural crest origin, In addition RET products (Ret) are involved in determining cell fate during the differentiation of the enteric nervous system and during renal organogenesis. However, as yet, no direct evidence exists to indicate that the Ret kinase activity might interfere in a specific way with cellular differentiation, or proliferation, of a neural crest derived cell line. By using two constitutively activated forms of RET (RET/PTC1 and RET/PTC3) in transient transfection experiments, we have obtained evidence that active RET could reprogramme the gene expression pattern in the rat pheochromocytoma PC12 cell line. Transcription driven by gene promoters, such as NGFI-A and vgf, which belong, respectively, to primary and delayed response genes to nerve growth factor (NGF), and by the neuron-specific enolase (NSE) promoter, is rapidly induced by the expression of activated RET oncogenes. This induction is not elicited in other non neural derived cell types tested. We also demonstrate that endogenous vas activity is required for RET induction of these neural markers. Finally, in the RET/PTC transfected PC12 cells, NGF is unable to induce further their transcription. This suggests that RET/PTC could share an intracellular signalling pathway with the NGF-receptor.	UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80131 NAPLES,ITALY; FDN G PASCALE,IST STUDIO & CURA TUMORI,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; CNR,INST NEUROBIOL,I-00137 ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; IRCCS Fondazione Pascale; Universita Mediterranea di Reggio Calabria; Consiglio Nazionale delle Ricerche (CNR)			Califano, Daniela/Y-6313-2018; De Vita, Gabriella/H-4422-2011	Califano, Daniela/0000-0001-6945-3209; De Vita, Gabriella/0000-0002-7302-1174; Fusco, Alfredo/0000-0003-3332-5197				ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ANTORO M, 1994, ONCOGENE, V9, P509; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P1; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BAYBIS M, 1992, FEBS LETT, V308, P202, DOI 10.1016/0014-5793(92)81274-P; BONGARZONE I, 1994, CANCER RES, V54, P2979; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DAHMER MK, 1988, ENDOCRINOLOGY, V122, P2109, DOI 10.1210/endo-122-5-2109; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRECO A, 1993, CELL GROWTH DIFFER, V4, P539; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIECO M, 1994, ONCOGENE, V9, P2531; HAWLEY RJ, 1992, J NEUROSCI, V12, P2573; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KUJUBU DA, 1987, ONCOGENE, V1, P257; LANZI C, 1992, ONCOGENE, V7, P2189; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEVI A, 1980, SCIENCE, V229, P3469; LUKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490; MILLBRANDT J, 1987, SCIENCE, V238, P797; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; POSSENTI R, 1992, P NATL ACAD SCI USA, V89, P3815, DOI 10.1073/pnas.89.9.3815; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SCHMECHEL D, 1983, CURRENT METHODS CELL, V1, P1; SCHMECHEL DE, 1980, BRAIN RES, V190, P195, DOI 10.1016/0006-8993(80)91169-5; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOGARI A, 1985, J NEUROSCI, V5, P307; VANDENPOL AN, 1989, J NEUROSCI, V9, P4122; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P133, DOI 10.1016/0304-419X(93)90002-T; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	55	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					107	112						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624117				2022-12-28	WOS:A1995RJ29500013
J	YI, TL; WILLMAN, CL				YI, TL; WILLMAN, CL			CLONING OF THE MURINE C-FGR PROTO-ONCOGENE CDNA AND INDUCTION OF C-FGR EXPRESSION BY PROLIFERATION AND ACTIVATION FACTORS IN NORMAL BONE MARROW-DERIVED MONOCYTIC CELLS	ONCOGENE			English	Article									UNIV NEW MEXICO,SCH MED,CTR CANC,DEPT CELL BIOL,900 CAMINO SALUD NE,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT PATHOL,ALBUQUERQUE,NM 87131	University of New Mexico; University of New Mexico					NIDDK NIH HHS [KII DK-01284] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001284] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS DO, 1987, IMMUNOL REV, V97, P5, DOI 10.1111/j.1600-065X.1987.tb00514.x; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DALESSIO JM, 1987, FOCUS, V9, P1; FALK LA, 1988, J IMMUNOL, V140, P2652; GRABSTEIN KH, 1986, SCIENCE, V232, P506, DOI 10.1126/science.3083507; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HORIGUCHI J, 1987, BLOOD, V69, P1259; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; INOUE K, 1987, ONCOGENE, V1, P301; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KLEMSZ MJ, 1987, NUCLEIC ACIDS RES, V15, P9600, DOI 10.1093/nar/15.22.9600; KOERNER TJ, 1987, J IMMUNOL, V139, P239; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MALISSEN M, 1983, SCIENCE, V221, P750, DOI 10.1126/science.6410508; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MORRISSEY PJ, 1987, J IMMUNOL, V139, P1113; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; NAHARRO G, 1983, J VIROL, V47, P611, DOI 10.1128/JVI.47.3.611-619.1983; PAWSON T, 1988, ONCOGENE, V3, P491; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TRONICK SR, 1985, P NATL ACAD SCI USA, V82, P6595, DOI 10.1073/pnas.82.19.6595; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; WARREN MK, 1986, J IMMUNOL, V137, P2281; WILLMAN CL, 1987, P NATL ACAD SCI USA, V84, P4480, DOI 10.1073/pnas.84.13.4480; WILLMAN CL, IN PRESS J EXP MED; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	43	49	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1081	1087						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2674853				2022-12-28	WOS:A1989AM53100005
J	BAUER, SR; PIECHACZYK, M; NORDAN, RP; OWENS, JD; NEPVEU, A; MARCU, KB; MUSHINSKI, JF				BAUER, SR; PIECHACZYK, M; NORDAN, RP; OWENS, JD; NEPVEU, A; MARCU, KB; MUSHINSKI, JF			ALTERED MYC-GENE TRANSCRIPTION AND INTRON-INDUCED STABILIZATION OF MYC RNAS IN 2 MOUSE PLASMACYTOMAS	ONCOGENE			English	Article									NCI,GENET LAB,BETHESDA,MD 20892; UNIV MARYLAND,DEPT BIOCHEM,COLLEGE PK,MD 20742; UNIV MONTPELLIER 2,BIOL MOLEC LAB,F-34060 MONTPELLIER,FRANCE; CTR PAUL LAMARQUE,BIOCHEM LAB,F-34033 MONTPELLIER,FRANCE; SUNY STONY BROOK,DEPT BIOCHEM,STONY BROOK,NY 11794	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland College Park; Universite de Montpellier; Universite de Montpellier; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Bauer, Steven/G-5559-2012; /AAB-8315-2020; PIECHACZYK, Marc/E-7896-2013	PIECHACZYK, Marc/0000-0003-1367-2597; Bauer, Steven/0000-0003-2831-846X	NCI NIH HHS [CA 36246] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036246] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; ALT FW, 1982, MOL CELL BIOL, V2, P386, DOI 10.1128/MCB.2.4.386; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BONNIEU A, 1988, ONCOGENE RES, V3, P155; CECH TR, 1983, CELL, V34, P713, DOI 10.1016/0092-8674(83)90527-5; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; FAHRLANDER PD, 1985, P NATL ACAD SCI USA, V82, P3746, DOI 10.1073/pnas.82.11.3746; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HU NT, 1982, GENE, V17, P271; Jacob S T, 1973, Prog Nucleic Acid Res Mol Biol, V13, P93, DOI 10.1016/S0079-6603(08)60101-4; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KEATH EJ, 1984, CELL, V37, P521, DOI 10.1016/0092-8674(84)90382-9; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LANG RB, 1982, NUCLEIC ACIDS RES, V10, P611, DOI 10.1093/nar/10.2.611; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LOENEN WAM, 1980, GENE, V10, P249, DOI 10.1016/0378-1119(80)90054-2; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MCCORMACK JE, 1984, P NATL ACAD SCI-BIOL, V81, P5546, DOI 10.1073/pnas.81.17.5546; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MUSHINSKI JF, 1983, P NATL ACAD SCI-BIOL, V80, P1073, DOI 10.1073/pnas.80.4.1073; MUSHINSKI JF, 1988, CELLULAR ONCOGENE AC, P181; MUSHINSKI JF, 1985, MECHANISMS B CELL NE, P237; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1987, ONCOGENE, V1, P243; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NORDAN RP, 1986, SCIENCE, V233, P566, DOI 10.1126/science.3726549; OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; PERRY RP, 1983, CELL, V33, P647, DOI 10.1016/0092-8674(83)90006-5; PERSSON H, 1984, SCIENCE, V225, P687, DOI 10.1126/science.6431612; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PIECHACZYK M, 1986, CURR TOP MICROBIOL, V132, P331; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; POTTER M, 1984, SURV SYN PATHOL RES, V3, P499; POTTER M, 1984, ADV VIRAL ONCOL, V4, P139; PREHN J, 1984, NUCLEIC ACIDS RES, V12, P8987, DOI 10.1093/nar/12.23.8987; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; SWARTWOUT SG, 1987, MOL CELL BIOL, V7, P2052, DOI 10.1128/MCB.7.6.2052; SZAJNERT MF, 1987, NUCLEIC ACIDS RES, V15, P4553, DOI 10.1093/nar/15.11.4553; TAUB R, 1982, P NATL ACAD SCI USA, V79, P7839; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WIRSCHUBSKY Z, 1984, INT J CANCER, V33, P477, DOI 10.1002/ijc.2910330410; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x	63	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					615	623						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2657576				2022-12-28	WOS:A1989U768800012
J	RIGHI, M; PIERANI, A; BOGLIA, A; DELIBERO, G; MORI, L; MARINI, V; RICCIARDICASTAGNOLI, P				RIGHI, M; PIERANI, A; BOGLIA, A; DELIBERO, G; MORI, L; MARINI, V; RICCIARDICASTAGNOLI, P			GENERATION OF NEW ONCOGENIC MURINE RETROVIRUSES BY COTRANSFECTION OF CLONED AKR AND MH2 PROVIRUSES	ONCOGENE			English	Article											RIGHI, M (corresponding author), UNIV MILAN, DEPT PHARMACOL, CNR, CTR CYTOPHARMACOL, I-20129 MILAN, ITALY.		Pierani, Alessandra/O-6136-2017; Righi, Marco Giovanni Enea/M-9003-2019; Righi, Marco Giovanni Enea/G-5171-2011; Righi, Marco/P-4332-2019	Pierani, Alessandra/0000-0002-4872-4791; Righi, Marco Giovanni Enea/0000-0003-1181-0327; Righi, Marco Giovanni Enea/0000-0003-1181-0327; 				ALEXANDER RW, 1979, J NATL CANCER I, V62, P359; ANDERSON RA, 1982, P NATL ACAD SCI-BIOL, V79, P2748, DOI 10.1073/pnas.79.9.2748; ANDERSON SM, 1983, J VIROL, V46, P594, DOI 10.1128/JVI.46.2.594-605.1983; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BLASI E, 1986, LEUKOCYTES HOST DEFE, P275; CARR JG, 1960, BRIT J CANCER, V14, P77, DOI 10.1038/bjc.1960.9; CLEVELAND JL, 1986, J CELL BIOCHEM, V30, P195, DOI 10.1002/jcb.240300303; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; DODEMONT HJ, 1982, EMBO J, V1, P167, DOI 10.1002/j.1460-2075.1982.tb01142.x; GALIBERT F, 1984, EMBO J, V3, P1333, DOI 10.1002/j.1460-2075.1984.tb01972.x; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GOLDSTEIN JL, 1980, J BIOL CHEM, V255, P1839; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P49; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HARTLEY JW, 1975, VIROLOGY, V65, P128, DOI 10.1016/0042-6822(75)90013-6; JANSEN HW, 1983, EMBO J, V2, P1969, DOI 10.1002/j.1460-2075.1983.tb01686.x; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; JOYNER A, 1983, NATURE, V305, P556, DOI 10.1038/305556a0; KAN NC, 1983, P NATL ACAD SCI-BIOL, V80, P6566, DOI 10.1073/pnas.80.21.6566; KAN NC, 1984, P NATL ACAD SCI USA, V81, P3004; KESKIOJA J, 1982, J CELL BIOCHEM, V20, P139, DOI 10.1002/jcb.240200206; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; KRETSCHMER PJ, 1981, NUCLEIC ACIDS RES, V9, P6199, DOI 10.1093/nar/9.22.6199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINIAL M, 1982, VIROLOGY, V119, P382, DOI 10.1016/0042-6822(82)90097-6; LOWY DR, 1980, P NATL ACAD SCI-BIOL, V77, P614, DOI 10.1073/pnas.77.1.614; MORI L, 1985, EMBO J, V4, P2025, DOI 10.1002/j.1460-2075.1985.tb03887.x; PERUCHO M, 1980, CELL, V22, P309, DOI 10.1016/0092-8674(80)90178-6; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1983, J VIROL, V45, P914, DOI 10.1128/JVI.45.3.914-924.1983; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; ROSS J, 1971, NATURE-NEW BIOL, V231, P163, DOI 10.1038/newbio231163a0; SAULE S, 1984, EXP CELL RES, V155, P496, DOI 10.1016/0014-4827(84)90209-X; SHEVACH EM, 1984, FUNDAMENTAL IMMUNOLO, P61; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	45	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					223	230						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2927945				2022-12-28	WOS:A1989U567500014
J	TAKAHASHI, M; BUMA, Y; IWAMOTO, T; INAGUMA, Y; IKEDA, H; HIAI, H				TAKAHASHI, M; BUMA, Y; IWAMOTO, T; INAGUMA, Y; IKEDA, H; HIAI, H			CLONING AND EXPRESSION OF THE RET PROTO-ONCOGENE ENCODING A TYROSINE KINASE WITH 2 POTENTIAL TRANSMEMBRANE DOMAINS	ONCOGENE			English	Article									NAGOYA UNIV,SCH MED,DEPT IMMUNOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Nagoya University	TAKAHASHI, M (corresponding author), AICHI CANC CTR,RES INST,EXPTL PATHOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN.		TAKAHASHI, Masahide/I-7244-2014; Takahashi, Masahide/AAN-4770-2020	Takahashi, Masahide/0000-0002-2803-2683				BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BASLER K, 1988, CELL, V54, P299; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BRAELL WA, 1982, CELL, V28, P23, DOI 10.1016/0092-8674(82)90371-3; CHAN AML, 1987, ONCOGENE, V1, P229; COPELAND NG, 1979, CELL, V17, P993, DOI 10.1016/0092-8674(79)90338-6; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DAVIDSON WF, 1986, J IMMUNOL, V136, P4075; DAVIDSON WF, 1985, P NATL ACAD SCI USA, V82, P1219, DOI 10.1073/pnas.82.4.1219; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; HIAI H, 1982, GANN, V73, P704; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; KATAGIRI T, 1988, J EXP MED, V167, P741, DOI 10.1084/jem.167.3.741; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; Murphy E. D., 1978, Genetic control of autoimmune disease. Proceedings of the workshop on the genetic control of autoimmune disease held in Bloomfield Hills, Michigan, USA, on July 10-12, 1978., P207; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NEMAZEE DA, 1985, EUR J IMMUNOL, V15, P760, DOI 10.1002/eji.1830150804; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; ROTHS JB, 1984, J EXP MED, V159, P1, DOI 10.1084/jem.159.1.1; SAMELSON LE, 1986, NATURE, V324, P674, DOI 10.1038/324674a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG JYJ, 1984, CELL, V36, P349; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	37	490	514	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					571	578						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3078962				2022-12-28	WOS:A1988R516300014
J	KUPPUSWAMY, M; SUBRAMANIAN, T; CHINNADURAI, G				KUPPUSWAMY, M; SUBRAMANIAN, T; CHINNADURAI, G			SEPARATION OF IMMORTALIZATION AND T24-RAS ONCOGENE COOPERATIVE FUNCTIONS OF ADENOVIRUS E1A	ONCOGENE			English	Article									ST LOUIS UNIV,MED CTR,INST MOLEC VIROL,3681 PK AVE,ST LOUIS,MO 63110	Saint Louis University					NCI NIH HHS [CA-31719, CA-33616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033616, R01CA031719] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1984, ADENOVIRUSES, P339; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P2329; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULFENDAHL PJ, 1987, EMBO J, V6, P2037, DOI 10.1002/j.1460-2075.1987.tb02468.x; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	24	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					613	615						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	2968534				2022-12-28	WOS:A1988N841500013
J	VERSNEL, MA; HAGEMEIJER, A; BOUTS, MJ; VANDERKWAST, TH; HOOGSTEDEN, HC				VERSNEL, MA; HAGEMEIJER, A; BOUTS, MJ; VANDERKWAST, TH; HOOGSTEDEN, HC			EXPRESSION OF C-SIS (PDGF B-CHAIN) AND PDGF A-CHAIN GENES IN 10 HUMAN-MALIGNANT MESOTHELIOMA CELL-LINES DERIVED FROM PRIMARY AND METASTATIC TUMORS	ONCOGENE			English	Article									ERASMUS UNIV, DEPT PATHOL, 3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV, DEPT PULM MED, 3000 DR ROTTERDAM, NETHERLANDS; ACAD HOSP DIJKZIGT, ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC	VERSNEL, MA (corresponding author), ERASMUS UNIV, DEPT CELL BIOL IMMUNOL & GENET, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.			Van der Kwast, Theodorus/0000-0001-8640-5786				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARRETT TB, 1984, P NATL ACAD SCI-BIOL, V81, P6772, DOI 10.1073/pnas.81.21.6772; BENHAM FJ, 1984, EMBO J, V3, P2635, DOI 10.1002/j.1460-2075.1984.tb02186.x; BETSHOLTZ C, 1984, CELL, V39, P447, DOI 10.1016/0092-8674(84)90452-5; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BETSHOLTZ C, 1983, BIOCHEM BIOPH RES CO, V117, P176, DOI 10.1016/0006-291X(83)91557-7; DEUEL TF, 1983, SCIENCE, V221, P1348, DOI 10.1126/science.6310754; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; FAVERA RD, 1982, SCIENCE, V218, P686; GERWIN B, 1987, J CELL BIOCHEM, P58; GERWIN BI, 1987, EUR J CANCER CLIN ON, V23, P1752, DOI 10.1016/0277-5379(87)90552-9; GOUSTIN AS, 1985, CELL, V41, P301, DOI 10.1016/0092-8674(85)90083-2; GRAVES DT, 1984, SCIENCE, V226, P972, DOI 10.1126/science.6209798; GROFFEN J, 1983, J EXP MED, V158, P9, DOI 10.1084/jem.158.1.9; Harnden DG, 1985, INT SYSTEM HUMAN CYT; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HOLLEY RW, 1975, NATURE, V258, P487, DOI 10.1038/258487a0; JEFFREYS AJ, 1977, CELL, V12, P429, DOI 10.1016/0092-8674(77)90119-2; Maniatis T, 1982, MOL CLONING LABORATO; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MORTON CC, 1987, HGM, V9, P98; NISTER M, 1984, P NATL ACAD SCI-BIOL, V81, P926, DOI 10.1073/pnas.81.3.926; PANTAZIS P, 1985, P NATL ACAD SCI USA, V82, P2404, DOI 10.1073/pnas.82.8.2404; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SWAN DC, 1982, P NATL ACAD SCI-BIOL, V79, P4691, DOI 10.1073/pnas.79.15.4691; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TODARO GJ, 1978, CANCER RES, V38, P4147; WAGNER J C, 1960, Br J Ind Med, V17, P260; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; WHITAKER D, 1984, J PATHOL, V143, P147, DOI 10.1002/path.1711430303	32	86	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					601	605						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	3290807				2022-12-28	WOS:A1988N841500011
J	CHEN, IT; SMITH, ML; OCONNOR, PM; FORNACE, AJ				CHEN, IT; SMITH, ML; OCONNOR, PM; FORNACE, AJ			DIRECT INTERACTION OF GADD45 WITH PCNA AND EVIDENCE FOR COMPETITIVE INTERACTION OF GADD45 AND P2L(WAF1/CIP1) WITH PCNA	ONCOGENE			English	Article						GADD45; PCNA; P21; WAF1; CIP1; P53; XP-A	CELL NUCLEAR ANTIGEN; DNA POLYMERASE-DELTA; GENE-TRANSCRIPTION; AUXILIARY PROTEIN; CYCLIN PCNA; P53; REPLICATION; INHIBITOR; IRRADIATION; COMPONENT	We have previously shown (Smith et al., 1994) that antibodies raised against the growth arrest and DNA damage inducible protein Gadd45 co-precipitate proliferating cell nuclear antigen (PCNA), a protein involved in DNA replication and repair. Here we demonstrate that Gadd45 can directly bind to PCNA using a Far-western blotting approach. In this assay, a Gadd45 bacterial expression vector was modified to allow synthesis of purified P-32-labeled Gadd45 fusion protein. This protein was used to detect filter bound PCNA protein, while filter bound Gadd45 protein could also be detected by free PCNA molecules. Using recombinant proteins in conjunction with immunoprecipitation and immunoblotting, we show that Gadd45 competes with p21 for binding to PCNA and conversely, p21 blocks the ability of Gadd45 to bind PCNA. In addition, p21 appears to disrupt PCNA trimers whereas Gadd45 has a lesser effect. PCNA trimer disruption was also observed in UV-irradiated cells but not in repair-defective xeroderma pigmentosum group A (XP-A) cells.	NCI, DIV CANC TREATMENT, DEV THERAPEUT PROGRAM, MOLEC PHARMACOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CELIS JE, 1987, FEBS LETT, V220, P1, DOI 10.1016/0014-5793(87)80865-7; CHEN IT, 1995, UNPUB ONCOGENE; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALL PA, 1995, ONCOGENE, V10, P2427; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; MICHIELI P, 1994, CANCER RES, V54, P3391; MIURA M, 1992, EXP CELL RES, V201, P541, DOI 10.1016/0014-4827(92)90308-U; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, pU3559; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1995, INT J ONCOL, V6, P937	45	122	126	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	1995	11	10					1931	1937						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478510				2022-12-28	WOS:A1995TF29700001
J	TAMURA, T; AOYAMA, N; SAYA, H; HAGA, H; FUTAMI, S; MIYAMOTO, M; KOH, T; ARIYASU, T; TACHI, M; KASUGA, M; TAKAHASHI, R				TAMURA, T; AOYAMA, N; SAYA, H; HAGA, H; FUTAMI, S; MIYAMOTO, M; KOH, T; ARIYASU, T; TACHI, M; KASUGA, M; TAKAHASHI, R			INDUCTION OF FAS-MEDIATED APOPTOSIS IN P53-TRANSFECTED HUMAN COLON-CARCINOMA CELLS	ONCOGENE			English	Article						P53; FAS; APOPTOSIS; COLON CANCER	WILD-TYPE P53; TUMOR-NECROSIS-FACTOR; HUMAN GASTRIC-CANCER; SUPPRESSOR GENE; GROWTH; MUTATIONS; RECEPTOR; PROTEIN; LINE; DNA	To investigate the biological function of p53 in colon carcinoma cells, a wild-type p53 expression plasmid under the control of the human cytomegalovirus promoter was stably transfected into the human colon adenocarcinoma cell line WiDr, which carries a mutation of the p53 gene at codon 273. Exogenous wild-type p53 transcripts were detected at various expression levels in 8 of 117 G418-resistant clones. The growth rates of the wild-type p53+ clones in culture did not change significantly. The efficiency of colony formation in soft agar, however, was completely suppressed in two wild-type p53+ clones. This is the first to demonstrate the feasibility of stable transfection of the wild-type p53 gene under the control of non-inducible promoter in human colon cancer cells. The major alteration found was that wild-type p53+ cells which were incubated with anti-Fas IgM showed marked cytolysis,vith preferential overexpression of wild-type p53 accompanied by overexpression of a cyclin-dependent kinase inhibitor, WAF1, whereas the endogenous mutant p53 retained its expression level. The findings suggest that a Fas-initiated pathway is incidentally linked to a p53-dependent apoptotic pathway through the reconstituted wild-type p53 gene in WiDr cells. This model should help elucidating the additional role of the p53 tumor suppressor gene and the mechanism of apoptosis in colon carcinoma cells.	KYOTO UNIV,GRAD SCH MED,DEPT PATHOL & TUMOR BIOL,SAKYO KU,KYOTO 606,JAPAN; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT ONCOL,KUMAMOTO 860,JAPAN	Kyoto University; Kobe University; Kumamoto University			Saya, Hideyuki/J-4325-2013					BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; CAJOT JF, 1992, CANCER RES, V52, P6956; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN YM, 1991, ONCOGENE, V6, P1799; CHENG JH, 1995, J IMMUNOL, V154, P1239; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; FRITSCHE M, 1993, ONCOGENE, V8, P307; HABUCHI T, 1993, CANCER RES, V53, P3795; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HARPER JW, 1993, CELL, V75, P805; HOLSTEIN M, 1991, SCIENCE, V253, P49; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KYO E, 1993, INT J ONCOL, V3, P265; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MATOZAKI T, 1992, CANCER RES, V52, P4335; MATOZAKI T, 1992, BIOCHEM BIOPH RES CO, V182, P215, DOI 10.1016/S0006-291X(05)80133-0; MERRITT AJ, 1994, CANCER RES, V54, P614; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; RADINSKY R, 1994, ONCOGENE, V9, P1877; RAITANO AB, 1990, J BIOL CHEM, V265, P10466; RIDGWAY PJ, 1993, ONCOGENE, V8, P1069; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STEIN J, 1993, J GEN VIROL, V74, P2333, DOI 10.1099/0022-1317-74-11-2333; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1992, CANCER RES, V52, P2340; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VIKHANSKAYA F, 1994, NUCLEIC ACIDS RES, V22, P1012, DOI 10.1093/nar/22.6.1012; WONG GHW, 1994, J IMMUNOL, V152, P1951; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	44	93	93	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					1939	1946						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478511				2022-12-28	WOS:A1995TF29700002
J	SAITO, Y; OGAWA, K				SAITO, Y; OGAWA, K			WILD-TYPE P53 AND C-MYC COOPERATION IN GENERATING APOPTOSIS OF A RAT HEPATOCELLULAR-CARCINOMA CELL-LINE (FAA-HTC1)	ONCOGENE			English	Article						P53; C-MYC; APOPTOSIS; CELL GROWTH	MYELOID LEUKEMIC-CELLS; CANCER-CHEMOTHERAPY; MESSENGER-RNA; CYCLE; DEATH; INDUCTION; BCL-2; MUTATIONS; RADIATION; PROTEIN	p53 and c-myc are both known to be involved in apoptotic cell death as well as positive or negative regulation of cell proliferation, but it is not well established whether their functions are mechanistically correlated. We found that FAA-HTC1 cells, a rat hepatocellular carcinoma cell line, expressed c-myc independently of cell cycle and no detectable p53. To investigate possible co-operation between p53 and c-myc, the dexamethasone (Dex)-inducible wild type rat p53 was stably transfected into this cell line and c-myc expression was suppressed by treatment with c-myc antisense oligonucleotide (AS). p53 expression in the p53-introduced derivative resulted in apoptotic cell death, but it did not inhibit proliferative growth of the viable cells. On the other hand, when c-myc was suppressed in the p53-expressing cells, both apoptosis and cell growth were inhibited. These results indicate that p53 can act in the same cells either as a growth-inhibitor or apoptosis-inducer depending on the status of c-myc expression.	ASAHIKAWA MED COLL,DEPT PATHOL,ASAHIKAWA 078,HOKKAIDO,JAPAN	Asahikawa Medical College								ASKEW DS, 1991, ONCOGENE, V6, P1915; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLOMBEL M, 1992, CANCER RES, V52, P4313; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FUJIWARA T, 1994, CANCER RES, V54, P2287; FUKUDA I, 1992, CELL STRUCT FUNCT, V17, P427, DOI 10.1247/csf.17.427; FURUKAWA K, 1987, Tumor Research, V22, P71; HALDAR S, 1994, CANCER RES, V54, P2095; HARPER JW, 1993, CELL, V75, P805; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KADOHAMA T, 1994, ONCOGENE, V9, P2845; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERRITT AJ, 1994, CANCER RES, V54, P614; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; RADINSKY R, 1994, ONCOGENE, V9, P1877; RAMQVIST T, 1993, ONCOGENE, V8, P1495; ROBINSON WS, 1994, ANNU REV MED, V45, P297; ROBINSON WS, 1994, ANNU REV MED, V13, P711; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SAETER G, 1990, Critical Reviews in Oncogenesis, V1, P437; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SOURCCI T, 1988, NUCLEIC ACIDS RES, V16, P11384; STRANGE R, 1992, DEVELOPMENT, V115, P49; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TSUJI K, 1994, MOL CARCINOGEN, V9, P167, DOI 10.1002/mc.2940090308; WANG YS, 1993, ONCOGENE, V8, P3427; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	53	25	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1013	1018						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566958				2022-12-28	WOS:A1995RX18000001
J	SASTRY, L; LIN, WH; WONG, WT; DIFIORE, PP; SCOPPA, CA; KING, CR				SASTRY, L; LIN, WH; WONG, WT; DIFIORE, PP; SCOPPA, CA; KING, CR			QUANTITATIVE-ANALYSIS OF GRB2-SOS1 INTERACTION - THE N-TERMINAL SH3 DOMAIN OF GRB2 MEDIATES AFFINITY	ONCOGENE			English	Article						GRB2; SOS1; BIACORE; SPR; KINETICS	RECEPTOR TYROSINE KINASES; BIOSPECIFIC INTERACTION ANALYSIS; NUCLEOTIDE EXCHANGE FACTOR; SURFACE-PLASMON RESONANCE; PHOSPHORYLATED PEPTIDES; SIGNAL TRANSDUCTION; RAS; PROTEIN; BINDS; ASSOCIATION	Grb2 is an adaptor protein that links receptor and cytoplasmic tyrosine kinases to the Ras signalling pathway by binding the Ras-specific guanine nucleotide exchange factor, Sos1, through its SH3 domains, The Grb2-SH3 domain binding has been localized to the carboxy-terminal two hundred amino acids of Sos1 (Sos1-c). By using real time biospecific interaction analysis (BIAcore), we studied the kinetic parameters and binding affinity of the Grb2-Sos1-c interaction, The binding of Grb2 to Sos1-c is a high affinity interaction with a moderate association rate (9.45 x 10(4) per M per s), a slow dissociation rate (13.8 x 10(-5) s), and an affinity constant of 1.48 nM. BIAcore measurements on isolated N-terminal and C-terminal SH3 domains (NSH3 and CSH3) further indicate that the high affinity Grb2-Sos1-c interaction is primarily mediated through the NSH3 domain (K-d=1.68 nM). The CSH3 domain shows substantially reduced binding to Sos1-c in these measurements, Inhibition studies with BIAcore using proline rich peptides derived from the C-terminus of Sos1 show that there is a single major binding site for Grb2 in Sos1, This binding site is contained within the peptide N20, which corresponds to amino acids 1143-1162 of Sos1, This peptide completely blocks the Grb2-Sos1-c and NSH3-Sos1-c interactions with IC50 values of 8 mu M and 4 mu M respectively, The discrete interaction between the NSH3 domain and the N20 peptide may be amenable for drug discovery through screening or peptidomimetic approaches.	ONCOL INC, GAITHERSBURG, MD 20878 USA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; GEORGETOWN UNIV, MED CTR, LOMBARDI CANC CTR, WASHINGTON, DC 20007 USA; FAC MED & CHIRURG, IST MICROBIOL, BARI, ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950				BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAGERSTAM L, 1991, TECHNIQUES PROTEIN C, V2, P65; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GRANZOW R, 1902, BIOTECHNOLOGY, V10, P390; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MIKI H, 1994, J BIOL CHEM, V269, P5489; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; REIF K, 1994, J BIOL CHEM, V269, P14081; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; 1991, BIACORE SYSTEM MANUA	31	52	56	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	1995	11	6					1107	1112						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566970				2022-12-28	WOS:A1995RX18000013
J	SENFTEN, M; SCHENKER, G; SOWADSKI, JM; BALLMERHOFER, K				SENFTEN, M; SCHENKER, G; SOWADSKI, JM; BALLMERHOFER, K			CATALYTIC ACTIVITY AND TRANSFORMATION POTENTIAL OF V-SRC REQUIRE ARGININE-385 IN THE SUBSTRATE-BINDING POCKET	ONCOGENE			English	Note						SRC; TYROSINE KINASE; ONCOGENE; CATALYSIS; PHOSPHORYLATION; RSV	ROUS-SARCOMA VIRUS; DEPENDENT PROTEIN-KINASE; MIDDLE-T-ANTIGEN; TYROSINE PHOSPHORYLATION; CELL-TRANSFORMATION; MONOCLONAL-ANTIBODIES; PEPTIDE INHIBITOR; CRYSTAL-STRUCTURE; PP60C-SRC KINASE; TUMOR-ANTIGEN	Tyrosine kinases are important mediators of signal transduction in eukaryotic cells. In order to better understand the mechanism of catalysis we studied a set of mutants of the prototype tyrosine kinase, the c-Src protein, a homologue of the Rous Sarcoma virus oncogene. Based on an X-ray structure of cAMP-dependent protein kinase (cAPK) we mutated an arginine residue conserved in subdomain VI of all known kinases to a non-charged residue. This residue coordinates phosphate of the autophosphorylation site located in subdomain VII of cAPK and this interaction has been proposed to be crucial for substrate binding. The mutant R385A of c-Src had low kinase activity towards exogenous substrates yet was able to autophosphorylate at tyrosine 416. When introduced into an activated v-src gene the R385A, mutation totally blocked cell transformation. Our data suggest that the function of the conserved arginine 385 is to coordinate the phosphate of the autophosphorylation site and to provide in this way a stable template for substrate binding.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	Friedrich Miescher Institute for Biomedical Research; University of California System; University of California San Diego				Ballmer-Hofer, Kurt/0000-0002-3800-9129				BALLMERHOFER K, 1987, VIRUS RES, V6, P345, DOI 10.1016/0168-1702(87)90066-9; BENZEEV A, 1984, BIOCHIM BIOPHYS ACTA, V780, P197, DOI 10.1016/0304-419X(85)90003-4; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CZERNILOFSKY AP, 1980, NATURE, V287, P198, DOI 10.1038/287198a0; ERIKSON RL, 1984, ADV CYCLIC NUCL PROT, V17, P457; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FUJITA DJ, 1981, VIROLOGY, V111, P223, DOI 10.1016/0042-6822(81)90667-X; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOLME TC, 1986, BRIT J CANCER, V53, P465, DOI 10.1038/bjc.1986.74; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KARESS RE, 1981, CELL, V24, P155, DOI 10.1016/0092-8674(81)90511-0; KARLSSON R, 1993, ACTA CRYSTALLOGR D, V49, P381, DOI 10.1107/S0907444993002306; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; KELLIE S, 1987, BIOCHEM SOC T, V15, P791, DOI 10.1042/bst0150791; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1993, ACTA CRYSTALLOGR D, V49, P357, DOI 10.1107/S0907444993000502; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MANESS PF, 1983, MOL CELL BIOL, V3, P102, DOI 10.1128/MCB.3.1.102; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MUSER J, 1989, ONCOGENE, V4, P1433; NIGG EA, 1986, VIROLOGY, V151, P50, DOI 10.1016/0042-6822(86)90103-0; OKADA M, 1991, J BIOL CHEM, V266, P24249; OPPERMANN H, 1979, P NATL ACAD SCI USA, V76, P1804, DOI 10.1073/pnas.76.4.1804; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEREZ L, 1993, P NATL ACAD SCI USA, V90, P8113, DOI 10.1073/pnas.90.17.8113; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423	48	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					199	203						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7529917				2022-12-28	WOS:A1995QA98000023
J	MARTINERIE, C; HUFF, V; JOUBERT, I; BADZIOCH, M; SAUNDERS, G; STRONG, L; PERBAL, B				MARTINERIE, C; HUFF, V; JOUBERT, I; BADZIOCH, M; SAUNDERS, G; STRONG, L; PERBAL, B			STRUCTURAL-ANALYSIS OF THE HUMAN NOV PROTOONCOGENE AND EXPRESSION IN WILMS-TUMORS	ONCOGENE			English	Note							FACTOR-II GENE; PLASMODIUM-FALCIPARUM; WT1	We have cloned and sequenced the nov gene (novH) which is the homolog of the chicken nov proto-oncogene overexpressed in avian nephroblastomas. The novH gene is highly conserved and encodes a putative IGF-binding protein similar to that of chicken. We report that relative to autologous normal kidney expression of novH is elevated in Wilms tumors containing predominantly stromal elements and is inversely correlated in these tumors to the expression of WT1. Our results suggest that the regulation of IGFII expression by WT1 and increase of novH in Wilms tumors might be interrelated and represent a key element in tumor development in human.	INST CURIE,ONCOL VIRALE & MOLEC LAB,F-91405 ORSAY,FRANCE; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL PEDIAT,HOUSTON,TX; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030; UNIV PARIS 07,UFR BIOCHIM,DENIS DIDEROT,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; UDICE-French Research Universities; Universite Paris Cite								ALEY SB, 1986, J EXP MED, V164, P1915, DOI 10.1084/jem.164.6.1915; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BECKWITH JB, 1986, J UROLOGY, V136, P320, DOI 10.1016/S0022-5347(17)44854-3; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GANSLER T, 1989, AM J PATHOL, V135, P961; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GONZALEZCRUSSI F, 1984, WILMS TUMOR NEPHROBL, P207; HEINE U, 1962, JNCI-J NATL CANCER I, V29, P41; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HUFF V, 1990, HUM GENET, V84, P253; ISHIGURO H, 1962, J NATL CANCER I, V29, P1; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; MARTINERIE C, 1992, ONCOGENE, V7, P2529; MATSUNAGA E, 1981, HUM GENET, V57, P231; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; PRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; SORET J, 1989, J VIROL, V63, P1803, DOI 10.1128/JVI.63.4.1803-1807.1989; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828	28	65	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2729	2732						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	7520150				2022-12-28	WOS:A1994PC05400035
J	OHNO, S; MIGITA, S; MURAKAMI, S				OHNO, S; MIGITA, S; MURAKAMI, S			C-MYC-S-MU REARRANGEMENT IN A MURINE PLASMACYTOMA WITHOUT VISIBLE CHROMOSOMAL TRANSLOCATIONS	ONCOGENE			English	Note									KANAZAWA UNIV,CANC RES INST,DIV BIOPHYS,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University	OHNO, S (corresponding author), KANAZAWA UNIV,CANC RES INST,DEPT MOLEC IMMUNOL,13-1 TAKARA MACHI,KANAZAWA,ISHIKAWA 920,JAPAN.							CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DREAZEN O, 1987, LANCET, V1, P1402; FAHRLANDER PD, 1985, P NATL ACAD SCI USA, V82, P3746, DOI 10.1073/pnas.82.11.3746; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; MERWIN RM, 1963, J NAT CANC, V31, P998; MORRIS CM, 1986, NATURE, V320, P281, DOI 10.1038/320281a0; NESBITT MN, 1973, CHROMOSOMA, V41, P145, DOI 10.1007/BF00319691; OHNO S, 1988, INT J CANCER, V41, P595, DOI 10.1002/ijc.2910410420; OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762; OHNO S, 1979, CELL, V18, P1001, DOI 10.1016/0092-8674(79)90212-5; ROSENBERG SM, 1985, GENE, V39, P313, DOI 10.1016/0378-1119(85)90330-0; SAKANO H, 1980, NATURE, V286, P676, DOI 10.1038/286676a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STANTON LW, 1984, P NATL ACAD SCI-BIOL, V81, P829, DOI 10.1073/pnas.81.3.829; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; WANG HC, 1972, NATURE-NEW BIOL, V235, P52, DOI 10.1038/newbio235052a0; ZABAROVSKY ER, 1986, GENE, V42, P119, DOI 10.1016/0378-1119(86)90158-7; 1972, J HERED, V63, P69	20	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1513	1517						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687771				2022-12-28	WOS:A1989CB65900015
J	ARENZANASEISDEDOS, F; ISRAEL, N; BACHELERIE, F; HAZAN, U; ALCAMI, J; DAUTRY, F; VIRELIZIER, JL				ARENZANASEISDEDOS, F; ISRAEL, N; BACHELERIE, F; HAZAN, U; ALCAMI, J; DAUTRY, F; VIRELIZIER, JL			C-HA-RAS TRANSFECTION INDUCES HUMAN IMMUNODEFICIENCY VIRUS (HIV) TRANSCRIPTION THROUGH THE HIV-ENHANCER IN HUMAN-FIBROBLASTS AND ASTROCYTES	ONCOGENE			English	Article									INST PASTEUR,IMMUNOL VIRALE LAB,F-75724 PARIS 15,FRANCE; INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,F-94805 VILLEJUIF,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UNICANCER; Gustave Roussy			BACHELERIE, FRANCOISE/F-8823-2013; Arenzana-Seisdedos, Fernando/E-5835-2016; Alcami, Pepe/T-2242-2018	BACHELERIE, FRANCOISE/0000-0002-0399-3277; Alcami, Pepe/0000-0003-0023-7377				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHANG EH, 1982, P NATL ACAD SCI-BIOL, V79, P4848, DOI 10.1073/pnas.79.16.4848; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; HARADA S, 1986, VIROLOGY, V154, P249, DOI 10.1016/0042-6822(86)90451-4; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; LANGLADEDEMOYEN P, 1988, J IMMUNOL, V141, P1949; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MORRIS JDH, 1989, ONCOGENE, V4, P27; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	29	18	18	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1359	1362						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2682462				2022-12-28	WOS:A1989AX65900013
J	ERISMAN, MD; SCOTT, JK; WATT, RA; ASTRIN, SM				ERISMAN, MD; SCOTT, JK; WATT, RA; ASTRIN, SM			THE C-MYC PROTEIN IS CONSTITUTIVELY EXPRESSED AT ELEVATED LEVELS IN COLORECTAL-CARCINOMA CELL-LINES	ONCOGENE			English	Article									SK&F LABS, SWEDELAND, PA 19479 USA		ERISMAN, MD (corresponding author), FOX CHASE CANC CTR, INST CANC RES, PHILADELPHIA, PA 19111 USA.				NATIONAL CANCER INSTITUTE [P30CA006927, R01CA040636] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927, CA-40636] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BEIMLING P, 1985, BIOCHEMISTRY-US, V24, P6349, DOI 10.1021/bi00344a005; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; BRAVO R, 1985, EXP CELL RES, V160, P540, DOI 10.1016/0014-4827(85)90200-9; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CALABRETTA B, 1985, CANCER RES, V45, P6000; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CERNI C, 1987, EXP CELL RES, V168, P439, DOI 10.1016/0014-4827(87)90016-4; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DENHARDT DT, 1986, BIOCHIM BIOPHYS ACTA, V865, P83, DOI 10.1016/0304-419X(86)90024-7; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DREWINKO B, 1984, CANCER RES, V44, P4241; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; ERISMAN MD, 1988, IN PRESS ONCOGENE HD; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GUILLEM JG, 1987, CANCER RES, V47, P2036; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MAKOWSKI DR, 1985, PHARMACOL THERAPEUT, V27, P63, DOI 10.1016/0163-7258(85)90065-8; MOORE JP, 1987, ONCOGENE RES, V2, P65; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; ROTHBERG PG, 1984, MOL CELL BIOL, V4, P1096, DOI 10.1128/MCB.4.6.1096; ROTHBERG PG, 1985, BRIT J CANCER, V52, P629, DOI 10.1038/bjc.1985.237; SCHWAB M, 1986, MOL CELL BIOL, V6, P2752, DOI 10.1128/MCB.6.7.2752; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHUIN T, 1986, CANCER RES, V46, P5302; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPECTOR DL, 1987, ONCOGENE, V1, P5; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; STEWART J, 1986, BRIT J CANCER, V53, P1, DOI 10.1038/bjc.1986.1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; VOGT M, 1986, MOL CELL BIOL, V6, P3545, DOI 10.1128/MCB.6.10.3545; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	64	65	66	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1988	2	4					367	378						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3283655				2022-12-28	WOS:A1988M947200009
J	SCHULTZ, AM; COPELAND, T; OROSZLAN, S; RAPP, UR				SCHULTZ, AM; COPELAND, T; OROSZLAN, S; RAPP, UR			IDENTIFICATION AND CHARACTERIZATION OF C-RAF PHOSPHOPROTEINS IN TRANSFORMED MURINE CELLS	ONCOGENE			English	Article									NCI,FREDERICK CANC RES FACIL,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SCHULTZ, AM (corresponding author), NCI,FREDERICK CANC RES FACIL,MOLEC VIROL & CARCINOGENESIS LAB,BRI BASIC RES PROGRAM,FREDERICK,MD 21701, USA.				NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FLORDELLIS CS, 1985, VIROLOGY, V141, P267, DOI 10.1016/0042-6822(85)90257-0; FUKUI M, 1985, P NATL ACAD SCI USA, V82, P5954, DOI 10.1073/pnas.82.17.5954; GRAZIANO SL, 1987, CANCER RES, V47, P2148; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; INOUE M, 1977, J BIOL CHEM, V252, P7610; ISHIKAWA F, 1986, JPN J CANCER RES, V77, P1183; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; KESKIOJA J, 1982, J CELL BIOCHEM, V20, P139, DOI 10.1002/jcb.240200206; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOLCH W, IN PRESS BIOCH BIOPH; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOLDERS H, 1985, EMBO J, V4, P693, DOI 10.1002/j.1460-2075.1985.tb03685.x; MUELLER R, 1984, EMBO (European Molecular Biology Organization) Journal, V3, P1121; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PATCHINSKY T, 1986, MOL CELL BIOL, V6, P739; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; PERINI F, 1979, ANAL BIOCHEM, V94, P431, DOI 10.1016/0003-2697(79)90386-5; RAPP UR, 1975, VIROLOGY, V65, P392, DOI 10.1016/0042-6822(75)90045-8; RAPP UR, 1985, RECENT RES CANCER, V99, P221; RAPP UR, 1980, P NATL ACAD SCI-BIOL, V77, P624, DOI 10.1073/pnas.77.1.624; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1983, J VIROL, V45, P914, DOI 10.1128/JVI.45.3.914-924.1983; RAPP UR, 1983, J VIROL, V45, P755, DOI 10.1128/JVI.45.2.755-765.1983; SARIBAN E, 1987, BLOOD, V69, P1437; SCHULTZ A, 1984, VIROLOGY, V133, P431, DOI 10.1016/0042-6822(84)90409-4; SCHULTZ AM, 1983, J VIROL, V46, P355, DOI 10.1128/JVI.46.2.355-361.1983; SCHULTZ AM, 1984, VIROLOGY, V135, P417, DOI 10.1016/0042-6822(84)90197-1; SCHULTZ AM, 1979, J VIROL, V30, P255, DOI 10.1128/JVI.30.1.255-266.1979; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; TAHIRA T, 1987, NUCLEIC ACIDS RES, V15, P4809, DOI 10.1093/nar/15.12.4809; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TEYSSIER JR, 1986, J NATL CANCER I, V77, P1187; YANG JC, 1982, ANAL BIOCHEM, V122, P360, DOI 10.1016/0003-2697(82)90295-0; YOSHIDA MA, 1986, CANCER RES, V46, P2139	47	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					187	193						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	3285297				2022-12-28	WOS:A1988M086000013
J	UZAWA, N; YOSHIDA, MA; OSHIMURA, M; IKEUCHI, T				UZAWA, N; YOSHIDA, MA; OSHIMURA, M; IKEUCHI, T			SUPPRESSION OF TUMORIGENICITY IN 3 DIFFERENT CELL-LINES OF HUMAN ORAL SQUAMOUS-CELL CARCINOMA BY INTRODUCTION OF CHROMOSOME 3P VIA MICROCELL-MEDIATED CHROMOSOME TRANSFER	ONCOGENE			English	Article						CHROMOSOME 3; SQUAMOUS CELL CARCINOMA; MICROCELL FUSION; ORAL CANCER; TUMOR SUPPRESSOR GENE	SHORT ARM; LUNG-CANCER; RAS ONCOGENE; ALLELIC LOSS; HEAD; HETEROZYGOSITY; FREQUENCY; DELETION; REGIONS; TUMORS	It has been suggested that loss of the short arm of chromosome 3 is one of the most frequent abnormalities in human head and neck cancers including oral squamous cell carcinomas (SCC) and that one or more putative tumor suppressor gene(s) which may contribute to the initiation and/or progression of these tumors might be located on chromosome 3p. In this study, we examined the effects of introducing human chromosome 3 or 7 by microcell hybridization on the tumor-associated phenotypes of three different human oral SCC cell lines, HSC-2, HSC-3 and HSC-4. Transfer of a single chromosome 3p completely suppressed the tumorigenicity of all three parental cell lines, which showed a significant decrease in growth rate in vitro and morphological changes. In contrast, transfer of chromosome 7 had no effect on HSC-2 and HSC-4 cells, although it suppressed the tumorigenicity of HSC-3 cells without modifying their in vitro growth properties. Our findings provide additional confirmatory evidence that loss or inactivation of putative tumor suppressor gene(s) present on chromosome 3p might be primarily involved in the development of human oral SCC. The possibility that chromosome 7 may carry another tumor suppressor gene(s) is also discussed.	TOKYO MED & DENT UNIV,FAC DENT,DEPT ORAL & MAXILLOFACIAL SURG 1,BUNKYO KU,TOKYO 113,JAPAN; TOTTORI UNIV,FAC MED,SCH LIFE SCI,DEPT MOLEC & CELL GENET,YONAGO,TOTTORI 683,JAPAN	Tokyo Medical & Dental University (TMDU); Tottori University	UZAWA, N (corresponding author), TOKYO MED & DENT UNIV,MED RES INST,DEPT CYTOGENET,BUNKYO KU,1-5-45 YUSHIMA,TOKYO 113,JAPAN.							BERENSON JR, 1989, ONCOGENE, V4, P111; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; CHANG SE, 1991, INT J CANCER, V48, P409, DOI 10.1002/ijc.2910480318; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DRABKIN H, 1988, P NATL ACAD SCI USA, V85, P9258, DOI 10.1073/pnas.85.23.9258; EHLEN T, 1990, ONCOGENE, V5, P219; ELNAGGAR AK, 1993, CANCER, V72, P881, DOI 10.1002/1097-0142(19930801)72:3<881::AID-CNCR2820720337>3.0.CO;2-Q; FIELD JK, 1989, ONCOGENE, V4, P1463; FIELD JK, 1987, J ORAL PATHOL MED, V16, P97, DOI 10.1111/j.1600-0714.1987.tb01474.x; HANSEN MF, 1987, CANCER RES, V47, P5518; HARRIS H, 1988, CANCER RES, V48, P3302; HEO DS, 1989, CANCER RES, V49, P5167; HIBI K, 1992, ONCOGENE, V7, P445; JIN YS, 1993, ORAL ONCOL, V29B, P257, DOI 10.1016/0964-1955(93)90045-G; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; LARGEY JS, 1994, ORAL SURG ORAL MED O, V77, P260, DOI 10.1016/0030-4220(94)90295-X; LATIF F, 1992, CANCER RES, V52, P1451; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MAESTRO R, 1993, CANCER RES, V53, P5775; MOMOSE F, 1989, J ORAL PATHOL MED, V18, P391, DOI 10.1111/j.1600-0714.1989.tb01570.x; MORITA R, 1991, CANCER RES, V51, P820; NAWROZ H, 1994, CANCER RES, V54, P1152; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; ONO T, 1993, JPN J GENET, V68, P617, DOI 10.1266/jjg.68.617; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RUMSBY G, 1990, BRIT J CANCER, V61, P365, DOI 10.1038/bjc.1990.80; SAKAI E, 1992, INT J CANCER, V52, P867, DOI 10.1002/ijc.2910520606; SANDBERG AA, 1988, CANCER RES, V48, P1049; SARANATH D, 1991, BRIT J CANCER, V63, P573, DOI 10.1038/bjc.1991.133; SATO T, 1991, CANCER RES, V51, P5794; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; SAXON PJ, 1986, EMBO J, V15, P3461; SHIMIZU M, 1990, ONCOGENE, V5, P185; SOMERS KD, 1990, ONCOGENE, V5, P915; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; TAKAHASHI E, 1992, GENOMICS, V13, P1047, DOI 10.1016/0888-7543(92)90018-N; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; UZAWA K, 1994, INT J CANCER, V58, P814, DOI 10.1002/ijc.2910580611; WU CL, 1994, CANCER RES, V54, P6484; YAMADA H, 1990, ONCOGENE, V5, P1141; YAMAMOTO T, 1986, CANCER RES, V46, P414; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, CANCER RES, V49, P3598; YOSHIDA MA, 1986, CANCER RES, V46, P2139; YOSHIDA MA, 1994, MOL CARCINOGEN, V9, P114, DOI 10.1002/mc.2940090303; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	55	32	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					1997	2004						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478518				2022-12-28	WOS:A1995TF29700009
J	DEJARDIN, E; BONIZZI, G; BELLAHCENE, A; CASTRONOVO, V; MERVILLE, MP; BOURS, V				DEJARDIN, E; BONIZZI, G; BELLAHCENE, A; CASTRONOVO, V; MERVILLE, MP; BOURS, V			HIGHLY-EXPRESSED P100/P52 (NFKB2) SEQUESTERS OTHER NF-KAPPA-B-RELATED PROTEINS IN THE CYTOPLASM OF HUMAN BREAST-CANCER CELLS	ONCOGENE			English	Article						TRANSCRIPTION FACTORS; NF-KAPPA-B; NFKB2; BREAST CANCER	DNA-BINDING SUBUNIT; V-REL ONCOGENE; TRANSCRIPTION FACTORS; P65 SUBUNIT; C-REL; ANTISENSE INHIBITION; ONCOPROTEIN BCL-3; GENE-EXPRESSION; P50; PRECURSOR	Several observations have suggested that NF-kappa B transcription factors could be involved in carcinogenesis. To investigate the possibility that members of the NF-kappa B family participate in the molecular control of the transformed phenotype, we examined the expression of these proteins in human breast cancer cell lines as web as in primary tumors. Western Immunoblots demonstrated high expression of the p52 precursor p100 (NFKB2) in several breast cancer cell lines while human mammary epithelial cells express this protein only faintly. Eighteen primary breast tumors out of 24 displayed significant expression of the p100/p52 protein. In MDA-MB-435 cells, overexpressed p100 and p52 are predominantly cytoplasmic and coimmunoprecipitation experiments demonstrated that p100 sequesters the heterodimer p50/p65 in the cytoplasm. We demonstrate that most p65 protein is complexed with p100 in these cells while it is complexed predominantly with I kappa B-alpha in cell lines expressing less p100. Our data strengthen the hypothesis that NF-kappa B could be involved in carcinogenesis and suggest that the p100/p52 NF-kappa B submit could play a role in the development of human breast cancers, possibly by sequestering other NF-kappa B-related proteins in the cytoplasm.	UNIV LIEGE,DEPT MED ONCOL,B-4000 LIEGE,BELGIUM; UNIV LIEGE,DEPT MED CHEM,B-4000 LIEGE,BELGIUM; UNIV LIEGE,METASTASIS RES LAB,B-4000 LIEGE,BELGIUM	University of Liege; University of Liege; University of Liege			Dejardin, Emmanuel/AAE-9076-2021					ABMAYR SM, 1990, CURRENT PROTOCOLS MO; ANISOWICZ A, 1991, J IMMUNOL, V147, P250; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; DODRZANSKI P, 1993, MOL CELL BIOL, V13, P1572; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FRIGERI LG, 1992, J IMMUNOL, V148, P861; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; LIPTAY S, 1992, GENOMICS, V13, P287, DOI 10.1016/0888-7543(92)90244-M; LU D, 1991, ONCOGENE, V6, P1235; MATHEW S, 1993, ONCOGENE, V8, P191; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MOORE BE, 1988, MUTAT RES, V195, P79, DOI 10.1016/0165-1110(88)90016-4; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PEPIN N, 1994, VIROLOGY, V204, P706, DOI 10.1006/viro.1994.1586; PLASKIN D, 1993, J EXP MED, V177, P1651; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SATO H, 1993, ONCOGENE, V8, P395; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SOULE HD, 1986, IN VITRO CELL DEV B, V22, P6, DOI 10.1007/BF02623435; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; WU HY, 1994, J BIOL CHEM, V269, P20067; ZHANG JD, 1994, ONCOGENE, V9, P1931	54	124	127	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1835	1841						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478612				2022-12-28	WOS:A1995TD09400019
J	JOHNSON, DG				JOHNSON, DG			REGULATION OF E2F-1 GENE-EXPRESSION BY P130 (RB2) AND D-TYPE CYCLIN KINASE-ACTIVITY	ONCOGENE			English	Article						E2F; D-TYPE CYCLIN; P130 (RB2); TRANSCRIPTIONAL REPRESSION	TRANSCRIPTION FACTOR; RETINOBLASTOMA PROTEIN; GROWTH SUPPRESSION; BINDING PROTEIN; CELLULAR GENES; PRODUCT; CLONING; IDENTIFICATION; PROMOTER; FAMILY	Previous experiments have demonstrated that the regulation of E2F-1 transcription factor activity is critical for the maintenance of normal cell proliferation control. Regulation of E2F-1 is accomplished through at least two mechanisms: posttranslational regulation by binding proteins such as Rb and transcriptional regulation of the E2F-1 gene. The E2F-1 gene promoter has recently been isolated to examine this latter aspect of E2F-1 regulation. Preliminary studies demonstrate that the E2F-1 promoter is under E2F-dependent negative control during the cell growth response, being transcriptionally repressed through E2F sites in GO and early G1. We now demonstrate that the presence of an E2F DNA-binding complex containing the Rb-related p13O protein (Rb2) correlates with E2F-1 gene repression and that overexpression of p13O inhibits transcription from the E2F-1 promoter. Moreover, D-type cyclin-dependent kinase activity specifically activates the E2F-1 promoter by relieving E2F-mediated repression but is inhibited by coexpression of the cdk4 and cdk6 inhibitor p16 (CDKN2, MTS1, INK4). Taken together, these findings suggest that E2F-1 gene expression is controlled during cell cycle progression by a regulatory network involving at least one oncogene (cyclin D1) and several potential tumor suppressor genes.			JOHNSON, DG (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CARCINOGENESIS,DIV SCI PK RES,SMITHVILLE,TX 78957, USA.			Johnson, David/0000-0002-6223-1790				ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COLBRINIK D, 1993, GENE DEV, V7, P2392; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DAGNINO L, 1995, CELL GROWTH DIFFER, V6, P191; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GIAN KL, 1994, GENE DEV, V8, P2939; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1993, CELL, V70, P993; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAYOL X, 1993, ONCOGENE, V8, P2561; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MELILLO RM, 1994, MOL CELL BIOL, V14, P8241, DOI 10.1128/MCB.14.12.8241; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1992, SCIENCE, V258, P424; OHTANIFUJITA N, 1994, ONCOGENE, V6, P1703; OSWALD F, 1994, ONCOGENE, V9, P2029; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHULZE A, 1994, ONCOGENE, V9, P3475; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAO A, 1995, ONCOGENE, V10, P221; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITH EJ, 1995, MOL CELL BIOL, V15, P338, DOI 10.1128/MCB.15.1.338; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; YEUNG RS, 1993, ONCOGENE, V8, P3465	64	83	84	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1685	1692						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478595				2022-12-28	WOS:A1995TD09400002
J	DEJONG, R; HAATAJA, L; VONCKEN, JW; HEISTERKAMP, N; GROFFEN, J				DEJONG, R; HAATAJA, L; VONCKEN, JW; HEISTERKAMP, N; GROFFEN, J			TYROSINE PHOSPHORYLATION OF MURINE CRKL	ONCOGENE			English	Article						SH2-SH3 ADAPTER PROTEIN; BCR/ABL; LEUKEMIA	BCR/ABL TRANSGENIC MICE; P210 BCR-ABL; SH3 DOMAINS; P160 BCR; PROTEINS; GENE; TRANSFORMATION; LEUKEMIA; BINDING; CELLS	The SH2/SH3 adaptor protein Crkl is abnormally phosphorylated on tyrosine by the Bcr/Abl protein in leukemic cells from patients with Philadelphia-chromosome (Ph)positive leukemia. However, the state of tyrosine-phosphorylation of crkl in normal tissues is unknown. In the current study, we identified mouse crkl by cDNA cloning and examined expression levels and tyrosine-phosphorylation of the mouse crkl protein during embryogenesis and in adult tissues. Tyrosine-phosphorylation of crkl was prominent during early development, but decreased at later embryonic stages and in newborn mice. Expression of both crkl and the related crk was ubiquitous in the adult. However, crkl differed considerably from crk in relative tissue distribution, and was more abundant in hematopoietic tissues. With exception of the lung, crkl was mostly present in a non-tyrosine phosphorylated form. Consistent with our previous findings in human patients, murine crkl was phosphorylated on tyrosine in leukemic tissues of BCR/ABL transgenic animals, but was non-tyrosine phosphorylated in normal mouse bone marrow. We conclude that this crkl tyrosine-phosphorylation by Bcr/Abl in hematopoietic cells is clearly aberrant and is consistently linked to the development of leukemia. Identification of proteins interacting with tyrosine-phosphorylated crkl in the leukemic cells of BCR/ABL transgenic mice should reveal members of signal transduction pathways activated in Ph-positive leukemia.	CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,MOLEC DIAGNOST SECT,LOS ANGELES,CA 90027	Children's Hospital Los Angeles			Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NCI NIH HHS [CA 50248, CA 47456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047456, R01CA050248, R55CA047456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; CAMPBELL ML, 1990, ONCOGENE, V5, P773; DRUKER B, 1992, BLOOD, V79, P2215; ERNST TJ, 1994, J BIOL CHEM, V269, P5764; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1993, CAUSES CONSEQUENCES, P359; Heisterkamp Nora, 1991, Transgenic Research, V1, P45, DOI 10.1007/BF02512996; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LU D, 1993, BLOOD, V82, P1257; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUGUCHI T, 1994, J BIOL CHEM, V7, P5016; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MURRAY JF, 1986, NORMAL LUNG; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TENHOEVE J, 1993, GENOMICS, V18, P588, DOI 10.1016/S0888-7543(05)80360-X; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VANETTEN RA, 1993, LEUKEMIA ADV RES TRE; VONCKEN, IN PRESS; VONCKEN JW, 1992, BLOOD, V79, P1029; VONCKEN JW, 1992, CANCER RES, V52, P4534; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F	37	34	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1469	1474						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478571				2022-12-28	WOS:A1995TC53500005
J	MILLER, ME; ENGEL, DA; SMITH, MM				MILLER, ME; ENGEL, DA; SMITH, MM			CYCLIC-AMP SIGNALING IS REQUIRED FOR FUNCTION OF THE N-TERMINAL AND CR-1 DOMAINS OF ADENOVIRUS E1A IN SACCHAROMYCES-CEREVISIAE	ONCOGENE			English	Article						GENE REGULATION; TRANSCRIPTION; YEAST; GENETICS	EARLY REGION-1A POLYPEPTIDES; RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; DNA-BINDING ACTIVITY; FOS MESSENGER-RNA; ADENYLATE-CYCLASE; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; CDC28 MUTATION; 1A PROTEINS	We have constructed yeast vectors in which derivatives of the adenovirus E1A gene are expressed from the GAL1 promoter. Cells expressing E1A(289) grow poorly and accumulate cells with a 1C DNA content. Using a series of E1A deletion mutants, we have identified three regions within the E1A protein that are necessary for the G(1) growth phenotype; each deletion partially relieves the growth defect. These deletions span residues 4-25, 38-60 and 140-186, which fall within the N-terminal, CR1 and CR3 domains of E1A respectively. Expression of the first 82 residues of E1A, spanning just the N-terminal and CR1 domains, strongly inhibits yeast cell growth in G(1) showing that these domains can function independently of other domains of E1A. Using this strong growth inhibition, we isolated a yeast mutant in the net1 gene that conferred resistance to the expression of E1A(1-82). The mutant was insensitive to expression of both E1A(1-82) and full length E1A, but remained sensitive to the toxicity caused by over-expression of a Ga14p-VP16 fusion. Finally, we found that the function of E1A in yeast depends on the cyclic AMP signaling pathway, providing a striking parallel with the action of E1A at the c-fos promoter in mammalian cells. These results suggest that a genetic analysis of the yeast model system will provide relevant new insights into mechanisms of gene regulation by E1A proteins.	UNIV VIRGINIA, SCH MED, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028920] Funding Source: NIH RePORTER; NCI NIH HHS [5T3 CA09109] Funding Source: Medline; NIGMS NIH HHS [GM28920] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARTLETT R, 1990, BIOESSAYS, V12, P457, DOI 10.1002/bies.950121002; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Coulombe Benoit, 1992, Gene Expression, V2, P99; DYSON N, 1992, CANCER SURV, V12, P161; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ENGEL DA, 1991, P NATL ACAD SCI USA, V88, P3957, DOI 10.1073/pnas.88.9.3957; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GEDRICH RW, 1992, J VIROL, V66, P5849, DOI 10.1128/JVI.66.10.5849-5859.1992; GEDRICH RW, 1995, J VIROL, V69, P2333, DOI 10.1128/JVI.69.4.2333-2340.1995; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HANDA H, 1987, GENE, V58, P127; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1988, ANTIBODIES LABORATOR; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; JANASWAMI PM, 1992, J BIOL CHEM, V267, P24886; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KLEIN C, 1994, MOL CELL BIOL, V14, P1920, DOI 10.1128/MCB.14.3.1920; KORNUC M, 1988, MOL CELL BIOL, V8, P3717, DOI 10.1128/MCB.8.9.3717; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MAI B, 1993, FEBS LETT, V321, P153, DOI 10.1016/0014-5793(93)80098-F; MALHOTRA P, 1993, J BIOL CHEM, V268, P20392; Matsumoto K, 1985, Yeast, V1, P15, DOI 10.1002/yea.320010103; NEVINS JR, 1992, SCIENCE, V258, P424; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; REED SI, 1992, CIBA F SYMP, V170, P7; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; ROWE DT, 1983, VIROLOGY, V127, P253, DOI 10.1016/0042-6822(83)90142-3; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RYMOND BC, 1983, GENE, V25, P249, DOI 10.1016/0378-1119(83)90229-9; Sambrook J, 1989, MOL CLONING LABORATO; SELLERS JW, 1990, MOL CELL BIOL, V10, P5077, DOI 10.1128/MCB.10.10.5077; Sherman F., 1982, METHODS YEAST GENETI; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH MM, 1991, METHOD CELL BIOL, V35, P485; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TATCHELL K, 1986, J BACTERIOL, V166, P364, DOI 10.1128/jb.166.2.364-367.1986; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VINCENT AC, 1992, MOL CELL BIOL, V12, P5394, DOI 10.1128/MCB.12.12.5394; WADA T, 1990, BIOCHEM BIOPH RES CO, V170, P470, DOI 10.1016/0006-291X(90)92115-G; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE SP, 1983, J VIROL, V46, P1003, DOI 10.1128/JVI.46.3.1003-1013.1983; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZHOU QJ, 1995, J VIROL, V69, P4323, DOI 10.1128/JVI.69.7.4323-4330.1995; ZIELER HA, 1995, MOL CELL BIOL, V15, P3227	79	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1623	1630						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478587				2022-12-28	WOS:A1995TC53500021
J	BUDAY, L; WARNE, PH; DOWNWARD, J				BUDAY, L; WARNE, PH; DOWNWARD, J			DOWN-REGULATION OF THE RAS ACTIVATION PATHWAY BY MAP KINASE PHOSPHORYLATION OF SOS	ONCOGENE			English	Article						SOS; PAS; MAP KINASE; T CELL	NUCLEOTIDE EXCHANGE FACTOR; SIGNAL TRANSDUCTION; LYMPHOCYTES-T; RECEPTOR; PROTEIN; GRB2; P21RAS; STIMULATION; COMPLEX; BINDS	Formation of a complex of the nucleotide exchange factor Sos, the SH2 and SH3 containing adaptor protein Grb2/Sem-5 and tyrosine phosphorylated EGF receptor and She has been implicated in the activation of Ras by epidermal growth factor (EGF) in fibroblasts: related mechanisms for activation of Ras operate in other cell types. An increase in the apparent molecular weight of Sos has been reported to occur after several minutes of receptor stimulation due to phosphorylation by mitogen-activated protein (MAP) kinases. We report here that treatment of human peripheral blood T lymphoblasts with phorbol esters causes a similar shift in mobility of Sos. This modification of Sos does not alter its ability to bind Grb2, but correlates with strong inhibition of the binding of the Sos/Grb2 complex to tyrosine phosphorylated sequences, either a tyrosine phosphopeptide in cell lysates or p36 in intact cells. This effect, along with the mobility shift of Sos, can be mimicked in vitro by phosphorylation of Sos by the mitogen-activated protein kinase, ERK1. A novel negative feedback mechanism therefore exists whereby activation of MAP kinases through Ras results in the uncoupling of the Sos/Grb2 complex from tyrosine kinase substrates without blocking the interaction of Sos with Grb2.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; SEMMELWEIS UNIV MED,SCH MED,INST BIOCHEM 1,H-1088 BUDAPEST,HUNGARY	Cancer Research UK; Semmelweis University				Downward, Julian/0000-0002-2331-4729				BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; HALLBERG B, 1994, J BIOL CHEM, V270, P3913; HARLOW E, 1988, ANTIBODIES LABORATOR; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; NEL AE, 1990, J IMMUNOL, V144, P2683; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; WATERS SB, 1995, MOL CELL BIOL, V15, P2791	21	103	104	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1327	1331						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478553				2022-12-28	WOS:A1995RY96700013
J	PERREM, K; RAYNER, J; VOSS, T; STURZBECHER, H; JACKSON, P; BRAITHWAITE, A				PERREM, K; RAYNER, J; VOSS, T; STURZBECHER, H; JACKSON, P; BRAITHWAITE, A			P53 REPRESSES SV40 TRANSCRIPTION BY PREVENTING FORMATION OF TRANSCRIPTION COMPLEXES	ONCOGENE			English	Article						P53; SV40; GENE REPRESSION	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN HSP70 PROMOTER; BINDING PROTEIN; CHLORAMPHENICOL ACETYLTRANSFERASE; NEGATIVE REGULATION; DNA-REPLICATION; MAMMALIAN-CELLS; GENE-PRODUCT; MUTANT P53	There is now much evidence to suggest that the p53 tumour suppressor protein functions to monitor the integrity of the genome. When DNA damage is detected, p53 suppresses cell growth to allow repair or directs the cell into apoptosis. The mechanism of action of p53 is as yet unclear but recent evidence has accumulated to suggest that p53 might act by regulating gene expression. Consistent with this model, p53 can both activate and repress a number of viral and cellular promoters. p53 has also been shown to bind to the CCAAT-binding Factor and TATA-binding protein (TBP), and there is direct evidence that p53 represses in vitro transcription by preventing TBP from binding DNA. We now provide evidence that p53 can repress transcription from the SV40 promoter by disrupting DNA/protein complexes involving transcription factor Sp1.	AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV CELL BIOL, CELL TRANSFORMAT GRP, CANBERRA, ACT 2601, AUSTRALIA; UNIV HAMBURG, HEINRICH PETTE INST EXPTL VIROL & IMMUNOL, D-20251 HAMBURG, GERMANY	Australian National University; John Curtin School of Medical Research; Heinrich Pette Institute; University of Hamburg								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN DR, 1994, P NATL ACAD SCI USA, V91, P4372, DOI 10.1073/pnas.91.10.4372; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; JACKSON P, 1993, ONCOGENE, V8, P589; JACKSON P, 1995, IN PRESS GENE EXPRES, V5; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MIYASHITA T, 1994, CANCER RES, V54, P3131; NABEL GJ, 1988, SCIENCE, V239, P1299, DOI 10.1126/science.2830675; PAULY M, 1992, NUCLEIC ACIDS RES, V20, P975, DOI 10.1093/nar/20.5.975; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; STURZBECHER HW, 1988, CANCER CELL, V6, P159; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TOOZE J, 1980, DNA TUMOR VIRUSES 2; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629	57	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1299	1307						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478550				2022-12-28	WOS:A1995RY96700010
J	REYMOND, A; BRENT, R				REYMOND, A; BRENT, R			P16 PROTEINS FROM MELANOMA-PRONE FAMILIES ARE DEFICIENT IN BINDING TO CDK4	ONCOGENE			English	Article						P16(INK4A); CDK4; CDK6; CKI, MELANOMA; 2-HYBRIDS	TRANSFORMATION	The tumor suppressor candidate p16(INK4) is a cyclin-dependent kinase inhibitor that inhibits cell proliferation, The p16 coding gene is often mutated in glioblastomas, pancreatic adenocarcinomas and melanoma-prone pedigrees, but, until recently, the significance of these allelic variants has remained unclear. Here, we used interaction mating and coprecipitation to measure interaction of seven p16 allelic variants detected in melanoma-prone pedigrees with Cyclin-dependent kinases (Cdks), We found that most variants were deficient in interaction with Cdk4 and Cdk6. One defective variant was found both in cancer prone families and in the control population and therefore previously defined as a common polymorphism. Another variant, which is weakly linked to familial cancer, is only slightly affected in interaction with Cdks. These results are consistent with the idea that p16 allelic variants that decrease Cdk interaction predispose individuals who carry them to an increased risk of cancer. Moreover, they suggest that determination of affinity between p16 mutants and partner proteins may help identify functionally-significant allelic variants not detected by classical human genetic techniques.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	REYMOND, A (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,50 BLOSSOM ST,BOSTON,MA 02114, USA.			Reymond, Alexandre/0000-0003-1030-8327				AUSBEL FM, 1987, CURRENT PROTOCOLS MO; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOLEMIS E, 1992, MOL CELL BIOL, V8, P1614; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REYMOND A, 1993, NUCLEIC ACIDS RES, V21, P3615, DOI 10.1093/nar/21.16.3615; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	24	94	94	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1173	1178						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566978				2022-12-28	WOS:A1995RX18000021
J	MAMAJIWALLA, SN; BURGESS, DR				MAMAJIWALLA, SN; BURGESS, DR			DIFFERENTIAL REGULATION OF THE ACTIVITY OF THE 42 KD MITOGEN-ACTIVATED PROTEIN-KINASE (P42(MAPK)) DURING ENTEROCYTE DIFFERENTIATION IN-VIVO	ONCOGENE			English	Article						MAP KINASE; INTESTINAL EPITHELIUM; DIFFERENTIATION	HUMAN-COLON-CARCINOMA; SERINE THREONINE KINASES; MAP KINASE; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; GROWTH; CELLS; INSULIN; IDENTIFICATION; PHOSPHATASE	The family of mitogen activated protein (MAP) kinases appear to play a central role in relaying signals generated by receptor protein tyrosine kinases (RPTK) from the cell surface to the nucleus, We previously demonstrated that undifferentiated and mitotically active crypt cells have high levels of tyrosine phosphorylated proteins (DR Burgess, W Jiang, S Mamajiwalla and W Kinsey. 1989, J. Cell Biol., 109: 2139) possibly due to the activation of RPTKs and also have high pp60(mapk) protein tyrosine kinase activity (CA Cartwright, SN Mamajiwalla, SA Skolnik, W Eckhart and DR Burgess, 1993. Oncogene. 8: 1033) when compared to differentiated, non-mitotic villus cells. Since activation of RPTKs leading to cell proliferation or differentiation involves activation of the Ras-MAP kinase pathway, we chose to determine in this study if the activity of the MAP kinases were also regulated during differentiation of normal adult enterocytes. Our data show that although the 42 kD MAP kinase (p42(mapk)) was expressed in both crypt and villus cells, it was phosphorylated on tyrosine and active only in the crypt cells, Our data further suggest that p42(mapk) is inactivated during differentiation, possibly by a protein tyrosine phosphatase, Immunofluorescence studies revealed that p42(mapk) localized to the nuclei in both undifferentiated and differentiated enterocytes and colocalized with phosphotyrosine containing proteins at the region of the junctional complex, These results suggest that p42(mapk) and its regulators are tightly controlled during enterocyte differentiation in vivo and implicate p42(mapk) as a key regulatory molecule in the normal development of the epithelium.	UNIV PITTSBURGH, DEPT BIOL SCI, PITTSBURGH, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031643] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31643] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BARRETT CB, 1992, J BIOL CHEM, V267, P4408; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGESS DR, 1989, J CELL BIOL, V109, P2139, DOI 10.1083/jcb.109.5.2139; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; CARRASCO D, 1993, CELL GROWTH DIFFER, V4, P849; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FATH KR, 1990, DEVELOPMENT, V109, P449; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; KOZMA LM, 1991, METHOD ENZYMOL, V201, P28; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Le Blond CP, 1976, STEM CELLS RENEWING, P7; LEE H, 1993, J BIOL CHEM, V268, P8181; LEE HS, 1993, J BIOL CHEM, V268, P5255; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAMAJIWALLA SN, 1992, CURR TOP DEV BIOL, V26, P123, DOI 10.1016/S0070-2153(08)60443-3; MARIAN B, 1989, CANCER RES, V49, P4231; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PARK JS, 1993, ONCOGENE, V8, P2627; POSADA J, 1992, MOL BIOL CELL, V3, P583, DOI 10.1091/mbc.3.6.583; POTTEN CS, 1982, CYTOTOXIC INSULT TIS, P105; PULVERER BJ, 1993, ONCOGENE, V8, P407; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROSSOMANDO AJ, 1992, P NATL ACAD SCI USA, V89, P5779, DOI 10.1073/pnas.89.13.5779; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SMITH MW, 1991, CURR TOP MEMBR, V39, P153; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STIDWILL RP, 1986, DEV BIOL, V114, P381, DOI 10.1016/0012-1606(86)90202-2; STURGILL TW, 1991, METHOD ENZYMOL, V200, P342; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOBE K, 1991, J BIOL CHEM, V266, P24793; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; Wilson Clive, 1994, Trends in Cell Biology, V4, P409, DOI 10.1016/0962-8924(94)90094-9; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WRIGHT N, 1973, GUT, V14, P701, DOI 10.1136/gut.14.9.701; WRIGHT NA, 1975, CELL TISSUE KINET, V8, P361, DOI 10.1111/j.1365-2184.1975.tb01500.x; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	65	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					377	386						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7542764				2022-12-28	WOS:A1995RK95700018
J	STRAND, D; UNGER, S; CORVI, R; HARTENSTEIN, K; SCHENKEL, H; KALMES, A; MERDES, G; NEUMANN, B; KRIEGSCHNEIDER, F; COY, JF; POUSTKA, A; SCHWAB, M; MECHLER, BM				STRAND, D; UNGER, S; CORVI, R; HARTENSTEIN, K; SCHENKEL, H; KALMES, A; MERDES, G; NEUMANN, B; KRIEGSCHNEIDER, F; COY, JF; POUSTKA, A; SCHWAB, M; MECHLER, BM			A HUMAN HOMOLOG OF THE DROSOPHILA TUMOR-SUPPRESSOR GENE L(2)GL MAPS TO 17P11.2-12 AND CODES FOR A CYTOSKELETAL PROTEIN THAT ASSOCIATES WITH NONMUSCLE MYOSIN-II HEAVY-CHAIN	ONCOGENE			English	Article						TUMOR SUPPRESSOR GENE; DROSOPHILA L(2)GL GENE; HUMAN CHROMOSOME 17; CYTOSKELETON; NONMUSCLE MYOSIN II	BREAST-CANCER; RECESSIVE ONCOGENE; OVARIAN-CARCINOMA; CHROMOSOME 17P; ALLELE LOSSES; P53 MUTATIONS; MELANOGASTER; EXPRESSION; EZRIN; DELETIONS	Inactivation of the tumour suppressor gene lethal(2) giant larvae (D-lgl) of Drosophila leads to malignant transformation of the presumptive adult optic centers in the larval brain and tumours of the imaginal discs. These from the disorganization of a in which the D-LGL protein participates. Here we describe the isolation of a cDNA encoding the human homologue to the D-lgl gene designated as hugl. The hugl cDNA detects a locus spanning at least 25 kilobases (kb) in human chromosome band 17p11.2-12, which is centromeric to the p53 gene and recognizes a 4.5 kb RNA transcript. The hugl gene is expressed in brain, kidney and muscle but is barely seen in heart and placenta. Sequence analysis of the hugl cDNA demonstrates a long open reading frame, which has the potential to encode a protein of 1057 amino acids with a predicted molecular weight of 115 kDaltons (kD). To further substantiate and identify the HUGL protein, we have prepared polyclonal rabbit antibodies against synthetic peptides corresponding to the amino and carboxyl termini of the conceptual translation product of the hugl gene. The affinity-purified anti-HUGL antibodies recognize a single protein with an apparent molecular weight of similar to 115 kD, Similar to the Drosophila protein, HUGL is part of a cytoskeletal network and, is associated with nonmuscle myosin II heavy chain and a kinase that specifically phosphorylates HUGL at serine residues.	DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT CYTOGENET, D-69120 HEIDELBERG, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT MOLEC GENOME ANAL, D-69120 HEIDELBERG, GERMANY; UNIV WURZBURG, INST MED RADIAT & CELL RES, D-97078 WURZBURG, GERMANY; MED CLIN 3, D-68305 MANNHEIM, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Wurzburg	STRAND, D (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT DEV GENET, NEUENHEIMER FELD 280, D-69120 HEIDELBERG, GERMANY.							ADAMSON R, 1994, ONCOGENE, V9, P2077; ALBRECHT S, 1994, NEUROPATH APPL NEURO, V20, P74, DOI 10.1111/j.1365-2990.1994.tb00959.x; ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BARDI G, 1993, INT J CANCER, V55, P422, DOI 10.1002/ijc.2910550317; BARKER PE, 1993, METHODS MOL GENETICS, V2, P129; BOEDIGHEIMER M, 1993, DEVELOPMENT, V118, P1291; BRIDGES CB, 1944, CARNEGIE I WASHINGTO, V522; Bryant Peter J., 1993, Trends in Cell Biology, V3, P31, DOI 10.1016/0962-8924(93)90147-S; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; COLLINS C, 1991, GENOMICS, V11, P997, DOI 10.1016/0888-7543(91)90025-A; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; ECCLES DM, 1990, ONCOGENE, V5, P1599; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; GATEFF E, 1994, INT J DEV BIOL, V38, P565; GATEFF E, 1969, NATL CANCER I MONOGR, P365; GATEFF E, 1989, Critical Reviews in Oncogenesis, V1, P221; GOLUBOVSKY MD, 1980, GENETICA, V52-3, P139; Golubovsky MD, 1978, DROSOPH INF SERV, V53, P179; GREEN MM, 1979, GENETICS, V92, P823; GRIFFIN CA, 1988, CANCER RES, V48, P175; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISOMURA M, 1994, GENE CHROMOSOME CANC, V9, P173, DOI 10.1002/gcc.2870090305; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JACOB L, 1987, CELL, V50, P215, DOI 10.1016/0092-8674(87)90217-0; JOHANSSON M, 1994, INT J ONCOL, V5, P17; JONES E, 1994, GENE CHROMOSOME CANC, V11, P163, DOI 10.1002/gcc.2870110305; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; LUTZELSCHWAB R, 1986, MOL GEN GENET, V204, P58, DOI 10.1007/BF00330187; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MECHLER B, 1990, CANCER SURV, V9, P505; MECHLER BM, 1994, J BIOSCIENCES, V19, P537; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; MECHLER BM, 1990, TUMOR SUPPRESSOR GEN, P123; MERTENS F, 1994, GENE CHROMOSOME CANC, V10, P221, DOI 10.1002/gcc.2870100402; OPPER M, 1987, ONCOGENE, V1, P91; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; RADFORD DM, 1993, CANCER RES, V53, P2947; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; SATO N, 1992, J CELL SCI, V103, P131; SATO T, 1990, CANCER RES, V50, P7184; SAVELYEVA L, 1994, AM J HUM GENET, V55, P334; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; STAND D, 1994, J CELL BIOL, V127, P1361; STRAND D, 1991, ADV ENZYME REGUL, V31, P339, DOI 10.1016/0065-2571(91)90022-E; STRAND D, 1994, J CELL BIOL, V127, P1345, DOI 10.1083/jcb.127.5.1345; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; TOMOTSUNE D, 1993, NATURE, V365, P69, DOI 10.1038/365069a0; TOROK I, 1993, ONCOGENE, V8, P1537; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSAO SW, 1991, ANTICANCER RES, V11, P1975; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7	60	94	97	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					291	301						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7542763				2022-12-28	WOS:A1995RK95700010
J	BUCK, V; ALLEN, KE; SORENSEN, T; BYBEE, A; HIJMANS, EM; VOORHOEVE, PM; BERNARDS, R; LATHANGUE, NB				BUCK, V; ALLEN, KE; SORENSEN, T; BYBEE, A; HIJMANS, EM; VOORHOEVE, PM; BERNARDS, R; LATHANGUE, NB			MOLECULAR AND FUNCTIONAL-CHARACTERIZATION OF E2F-5, A NEW MEMBER OF THE E2F FAMILY	ONCOGENE			English	Article						E2F; DP; TRANSCRIPTION FACTOR; CELL CYCLE	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; CYCLIN-A; BINDING PROTEIN; CLONING; COMPLEX; CDNA; P107; IDENTIFICATION; EXPRESSION	The transcription factor DRTF1/E2F is implicated in the control of cellular proliferation due to its interaction with key regulators of cell cycle progression, such as the retinoblastoma tumour suppressor gene product and related pocket proteins, cyclins and cyclin-dependent kinases. DRTF1/E2F DNA binding activity arises when a member of two distinct families of proteins, DP and E2F, interact as DP/E2F heterodimers. Here, we report the isolation and characterisation of a new member of the E2F family of proteins, called E2F-5. E2F-5 was isolated through a yeast two hybrid assay in which a 14.5 d.p.c. mouse embryo library was screened for molecules capable of binding to murine DP-1, but also interacts with all known members of the DP family of proteins. E2F-5 exists as a physiological heterodimer with DP-1 in the generic DRTF1/E2F DNA binding activity present in mammalian cell extracts, an interaction which results in co-operative DNA binding activity and transcriptional activation through the E2F site. A potent transcriptional activation domain, which functions in both yeast and mammalian cells and resides in the C-terminal region of E2F-5, is specifically inactivated upon pocket protein binding. Comparison of the sequence with other members of the family indicates that E2F-5 shows a greater level of similarity with E2F-4 than to E2F-1, -2 and -3. The structural and functional similarity of E2F-5 and E2F-4 defines a subfamily of E2F proteins.	NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND; NETHERLANDS CANC INST,DIV MOLEC CARCINOGENESIS,1066 CX AMSTERDAM,NETHERLANDS	MRC National Institute for Medical Research; Netherlands Cancer Institute				Allen, Liz/0000-0001-8579-7730				BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GIRLING R, 1994, MOL BIOL CELL, V5, P1081, DOI 10.1091/mbc.5.10.1081; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HEIBERT SW, 1992, GENE DEV, V6, P177; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIJMANS EM, 1995, IN PRESS MOL CELL BI; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOOSS KU, 1994, EMBO J, V13, P1467, DOI 10.1002/j.1460-2075.1994.tb06401.x; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; NEVINS JR, 1992, SCIENCE, V258, P424; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	36	44	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					31	38						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7542760				2022-12-28	WOS:A1995RJ29500005
J	DURO, D; BERNARD, O; DELLAVALLE, V; BERGER, R; LARSEN, CJ				DURO, D; BERNARD, O; DELLAVALLE, V; BERGER, R; LARSEN, CJ			A NEW-TYPE OF P16(INK4)/MTS1 GENE TRANSCRIPT EXPRESSED IN B-CELL MALIGNANCIES	ONCOGENE			English	Article						P(16INK4)/MTS1 GENE EXPRESSION; LYMPHOID PROLIFERATIONS; CYTOGENETICS	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; SHORT ARM; NONRANDOM ABNORMALITIES; LYMPHOMATOUS FEATURES; HOMOZYGOUS DELETIONS; CHROMOSOME-9; INTERFERON; TRANSLOCATION; ASSOCIATION	Chromosome band 9p21-22 is frequently altered by nonrandom abnormalities, mainly deletions, in hemopoietic malignancies of the lymphoid lineage. We have analysed a translocation t(9;14)(p21-p22;q11) in a B-cell type acute lymphoblastic leukemia. Location of the 14q11 breakpoint within the TCR-alpha/delta locus allowed the isolation of a fusion transcript composed of a 3' segment containing part of the constant region of the TCR-alpha gene and a 5' segment from chromosome 9, designated 0.18. This 0.18 segment was also part of cDNAs isolated from two tumoral B-cell lines (RPMI-8226, Raji). In both cases, 0.18 was juxtaposed 5' to a sequence corresponding to exons 2 and 3 of the p16(INK4)/MTS1 gene which is located on band 9p21-22. Unexpectedly, none of the two ATG codons found in 0.18 was in phase with that of the exons 2 and 3 of p16(INK4)/MTS1. Furthermore, in vitro translation product of a RPMI-8226 cDNA clone generated a product that was not immunoprecipitated by antibodies specific of the C-terminal end of the p16(INK4)/MTS1 protein. Evidence for similar transcripts in non tumoral lymphoid B cells (unstimulated peripheral blood lymphocytes (PBL) and lymphoblastoid cell lines) were obtained by using amplimers representative of the 0.18 segment and the p16(INK4)/MTS1 exon 2. Altogether, these data are consistent with the existence of a new type of p16(INK4)/MTS1 transcript whose significance is discussed.	INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE; CNRS,SDI 16954,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS)			Bernard, Olivier A./E-5721-2016	Bernard, Olivier/0000-0002-0463-9747				BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1992, J EXP MED, V176, P915; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CARROLL AJ, 1987, BLOOD, V70, P1962; CARROLL AJ, 1987, BLOOD, V69, P735; CHENG JQ, 1994, CANCER RES, V54, P5547; CHILCOTE RR, 1985, NEW ENGL J MED, V313, P286, DOI 10.1056/NEJM198508013130503; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLEMAN A, 1994, CANCER RES, V54, P344; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; DURO D, 1994, CR ACAD SCI III-VIE, V317, P913; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HEYMAN M, 1993, INT J CANCER, V54, P748, DOI 10.1002/ijc.2910540507; HUANG DP, 1994, CANCER RES, V54, P4003; ISSHIKI K, 1994, ONCOGENE, V9, P1649; JAMES CD, 1993, CANCER RES, V53, P3674; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEEN AJ, 1994, ONCOGENE, V9, P2083; KOWALCZYK J, 1983, CANCER GENET CYTOGEN, V9, P383, DOI 10.1016/0165-4608(83)90086-9; LAABI Y, 1992, EMBO J, V11, P3897, DOI 10.1002/j.1460-2075.1992.tb05482.x; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; MATHIEUMAHUL D, 1986, J EXP MED, V163, P1308, DOI 10.1084/jem.163.5.1308; MATHIEUMAHUL D, 1985, EMBO J, V4, P3427, DOI 10.1002/j.1460-2075.1985.tb04100.x; MITELMAN F, 1991, CATALOG CHROMOSOME A; MORI T, 1994, CANCER RES, V54, P3396; MURPHY SB, 1989, BLOOD, V74, P409; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1992, CANCER RES, V52, P2523; ORLOW I, 1994, CANCER RES, V54, P2848; ROMANROMAN S, 1991, EUR J IMMUNOL, V21, P2848; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SOULARD M, 1991, EXP CELL RES, V193, P59, DOI 10.1016/0014-4827(91)90538-6; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TSAI YC, 1990, CANCER RES, V50, P44	44	154	166	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					21	29						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624129				2022-12-28	WOS:A1995RJ29500004
J	ZHAO, JF; NAKANO, H; SHARMA, S				ZHAO, JF; NAKANO, H; SHARMA, S			SUPPRESSION OF RAS AND MOS TRANSFORMATION BY RADICICOL	ONCOGENE			English	Article						RADICICOL; RAS; MOS; SUPPRESSION; ERKS; GAP-P62	GTPASE-ACTIVATING PROTEIN; GAP-ASSOCIATED PROTEINS; TYROSINE KINASES; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; XENOPUS OOCYTES; MAP KINASE; IN-VITRO; PHOSPHORYLATION; RECEPTOR	Activated versions of ras and mos oncogenes subvert the signal transduction pathway by mimicking transducers at the plasma membrane and cytosol respectively. Radicicol (UCS1006), an antifungal antibiotic, had the ability to suppress transformation by ras and mos oncogenes in a rapid, reversible and dose-dependent manner. UCS1006 inhibited MAP kinase activity (both ERK1 and ERK2) in untransformed as well as uas and mos transformed cells. However, ERK2 but not ERK1 activity was constitutively elevated in ras and mos transformed cells used in this study. In addition, a 62 kDa (kilodalton) phosphoprotein was identified whose tyrosine phosphorylation was inhibited by UCS1006, in both ras and mos transformed cells. This 62 kDa phosphoprotein, which was found to be heavily phosphorylated on tyrosine residues only in the ras and mos transformed cells but not in untransformed NIH3T3 cells, was identical to the previously described GAP-associated tyrosine phosphoprotein, p62, that is the major target for phosphorylation in cells transformed by tyrosine kinase oncogenes. These results suggest that agents such as radicicol can suppress transformation by diverse oncogenes such as src, ras and mos at least in part by inhibiting the function of key signal transduction intermediates such as MAP kinase and GAP-associated p62.	UNIV TENNESSEE,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163; KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,TOKYO 194,JAPAN	University of Tennessee System; University of Tennessee Health Science Center; Kyowa Kirin Ltd					NCI NIH HHS [CA 55983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOS JL, 1989, CANCER RES, V49, P4682; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; DELMOTTE P, 1953, NATURE, V171, P344, DOI 10.1038/171344a0; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FILVAROFF E, 1992, MOL CELL BIOL, V12, P5319, DOI 10.1128/MCB.12.12.5319; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KWON HJ, 1992, CANCER RES, V52, P6926; KWON HJ, 1992, BIOSCI BIOTECH BIOCH, V56, P538; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; McCAPRA FRANK, 1964, TETRAHEDRON LETT, V15/16, P869; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; OIKAWA T, 1993, EUR J PHARMACOL, V241, P221, DOI 10.1016/0014-2999(93)90206-W; PARK S, 1993, J BIOL CHEM, V268, P25728; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHARMA SV, 1993, ONCOGENE, V8, P939; SHARMA SV, 1992, ONCOGENE, V7, P193; SINGH B, 1992, MOL CARCINOGEN, V6, P182, DOI 10.1002/mc.2940060303; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOPOL LZ, 1995, CELL GROWTH DIFFER, V6, P27; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANDEWOUDE GF, 1990, ORIGINS HUMAN CANCER; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEINBERG RA, 1991, ORIGINS HUMAN CANCER; WEINBERG RA, 1989, ONCOGENES MOL ORIGIN, P45; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; ZHENG XF, 1993, NATURE, V364, P308	65	56	64	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					161	173						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624124				2022-12-28	WOS:A1995RJ29500019
J	HIMES, SR; COLES, LS; KATSIKEROS, R; LANG, RK; SHANNON, MF				HIMES, SR; COLES, LS; KATSIKEROS, R; LANG, RK; SHANNON, MF			HTLV-1 TAX ACTIVATION OF THE GM-CSF AND G-CSF PROMOTERS REQUIRES THE INTERACTION OF NF-KB WITH OTHER TRANSCRIPTION FACTOR FAMILIES	ONCOGENE			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; COLONY-STIMULATING FACTOR; TUMOR NECROSIS FACTOR; LONG TERMINAL REPEAT; KAPPA-B; FACTOR GENE; TRANS-ACTIVATION; INTERLEUKIN-2 RECEPTOR; NUCLEAR FACTOR	The trans-activator protein, tax, from the human T leukemia virus type 1 (HTLV-1) trans-activates both viral and cellular genes. It has previously been shown that granulocyte macrophage-colony stimulating factor (GM-CSF) is constitutively expressed in HTLV-1 infected cells and in cells artificially expressing tax. We show here that the GM-CSF promoter is tax responsive in fibroblasts and T cells, whereas the granulocyte (G)-CSF promoter is tax responsive only in fibroblasts. The tax protein can activate cellular genes through at least two families of transcription factors; the NF-kB/rel and CREB/ATF families. We have used mutant tax proteins to show that the activation of NF-kB proteins is essential for tax trans-activation of both the GM-CSF and G-CSF promoters. The ability of tax to activate CREB/ATF proteins is also essential for GM-CSF trans-activation. We have identified a 44 bp region of the GM-CSF promoter that contains tax responsive elements. This region contains a classical NF-kB site, a CK-1 element that can bind the NF-kB p65 protein, as well as a putative ATF binding site. The tax response of the G-CSF promoter requires not only the conserved CK-1 sequence but also an adjacent NF-IL6 binding site that may explain the cell restricted function of the G-CSF promoter.	INST MED & VET SCI,HANSON CTR CANC RES,DIV HUMAN IMMUNOL,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALEXANDRE C, 1991, ONCOGENE, V6, P1851; AZIZUKI S, 1987, LANCET, V1, P156; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GREEN JE, 1989, MOL CELL BIOL, V9, P4731, DOI 10.1128/MCB.9.11.4731; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3653, DOI 10.1073/pnas.84.11.3653; JACOBSON S, 1988, NATURE, V331, P540, DOI 10.1038/331540a0; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; KOEFFLER HP, 1988, MOL CELL BIOL, V8, P3432, DOI 10.1128/MCB.8.8.3432; KUCZEK ES, 1991, J IMMUNOL, V146, P2426; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NIMER SD, 1989, ONCOGENE, V4, P671; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PICCARDO P, 1988, ANN NEUROL S, V23, P156; ROONEY RJ, 1990, MOL CELL BIOL, V10, P5138, DOI 10.1128/MCB.10.10.5138; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; Shannon MF, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046923; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUGIMOTO K, 1990, INT IMMUNOL, V2, P787, DOI 10.1093/intimm/2.8.787; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAN TH, 1989, MOL CELL BIOL, V9, P1733, DOI 10.1128/MCB.9.4.1733; WACHSMAN W, 1986, SEMIN HEMATOL, V23, P246; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WOOD KV, 1991, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P543; XU YL, 1990, J BIOL CHEM, V265, P20285; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	46	97	98	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3189	3197						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	7504230				2022-12-28	WOS:A1993MG78200001
J	MCCAFFERY, RE; COGGINS, LW; DOHERTY, I; KENNEDY, I; OPREY, M; MCCOLL, L; CAMPO, MS				MCCAFFERY, RE; COGGINS, LW; DOHERTY, I; KENNEDY, I; OPREY, M; MCCOLL, L; CAMPO, MS			MULTIPLE HARVEY-RAS GENES IN THE BOVINE GENOME	ONCOGENE			English	Article									BEATSON INST CANC RES, GARSCUBE ESTATE, GLASGOW G61 1BD, SCOTLAND	Beatson Institute								ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISHOP JM, 1985, TRENDS GENET, V1, P245, DOI 10.1016/0168-9525(85)90094-0; BROWN K, 1988, MOL CARCINOGEN, V1, P161, DOI 10.1002/mc.2940010304; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHANG EH, 1982, P NATL ACAD SCI-BIOL, V79, P4848, DOI 10.1073/pnas.79.16.4848; CHATTOPADHYAY SK, 1982, NATURE, V296, P361, DOI 10.1038/296361a0; Coggins LW, 1987, ELECTRON MICROS, P1; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P820, DOI 10.1073/pnas.80.3.820; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HESS JF, 1984, SCIENCE, V226, P67, DOI 10.1126/science.6474190; HUNTER T, 1984, JNCI-J NATL CANCER I, V73, P773; LEUNG DW, 1984, BIO-TECHNOL, V2, P458, DOI 10.1038/nbt0584-458; Maniatis T., 1982, MOL CLONING; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; NEIL JC, 1984, NATURE, V308, P814, DOI 10.1038/308814a0; OBRIEN SJ, 1983, NATURE, V302, P839, DOI 10.1038/302839a0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RIMM DL, 1980, GENE, V12, P301, DOI 10.1016/0378-1119(80)90113-4; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2	29	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1989	4	12					1441	1448						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687766				2022-12-28	WOS:A1989CB65900004
J	SULLIVAN, NF; WILLIS, AE				SULLIVAN, NF; WILLIS, AE			ELEVATION OF C-MYC PROTEIN BY DNA STRAND BREAKAGE	ONCOGENE			English	Article											SULLIVAN, NF (corresponding author), IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND.			Willis, Anne/0000-0002-1470-8531				ADAMS RLP, 1967, J BIOL CHEM, V242, P1314; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BIRNBOIM HC, 1982, SCIENCE, V215, P1247, DOI 10.1126/science.6276978; BRENT TP, 1988, P NATL ACAD SCI USA, V85, P1759, DOI 10.1073/pnas.85.6.1759; BURGER RM, 1981, J BIOL CHEM, V256, P1636; CERNI C, 1987, EXP CELL RES, V168, P439, DOI 10.1016/0014-4827(87)90016-4; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CLEAVER JE, 1978, BIOCHIM BIOPHYS ACTA, V516, P489, DOI 10.1016/0304-419X(78)90020-3; CRAWFORD D, 1988, ONCOGENE, V3, P27; DEAN M, 1986, J BIOL CHEM, V261, P9161; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; DURKACZ BW, 1981, BIOCHEM BIOPH RES CO, V101, P1433, DOI 10.1016/0006-291X(81)91607-7; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FORNACE AJ, 1976, P NATL ACAD SCI USA, V73, P39, DOI 10.1073/pnas.73.1.39; FUJIWARA Y, 1977, J MOL BIOL, V113, P635, DOI 10.1016/0022-2836(77)90227-3; GOSS P, 1977, CANCER RES, V37, P152; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; IYER VN, 1963, P NATL ACAD SCI USA, V50, P355, DOI 10.1073/pnas.50.2.355; JAMES MR, 1982, BIOCHEMISTRY-US, V21, P4007, DOI 10.1021/bi00260a016; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1984, CURR TOP MICROBIOL, V113, P117; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KURAMOCHI H, 1981, J ANTIBIOT, V34, P576, DOI 10.7164/antibiotics.34.576; LATCHMAN HM, 1984, NATURE, V310, P592; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; MITCHELL DL, 1988, MUTAT RES, V193, P53, DOI 10.1016/0167-8817(88)90007-7; MOORE JP, 1986, J BIOL CHEM, V261, P8158; MOORE JP, 1987, ONCOGENE RES, V2, P65; MORGAN WF, 1983, CANCER RES, V43, P3104; NICKERSON JA, 1989, P NATL ACAD SCI USA, V86, P177, DOI 10.1073/pnas.86.1.177; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RONAI ZA, 1988, ONCOGENE, V2, P201; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; Singer B., 1983, MOL BIOL MUTAGENS CA, P45; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SPECTOR DL, 1987, ONCOGENE, V1, P5; SQUIRES S, 1983, CARCINOGENESIS, V4, P565, DOI 10.1093/carcin/4.5.565; SULLIVAN NF, 1988, CURR TOP MICROBIOL, V141, P208; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; TEO IA, 1983, CARCINOGENESIS, V4, P559, DOI 10.1093/carcin/4.5.559; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TSOPANAKIS C, 1978, EUR J BIOCHEM, V90, P337, DOI 10.1111/j.1432-1033.1978.tb12610.x; VANSTRAATEN JP, 1987, ONCOGENE RES, V1, P221; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448	54	40	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1989	4	12					1497	1502						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687769				2022-12-28	WOS:A1989CB65900012
J	DUDEK, H; REDDY, EP				DUDEK, H; REDDY, EP			IDENTIFICATION OF 2 TRANSLATIONAL PRODUCTS FOR C-MYB	ONCOGENE			English	Article											DUDEK, H (corresponding author), WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA044463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1 CA 44463] Funding Source: Medline; NIGMS NIH HHS [5T32 GM 07229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BADING H, 1987, ONCOGENE, V1, P395; BADING H, 1988, ONCOGENE, V3, P257; BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; CHALLBERG MD, 1979, P NATL ACAD SCI USA, V76, P655, DOI 10.1073/pnas.76.2.655; GEORGE DG, 1986, NUCLEIC ACIDS RES, V14, P11, DOI 10.1093/nar/14.1.11; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELLICI PG, 1984, SCIENCE, V224, P1117; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; REDDY EP, 1988, ONCOGENE HDB, P327; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WEINSTEIN Y, 1987, J VIROL, V61, P2339, DOI 10.1128/JVI.61.7.2339-2343.1987; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	40	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1061	1066						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2674850				2022-12-28	WOS:A1989AM53100001
J	REED, JC; HALDAR, S; CUDDY, MP; CROCE, C; MAKOVER, D				REED, JC; HALDAR, S; CUDDY, MP; CROCE, C; MAKOVER, D			DEREGULATED BCL2 EXPRESSION ENHANCES GROWTH OF A HUMAN B-CELL LINE	ONCOGENE			English	Article									UNIV PENN,DEPT INTERNAL MED,RHEUMATOL SECT 3,PHILADELPHIA,PA 19104; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS RES INST,PHILADELPHIA,PA 19140	University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	REED, JC (corresponding author), UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NATIONAL CANCER INSTITUTE [R01CA047956] Funding Source: NIH RePORTER; NCI NIH HHS [CA47956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1989, P NATL ACAD SCI USA, V86, P2771, DOI 10.1073/pnas.86.8.2771; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1984, P NATL ACAD SCI-BIOL, V81, P593, DOI 10.1073/pnas.81.2.593; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; NGAN BY, 1988, NEW ENGL J MED, V318, P1638, DOI 10.1056/NEJM198806233182502; NOWELL PC, 1988, FASEB J, V2, P3054, DOI 10.1096/fasebj.2.15.3056765; REED J, 1986, MOL CEL BIOL, V6, P3361; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; ROSENBERG SA, 1982, CANCER, V49, P2112; SCALA G, 1987, J IMMUNOL, V138, P2527; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHIGEKAWA K, 1988, BIOTECHNIQUES, V6, P742; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TOSATO G, 1988, SCIENCE, V239, P502, DOI 10.1126/science.2829354; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904	23	30	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1123	1127						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2789359				2022-12-28	WOS:A1989AM53100011
J	RON, D; GRAZIANI, G; AARONSON, SA; EVA, A				RON, D; GRAZIANI, G; AARONSON, SA; EVA, A			THE N-TERMINAL REGION OF PROTO-DBL DOWN REGULATES ITS TRANSFORMING ACTIVITY	ONCOGENE			English	Article											RON, D (corresponding author), NCI, CELLULAR & MOLEC BIOL LAB, BLDG 37, ROOM 1E24, BETHESDA, MD 20892 USA.		Eva, Alessandra/J-8268-2016; Graziani, Grazia/G-5747-2012	Eva, Alessandra/0000-0003-2949-078X; Graziani, Grazia/0000-0002-0221-768X				ARVUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334; BALMAIN A, 1985, BRIT J CANCER, V51, P1, DOI 10.1038/bjc.1985.1; Barbacid M, 1986, Important Adv Oncol, P3; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1987, ONCOGENE, V1, P355; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GRAZIANI G, 1989, IN PRESS ONCOGENE; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KINGSTON RE, 1985, CELL, V41, P3, DOI 10.1016/0092-8674(85)90049-2; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; RADKE K, 1983, J CELL BIOL, V97, P1601, DOI 10.1083/jcb.97.5.1601; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STOLZENBACH F, 1966, METHOD ENZYMOL, V9, P278; TAHARA SM, 1982, EUR J BIOCHEM, V126, P395; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WANG JYJ, 1984, CELL, V36, P349; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WIDNELL CC, 1968, P NATL ACAD SCI USA, V61, P1050, DOI 10.1073/pnas.61.3.1050; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	40	45	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1989	4	9					1067	1072						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2674851				2022-12-28	WOS:A1989AM53100002
J	VERMA, RS; MACERA, MJ; BENN, P; GROFFEN, J				VERMA, RS; MACERA, MJ; BENN, P; GROFFEN, J			MOLECULAR CHARACTERIZATION OF VARIANT TRANSLOCATIONS IN CHRONIC MYELOGENOUS LEUKEMIA	ONCOGENE			English	Note									LIFECODES CORP,VALHALLA,NY; CHILDRENS HOSP,LOS ANGELES,CA 90027	Children's Hospital Los Angeles	VERMA, RS (corresponding author), SUNY HLTH SCI CTR,LONG ISL COLL HOSP,340 HENRY ST,BROOKLYN,NY 11201, USA.		Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273				ALIMENA G, 1987, CANCER GENET CYTOGEN, V27, P21, DOI 10.1016/0165-4608(87)90255-X; ANDREWS DF, 1987, LEUKEMIA, V1, P718; Bartram C R, 1985, Haematol Blood Transfus, V29, P150; BARTRAM CR, 1988, LEUKEMIA, V2, P63; BARTRAM CR, 1985, J EXP MED, V162, P2175, DOI 10.1084/jem.162.6.2175; BARTRAM CR, 1985, EMBO J, V4, P683, DOI 10.1002/j.1460-2075.1985.tb03683.x; BENBASSAT I, 1988, LEUKEMIA, V2, P704; BENN P A, 1988, Journal of Tumor Marker Oncology, V3, P101; BERNSTEIN R, 1988, SEMIN HEMATOL, V25, P20; BLENNERHASSETT GT, 1988, LEUKEMIA, V2, P648; BOTTI AC, 1988, CANCER GENET CYTOGEN, V35, P51, DOI 10.1016/0165-4608(88)90121-5; Canaani E, 1985, Haematol Blood Transfus, V29, P154; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHAMPLIN RE, 1985, LEUKEMIA RECENT ADV, P651; CHEN SJ, 1988, LEUKEMIA, V2, P634; COLLINS SJ, 1989, BLOOD, V73, P1028; CROCE CM, 1987, P NATL ACAD SCI USA, V84, P7174, DOI 10.1073/pnas.84.20.7174; DREAZEN O, 1988, SEMIN HEMATOL, V25, P35; DREAZEN O, 1988, BLOOD, V71, P797; EISENBERG A, 1988, LEUKEMIA, V2, P642; GALE RP, 1985, BRIT J HAEMATOL, V60, P395, DOI 10.1111/j.1365-2141.1985.tb07436.x; GERHARD DS, 1981, P NATL ACAD SCI-BIOL, V78, P3755, DOI 10.1073/pnas.78.6.3755; GOLDMAN JM, 1987, BRIT J HAEMATOL, V66, P435, DOI 10.1111/j.1365-2141.1987.tb01323.x; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROFFEN J, 1987, ADV VIRAL ONCOL, V7, P77; HAGEMEIJER A, 1984, CANCER GENET CYTOGEN, V13, P1, DOI 10.1016/0165-4608(84)90083-9; Heim S, 1987, ADV VIRAL ONCOL, V7, P53; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HURET JL, 1987, ANN GENET-PARIS, V30, P175; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LATT SA, 1983, J VIROL, V45, P1195, DOI 10.1128/JVI.45.3.1195-1199.1983; LEIBOWITZ D, 1985, BLOOD, V66, P243; LEMAISTRE A, 1989, BLOOD, V73, P889; LIFSHITZ B, 1988, ONCOGENE, V2, P113; Maniatis T., 1982, MOL CLONING; MASERATI E, 1988, HUM GENET, V78, P248, DOI 10.1007/BF00291671; MILLS KI, 1988, BLOOD, V72, P1237; MIURA I, 1988, CANCER GENET CYTOGEN, V34, P53, DOI 10.1016/0165-4608(88)90168-9; MORRIS CM, 1986, NATURE, V320, P281, DOI 10.1038/320281a0; OHYASHIKI JH, 1988, CANCER GENET CYTOGEN, V35, P151, DOI 10.1016/0165-4608(88)90236-1; PALKA G, 1988, ANN GENET-PARIS, V31, P190; PRZEPIORKA D, 1988, CANCER GENET CYTOGEN, V36, P117, DOI 10.1016/0165-4608(88)90081-7; PUGH WC, 1985, BRIT J HAEMATOL, V60, P457, DOI 10.1111/j.1365-2141.1985.tb07443.x; ROSSON D, 1988, MUTAT RES, V195, P231, DOI 10.1016/0165-1110(88)90002-4; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOKAL JE, 1988, SEMIN HEMATOL, V25, P49; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAM K, 1985, NEW ENGL J MED, V313, P1429, DOI 10.1056/NEJM198512053132301; STRIFE A, 1988, SEMIN HEMATOL, V25, P1; SZABO P, 1988, MOL BIOL MED, V5, P139; VANDERPLAS DC, 1989, BLOOD, V73, P1038; VERMA RS, 1987, LEUKEMIA RES, V11, P833, DOI 10.1016/0145-2126(87)90068-3; VERMA RS, 1985, BLUT, V50, P129, DOI 10.1007/BF00320068; VERMA RS, 1989, HUMAN CHROMOSOMES MA; VERMA RS, 1988, IN VIVO, V2, P257; WEINSTEIN ME, 1988, CANCER GENET CYTOGEN, V55, P223; YOFFE G, 1987, EXP HEMATOL, V15, P725; YOUNG BD, 1988, BRIT J CANCER, V58, P58; Yunis J J, 1986, Important Adv Oncol, P93	59	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1145	1148						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2674857				2022-12-28	WOS:A1989AM53100015
J	FINLEY, GG; SCHULZ, NT; HILL, SA; GEISER, JR; PIPAS, JM; MEISLER, AI				FINLEY, GG; SCHULZ, NT; HILL, SA; GEISER, JR; PIPAS, JM; MEISLER, AI			EXPRESSION OF THE MYC GENE FAMILY IN DIFFERENT STAGES OF HUMAN COLORECTAL-CANCER	ONCOGENE			English	Article									UNIV PITTSBURGH,SCH MED,DEPT MED,PITTSBURGH,PA 15240; UNIV PITTSBURGH,VET ADM MED CTR,SCH MED,PITTSBURGH,PA 15240; UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA046547] Funding Source: NIH RePORTER; NCI NIH HHS [CA46547] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER RJ, 1986, GASTROENTEROLOGY, V91, P1503, DOI 10.1016/0016-5085(86)90208-8; ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; ASTLER VB, 1954, ANN SURG, V139, P846, DOI 10.1097/00000658-195406000-00015; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Bussey H.J.R., 1975, FAMILIAL POLYPOSIS C; CALABRETTA B, 1985, CANCER RES, V45, P6000; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; ERISMAN MD, 1988, CANCER RES, V48, P1350; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; Farber E, 1980, Adv Cancer Res, V31, P125, DOI 10.1016/S0065-230X(08)60658-2; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FOULDS L, 1975, NEOPLASTIC DEV, V2; GARDNER EJ, 1962, AM J HUM GENET, V14, P376; GOODRIDGE AG, 1984, ARCH BIOCHEM BIOPHYS, V230, P82, DOI 10.1016/0003-9861(84)90088-2; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRIFFITHS DFR, 1988, NATURE, V333, P461, DOI 10.1038/333461a0; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; JOHNSON LR, 1988, PHYSIOL REV, V68, P456, DOI 10.1152/physrev.1988.68.2.456; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; Maniatis T., 1982, MOL CLONING; MELTZER SJ, 1987, GASTROENTEROLOGY, V92, P1174, DOI 10.1016/S0016-5085(87)91074-2; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; POTTEN CS, 1979, BIOCHIM BIOPHYS ACTA, V560, P281, DOI 10.1016/0304-419X(79)90022-2; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RULEY HE, 1984, CANCER CELL, V2, P481; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHEINESS D, 1979, J VIROL, V31, P514, DOI 10.1128/JVI.31.2.514-521.1979; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART J, 1986, BRIT J CANCER, V53, P1, DOI 10.1038/bjc.1986.1; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TORELLI G, 1987, CANCER RES, V47, P5266; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	59	91	92	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					963	971						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2668847				2022-12-28	WOS:A1989AJ29700003
J	MAHADEVAN, LC; TARGETT, K; HEATH, JK				MAHADEVAN, LC; TARGETT, K; HEATH, JK			2-AMINOPURINE ABOLISHES EPIDERMAL GROWTH FACTOR-STIMULATED PHOSPHORYLATION OF COMPLEXED AND CHROMATIN-ASSOCIATED FORMS OF A 33KDA PHOSPHOPROTEIN	ONCOGENE			English	Article											MAHADEVAN, LC (corresponding author), UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND.							BERRIDGE MJ, 1986, ONCOGENES GROWTH CON, P147; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; BRAVO R, 1986, ONCOGENES GROWTH CON, P253; CHAN YL, 1988, J BIOL CHEM, V263, P2891; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DOWNES CP, 1985, MOL ASPECTS CELLULAR, V4, P3; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HERRLICH P, 1987, ENERGETICS CELL; HUNTER T, 1986, ONCOGENES GROWTH CON, P138; KAIBUCHI K, 1986, J BIOL CHEM, V261, P1187; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; MAHADEVAN LC, 1988, ONCOGENE, V2, P249; MAHADEVAN LC, 1989, RECEPTOR PRACTICAL A; MARTINPEREZ J, 1983, P NATL ACAD SCI-BIOL, V80, P926, DOI 10.1073/pnas.80.4.926; MOOLENAAR WH, 1986, ONCOGENES GROWTH CON, P160; NILSENHAMILTON M, 1981, ANAL BIOCHEM, V115, P438, DOI 10.1016/0003-2697(81)90030-0; NILSENHAMILTON M, 1979, NATURE, V279, P444, DOI 10.1038/279444a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLIVIER AR, 1988, P NATL ACAD SCI USA, V85, P4720, DOI 10.1073/pnas.85.13.4720; PARKER PJ, 1986, ONCOGENES GROWTH CON, P154; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; POUYSSEGUR J, 1985, CANCER CELL, V3, P409; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAMJOUE HPR, 1977, J BIOL CHEM, V252, P9065; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHIBANUMA M, 1987, EUR J BIOCHEM, V164, P15, DOI 10.1111/j.1432-1033.1987.tb10985.x; THOMAS G, 1980, CELL, V19, P1015, DOI 10.1016/0092-8674(80)90092-6; THOMAS G, 1979, P NATL ACAD SCI USA, V76, P3952, DOI 10.1073/pnas.76.8.3952; WETTENHALL REH, 1988, BIOCHEMISTRY-US, V27, P170, DOI 10.1021/bi00401a026; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	40	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					699	706						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2786618				2022-12-28	WOS:A1989AA66000005
J	ALEXANDER, WS; BERNARD, O; CORY, S; ADAMS, JM				ALEXANDER, WS; BERNARD, O; CORY, S; ADAMS, JM			LYMPHOMAGENESIS IN E-MU-MYC TRANSGENIC MICE CAN INVOLVE RAS MUTATIONS	ONCOGENE			English	Article									ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Cory, Suzanne/E-1642-2013; Adams, Jerry M/E-1199-2013	Cory, Suzanne/0000-0002-6818-3451; Adams, Jerry/0000-0002-4360-8628	NCI NIH HHS [CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; CLEVELAND JL, 1986, J CELL BIOCHEM, V30, P195, DOI 10.1002/jcb.240300303; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CORY S, 1983, EMBO J, V2, P697, DOI 10.1002/j.1460-2075.1983.tb01487.x; DIAMOND LE, 1988, MOL CELL BIOL, V8, P2233, DOI 10.1128/MCB.8.5.2233; EVA A, 1986, CARCINOGENESIS, V7, P1931, DOI 10.1093/carcin/7.11.1931; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GUERRERO I, 1985, P NATL ACAD SCI USA, V82, P7810, DOI 10.1073/pnas.82.23.7810; Hariharan I K, 1988, Oncogene Res, V3, P387; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; ISHIKAWA F, 1986, P NATL ACAD SCI USA, V83, P3209, DOI 10.1073/pnas.83.10.3209; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LANGDON WY, 1988, ONCOGENE RES, V3, P271; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARK GE, 1986, P NATL ACAD SCI USA, V83, P6312, DOI 10.1073/pnas.83.17.6312; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; PERUCHO M, 1980, COLD SPRING HARB SYM, V45, P829, DOI 10.1101/SQB.1981.045.01.101; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS E, 1983, P NATL ACAD SCI-BIOL, V80, P4679, DOI 10.1073/pnas.80.15.4679; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TOKSOZ D, 1987, ONCOGENE, V1, P409	37	47	48	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					575	581						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2657573				2022-12-28	WOS:A1989U768800007
J	TROJANOWSKA, M; WU, L; LEROY, EC				TROJANOWSKA, M; WU, L; LEROY, EC			ELEVATED EXPRESSION OF C-MYC PROTO-ONCOGENE IN SCLERODERMA FIBROBLASTS	ONCOGENE			English	Article											TROJANOWSKA, M (corresponding author), MED UNIV S CAROLINA,DEPT MED,DIV RHEUMATOL & IMMUNOL,CSB912,171 ASHLEY AVE,CHARLESTON,SC 29425, USA.			Trojanowska, Maria/0000-0001-9550-7178				ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; COLE MD, 1987, CURRENT COMMUNICATIO, P192; DALLAFAVERA R, 1987, CURRENT COMMUNICATIO, P152; FALANGA V, 1988, MAY ARA SCI M HOUST; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LEROY EC, 1981, COLLAGEN REL RES, V1, P301; LEROY EC, 1974, J CLIN INVEST, V54, P880, DOI 10.1172/JCI107827; LEROY EC, 1982, P NATL ACAD SCI-BIOL, V79, P1286, DOI 10.1073/pnas.79.4.1286; MANIATIS T, 1982, MOL CLONING LABORATO; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; PENN A, 1986, P NATL ACAD SCI USA, V83, P7951, DOI 10.1073/pnas.83.20.7951; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; ROSSI P, 1988, IN PRESS CELL; RUSSELL SB, 1988, P NATL ACAD SCI USA, V85, P587, DOI 10.1073/pnas.85.2.587; Smith E., UNPUB; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; UITTO J, 1979, J CLIN INVEST, V64, P921, DOI 10.1172/JCI109558; WHITE BA, 1982, J BIOL CHEM, V257, P8569	23	44	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					477	481						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3078955				2022-12-28	WOS:A1988Q773900018
J	DRAETTA, G; BEACH, D; MORAN, E				DRAETTA, G; BEACH, D; MORAN, E			SYNTHESIS OF P34, THE MAMMALIAN HOMOLOG OF THE YEAST CDC2+/CDC28 PROTEIN-KINASE, IS STIMULATED DURING ADENOVIRUS-INDUCED PROLIFERATION OF PRIMARY BABY RAT-KIDNEY CELLS	ONCOGENE			English	Article											DRAETTA, G (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.				NATIONAL CANCER INSTITUTE [P30CA045508, P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034607] Funding Source: NIH RePORTER; NCI NIH HHS [CA-13106, CA-45508] Funding Source: Medline; NIGMS NIH HHS [GM 34607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS RLP, 1967, J BIOL CHEM, V242, P1314; ANDERSON CW, 1974, P NATL ACAD SCI USA, V71, P2756, DOI 10.1073/pnas.71.7.2756; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; DOEFLER W, 1984, CURR TOP MICROBIOL I, V109; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; FERRARI S, 1987, BIOESSAYS, V7, P9, DOI 10.1002/bies.950070103; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HAYLES J, 1986, J CELL SCI, P155; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEWIS JB, 1980, CELL, V21, P303, DOI 10.1016/0092-8674(80)90138-5; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1980, GENETICS, V96, P627; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLNICK D, 1982, J VIROL, V42, P106, DOI 10.1128/JVI.42.1.106-113.1982; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEREB AJ, 1977, GENE, V2, P115, DOI 10.1016/0378-1119(77)90012-9; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	37	65	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1988	2	6					553	557						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	2838787				2022-12-28	WOS:A1988N841500004
J	GAUWERKY, CE; HOXIE, J; NOWELL, PC; CROCE, CM				GAUWERKY, CE; HOXIE, J; NOWELL, PC; CROCE, CM			PRE-B-CELL LEUKEMIA WITH A T(8-14) AND A T(14-18) TRANSLOCATION IS PRECEDED BY FOLLICULAR LYMPHOMA	ONCOGENE			English	Article									WISTAR INST ANAT & BIOL,3601 SPRUCE ST,PHILADELPHIA,PA 19104; UNIV PENN,CTR CANC,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NCI NIH HHS [CA 39860, CA 15822] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039860, P01CA015822] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER A, 1982, P NATL ACAD SCI-BIOL, V79, P3260, DOI 10.1073/pnas.79.10.3260; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; CROCE CM, 1986, COLD SPRING HARB SYM, V51, P891, DOI 10.1101/SQB.1986.051.01.102; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DOLBY TW, 1980, P NATL ACAD SCI US, V77, P6026; ERIKSON J, 1982, P NATL ACAD SCI-BIOL, V79, P5611, DOI 10.1073/pnas.79.18.5611; GALLAGHER CJ, 1986, J CLIN ONCOL, V4, P1470, DOI 10.1200/JCO.1986.4.10.1470; HALUSKA FG, 1987, P NATL ACAD SCI USA, V84, P6835, DOI 10.1073/pnas.84.19.6835; HALUSKA FG, 1986, NATURE, V324, P158, DOI 10.1038/324158a0; KORSMEYER SJ, 1981, P NATL ACAD SCI-BIOL, V78, P7096, DOI 10.1073/pnas.78.11.7096; MANIATIS T, 1984, MOL CLONING LABORATO; MCBRIDE OW, 1982, J EXP MED, V155, P1480, DOI 10.1084/jem.155.5.1480; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RICHARDSON ME, 1987, BLOOD, V70, P444; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; WIMAN KG, 1984, P NATL ACAD SCI-BIOL, V81, P6798, DOI 10.1073/pnas.81.21.6798; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108	25	109	110	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					431	435						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	3131717				2022-12-28	WOS:A1988N434800003
J	SUAREZ, HG; DUVILLARD, JA; CAILLOU, B; SCHLUMBERGER, M; TUBIANA, M; PARMENTIER, C; MONIER, R				SUAREZ, HG; DUVILLARD, JA; CAILLOU, B; SCHLUMBERGER, M; TUBIANA, M; PARMENTIER, C; MONIER, R			DETECTION OF ACTIVATED RAS ONCOGENES IN HUMAN THYROID CARCINOMAS	ONCOGENE			English	Article									INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy	SUAREZ, HG (corresponding author), INST RECH SCI CANC,F-94802 VILLEJUIF,FRANCE.							AZZARONE B, 1985, EXP CELL RES, V159, P451, DOI 10.1016/S0014-4827(85)80018-5; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BYAR DP, 1979, EUR J CANCER, V15, P1033, DOI 10.1016/0014-2964(79)90291-3; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DER CJ, 1983, CELL, V32, P201, DOI 10.1016/0092-8674(83)90510-X; FEINBERG AP, 1983, SCIENCE, V220, P1175, DOI 10.1126/science.6304875; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HEIDINGER LE, 1974, INT HISTOLOGICAL CLA, V11; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUAREZ HG, 1985, RETROVIRUSES HUMAN P, P509; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TERRIER P, 1987, IN PRESS BRIT J CANC; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WISEMAN RW, 1986, P NATL ACAD SCI USA, V83, P5825, DOI 10.1073/pnas.83.16.5825; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0	26	105	107	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					403	406						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3283656				2022-12-28	WOS:A1988M947200014
J	KOENEN, M; SIPPEL, AE; TRACHMANN, C; BISTER, K				KOENEN, M; SIPPEL, AE; TRACHMANN, C; BISTER, K			PRIMARY STRUCTURE OF THE CHICKEN C-MIL PROTEIN - IDENTIFICATION OF DOMAINS SHARED WITH OR ABSENT FROM THE RETROVIRAL V-MIL PROTEIN	ONCOGENE			English	Article									MAX PLANCK INST MOLEC GENET,OTTO WARBURG LAB,D-1000 BERLIN 33,FED REP GER; UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,NEUENHEIMER FELD 282,D-6900 HEIDELBERG,FED REP GER	Max Planck Society; Ruprecht Karls University Heidelberg			Bister, Klaus/AFA-9400-2022	Bister, Klaus/0000-0001-6545-5653				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BIEGALKE B, 1987, J VIROL, V61, P1949, DOI 10.1128/JVI.61.6.1949-1956.1987; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BISTER K, 1987, ADV VIRAL ONCOL, V6, P45; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; CARPENTER D, 1987, NATURE, V325, P107, DOI 10.1038/325107a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DOZIER C, 1987, MOL CELL BIOL, V7, P1995, DOI 10.1128/MCB.7.5.1995; FLORDELLIS CS, 1985, VIROLOGY, V141, P267, DOI 10.1016/0042-6822(85)90257-0; FUKUI M, 1987, MOL CELL BIOL, V7, P1776, DOI 10.1128/MCB.7.5.1776; GALIBERT F, 1984, EMBO J, V3, P1333, DOI 10.1002/j.1460-2075.1984.tb01972.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOELET P, 1982, P NATL ACAD SCI-BIOL, V79, P5818, DOI 10.1073/pnas.79.19.5818; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISHIKAWA F, 1986, P NATL ACAD SCI USA, V83, P3209, DOI 10.1073/pnas.83.10.3209; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; JANSEN HW, 1985, VIROLOGY, V142, P248, DOI 10.1016/0042-6822(85)90333-2; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; JANSEN HW, 1985, VIROLOGY, V143, P359, DOI 10.1016/0042-6822(85)90376-9; JANSEN HW, 1984, VIROLOGY, V137, P217, DOI 10.1016/0042-6822(84)90028-X; JANSEN HW, 1983, EMBO J, V2, P1969, DOI 10.1002/j.1460-2075.1983.tb01686.x; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KAN NC, 1983, P NATL ACAD SCI-BIOL, V80, P6566, DOI 10.1073/pnas.80.21.6566; KAN NC, 1984, P NATL ACAD SCI-BIOL, V81, P3000, DOI 10.1073/pnas.81.10.3000; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; LAPEYRE B, 1985, GENE, V37, P215, DOI 10.1016/0378-1119(85)90275-6; MANIATIS T, 1982, MOL CLONING LABORATO; MCDONNELL DP, 1987, SCIENCE, V235, P1214, DOI 10.1126/science.3029866; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MOELDERS H, 1985, EMBO (European Molecular Biology Organization) Journal, V4, P693; MURRAY AW, 1987, TRENDS BIOCHEM SCI, V12, P53, DOI 10.1016/0968-0004(87)90026-0; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; PALMIERI S, 1987, J VIROL, V61, P1717, DOI 10.1128/JVI.61.5.1717-1721.1987; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PATSCHINSKY T, 1986, MOL CELL BIOL, V6, P739, DOI 10.1128/MCB.6.2.739; RAMSAY G, 1982, EMBO J, V1, P1111, DOI 10.1002/j.1460-2075.1982.tb01305.x; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; TAHIRA T, 1987, NUCLEIC ACIDS RES, V15, P4809, DOI 10.1093/nar/15.12.4809; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; VANBEVEREN C, 1986, CURR TOP MICROBIOL, V123, P73; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7; WALTHER N, 1985, J VIROL, V54, P576, DOI 10.1128/JVI.54.2.576-585.1985; WEINBERGER C, 1985, NATURE, V318, P670, DOI 10.1038/318670a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0	62	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					179	185						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	3285296				2022-12-28	WOS:A1988M086000012
J	MUTHUSWAMY, SK; MULLER, WJ				MUTHUSWAMY, SK; MULLER, WJ			ACTIVATION OF SRC FAMILY KINASES IN NEU-INDUCED MAMMARY-TUMORS CORRELATES WITH THEIR ASSOCIATION WITH DISTINCT SETS OF TYROSINE-PHOSPHORYLATED PROTEINS IN-VIVO	ONCOGENE			English	Article						C-YES; FYN; TYROSINE PHOSPHORYLATION; MAMMARY TUMORS	GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; HUMAN-BREAST-CANCER; MIDDLE-T-ANTIGEN; SIGNAL-TRANSDUCTION; METASTATIC DISEASE; SH3 DOMAINS; ONCOGENE; SUBSTRATE; MICE	Overexpression and amplification of the erbB-2 (nea) is thought to play a major role in mammary cancer. Although studies suggest that Neu is directly involved in the genesis of mammary tumors, the molecular mechanism by which Neu induces tumors is not well understood. Recently, we have demonstrated that the activity of c-Src tyrosine kinase is elevated in Neu-induced mammary tumors and this elevated activity correlates with its capacity to physically associate with Neu. To explore whether other members of the c-Src family are activated in these mammary tumors, we measured the in vitro kinase activity of the c-Yes and Fyn kinases in protein extracts derived from mammary tumor tissue and morphological normal adjacent tissue. These analyses revealed that c-Yes kinase activity was elevated in Neu-induced tumors by comparison to the adjacent tissue. By contrast, no significant activation of the Fyn kinase was noted in these tumors. Activation of c-Yes tyrosine kinase correlated with the capacity of c-Yes to associate with Neu in vivo in lysates derived from primary tumor samples. Studies with Rat.2 fibroblasts overexpressing activated Neu revealed that c-Src requires the presence of tyrosine phosphoryated Neu for its ability to interact with Neu in vivo. Moreover, analyses using radiolabeled c-Yes SH2 fusion protein revealed that this interaction is Likely occurring in a direct fashion. Although both c-Src and c-Yes kinase associate with Neu in vivo, a tyrosine phosphorylated protein of 89 kd (p89) was found associated with c-Src but not with c-Yes in cell lysates derived from mammary epithelial cells transformed by either Neu or PyV middle T antigen. Furthermore, this tyrosine phosphorylated protein was not detected in c-Src complexes derived from fibroblasts transformed by either Neu or PyV middle T. These observations suggest that p89 associates with c-Src only in mammary epithelial cells and not in fibroblasts.	MCMASTER UNIV, DEPT BIOL, HAMILTON, ON, CANADA; MCMASTER UNIV, INST MOLEC BIOL & BIOTECHNOL, DEPT PATHOL, CANC RES GRP, HAMILTON, ON, CANADA	McMaster University; McMaster University			Muthuswamy, Senthil K/AGY-2834-2022	Muthuswamy, Senthil K/0000-0001-6564-9634				BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DOUGALL WC, 1994, ONCOGENE, V9, P2109; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; JALLAL B, 1992, J BIOL CHEM, V267, P4357; JANES PW, 1994, ONCOGENE, V9, P3601; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KIEFER F, 1994, CURR BIOL, V4, P100, DOI 10.1016/S0960-9822(94)00025-4; KLAGES S, 1993, ONCOGENE, V8, P713; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PARK JS, 1993, ONCOGENE, V8, P2627; PATERSON MC, 1991, CANCER RES, V51, P556; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RON D, 1992, BIOTECHNIQUES, V13, P866; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEGATTO O, 1992, ONCOGENE, V7, P1339; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; THOMAS JE, 1993, ONCOGENE, V8, P2521; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; ZHAN X, 1994, J BIOL CHEM, V269, P20221	58	80	87	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	1995	11	9					1801	1810						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478608				2022-12-28	WOS:A1995TD09400015
J	XU, L; MENG, Y; WALLEN, R; DEPINHO, RA				XU, L; MENG, Y; WALLEN, R; DEPINHO, RA			LOSS OF TRANSCRIPTIONAL ATTENUATION IN N-MYC IS ASSOCIATED WITH PROGRESSION TOWARDS A MORE MALIGNANT PHENOTYPE	ONCOGENE			English	Article						N-MYC PROTOONCOGENE; TRANSCRIPTIONAL ATTENUATION; MALIGNANT PROGRESSION	ZINC-FINGER PROTEIN; C-MYC; SEQUENCE REQUIREMENTS; GENE-EXPRESSION; 1ST EXON; CELLS; ELONGATION; FAMILY; BLOCK; PROMOTER	The modulation of RNA polymerase II processivity through the untranslated N-myc first exon represents an important mechanism governing N-myc mRNA levels during normal development. In this study, we employed the rat embryo fibroblast (REF) cooperation assay as a functional means to (i) map N-myc first exon sequences involved in the regulation of N-myc gene expression and specifically their contribution to controlling a block to transcriptional elongation and (ii) determine whether this transcriptional control mechanism plays a role in governing the oncogenic activity of N-myc. Transfection of N-myc expression constructs harboring various deletions within the untranslated first exon revealed that a region encoding a potential stem-loop structure followed by a thymine stretch (stem-loop/T region) was required for efficient transcriptional attenuation. The increase in transcriptional read-through associated with all deletions involving the stem-loop/T region also resulted in a more aggressive malignant phenotype as evidenced by a significant enhancement in the subcloning efficiency of N-myc/ras transformed foci. Most significantly, when cell lines generated from overexpression of the intact N-myc expression construct were selected for anchorage-independent growth, a strong block to transcriptional elongation was completely eliminated in all cases examined. Since the subcloning efficiency of transformed foci and the capacity of permanently established cell lines for anchorage-independent growth are direct correlates of more advanced stages of malignant transformation, our findings suggest that loss of transcriptional attenuation represents an important genetic event in the progression of N-myc-induced cellular transformation.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine				DePinho, Ronald/0000-0002-5625-577X	NICHD NIH HHS [HD283117 2P30CA13330-20] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; RAMAMURTHY V, 1990, MOL CELL BIOL, V10, P1484, DOI 10.1128/MCB.10.4.1484; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2456, DOI 10.1128/MCB.13.4.2456; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SPENCER CA, 1990, ONCOGENE, V5, P777; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; XU L, 1993, ONCOGENE, V8, P2547; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	31	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	1995	11	9					1865	1872						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478616				2022-12-28	WOS:A1995TD09400023
J	FERRAO, P; MACMILLAN, EM; ASHMAN, LK; GONDA, TJ				FERRAO, P; MACMILLAN, EM; ASHMAN, LK; GONDA, TJ			ENFORCED EXPRESSION OF FULL-LENGTH C-MYB LEADS TO DENSITY-DEPENDENT TRANSFORMATION OF MURINE HEMATOPOIETIC-CELLS	ONCOGENE			English	Article						MYB; TRANSFORMATION; FULL-LENGTH; DENSITY-DEPENDENCE; RETROVIRUS	AVIAN-MYELOBLASTOSIS VIRUS; PLASMACYTOID LYMPHOSARCOMAS; ERYTHROLEUKEMIA-CELLS; HEMATOPOIETIC-CELLS; PROTEIN TRUNCATION; ONCOGENE PRODUCT; COLON-CARCINOMA; DNA-BINDING; ACTIVATION; DIFFERENTIATION	The oncogenic activation of c-myb has been associated with structural alterations to the Myb protein. Although such alterations can increase the ability of Myb to transform haemopoietic cells, it has been unresolved whether over-expression of wild type (WT) c-Myb can lead to transformation. We show here that infection with a retrovirus that expresses WT i.e. full length c-Myb leads to transformation of primary haemopoietic cells (as indicated by clonogenic assays). The transformed cells are similar to those obtained with carboxyl-truncated (CT) c-Myb in that they show phenotypic and morphological characteristics of early myeloid cells and remain dependent on exogenous growth factors. Cells expressing WTMyb form lower numbers of colonies on average and have a greater tendency to spontaneously differentiate than those expressing truncated c-Myb. Additionally, our results show that transformation by both forms of Myb is dependent on the density at which the infected cells are cultured, and that low levels of transformation can be increased by addition of conditioned medium from myb transformed cells grown at high density. This implies that transformation can be enhanced by the effects of an autocrine growth factor. Moreover, the production of, or sensitivity to, such a factor may be influenced by Myb itself, since CT Myb-infected cells cultured at low densities show higher levels of transformation than WT Myb-infected cells.	INST MED & VET SCI,DIV HUMAN IMMUNOL,ADELAIDE,SA 5000,AUSTRALIA; INST MED & VET SCI,HANSON CTR CANC RES,ADELAIDE,SA 5000,AUSTRALIA; INST MED & VET SCI,DIV HAEMATOL,LEUKAEMIA RES UNIT,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia; Institute Medical & Veterinary Science Australia; Institute Medical & Veterinary Science Australia			ASHMAN, LEONIE/G-7631-2013	ASHMAN, LEONIE/0000-0003-3559-3611				ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BARTELLA C, 1987, SCIENCE, V235, P1064; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; GARRIDO C, 1992, J VIROL, V66, P6773, DOI 10.1128/JVI.66.11.6773-6776.1992; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1993, BLOOD, V82, P2813; GONDA TJ, 1991, SEMINARS VIROLOGY, V2, P351; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HU YL, 1991, ONCOGENE, V6, P1549; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; MACMILLAN EM, 1994, BLOOD, V83, P209; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; METCALF D, 1982, INT J CANCER, V30, P773, DOI 10.1002/ijc.2910300616; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WEINSTEIN Y, 1987, J VIROL, V61, P2339, DOI 10.1128/JVI.61.7.2339-2343.1987; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WINQVIST R, 1985, CANCER GENET CYTOGEN, V18, P251, DOI 10.1016/0165-4608(85)90090-1; YANAGISAWA H, 1991, BIOCHIM BIOPHYS ACTA, V1088, P3810	38	43	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1631	1638						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478588				2022-12-28	WOS:A1995TC53500022
J	PORCELLINI, A; CIULLO, I; PANNAIN, S; FENZI, G; AVVEDIMENTO, E				PORCELLINI, A; CIULLO, I; PANNAIN, S; FENZI, G; AVVEDIMENTO, E			SOMATIC MUTATIONS IN THE VI-TRANSMEMBRANE SEGMENT OF THE THYROTROPIN RECEPTOR CONSTITUTIVELY ACTIVATE CAMP SIGNALING IN THYROID HYPERFUNCTIONING ADENOMAS	ONCOGENE			English	Article						THYROTROPIN RECEPTOR; CAMP-DEPENDENT TRANSCRIPTION PCR; MUTATIONS; NEOPLASMS GENETICS	PHOSPHATIDYLINOSITOL; ONCOGENE; TUMORS	We have discovered two somatic mutations in the VI transmembrane domain of the thyrotropin receptor gene in thyroid hyperfunctioning adenomas, The mutated amino acid residues are phenylalanine 631 (to cysteine) and threonine 632 (to isoleucine), Cloning and expression of the mutated versions of the receptor in COS cells increased significantly the basal and the TSH-induced cAMP levels compared to the wild type receptor, Moreover, the expression of a reporter gene under the control of the cAMP-inducible promoter, was likewise constitutively activated in cells expressing the 631 and 632 TSH receptor mutants relative to the wild type, These data indicate that the VI transmembrane segment in the TSH receptor and presumably in the other G-protein coupled receptors is a critical domain for the activation of G-protein signalling and that the mutations described here may be the cause of the thyroid hyperfunctioning adenoma.	UNIV REGGIO CALABRIA, FAC MED CATANZARO, DIPARTIMENTO MED SPERIMENTALE, CATANZARO, ITALY; UNIV NAPLES FEDERICO II, FAC MED, DIPARTIMENTO ENDOCRINOL, I-80131 NAPLES, ITALY; UNIV NAPLES FEDERICO II, CTR ENDOCRINOL & ONCOL MOLEC, I-80131 NAPLES, ITALY	Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; University of Naples Federico II; University of Naples Federico II			Porcellini, Antonio/E-1900-2011	Porcellini, Antonio/0000-0001-6882-9518				AVVEDIMENTO VE, 1984, BIOCHEM BIOPH RES CO, V122, P472; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAENHAUT C, 1991, BIOCHIMIE, V73, P29, DOI 10.1016/0300-9084(91)90070-H; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PASCHKE R, 1994, J CLIN ENDOCR METAB, V79, P1785, DOI 10.1210/jc.79.6.1785; PORCELLINI A, 1994, J CLIN ENDOCR METAB, V79, P657, DOI 10.1210/jc.79.2.657; REN Q, 1993, J BIOL CHEM, V268, P16483; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SUAREZ HG, 1991, ONCOGENE, V6, P677; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P109	22	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	1995	11	6					1089	1093						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566968				2022-12-28	WOS:A1995RX18000011
J	XUAN, JW; CHIN, JL; GUO, YZ; CHAMBERS, AF; FINKELMAN, MA; CLARKE, MW				XUAN, JW; CHIN, JL; GUO, YZ; CHAMBERS, AF; FINKELMAN, MA; CLARKE, MW			ALTERNATIVE SPLICING OF PSP94 (PROSTATIC SECRETORY PROTEIN OF 94 AMINO-ACIDS) MESSENGER-RNA IN PROSTATE TISSUE	ONCOGENE			English	Article						PROSTATE TUMOR; PSP94 (PROSTATIC SECRETORY PROTEIN OF 94 AMINO ACIDS); ALTERNATIVE SPLICING; CDNA SEQUENCE	INHIBIN-LIKE MATERIAL; HUMAN SEMINAL PLASMA; HUMAN BETA-MICROSEMINOPROTEIN; CARCINOMA CELL-LINES; MOLECULAR-CLONING; RHESUS-MONKEY; SEQUENCE; PEPTIDE; GENE; EXPRESSION	While performing reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of total mRNA from prostate cancer specimens, two forms of PSP94 cDNA were detected, RT-PCR products were analysed by Southern blotting and probing with exon-specific oligonucleotides, In the short form of PSP94 mRNA, designated as PSP57, exon III was found to be deleted, The two mRNA forms were confirmed by cloning and sequencing of the RT-PCR products and were found to result from alternative splicing, The alternatively spliced form, PSP57, was characterized by sequence analysis, PSP94 and PSP57 possess identical exons I and II, including identical secretion signal peptide and the 5' untranslated sequences, PSP57 has a frame-shifted exon IV and encodes a putative 57 amino acid protein with a navel, highly basic C-terminus of 41 amino acids, PSP57 mRNA was detected in other urogenital tissues (kidney, bladder) and in most tumor cell lines tested, but was not detectable in other tissues such as breast and lung, In prostate tumor cell lines, PSP57 mRNA was aberrantly spliced and localized in the nuclear fraction of the cell, Our results suggest the possible existence of a novel PSP protein that originates from alternative splicing of PSP94 mRNA in urogenital tissues.	UNIV WESTERN ONTARIO,DEPT SURG,DIV UROL,LONDON,ON N6A 5C1,CANADA; UNIV WESTERN ONTARIO,DEPT ONCOL,LONDON,ON N6A 5C1,CANADA; UNIV WESTERN ONTARIO,LONDON REG CANC CTR,LONDON,ON N6A 5C1,CANADA; UNIV WESTERN ONTARIO,DEPT MICROBIOL & IMMUNOL,LONDON,ON N6A 5C1,CANADA; PROCYON BIOPHARMA INC,LONDON,ON N6L 1A8,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)			Chambers, Ann F/L-6285-2015	Chambers, Ann F/0000-0002-9509-5123				ABRAHAMSSON PA, 1988, PROSTATE, V12, P39, DOI 10.1002/pros.2990120106; AKIYAMA K, 1985, BIOCHIM BIOPHYS ACTA, V829, P288, DOI 10.1016/0167-4838(85)90200-6; ALPERT G, 1992, J INFECT DIS, V165, P494, DOI 10.1093/infdis/165.3.494; BRAR A, 1988, J ANDROL, V99, P253; DOCTOR VM, 1986, BRIT J CANCER, V53, P547, DOI 10.1038/bjc.1986.85; DUBE JY, 1987, J UROLOGY, V138, P883, DOI 10.1016/S0022-5347(17)43408-2; DUBE JY, 1987, J ANDROL, V8, P182; FISHER CJ, 1994, CRIT CARE MED, V22, P553, DOI 10.1097/00003246-199404000-00008; FOA C, 1977, CANCER RES, V37, P3957; GARDE S, 1993, PROSTATE, V22, P225, DOI 10.1002/pros.2990220305; GARDE SV, 1993, CANCER LETT, V70, P159, DOI 10.1016/0304-3835(93)90226-Y; GREEN CB, 1990, BIOCHEM BIOPH RES CO, V167, P1184, DOI 10.1016/0006-291X(90)90648-7; HARA M, 1989, J LAB CLIN MED, V113, P541; KHARBANDA K, 1990, PROSTATE, V16, P163, DOI 10.1002/pros.2990160207; KHARBANDA K, 1991, PROSTATE, V18, P59, DOI 10.1002/pros.2990180106; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG ZG, 1991, BIOCHEM BIOPH RES CO, V180, P356, DOI 10.1016/S0006-291X(05)81300-2; LIU AY, 1993, CANCER LETT, V74, P91, DOI 10.1016/0304-3835(93)90049-F; LOKESHWAR BL, 1993, CANCER RES, V53, P4855; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MARRA MM, 1992, J IMMUNOL, V144, P662; MBIKAY M, 1987, DNA-J MOLEC CELL BIO, V6, P23, DOI 10.1089/dna.1987.6.23; MUNDLE SD, 1993, CELL BIOL INT, V17, P587, DOI 10.1006/cbir.1993.1103; MUTA T, 1987, J BIOCHEM-TOKYO, V101, P1321, DOI 10.1093/oxfordjournals.jbchem.a121999; NOLET S, 1991, GENOMICS, V9, P775, DOI 10.1016/0888-7543(91)90375-O; NOLET S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P247, DOI 10.1016/0167-4781(91)90016-F; PRICE JE, 1990, CANCER RES, V50, P717; SAMBROOK J, 1969, MOL CLONING LABORATO; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; SEIDAH NG, 1984, FEBS LETT, V175, P349, DOI 10.1016/0014-5793(84)80766-8; SHETH AR, 1991, PERSPECTIVE PRIMATES, P235; SHETH AR, 1988, PROGR ENDOCRINOLOGY, P301; SHETH NA, 1987, CANCER LETT, V36, P93, DOI 10.1016/0304-3835(87)90106-6; SHETH NA, 1987, INHIBINS, V2, P109; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STARR L, 1992, BIOTECHNIQUES, V13, P612; TENI TR, 1988, CANCER LETT, V43, P9, DOI 10.1016/0304-3835(88)90205-4; ULVSBACK M, 1989, BIOCHEM BIOPH RES CO, V164, P1310, DOI 10.1016/0006-291X(89)91812-3; ULVSBACK M, 1991, GENOMICS, V11, P920, DOI 10.1016/0888-7543(91)90015-7; XUAN JW, 1994, GENOMICS, V20, P129, DOI 10.1006/geno.1994.1139; XUAN JW, 1994, J CELL BIOCHEM, V54, P247, DOI 10.1002/jcb.240540213	41	32	37	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1041	1047						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566962				2022-12-28	WOS:A1995RX18000005
J	HAMAGUCHI, M; YAMAGATA, S; THANT, AA; XIAO, HY; IWATA, H; MAZAKI, T; HANAFUSA, H				HAMAGUCHI, M; YAMAGATA, S; THANT, AA; XIAO, HY; IWATA, H; MAZAKI, T; HANAFUSA, H			AUGMENTATION OF METALLOPROTEINASE (GELATINASE) ACTIVITY SECRETED FROM ROUS-SARCOMA VIRUS-INFECTED CELLS CORRELATES WITH TRANSFORMING ACTIVITY OF SRC	ONCOGENE			English	Article						SRC; TRANSFORMATION; ROUS SARCOMA VIRUS; METALLOPROTEINASE; GELATINASE	CHICKEN-EMBRYO FIBROBLASTS; BASEMENT-MEMBRANE COLLAGEN; PROTEIN-KINASE ACTIVITY; GENE-PRODUCT; MORPHOLOGICAL TRANSFORMATION; TYROSINE PHOSPHORYLATION; TISSUE INHIBITOR; C-SRC; ASSOCIATION; MATRIX	To search for the biochemical properties of cells relevant to transformation by p60(v-src), we examined the activities and amounts of metalloproteinase (gelatinase) released from chicken embryonic fibroblasts infected with various mutants of Rous sarcoma virus by zymography and immunoblotting, While nontransforming Src proteins, including cellular p60(c-src) and its nonmyristylated form, had no stimulatory effect, wild-type p60(v-src) and the transforming mutant of cellular p60(c-src) stimulated the secretion and proteolytic activation of metalloproteinases, Moreover, the activation of metalloproteinase secretion strongly correlated with the invasiveness of cells assayed by the modified Boyden Chamber method, Chimeric mutants between v-src and c-src, which are transforming but produce less distinct morphological changes in infected cells, also stimulated the secretion of metalloproteinases as well as wild-type p60(v-src). Deletion mutants of v-Src in which varying portions of the NH2-terminal half of p60(v-src) are deleted stimulated secretion to a level similar to that of wild-type regardless of the degree of morphological change they induce, Together with Src protein, other oncogene products including Yes, Fps, ErbB and Crk were also found to stimulate the secretion of metalloproteinases, Thus, these results suggest that transformation of cells with src and other oncogenes is closely secretion of metalloproteinases associated with the enhanced that may play an important role in tumor invasion and metastasis.	AICHI CANC CTR,RES INST,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; ROCKEFELLER UNIV,NEW YORK,NY 10021	Aichi Cancer Center; Rockefeller University	HAMAGUCHI, M (corresponding author), NAGOYA UNIV,SCH MED,DEPT MOLEC PATHOGENESIS,SHOWA KU,TSURUMAI CHO 65,NAGOYA,AICHI 466,JAPAN.							ALBINI A, 1987, CANCER RES, V47, P3239; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; CHEN JM, 1991, J BIOL CHEM, V266, P5113; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; FELDMAN RA, 1983, J VIROL, V45, P782, DOI 10.1128/JVI.45.2.782-791.1983; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HANAFUSA H, 1969, P NATL ACAD SCI USA, V77, P1311; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HAYMAN MJ, 1983, CELL, V32, P579, DOI 10.1016/0092-8674(83)90477-4; HOWARD EW, 1991, J BIOL CHEM, V266, P13070; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KAWAI S, 1980, P NATL ACAD SCI-BIOL, V77, P6199, DOI 10.1073/pnas.77.10.6199; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; LIOTTA LA, 1986, CANCER RES, V46, P1; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MULLINS DE, 1983, BIOCHIM BIOPHYS ACTA, V695, P177, DOI 10.1016/0304-419X(83)90011-2; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; STETLERSTEVENSO.WG, 1989, J BIOL CHEM, V264, P1353; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YAMADA KM, 1978, NATURE, V275, P179, DOI 10.1038/275179a0; YAMAGATA S, 1991, CANCER LETT, V59, P51, DOI 10.1016/0304-3835(91)90135-5	38	61	63	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1037	1043						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7535415				2022-12-28	WOS:A1995QN35300002
J	WANG, XJ; GREENHALGH, DA; LU, XR; BICKENBACH, JR; ROOP, DR				WANG, XJ; GREENHALGH, DA; LU, XR; BICKENBACH, JR; ROOP, DR			TGF-ALPHA AND V-FOS COOPERATION IN TRANSGENIC MOUSE EPIDERMIS INDUCES ABERRANT KERATINOCYTE DIFFERENTIATION AND STABLE, AUTONOMOUS PAPILLOMAS	ONCOGENE			English	Article						CARCINOGENESIS; DIFFERENTIATION; ONCOGENE; GROWTH FACTOR	GROWTH-FACTOR-ALPHA; GRB2 ADAPTER PROTEIN; C-FOS; SKIN CARCINOGENESIS; HA-RAS; GENE-EXPRESSION; NUCLEOTIDE EXCHANGE; ALTERED REGULATION; PHORBOL ESTERS; MICE	To assess the synergistic effect of growth and transcription factor deregulation on carcinogenesis in vivo, mating experiments were performed between transgenic mice expressing human TGF alpha or v-fos exclusively in the epidermis by means of a human keratin K1-based targeting vector (HK1.fos, HK1.TGF alpha and HK1.fos/alpha). While HK1.TGF alpha mice exhibited mild epidermal hyperplasia resulting in a wrinkled appearance, this hyperplasia was significantly increased in HK1,fos/alpha mice which also exhibited a novel opalescent and peeling skin phenotype, HK1.fos/alpha keratinocyte differentiation was considerably deregulated with cornified cells appearing in the granular layer, granular cells in the spinous layer and a sixfold increase in BrdU labeling over normal. In addition, hyperplastic HK1.fos/alpha epidermis exhibited aberrant loricrin, filagrin and novel K13 expression associated with v-fos expression, Unlike adult HK1.TGF alpha controls, hyperplasia persisted in HK1,fos/alpha adults which also rapidly developed autonomous squamous cell papillomas, These results demonstrate that v-fos and TGF alpha over-expression can cooperate to reprogram keratinocyte differentiation and elicit the early stages of neoplasia. Moreover, TGF alpha over-expression appeared to play an early, initiating role in HK1.fos/alpha papilloma etiology, and a promotion role in the accelerated appearance of v-fos wound-associated preneoplastic phenotypes, However, the stable persistence of HK1.fos/alpha papillomas for up to 12 months, suggests that additional events are required for malignant conversion.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT DERMATOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine					NATIONAL CANCER INSTITUTE [R01CA052607] Funding Source: NIH RePORTER; NCI NIH HHS [CA52607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BASSETSEGUIN N, 1994, ONCOGENE, V9, P765; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHANG EH, 1982, NATURE, V297, P478; CHARDIN P, 1993, SCIENCE, V260, P1358; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORI G, 1994, SEMIN CANCER BIOL, V5, P3; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CUTRY AF, 1988, BIOCHEM BIOPH RES CO, V152, P216, DOI 10.1016/S0006-291X(88)80702-2; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FINZI E, 1988, MOL CARCINOGEN, V1, P7, DOI 10.1002/mc.2940010105; FISHER C, 1991, DEVELOPMENT, V111, P253; FRIEDBERG T, 1990, ARCH BIOCHEM BIOPHYS, V279, P167, DOI 10.1016/0003-9861(90)90477-G; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FURSTENBERGER G, 1989, INT J CANCER, V43, P915; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLICK AB, 1991, MOL CARCINOGEN, V4, P210, DOI 10.1002/mc.2940040308; GREENHALGH DA, 1990, P NATL ACAD SCI USA, V87, P643, DOI 10.1073/pnas.87.2.643; GREENHALGH DA, 1994, ADV CANCER RES, V64, P247, DOI 10.1016/S0065-230X(08)60840-4; GREENHALGH DA, 1993, CANCER RES, V53, P5071; GREENHALGH DA, 1993, ONCOGENE, V8, P2145; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HAYAT MA, 1972, BASIC ELECTRON MICRO; HOGAN B, 1982, MANIPULATING MOUSE E; HUITFELDT HS, 1991, CARCINOGENESIS, V12, P2063, DOI 10.1093/carcin/12.11.2063; IMAMOTO A, 1991, MOL CARCINOGEN, V4, P52, DOI 10.1002/mc.2940040109; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JHAPPAN C, 1994, CELL GROWTH DIFFER, V5, P385; KIM SH, 1993, J CELL BIOL, V123, P87; LAND H, 1983, NATURE, V304, P546; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LU B, 1994, J BIOL CHEM, V269, P7443; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROOP DR, 1988, CANCER RES, V48, P3245; ROSEJOHN S, 1988, CARCINOGENESIS, V9, P831, DOI 10.1093/carcin/9.5.831; ROTHNAGEL JA, 1987, J BIOL CHEM, V262, P15643; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAGER SM, 1991, NEUROSCI RES, V29, P549; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SHAUI K, 1993, SCIENCE, V261, P1744; SINN E, 1987, CELL, V49, P415; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH GH, 1990, CELL GROWTH DIFFER, V1, P161; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TOFTGARD R, 1985, CARCINOGENESIS, V6, P655, DOI 10.1093/carcin/6.4.655; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; VAUGHAN TJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P322, DOI 10.1016/0167-4781(92)90170-5; WANG XJ, 1994, MOL CARCINOGEN, V10, P15, DOI 10.1002/mc.2940100104; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; YUSPA SH, 1980, TRANSPLANT P, V12, P114	68	42	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					279	289						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7530825				2022-12-28	WOS:A1995QC62400007
J	EHRHART, JC; DUTHU, A; ULLRICH, S; APPELLA, E; MAY, P				EHRHART, JC; DUTHU, A; ULLRICH, S; APPELLA, E; MAY, P			SPECIFIC INTERACTION BETWEEN A SUBSET OF THE P53-PROTEIN FAMILY AND HEAT-SHOCK PROTEINS HSP72/HSC73 IN A HUMAN OSTEO-SARCOMA CELL-LINE	ONCOGENE			English	Article									NCI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	EHRHART, JC (corresponding author), INST RECH SCI CANC,UNITE ONCOL MOLEC,BP 8,F-94802 VILLEJUIF,FRANCE.							BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; CHO HY, 1976, SCIENCE, V194, P951, DOI 10.1126/science.62397; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CRAWFORD LV, 1982, ADV VIRAL ONCOL, P3; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; DUTHU A, 1985, VIROLOGY, V147, P275, DOI 10.1016/0042-6822(85)90130-8; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; Franza BR, 1984, CANC CELLS, V1, P137; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KLEIN G, 1982, ADV VIRAL ONCOLOGY, V2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1987, ONCOGENE, V1, P241; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATLASHEWSKI G, 1987, ONCOGENE RES, V1, P77; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MCALLISTER RM, 1971, CANCER-AM CANCER SOC, V27, P397, DOI 10.1002/1097-0142(197102)27:2<397::AID-CNCR2820270224>3.0.CO;2-X; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MORRISON B, 1983, J VIROL, V47, P106, DOI 10.1128/JVI.47.1.106-114.1983; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; RHIM JS, 1977, INT J CANCER, V19, P505, DOI 10.1002/ijc.2910190411; RHIM JS, 1975, INT J CANCER, V16, P840, DOI 10.1002/ijc.2910160516; RHIM JS, 1975, NATURE, V256, P751, DOI 10.1038/256751a0; ROGERS MJ, 1979, P NATL ACAD SCI USA, V76, P1415, DOI 10.1073/pnas.76.3.1415; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SEFTON BM, 1982, J VIROL, V44, P467, DOI 10.1128/JVI.44.2.467-474.1982; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TAINSKY MA, 1987, MOL CELL BIOL, V7, P1280, DOI 10.1128/MCB.7.3.1280; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YANG YHJ, 1979, J GEN VIROL, V43, P447	57	84	86	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					595	603						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	2978869				2022-12-28	WOS:A1988R516300017
J	MANNE, V				MANNE, V			A NOVEL CANDIDATE FOR RECEPTOR-COUPLED PHOSPHOLIPASE-C PURIFIED FROM HUMAN-PLATELETS	ONCOGENE			English	Article											MANNE, V (corresponding author), WISTAR INST ANAT & BIOL,36TH ST & SPRUCE,PHILADELPHIA,PA 19104, USA.		manne, veeraswamy/B-1954-2010	manne, veeraswamy/0000-0002-1179-5529	PHS HHS [21124] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BANNO Y, 1986, BIOCHEM BIOPH RES CO, V136, P713, DOI 10.1016/0006-291X(86)90498-5; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BILLAH MM, 1980, J BIOL CHEM, V255, P227; CHAU LY, 1982, BIOCHIM BIOPHYS ACTA, V713, P344; COCKCROFT S, 1984, BIOCHEM J, V221, P477, DOI 10.1042/bj2210477; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; DAWSON RMC, 1973, FORM FUNCTION PHOSPH, P97; DECKMYN H, 1986, J BIOL CHEM, V261, P6553; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; HAKATA H, 1982, J BIOCHEM-TOKYO, V92, P929, DOI 10.1093/oxfordjournals.jbchem.a134008; HIRASAWA K, 1982, BIOCHEM J, V205, P437, DOI 10.1042/bj2050437; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; IRVINE RF, 1982, CELL CALCIUM, V3, P295, DOI 10.1016/0143-4160(82)90018-5; IRVINE RF, 1984, BIOCHEM J, V218, P177, DOI 10.1042/bj2180177; JACKOWSKI S, 1986, J BIOL CHEM, V261, P4978; KATAN M, 1987, EUR J BIOCHEM, V168, P413, DOI 10.1111/j.1432-1033.1987.tb13435.x; LENSTRA R, 1984, BIOCHIM BIOPHYS ACTA, V792, P199, DOI 10.1016/0005-2760(84)90223-6; LITOSCH I, 1985, J BIOL CHEM, V260, P5464; LOW MG, 1983, BIOCHEM J, V215, P325, DOI 10.1042/bj2150325; LOW MG, 1986, BIOCHEM J, V237, P139, DOI 10.1042/bj2370139; MAJERUS PW, 1984, CELL, V37, P701, DOI 10.1016/0092-8674(84)90405-7; MANNE V, 1987, BIOCHEM J, V243, P763, DOI 10.1042/bj2430763; MANNE V, 1987, ONCOGENE, V2, P49; NAKAMURA K, 1985, THROMB RES, V38, P513, DOI 10.1016/0049-3848(85)90184-7; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; REBECCHI MJ, 1987, BIOCHEM J, V245, P49, DOI 10.1042/bj2450049; RUGGIERO M, 1985, BIOCHEM BIOPH RES CO, V131, P1198, DOI 10.1016/0006-291X(85)90218-9; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1986, BIOCHEM BIOPH RES CO, V136, P713; SIESS W, 1983, BIOCHIM BIOPHYS ACTA, V752, P329, DOI 10.1016/0005-2760(83)90131-5; SMITH CD, 1985, J BIOL CHEM, V260, P5875; WILCHEK M, 1984, METHOD ENZYMOL, V104, P3	35	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					579	585						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	2856255				2022-12-28	WOS:A1988R516300015
J	LAVIALLE, C; MODJTAHEDI, N; CASSINGENA, R; BRISON, O				LAVIALLE, C; MODJTAHEDI, N; CASSINGENA, R; BRISON, O			HIGH C-MYC AMPLIFICATION LEVEL CONTRIBUTES TO THE TUMORIGENIC PHENOTYPE OF THE HUMAN-BREAST CARCINOMA CELL-LINE SW-613-S	ONCOGENE			English	Article									INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,UA 1158,F-94805 VILLEJUIF,FRANCE; INST RECH SCI CANC,CNRS,ER 278,F-94802 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS)			MODJTAHEDI, Nazanine/D-4377-2017; Lavialle, Christian/B-3775-2009; Lavialle, Christian/O-2329-2019					ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARLONI G, 1988, FEBS LETT, V233, P268, DOI 10.1016/0014-5793(88)80440-X; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DRON D, 1986, MOL CELL BIOL, V6, P1374; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JOHNSON BE, 1986, J CLIN INVEST, V78, P525, DOI 10.1172/JCI112604; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; LEVINSON AD, 1986, TRENDS GENET, V2, P81, DOI 10.1016/0168-9525(86)90184-8; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MACIEIRACOELHO A, 1982, EXP CELL RES, V141, P325, DOI 10.1016/0014-4827(82)90220-8; MODJTAHEDI N, 1985, CANCER RES, V45, P4372; MODJTAHEDI N, 1988, EXP CELL RES, V174, P58, DOI 10.1016/0014-4827(88)90142-5; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NICOLAS JF, 1983, COLD SPRING HARBOR C, V10, P469; NISHIMURA S, 1987, BIOCHEM J, V243, P313, DOI 10.1042/bj2430313; SANTOS E, 1983, P NATL ACAD SCI-BIOL, V80, P4679, DOI 10.1073/pnas.80.15.4679; SCHWAB M, 1985, NATURE, V315, P345, DOI 10.1038/315345a0; SHIMKE RT, 1984, CELL, V37, P705; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; SUAREZ HG, 1987, ONCOGENE RES, V1, P201; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; VARMUS HE, 1984, ANNU REV GENET, V18, P553; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513	36	43	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					335	339						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	3060796				2022-12-28	WOS:A1988Q436700013
J	FUJIWARA, S; FISHER, RJ; SETH, A; BHAT, NK; SHOWALTER, SD; ZWEIG, M; PAPAS, TS				FUJIWARA, S; FISHER, RJ; SETH, A; BHAT, NK; SHOWALTER, SD; ZWEIG, M; PAPAS, TS			CHARACTERIZATION AND LOCALIZATION OF THE PRODUCTS OF THE HUMAN HOMOLOGS OF THE V-ETS ONCOGENE	ONCOGENE			English	Article									NCI, MOLEC ONCOL LAB, FREDERICK, MD 21701 USA; PROGRAM RESOURCES INC, NUCL ACID & PROT SYNTH LAB, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fisher, Robert/B-1431-2009					BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIAZ MO, 1986, SCIENCE, V231, P265, DOI 10.1126/science.3455787; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; Drabkin H.D., 1986, ADV GENE TECHNOLOGY, P112; ELDER JH, 1977, J BIOL CHEM, V252, P6510; FUJIWARA S, 1987, ADV GENE TECHNOLOGY, P77; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HOFFMANN GR, 1985, ANEUPLOIDY ETIOLOGY, P539; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1984, J VIROL, V50, P280, DOI 10.1128/JVI.50.1.280-283.1984; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUTENBERGER JA, 1983, GENE, V23, P75, DOI 10.1016/0378-1119(83)90218-4; LAUTENBERGER JA, 1984, GENE ANAL TECH, V1, P63; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NUNN M, 1984, VIROLOGY, V139, P330, DOI 10.1016/0042-6822(84)90378-7; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PAPAS TS, IN PRESS ONCOGENE HD; PATTERSON D, 1987, SCI AM, V257, P52, DOI 10.1038/scientificamerican0887-52; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; SACCHI N, 1986, SCIENCE, V231, P379, DOI 10.1126/science.3941901; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WATSON DK, 1986, P NATL ACAD SCI USA, V83, P1792, DOI 10.1073/pnas.83.6.1792	32	69	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1988	2	2					99	103						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	3285299				2022-12-28	WOS:A1988M086000001
J	KENT, J; CORIAT, AM; SHARPE, PT; HASTIE, ND; VANHEYNINGEN, V				KENT, J; CORIAT, AM; SHARPE, PT; HASTIE, ND; VANHEYNINGEN, V			THE EVOLUTION OF WT1 SEQUENCE AND EXPRESSION PATTERN IN THE VERTEBRATES	ONCOGENE			English	Article						WILMS TUMOR; SEQUENCE COMPARISON; UROGENITAL DEVELOPMENT	WILMS-TUMOR GENE; DENYS-DRASH SYNDROME; KIDNEY DEVELOPMENT; UROGENITAL SYSTEM; DNA; MUTATIONS; PROTEIN; BINDING; NEPHROBLASTOMAS; SUBSTITUTION	WT1 is a Wilms' tumour predisposition gene, encoding a protein with four C-terminal Kruppel-type zinc fingers, which is also a major regulator of kidney and gonadal development, To pinpoint key regulatory domains involved in development and evolution of the vertebrate genitourinary system, we have isolated WT1 orthologues from all gnathostome classes. Partial nucleotide sequence from chick, alligator, Xenopus laevis and zebrafish reveals extensive conservation, Both the zinc fingers and the transregulatory domain exhibit a high level of similarity in all the species examined. However, of the two alternatively spliced regions only one, the three amino acid KTS insertion between zinc fingers 3 and 4, is found in species other than mammals, The 17 amino acid insertion at the C-terminal end of the transregulatory domain is present only in mammals, Residues with reported human pathological mutations are also unaltered across species, underlining their structural significance, Studies in chick and alligator reveal that the mammalian intermediate mesoderm expression pattern is conserved in birds and reptiles. A wider role in mesodermal differentiation is suggested by expression in some paraxial and lateral mesoderm derivatives.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; GUYS & ST THOMAS MED & DENT SCH,DEPT CRANIOFACIAL DEV,LONDON SE1 9RT,ENGLAND; MRC,LONDON W1N 4AL,ENGLAND	University of Edinburgh; University of London; King's College London			van Heyningen, Veronica/B-8039-2008; VAN HEYNINGEN, Veronica/GYE-0531-2022	van Heyningen, Veronica/0000-0003-0359-0141; Sharpe, Paul/0000-0003-2116-9561; Kent, Jill/0000-0001-7766-2473	Medical Research Council [MC_U127527199] Funding Source: Medline; MRC [MC_U127527199] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ARMSTRONG JF, 1992, MECH DEVELOP, V40, P85; BACKUS JW, 1991, NUCLEIC ACIDS RES, V19, P6781, DOI 10.1093/nar/19.24.6781; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BARDEESY N, 1994, GENOMICS, V21, P663, DOI 10.1006/geno.1994.1333; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BOYD AC, 1993, NUCLEIC ACIDS RES, V21, P817, DOI 10.1093/nar/21.4.817; Bruening Wendy, 1994, Seminars in Developmental Biology, V5, P333, DOI 10.1006/sedb.1994.1042; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DEHEINE V, 1962, J NATL CANCER I, V29, P41; DENYS P, 1967, ARCH FR PEDIATR, V24, P729; DRASH A, 1970, J PEDIATR-US, V76, P585, DOI 10.1016/S0022-3476(70)80409-7; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; ELKAN E, 1963, CANCER RES, V23, P1641; Ferguson M.W.J., 1987, P427; FERGUSON MWJ, 1982, NATURE, V296, P850, DOI 10.1038/296850a0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HASTIE ND, 1994, ANNU REV GENET, V28, P523; JASMIN G, 1970, CANCER RES, V30, P321; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; JONES DSC, 1990, NUCLEIC ACIDS RES, V18, P7463; KENT GC, 1987, COMP ANATOMY VERTEBR; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LI WH, 1985, MOL BIOL EVOL, V2, P150; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; LITTLE MH, 1993, HUM MOL GENET, V2, P259, DOI 10.1093/hmg/2.3.259; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MADDEN SL, 1993, ONCOGENE, V8, P1713; MASAHITO P, 1992, CANCER RES, V52, P2575; MIERAU GW, 1987, ULTRASTRUCT PATHOL, V11, P313, DOI 10.3109/01913128709048329; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEIUWKOOP PD, 1967, NORMAL TABLE XENOPUS; PARK S, 1993, CANCER RES, V53, P4757; PARK S, 1993, NAT GENET, V5, P363, DOI 10.1038/ng1293-363; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Romanoff A., 1960, THE AVIAN EMBRYO, V1, P429; Saxen L., 1987, ORGANOGENESIS KIDNEY; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; SHARMA PM, 1992, CANCER RES, V52, P6407; SOUSSI T, 1990, ONCOGENE, V5, P945; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WASHABAUGH CH, 1993, J MORPHOL, V218, P107, DOI 10.1002/jmor.1052180109; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; YOUNG JL, 1975, J PEDIATR-US, V86, P254, DOI 10.1016/S0022-3476(75)80484-7; 1991, PROGRAM MANUAL GCG P, V575	60	104	111	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1781	1792						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478606				2022-12-28	WOS:A1995TD09400013
J	ZHU, TH; BODEM, J; KEPPEL, E; PARO, R; ROYERPOKORA, B				ZHU, TH; BODEM, J; KEPPEL, E; PARO, R; ROYERPOKORA, B			A SINGLE ANCESTRAL GENE OF THE HUMAN LIM DOMAIN ONCOGENE FAMILY LMO IN DROSOPHILA - CHARACTERIZATION OF THE DROSOPHILA DLMO GENE	ONCOGENE			English	Article						TTG/RBTN T CELL ONCOGENES; LIM PROTEINS; STRUCTURAL CONSERVATION	CYSTEINE-RICH PROTEIN; 5' NONCODING REGION; MESSENGER-RNA; SECONDARY STRUCTURE; INSULIN GENE; CELL; MOTIF; TRANSLOCATIONS; MELANOGASTER; CHROMOSOME	Members of the human TTG/RBTN family, now renamed 'LMO' for LIM-only proteins, encode proteins with two tandem copies of a LIM motif. There are three members of this family, two have been isolated at the sites of chromosomal translocations in T-cell leukaemia. The function of the LIM motifs is at present unknown. We found that the LMO-2 gene is highly conserved between mammals, Drosophila and yeast. As a first step to obtain a model system for studying the function of the LIM motifs we have isolated the Drosophila homologue Dlmo. In contrast to mammals Drosophila appears to have only one lmo gene. A 2087 bp cDNA clone was isolated from a larval cDNA library, encoding a protein of 266 amino acids. A second transcript with an alternative 5' end was identified in RNA from embryos. The Drosophila Imo protein consists of two tandem copies of the conserved LIM domain characteristic of the human LMO family and an extended amino and carboxy terminus, which is not present in the human proteins. The amino acid sequence similarity with human LMO-1 and LMO-2 in LIM 1 is 79% and 69% and in LIM-2 90% and 60%, respectively. In addition a short stretch of 25 nucleotides with a homology of 83% between LMO-2 and Dlmo is found in the 3' UTR. Dlmo, like LMO-1, has an intron after the second LIM encoding region, which is not present in LMO-2. It is expressed maternally and at a high level in early embryogenesis as well as in adults. Interestingly we observed that the Dlmo protein is immunologically related to LMO-2 and can be detected by immunohistochemistry in early cellular blastoderm embryos. The gene was localised to a genetically well characterized region (17C on the X chromosome) opening the way for identification of mutations.	UNIV HEIDELBERG,INST HUMAN GENET,HEIDELBERG,GERMANY; UNIV HEIDELBERG,CTR MOLEC BIOL,W-6900 HEIDELBERG,GERMANY; NANKAI UNIV,INST MED,TIANJIN,PEOPLES R CHINA	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Nankai University				Bodem, Jochen/0000-0003-1908-4091				Baptiste J, 1991, NUCLEIC ACIDS RES, V19, P5227; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; EBERL DF, 1992, GENETICS, V130, P569; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; HALUSKA FG, 1987, TRENDS GENET, V3, P11, DOI 10.1016/0168-9525(87)90155-7; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KIESS M, 1995, ONCOGENE, V10, P61; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1988, MOL CELL BIOL, V8, P2737, DOI 10.1128/MCB.8.7.2737; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MARIOL MC, 1987, MOL CELL BIOL, V7, P3244, DOI 10.1128/MCB.7.9.3244; MATTOX WW, 1984, MOL CELL BIOL, V4, P1343, DOI 10.1128/MCB.4.7.1343; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MIZUNO K, 1994, ONCOGENE, V9, P1605; MULLER AJ, 1989, MOL CELL BIOL, V9, P5234, DOI 10.1128/MCB.9.11.5234; NALIK P, 1989, MOL CELL ENDOCRINOL, V62, P235, DOI 10.1016/0303-7207(89)90010-5; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROYERPOKORA B, 1995, ONCOGENE, V10, P1353; ROYERPOKORA B, 1992, GENE CHROMOSOME CANC, V5, P132, DOI 10.1002/gcc.2870050207; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; 1994, DROSOPHILA GENETIC D	42	18	18	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1283	1290						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478548				2022-12-28	WOS:A1995RY96700008
J	TAHARA, H; KAMADA, K; SATO, E; TSUYAMA, N; KIM, JK; HARA, E; ODA, K; IDE, T				TAHARA, H; KAMADA, K; SATO, E; TSUYAMA, N; KIM, JK; HARA, E; ODA, K; IDE, T			INCREASE IN EXPRESSION LEVELS OF INTERFERON-INDUCIBLE GENES IN SENESCENT HUMAN-DIPLOID FIBROBLASTS AND IN SV40-TRANSFORMED HUMAN FIBROBLASTS WITH EXTENDED LIFE-SPAN	ONCOGENE			English	Article						SENESCENT CELLS; SV40-TRANSFORMED CELLS; INTERFERON; INTERFERON-INDUCIBLE GENES	GROWTH-FACTOR; DNA-SYNTHESIS; HUMAN-CELLS; SIMIAN VIRUS-40; MESSENGER-RNA; T-ANTIGEN; BETA; INHIBITION; INVITRO; SPAN	The normal human fibroblast line, TIG-3 which senesces at around 80 population doubling levels (PDLs), expressed interferon (IFN)-inducible genes such as 6-16, 2', 5'-oligoadenylate synthetase (2,5-A) and HLA B7 near the end of the proliferative lifespan. Other normal fibroblast line such as MRC-5 also expressed IFN-inducible genes when senesced. Clones transformed with SV40 T-antigen, which extended their proliferative lifespan by about 20-30 PDLs, also expressed IFN-inducible genes during their extended life. Anti-IFN-beta antibodies added in culture medium repressed the expression of IFN-inducible gene in both senescent and life-extended SV40-transformed IFN-beta repressed DNA synthesis in normal TIG-3 and induced IFN-inducible genes in both normal and SV40-transformed TIG-3. Conditioned medium recovered from life-extended SV40-transformed cells contained IFN-beta, but not IFN-alpha, IFN-gamma or TNF-alpha and possessed an activity that inhibited DNA synthesis of young TIG-3. Addition of anti-IFN-beta antibodies into the medium enhanced the serum-induced DNA synthesis of near senescent (91% lifespan completed) TIG-3, while it neither induced DNA synthesis in fully senescent TIG-3 nor extended the proliferative lifespan of TIG-3. These results suggest that normal and SV40-transformed human fibroblasts increase expression of IFN-beta with increasing proliferative age especially near the end of their lifespan resulting in induction of IFN-inducible genes and possibly in growth repression.	HIROSHIMA UNIV,SCH MED,DEPT CELLULAR & MOLEC BIOL,HIROSHIMA 734,JAPAN; SCI UNIV TOKYO,DEPT APPL BIOL SCI,NODA,CHIBA 278,JAPAN	Hiroshima University; Tokyo University of Science								BURMER GC, 1983, EXP CELL RES, V145, P79, DOI 10.1016/S0014-4827(83)80010-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFINIS GJ, 1981, J GEN VIROL, V52, P169, DOI 10.1099/0022-1317-52-1-169; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DRESCHERLINCOLN CK, 1984, EXP CELL RES, V153, P208, DOI 10.1016/0014-4827(84)90462-2; DRESCHERLINCOLN CK, 1983, EXP CELL RES, V144, P455, DOI 10.1016/0014-4827(83)90424-X; EINAT M, 1985, P NATL ACAD SCI USA, V82, P7608, DOI 10.1073/pnas.82.22.7608; ELEFTHERIOU CS, 1993, BIOCHIM BIOPHYS ACTA, V1180, P304, DOI 10.1016/0925-4439(93)90055-6; FELLOUS M, 1982, P NATL ACAD SCI-BIOL, V79, P3082, DOI 10.1073/pnas.79.10.3082; FORSBERG K, 1988, J CELL PHYSIOL, V136, P266, DOI 10.1002/jcp.1041360208; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; FRIEDMAN RL, 1979, INTERFERON INTERACTI, V1; GERFAUX J, 1989, CANCER RES, V49, P1241; GIRARDI AJ, 1966, ANN MED EXP BIOL FEN, V44, P242; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GOLDSTEIN S, 1969, LANCET, V1, P424; GOLDSTEIN S, 1978, SCIENCE, V199, P781, DOI 10.1126/science.622567; GOLDSTEIN S, 1989, EXP GERONTOL, V24, P461, DOI 10.1016/0531-5565(89)90052-1; HARA E, 1993, ANAL BIOCHEM, V214, P58, DOI 10.1006/abio.1993.1456; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HERZOG H, 1990, NUCLEIC ACIDS RES, V18, P4600, DOI 10.1093/nar/18.15.4600; HISCOTT J, 1988, MOL CELL BIOL, V8, P3397, DOI 10.1128/MCB.8.8.3397; IDE T, 1984, EXP CELL RES, V150, P321, DOI 10.1016/0014-4827(84)90575-5; IWATA A, 1988, J BIOCHEM-TOKYO, V104, P247, DOI 10.1093/oxfordjournals.jbchem.a122451; JACOBS JP, 1970, NATURE, V227, P168, DOI 10.1038/227168a0; KOHASE M, 1987, MOL CELL BIOL, V7, P273, DOI 10.1128/MCB.7.1.273; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; KUMAR S, 1992, P NATL ACAD SCI USA, V89, P4683, DOI 10.1073/pnas.89.10.4683; LALLEMAND C, 1992, ONCOGENE, V7, P1109; LUMPKIN CK, 1986, SCIENCE, V232, P393, DOI 10.1126/science.2421407; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MARTIN GM, 1970, LAB INVEST, V23, P86; MATSUO M, 1982, J GERONTOL, V37, P33, DOI 10.1093/geronj/37.1.33; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NORWOOD TH, 1974, P NATL ACAD SCI USA, V71, P2231, DOI 10.1073/pnas.71.6.2231; OHASHI M, 1980, EXP GERONTOL, V15, P121, DOI 10.1016/0531-5565(80)90083-2; OLESZAK E, 1980, J INTERFERON RES, V1, P37, DOI 10.1089/jir.1980.1.37; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; SCHNEIDER EL, 1976, P NATL ACAD SCI USA, V73, P3584, DOI 10.1073/pnas.73.10.3584; TAHARA H, 1994, BIOCHEM BIOPH RES CO, V199, P1108, DOI 10.1006/bbrc.1994.1345; TOVEY MG, 1987, P NATL ACAD SCI USA, V84, P5038, DOI 10.1073/pnas.84.14.5038; TSUYAMA N, 1991, CELL STRUCT FUNCT, V16, P55, DOI 10.1247/csf.16.55; WISTROM C, 1992, EXP CELL RES, V199, P355, DOI 10.1016/0014-4827(92)90445-E; YANISHEVSKY RM, 1980, EXP CELL RES, V126, P469, DOI 10.1016/0014-4827(80)90290-6; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	49	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1125	1132						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566972				2022-12-28	WOS:A1995RX18000015
J	THOMPSON, TC; PARK, SH; TIMME, TL; REN, C; EASTHAM, JA; DONEHOWER, LA; BRADLEY, A; KADMON, D; YANG, G				THOMPSON, TC; PARK, SH; TIMME, TL; REN, C; EASTHAM, JA; DONEHOWER, LA; BRADLEY, A; KADMON, D; YANG, G			LOSS OF P53 FUNCTION LEADS TO METASTASIS IN RAS+MYC-INITIATED MOUSE PROSTATE-CANCER	ONCOGENE			English	Article						P53; METASTASES; PROSTATE CANCER	MESSENGER-RNA LEVELS; WILD-TYPE P53; MOUSE PROSTATE; SV40-TRANSFORMED CELLS; CARCINOMA-CELLS; GENE MUTATION; GROWTH; CANCER; ONCOGENES; MYC	To study the interactions between dominantly acting oncogenes and tumor suppressor genes we used p53 'knockout' mouse urogenital sinus tissue for retroviral transduction of ras and myc in the mouse prostate reconstitution (MPR) model system. Epithelial hyperplasia was observed in all wild-type p53 MPRs with one small focal cancer and no evidence of metastasis. Prostatic cancer was found in 100% of the heterozygous and homozygous p53 mutant MPRs with metastatic deposits in 95% of the mice. The pattern of metastasis was remarkably similar to that in human prostate cancer with gross metastatic deposits in the lung, lymph nodes, bone and liver of many animals. Progression of carcinomas in the ras+myc-initiated heterozygous p53 mutant MPRs was invariably associated with either complete loss, partial deletion or loss of expression of the wild-type p53 allele. Southern blotting analysis of proviral-cellular DNA junction fragments in primary carcinomas and cell lines derived from metastatic deposits revealed that metastases do not necessarily seed out from the most abundant clone in the primary carcinoma.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT RADIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC VIROL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	THOMPSON, TC (corresponding author), BAYLOR COLL MED,DEPT UROL,HOUSTON,TX 77030, USA.			Bradley, Allan/0000-0002-2349-8839	NCI NIH HHS [P50-CA58204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058204] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BODNER SM, 1992, ONCOGENE, V7, P743; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EGAWA S, 1992, MOL CARCINOGEN, V5, P52, DOI 10.1002/mc.2940050110; ELIYAHU D, 1988, ONCOGENE, V3, P313; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GREENE DR, 1994, J UROLOGY, V151, P1301, DOI 10.1016/S0022-5347(17)35236-9; GREENE DR, 1991, CANCER RES, V51, P4084; Hart I R, 1982, Cancer Metastasis Rev, V1, P5, DOI 10.1007/BF00049477; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARVEY M, 1993, ONCOGENE, V8, P2457; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERBEL RS, 1988, CANCER SURV, V7, P597; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACAULEY A, 1988, J VIROL, V62, P4712, DOI 10.1128/JVI.62.12.4712-4721.1988; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Maniatis T, 1989, DECONTAMINATION DILU; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERZ VW, 1991, MOL ENDOCRINOL, V5, P503, DOI 10.1210/mend-5-4-503; MIDGLEY CA, 1992, J CELL SCI, V101, P183; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; NICOLSON GL, 1988, CANCER METAST REV, V7, P143, DOI 10.1007/BF00046483; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; PURDIE CA, 1994, ONCOGENE, V9, P603; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAWIN K, 1993, CANCER RES, V53, P4461; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Steeg P S, 1991, Semin Cancer Biol, V2, P105; TAYLOR WR, 1992, ONCOGENE, V7, P1383; THOMPSON TC, 1990, CANCER CELL-MON REV, V2, P345; THOMPSON TC, 1993, MOL CARCINOGEN, V7, P165, DOI 10.1002/mc.2940070307; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TIMME TL, 1994, BIOTECHNIQUES, V17, P460; VAN MEIR EG, 1994, CANCER RES, V54, P649; WEINBERG RA, 1991, ORIGINS OF HUMAN CANCER, P1; WEINSTATSASLOW D, 1994, FASEB J, V8, P401, DOI 10.1096/fasebj.8.6.7513289; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	58	116	122	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					869	879						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7534899				2022-12-28	WOS:A1995QL03800008
J	KOSHIMIZU, U; TSUJIMURA, T; ISOZAKI, K; NOMURA, S; FURITSU, T; KANAKURA, Y; KITAMURA, Y; NISHIMUNE, Y				KOSHIMIZU, U; TSUJIMURA, T; ISOZAKI, K; NOMURA, S; FURITSU, T; KANAKURA, Y; KITAMURA, Y; NISHIMUNE, Y			W-N MUTATION OF C-KIT RECEPTOR AFFECTS ITS POSTTRANSLATIONAL PROCESSING AND EXTRACELLULAR EXPRESSION	ONCOGENE			English	Article							CULTURED MAST-CELLS; INTRACELLULAR-TRANSPORT; PROTO-ONCOGENE; INSULIN-RECEPTOR; TYROSINE KINASE; V-KIT; MOUSE; LOCUS; MICE; DOMAIN	The W locus of mice encodes the c-kit receptor tyrosine kinase. Recently, we characterized a novel mutant allele, W-n, and demonstrated that the c-kit protein synthesized in W-n/W-n cultured mast cells (CMC) was reduced in size and not expressed on their surface (Tsujimura et al., 1993). In this study, we further examined biochemical nature of the mutant form of c-kit protein, by using W-n/W-n CMC and 293T cells transfected with W-n-type c-kit cDNA (c-kit(Wn)). The c-kit product synthesized in W-n/W-n CMC was truncated almost all cytoplasmic domain and was less glycosylated. In c-kif(Wn)-tranfected cells, both glycosylation and extracellular expression of c-kit protein was also impaired, however, no truncation was detected. These results indicate that W-n-mutant form of c-kit product is insufficient in maturation, which is associated with impairments in the transport to the plasma membrane, and retention of the mutant protein in endoplasmic reticulum is suggested. This is the first demonstration of the c-kit mutation affecting posttranslational processing its product.	OSAKA UNIV,RES INST MICROBIAL DIS,OSAKA,JAPAN; OSAKA UNIV,SCH MED,DEPT PATHOL,OSAKA,JAPAN; OSAKA UNIV,SCH MED,DEPT INTERNAL MED,OSAKA,JAPAN	Osaka University; Osaka University; Osaka University								ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; DOYLE C, 1985, J CELL BIOL, V100, P704, DOI 10.1083/jcb.100.3.704; DOYLE C, 1986, J CELL BIOL, V103, P1193, DOI 10.1083/jcb.103.4.1193; ESSER V, 1988, J BIOL CHEM, V263, P13276; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEISSLER EN, 1981, GENETICS, V97, P337; GO S, 1980, J HERED, V71, P41, DOI 10.1093/oxfordjournals.jhered.a109308; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREEN MC, 1990, GENETIC VARIANTS STR, P383; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; HURTLEY SM, 1993, TRENDS BIOCHEM SCI, V18, P3, DOI 10.1016/0968-0004(93)90078-2; ISHIHARA K, 1992, P NATL ACAD SCI USA, V89, P633, DOI 10.1073/pnas.89.2.633; KADOWAKI T, 1991, J BIOL CHEM, V266, P21224; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, BLOOD, V53, P492; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEV S, 1993, MOL CELL BIOL, V13, P2224, DOI 10.1128/MCB.13.4.2224; LOBELL RB, 1993, J BIOL CHEM, V268, P1207; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MCCULLOCH EA, 1964, SCIENCE, V144, P844, DOI 10.1126/science.144.3620.844; MIURA O, 1989, J BIOL CHEM, V264, P18213; NAKAHATA T, 1982, BLOOD, V60, P352; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; PREFFER SR, 1987, ANN REV BIOCH, V56, P829; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, GENOME ANAL, V3, P105; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; RUSSELL ES, 1968, ARCH BIOCHEM BIOPHYS, V125, P594, DOI 10.1016/0003-9861(68)90617-6; SAKAMAKI K, 1989, BIOL REPROD, V41, P1097, DOI 10.1095/biolreprod41.6.1097; SEVERINSSON L, 1989, EUR J BIOCHEM, V182, P679, DOI 10.1111/j.1432-1033.1989.tb14879.x; Silvers W.K., 1979, COAT COLORS MICE, P206; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TONO T, 1992, BLOOD, V80, P1448; TSUJIMURA T, 1993, BLOOD, V81, P2530; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILLIAMS DB, 1988, J BIOL CHEM, V263, P4549; WILLIAMS DE, 1992, DEV BIOL, V151, P368, DOI 10.1016/0012-1606(92)90176-H; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YEE NS, 1993, J BIOL CHEM, V268, P14189	56	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					157	162						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	7508100				2022-12-28	WOS:A1994MW24700019
J	GRAZIANI, G; RON, D; EVA, A; SRIVASTAVA, SK				GRAZIANI, G; RON, D; EVA, A; SRIVASTAVA, SK			THE HUMAN DBL-PROTO-ONCOGENE PRODUCT IS A CYTOPLASMIC PHOSPHOPROTEIN WHICH IS ASSOCIATED WITH THE CYTOSKELETAL MATRIX	ONCOGENE			English	Article									NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1E24,BETHESDA,MD 20892; GEORGETOWN UNIV,CTR CANC,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University			Eva, Alessandra/J-8268-2016; Graziani, Grazia/G-5747-2012	Eva, Alessandra/0000-0003-2949-078X; Graziani, Grazia/0000-0002-0221-768X	NATIONAL CANCER INSTITUTE [R29CA046455] Funding Source: NIH RePORTER; NCI NIH HHS [CA-46455] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARVUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BENZEEV A, 1979, CELL, V17, P859, DOI 10.1016/0092-8674(79)90326-X; BOSS MA, 1981, J VIROL, V40, P472, DOI 10.1128/JVI.40.2.472-481.1981; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1987, ONCOGENE, V1, P355; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; FRANKE WW, 1978, EXP CELL RES, V116, P429, DOI 10.1016/0014-4827(78)90466-4; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAY AJ, 1974, VIROLOGY, V60, P398, DOI 10.1016/0042-6822(74)90335-3; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; MANGER R, 1986, J VIROL, V59, P66, DOI 10.1128/JVI.59.1.66-72.1986; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; RADKE K, 1983, J CELL BIOL, V97, P1601, DOI 10.1083/jcb.97.5.1601; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; SCHATZMAN RC, 1986, MOL CELL BIOL, V6, P1329, DOI 10.1128/MCB.6.4.1329; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SINGER SJ, 1974, ANNU REV BIOCHEM, V43, P805, DOI 10.1146/annurev.bi.43.070174.004105; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STOLZENBACH F, 1966, METHOD ENZYMOL, V9, P278; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG LH, 1988, VIRUS RES, V9, P159; WIDNELL CC, 1968, P NATL ACAD SCI USA, V61, P1050, DOI 10.1073/pnas.61.3.1050; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0	32	38	39	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					823	829						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2666904				2022-12-28	WOS:A1989AE58400002
J	LAGARDE, AE				LAGARDE, AE			METASTATIC CONVERSION OF FACTOR-DEPENDENT LUNG FIBROBLASTS (CCL39) REQUIRES OVER-EXPRESSION OF ONCOGENES WHICH INDUCE HIGH-RATE OF AUTONOMOUS REPLICATION	ONCOGENE			English	Article									UNIV TORONTO,DEPT MED GENET,TORONTO M5G 1X5,ONTARIO,CANADA	University of Toronto	LAGARDE, AE (corresponding author), MT SINAI HOSP,RES INST,DIV CANC & CELL BIOL,ROOM 876,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA.							ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BAUER EA, 1985, P NATL ACAD SCI USA, V82, P4132, DOI 10.1073/pnas.82.12.4132; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277, DOI 10.1073/pnas.83.14.5277; CHADWICK DE, 1988, J NATL CANCER I, V80, P318, DOI 10.1093/jnci/80.5.318; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHUA CC, 1985, J BIOL CHEM, V260, P5213; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COLLARD JG, 1987, CANCER RES, V47, P754; DENHARDT DT, 1987, ONCOGENE, V2, P55; DENHARDT DT, 1986, BIOCHIM BIOPHYS ACTA, V865, P83, DOI 10.1016/0304-419X(86)90024-7; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; GARBISA S, 1987, CANCER RES, V47, P1523; GREENBERG AH, 1987, CANCER RES, V47, P4801; GREIG RG, 1985, P NATL ACAD SCI USA, V82, P3698, DOI 10.1073/pnas.82.11.3698; GRIMALDI G, 1986, EMBO J, V5, P855, DOI 10.1002/j.1460-2075.1986.tb04295.x; HANNINK M, 1984, SCIENCE, V226, P1197, DOI 10.1126/science.6095451; HILL SA, 1988, J NATL CANCER I, V80, P484, DOI 10.1093/jnci/80.7.484; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; MACHIDA CM, 1988, MOL CELL BIOL, V8, P2479, DOI 10.1128/MCB.8.6.2479; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; OWEN RD, 1987, MOL CELL BIOL, V7, P2512, DOI 10.1128/MCB.7.7.2512; PEREZRODRIGUEZ R, 1981, J CELL PHYSIOL, V109, P387, DOI 10.1002/jcp.1041090303; PEREZRODRIGUEZ R, 1982, INT J CANCER, V29, P309, DOI 10.1002/ijc.2910290314; PICHON F, 1988, ONCOGENE, V3, P373; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; RADINSKY R, 1987, P NATL ACAD SCI USA, V84, P5143, DOI 10.1073/pnas.84.15.5143; RENWICK DE, 1986, JNCI-J NATL CANCER I, V77, P105; RODECK U, 1987, INT J CANCER, V40, P687, DOI 10.1002/ijc.2910400520; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SADOWSKI I, 1988, ONCOGENE, V2, P241; SALO T, 1985, J BIOL CHEM, V260, P8526; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STORER RD, 1988, ONCOGENE, V2, P141; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; VANOBBERGHENSCHILLING E, 1983, J CELL PHYSIOL, V115, P123, DOI 10.1002/jcp.1041150204; VANOBBERGHENSCHILLING E, 1983, EXP CELL RES, V147, P369, DOI 10.1016/0014-4827(83)90219-7; VOUSDEN KH, 1986, INT J CANCER, V37, P425, DOI 10.1002/ijc.2910370315; WAGHORNE C, 1987, ONCOGENE, V1, P149; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917	51	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					889	895						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2755702				2022-12-28	WOS:A1989AE58400011
J	PAWSON, T				PAWSON, T			NON-CATALYTIC DOMAINS OF CYTOPLASMIC PROTEIN-TYROSINE KINASES - REGULATORY ELEMENTS IN SIGNAL TRANSDUCTION	ONCOGENE			English	Review											PAWSON, T (corresponding author), MT SINAI HOSP, RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA.		Pawson, Tony J/E-4578-2013					ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSON DD, 1981, J VIROL, V37, P445, DOI 10.1128/JVI.37.1.445-458.1981; ANDERSON SK, 1987, J VIROL, V61, P1893, DOI 10.1128/JVI.61.6.1893-1900.1987; BARKER WC, 1982, P NATL ACAD SCI USA, V79, P836; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BRANTON D, 1981, CELL, V24, P24, DOI 10.1016/0092-8674(81)90497-9; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BRISTOL A, 1988, IN PRESS COLD SPRING, V53; BRUGGE JS, 1984, J BIOL CHEM, V259, P4550; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; BRYANT D, 1982, J VIROL, V44, P683, DOI 10.1128/JVI.44.2.683-691.1982; BUSS JE, 1984, J VIROL, V53, P7; CALLES CJ, 1988, NATURE, V332, P548; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; EDWARDS AM, 1988, MOL CELL BIOL, V8, P2655, DOI 10.1128/MCB.8.6.2655; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FELDMAN RA, 1983, J VIROL, V45, P782, DOI 10.1128/JVI.45.2.782-791.1983; GARBER EA, 1985, MOL CELL BIOL, V5, P2781, DOI 10.1128/MCB.5.10.2781; GONZALES RA, 1985, BIOCHEM J, V232, P799, DOI 10.1042/bj2320799; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KITAMURA N, 1983, J VIROL, V46, P985, DOI 10.1128/JVI.46.3.985-992.1983; LAZARIDES E, 1982, CELL, V31, P504; LEHTO VP, 1988, NATURE, V334, P388, DOI 10.1038/334388a0; LEVINSON AD, 1981, P NATL ACAD SCI-BIOL, V78, P1624, DOI 10.1073/pnas.78.3.1624; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MANGER R, 1986, J VIROL, V59, P66, DOI 10.1128/JVI.59.1.66-72.1986; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; OPPERMANN H, 1981, VIROLOGY, V108, P47, DOI 10.1016/0042-6822(81)90526-2; POTTS WM, 1988, IN PRESS ONCOGENE RE; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; ROHRSCHNEIDER LR, 1984, ADV VIRAL ONCOL, V4, P269; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SADOWSKI I, 1987, ONCOGENE, V1, P181; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WANG HCR, 1989, IN PRESS J VIROL; WEINMASTER G, 1986, EMBO J, V5, P69, DOI 10.1002/j.1460-2075.1986.tb04179.x; WEINMASTER G, 1983, J VIROL, V45, P29; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	76	270	281	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1988	3	5					491	495						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3078956				2022-12-28	WOS:A1988R516300001
J	HUEBNER, K; CANNIZZARO, LA; NAKAMURA, T; HILLOVA, J; MARIAGESAMSON, R; HECHT, F; HILL, M; CROCE, CM				HUEBNER, K; CANNIZZARO, LA; NAKAMURA, T; HILLOVA, J; MARIAGESAMSON, R; HECHT, F; HILL, M; CROCE, CM			A REARRANGED TRANSFORMING GENE, TRE, IS MADE UP OF HUMAN SEQUENCES DERIVED FROM CHROMOSOME REGION-5Q, REGION-17Q AND REGION-18Q	ONCOGENE			English	Article									INST CANCEROL & IMMUNOGENET,CNRS,ER 148,F-94804 VILLEJUIF,FRANCE; SW BIOMED RES INST,CTR GENET,TEMPE,AZ 85281	Centre National de la Recherche Scientifique (CNRS)	HUEBNER, K (corresponding author), WISTAR INST ANAT & BIOL,36TH ST & SPRUCE,PHILADELPHIA,PA 19114, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NATIONAL CANCER INSTITUTE [R35CA039860, P01CA021124, P01CA025875] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39860, CA-25875, CA-21124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CANAANI E, 1984, LANCET, V1, P593; CANNIZZARO LA, 1984, CYTOGENET CELL GENET, V38, P308, DOI 10.1159/000132079; CANNIZZARO LA, 1987, AM J HUM GENET, V41, P1; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CROCE CM, 1987, P NATL ACAD SCI USA, V84, P7174, DOI 10.1073/pnas.84.20.7174; DAYTON AI, 1984, P NATL ACAD SCI-BIOL, V81, P4495, DOI 10.1073/pnas.81.14.4495; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P7581, DOI 10.1073/pnas.80.24.7581; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FAVERA RD, 1982, P NATL ACAD SCI USA, V79, P7824; FAVERA RD, 1982, SCIENCE, V218, P686; GROFFEN J, 1983, NUCLEIC ACIDS RES, V11, P6331, DOI 10.1093/nar/11.18.6331; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HUEBNER K, 1985, SCIENCE, V230, P1282, DOI 10.1126/science.2999978; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P1403, DOI 10.1073/pnas.83.5.1403; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEBEAU MM, 1986, SCIENCE, V231, P984, DOI 10.1126/science.3484837; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LESSIN S, 1988, IN PRESS J INVEST DE; MERGIA A, 1986, BIOCHEM BIOPH RES CO, V138, P644, DOI 10.1016/S0006-291X(86)80545-9; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NIENHUIS AW, 1985, CELL, V42, P421, DOI 10.1016/0092-8674(85)90099-6; OHYASHIKI JH, 1987, CANCER GENET CYTOGEN, V25, P341, DOI 10.1016/0165-4608(87)90195-6; PETTENATI MJ, 1987, P NATL ACAD SCI USA, V84, P2970, DOI 10.1073/pnas.84.9.2970; ROWLEY JD, 1977, INT J CANCER, V20, P869, DOI 10.1002/ijc.2910200608; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; VANDENBERGHE H, 1985, CANCER GENET CYTOGEN, V17, P189, DOI 10.1016/0165-4608(85)90016-0; WEINBERGER C, 1985, CYTOGENET CELL GENET, V40, P776	41	36	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					449	455						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3274085				2022-12-28	WOS:A1988Q773900014
J	DONAHUE, LM; STEIN, GH				DONAHUE, LM; STEIN, GH			HIGH-EFFICIENCY DNA-MEDIATED TRANSFORMATION OF HUMAN-DIPLOID FIBROBLASTS	ONCOGENE			English	Article											DONAHUE, LM (corresponding author), UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309, USA.				NIA NIH HHS [AG00947] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BELL E, 1978, SCIENCE, V202, P1158, DOI 10.1126/science.725592; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN S, 1987, J VIROL, V61, P3521, DOI 10.1128/JVI.61.11.3521-3527.1987; CORSARO CM, 1977, NATURE, V268, P737, DOI 10.1038/268737a0; CORSARO CM, 1977, P NATL ACAD SCI USA, V74, P4476, DOI 10.1073/pnas.74.10.4476; CORSARO CM, 1975, EXP CELL RES, V95, P39, DOI 10.1016/0014-4827(75)90606-0; DONIGER J, 1983, SCIENCE, V222, P114; FRY DG, 1986, J CELL PHYSIOL, V128, P313, DOI 10.1002/jcp.1041280225; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAHAM FL, 1980, INTRO MACROMOLECULES, P3; GRODZICKER T, 1980, CELL, V21, P453, DOI 10.1016/0092-8674(80)90482-1; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HOEIJMAKERS JHJ, 1987, EXP CELL RES, V169, P111, DOI 10.1016/0014-4827(87)90230-8; Maniatis T., 1982, MOL CLONING; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; NICHOLS WW, 1977, SCIENCE, V196, P60, DOI 10.1126/science.841339; PALMER TD, 1987, MOL MECH REGULATION, P307; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUTHERLAND BM, 1985, P NATL ACAD SCI USA, V82, P2399, DOI 10.1073/pnas.82.8.2399; SUTHERLAND BM, 1984, CANCER RES, V44, P2769; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YANISHEVSKY R, 1974, J CELL PHYSIOL, V84, P165, DOI 10.1002/jcp.1040840202	23	15	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					221	224						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	3412775				2022-12-28	WOS:A1988Q053400014
J	YOKOTA, J; YAMAMOTO, T; MIYAJIMA, N; TOYOSHIMA, K; NOMURA, N; SAKAMOTO, H; YOSHIDA, T; TERADA, M; SUGIMURA, T				YOKOTA, J; YAMAMOTO, T; MIYAJIMA, N; TOYOSHIMA, K; NOMURA, N; SAKAMOTO, H; YOSHIDA, T; TERADA, M; SUGIMURA, T			GENETIC ALTERATIONS OF THE C-ERBB-2 ONCOGENE OCCUR FREQUENTLY IN TUBULAR ADENOCARCINOMA OF THE STOMACH AND ARE OFTEN ACCOMPANIED BY AMPLIFICATION OF THE V-ERBA HOMOLOG	ONCOGENE			English	Article									UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN; NIPPON VET & ZOOTECH COLL,MOLEC ONCOL LAB,TAITO KU,TOKYO 110,JAPAN	University of Tokyo; Nippon Veterinary & Life Science University	YOKOTA, J (corresponding author), NATL CANC CTR,RES INST,1-1 TSUKIJI S CHOME,CHUO KU,TOKYO 104,JAPAN.							AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAYTON AI, 1984, P NATL ACAD SCI-BIOL, V81, P4495, DOI 10.1073/pnas.81.14.4495; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; HUERRE C, 1982, P NATL ACAD SCI-BIOL, V79, P6627, DOI 10.1073/pnas.79.21.6627; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KINZLER KW, 1986, P NATL ACAD SCI USA, V83, P1031, DOI 10.1073/pnas.83.4.1031; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; MORI S, IN PRESS VIRCHOWS AR; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPURR NK, 1984, EMBO J, V3, P159, DOI 10.1002/j.1460-2075.1984.tb01777.x; STARK GR, 1986, CANCER SURV, V5, P1; VIJVER M, 1987, MOL CELL BIOL, V7, P2019; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YOKOTA J, 1986, LANCET, V1, P765; ZABEL BU, 1984, P NATL ACAD SCI-BIOL, V81, P4874, DOI 10.1073/pnas.81.15.4874; ZHOU D, 1987, IN PRESS CANCER RES; 1981, JAPAN J SURG, V11, P140	24	282	285	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					283	287						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3281095				2022-12-28	WOS:A1988M593100012
J	VANTVEER, LJ; HERMENS, R; VANDENBERGBAKKER, LAM; CHENG, NC; FLEUREN, GJ; BOS, JL; CLETON, FJ; SCHRIER, PI				VANTVEER, LJ; HERMENS, R; VANDENBERGBAKKER, LAM; CHENG, NC; FLEUREN, GJ; BOS, JL; CLETON, FJ; SCHRIER, PI			RAS ONCOGENE ACTIVATION IN HUMAN OVARIAN-CARCINOMA	ONCOGENE			English	Article									UNIV HOSP LEIDEN,DEPT CLIN ONCOL,POB 9600,2300 RC LEIDEN,NETHERLANDS; UNIV HOSP LEIDEN,DEPT PATHOL,2300 RC LEIDEN,NETHERLANDS; STATE UNIV LEIDEN,DEPT MED BIOCHEM,SYLVIUS LABS,2312 AV LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC			Hermens, Rosella P.M.G./N-3581-2014	Hermens, Rosella P.M.G./0000-0001-7624-7120				ANDERSON SJ, 1982, J VIROL, V44, P696, DOI 10.1128/JVI.44.2.696-702.1982; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1986, NUCLEIC ACIDS RES, V14, P1209, DOI 10.1093/nar/14.3.1209; BOS JL, 1987, IN PRESS MUT RES; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FEIG LA, 1984, SCIENCE, V223, P698, DOI 10.1126/science.6695178; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FILMUS JE, 1985, CANCER RES, V45, P4468; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLICK GE, 1985, P NATL ACAD SCI USA, V82, P1795, DOI 10.1073/pnas.82.6.1795; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUSELLA J, 1979, P NATL ACAD SCI USA, V76, P5239, DOI 10.1073/pnas.76.10.5239; HOFKER MH, 1986, AM J HUM GENET, V39, P438; JANSSEN JWG, 1987, ONCOGENE, V1, P175; JELINEK WR, 1980, P NATL ACAD SCI-BIOL, V77, P1398, DOI 10.1073/pnas.77.3.1398; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; KURZROCK R, 1986, CANCER RES, V46, P1530; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OHUCHI N, 1987, CANCER RES, V47, P1413; OHUCHI N, 1986, CANCER RES, V46, P2511; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; RIOU G, 1984, CR ACAD SCI III-VIE, V299, P575; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SHEN VWP, 1987, ONCOGENE, V1, P157; SHIH TY, 1979, VIROLOGY, V96, P64, DOI 10.1016/0042-6822(79)90173-9; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TANAKA T, 1986, CANCER RES, V46, P1465; TAYA Y, 1984, EMBO J, V3, P2943, DOI 10.1002/j.1460-2075.1984.tb02236.x; THEILLET C, 1986, CANCER RES, V46, P4776; THOR A, 1984, NATURE, V311, P562, DOI 10.1038/311562a0; VANTVEER LJ, 1984, MOL CELL BIOL, V4, P2532, DOI 10.1128/MCB.4.11.2532; VARMUS HE, 1984, ANNU REV GENET, V18, P533; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VERWEIJ CL, 1985, NUCLEIC ACIDS RES, V13, P4699, DOI 10.1093/nar/13.13.4699; VIOLA MV, 1985, J EXP MED, V161, P1213, DOI 10.1084/jem.161.5.1213; VIOLA MV, 1986, NEW ENGL J MED, V314, P133, DOI 10.1056/NEJM198601163140301; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	61	85	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					157	165						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	3285294				2022-12-28	WOS:A1988M086000009
J	VONMELCHNER, H; HOUSMAN, DE				VONMELCHNER, H; HOUSMAN, DE			THE EXPRESSION OF NEOMYCIN PHOSPHOTRANSFERASE IN HUMAN PROMYELOCYTIC LEUKEMIA-CELLS (HL60) DELAYS THEIR DIFFERENTIATION	ONCOGENE			English	Article									MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [R37CA017575, R01CA017575] Funding Source: NIH RePORTER; NCI NIH HHS [CA 17575] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CONE RD, 1984, P NATL ACAD SCI-BIOL, V81, P6349, DOI 10.1073/pnas.81.20.6349; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; VONMELCHNER H, 1985, J CELL PHYSIOL, V125, P573, DOI 10.1002/jcp.1041250329	11	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					137	140						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	2835723				2022-12-28	WOS:A1988M086000006
J	GU, J; DUBNER, R; FORNACE, AJ; IADAROLA, MJ				GU, J; DUBNER, R; FORNACE, AJ; IADAROLA, MJ			UREB1, A TYROSINE-PHOSPHORYLATED NUCLEAR-PROTEIN, INHIBITS P53 TRANSACTIVATION	ONCOGENE			English	Note						UREB1; P53; TRANSACTIVATION; SUPPRESSION; TUMOR SUPPRESSOR; TYROSINE PHOSPHORYLATION	WILD-TYPE; E6-AP; E6; UBIQUITINATION; TRANSFORMATION; EXPRESSION; COMPLEX; MUTANT; GROWTH; FORMS	Tumor suppressor p53 is a transcription activator that upregulates target genes containing the p53 binding site, UREB1, a DNA binding protein that is tyrosine phosphorylated in vivo, shares a significant homology with the human papilloma virus E6 associated protein (E6-AP). E6-AP forms a ternary complex with E6 and p53 and participates in the ubiquitination of p53. Based on the homology with E6-AP, but taking into account the nuclear localization of UREB1 and its smaller size, the present study used a transient transfection system to examine whether UREB1 influenced p53-stimulated transcription. Co-transfection of a vector expressing wildtype UREB1 with one expressing p53 into H1299, a p53 negative cell line, resulted in a pronounced suppression of p53 transactivation. The inhibitory effect was significantly attenuated by mutation of a tyrosine residue in the consensus tyrosine phosphorylation sequence of UREB1. These data suggest that optimal suppression of p53 transactivation requires tyrosine phosphorylated UREB1 and that tyrosine phosphorylation and dephosphorylation processes may be involved in the regulation of p53 transactivation.	NCI,MOLEC PHARMACOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	GU, J (corresponding author), NIDR,NEUROBIOL & ANESTHESIOL BRANCH,BLDG 49,RM 1A11,49 CONVENT DR,MSC-4410,BETHESDA,MD 20892, USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				[Anonymous], 1994, PROGRAM MANUAL WISCO; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CANTLEY LC, 1991, CELL, V25, P281; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; GU J, 1994, MOL BRAIN RES, V24, P77, DOI 10.1016/0169-328X(94)90120-1; GU J, 1994, BIOTECHNIQUES, V17, P257; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MESSERSMITH DJ, 1994, MOL CELL NEUROSCI, V5, P238, DOI 10.1006/mcne.1994.1028; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1993, P NATL ACAD SCI USA, V91, P8797; SCHREIBER E, 1980, NUCLEIC ACIDS RES, V17, P6419; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YOUNISHROUACH E, 1991, NATURE, V352, P345	27	20	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2175	2178						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478539				2022-12-28	WOS:A1995TF29700030
J	WICK, ST; DUBAY, MM; IMANIL, I; BRIZUELA, L				WICK, ST; DUBAY, MM; IMANIL, I; BRIZUELA, L			BIOCHEMICAL AND MUTAGENIC ANALYSIS OF THE MELANOMA TUMOR-SUPPRESSOR GENE-PRODUCT P16	ONCOGENE			English	Article						P16; MTS1; CDK4; ANKYRIN REPEATS	D-TYPE CYCLINS; CELL-CYCLE; IDENTIFICATION; PROTEIN; G(1)	P16 was originally discovered by its ability to interact with CDK4 and to specifically inhibit the catalytic activity of the CDK4/D1 kinase. Increased attention has focused on the p16 gene because of its location on chromosome 9p21, a region involved in chromosomal rearrangements in a large number of tumor types. The p16 gene is also mutated in a large number of tumor cell lines and primary tumor cells. Furthermore, linkage analysis studies suggest that the p16 gene is involved in familial melanoma susceptibility. Due to the oncogenic potential of mutations in this tumor suppressor, it is important to identify and characterize those mutations which alter p16 activity. We have performed a systematic analysis of melanoma associated p16 mutants and of mutants generated in charge to Ala mutagenesis. Using microtiter plate assays to measure both p16-cdk4 binding and cdk4/D1 kinase activity, we show here that the melanoma associated mutants are defective, as are some of the Ala mutants. These results support the idea that p16 mutation, via its deregulation of the cdk4/D1 pathway, is of biological significance in the development of melanoma. Furthermore, we have defined a region within the p16 molecule in which changes are likely to result in a defective protein.			WICK, ST (corresponding author), MITOTIX INC,1 KENDALL SQ,BLD 600,CAMBRIDGE,MA 02139, USA.			Wick, Scott/0000-0002-6906-4980				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DIUNPHY WG, 1989, CELL, V54, P423; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GIANI C, 1994, CANCER RES, V54, P6338; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V24, P6353; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KARP JE, 1995, NAT MED, V1, P309, DOI 10.1038/nm0495-309; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LAMB A, 1994, SCIENCE, V264, P346; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OHTSUBO M, 1995, IN PRESS MOL CELL BI; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SEGEL IH, 1975, ENZYME KINETICS, P129; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	42	41	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2013	2019						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478520				2022-12-28	WOS:A1995TF29700011
J	HERZOG, CR; WANG, Y; YOU, M				HERZOG, CR; WANG, Y; YOU, M			ALLELIC LOSS OF DISTAL CHROMOSOME-4 IN MOUSE LUNG-TUMORS LOCALIZE A PUTATIVE TUMOR-SUPPRESSOR GENE TO A REGION HOMOLOGOUS WITH HUMAN-CHROMOSOME 1P36	ONCOGENE			English	Article						LOH; CHROMOSOME 4; MOUSE LUNG; TUMOR SUPPRESSOR GENE	SHORT ARM; HETEROZYGOSITY; DELETION; PHEOCHROMOCYTOMAS; NEOPLASIA; CARCINOMA; BREAST; CANCER	Loss of heterozygosity (LOH) of distal chromosome 4 was studied to localize a putative tumor suppressor gene in mouse lung neoplasia. Previous studies have implicated this region and its homologue on human chromosome 1p36-34 as sites of potential tumor suppressor genes. One hundred adenocarcinomas and 38 adenomas of the mouse lung mere examined for LOH using nine simple sequence length polymorphism markers in a polymerase chain reaction-based approach. Forty-four adenocarcinomas displayed allele loss, all of which included losses at marker D4MIT54, which defined a critical region of 3 centiMorgans as the likely location of a putative tumor suppressor gene. In 58% of the tumors displaying LOH, all markers used in this study incurred allele loss. In contrast, retention of heterozygosity was observed at all markers tested in each of the adenomas studied, which suggests that the inactivation of this tumor suppressor gene participates in mouse lung tumor progression.	MED COLL OHIO, DEPT PATHOL, TOLEDO, OH 43699 USA						NATIONAL CANCER INSTITUTE [R29CA058554, R01CA058554] Funding Source: NIH RePORTER; NCI NIH HHS [CA58554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT CM, 1994, MAMM GENOME, V5, pS51; BELLO MJ, 1994, INT J CANCER, V57, P172, DOI 10.1002/ijc.2910570207; BELLO MJ, 1994, GENE CHROMOSOME CANC, V9, P296, DOI 10.1002/gcc.2870090411; BIECHE I, 1993, CANCER RES, V53, P1990; Biegel J., 1994, American Journal of Human Genetics, V55, pA51; BUNNELL BA, 1990, SOMAT CELL MOLEC GEN, V16, P151, DOI 10.1007/BF01233045; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DING SF, 1992, BRIT J CANCER, V65, P809, DOI 10.1038/bjc.1992.173; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; DRACOPOLI NC, 1994, CYTOGENET CELL GENET, V67, P143, DOI 10.1159/000133816; ENOMOTO H, 1994, ONCOGENE, V9, P2785; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GIBAS Z, 1994, GENE CHROMOSOME CANC, V9, P216, DOI 10.1002/gcc.2870090310; HERZOG CR, 1994, CANCER RES, V54, P4007; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KHOSLA S, 1991, J CLIN INVEST, V87, P1691, DOI 10.1172/JCI115186; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; LEE GH, 1995, GENETICS, V139, P387; LEISTER I, 1990, CANCER RES, V50, P7232; LUONGO C, 1994, CANCER RES, V54, P5947; MATHEW S, 1994, CANCER RES, V54, P6265; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MOCK BA, 1994, MAMM GENOME, V5, P191, DOI 10.1007/BF00352357; MOLEY JF, 1992, CANCER RES, V52, P770; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; SIMON D, 1991, ONCOGENE, V6, P765; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804	31	42	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	1995	11	9					1811	1815						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478609				2022-12-28	WOS:A1995TD09400016
J	VIGLIETTO, G; CHIAPPETTA, G; MARTINEZTELLO, FJ; FUKUNAGA, FH; TALLINI, G; RIGOPOULOU, D; VISCONTI, R; MASTRO, A; SANTORO, M; FUSCO, A				VIGLIETTO, G; CHIAPPETTA, G; MARTINEZTELLO, FJ; FUKUNAGA, FH; TALLINI, G; RIGOPOULOU, D; VISCONTI, R; MASTRO, A; SANTORO, M; FUSCO, A			RET/PTC ONCOGENE ACTIVATION IS AN EARLY EVENT IN THYROID CARCINOGENESIS	ONCOGENE			English	Note						RET PROTOONCOGENE; RET/PTC ONCOGENE; THYROID; OCCULT CARCINOMAS; RT-PCR	RET TYROSINE KINASE; PAPILLARY CARCINOMAS; PROTOONCOGENE	RET/PTC oncogene activation occurs in about 20% of human thyroid papillary carcinomas, However, it is not known yet whether it is an early or late event in the process of thyroid carcinogenesis, Here we demonstrate, by using a combined immunohistochemical and reverse-transcriptase-polymerase chain reaction based approach, that RET/PTC activation is present in 11 out of 26 occult thyroid papillary carcinomas analysed. Therefore, we conclude that it represents an early event in the process of thyroid cell transformation.	IST NAZL TUMORI,FDN SENATORE PASCALE,I-80131 NAPLES,ITALY; UNIV COMPLUTENSE MADRID,HOSP UNIV 12 OCTUBRE,DEPT PATHOL,E-28041 MADRID,SPAIN; KUAKINI MED CTR,HONOLULU,HI 96817; YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06520; UNIV COMPLUTENSE MADRID,HOSP UNIV 12 OCTUBRE,SERV ENDOCRINOL,E-28041 MADRID,SPAIN; UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	IRCCS Fondazione Pascale; Complutense University of Madrid; Hospital Universitario 12 de Octubre; Yale University; Complutense University of Madrid; Hospital Universitario 12 de Octubre; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria			Visconti, Roberta/C-5299-2009; Viglietto, Giuseppe/AAC-2852-2019; Tallini, Giovanni/F-7850-2013	Viglietto, Giuseppe/0000-0003-2327-7515; Tallini, Giovanni/0000-0003-0113-6682; Fusco, Alfredo/0000-0003-3332-5197; Visconti, Roberta/0000-0001-7613-3801				BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUKUNAGA FH, 1975, CANCER-AM CANCER SOC, V36, P1095, DOI 10.1002/1097-0142(197509)36:3<1095::AID-CNCR2820360338>3.0.CO;2-9; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; IKEDA I, 1990, ONCOGENE, V5, P1291; JACKSON DP, 1989, LANCET, V1, P1391; LANZI C, 1992, ONCOGENE, V7, P2189; MARTINEZTELLO FJ, 1993, CANCER-AM CANCER SOC, V71, P4022, DOI 10.1002/1097-0142(19930615)71:12<4022::AID-CNCR2820711236>3.0.CO;2-O; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509	16	221	233	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1207	1210						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566982				2022-12-28	WOS:A1995RX18000025
J	RACHMILEWITZ, J; ELKIN, M; ROSENSAFT, J; GELMANKOHAN, Z; ARIEL, I; LUSTIG, O; SCHNEIDER, T; GOSHEN, R; BIRAN, H; DEGROOT, N; HOCHBERG, A				RACHMILEWITZ, J; ELKIN, M; ROSENSAFT, J; GELMANKOHAN, Z; ARIEL, I; LUSTIG, O; SCHNEIDER, T; GOSHEN, R; BIRAN, H; DEGROOT, N; HOCHBERG, A			H19 EXPRESSION AND TUMORIGENICITY OF CHORIOCARCINOMA DERIVED CELL-LINES	ONCOGENE			English	Article						H19; CHORIOCARCINOMA CELL LINES; TUMOR SUPPRESSOR GENE; ONCOGENE	GROWTH FACTOR-II; IMPRINTED GENES; WILMS-TUMORS; CANCER; CHROMOSOME-11; DIFFERENTIATION; RELAXATION; MUTATION; INVITRO; INVIVO	Certain embryonal tumors demonstrate a loss of heterozygosity at the parentally imprinted region of chromosome 11p15.5. It has been hypothesized that this implicates a tumor suppressor gene at this locus. The human H19 gene maps to 11p15.5, is expressed in fetal tissues including the placenta and is paternally imprinted, Here we show that the abundance of H19 transcripts in cells of two choriocarcinoma derived cell lines (JAr and JEG-3) differs greatly. While JAr cells express high levels of H19 RNA, the expression of H19 in JEG-3 cells is much lower than that of normal trophoblasts, Cells of these two cell lines were subcutaneously injected into nude mice with subsequent tumor formation, A fivefold increase in the H19 RNA level was measured in tumors derived from JEG-3 cell lines as compared to these cells before injection, However this increase in H19 RNA did not alter the clonogenicity in soft agar nor the growth rate of the cells derived from these tumors as compared to the original JEG-3 cells, Nevertheless, the cells retaining the elevated level of H19 transcripts were more tumorigenic than the original cells, We propose that there is a selection of cells expressing high levels of H19 from the total JEG-3 cell population during the microevolution of tumor formation. These observations, together with our previous publications on H19 expression in human cancers, do not support the notion of a tumor suppressor role for the H19 gene.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; KAPLAN HOSP,CLIN GENET UNIT,REHOVOT,ISRAEL; HADASSAH UNIV HOSP,DEPT PATHOL,IL-91120 JERUSALEM,ISRAEL; KAPLAN HOSP,DEPT ONCOL,REHOVOT,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Kaplan Medical Center; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Kaplan Medical Center								ARIEL I, 1994, GYNECOL ONCOL, V53, P212, DOI 10.1006/gyno.1994.1118; ARIEL I, 1995, UROLOGY, V45, P335, DOI 10.1016/0090-4295(95)80030-1; BIRANNAN C, 1994, MOL CELL BIOL, V15, P123; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FRESHNEY RI, 1990, CULTURE ANIMAL CELLS, P142; GILEADI O, 1988, PLACENTAL PROTEIN HO, P251; GLASER A, 1992, MOL REPROD DEV, V33, P7, DOI 10.1002/mrd.1080330103; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P477, DOI 10.1007/BF01534910; GLEN AE, 1993, CURR OPIN GENE DEV, V3, P418; GOSHEN R, 1993, MOL REPROD DEV, V34, P374, DOI 10.1002/mrd.1080340405; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HASHIMOTO K, 1995, NAT GENET, V9, P109, DOI 10.1038/ng0295-109; HOCHBERG A, 1992, CANCER RES, V52, P3713; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JONES NJ, 1990, MUTAGENESIS, V5, P15, DOI 10.1093/mutage/5.1.15; JUNIEN C, 1992, GENOMICS, V12, P620, DOI 10.1016/0888-7543(92)90461-Z; Junien C, 1992, CURR OPIN GENET DEV, V2, P431, DOI 10.1016/S0959-437X(05)80154-6; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; LU X, 1988, EXP CELL RES, V174, P199, DOI 10.1016/0014-4827(88)90155-3; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; Mazur M. T., 1987, GESTATIONAL TROPHOBL, P45; MCDONALD RJ, 1987, METHOD ENZYMOL, V152, P221; MUTTER GL, 1993, AM J HUM GENET, V53, P1096; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; RACHMILEWITZ J, 1992, MOL REPROD DEV, V32, P196, DOI 10.1002/mrd.1080320303; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; RACHMILEWITZ J, 1993, CELL GROWTH DIFFER, V4, P395; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; ROTHMAN PA, 1992, MOL REPROD DEV, V33, P1, DOI 10.1002/mrd.1080330102; Sambrook J, 1989, MOL CLONING LABORATO; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SEKIYA S, 1987, ARCH GYNECOL OBSTET, V241, P111, DOI 10.1007/BF00931231; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	38	37	41	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					863	870						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7545806				2022-12-28	WOS:A1995RU79800006
J	RANE, SG; REDDY, EP				RANE, SG; REDDY, EP			JAK3 - A NOVEL JAK KINASE ASSOCIATED WITH TERMINAL DIFFERENTIATION OF HEMATOPOIETIC-CELLS	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; COLONY-STIMULATING FACTOR; GRANULOCYTIC DIFFERENTIATION; INTERLEUKIN-3; RECEPTOR; LINE; EXPRESSION; LEUKEMIA; PATHWAY	The Janus Kinases (JAK) JAK1, JAK2, and TYK2 are protein tyrosine kinases which play a pivotal role in the signal transduction process mediated by cytokines. These kinases appear to transduce signals via their substrates which modulate programs of gene expression specific to the respective signals. It is becoming increasingly evident that certain cytokines such as Granulocyte Colony Stimulating Factor (GCSF) can transmit signals for both cellular proliferation and differentiation. It is at present unclear whether both of these signals are transmitted by the same JAK kinase or whether an entire family of such kinases are involved in this process. To determine if additional members of JAK kinase family exist, we designed a polymerase chain reaction based strategy which resulted in the identification of a new member of the JAK kinase family. This new kinase, which we have named JAK3 is encoded by a 4.3 kb mRNA transcript. Nucleotide sequence analysis of a full length cDNA derived from this mRNA revealed that it encodes an open reading frame of 3897 bp. The protein encoded by this mRNA contains the double catalytic domain characteristic of the JAK family kinases. The most striking difference between JAK3 and the other JAK kinases is the presence of two stretches of additional amino acid sequence of 147 and 28 residues which span between amino acid positions 322 to 469 and 632 to 660 respectively. Expression studies indicate that JAK3 is expressed at very low levels in immature hematopoietic cells, but its expression is dramatically up-regulated during terminal differentiation of these cells, These results suggest that JAK3 plays an important role in the differentiation of hematopoietic cells.	TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [P30CA012227, P01CA052009] Funding Source: NIH RePORTER; NCI NIH HHS [CA 12227, CA 52009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Ausubel FM., 2006, ENZYMATIC MANIPULATI; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; ROVERA G, 1987, ONCOGENE, V1, P29; RUI H, 1994, J BIOL CHEM, V269, P5364; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	26	126	137	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2415	2423						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7518579				2022-12-28	WOS:A1994NX62900037
J	GRAND, RJA; BYRD, PJ; GRABHAM, PW; GREGORY, CD; HUEN, DS; MERRICK, RM; YOUNG, LS; GALLIMORE, PH				GRAND, RJA; BYRD, PJ; GRABHAM, PW; GREGORY, CD; HUEN, DS; MERRICK, RM; YOUNG, LS; GALLIMORE, PH			THE EXPRESSION OF THE RETINOBLASTOMA GENE-PRODUCT RB1 IN PRIMARY AND ADENOVIRUS-TRANSFORMED HUMAN-CELLS	ONCOGENE			English	Article											GRAND, RJA (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT CANC STUDIES,CANCER RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.		Young, Lawrence S/B-7213-2009; Huen, David/F-3676-2014	Young, Lawrence S/0000-0003-3919-4298; Huen, David/0000-0002-9900-2297				BOOKSTEIN R, 1988, P NATL ACAD SCI USA, V85, P2210, DOI 10.1073/pnas.85.7.2210; BYRD P, 1982, NATURE, V298, P69, DOI 10.1038/298069a0; BYRD PJ, 1988, ONCOGENE, V2, P477; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOORBAR J, 1986, EMBO J, V5, P355, DOI 10.1002/j.1460-2075.1986.tb04219.x; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; FIGGE J, 1988, NATURE, V334, P109, DOI 10.1038/334109a0; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; Gallimore PH, 1984, CANCER CELL, V2, P519; GLUZMAN Y, 1980, P NATL ACAD SCI-BIOL, V77, P3898, DOI 10.1073/pnas.77.7.3898; GODBOUT R, 1983, NATURE, V304, P451, DOI 10.1038/304451a0; GRABHAM PW, 1988, EXP EYE RES, V47, P123, DOI 10.1016/0014-4835(88)90029-2; GRAND RJA, 1984, J GEN VIROL, V65, P2149, DOI 10.1099/0022-1317-65-12-2149; GRAND RJA, 1986, EMBO J, V5, P1253, DOI 10.1002/j.1460-2075.1986.tb04354.x; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JOHNSON GD, 1982, J IMMUNOL METHODS, V55, P231, DOI 10.1016/0022-1759(82)90035-7; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MANOS MM, 1985, J VIROL, V53, P120, DOI 10.1128/JVI.53.1.120-127.1985; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; PARASKEVA C, 1982, J GEN VIROL, V58, P73, DOI 10.1099/0022-1317-58-1-73; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; YOKOTA J, 1988, ONCOGENE, V3, P471	37	23	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1291	1298						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2682458				2022-12-28	WOS:A1989AX65900004
J	KATZAV, S; MARTINZANCA, D; BARBACID, M; HEDGE, AM; ISFORT, R; IHLE, JN				KATZAV, S; MARTINZANCA, D; BARBACID, M; HEDGE, AM; ISFORT, R; IHLE, JN			THE TRK ONCOGENE ABROGATES GROWTH-FACTOR REQUIREMENTS AND TRANSFORMS HEMATOPOIETIC-CELLS	ONCOGENE			English	Article									NCI, FREDERICK CANC RES FACIL, BRI BASIC RES PROGRAM, MOLEC MECHANISMS LEUKEMOGENESIS SECT, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	KATZAV, S (corresponding author), NCI, FREDERICK CANC RES FACIL, DEV ONCOL SECT, FREDERICK, MD 21701 USA.				NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101, P30 CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FRACKELTON AR, 1983, MOL CELL BIOL, V3, P1343, DOI 10.1128/MCB.3.8.1343; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAPEL AJ, 1986, LYMPHOKINE RES, V5, P249; HARIHARAN IK, 1988, IN PRESS ONCOGENE RE, V3; Ihle J N, 1989, Year Immunol, V5, P59; IHLE JN, 1982, J IMMUNOL, V129, P1377; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; JHAPPAN C, 1986, J VIROL, V60, P750, DOI 10.1128/JVI.60.2.750-753.1986; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; WATSON JD, 1987, J IMMUNOL, V139, P123; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673	29	31	31	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1989	4	9					1129	1135						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2674855				2022-12-28	WOS:A1989AM53100012
J	SEIMIYA, H; SAWABE, T; TOHO, M; TSURUO, T				SEIMIYA, H; SAWABE, T; TOHO, M; TSURUO, T			PHORBOL ESTER-RESISTANT MONOBLASTOID LEUKEMIA-CELLS WITH A FUNCTIONAL MITOGEN-ACTIVATED PROTEIN-KINASE CASCADE BUT WITHOUT RESPONSIVE PROTEIN-TYROSINE PHOSPHATASES	ONCOGENE			English	Article						TPA; MAP KINASE; PTPASE	COMMON ANTIGEN CD45; PHOSPHOTYROSINE PHOSPHATASE; INDUCED DIFFERENTIATION; CYTOSKELETAL ORGANIZATION; SEQUENCE SIMILARITY; C ACTIVATION; U937 CELLS; SH2 DOMAIN; MOTH-EATEN; RECEPTOR	Human monoblastoid leukemia U937 cells differentiate to monocyte/macrophage upon treatment with phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA). Previous studies, including our own, have demonstrated that drug-induced differentiation of leukemia cells is associated with genetic and enzymatic activations of protein tyrosine phosphatases (PTPases). In this study, to further investigate a relationship between PTPase activation and leukemic differentiation, we established TPA-resistant U937 variant UT16 cells. Unlike known TPA-resistant cells whose resistance is mainly due to lack or down modulation of protein kinase C (PKC), UT16 cells showed TPA-induced activation of PKC, Raf-1, and ERK/MAP kinases similar to the parental U937 cells. Interestingly, however, UT16 cells exhibited altered binding activity of AP-1 complexes, decreased ability to induce c-jun and c-fos gene expressions, and failure to differentiate to a monocytic lineage. Based on these observations, UT16 cells could be considered a novel type of TPA-resistant cell. Among UT16 cells, most of TPA-inducible PTPase genes, PTP-1C, PTP-MEG2, P19-PTP, HPTP epsilon, and PTP-U1, did not respond to TPA. Consistently, TPA increased PTPase enzymatic activity in U937 but not in UT16 cells. Taken together, activation of PTPases is well correlated with TPA-induced differentiation of U937 cells. These findings indicate that gene expression and enzymatic activity of some PTPase isozymes described here are regulated by a TPA-mediated signaling event and are likely to be used as biomarkers for the monocytic differentiation of myeloid leukemia cells.	UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN; JAPANESE FDN CANC RES, CTR CANC CHEMOTHERAPY, TOSHIMA KU, TOKYO 170, JAPAN	University of Tokyo; Japanese Foundation for Cancer Research				Seimiya, Hiroyuki/0000-0003-3314-9736				ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER TM, 1990, CANCER RES, V50, P6323; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHIDA K, 1986, CANCER RES, V46, P1055; DENHERTOG J, 1992, BIOCHEM BIOPH RES CO, V184, P1241, DOI 10.1016/S0006-291X(05)80015-4; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FRANK DA, 1988, CANCER RES, V48, P52; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; HALL LR, 1988, J IMMUNOL, V141, P2781; HASS R, 1991, CELL GROWTH DIFFER, V2, P541; HASS R, 1989, EUR J CELL BIOL, V48, P282; HASS R, 1993, CELL GROWTH DIFFER, V4, P657; HONDA H, 1994, BLOOD, V84, P4186, DOI 10.1182/blood.V84.12.4186.bloodjournal84124186; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KREUTTER D, 1985, J BIOL CHEM, V260, P5979; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PALLEN CJ, 1988, COLD SPRING HARB SYM, V53, P447, DOI 10.1101/SQB.1988.053.01.052; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEIMIYA H, 1995, ONCOGENE, V10, P1731; SEIMIYA H, 1993, CELL GROWTH DIFFER, V4, P1033; SEIMIYA H, 1993, J BIOCHEM-TOKYO, V113, P687, DOI 10.1093/oxfordjournals.jbchem.a124104; SHEN SH, 1991, NATURE, V353, P868, DOI 10.1038/353868b0; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SOZERI O, 1992, ONCOGENE, V7, P2259; STONE RL, 1994, J BIOL CHEM, V269, P31323; SZABO E, 1994, CELL GROWTH DIFFER, V5, P439; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; TSUNEIZUMI K, 1994, FEBS LETT, V347, P9, DOI 10.1016/0014-5793(94)00491-9; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WATANABE T, 1985, BIOCHEM BIOPH RES CO, V126, P999, DOI 10.1016/0006-291X(85)90284-0; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YANO T, 1991, BIOCHEM BIOPH RES CO, V175, P1144, DOI 10.1016/0006-291X(91)91685-6; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007	61	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	1995	11	10					2047	2054						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478524				2022-12-28	WOS:A1995TF29700015
J	BRAUNINGER, A; STREBHARDT, K; RUBSAMENWAIGMANN, H				BRAUNINGER, A; STREBHARDT, K; RUBSAMENWAIGMANN, H			IDENTIFICATION AND FUNCTIONAL-CHARACTERIZATION OF THE HUMAN AND MURINE POLO-LIKE KINASE (PLK) PROMOTER	ONCOGENE			English	Article						SERINE THERONINE KINASE; PROMOTER; POLO-LIKE KINASE (PLK)	PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTORS; BINDING PROTEINS; ENHANCER-BINDING; DNA-BINDING; GENE; DROSOPHILA; CLONING; ENCODES	The Plk gene encodes a serine/theronine kinase which is located in the nucleus. Northern blot analysis linked Plk expression to the proliferative activity of cells and tissues. To analyse the transcriptional regulation of the Plk gene we have isolated several human genomic clones containing the Plk promoter. RNAse protection assays revealed three major transcription start sites within a 40 bp region centered around the 5' end of the known human cDNA and 6 minor Cap sites. A genomic fragment of 2.3 kb located 5' to the translation start sites drives the expression of the CAT-reporter in transient transfections in human (EPLC, HeLa) and mouse (NIH3T3, 32D) cell lines in an orientation dependent fashion. The 2.3 kb genomic fragment contains a CCAAT motif located 30-70 bp upstream of the Cap sites and two overlapping Spl sites 20 bp further upstream. Additional sequence motif homologues to binding sites of known transcription factors could be identified. In addition to the human Plk promoter, the mouse Plk promoter was isolated. The sequence alignment of the human and murine promoter revealed three regions with extensive sequence homology within a region of 300 bp immediately upstream of the Cap sites. A fourth region of homology encompassing 90 bp about 2.1 kb 5' of the Cap sites was identified as web. Deletion of various regions within the 2.3 kb promoter fragment identified several domains involved in the regulation of the human Plk promoter. The 300 bp region immediately 5' of the Cap sites which is highly conserved between mouse and man is essential for promoter activity. 3' deletions including the CCAAT site abolished promoter activity. Growing 5' deletions within the core region of the promoter reduces transcriptional activity. Furthermore, using deletion clones we identified regions 5' of the core region which enhance or silence the transcriptional activity of the core promoter.	CHEMOTHERAPEUT FORSCHUNGSINST,D-60596 FRANKFURT,GERMANY; BAYER AG,D-42113 WUPPERTAL,GERMANY	Bayer AG			Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Ausubel F. M., 1993, CURRENT PROTOCOLS MO, V1; AUSUBEL FM, 1993, CURRENT PROTOCOLS MO, V2; BEPLER G, 1988, DIFFERENTIATION, V37, P158, DOI 10.1111/j.1432-0436.1988.tb00806.x; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; COPERTINO DW, 1995, P NATL ACAD SCI USA, V92, P2131, DOI 10.1073/pnas.92.6.2131; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; MILLIGAN JF, 1987, NUC ACIDS RES, V15, P8789; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHARON G, 1990, GENETICS, V125, P487; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SUNKEL CE, 1988, J CELL SCI, V89, P25; WHITE MRA, 1992, ONCOGENE, V7, P677; WRITH T, 1988, EMBO J, V7, P3109; ZACKSENHAUS E, 1993, ONCOGENE, V8, P2343	40	23	24	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1793	1800						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478607				2022-12-28	WOS:A1995TD09400014
J	LI, CY; NAGASAWA, H; DAHLBERG, WK; LITTLE, JB				LI, CY; NAGASAWA, H; DAHLBERG, WK; LITTLE, JB			DIMINISHED CAPACITY FOR P53 IN MEDIATING A RADIATION-INDUCED G(1) ARREST IN ESTABLISHED HUMAN TUMOR-CELL LINES	ONCOGENE			English	Article						G(1)-ARREST; P53; RB; RADIATION; HUMAN PAPILLOMA VIRUS E6; HUMAN TUMOR CELLS	ATAXIA-TELANGIECTASIA; CHROMOSOMAL-ABERRATIONS; CYCLE PROGRESSION; X-IRRADIATION; CANCER; FIBROBLASTS; MUTATIONS; INDUCTION; ONCOGENE; PROTEIN	It has been reported that the p53 gene mediates an ionizing radiation-induced G(1) arrest in mammalian cells. To further characterize this important phenomenon, a panel of seven human diploid fibroblast cell strains and 14 human tumor cell lines from a variety of sources with both wild-type and mutant p53 status were assayed for their susceptibility to G(1) arrest after gamma-ray irradiation by a continuous labeling [H-3]thymidine incorporation technique. An irreversible G(1)-block involving 20-70% of the cell population was observed in diploid fibroblasts irradiated with 4 Gy. The block was abolished by transfection with the Human Papilloma Virus E6 gene and in an ataxia telangiectasia (AT) tell line, indicating a role for the AT and p53 genes respectively in this process. In contrast to wild-type normal fibroblast cell strains, the G(1)-block in all tumor cell lines was significantly reduced, irrespective of their p53 status. None of the nine human tumor cell lines with mutant p53 genes showed a significant G(1)-block following irradiation with 4 Gy. Among the five tumor cell lines expressing wild-type p53, two showed no apparent G(1)-block. The remaining three showed a G(1)-block involving only 8-15% of the cell population, a block much smaller in magnitude than that seen in diploid fibroblasts. Finally, a diploid fibroblast cell strain and a tumor cell line, both showing a normal p53 and p21/WAF1 expression pattern, were examined for pRb phosphorylation before and after irradiation. The diploid fibroblast cell strain showed a significant G(1)-arrest and a clear inhibition of pRb phosphorylation by irradiation whereas the tumor cells showed no G(1)-arrest and no inhibition of pRb phosphorylation. These results suggest that (1) multiple genetic factors may modulate the occurrence and magnitude of the G(1)-arrest induced by exposure to ionizing radiation, (2) the capacity for p53 to mediate a radiation-induced G(1) arrest is significantly reduced in tumor cells, (3) the disruption of G(1)-block modulating factor(s) other than p53 may be an important step in carcinogenesis.			LI, CY (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,665 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Li, Chuan-Yuan/H-4148-2013		NATIONAL CANCER INSTITUTE [R35CA047542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47542] Funding Source: Medline; NIEHS NIH HHS [ES0002] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALTMAN KI, 1970, RAD BIOCHEM, V1, P189; BRACHMAN DG, 1993, CANCER RES, V53, P3667; CASEY G, 1991, ONCOGENE, V6, P1991; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HE J, 1994, CANCER RES, V54, P5804; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISSACS WB, 1991, CANCER RES, V51, P4716; JIANG W, 1992, CANCER RES, V52, P2980; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1992, CELL, V71, P687; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEONARDO AD, 1994, GENE DEV, V8, P2540; LI CY, 1995, INT J ONCOL, V7, P223; LITTLE J B, 1970, Radiation Research, V44, P674, DOI 10.2307/3573149; LITTLE JB, 1968, NATURE, V218, P1064, DOI 10.1038/2181064a0; LITTLE JB, 1985, RADIAT RES, V101, P81, DOI 10.2307/3576305; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; LITTLE JB, 1969, NATURE, V224, P804, DOI 10.1038/224804a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAGASAWA H, 1985, MUTAT RES, V148, P71, DOI 10.1016/0027-5107(85)90209-X; NAGASAWA H, 1995, CANCER RES, V55, P1842; NAGASAWA H, 1994, INT J RADIAT BIOL, V66, P373, DOI 10.1080/09553009414551311; NAGASAWA H, 1984, RADIAT RES, V97, P537, DOI 10.2307/3576145; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Sambrook J, 1989, MOL CLONING LABORATO; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1994, NATURE, V366, P701	39	71	73	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1885	1892						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478618				2022-12-28	WOS:A1995TD09400025
J	FUJII, M; CHUHJO, T; MINAMINO, T; MASAAKI, N; MIYAMOTO, K; SEIKI, M				FUJII, M; CHUHJO, T; MINAMINO, T; MASAAKI, N; MIYAMOTO, K; SEIKI, M			IDENTIFICATION OF THE TAX INTERACTION REGION OF SERUM RESPONSE FACTOR THAT MEDIATES THE ABERRANT INDUCTION OF IMMEDIATE-EARLY GENES THROUGH CARG BOXES BY HTLV-I TAX	ONCOGENE			English	Article						HTLV-I; TAX; SRF; TRANSCRIPTION	T-CELL LEUKEMIA; VIRUS TYPE-I; C-FOS PROMOTER; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; AUTO-REGULATION; PROTEIN ELK-1; ELEMENT; EXPRESSION; TRANSACTIVATION	Tax of human T-cell leukemia virus type I (HTLV-I) activates transcription at a CArG box of various immediate early genes such as the proto-oncogene c-fos. To do this, Tax does not directly bind to the CArG box, but instead binds to the CArG binding factor SRF. In this study, we investigated the domain of SRF required for the activation by Tax and studied the role of this domain on transcriptional regulation at the CArG box. Using a fusion protein of SRF with a yeast transcription factor GAL4, the 14 amino acid (aa) portion (aa 422-435) of SRF was identified as the domain required for Tax activation [Tax-responsive region of SRF (TRRS)]. By means of a two hybrid system, we showed that TRRS was essential for the interaction of SRF with Tax in vivo. The over-expression of SRF with a deletion of TRRS inhibited the Tax activation at the CArG box. Thus, TRRS is the domain of SRF that is essential for Tax activation at the CArG box. Unlike to Tax activation, TRRS was not required for TPA (12-o-tetradecanoylphobol-13-acetate) induction at the CArG box, but a TRRS deletion enhanced the basal activity at the CArG box both under serum-starved and TPA-stimulated conditions. These results suggest that TRRS negatively regulates the transcriptional activation function of SRF, and consequently contributes to the low basal activity at the CArG box before TPA induction.	KANAZAWA UNIV,CANC RES INST,DEPT MOLEC ONCOL & VIROL,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,DEPT INTERNAL MED 3,KANAZAWA,ISHIKAWA 920,JAPAN; HOKURIKU UNIV,SCH PHARM,DEV MED RES LAB,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University; Kanazawa University; Hokuriku University			Seiki, Motoharu/K-9443-2015					AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; ALEXANDRE C, 1991, ONCOGENE, V6, P1851; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DECAPRIO JA, 1988, CELL, V15, P275; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1994, J VIROL, V68, P7275, DOI 10.1128/JVI.68.11.7275-7283.1994; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P2349; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOW KG, 1994, MOL CELL BIOL, V14, P4958, DOI 10.1128/MCB.14.7.4958; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; NAGATA K, 1989, J VIROL, V68, P3220; NERENBERG M, 1988, SCIENCE, V237, P1324; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OSAME M, 1986, LANCET, V1, P1031; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; SUGAMURA K, 1993, RETROVIRIDAE, V2, P399; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; TSUCHIYA H, 1994, ONCOGENE, V9, P337; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; WHITE P, 1988, NATURE, V334, P124; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	55	37	37	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					7	14						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624133				2022-12-28	WOS:A1995RJ29500002
J	ZALCMAN, G; CLOSSON, V; LINARESCRUZ, G; LEREBOURS, F; HONORE, N; TAVITIAN, A; OLOFSSON, B				ZALCMAN, G; CLOSSON, V; LINARESCRUZ, G; LEREBOURS, F; HONORE, N; TAVITIAN, A; OLOFSSON, B			REGULATION OF RAS-RELATED RHOB PROTEIN EXPRESSION DURING THE CELL-CYCLE	ONCOGENE			English	Article						GTP-BINDING PROTEIN; RHO; RNA EXPRESSION; PROTEIN EXPRESSION; CELL CYCLE	GTP-BINDING-PROTEIN; NERVE GROWTH-FACTOR; SWISS 3T3 CELLS; ADP-RIBOSYLATION; GENE-PRODUCT; HUMAN HOMOLOG; SACCHAROMYCES-CEREVISIAE; CLOSTRIDIUM-BOTULINUM; MOLECULAR-CLONING; FAMILY	The immediate-early gene rhoB codes for a small GTP-binding protein highly homologous to the RhoA protein, While RhoA is known to regulate the assembly of focal adhesions and stress fibers in response to growth factors, the function of RhoB remains unknown. In a first attempt to elucidate its function, we examined the variation of the RhoB protein expression in response to induction of its mRNA. We report here that RhoB is an unstable protein rapidly and transiently induced by growth factors in PC12 and HeLa cells. Moreover, RhoB protein accumulation is periodic through the cell cycle. First detected at the G1/S phase transition, the level of the RhoB protein is maximal during the S phase and declines at the S/G2-M transition. This timing suggests that RhoB plays a role in the G1/S phase transition and/or in the S phase of the cell cycle. We also confirm here a vesicular and perinuclear localization of the endogenous RhoB protein induced by growth factors.	FAC MED LARIBOISIERE, INSERM, U248, F-75010 PARIS, FRANCE; INST GENET MOLEC, PHARMACOL EXPTL LAB, F-75010 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			ZALCMAN, Gerard/P-4150-2015; ZALCMAN, Gerard/M-8113-2019; ZALCMAN, Gérard/L-7809-2015	ZALCMAN, Gérard/0000-0002-0343-9575				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ADAMSON P, 1992, J BIOL CHEM, V267, P20033; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DECREMOUX P, 1994, INT J CANCER, V59, P408, DOI 10.1002/ijc.2910590320; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DISBURY J, 1989, J BIOL CHEM, V264, P16378; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; HENGST L, 1990, EMBO J, V9, P1949, DOI 10.1002/j.1460-2075.1990.tb08322.x; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JUST I, 1994, J BIOL CHEM, V269, P10706; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LANG P, 1993, BIOCHEM BIOPH RES CO, V196, P1522, DOI 10.1006/bbrc.1993.2424; LANG P, 1992, J BIOL CHEM, V267, P11677; LINARESCRUZ G, 1994, J MICROSC-OXFORD, V173, P27, DOI 10.1111/j.1365-2818.1994.tb03425.x; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MORII N, 1992, J BIOL CHEM, V267, P20921; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; OLOFSSON B, 1988, ONCOGENE, V3, P231; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SUGAI M, 1992, J BIOL CHEM, V267, P2600; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; UEDA T, 1990, J BIOL CHEM, V265, P9373; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	62	81	85	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					1935	1945						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7539118				2022-12-28	WOS:A1995QZ92600007
J	WYLLIE, FS; HAUGHTON, MF; BLAYDES, JP; SCHLUMBERGER, M; WYNFORDTHOMAS, D				WYLLIE, FS; HAUGHTON, MF; BLAYDES, JP; SCHLUMBERGER, M; WYNFORDTHOMAS, D			EVASION OF P53-MEDIATED GROWTH-CONTROL OCCURS BY 3 ALTERNATIVE MECHANISMS IN TRANSFORMED THYROID EPITHELIAL-CELLS	ONCOGENE			English	Article						P53; CELL CYCLE; CHECK-POINT; TUMOR PROGRESSION; THYRO	WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; LARGE-T-ANTIGEN; MONOCLONAL-ANTIBODIES; ATAXIA-TELANGIECTASIA; SIMIAN VIRUS-40; MDM-2 ONCOGENE; DNA DAMAGE; MUTANT P53; CARCINOMA	Using the thyroid as a model of multistep epithelial tumorigenesis, we have used representative cell lines to correlate the degree of malignant transformation with the functional status of p53 and the integrity of cell-cycle check-points. Three distinct phenotypes were observed: Type I lines, derived from poorly-differentiate human thyroid cancers, expressed high levels of mutant p53 protein; Type II, also poorly-differentiate but derived from rat, showed over-expression of wild-type (wt) p53 with marked cell-cell heterogeneity: Type III, from well-differentiated human cancers, contained uniformly low levels of wt p53, All cell lines containing wt p53 retained a near-normal induction of p53 by DNA damage. However, the ability to undergo growth arrest differed strikingly, Whereas Type I and II lines had lost both G2/M and G1/S check points, Type III cells retained both. In Type III cells, as in diploid human fibroblasts, mutant p53 expression specifically abrogated G1/S check-point function with no other change in phenotype, These data demonstrate 3 mechanisms for evasion of p53 growth control: (i) direct mutation (ii) indirect inactivation, or (iii) 'avoidance' of activation, most probably due to failure to reach a critical threshold of DNA damage.	UNIV WALES COLL MED,DEPT PATHOL,CANC RES CAMPAIGN,THYROID TUMOUR BIOL RES GRP,CARDIFF CF4 4XN,S GLAM,WALES; INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE	Cardiff University; UNICANCER; Gustave Roussy			Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARNES DM, 1993, J PATHOL S, V169, P231; BLAYDES JP, IN PRESS ONCOGENE; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BOND JA, 1994, ONCOGENE, V9, P1885; BRASH DE, 1987, MOL CELL BIOL, V7, P2031, DOI 10.1128/MCB.7.5.2031; BURNS JS, 1992, MOL CARCINOGEN, V6, P129, DOI 10.1002/mc.2940060208; CHALLETON C, 1992, J ENDOCRINOL INVE S2, V15, P32; COOK PR, 1976, NATURE, V263, P679, DOI 10.1038/263679a0; CRAMER P, 1981, NATURE, V291, P671, DOI 10.1038/291671a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GORETZKI PE, 1989, ANN ENDOCRINOL, V50, P145; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARTWELL LH, 1992, CELL, V71, P541; HSU TC, 1989, INT J CANCER, V43, P403, DOI 10.1002/ijc.2910430310; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOPEZLARRAZA D, 1990, MUTAT RES, V232, P57, DOI 10.1016/0027-5107(90)90110-P; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MILNER J, 1987, ONCOGENE, V1, P453; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OCONNOR PM, 1993, CANCER RES, V53, P4776; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; SAKAMOTO A, 1983, CANCER, V52, P1849, DOI 10.1002/1097-0142(19831115)52:10<1849::AID-CNCR2820521015>3.0.CO;2-X; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WILLIAMS DW, 1989, THYROID TUMOURS MOL, P57; WILLIAMS NW, 1989, EXP CELL RES, V184, P316, DOI 10.1016/0014-4827(89)90331-5; WRIGHT PA, 1991, ONCOGENE, V6, P1693; WRIGHT PA, 1993, J PATH S, V169, P230; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1991, MOL CELL ENDOCRINOL, V76, P13, DOI 10.1016/0303-7207(91)90255-Q; WYLLIE FS, 1992, P ONCOGENES GROWTH C; WYNFORDTHOMAS D, 1990, MOL CELL BIOL, V10, P5365, DOI 10.1128/MCB.10.10.5365; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	54	41	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					49	59						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7529918				2022-12-28	WOS:A1995QA98000007
J	SU, ZZ; SHEN, RQ; OBRIAN, CA; FISHER, PB				SU, ZZ; SHEN, RQ; OBRIAN, CA; FISHER, PB			INDUCTION OF TRANSFORMATION PROGRESSION IN TYPE-5 ADENOVIRUS-TRANSFORMED RAT EMBRYO CELLS BY A CLONED PROTEIN-KINASE-C BETA(1)-GENE AND REVERSAL OF PROGRESSION BY 5-AZACYTIDINE	ONCOGENE			English	Article							PHORBOL ESTER RECEPTOR; ANCHORAGE-INDEPENDENT GROWTH; GENE-EXPRESSION; FIBROBLAST CELLS; CHEMICAL CARCINOGENS; TUMOR PROMOTERS; LEUCINE ZIPPER; DNA-BINDING; WILD-TYPE; PHENOTYPE	Protein kinase C (PKC) is a key component in signal transduction in eucaryotic cells and when specific PKC isoforms are over-expressed in immortal mammalian cells they can induce transformation-associated properties. In the present study we demonstrate that a cloned PKC beta1 gene can induce an enhanced expression of the transformed phenotype in type 5 adenovirus (Ad5)-transformed rat embryo (RE) cells (clone E11), a process termed transformation progression. Ell cells expressing the PKC beta1 gene, clone B1/PKC, produce PKC beta1 mRNA and display enhanced PKC enzymatic activity and binding of [H-3]-phorbol-12,13-dibutyrate (PDBu) to cell surface phorbol ester receptors. B1/PKC cells grow with increased efficiency in agar in comparison with parental Ell cells and anchorage-independence is further enhanced in both cell types by addition of the tumor promoting agent 12-0-tetradecanoyl-phorbol-13-acetate (TPA). A single-exposure of B1/PKC cells to 5-azacytidine (AZA), followed by growth in the absence of this demethylating agent, results in B1/PKC-AZA clones which display a stable reversion of the progression phenotype to that of the unprogressed parental Ell clone. Loss of the progression phenotype corresponds with a reduction in PKC beta1-induced biochemical and cellular changes. In contrast, progression-suppression does not involve an alteration in expression of the Ad5 transforming genes, E1A and E1B, or the endogenous PKC epsilon gene. TPA cannot induce the progression phenotype in B1/PKC-AZA cells, but it can reversibly induce an increase in the transcriptional rate and steady-state mRNA levels of PKC beta1 and c-jun and it increases AP-1 DNA-binding. These results indicate that the PKC beta1 gene can serve as a transformation progression-inducing gene in rat embryo cells previously transformed by Ad5 and progression may be mediated by the inactivation by methylation of an AZA-sensitive 'progression suppressor gene(s)'. The suppression process in B1/PKC cells is independent of expression of the Ad5-transforming genes but correlates directly with the reduced expression of the transfected PKC beta1 gene in AZA-treated B1/PKC cells.	COLUMBIA UNIV COLL PHYS & SURG, CTR COMPREHENS CANC, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, CTR COMPREHENS CANC, DEPT UROL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, INST CANC RES, NEW YORK, NY 10032 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Columbia University; Columbia University; Columbia University; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA035675, R01CA043208, R29CA052460] Funding Source: NIH RePORTER; NCI NIH HHS [CA35675, CA52460, CA43208] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BABISS LE, 1983, J VIROL, V46, P454, DOI 10.1128/JVI.46.2.454-465.1983; BABISS LE, 1985, SCIENCE, V228, P1099, DOI 10.1126/science.2581317; BABISS LE, 1984, J VIROL, V49, P731, DOI 10.1128/JVI.49.3.731-740.1984; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1992, J BIOL CHEM, V267, P12892; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BORNER C, 1988, P NATL ACAD SCI USA, V85, P2110, DOI 10.1073/pnas.85.7.2110; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DORSCHHASLER K, 1980, J VIROL, V34, P305; DUIGOU GJ, 1991, ONCOGENE, V6, P1813; DUIGOU GJ, 1990, MOL CELL BIOL, V10, P2027, DOI 10.1128/MCB.10.5.2027; DUIGOU GJ, 1989, ANN NY ACAD SCI, V567, P302, DOI 10.1111/j.1749-6632.1989.tb16487.x; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FISHER PB, 1979, CELL, V18, P695, DOI 10.1016/0092-8674(79)90124-7; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FISHER PB, 1978, P NATL ACAD SCI USA, V75, P2311, DOI 10.1073/pnas.75.5.2311; FISHER PB, 1979, NATURE, V281, P591, DOI 10.1038/281591a0; FISHER PB, 1979, CANCER RES, V39, P3051; FISHER PB, 1984, MECHANISMS TUMOR PRO, V3, P57; FRIEDMAN JM, 1986, MOL CELL BIOL, V6, P3791, DOI 10.1128/MCB.6.11.3791; HALAZONETIS TD, 1992, ANTICANCER RES, V12, P285; HARRINGTON MA, 1988, MOL CELL BIOL, V8, P4322, DOI 10.1128/MCB.8.10.4322; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P197; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRAUSS RS, 1989, ONCOGENE, V4, P991; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NICOLSON GL, 1987, CANCER RES, V47, P1473; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOWELL PC, 1986, CANCER RES, V46, P2203; OBRIAN CA, 1989, FEBS LETT, V246, P78, DOI 10.1016/0014-5793(89)80257-1; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1986, FEBS LETT, V203, P111, DOI 10.1016/0014-5793(86)80724-4; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PERKINS AS, 1983, MOL CELL BIOL, V3, P1123, DOI 10.1128/MCB.3.6.1123; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; REDDY PG, 1993, METHODS MOL GENETICS, V1, P68; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCOTT RE, 1989, P NATL ACAD SCI USA, V86, P1652, DOI 10.1073/pnas.86.5.1652; SU ZZ, 1993, ONCOGENE, V8, P1211; SU ZZ, 1991, MOL CARCINOGEN, V4, P328, DOI 10.1002/mc.2940040412; SU ZZ, 1990, MOL CARCINOGEN, V3, P309, DOI 10.1002/mc.2940030512; SU ZZ, 1992, CELL MOL BIOL, V38, P27; SU ZZ, 1992, POLY ADP RIBOSYLATIO, P203; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; WARD NE, 1992, BIOCHEMISTRY-US, V31, P5905, DOI 10.1021/bi00140a029; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINSTEIN IB, 1988, CANCER RES, V48, P4135	68	8	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1123	1132						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	7510863				2022-12-28	WOS:A1994NC04800015
J	ASKER, C; STEINITZ, M; ANDERSSON, K; SUMEGI, J; KLEIN, G; INGVARSSON, S				ASKER, C; STEINITZ, M; ANDERSSON, K; SUMEGI, J; KLEIN, G; INGVARSSON, S			NUCLEOTIDE-SEQUENCE OF THE RAT BMYC GENE	ONCOGENE			English	Note									KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet			Ingvarsson, Sigurdur/E-7448-2011	Ingvarsson, Sigurdur/0000-0003-4125-1714	NCI NIH HHS [3R01CA14054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BONNIEU A, 1988, ONCOGENE RES, V3, P155; BROOKS BJ, 1987, ADV VIRAL ONCOL, V7, P155; CAVALIERI F, 1988, ONCOGENE, V2, P289; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DEGREVE J, 1988, MOL CELL BIOL, V8, P4381, DOI 10.1128/MCB.8.10.4381; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EVAN GI, 1989, IN PRESS MOL CELL BI, V9; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HALLEWELL RA, 1980, GENE, V9, P27, DOI 10.1016/0378-1119(80)90165-1; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HAYASHI K, 1987, NUCLEIC ACIDS RES, V15, P6419, DOI 10.1093/nar/15.16.6419; HENRIKSSON M, 1988, ONCOGENE, V3, P587; HOPPE J, 1981, EUR J BIOCHEM, V17, P585; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; IKEGAKI N, 1989, EMBO J, V8, P1793, DOI 10.1002/j.1460-2075.1989.tb03573.x; INGVARSSON S, 1988, ONCOGENE, V3, P679; INGVARSSON S, 1988, MOL CELL BIOL, V8, P3168, DOI 10.1128/MCB.8.8.3168; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; ONCLERCQ R, 1988, J VIROL, V62, P4533, DOI 10.1128/JVI.62.12.4533-4537.1988; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; RECHSTEINER M, 1987, TRENDS BIOCHEM SCI, V12, P390; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SEJERSEN T, 1987, EXP CELL RES, V172, P304, DOI 10.1016/0014-4827(87)90389-2; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMALL D, 1977, BIOCHEM BIOPH RES CO, V79, P341, DOI 10.1016/0006-291X(77)90101-2; STADEN R, 1980, NUCLEIC ACIDS RES, V8, P3673, DOI 10.1093/nar/8.16.3673; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	47	18	20	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1523	1527						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687773				2022-12-28	WOS:A1989CB65900017
J	FAINSTEIN, E; EINAT, M; GOKKEL, E; MARCELLE, C; CROCE, CM; GALE, RP; CANAANI, E				FAINSTEIN, E; EINAT, M; GOKKEL, E; MARCELLE, C; CROCE, CM; GALE, RP; CANAANI, E			NUCLEOTIDE-SEQUENCE ANALYSIS OF HUMAN ABL AND BCR-ABL CDNAS	ONCOGENE			English	Article									TEMPLE UNIV,FELS INST,PHILADELPHIA,PA 19122; UNIV CALIF LOS ANGELES,MED CTR,DEPT MED,LOS ANGELES,CA 90024	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	FAINSTEIN, E (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Friedman-Einat, Miriam/0000-0002-9451-1025				CARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LAUB O, 1983, J VIROL, V48, P271, DOI 10.1128/JVI.48.1.271-280.1983; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MESMASSON AM, 1987, P NATL ACAD SCI USA, V84, P207; MOAV B, 1986, GENE, V48, P297, DOI 10.1016/0378-1119(86)90089-2; NOWELL PC, 1960, SCIENCE, V132, P1497; PAWSON T, 1988, ONCOGENE, V3, P491; PENDERGAST AM, 1987, MOL CELL BIOL, V7, P4280, DOI 10.1128/MCB.7.12.4280; PINHASI O, 1984, MOL CELL BIOL, V4, P2180, DOI 10.1128/MCB.4.10.2180; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0	30	61	74	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1477	1481						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687768				2022-12-28	WOS:A1989CB65900009
J	DEPPERT, W; STEINMAYER, T; RICHTER, W				DEPPERT, W; STEINMAYER, T; RICHTER, W			COOPERATION OF SV40 LARGE T-ANTIGEN AND THE CELLULAR PROTEIN-P53 IN MAINTENANCE OF CELL-TRANSFORMATION	ONCOGENE			English	Article									UNIV ULM,BIOCHEM ABT,D-7900 ULM,FED REP GER	Ulm University	DEPPERT, W (corresponding author), UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,D-2000 HAMBURG 20,FED REP GER.		Richter, Wiltrud/V-3217-2017	Richter, Wiltrud/0000-0003-4694-2768				BOUCK N, 1984, J VIROL, V49, P997, DOI 10.1128/JVI.49.3.997-1001.1984; BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; CRAWFORD LV, 1986, INT REV EXP PATHOL, V25, P1; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; DEPPERT W, 1989, NATO ASI SER, V434, P399; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINZPETER M, 1987, ONCOGENE, V1, P119; JENKINS JR, 1988, ONCOGENE HDB; KELLEY S, 1980, J VIROL, V33, P550, DOI 10.1128/JVI.33.1.550-552.1980; LINZER DIH, 1979, VIROLOGY, V98, P308, DOI 10.1016/0042-6822(79)90554-3; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MONTENARH M, 1984, J VIROL, V49, P658, DOI 10.1128/JVI.49.3.658-664.1984; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PINTEL D, 1981, J VIROL, V38, P518, DOI 10.1128/JVI.38.2.518-528.1981; RASSOULZADEGAN M, 1978, J VIROL, V28, P421, DOI 10.1128/JVI.28.2.421-426.1978; RASSOULZADEGAN M, 1978, J VIROL, V28, P1; Rigby P. W. J., 1983, ADV VIRAL ONCOL, V3, P31; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STAUFENBIEL M, 1984, J CELL BIOL, V98, P1886, DOI 10.1083/jcb.98.5.1886; TOOZE J, 1981, MOL BIOL TUMOR VIRUS, V2	24	53	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1103	1110						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2674854				2022-12-28	WOS:A1989AM53100008
J	DIMARCO, E; PIERCE, JH; FLEMING, TP; KRAUS, MH; MOLLOY, CJ; AARONSON, SA; DIFIORE, PP				DIMARCO, E; PIERCE, JH; FLEMING, TP; KRAUS, MH; MOLLOY, CJ; AARONSON, SA; DIFIORE, PP			AUTOCRINE INTERACTION BETWEEN TGF-ALPHA AND THE EGF-RECEPTOR - QUANTITATIVE REQUIREMENTS FOR INDUCTION OF THE MALIGNANT PHENOTYPE	ONCOGENE			English	Article									NCI,MOLEC & CELLULAR BIOL LAB,BLDG 37,ROOM 1E24,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Molloy, Christopher/A-6821-2013; Di Fiore, Pier Paolo/K-2130-2012; Di Marco, Eddi/AAB-5162-2021	Molloy, Christopher/0000-0003-2964-6166; Di Fiore, Pier Paolo/0000-0002-2252-0950; 				BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1983, P NATL ACAD SCI-BIOL, V80, P5627, DOI 10.1073/pnas.80.18.5627; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DECKER SJ, 1984, MOL CELL BIOL, V4, P571, DOI 10.1128/MCB.4.4.571; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1987, CANCER RES, V47, P707; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; FINZI E, 1987, P NATL ACAD SCI USA, V84, P3733, DOI 10.1073/pnas.84.11.3733; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HANNINK M, 1988, J CELL BIOL, V107, P287, DOI 10.1083/jcb.107.1.287; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUANG SS, 1988, J BIOL CHEM, V263, P12608; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1985, NUCLEIC ACIDS RES, V13, P8477, DOI 10.1093/nar/13.23.8477; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARQUARDT H, 1983, P NATL ACAD SCI-BIOL, V80, P4684; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MAYES ELV, 1984, EMBO J, V3, P531, DOI 10.1002/j.1460-2075.1984.tb01842.x; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; STOSCHECK CM, 1985, ENDOCRINOLOGY, V116, P528, DOI 10.1210/endo-116-2-528; TODARO GJ, 1976, NATURE, V264, P26, DOI 10.1038/264026a0; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; USHIRO H, 1980, J BIOL CHEM, V255, P8363; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; XU YH, 1984, P NATL ACAD SCI-BIOL, V81, P7308, DOI 10.1073/pnas.81.23.7308; YOKOTA J, 1986, LANCET, V1, P765	62	272	276	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					831	838						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2755700				2022-12-28	WOS:A1989AE58400003
J	REISSMANN, PT; SIMON, MA; LEE, WH; SLAMON, DJ				REISSMANN, PT; SIMON, MA; LEE, WH; SLAMON, DJ			STUDIES OF THE RETINOBLASTOMA GENE IN HUMAN SARCOMAS	ONCOGENE			English	Article									UNIV CHICAGO, PRITZKER SCH MED, DEPT SURG, CHICAGO, IL 60637 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT PATHOL, LA JOLLA, CA 92093 USA	University of Chicago; University of California System; University of California San Diego	REISSMANN, PT (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA.				NCI NIH HHS [CA36827] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036827] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; ABRAMSON DH, 1976, T AM ACAD OPHTHALMOL, V81, pP454; BALABAN G, 1982, CANCER GENET CYTOGEN, V6, P213, DOI 10.1016/0165-4608(82)90058-9; BENEDICT WF, 1983, CANCER GENET CYTOGEN, V10, P311, DOI 10.1016/0165-4608(83)90090-0; BOOKSTEIN R, 1988, P NATL ACAD SCI USA, V85, P2210, DOI 10.1073/pnas.85.7.2210; CAVENEE W, 1984, AM J HUM GENET, V36, P10; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHAUM E, 1984, CYTOGENET CELL GENET, V38, P82, DOI 10.1159/000132037; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; ENNEKING WF, 1975, CANCER-AM CANCER SOC, V36, P2192, DOI 10.1002/cncr.2820360937; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GALLIE BL, 1986, J CELL BIOCHEM, V32, P215, DOI 10.1002/jcb.240320308; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HOVIG E, 1987, CANCER GENET CYTOGEN, V24, P327, DOI 10.1016/0165-4608(87)90115-4; KITCHIN FD, 1974, J MED GENET, V11, P244, DOI 10.1136/jmg.11.3.244; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1976, NEW ENGL J MED, V295, P1120, DOI 10.1056/NEJM197611112952007; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MALAWER MM, 1985, CANCER PRINCIPLES PR, P1293; MANIATIS T, 1982, MOL CLONING LABORATO, P282; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; MITELMAN F, 1983, CHROMOSOMES CANCER M, P61; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; Reese A, 1976, TUMORS EYE; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VOGEL F, 1979, HUM GENET, V52, P1; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106	31	116	117	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1989	4	7					839	843						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2755701				2022-12-28	WOS:A1989AE58400004
J	TAKAHASHI, M; BUMA, Y; HIAI, H				TAKAHASHI, M; BUMA, Y; HIAI, H			ISOLATION OF RET PROTO-ONCOGENE CDNA WITH AN AMINO-TERMINAL SIGNAL SEQUENCE	ONCOGENE			English	Note											TAKAHASHI, M (corresponding author), AICHI CANC CTR,RES INST,EXPTL PATHOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN.		Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; 				SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	5	154	157	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					805	806						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2660074				2022-12-28	WOS:A1989AA66000018
J	HECKFORD, SE; GELMANN, EP; MATIS, LA				HECKFORD, SE; GELMANN, EP; MATIS, LA			DISTINCT MECHANISMS OF C-MYC AND LYMPHOKINE GENE-EXPRESSION IN AN ANTIGEN SPECIFIC T-CELL CLONE	ONCOGENE			English	Article									US FDA,CTR BIOL EVALUAT & RES,DIV BIOCHEM & BIOPHYS,BETHESDA,MD 20892; NCI,MED BRANCH,BETHESDA,MD 20892	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BROOME HE, 1987, MOL CELL BIOL, V7, P2988, DOI 10.1128/MCB.7.8.2988; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DEPPER JM, 1984, J IMMUNOL, V133, P3054; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GRAY PW, 1983, P NATL ACAD SCI-BIOL, V80, P5842, DOI 10.1073/pnas.80.19.5842; HECKFORD SE, 1986, J IMMUNOL, V137, P3652; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; KASHIMA N, 1985, NATURE, V313, P402, DOI 10.1038/313402a0; KATZEN D, 1985, J IMMUNOL, V135, P1840; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; LARN S, 1985, CANCER CELLS, V3; MANIATIS T, 1982, MOL CLONING LABORATO; MARTIN MB, 1986, J BIOL CHEM, V261, P2355; MATIS LA, 1983, J IMMUNOL, V130, P1527; MATIS LA, 1985, J IMMUNOL, V135, P703; MILLS GB, 1985, J IMMUNOL, V134, P1640; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; OETTGEN HC, 1985, CELL, V40, P583, DOI 10.1016/0092-8674(85)90206-5; PARNES JR, 1981, P NATL ACAD SCI-BIOL, V78, P2253, DOI 10.1073/pnas.78.4.2253; PAUZA CD, 1987, MOL CELL BIOL, V7, P342, DOI 10.1128/MCB.7.1.342; REED JC, 1987, ONCOGENE, V1, P223; REED JC, 1985, MOL CELL BIOL, V5, P3361, DOI 10.1128/MCB.5.12.3361; REED JC, 1985, P NATL ACAD SCI USA, V82, P4221, DOI 10.1073/pnas.82.12.4221; ROSENBERG SA, 1984, SCIENCE, V223, P1412, DOI 10.1126/science.6367046; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; SHAW J, 1987, MOL IMMUNOL, V24, P409, DOI 10.1016/0161-5890(87)90014-9; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WANG A, 1984, SCIENCE, V224, P1431, DOI 10.1126/science.6427925; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1987, J IMMUNOL, V138, P2169; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	45	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					415	421						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3152599				2022-12-28	WOS:A1988Q773900009
J	MIYAGAWA, K; SAKAMOTO, H; YOSHIDA, T; YAMASHITA, Y; MITSUI, Y; FURUSAWA, M; MAEDA, S; TAKAKU, F; SUGIMURA, T; TERADA, M				MIYAGAWA, K; SAKAMOTO, H; YOSHIDA, T; YAMASHITA, Y; MITSUI, Y; FURUSAWA, M; MAEDA, S; TAKAKU, F; SUGIMURA, T; TERADA, M			HST-1 TRANSFORMING PROTEIN - EXPRESSION IN SILKWORM CELLS AND CHARACTERIZATION AS A NOVEL HEPARIN-BINDING GROWTH-FACTOR	ONCOGENE			English	Article									NATL CANC CTR,RES INST,DIV GENET,CHUO KU,TSUKIJI 5 CHOME,TOKYO 104,JAPAN; DAIICHI SEIYAKO RES INST,MOLEC BIOL RES LAB,EDOGAWA KU,TOKYO 134,JAPAN; TOTTORI UNIV,FAC AGR,TOTTORI 680,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; AGCY IND SCI & TECHNOL,FERMENTAT RES INST,DIV CELL SCI & TECHNOL,IBARAKI 305,JAPAN	National Cancer Center - Japan; Tottori University; University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST)								ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; ESCH F, 1985, BIOCHEM BIOPH RES CO, V133, P554, DOI 10.1016/0006-291X(85)90942-8; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GARDINER GR, 1975, J INVERTEBRATE PATHO, V16, P284; GIMENEZGALLEGO G, 1985, SCIENCE, V230, P1385, DOI 10.1126/science.4071057; GOSPODAROWICZ D, 1987, METHOD ENZYMOL, V147, P106; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; IMAMURA T, 1987, EXP CELL RES, V172, P92, DOI 10.1016/0014-4827(87)90096-6; INAGAKI Y, 1988, J VIROL, V62, P1640, DOI 10.1128/JVI.62.5.1640-1646.1988; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; KODA T, 1987, JPN J CANCER RES, V78, P325; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINEMEYER DL, 1987, BIO-TECHNOL, V5, P960, DOI 10.1038/nbt0987-960; LOBB R, 1986, J BIOL CHEM, V261, P1924; LOBB RR, 1985, BIOCHEMISTRY-US, V24, P4969, DOI 10.1021/bi00340a001; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MAEDA S, 1985, NATURE, V315, P592, DOI 10.1038/315592a0; MARUMOTO Y, 1987, J GEN VIROL, V68, P2599, DOI 10.1099/0022-1317-68-10-2599; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; MIYAZONO K, 1985, BIOCHEM BIOPH RES CO, V126, P83, DOI 10.1016/0006-291X(85)90574-1; MOSCATELLI D, 1987, P NATL ACAD SCI USA, V84, P5778, DOI 10.1073/pnas.84.16.5778; NAKAGAMA H, 1987, JPN J CANCER RES, V78, P651; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SAKAMOTO H, 1988, BIOCHEM BIOPH RES CO, V151, P965, DOI 10.1016/S0006-291X(88)80460-1; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SOMMER A, 1987, BIOCHEM BIOPH RES CO, V144, P543, DOI 10.1016/S0006-291X(87)80001-3; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YOSHIDA MC, 1988, P NATL ACAD SCI USA, V85, P4861, DOI 10.1073/pnas.85.13.4861; YOSHIDA T, 1987, BIOCHEM BIOPH RES CO, V142, P1019, DOI 10.1016/0006-291X(87)91516-6; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YUASA Y, 1987, JPN J CANCER RES, V78, P1036	41	46	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					383	389						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	2978866				2022-12-28	WOS:A1988Q773900005
J	HERZOG, NK; SINGH, B; ELDER, J; LIPKIN, I; TRAUGER, RJ; MILLETTE, CF; GOLDMAN, DS; WOLFES, H; COOPER, GM; ARLINGHAUS, RB				HERZOG, NK; SINGH, B; ELDER, J; LIPKIN, I; TRAUGER, RJ; MILLETTE, CF; GOLDMAN, DS; WOLFES, H; COOPER, GM; ARLINGHAUS, RB			IDENTIFICATION OF THE PROTEIN PRODUCT OF THE C-MOS PROTO-ONCOGENE IN MOUSE TESTES	ONCOGENE			English	Article									SCRIPPS CLIN & RES FDN, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; HARVARD UNIV, SCH MED, DEPT ANAT & CELL BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MOLEC GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Scripps Research Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	HERZOG, NK (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC PATHOL, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD015269] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA045125] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA45125] Funding Source: Medline; NICHD NIH HHS [HD15269] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BELLVE AR, 1977, J HISTOCHEM CYTOCHEM, V25, P480, DOI 10.1177/25.7.893996; BLOUNT P, 1986, BRAIN RES, V382, P257, DOI 10.1016/0006-8993(86)91335-1; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HUNTER T, 1986, ENZYMES, V17, P192; JONES M, 1980, P NATL ACAD SCI-BIOL, V77, P2651, DOI 10.1073/pnas.77.5.2651; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAXWELL SA, 1985, J VIROL, V55, P874, DOI 10.1128/JVI.55.3.874-876.1985; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OGISO Y, 1986, BIOCHEM BIOPH RES CO, V140, P477, DOI 10.1016/0006-291X(86)90757-6; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; SINGH B, 1986, VIROLOGY, V152, P502, DOI 10.1016/0042-6822(86)90156-X; SWAN D, 1982, J VIROL, V44, P752, DOI 10.1128/JVI.44.2.752-754.1982; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817	24	52	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1988	3	2					225	229						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	2970613				2022-12-28	WOS:A1988Q053400015
J	KUPPUSWAMY, M; CHINNADURAI, G				KUPPUSWAMY, M; CHINNADURAI, G			CELL TYPE DEPENDENT TRANSFORMATION BY ADENOVIRUS 5 E1A PROTEINS	ONCOGENE			English	Article									ST LOUIS UNIV,MED CTR,INST MOLEC VIROL,3681 PK AVE,ST LOUIS,MO 63110	Saint Louis University					NATIONAL CANCER INSTITUTE [R01CA033616, R01CA031719] Funding Source: NIH RePORTER; NCI NIH HHS [CA-31719, CA-33616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABISS LE, 1983, P NATL ACAD SCI-BIOL, V80, P1352, DOI 10.1073/pnas.80.5.1352; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GLENN GM, 1985, J VIROL, V56, P66, DOI 10.1128/JVI.56.1.66-74.1985; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1984, ADENOVIRUSES, P339; HALEY KP, 1984, NATL ACAD SCI US, V81, P5743; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HO YS, 1982, VIROLOGY, V122, P109, DOI 10.1016/0042-6822(82)90381-6; HURWITZ DR, 1985, J VIROL, V54, P358, DOI 10.1128/JVI.54.2.358-363.1985; HURWITZ DR, 1985, P NATL ACAD SCI USA, V82, P163, DOI 10.1073/pnas.82.1.163; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KIMELMAN D, 1986, MOL CELL BIOL, V6, P1487, DOI 10.1128/MCB.6.5.1487; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; ROBERTS BE, 1985, J VIROL, V56, P404, DOI 10.1128/JVI.56.2.404-413.1985; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; ULFENDAHL PJ, 1987, EMBO J, V6, P2037, DOI 10.1002/j.1460-2075.1987.tb02468.x; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WINBERG G, 1984, EMBO J, V3, P1907, DOI 10.1002/j.1460-2075.1984.tb02066.x; YEE S, 1985, VIROLOGY, V147, P315; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	37	22	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					567	572						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	2968533				2022-12-28	WOS:A1988N841500006
J	LI, WJ; KLOETZER, WS; ARLINGHAUS, RB				LI, WJ; KLOETZER, WS; ARLINGHAUS, RB			A NOVEL 53 KDA PROTEIN COMPLEXED WITH P210BCR-ABL IN HUMAN CHRONIC MYELOGENOUS LEUKEMIA-CELLS	ONCOGENE			English	Article									JOHNSON & JOHNSON BIOTECHNOL CTR INC,SAN DIEGO,CA 92121	Johnson & Johnson	LI, WJ (corresponding author), UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [P30CA016672, R01CA045125] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA45125] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HOUGHTEN RA, 1986, BIOTECHNIQUES, V4, P522; HUHN RD, 1987, IN PRESS P NATL ACAD; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JAY G, 1981, P NATL ACAD SCI-BIOL, V78, P2932, DOI 10.1073/pnas.78.5.2932; KIT S, 1969, INT J CANCER, V4, P383; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAXWELL SA, 1987, CANCER RES, V47, P1731; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; PRYWES R, 1985, J VIROL, V54, P114, DOI 10.1128/JVI.54.1.114-122.1985; RICHARDSON JM, 1987, CANCER RES, V47, P4066; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SEKI J, 1986, CANCER RES, V46, P907; SHTIVELMAN E, 1985, NATURE, V315, P758; SMITH AE, 1983, ADV VIRAL ONCOL, V3, P3; STAM K, 1985, NEW ENGL J MED, V313, P1429, DOI 10.1056/NEJM198512053132301; WALTER G, 1982, P NATL ACAD SCI-BIOL, V79, P4025, DOI 10.1073/pnas.79.13.4025; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0	37	15	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					559	566						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	3133627				2022-12-28	WOS:A1988N841500005
J	EDWARDS, PAW; WARD, JL; BRADBURY, JM				EDWARDS, PAW; WARD, JL; BRADBURY, JM			ALTERATION OF MORPHOGENESIS BY THE V-MYC ONCOGENE IN TRANSPLANTS OF MAMMARY-GLAND	ONCOGENE			English	Article											EDWARDS, PAW (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.		Edwards, Paul A/M-8291-2014	Edwards, Paul A/0000-0002-4789-3374				BOTTERI FM, 1987, MOL CELL BIOL, V7, P3178, DOI 10.1128/MCB.7.9.3178; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CARDIFF RD, 1984, ADV CANCER RES, V42, P167, DOI 10.1016/S0065-230X(08)60458-3; DECOSSE JJ, 1983, CANCER SURVEYS, V2, P1; DEOME KB, 1959, CANCER RES, V19, P515; DOTTO GP, 1985, NATURE, V318, P472; EDWARDS PAW, 1984, DIFFERENTIATION, V25, P247, DOI 10.1111/j.1432-0436.1984.tb01363.x; ETHIER SP, 1984, CANCER RES, V44, P4517; FAULKIN LJ, 1960, J NATL CANCER I, V24, P953; FRANZ T, 1986, P NATL ACAD SCI USA, V83, P3292, DOI 10.1073/pnas.83.10.3292; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Jones W., 1983, J TISSUE CULTURE MET, V8, P17; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MANIATIS T, 1982, MOL CLONING LABORATO; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; Medina D., 1982, MOUSE BIOMEDICAL RES, VIV, P373; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; ROTHSTEIN SJ, 1980, CELL, V19, P795, DOI 10.1016/S0092-8674(80)80055-9; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SINGH L, 1984, NUCLEIC ACIDS RES, V12, P5627, DOI 10.1093/nar/12.14.5627; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STACEY A, 1984, J VIROL, V50, P725, DOI 10.1128/JVI.50.3.725-732.1984; STEWART CL, 1985, EMBO J, V4, P3701, DOI 10.1002/j.1460-2075.1985.tb04138.x; STOCKING C, 1985, P NATL ACAD SCI USA, V82, P5746, DOI 10.1073/pnas.82.17.5746; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; WAGNER EF, 1985, EMBO J, V4, P663, DOI 10.1002/j.1460-2075.1985.tb03680.x; WEISS R, 1985, RNA TUMOUR VIRUSES S, V2	31	39	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					407	412						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3283657				2022-12-28	WOS:A1988M947200015
J	IBSON, JM; RABBITTS, PH				IBSON, JM; RABBITTS, PH			SEQUENCE OF A GERM-LINE N-MYC GENE AND AMPLIFICATION AS A MECHANISM OF ACTIVATION	ONCOGENE			English	Article											IBSON, JM (corresponding author), LUDWIG INST CANC RES, CAMBRIDGE CB2 2QH, ENGLAND.							ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BANKIER AT, 1983, TECHNIQUES NUCLEIC B, V5, P1; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; IBSON JM, 1987, J CELL BIOCHEM, V33, P267, DOI 10.1002/jcb.240330405; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIBUYA M, 1985, MOL CELL BIOL, V5, P414, DOI 10.1128/MCB.5.2.414; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1722; TAYA Y, 1986, EMBO J, V5, P1215, DOI 10.1002/j.1460-2075.1986.tb04349.x; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019	25	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					399	402						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	2834684				2022-12-28	WOS:A1988M947200013
J	JORDANO, J; PERUCHO, M				JORDANO, J; PERUCHO, M			INITIAL CHARACTERIZATION OF A POTENTIAL TRANSCRIPTIONAL ENHANCER FOR THE HUMAN C-K-RAS GENE	ONCOGENE			English	Article											JORDANO, J (corresponding author), SUNY STONY BROOK,DEPT BIOCHEM,STONY BROOK,NY 11794, USA.		Jordano, Juan/J-5829-2012	Jordano, Juan/0000-0002-2583-4453; Perucho, Manuel/0000-0002-2169-2662	NCI NIH HHS [CA33021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIENZ M, 1986, CELL, V45, P753, DOI 10.1016/0092-8674(86)90789-0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BUETTI E, 1986, J MOL BIOL, V190, P379, DOI 10.1016/0022-2836(86)90009-4; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHARNAY P, 1984, CELL, V38, P251, DOI 10.1016/0092-8674(84)90547-6; CORDINGLEY MG, 1987, CELL, V48, P262; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUJIMURA FK, 1986, NUCLEIC ACIDS RES, V14, P2845, DOI 10.1093/nar/14.7.2845; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P964, DOI 10.1128/MCB.5.5.964; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HENNINGHAUSEN L, 1985, NATURE, V314, P284; HERR W, 1985, NATURE, V313, P711, DOI 10.1038/313711a0; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; HONKAWA H, 1987, MOL CELL BIOL, V7, P2933, DOI 10.1128/MCB.7.8.2933; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JORDANO J, 1986, NUCLEIC ACIDS RES, V14, P7361, DOI 10.1093/nar/14.18.7361; KHOURY G, 1983, CELL, V33, P313, DOI 10.1016/0092-8674(83)90410-5; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; LEEGWATER PAJ, 1986, EMBO J, V5, P381, DOI 10.1002/j.1460-2075.1986.tb04223.x; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; MANIATIS T, 1982, MOL CLONING LABORATO; Maxam A M, 1980, Methods Enzymol, V65, P499; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; MULLER R, 1983, MOL CELL BIOL, V3, P1062; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NAKANO H, 1984, P NATL ACAD SCI-BIOL, V81, P71, DOI 10.1073/pnas.81.1.71; NOWOCK J, 1982, CELL, V30, P607, DOI 10.1016/0092-8674(82)90257-4; NOWOCK J, 1985, NUCLEIC ACIDS RES, V13, P2045, DOI 10.1093/nar/13.6.2045; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; OSTAPCHUK P, 1986, P NATL ACAD SCI USA, V83, P8550, DOI 10.1073/pnas.83.22.8550; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SERGEANT A, 1984, J MOL BIOL, V180, P577, DOI 10.1016/0022-2836(84)90028-7; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPANDIDOS DA, 1986, FEBS LETT, V203, P169, DOI 10.1016/0014-5793(86)80736-0; THEISEN M, 1986, EMBO J, V5, P719, DOI 10.1002/j.1460-2075.1986.tb04273.x; VANDYKE MW, 1987, MOL CELL BIOL, V7, P1021, DOI 10.1128/MCB.7.3.1021; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WILDEMAN AG, 1986, MOL CELL BIOL, V6, P2098, DOI 10.1128/MCB.6.6.2098; WINTER E, 1985, P NATL ACAD SCI USA, V82, P7575, DOI 10.1073/pnas.82.22.7575; YASWEN P, 1985, MOL CELL BIOL, V5, P780, DOI 10.1128/MCB.5.4.780	56	17	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					359	366						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3283654				2022-12-28	WOS:A1988M947200008
J	CAVALIERI, F; GOLDFARB, M				CAVALIERI, F; GOLDFARB, M			N-MYC PROTO-ONCOGENE EXPRESSION CAN INDUCE DNA-REPLICATION IN BALB/C 3T3 FIBROBLASTS	ONCOGENE			English	Article											CAVALIERI, F (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,630 W 168 ST,NEW YORK,NY 10032, USA.				NATIONAL CANCER INSTITUTE [P01CA022376] Funding Source: NIH RePORTER; NCI NIH HHS [CA22376] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; ARMELIN HA, 1984, NATURE, V310, P656; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CAVALIERI F, 1987, MOL CELL BIOL, V7, P3554, DOI 10.1128/MCB.7.10.3554; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KELLY K, 1986, ANNU REV IMMUNOL, V4, P327; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; SHARP PA, 1974, COLD SPRING HARB SYM, V39, P457, DOI 10.1101/SQB.1974.039.01.058; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	24	24	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					289	291						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3281096				2022-12-28	WOS:A1988M593100013
J	WATSON, RJ				WATSON, RJ			A TRANSCRIPTIONAL ARREST MECHANISM INVOLVED IN CONTROLLING CONSTITUTIVE LEVELS OF MOUSE C-MYB MESSENGER-RNA	ONCOGENE			English	Article											WATSON, RJ (corresponding author), ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND LABS,DOMINION HOUSE,BARTHOLOMEW CLOSE,LONDON EC1A 7BE,ENGLAND.							BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BISHOP JM, 1985, MOL BIOL TUMOR VIR 4, P351; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CASTLE S, 1985, BIOCHEM BIOPH RES CO, V132, P688, DOI 10.1016/0006-291X(85)91187-8; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; CRAIG RW, 1984, CANCER RES, V44, P442; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NEPVEU A, 1987, ONCOGENE, V1, P243; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PAUZA CD, 1987, MOL CELL BIOL, V7, P342, DOI 10.1128/MCB.7.1.342; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; RENZ M, 1987, NUCLEIC ACIDS RES, V15, P277, DOI 10.1093/nar/15.1.277; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SPANDIDOS DA, 1982, EMBO J, V1, P15, DOI 10.1002/j.1460-2075.1982.tb01117.x; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; WATSON RJ, 1987, EMBO J, V6, P1643, DOI 10.1002/j.1460-2075.1987.tb02413.x; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	33	77	79	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					267	272						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3281094				2022-12-28	WOS:A1988M593100009
J	APPEL, K; WAGNER, P; BOLDYREFF, B; ISSINGER, OG; MONTENARH, M				APPEL, K; WAGNER, P; BOLDYREFF, B; ISSINGER, OG; MONTENARH, M			MAPPING OF THE INTERACTION SITES OF THE GROWTH SUPPRESSOR PROTEIN P53 WITH THE REGULATORY BETA-SUBUNIT OF PROTEIN-KINASE CK2	ONCOGENE			English	Article						P53; GROWTH SUPPRESSOR PROTEIN; PROTEIN KINASE; PHOSPHORYLATION	WILD-TYPE P53; DNA-BINDING FUNCTION; CELL-CYCLE CONTROL; CASEIN KINASE-2; T-ANTIGEN; TRANSFORMED-CELLS; TUMOR-ANTIGEN; PHOSPHORYLATION; DOMAIN; OLIGOMERIZATION	p53 plays an essential role in cellular growth control. Some of its distinct biological functions are regulated by interaction with cellular proteins. We have previously (Wagner et al., 1994) shown that p53 binds to the regulatory subunit of protein kinase CK2. Using C-terminal protein fragments of p53 we now demonstrate that the region between amino acids 287 and 340 on the polypeptide chain of p53 is critical for binding of p53 to the beta-subunit of CK2. Neither phosphorylation at the p34(cdc2) site (aa315) nor at the CK2 site (aa392) is necessary for binding of p53 to the beta-subunit of CK2. Using deletion mutants of the beta-subunit of CK2 we also show that an internal region between amino acids 72 and 149 of the beta-subunit of CK2 is necessary for binding to p53. Thus, this study defines new functional regions on the polypeptide chains of p53 and of protein kinase CK2.	UNIV SAARLAND,D-66421 HOMBURG,GERMANY	Saarland University			Montenarh, Mathias/AAB-6689-2020					ADDISON C, 1990, ONCOGENE, V5, P423; APPEL K, 1994, INT J ONCOL, V5, P667; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOLDYREFF B, 1994, CELL MOL BIOL RES, V40, P391; BOLDYREFF B, 1992, BIOCHEM BIOPH RES CO, V188, P228, DOI 10.1016/0006-291X(92)92374-7; BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; CHEN J, 1993, MOL CELL BIOL, V13, P4104; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FISCELLA M, 1994, ONCOGENE, V9, P3249; GOTZ C, 1995, INT J ONCOL, V6, P1129; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; IWABUCHI K, 1993, ONCOGENE, V8, P1693; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1994, GASTROENTEROLOGY, V106, P1708, DOI 10.1016/0016-5085(94)90431-6; KRAISS S, 1990, ONCOGENE, V5, P845; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1994, PHILOS T ROY SOC B, V345, P277, DOI 10.1098/rstb.1994.0106; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; LORENZ A, 1992, INT J ONCOL, V1, P571; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MIYASHITA T, 1995, CELL, V80, P293; OROURKE RW, 1990, ONCOGENE, V5, P1829; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; REIHSAUS E, 1990, ONCOGENE, V5, P137; REIHSAUS E, 1992, EXP CELL RES, V199, P10, DOI 10.1016/0014-4827(92)90456-I; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SELTER H, 1994, INT J BIOCHEM, V26, P145, DOI 10.1016/0020-711X(94)90139-2; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; SOUSSI T, 1990, ONCOGENE, V5, P945; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WAGNER P, 1994, INT J ONCOL, V4, P987; WAGNER P, 1994, INT J ONCOL, V4, P491; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	67	71	72	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					1971	1978						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478515				2022-12-28	WOS:A1995TF29700006
J	KWON, TK; BUCHHOLZ, MA; GABRIELSON, EW; NORDIN, AA				KWON, TK; BUCHHOLZ, MA; GABRIELSON, EW; NORDIN, AA			A NOVEL CYTOPLASMIC SUBSTRATE FOR CDK4 AND CDK6 IN NORMAL AND MALIGNANT EPITHELIAL DERIVED CELLS	ONCOGENE			English	Article						CYCLIN-DEPENDENT KINASE; G1 CYCLINS; CELL CYCLE; BREAST CELL CARCINOMA; LUNG CELL CARCINOMA	RETINOBLASTOMA SUSCEPTIBILITY GENE; BREAST-CANCER; PROTEIN; EXPRESSION; CYCLINS; IDENTIFICATION; AMPLIFICATION	Cyclins and cyclin-dependent kinases (cdk) have been identified as important regulators of cell replication. Molecular alteration in the cdk pathways appear to be important in cancer with some cyclins (eg cyclin D and E) proposed to be oncogenes and some inhibitors of cdk (eg p16) proposed to be tumor suppressor genes, In human breast carcinoma cell line MDA361 both cyclin D and E are overexpressed and cdk 4 and 6 are the predominate kinases which phosphorylate retinoblastoma protein and to a greater extent a novel 88 kDa protein. This 88 kDa protein was detected as a significant substrate in five of seven breast carcinoma cell lines, three lung carcinoma cell lines as well as in primary breast and lung epithelium. Normal human and murine T lymphocytes and established lymphoid cell lines are devoid of this protein and minimal amounts were detected in normal human fibroblast. In contrast to retinoblastoma protein, the 88 kDa protein appears to be more prevalent in the cytosolic than the nuclear subfraction. The phosphorylation of this 88 kDa protein by the G(1) associated cdks suggest that this protein may represent another targeted substrate regulating the G(1) phase of the cell cycle.	NIA,GERONTOL RES CTR,CLIN IMMUNOL SECT,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University					NCI NIH HHS [P20 CA-ES 66204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P20CA066204] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HANNA Z, 1993, ONCOGENE, V8, P1661; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KAMB A, 1994, SCIENCE, V246, P436; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KIM YH, 1992, J IMMUNOL, V149, P17; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAN S, 1981, J SURG ONCOL, V18, P317, DOI 10.1002/jso.2930180313; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NOBORI T, 1994, SCIENCE, V264, P753; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PETERS G, 1994, J CELL SCI S, V18, P89; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHERR CJ, 1993, CELL, V73, P1053	33	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2077	2083						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478527				2022-12-28	WOS:A1995TF29700018
J	CLARKE, AR; CUMMINGS, MC; HARRISON, DJ				CLARKE, AR; CUMMINGS, MC; HARRISON, DJ			INTERACTION BETWEEN MURINE GERMLINE MUTATIONS IN P53 AND APC PREDISPOSES TO PANCREATIC NEOPLASIA BUT NOT TO INCREASED INTESTINAL MALIGNANCY	ONCOGENE			English	Article						P53; APC; MIN; PANCREATIC CANCER; COLORECTAL CANCER	WILD-TYPE P53; P53-DEFICIENT MICE; CANCER; APOPTOSIS; TUMORS; MOUSE; GENE	Murine strains which bear constitutive inactivating mutations of either the APC or the p53 tumor suppressor genes are characterised by spontaneous tumors. APC mutated (Min) mice develop large and small bowel adenomas, a small proportion of which, in time, become malignant, p53 deficient mice develop predominantly lymphoma and sarcoma. By interbreeding these strains we have shown that there is cooperativity between these mutations, leading to a shift in phenotype. Most notably, this was characterised by a range of abnormalities of the exocrine pancreas in 83% of animals heterozygous for the APC mutation and constitutively null for functional p53, Dysplasia and preneoplastic foci were seen in 61% of these animals and pancreatic acinar cell adenocarcinoma in 22%. Analysis of these tumors showed them to have lost the remaining wild-type copy of APC. Similar loss of APC was not associated with the development of other extraintestinal tumors, Surprisingly, given the proposed role for loss of function mutations of the p53 gene in the development of human colorectal cancer, we have found no evidence for either an increase in the rate of adenoma formation in APC +/-, p53 -/- animals, or an increased rate of progression to malignancy compared with APC +/- p53 +/+ mice. These findings highlight striking tissue-specific differences in the tumor suppressor effects of p53.			CLARKE, AR (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,CRC LABS,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.		Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014; Cummings, Margaret/B-5747-2011	Cummings, Margaret/0000-0002-7657-0240; Clarke, Alan/0000-0002-4281-426X				ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARDER P, 1993, ONCOGENE, V8, P1397; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; HARRISON DJ, 1995, ONCOGENE, V10, P1615; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2457; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HAYES PC, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P441; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kaufman M.H., 1992, ATLAS MOUSE DEV; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KEURBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491; KLOPPEL G, 1984, PANCREATIC PATHOLOGY, pCH7; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LONGNECKER DS, 1992, YALE J BIOL MED, V65, P457; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUONGO C, 1994, CANCER RES, V54, P5947; MALCOMSON RDG, IN PRESS BRIT J CANC; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MERRITT AJ, 1994, CANCER RES, V54, P614; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; POWELL SM, 1992, NATURE, V59, P235; PURDIE CA, 1994, ONCOGENE, V9, P603; REDSTON MS, 1994, CANCER RES, V54, P3025; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YASHIMA K, 1994, INT J CANCER, V59, P43, DOI 10.1002/ijc.2910590110	36	87	87	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1913	1920						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478622				2022-12-28	WOS:A1995TD09400029
J	PASINI, B; HOFSTRA, RMW; YIN, L; BOCCIARDI, R; SANTAMARIA, G; GROOTSCHOLTEN, PM; CECCHERINI, I; PATRONE, G; PRIOLO, M; BUYS, CHCM; ROMEO, G				PASINI, B; HOFSTRA, RMW; YIN, L; BOCCIARDI, R; SANTAMARIA, G; GROOTSCHOLTEN, PM; CECCHERINI, I; PATRONE, G; PRIOLO, M; BUYS, CHCM; ROMEO, G			THE PHYSICAL MAP OF THE HUMAN RET PROTOONCOGENE	ONCOGENE			English	Article						RET PROTOONCOGENE; GENE STRUCTURE; MEN 2; HIRSCHSPRUNG DISEASE; CHROMOSOME 10	C-KIT GENE; TYROSINE KINASE; SEQUENCE SIMILARITY; PROTOONCOGENE RET; TRANSFORMING GENE; CDNA CLONING; CELL-LINE; LONG ARM; DNA; RECEPTOR	The RET proto-oncogene, a transmembrane tyrosine kinase receptor, is involved in the development of at least five different disease phenotypes. RET is activated through somatic rearrangements in a number of cases of papillary thyroid carcinoma while germ-line point mutations are associated with three inherited cancer syndromes MEN 2A, MEN 2B and FMTC. Moreover, point mutations or heterozygous deletions of RET are found in the dominant form of Hirschsprung disease or congenital colonic aganglionosis. We cloned the entire RET genomic sequence in a contig of cosmids encompassing 150 kb, from the CA repeat sTCL-2 to the region upstream the RET promoter, and established the position of the 20 exons of the RET gene with respect to a detailed restriction map based on eight endonucleases. A new highly polymorphic CA repeat sequence was identified within intron 5 of RET (RET-INT5). Finally the orientation of RET on chromosome 10q11.2 made it possible to orientate three other genes rearranged with RET in papillary thyroid carcinomas, namely H4/D10S170 on 10q21, R1 alpha on 17q23 and RFG2/Ele1 on 10q11.2.	IST GIANNINA GASLINI, GENET MOLEC LAB, I-16147 GENOA, ITALY; UNIV GRONINGEN, DEPT MED GENET, 9713 AW GRONINGEN, NETHERLANDS	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Groningen			Ceccherini, Isabella/P-8195-2014; Bocciardi, Renata/J-8577-2016; Pasini, Barbara/AHI-2004-2022; Santamaria, Giuseppe/AAB-4185-2021	Ceccherini, Isabella/0000-0001-8732-1955; Bocciardi, Renata/0000-0001-8415-3802; Pasini, Barbara/0000-0002-4373-1212; Santamaria, Giuseppe/0000-0002-7686-6703; Hofstra, Robert/0000-0001-7498-3829				ANDRE C, 1992, ONCOGENE, V7, P685; ANGRIST M, 1995, HUM MOL GENET, V4, P821, DOI 10.1093/hmg/4.5.821; ASAI N, 1995, MOL CELL BIOL, V15, P1613; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V9, P244; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; CARLSON KM, 1994, HUM MOL GENET, V3, P1207; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CECCHERINI I, 1994, ONCOGENE, V9, P3025; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; CONSALEZ GG, 1992, GENOMICS, V14, P557, DOI 10.1016/S0888-7543(05)80151-X; DAUWERSE HG, 1989, NUCLEIC ACIDS RES, V17, P3603, DOI 10.1093/nar/17.9.3603; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, J MED GENET, V31, P602, DOI 10.1136/jmg.31.8.602; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, GENE CHROMOSOME CANC, V12, P209, DOI 10.1002/gcc.2870120308; GARDNER E, 1994, HUM MOL GENET, V3, P1771, DOI 10.1093/hmg/3.10.1771; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ITOH F, 1992, ONCOGENE, V7, P1201; IWAMOTO T, 1993, ONCOGENE, V8, P1087; KUMA K, 1993, MOL BIOL EVOL, V10, P539; LAIRMORE TC, 1993, P NATL ACAD SCI USA, V90, P492, DOI 10.1073/pnas.90.2.492; LINDOR NM, 1995, J CLIN ENDOCR METAB, V80, P627, DOI 10.1210/jc.80.2.627; LORENZO MJ, 1995, ONCOGENE, V10, P1377; LYONNET S, 1993, NAT GENET, V4, P346, DOI 10.1038/ng0893-346; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; MOLE SE, 1993, HUM MOL GENET, V2, P247, DOI 10.1093/hmg/2.3.247; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SANTORO M, 1994, ONCOGENE, V9, P509; SCHNEIDER C, 1991, CLONIGN YAC VECTORS; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; SCHUSTER MK, 1994, HUM MOL GENET, V3, P677, DOI 10.1093/hmg/3.4.677; SCOTT A F, 1987, Genomics, V1, P113, DOI 10.1016/0888-7543(87)90003-6; SHERR CJ, 1990, BLOOD, V75, P1; SMITH CL, 1988, GENOME ANAL PRACTICA; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SOZZI G, 1994, GENE CHROMOSOME CANC, V9, P244, DOI 10.1002/gcc.2870090404; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TSUZUKI T, 1995, ONCOGENE, V10, P191; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; XING SH, 1994, BIOCHEM BIOPH RES CO, V205, P1526, DOI 10.1006/bbrc.1994.2840; YIN L, 1993, HUM MOL GENET, V2, P1803; Yin Luo, 1994, European Journal of Human Genetics, V2, P272	61	84	92	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	1995	11	9					1737	1743						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478601				2022-12-28	WOS:A1995TD09400008
J	GLOVER, HR; BAKER, DA; CELETTI, A; DIBB, NJ				GLOVER, HR; BAKER, DA; CELETTI, A; DIBB, NJ			SELECTION OF ACTIVATING MUTATIONS OF C-FMS IN FDC-P1 CELLS	ONCOGENE			English	Article						C-FMS; C-KIT; FDC-P1; TYROSINE KINASE; ACTIVATING MUTATION	COLONY-STIMULATING FACTOR; DEPENDENT PROTEIN-KINASE; FACTOR-I CSF-1; OP OP MOUSE; V-FMS; ONCOGENE PRODUCT; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; SURFACE EXPRESSION; CATALYTIC SUBUNIT	FDC-P1 haemopoietic cells were used to select mutations of c-fms that constitutively activate the receptor for macrophage-colony stimulating factor (M-CSF or CSF-1), One mutation changed Ser 929 to Gly within a Ser/Gly rich region of the C-terminal tail and a second changed a nearby, highly conserved Leu 926 for Pro. A third mutation (D802V) changed Asp 802 to Val within the alpha L12/beta 9 region of the tyrosine kinase domain, so supporting the crystallographic evidence that this region triggers kinase activation, A c-kit mutation exactly equivalent to D802V was previously identified in a leukamic cell line and was demonstrated here to be transforming. Surprisingly, although D802V potently transformed FDC-P1 cells, it could not induce Rat-2 fibroblast foci, even in the presence of M-CSF. It is suggested that the accelerated receptor degradation induced by D802V may account for its cell specific effect.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CHEM PATHOL,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London; Imperial College London			Celetti, Angela/AAY-7172-2020					BAKER DA, 1994, LEUKEMIA, V8, P141; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CARUANA G, 1993, EXP HEMATOL, V21, P761; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Dibb NJ, 1990, GROWTH FACTORS, V2, P301, DOI 10.3109/08977199009078018; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; HADWIGER A, 1986, EMBO J, V5, P689, DOI 10.1002/j.1460-2075.1986.tb04268.x; HALENBECK R, 1989, BIO-TECHNOL, V7, P710, DOI 10.1038/nbt0789-710; HAPEL AJ, 1984, BLOOD, V64, P786; HUNTER T, 1992, COLD SPRING HARB SYM, V57, P25, DOI 10.1101/SQB.1992.057.01.005; KARN J, 1989, ONCOGENE, V4, P773; KATO JY, 1989, MOL CELL BIOL, V9, P4069, DOI 10.1128/MCB.9.9.4069; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657; MCDONOUGH SK, 1971, CANCER RES, V31, P953; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; METCALF D, 1991, P NATL ACAD SCI USA, V88, P6239, DOI 10.1073/pnas.88.14.6239; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MORRISON DK, 1988, MOL CELL BIOL, V8, P176, DOI 10.1128/MCB.8.1.176; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; NICHOLS EJ, 1985, MOL CELL BIOL, V5, P3467, DOI 10.1128/MCB.5.12.3467; POLLARD JW, 1991, DEV BIOL, V48, P273; QUI F, 1988, EMBO J, V7, P1003; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; TSUJIMURA T, 1994, BLOOD, V83, P2619; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; WETTERS TV, 1992, EMBO J, V11, P551, DOI 10.1002/j.1460-2075.1992.tb05086.x; WIKTORJEDRZEJCZ.W, 1982, J EXP MED, V156, P1516; WIKTORJEDRZEJCZ.W, 1990, P NATL ACAD SCI USA, V87, P4828; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	52	22	22	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1347	1356						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478556				2022-12-28	WOS:A1995RY96700016
J	HERMEKING, H; FUNK, JO; REICHERT, M; ELLWART, JW; EICK, D				HERMEKING, H; FUNK, JO; REICHERT, M; ELLWART, JW; EICK, D			ABROGATION OF P53-INDUCED CELL-CYCLE ARREST BY C-MYC - EVIDENCE FOR AN INHIBITOR OF P21(WAF1/CIP1/SDI1)	ONCOGENE			English	Article						C-MYC; P53; P21; CDK2; CYCLINS; CELL CYCLE	PROTEIN; APOPTOSIS; TRANSCRIPTION; KINASES; GENE; P53	The tumour-suppressor p53 inhibits cell cycle progression by direct transactivation of the p21(WAF1/CIP1/SD11) gene, which encodes a universal inhibitor of cyclin dependent kinases (cdk). The proto-oncogene product c-Myc induces cell cycle progression and, in the absence of survival factors, apoptosis. However, a direct link between the cell cycle machinery and c-Myc has not yet been established, We show that c-Myc abrogates a p53-induced G1-arrest without elevating the expression of cdks or cyclins involved in the G1/S-transition, Instead, the results suggest that c-Myc interferes with the inhibitory action of p21 on cdk/cyclin-complexes by inducing a heat-labile inhibitor of p21, The inactivation of p21 and related cdk-inhibitors may explain several of the oncogenic actions of c-Myc, including the induction of proliferation, immortalisation and the inhibition of differentiation. Modulation of cdk activity by the induction of an inhibitor of cdk-inhibitors represents a novel mechanism of cell cycle regulation in mammalian cells.	GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT GMBH,INST EXPTL HAMATOL,D-81377 MUNICH,GERMANY; UNIV MUNICH,DERMATOL KLIN & POLIKLIN,MOLEK PATHOL ABT,D-80337 MUNICH,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	HERMEKING, H (corresponding author), GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT GMBH,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY.							ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELDEIRY WS, 1993, CELL, V75, P8817; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HHERMEKING H, 1994, SCIENCE, V265, P2091; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KIESER A, 1994, ONCOGENE, V9, P963; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, IN PRESS NATURE; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MICHIELI P, 1994, CANCER RES, V54, P3391; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RAGIMOV N, 1993, ONCOGENE, V8, P1183; SAMBROCK J, 1989, MOL CLONING LABORATO; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WOLF DA, 1995, ONCOGENE, V10, P2067; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	39	95	96	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1409	1415						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478565				2022-12-28	WOS:A1995RY96700025
J	ASHTONRICKARDT, PG; DUNLOP, MG; NAKAMURA, Y; MORRIS, RG; PURDIE, CA; STEEL, CM; EVANS, HJ; BIRD, CC; WYLLIE, AH				ASHTONRICKARDT, PG; DUNLOP, MG; NAKAMURA, Y; MORRIS, RG; PURDIE, CA; STEEL, CM; EVANS, HJ; BIRD, CC; WYLLIE, AH			HIGH-FREQUENCY OF APC LOSS IN SPORADIC COLORECTAL-CARCINOMA DUE TO BREAKS CLUSTERED IN 5Q21-22	ONCOGENE			English	Article									UNIV EDINBURGH,SCH MED,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; MRC,HUMAN GENET UNIT,EDINBURGH,SCOTLAND; UNIV UTAH,HOWARD HUGHES MED CTR,SALT LAKE CITY,UT 84112	University of Edinburgh; University of Edinburgh; Utah System of Higher Education; University of Utah	ASHTONRICKARDT, PG (corresponding author), UNIV EDINBURGH,DEPT PATHOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.		Dunlop, Malcolm G/F-1973-2011	Dunlop, Malcolm G/0000-0002-3033-5851; Purdie, Colin/0000-0002-1258-4010				ARMITAGE NC, 1985, BRIT J SURG, V72, P828, DOI 10.1002/bjs.1800721018; BAKER SJ, 1989, SCIENCE, V244, P211; BODMER WF, 1987, NATURE, V238, P1411; DRYJA TP, 1984, NEW ENGL J MED, V310, P550, DOI 10.1056/NEJM198403013100902; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; DUNLOP MG, 1989, IN PRESS GENOMICS; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERTI AD, 1988, CANCER GENET CYTOGEN, V34, P101, DOI 10.1016/0165-4608(88)90174-4; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; HOLGATE CS, 1986, J PATHOL, V149, P293, DOI 10.1002/path.1711490405; KHAN PM, 1988, HUM GENET, V79, P183, DOI 10.1007/BF00280563; KNUDSON AG, 1983, CANCER INVEST, V1, P187; LAW DJ, 1988, SCIENCE, V241, P961, DOI 10.1126/science.2841761; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LOTHE RA, 1988, CYTOGENET CELL GENET, V48, P167, DOI 10.1159/000132617; MACKAY J, 1988, LANCET, V2, P1384; MONPEZAT JP, 1988, INT J CANCER, V41, P404, DOI 10.1002/ijc.2910410315; MULERIS M, 1985, Annales de Genetique, V28, P206; NAKAMURA Y, 1988, AM J HUM GENET, V43, P638; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; OLAISEN B, 1987, CYTOGENET CELL GENET, V46, P147, DOI 10.1159/000132475; PETERSEN SE, 1986, CYTOMETRY, V7, P307, DOI 10.1002/cyto.990070403; QUIRKE P, 1987, J PATHOL, V151, P285, DOI 10.1002/path.1711510408; REES M, 1989, BRIT J CANCER, V59, P361, DOI 10.1038/bjc.1989.72; REICHMANN A, 1981, INT J CANCER, V28, P431, DOI 10.1002/ijc.2910280407; REMVIKOS Y, 1988, INT J CANCER, V42, P539, DOI 10.1002/ijc.2910420411; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART GD, 1987, NUCLEIC ACIDS RES, V15, P3939, DOI 10.1093/nar/15.9.3939; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; VANDERBROEK MH, 1988, ANTICANCER RES, V8, P1104; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WASMUTH J, 1988, CYTOGENET CELL GENET, V49, P55; WYLLIE AH, 1989, P ROY COLL PHYS EDIN, V19, P171; YUNIS JJ, 1987, ONCOGENE, V1, P59	39	118	119	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1989	4	10					1169	1174						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2797819				2022-12-28	WOS:A1989AU50800002
J	BARSAGI, D; GOMPERTS, BD				BARSAGI, D; GOMPERTS, BD			STIMULATION OF EXOCYTOTIC DE-GRANULATION BY MICROINJECTION OF THE RAS ONCOGENE PROTEIN INTO RAT MAST-CELLS	ONCOGENE			English	Article									UNIV LONDON UNIV COLL,DEPT EXPTL PATHOL,LONDON WC1E 6JJ,ENGLAND	University of London; University College London	BARSAGI, D (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Bar-Sagi, Dafna/0000-0003-2597-8948	NATIONAL CANCER INSTITUTE [R01CA039811] Funding Source: NIH RePORTER; NCI NIH HHS [CA07896, CA39811] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BLATTLER DP, 1972, J CHROMATOGR, V64, P147, DOI 10.1016/S0021-9673(00)92958-3; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CAPON DJ, 1982, NATURE, V304, P479; COCKCROFT S, 1987, J CELL BIOL, V105, P2745, DOI 10.1083/jcb.105.6.2745; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GOMPERTS BD, 1983, BIOCHEM J, V210, P737, DOI 10.1042/bj2100737; GOMPERTS BD, 1983, NATURE, V306, P64, DOI 10.1038/306064a0; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HORSFIELD GI, 1965, J PATHOL BACTERIOL, V90, P599, DOI 10.1002/path.1700900228; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; KAGAYAMA M, 1974, J CELL BIOL, V62, P519, DOI 10.1083/jcb.62.2.519; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUNOFF D, 1973, J CELL BIOL, V57, P252; LAWSON D, 1977, J CELL BIOL, V72, P242, DOI 10.1083/jcb.72.2.242; LOCHRIE MA, 1985, SCIENCE, V228, P96, DOI 10.1126/science.3856323; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MUELLER R, 1982, NATURE, V299, P640; NEUMANSILBERBERG FS, 1984, CELL, V37, P1027; PAPAGEORGE A, 1982, J VIROL, V44, P509, DOI 10.1128/JVI.44.2.509-519.1982; PAPAGEORGE AG, 1984, MOL CELL BIOL, V4, P23, DOI 10.1128/MCB.4.1.23; PEARCE FL, 1986, J PHYSIOL-LONDON, V372, P379, DOI 10.1113/jphysiol.1986.sp016014; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; PREISS J, 1986, J BIOL CHEM, V261, P8597; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; REIN A, 1985, MOL CELL BIOL, V5, P2257, DOI 10.1128/MCB.5.9.2257; REYMOND CD, 1984, CELL, V39, P141, DOI 10.1016/0092-8674(84)90199-5; ROHLICH P, 1971, J CELL BIOL, V51, P465, DOI 10.1083/jcb.51.2.465; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SLAMON DJ, 1984, P NATL ACAD SCI-BIOL, V81, P7141, DOI 10.1073/pnas.81.22.7141; SWANSON ME, 1986, J CELL BIOL, V103, P485, DOI 10.1083/jcb.103.2.485; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALLAR L, 1987, J BIOL CHEM, V262, P5049; WANG K, 1982, METHOD ENZYMOL, V85, P514; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WONG G, 1986, CANCER RES, V46, P6029; YAMADA K, 1987, BIOCHEM J, V247, P95, DOI 10.1042/bj2470095	57	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					463	469						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3078954				2022-12-28	WOS:A1988Q773900016
J	ELIYAHU, D; GOLDFINGER, N; PINHASIKIMHI, O; SHAULSKY, G; SKURNIK, Y; ARAI, N; ROTTER, V; OREN, M				ELIYAHU, D; GOLDFINGER, N; PINHASIKIMHI, O; SHAULSKY, G; SKURNIK, Y; ARAI, N; ROTTER, V; OREN, M			METH-A FIBRO-SARCOMA CELLS EXPRESS 2 TRANSFORMING MUTANT P53 SPECIES	ONCOGENE			English	Article									WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL; DNAX RES INST MOLEC & CELLULAR BIOL,PALO ALTO,CA	Weizmann Institute of Science; Weizmann Institute of Science; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.				Shaulsky, Gad/0000-0002-0532-0551	NCI NIH HHS [R01 CA 40099, R01 CA 40002] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040002, R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY C, 1988, IN PRESS MOL CELL BI; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KACZMAREK L, 1986, EXP CELL RES, V162, P268, DOI 10.1016/0014-4827(86)90445-3; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KLEIN G, 1982, ADV VIRAL ONCOLOGY, V2; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; MALTZMAN W, 1981, VIROLOGY, V112, P145, DOI 10.1016/0042-6822(81)90620-6; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MICHALOVITZ D, 1988, CELLULAR MOL BIOL TU, P247; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PARADA LF, 1983, MOL CELL BIOL, V3, P2298, DOI 10.1128/MCB.3.12.2298; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PINHASI O, 1984, MOL CELL BIOL, V4, P2180, DOI 10.1128/MCB.4.10.2180; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PROKOCIMER M, 1986, BLOOD, V68, P113; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROTTER V, 1983, J IMMUNOL, V131, P329; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; RUSCETTI SK, 1983, J VIROL, V46, P1022, DOI 10.1128/JVI.46.3.1022-1026.1983; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUSSI T, 1987, ONCOGENE, V1, P71; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; ZAKUTHOURI R, 1984, CANCER CELL, V2, P393	59	273	281	2	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					313	321						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	3060794				2022-12-28	WOS:A1988Q436700010
J	BERNARDS, A; PASKIND, M; BALTIMORE, D				BERNARDS, A; PASKIND, M; BALTIMORE, D			4 MURINE C-ABL MESSENGER-RNAS ARISE BY USAGE OF 2 TRANSCRIPTIONAL PROMOTERS AND ALTERNATIVE SPLICING	ONCOGENE			English	Article									MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	BERNARDS, A (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.				NCI NIH HHS [CA 38497] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA038497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELSON HT, 1970, CANCER RES, V30, P2213; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BERNARDS A, 1987, MOL CELL BIOL, V7, P3231, DOI 10.1128/MCB.7.9.3231; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; GODDARD JM, 1986, P NATL ACAD SCI USA, V83, P2172, DOI 10.1073/pnas.83.7.2172; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HOFFMANFALK H, 1983, CELL, V32, P589, DOI 10.1016/0092-8674(83)90478-6; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; LAUGHON A, 1986, MOL CELL BIOL, V6, P4676, DOI 10.1128/MCB.6.12.4676; LAVIA P, 1987, EMBO J, V6, P2773, DOI 10.1002/j.1460-2075.1987.tb02572.x; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; Maxam A M, 1980, Methods Enzymol, V65, P499; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SIVE HL, 1986, MOL CELL BIOL, V6, P3329, DOI 10.1128/MCB.6.10.3329; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WANG JYJ, 1984, CELL, V36, P349; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0	35	39	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1988	2	4					297	304						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3283651				2022-12-28	WOS:A1988M947200001
J	FORD, HL; SALIM, MM; CHAKRAVARTY, R; ALUIDDIN, V; ZAIN, SB				FORD, HL; SALIM, MM; CHAKRAVARTY, R; ALUIDDIN, V; ZAIN, SB			EXPRESSION OF MTS1, A METASTASIS-ASSOCIATED GENE, INCREASES MOTILITY BUT NOT INVASION OF A NONMETASTATIC MOUSE MAMMARY ADENOCARCINOMA CELL-LINE	ONCOGENE			English	Article						MTS1; METASTASIS; MOTILITY; BREAST CANCER MODEL	CALCIUM-BINDING PROTEIN; EXTRACELLULAR-MATRIX; MOLECULAR-CLONING; CARCINOMA CELLS; STRONG HOMOLOGY; TUMOR INVASION; MELANOMA-CELLS; MESSENGER-RNA; SEQUENCE; FAMILY	The mts1 gene codes for a 101 amino acid protein belonging to the S100 subfamily of Ca2+-binding proteins. Mts1 is overexpressed in metastatic cancers as compared to their nonmetastatic counterparts, and although mts1 is known to be involved in the metastatic phenotype (Davies et al., 1993; Grigorian et al., 1993), the role mts1 plays in this process is not clearly understood. In order to determine what role mts1 plays in the process of metastasis, we have transfection studies on nonmetastatic and mouse mammary adenocarcinoma cell lines, CSML0 and CSML100, respectively (Senin et al., 1983, 1984). The metastatic variant, CSML100, expresses high levels of mts1, whereas the nonmetastatic variant, CSML0, expresses almost no mts1. CSML0 cells transfected with mts1 were assessed in in vitro motility and invasion assays, as web as in vivo metastasis assays to determine the role of mts1 in these processes, Cell lines expressing mts1 display an altered morphology as, well as increased motility in modified Boyden chemotaxis chambers, However, no significant increase in in vitro invasion or in in vivo metastasis was observed. Therefore, the presence of mts1 may be important for metastasis by increasing motility, but may not be sufficient for invasion in vitro or metastasis in vivo. Very low levels of type IV collagenase activities were observed in CSML0 cells and the transfectants, as opposed to the highly metastatic CSML100 cells, where high levels of type IV collagenase activities were observed. It is possible that the presence of these proteases in addition to mts1 may be responsible for the high metastatic potential of the CSML100 in vivo.	UNIV ROCHESTER,SCH MED,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NCI NIH HHS [P30CA11198, R01CA62376] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198, R01CA062376] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAHLER DW, 1985, J IMMUNOL, V134, P2790; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN PD, 1990, CANCER RES, V550, P6184; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; Carson FL, 1990, HISTOTECHNOLOGY SELF; DAVIES BR, 1993, ONCOGENE, V8, P999; DELEON M, 1991, J NEUROSCI RES, V29, P155; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORD HL, 1995, ONCOGENE, V10, P1597; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GLENNEY JR, 1989, J CELL BIOL, V108, P569, DOI 10.1083/jcb.108.2.569; GRAHAM CH, 1994, EXP CELL RES, V214, P93, DOI 10.1006/excr.1994.1237; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KORCZAK B, 1991, CELL GROWTH DIFFER, V2, P335; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIOTTA LA, 1983, LAB INVEST, V49, P636; LIOTTA LA, 1986, CANCER RES, V46, P1; MAEMURA M, 1994, BREAST CANCER RES TR, V32, P239, DOI 10.1007/BF00666002; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MIZUTANI T, 1993, CANCER, V72, P2083, DOI 10.1002/1097-0142(19931001)72:7<2083::AID-CNCR2820720705>3.0.CO;2-1; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; POSTLETHWAITE AE, 1976, J EXP MED, V144, P1188, DOI 10.1084/jem.144.5.1188; RAY JM, 1994, EUR RESPIR J, V7, P2062; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIRRMACHER V, 1985, ADV CANCER RES, V43, P1, DOI 10.1016/S0065-230X(08)60942-2; SENIN VM, 1984, VESTNIK USSR ACAD ME, V5, P85; SENIN VM, 1983, EXP ONCOL USSR, V5, P35038; SILBERMAN S, 1990, EXP CELL RES, V189, P64, DOI 10.1016/0014-4827(90)90257-B; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STETLERSTEVENSO.WG, 1993, ANNU REV CELL BIOL, V9, P541; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; TANIGUCHI S, 1990, BIOCHEM BIOPH RES CO, V168, P520, DOI 10.1016/0006-291X(90)92352-Z; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; WETERMAN MAJ, 1992, CANCER RES, V52, P1291; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	48	59	60	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2067	2075						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478526				2022-12-28	WOS:A1995TF29700017
J	HERZINGER, T; FUNK, JO; HILLMER, K; EICK, D; WOLF, DA; KIND, P				HERZINGER, T; FUNK, JO; HILLMER, K; EICK, D; WOLF, DA; KIND, P			ULTRAVIOLET-B IRRADIATION-INDUCED G2 CELL-CYCLE ARREST IN HUMAN KERATINOCYTES BY INHIBITORY PHOSPHORYLATION OF THE CDC2 CELL-CYCLE KINASE	ONCOGENE			English	Article						UV IRRADIATION; P53; G2/M CHECKPOINT; CDC2; KERATINOCYTES; SKIN CANCER	WEE1 PROTEIN-KINASE; FISSION YEAST; IONIZING-RADIATION; CHECKPOINTS	In response to genotoxic stress, cell cycle progression can be arrested at certain checkpoints which serve to maintain genomic integrity. We have investigated the mechanism of ultraviolet B (UVB) irradiation-induced cell cycle arrest in normal human keratinocytes and in the HaCaT keratinocyte cell line which carries mutant p53 tumour suppressor protein. While only normal keratinocytes showed a delay in G1 following sublethal UVB irradiation both cell types exhibited prolonged G2 arrest attributable to rapid inhibition of cyclin B-associated cdc2 kinase activity. This inhibition coincided with increased tyrosine phosphorylation of cdc2 and was reversed by the cdc25C phosphatase in vitro. The data indicate that WE-induced G2 arrest in mammalian cells is mediated by inhibitory tyrosine phosphorylation of cdc2 and acts as a defense mechanism against DNA damage irrespective of the cells' p53 status.	GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY; UNIV MUNICH,DERMATOL KLIN & POLIKLIN,MOLEK PATHOL ABT,D-80337 MUNICH,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich			Wolf, Dieter/AAE-5890-2021	Wolf, Dieter/0000-0002-3761-1070				BARBET NC, 1993, NATURE, V364, P824, DOI 10.1038/364824a0; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CARMICHAEL J, 1987, CANCER RES, V47, P943; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; FREDERICK JE, 1993, PHOTOCHEM PHOTOBIOL, V57, P175, DOI 10.1111/j.1751-1097.1993.tb02274.x; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUILLOUF C, 1995, ONCOGENE, V10, P2263; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HERZINGER T, 1995, ONCOGENE, V10, P2079; HOFFMANN I, 1993, EMBO J, V12, P553; KASTAN MB, 1991, CANCER RES, V551, P6304; KAUFMANN WK, 1993, FASEB J, V7, P1188, DOI 10.1096/fasebj.7.12.8375618; KHARBANDA S, 1994, CANCER RES, V54, P1412; KO CB, 1994, BRIT J DERMATOL, V130, P269, DOI 10.1111/j.1365-2133.1994.tb02920.x; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LIU M, 1995, ONCOGENE, V10, P1955; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; PALAYOOR ST, 1995, RADIAT RES, V141, P235, DOI 10.2307/3579000; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; STEWART N, 1995, ONCOGENE, V10, P109; WOLF DA, 1993, MOL ENDOCRINOL, V7, P924, DOI 10.1210/me.7.7.924; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	37	107	108	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2151	2156						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478536				2022-12-28	WOS:A1995TF29700027
J	VEYRUNE, JL; CARILLO, S; VIE, A; BLANCHARD, JM				VEYRUNE, JL; CARILLO, S; VIE, A; BLANCHARD, JM			C-FOS MESSENGER-RNA INSTABILITY DETERMINANTS PRESENT WITHIN BOTH THE CODING AND THE 3'-NON-CODING REGION LINK THE DEGRADATION OF THIS MESSENGER-RNA TO ITS TRANSLATION	ONCOGENE			English	Article						MESSENGER-RNA STABILITY; TRANSLATION; AU-RICH SEQUENCES; C-FOS	MESSENGER-RNA DEGRADATION; IRON-RESPONSIVE ELEMENTS; PROTEIN-SYNTHESIS INHIBITORS; UNTRANSLATED REGION; RICH SEQUENCES; TRANSFERRIN RECEPTOR; STABILITY INVITRO; GENE-EXPRESSION; BINDING-PROTEIN; GROWTH-FACTORS	The instability of oncogenic mRNA such as c-fos mRNA is controlled in cis by sequences present in both the coding and the 3' untranslated regions (3'UTR). The latter contains AU-rich elements (ARE) which, depending on the cellular context, mediate either their rapid degradation or inhibit their translation. These observations, along with the known increase of the Life spans of many unstable mRNA promoted by inhibitors of protein synthesis, raise the possibility that both processes are linked. To investigate further the putative involvement of translation in both coding region and ARE-mediated rapid decay of c-fos mRNA, we designed an expression vector based on the use of the ferritin mRNA iron regulatory element (IRE). The latter structure links translation to intracellular iron concentration when inserted at the proper location within the 5'UTR. Rapid degradation of a beta-globin/c-fos 3'UTR construct was prevented by Desferrioxamine, an iron chelator, and facilitated by ferric ammonium citrate or hemin, while stability of other mRNAs not containing the IRE or the ARE were unchanged. The same conclusion was reached when tbe stability of a c-fos mRNA devoid of ARE was assessed in function of iron availability.	INST GENET MOLEC MONTPELLIER,CNRS,UMR 9942,F-34033 MONTPELLIER 1,FRANCE	Centre National de la Recherche Scientifique (CNRS)								AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; BELASCO J, CONTROL MESSENGER RN; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BONNIEU A, 1990, ONCOGENE, V5, P1585; BONNIEU A, 1989, ONCOGENE, V4, P881; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HENTZE MW, 1988, GENE, V72, P201, DOI 10.1016/0378-1119(88)90145-X; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; KRUYS VI, 1988, GENE, V72, P191, DOI 10.1016/0378-1119(88)90144-8; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MATTIA E, 1989, P NATL ACAD SCI USA, V86, P1801, DOI 10.1073/pnas.86.6.1801; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MYER VE, 1992, P NATL ACAD SCI USA, V89, P1296, DOI 10.1073/pnas.89.4.1296; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STEARNE PA, 1985, J IMMUNOL, V134, P3474; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	53	25	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2127	2134						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478533				2022-12-28	WOS:A1995TF29700024
J	FRANKLIN, GC; ADAM, GIR; MILLER, SJ; MONCRIEFF, CL; ULLERAS, E; OHLSSON, R				FRANKLIN, GC; ADAM, GIR; MILLER, SJ; MONCRIEFF, CL; ULLERAS, E; OHLSSON, R			AN INR-CONTAINING SEQUENCE FLANKING THE TATA BOX OF THE HUMAN C-SIS (PDGF-B) PROTOONCOGENE PROMOTER FUNCTIONS IN CIS AS A COACTIVATOR FOR ITS INTRONIC ENHANCER	ONCOGENE			English	Article						PDGF-B; C-SIS; INR; ENHANCER PROMOTER INTERACTIONS	GROWTH-FACTOR; CELL-LINES; TRANSCRIPTION INITIATION; REGULATORY ELEMENTS; MESSENGER-RNAS; 1ST INTRON; GENE; EXPRESSION; REGION; IDENTIFICATION	High-level activity of the human PDGF-B promoter in choriocarcinoma cell lines depends upon an atypical, intronic enhancer-like element which does not function with heterologous promoters tested. An extensive series of mutant PDGF-B promoter-driven constructs identified a sequence flanking the TATA box which is required specifically for enhancer-mediated transcription in human choriocarcinoma cell lines. This element, which we here term an enhancer-dependent cis co-activator (EDC) contains an Inr (initiator) consensus sequence upstream of the TATA box which is required, but not sufficient for its function. Requirement for the EDC is cell type-specific, since it was dispensable for enhancer-mediated transcription in a human breast cancer cell line. Although it lies within the region defined, the TATA box itself is not required for EDC function, or for basal promoter function which may derive from a second Inr-like sequence situated at the transcriptional start site. These observations indicate that interactions between some promoter and enhancer elements may be more complex than that generally described for 'classical' enhancer systems and may suggest an additional function for the initiator motif.			FRANKLIN, GC (corresponding author), UPPSALA UNIV,DEPT ANIM DEV & GENET,NORBYVAGEN 18A,S-75236 UPPSALA,SWEDEN.							BEHL C, 1993, NEUROSURGERY, V33, P697; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COLGAN J, 1995, P NATL ACAD SCI USA, V92, P1955, DOI 10.1073/pnas.92.6.1955; DESMARAIS D, 1992, EMBO J, V11, P2971, DOI 10.1002/j.1460-2075.1992.tb05367.x; DIRKS RPH, 1993, EUR J BIOCHEM, V216, P487, DOI 10.1111/j.1432-1033.1993.tb18167.x; FEN Z, 1991, ONCOGENE, V6, P953; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; GARCIA JV, 1986, NATURE, V322, P383, DOI 10.1038/322383a0; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HOLMGREN L, 1993, CANCER RES, V53, P2927; HOLMGREN L, 1991, DEVELOPMENT, V113, P749; Holmgren L, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209026929; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JIANG SW, 1995, J BIOL CHEM, V270, P3683, DOI 10.1074/jbc.270.8.3683; JIN HM, 1994, J BIOL CHEM, V269, P28648; KANEDA S, 1992, SOMAT CELL MOLEC GEN, V18, P409, DOI 10.1007/BF01233080; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KERMEKCHIEV M, 1991, GENE EXPRESSION, V1, P71; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; LI XL, 1994, EMBO J, V13, P400, DOI 10.1002/j.1460-2075.1994.tb06274.x; MATSUOKA S, 1993, EUR J BIOCHEM, V218, P173, DOI 10.1111/j.1432-1033.1993.tb18363.x; NISTER M, 1988, CANCER RES, V48, P3910; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; PERES R, 1987, CANCER RES, V47, P3425; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; TIJAN R, 1994, CELL, V77, P5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0	44	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1873	1884						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478617				2022-12-28	WOS:A1995TD09400024
J	RONDINELLI, RH; HASLAM, SZ; FLUCK, MM				RONDINELLI, RH; HASLAM, SZ; FLUCK, MM			THE ROLE OF OVARIAN HORMONES, AGE AND MAMMARY-GLAND DEVELOPMENT IN POLYOMAVIRUS MAMMARY TUMORIGENESIS	ONCOGENE			English	Article						MAMMARY TUMOR DEVELOPMENT; OVARIAN HORMONES; AGE; POLYOMAVIRUS	VIRUS ONCOGENICITY; BREAST-CANCER; NUDE-MICE; CARCINOGENESIS; INDUCTION; ESTROGEN; DISEASE; TISSUE; TUMORS; RATS	Polyomavirus infection of adolescent athmyic female mice causes a high incidence of mammary adenocarcinomas, We have examined the role of ovarian hormones, age and mammary gland developmental stage at infection on subsequent tumor induction, viral replication and gene expression, Ovariectomy (OVX) of adolescent mice 1 week before infection decreased mammary tumor incidence and number, and significantly increased tumor latency. Reduction in tumorigenesis mas observed to a lesser degree if mice mere OVX at the time of or after infection, indicating that ovarian hormones are mainly required for tumor initiation. Tumor incidence was also reduced with increasing age; OVX prior to infection at older ages drastically reduced tumor development. Treatment of OVX adult mice with estrogen + progesterone for 1-3 weeks prior to infection was unable to restore tumorigenesis to the level observed in intact mice. Thus, in contrast to adolescent mice, the continued presence of ovarian hormones after infection was required for maximal tumorigenesis in adult mice. The decreased tumorigenesis observed in older animals is not likely due to increased differentiation since late pregnant mice with well differentiated mammary glands remained highly susceptible to tumorigenesis. At 10 days post infection, the levels of viral genomes were moderately high and similar in all experimental groups. Early viral protein and middle T-associated kinase levels were undetectable in infected tissues in all experimental conditions. However, high levels were found in tumors, perhaps reflecting a high dosage requirement for oncogenesis.	MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT PHYSIOL,CELL & MOLEC BIOL PROGRAM,E LANSING,MI 48824	Michigan State University; Michigan State University					NCI NIH HHS [5R01 CA58763, 5R01 CA40104] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058763, R01CA040104] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUZZI A, 1990, New Biologist, V2, P533; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BANERJEE M R, 1976, TCA (Tissue Culture Association) Manual, V2, P457, DOI 10.1007/BF00918341; BEREBBI M, 1988, ONCOGENE, V2, P149; BEREBBI M, 1990, ONCOGENE, V5, P505; BODIAN CA, 1993, CANCER, V71, P3896, DOI 10.1002/1097-0142(19930615)71:12<3896::AID-CNCR2820711217>3.0.CO;2-I; BOICE JD, 1977, J NATL CANCER I, V59, P823, DOI 10.1093/jnci/59.3.823; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHEN MC, 1995, J VIROL, V69, P326, DOI 10.1128/JVI.69.1.326-333.1995; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DAO TL, 1959, JNCI-J NATL CANCER I, V23, P567; DAO TL, 1962, CANCER RES, V22, P973; DAO TL, 1969, SCIENCE, V165, P810, DOI 10.1126/science.165.3895.810; DAO TL, 1960, J NATL CANCER I, V25, P991; DAWE CJ, 1987, AM J PATHOL, V127, P243; DIFRONZO G, 1990, ANTICANCER RES, V10, P1699; GRUBBS CJ, 1983, J NATL CANCER I, V70, P209; GRUBBS CJ, 1983, J NATL CANCER I, V71, P625; GULLINO PM, 1975, J NATL CANCER I, V54, P401; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HASLAM SZ, 1988, ENDOCRINOLOGY, V122, P464, DOI 10.1210/endo-122-2-464; HASLAM SZ, 1992, ONCOGENE, V7, P1295; HASLAM SZ, 1992, J STEROID BIOCHEM, V42, P589, DOI 10.1016/0960-0760(92)90449-S; HASLAM SZ, 1989, ENDOCRINOLOGY, V125, P2766, DOI 10.1210/endo-125-5-2766; HASLAM SZ, 1980, INT J CANCER, V26, P349, DOI 10.1002/ijc.2910260315; HASLAM SZ, 1993, J CELL PHYSIOL, V155, P72, DOI 10.1002/jcp.1041550110; HUGGINS C, 1959, J EXP MED, V109, P25, DOI 10.1084/jem.109.1.25; KAPLAN D R, 1988, Biochimica et Biophysica Acta, V948, P345; KORFSMEIER KH, 1979, ANAT ANZEIGER, V145, P313; MERANZE DR, 1969, INT J CANCER, V4, P480, DOI 10.1002/ijc.2910040413; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NAGASAWA H, 1977, ACTA ENDOCRINOL-COP, V86, P794, DOI 10.1530/acta.0.0860794; NANDI S, 1958, J NATL CANCER I, V21, P1039; NERI C, 1990, CANCER RES, V50, P5892; RUSSO IH, 1990, BRIT J CANCER, V62, P243, DOI 10.1038/bjc.1990.268; RUSSO J, 1977, J NATL CANCER I, V59, P435, DOI 10.1093/jnci/59.2.435; RUSSO J, 1987, J NATL CANCER I, V78, P413; RUSSO J, 1979, AM J PATHOL, V96, P721; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; RUSSO J, 1978, J NATL CANCER I, V61, P1451; SHARKEY SM, 1986, CARCINOGENESIS, V7, P1991, DOI 10.1093/carcin/7.12.1991; SINHA DK, 1983, INT J CANCER, V31, P321, DOI 10.1002/ijc.2910310312; Swanson G M, 1994, J Natl Cancer Inst Monogr, P69; TOKUNAGA M, 1979, J NATL CANCER I, V62, P1347; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; VONDERHAAR BK, 1985, CONTROL CELL GROWTH, P11; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183, DOI 10.1210/endo-127-5-2183; WIRTH JJ, 1992, J VIROL, V66, P3278, DOI 10.1128/JVI.66.6.3278-3286.1992	50	9	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1817	1827						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478610				2022-12-28	WOS:A1995TD09400017
J	ONODERA, M; KUNISADA, T; NISHIKAWA, S; SAKIYAMA, Y; MATSUMOTO, S; NISHIKAWA, S				ONODERA, M; KUNISADA, T; NISHIKAWA, S; SAKIYAMA, Y; MATSUMOTO, S; NISHIKAWA, S			OVEREXPRESSION OF RETINOIC ACID RECEPTOR-ALPHA SUPPRESSES MYELOID CELL-DIFFERENTIATION AT THE PROMYELOCYTE STAGE	ONCOGENE			English	Article						RAR-ALPHA; RETROVIRAL-MEDIATED GENE TRANSFER; BONE MARROW CELLS; MYELOID; APL	ZINC FINGER GENE; THYROID-HORMONE; RAR-ALPHA; ALL-TRANS; MONOCLONAL-ANTIBODIES; BINDING-PROPERTIES; RESPONSE ELEMENTS; NUCLEAR RECEPTOR; DNA-BINDING; STEM-CELLS	Retinoic acid receptor (RAR) alpha is required to heterodimerize with retinoid X receptor (RXRs) in order to regulate myeloid differentiation. If so, it is expected that overexpression of normal RAR alpha may perturb the RAR alpha/ RXR heterodimer formation and also the differentiation of myeloid cells. We have described here the morphology and the RA response of human RAR alpha cDNA transduced murine bone marrow cells using a retroviral vector. Most of RAR alpha transduced cells displayed promyelocyte like morphology and their proportion of c-kit expressing population was increased remarkably compared with the control (Neo(r) gene transduced cells). Furthermore, this morphology was observed even after these cells were brought into the semisolid culture containing IL-3 alone. Interestingly, immature RAR alpha transduced cells differentiated into mature granulocytes under the condition of the high concentration of RA(10(-6)M). We did not observe any effect of RAR alpha on monocytes. These results indicate that overexpression of normal RAR alpha is sufficient for inducing maturation arrest of myeloid cell lineage that is similar to the phenotype found in the acute promyelocytic leukemia bearing PML-RAR alpha translocation.	KYOTO UNIV,FAC MED,DEPT MOLEC GENET,SAKYO KU,KYOTO 06001,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT PEDIAT,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Kyoto University; Hokkaido University								BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; Coffman R L, 1982, Immunol Rev, V69, P5; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAWSON MI, 1994, BLOOD, V84, P446; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KODAMA HA, 1982, J CELL PHYSIOL, V112, P89, DOI 10.1002/jcp.1041120114; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KRIEGLER M, 1990, LABORATORY MANUAL, P161; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROWLEY JD, 1987, LANCET, V5, P549; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; TOHDA S, 1992, LEUKEMIA, V6, P656; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VARTDAL F, 1987, TRANSPLANTATION, V43, P366, DOI 10.1097/00007890-198703000-00010; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	53	21	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1291	1298						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478549				2022-12-28	WOS:A1995RY96700009
J	RODABAUGH, KJ; BIGGS, RB; QURESHI, JA; BARRETT, AJ; WELCH, WR; BELL, DA; BERKOWITZ, RS; MOK, SC				RODABAUGH, KJ; BIGGS, RB; QURESHI, JA; BARRETT, AJ; WELCH, WR; BELL, DA; BERKOWITZ, RS; MOK, SC			DETAILED DELETION MAPPING OF CHROMOSOME 9P AND P16 GENE ALTERATIONS IN HUMAN BORDERLINE AND INVASIVE EPITHELIAL OVARIAN-TUMORS	ONCOGENE			English	Article						BORDERLINE OVARIAN TUMOR; OVARIAN CANCER; CHROMOSOME 9P; LOSS OF HETEROZYGOSITY; P16 GENE	UNIFOCAL ORIGIN; CARCINOMAS; HETEROZYGOSITY; CANCER	We used PCR amplification of tandem repeats to study the pattern of allelic loss in borderline and invasive ovarian epithelial tumors using 12 primer pairs to generate a detailed deletion map of chromosome 9p. In the invasive ovarian carcinomas, there were three regions displaying high frequency of loss of heterozygosity (LOH) ranging from 31-38%. In contrast, LOH was a rare event among the borderline ovarian tumors, with one region revealing a rate of 20% and the remaining regions only 0-8% LOH. Therefore, allelic loss does not seem to be important for the development of borderline ovarian tumors. We also examined p16 gene expression and mutations in ovarian cancer cell lines and invasive and borderline ovarian tumor tissues. Southern blot analysis revealed no losses of the p16 gene in either the invasive or borderline ovarian tumors. However, the ovarian carcinoma cell lines showed a 50% homozygous deletion rate, SSCP analysis detected a mobility shift in only one (borderline) tumor. Since the primary invasive ovarian tumors did not show any deletions or mutations, it appears that p16 does not play a role in the pathogenesis of these tumors.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED, DEPT OBSTET GYNECOL & REPROD BIOL, GYNECOL ONCOL LAB, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital					NATIONAL CANCER INSTITUTE [R01CA063381] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA63381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI T, 1994, GENE CHROMOSOME CANC, V10, P177, DOI 10.1002/gcc.2870100305; CAIRNS P, 1995, CANCER RES, V55, P224; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; CHENG JQ, 1994, CANCER RES, V54, P5547; EHLEN T, 1990, ONCOGENE, V5, P219; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; HUANG DP, 1994, CANCER RES, V54, P4003; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KRUK PA, 1990, LAB INVEST, V63, P132; LEE JH, 1990, CANCER RES, V50, P2724; MOK CH, 1992, CANCER RES, V52, P5119; MOK SC, 1995, GYNECOL ONCOL, V57, P299, DOI 10.1006/gyno.1995.1146; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; RUPPERT JM, 1993, CANCER RES, V53, P5093; SATO T, 1991, CANCER RES, V51, P5118; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; TSAO SW, 1993, GYNECOL ONCOL, V48, P5, DOI 10.1006/gyno.1993.1002; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; WERTHEIM I, 1995, P AM ASSOC CANC RES, V36, P545; XU L, 1994, CANCER RES, V54, P5262; ZHANG SY, 1994, CANCER RES, V54, P5050; ZHOU XL, 1994, ONCOGENE, V9, P3737; 1987, OBSTET GYNECOL, V156, P263	27	46	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1249	1254						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478544				2022-12-28	WOS:A1995RY96700004
J	STEEGENGA, WT; SHVARTS, A; VANLAAR, T; VANDEREB, AJ; JOCHEMSEN, AG				STEEGENGA, WT; SHVARTS, A; VANLAAR, T; VANDEREB, AJ; JOCHEMSEN, AG			ALTERED PHOSPHORYLATION AND OLIGOMERIZATION OF P53 IN ADENOVIRUS TYPE 12-TRANSFORMED CELLS	ONCOGENE			English	Article						P53; ADENOVIRUS; PHOSPHORYLATION; COMPLEXATION; STABILIZATION	CASEIN KINASE-II; LARGE-T-ANTIGEN; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; PRIMARY RAT-CELLS; TRANSFORMED-CELLS; SV40-TRANSFORMED CELLS; GENE AMPLIFICATION; E1B PROTEINS; CYCLE	Loss of function of the tumor-suppressor protein p53 is, in general, either caused by mutation, inducing a conformational change, or by binding to inactivating cellular (e.g. MDM2) or viral (e.g, SV40 large T) proteins. In adenovirus type 12 (Ad12)-transformed cells, p53 is stabilized without detectable binding to the Ad12 E1B/54 kDa protein and still present in a wild-type conformation but contains a mutant-like activity in cellular transformation, In this study we examined whether the changed characteristics of p53 in Ad12-transformed cells are correlated with changes in phosphorylation or complex formation of the protein, By making tryptic phosphopeptide maps we found a significant increase in the phosphorylation of the N-terminus of p53. Furthermore, expression of E1A was found to be essential for the altered phosphorylation, while expression of only Ad12 E1B/54 kDa is sufficient to increase the protein half-life. Additionally, we observed p53 to be present in increased molecular weight complexes in Ad12-transformed cells. We conclude that both the phosphorylation and oligomerization of p53 is changed as a result of Ad12 transformation.	LEIDEN UNIV, SYLVIUS LABS, MOLEC CARCINOGENESIS LAB, 2300 RA LEIDEN, NETHERLANDS	Leiden University; Leiden University - Excl LUMC								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAITHWAITE AW, 1991, ONCOGENE, V6, P781; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FISCELLA M, 1993, ONCOGENE, V8, P1519; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GARVIN AJ, 1993, AM J PATHOL, V142, P375; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JOCHEMSEN AG, 1987, EMBO J, V6, P3399, DOI 10.1002/j.1460-2075.1987.tb02663.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KRAISS S, 1992, BIOCHIM BIOPHYS ACTA, V1119, P11, DOI 10.1016/0167-4838(92)90227-5; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VAESSEN RTMJ, 1986, EMBO J, V5, P335, DOI 10.1002/j.1460-2075.1986.tb04217.x; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; VANDENHEUVEL SJL, 1993, J VIROL, V67, P5226, DOI 10.1128/JVI.67.9.5226-5234.1993; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	53	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	1995	11	1					49	57						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624131				2022-12-28	WOS:A1995RJ29500007
J	LARSEN, J; MEYER, S; STEINLEIN, P; BEUG, H; HAYMAN, MJ				LARSEN, J; MEYER, S; STEINLEIN, P; BEUG, H; HAYMAN, MJ			TRANSFORMATION OF CHICKEN BONE-MARROW CELLS BY THE V-SKI ONCOGENE	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; ERYTHROID-DIFFERENTIATION; LEUKEMIA-VIRUS; GROWTH-FACTOR; MIM-1 GENE; PHENOTYPE; MYB; INVITRO; EXPRESSION; MUSCLE	The effect of the v-ski oncogene on the transformation of chicken hematopoietic cells was examined. In initial experiments viruses encoding the v-ski oncoprotein did not transform chicken bone marrow cells. However, whereas viruses encoding the ts-v-sea oncoprotein transform solely erythroid cells, viruses encoding both the v-ski and the ts-v-sea oncogenes were found capable of transforming myeloid cells from the monocytic and/or granulocytic lineages in addition to erythroid cells. Analysis of cell clones transformed by the v-ski/ts-v-sea virus identified one clone that no longer expressed the v-sea protein, indicating that this protein was necessary for the initiation but not the maintenance of transformation. Subsequent experiments testing the effects of various growth factors on transformation of bone marrow cells by the v-ski oncogene product alone identified the avian c-kit ligand (stem cell factor; SCF) as being able to co-operate with the v-ski protein to cause transformation of chicken hematopoietic cells of both myeloid and erythroid lineages.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)					NATIONAL CANCER INSTITUTE [P01CA028146, R01CA042573] Funding Source: NIH RePORTER; NCI NIH HHS [CA42573, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1985, MODERN TRENDS HUMA 6, V29, P290; BOYER PL, 1993, ONCOGENE, V8, P457; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; DOMENGET C, 1992, ONCOGENE, V7, P2231; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GRAF T, 1976, VIROLOGY, V71, P423, DOI 10.1016/0042-6822(76)90370-6; HAYMAN MJ, 1987, PATHOL IMMUNOPATH R, V6, P390, DOI 10.1159/000157065; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; KAMPS MP, 1988, ONCOGENE, V2, P305; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KELLIHER MA, 1993, ONCOGENE, V8, P1249; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KORNFELD S, 1983, EXP CELL RES; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LARSEN J, 1992, ONCOGENE, V7, P1903; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; QUEVA C, 1992, DEVELOPMENT, V114, P125; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1990, ONCOGENE, V5, P1445; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; SUTRAVE P, 1991, ONCOGENE, V6, P353; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; Varmus H. E., 1982, RNA TUMOR VIRUSES, P369; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	40	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3221	3228						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	7504231				2022-12-28	WOS:A1993MG78200004
J	DASGUPTA, P; REDDY, EP				DASGUPTA, P; REDDY, EP			IDENTIFICATION OF ALTERNATIVELY SPLICED TRANSCRIPTS FOR HUMAN C-MYB - MOLECULAR-CLONING AND SEQUENCE-ANALYSIS OF HUMAN C-MYB EXON-9A SEQUENCES	ONCOGENE			English	Note									WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA044463, P01CA025875] Funding Source: NIH RePORTER; NCI NIH HHS [CA 25875, CA 44463] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; DUDEK H, 1989, ONCOGENE, V4, P1061; DUDEK H, 1989, IN PRESS ONCOGENE, V4; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FRANCHINI G, 1983, P NATL ACAD SCI-BIOL, V80, P7385, DOI 10.1073/pnas.80.24.7385; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Maxam A M, 1980, Methods Enzymol, V65, P499; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; REDDY EP, 1988, ONCOGENE HDB, P327; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	23	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1419	1423						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687764				2022-12-28	WOS:A1989CB65900001
J	OLSON, EN; CAPETANAKI, YG				OLSON, EN; CAPETANAKI, YG			DEVELOPMENTAL REGULATION OF INTERMEDIATE FILAMENT AND ACTIN MESSENGER-RNAS DURING MYOGENESIS IS DISRUPTED BY ONCOGENIC RAS GENES	ONCOGENE			English	Article									BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine	OLSON, EN (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BAINS W, 1984, MOL CELL BIOL, V4, P1449, DOI 10.1128/MCB.4.8.1449; BENNETT GS, 1979, J CELL BIOL, V82, P577, DOI 10.1083/jcb.82.2.577; CAFFREY JM, 1987, SCIENCE, V236, P570, DOI 10.1126/science.2437651; CAPETANAKI YG, 1983, CELL, V35, P411, DOI 10.1016/0092-8674(83)90174-5; CAPETANAKI YG, 1984, P NATL ACAD SCI-BIOL, V81, P6909, DOI 10.1073/pnas.81.22.6909; CAPETANAKI YG, 1984, MOL BIOL CYTOSKELETO, P415; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FERRARI S, 1986, MOL CELL BIOL, V6, P3614, DOI 10.1128/MCB.6.11.3614; FINKEL T, 1984, CELL, V37, P151, DOI 10.1016/0092-8674(84)90310-6; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; GARD DL, 1980, CELL, V19, P263, DOI 10.1016/0092-8674(80)90408-0; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GIBSON CW, 1986, MOL CELL BIOCHEM, V71, P61; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GOSSETT LA, 1988, J CELL BIOL, V106, P2127, DOI 10.1083/jcb.106.6.2127; HAYWARD LJ, 1986, J CELL BIOL, V102, P1485, DOI 10.1083/jcb.102.4.1485; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; HOLTZER H, 1975, P NATL ACAD SCI USA, V72, P4051, DOI 10.1073/pnas.72.10.4051; HYNES RO, 1976, DEV BIOL, V48, P35, DOI 10.1016/0012-1606(76)90043-9; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KACZMAREK L, 1985, P NATL ACAD SCI USA, V82, P5375, DOI 10.1073/pnas.82.16.5375; KAMATA T, 1984, NATURE, V310, P147, DOI 10.1038/310147a0; KAUFMAN SJ, 1988, P NATL ACAD SCI USA, V85, P9606, DOI 10.1073/pnas.85.24.9606; KELVIN DJ, 1989, J CELL BIOL, V108, P169, DOI 10.1083/jcb.108.1.169; MCGRATH JP, 1984, NATURE, V313, P241; MOSS PS, 1979, EXP CELL RES, V123, P95, DOI 10.1016/0014-4827(79)90425-7; NGAI J, 1984, J CELL BIOL, V99, P306, DOI 10.1083/jcb.99.1.306; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1983, J BIOL CHEM, V258, P2644; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; PATERSON BM, 1984, SCIENCE, V224, P1436, DOI 10.1126/science.6729461; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; SASSONECORSI P, 1988, CELL, V54, P533; SCHWARTZ RJ, 1981, BIOCHEMISTRY-US, V20, P4122, DOI 10.1021/bi00517a027; SCONTHAL A, 1988, CELL, V54, P325; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; STERNBERG EA, 1989, IN PRESS MOL CELL BI; SULLIVAN N, 1985, CANCER CELL, V3, P243; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	52	37	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					907	913						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2666910				2022-12-28	WOS:A1989AE58400014
J	DOOLEY, TP; WILSON, RE; JONES, NC; HART, IR				DOOLEY, TP; WILSON, RE; JONES, NC; HART, IR			POLYOMA MIDDLE T-ABROGATES TPA REQUIREMENT OF MURINE MELANOCYTES AND INDUCES MALIGNANT-MELANOMA	ONCOGENE			English	Note									IMPERIAL CANC RES FUND,GENE REGULAT LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,BIOL METASTASIS LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; Cancer Research UK								BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; COLLINS M, 1982, BIOCHEM BIOPH RES CO, V104, P1159, DOI 10.1016/0006-291X(82)91372-9; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; FOURNIER A, 1987, NATURE, V330, P767, DOI 10.1038/330767a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Maniatis T., 1982, MOL CLONING; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OOSTRA BA, 1983, NATURE, V304, P456, DOI 10.1038/304456a0; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SOLANKI V, 1981, P NATL ACAD SCI-BIOL, V78, P1722, DOI 10.1073/pnas.78.3.1722; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STABEL S, 1987, J CELL PHYSIOL, V130, P111, DOI 10.1002/jcp.1041300116; TOOZE J, 1980, MOL BIOL TUMOUR VIRU, V2; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; WONG G, 1973, NATURE-NEW BIOL, V241, P213, DOI 10.1038/newbio241213a0; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	26	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					531	535						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	2856252				2022-12-28	WOS:A1988R516300007
J	KHANDJIAN, EW; GAUCHAT, JF				KHANDJIAN, EW; GAUCHAT, JF			ONE SINGLE BURST OF SV40-GENE EXPRESSION INDUCES CELL-PROLIFERATION IN TRANSFORMING INFECTION OF MOUSE CELLS	ONCOGENE			English	Article									QUAI ERNEST ANSERMET,DEPT MOLEC BIOL 30,CH-1211 GENEVA 4,SWITZERLAND									ACHESON NH, 1980, MOL BIOL TUMOR VIR 2, P125; Anderson CW., 1986, CANC CELLS, V4, P395; CARROLL RB, 1974, P NATL ACAD SCI USA, V71, P3754, DOI 10.1073/pnas.71.9.3754; CHIA W, 1981, P NATL ACAD SCI-BIOL, V78, P6638, DOI 10.1073/pnas.78.11.6638; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; DARLIX JL, 1984, P NATL ACAD SCI-BIOL, V81, P5425, DOI 10.1073/pnas.81.17.5425; DEFROMENTEL CC, 1986, EXP CELL RES, V164, P35, DOI 10.1016/0014-4827(86)90452-0; DENHARDT DT, 1986, BIOCHIM BIOPHYS ACTA, V865, P83, DOI 10.1016/0304-419X(86)90024-7; DUTHU A, 1985, VIROLOGY, V147, P275, DOI 10.1016/0042-6822(85)90130-8; ERNOULTLANGE M, 1984, J VIROL, V50, P163, DOI 10.1128/JVI.50.1.163-173.1984; FUKS P, 1967, ISRAEL J MED SCI, V3, P912; FYRBERG EA, 1980, CELL, V19, P365, DOI 10.1016/0092-8674(80)90511-5; GARIGLIO P, 1981, NUCLEIC ACIDS RES, V9, P2589, DOI 10.1093/nar/9.11.2589; GAUCHAT JF, 1986, NUCLEIC ACIDS RES, V14, P9339, DOI 10.1093/nar/14.23.9339; GAUCHAT JF, 1985, THESIS U GENEVA SWIT; GILDEN RV, 1965, P NATL ACAD SCI USA, V53, P684, DOI 10.1073/pnas.53.3.684; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HANDA H, 1980, J VIROL, V34, P592, DOI 10.1128/JVI.34.3.592-597.1980; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; HISCOTT JB, 1981, J VIROL, V37, P802, DOI 10.1128/JVI.37.2.802-812.1981; KHANDJIAN EW, 1982, P NATL ACAD SCI-BIOL, V79, P1139, DOI 10.1073/pnas.79.4.1139; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P107, DOI 10.1007/BF00364822; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1985, PROC R SOC SER B-BIO, V226, P25, DOI 10.1098/rspb.1985.0077; LANGE M, 1981, J VIROL, V38, P940, DOI 10.1128/JVI.38.3.940-951.1981; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MANIATIS T, 1982, MOL CLONING LABORATO; MATTER JM, 1983, NUCLEIC ACIDS RES, V11, P1039, DOI 10.1093/nar/11.4.1039; MAY E, 1973, P NATL ACAD SCI USA, V70, P1654, DOI 10.1073/pnas.70.6.1654; MAY E, 1971, P NATL ACAD SCI USA, V68, P1208, DOI 10.1073/pnas.68.6.1208; Monier R., 1986, PAPOVAVIRIDAE, V1, P247; MUELLER C, 1978, CELL, V15, P579, DOI 10.1016/0092-8674(78)90026-0; OMILLI F, 1986, MOL CELL BIOL, V6, P1875, DOI 10.1128/MCB.6.6.1875; PUVION E, 1988, IN PRESS EXP CELL RE; RIGBY PWJ, 1985, PROC R SOC SER B-BIO, V226, P15, DOI 10.1098/rspb.1985.0076; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SCHWYZER M, 1980, J BIOL CHEM, V255, P5627; SEILERTUYNS A, 1981, J MOL BIOL, V151, P607, DOI 10.1016/0022-2836(81)90426-5; SETZER DR, 1980, CELL, V22, P361, DOI 10.1016/0092-8674(80)90346-3; SPECTOR DL, 1987, ONCOGENE, V1, P5; STOKER M, 1968, NATURE, V218, P234, DOI 10.1038/218234a0; TJIAN R, 1978, P NATL ACAD SCI USA, V75, P1279, DOI 10.1073/pnas.75.3.1279; TOPP WC, 1980, MOL BIOL TUMOR VIR 2, P205; WEIL R, 1978, BIOCHIM BIOPHYS ACTA, V516, P301, DOI 10.1016/0304-419X(78)90012-4; WINOCOUR E, 1963, VIROLOGY, V19, P158, DOI 10.1016/0042-6822(63)90005-9	47	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					195	200						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	2842716				2022-12-28	WOS:A1988Q053400010
J	BERGMAN, P; USTAV, M; SEDMAN, J; MORENOLOPEZ, J; VENNSTROM, B; PETTERSSON, U				BERGMAN, P; USTAV, M; SEDMAN, J; MORENOLOPEZ, J; VENNSTROM, B; PETTERSSON, U			THE E5 GENE OF BOVINE PAPILLOMAVIRUS TYPE-1 IS SUFFICIENT FOR COMPLETE ONCOGENIC TRANSFORMATION OF MOUSE FIBROBLASTS	ONCOGENE			English	Article									UNIV UPPSALA,CTR BIOMED,DEPT MED GENET,BOX 589,S-75123 UPPSALA,SWEDEN	Uppsala University			Sedman, Juhan/H-1820-2011; Ustav, Mart/G-6484-2017	Sedman, Juhan/0000-0003-2081-1452				AHOLA H, 1983, NUCLEIC ACIDS RES, V11, P2639, DOI 10.1093/nar/11.9.2639; ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BAKER CC, 1987, EMBO J, V6, P1027, DOI 10.1002/j.1460-2075.1987.tb04855.x; Broker T.R., 1986, CANCER CELL, V4, P17; BURKHARDT A, 1987, EMBO J, V6, P2381, DOI 10.1002/j.1460-2075.1987.tb02515.x; CHEN CY, 1982, NATURE, V299, P530; CHUVPILO SA, 1983, BIOORG KHIM+, V9, P1634; CONE RD, 1984, P NATL ACAD SCI-BIOL, V81, P6349, DOI 10.1073/pnas.81.20.6349; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DIMAIO D, 1987, CANCER CELLS, V5, P187; DVORETZKY I, 1980, VIROLOGY, V103, P369, DOI 10.1016/0042-6822(80)90195-6; Favaloro J, 1980, Methods Enzymol, V65, P718; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; HAUGEN TH, 1987, EMBO J, V6, P145, DOI 10.1002/j.1460-2075.1987.tb04732.x; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; HOWLEY PM, 1985, MOL CELL BIOL, V5, P3310, DOI 10.1128/MCB.5.11.3310; KAISER K, 1985, DNA CLONING PRACTICA, V1, P1; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LANCASTER WD, 1982, MICROBIOL REV, V46, P191, DOI 10.1128/MMBR.46.2.191-207.1982; LAW MF, 1981, P NATL ACAD SCI-BIOL, V78, P2727, DOI 10.1073/pnas.78.5.2727; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; LOWY DR, 1980, NATURE, V287, P72, DOI 10.1038/287072a0; LUSKY M, 1985, J VIROL, V53, P955, DOI 10.1128/JVI.53.3.955-965.1985; MANIATIS T, 1982, MOL CLONING LABORATO; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MANN R, 1985, J VIROL, V54, P401, DOI 10.1128/JVI.54.2.401-407.1985; NAKABAYASHI Y, 1983, P NATL ACAD SCI-BIOL, V80, P5832, DOI 10.1073/pnas.80.19.5832; RABSON MS, 1986, J VIROL, V60, P626, DOI 10.1128/JVI.60.2.626-634.1986; SARVER N, 1984, J VIROL, V52, P377, DOI 10.1128/JVI.52.2.377-388.1984; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPALHOLZ RA, 1987, J VIROL, V61, P2128; STEFFEN D, 1978, CELL, V15, P1003, DOI 10.1016/0092-8674(78)90284-2; STENLUND A, 1985, J MOL BIOL, V182, P541, DOI 10.1016/0022-2836(85)90240-2; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; WAGNER EF, 1985, EMBO J, V4, P663, DOI 10.1002/j.1460-2075.1985.tb03680.x; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YANG YC, 1985, P NATL ACAD SCI USA, V82, P1030, DOI 10.1073/pnas.82.4.1030; YANG YC, 1985, NATURE, V318, P575, DOI 10.1038/318575a0	43	36	37	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					453	459						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	2836779				2022-12-28	WOS:A1988N434800006
J	BOUCHARD, L; MATHIEU, F; BASTIN, M				BOUCHARD, L; MATHIEU, F; BASTIN, M			POLYOMA LARGE T CAN ACTIVATE MIDDLE T EXPRESSION BY A HIT-AND-RUN MECHANISM	ONCOGENE			English	Article									UNIV SHERBROOKE, DEPT MICROBIOL, SHERBROOKE J1H 5N4, QUEBEC, CANADA	University of Sherbrooke								ALT FW, 1978, J BIOL CHEM, V253, P1357; ALWINE JC, 1985, MOL CELL BIOL, V5, P1034, DOI 10.1128/MCB.5.5.1034; ASSELIN C, 1986, J VIROL, V57, P165, DOI 10.1128/JVI.57.1.165-172.1986; ASSELIN C, 1984, MOL CELL BIOL, V4, P755, DOI 10.1128/MCB.4.4.755; ASSELIN C, 1983, MOL CELL BIOL, V3, P1451, DOI 10.1128/MCB.3.8.1451; BIRD AP, 1980, GENE REITERATION GEN, V3, P61; BOUCHARD L, 1986, VIROLOGY, V155, P1, DOI 10.1016/0042-6822(86)90162-5; BOUCHARD L, 1984, VIROLOGY, V135, P53, DOI 10.1016/0042-6822(84)90116-8; BOUCHARD L, 1987, J VIROL, V61, P2448, DOI 10.1128/JVI.61.8.2448-2453.1987; BRADY J, 1984, P NATL ACAD SCI-BIOL, V81, P2040, DOI 10.1073/pnas.81.7.2040; COLBY WW, 1982, P NATL ACAD SCI-BIOL, V79, P5189, DOI 10.1073/pnas.79.17.5189; CROCE CM, 1985, BLOOD, V65, P1; CUZIN F, 1984, BIOCHIM BIOPHYS ACTA, V781, P193, DOI 10.1016/0167-4781(84)90084-8; FRIED M, 1965, VIROLOGY, V25, P669, DOI 10.1016/0042-6822(65)90098-X; GELINAS C, 1985, VIROLOGY, V146, P233, DOI 10.1016/0042-6822(85)90007-8; GREEN AR, 1986, EMBO J, V5, P707, DOI 10.1002/j.1460-2075.1986.tb04271.x; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; GRIFFIN BE, 1983, ADV CANCER RES, V39, P183, DOI 10.1016/S0065-230X(08)61036-2; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; IMPERIALE MJ, 1983, CELL, V35, P127, DOI 10.1016/0092-8674(83)90215-5; ITO Y, 1977, P NATL ACAD SCI USA, V74, P1259, DOI 10.1073/pnas.74.3.1259; KAMEN R, 1979, COLD SPRING HARB SYM, V44, P63, DOI 10.1101/SQB.1980.044.01.009; KELLER JM, 1984, CELL, V36, P381, DOI 10.1016/0092-8674(84)90231-9; KIMURA G, 1975, NATURE, V253, P639, DOI 10.1038/253639b0; KINGSTON RE, 1985, CELL, V41, P3, DOI 10.1016/0092-8674(85)90049-2; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; NOTTENBURG C, 1987, J VIROL, V61, P1828, DOI 10.1128/JVI.61.6.1828-1833.1987; PICHE A, 1987, J VIROL, V61, P845; RABBITTS TH, 1983, NATURE, V306, P806, DOI 10.1038/306806a0; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RASSOULZADEGAN M, 1978, J VIROL, V28, P421, DOI 10.1128/JVI.28.2.421-426.1978; RASSOULZADEGAN M, 1981, VIROLOGY, V114, P489, DOI 10.1016/0042-6822(81)90228-2; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RULEY HE, 1982, NUCLEIC ACIDS RES, V10, P4515, DOI 10.1093/nar/10.15.4515; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHAFFHAUSEN B, 1981, J VIROL, V40, P184, DOI 10.1128/JVI.40.1.184-196.1981; SEIF R, 1977, J VIROL, V24, P721, DOI 10.1128/JVI.24.3.721-728.1977; SMOLAR N, 1981, J VIROL, V38, P958, DOI 10.1128/JVI.38.3.958-967.1981; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOW ND, 1976, J GEN VIROL, V33, P447, DOI 10.1099/0022-1317-33-3-447; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; WAHL GM, 1979, J BIOL CHEM, V254, P8679; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	45	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1988	2	4					379	386						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3362552				2022-12-28	WOS:A1988M947200010
J	COLOMBO, MP; FERRARI, G; PARMIANI, G; WETTSTEIN, PJ				COLOMBO, MP; FERRARI, G; PARMIANI, G; WETTSTEIN, PJ			RETROVIRAL HETEROGENEITY IN MOUSE LYMPHOMAS	ONCOGENE			English	Article									WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	The Wistar Institute	COLOMBO, MP (corresponding author), IST NAZL STUDIO & CURA TUMORI,VIA VENEZIAN 1,I-20133 MILAN,ITALY.		Colombo, Mario P./V-7166-2017; Ferrari, Giuliana/AAB-5546-2019	Colombo, Mario P./0000-0003-0042-7955; Ferrari, Giuliana/0000-0003-0790-3133	NCI NIH HHS [CA-10815] Funding Source: Medline; PHS HHS [A1-16052] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACH FH, 1982, POTENTIAL ROLE T CEL, P7; BUCKLER CE, 1982, J VIROL, V41, P228, DOI 10.1128/JVI.41.1.228-236.1982; CARBONE G, 1983, INT J CANCER, V31, P483, DOI 10.1002/ijc.2910310414; CLARKE MF, 1983, NATURE, V305, P60, DOI 10.1038/305060a0; COLOMBO MP, 1987, P NATL ACAD SCI USA, V84, P189, DOI 10.1073/pnas.84.1.189; COLOMBO MP, 1983, IMMUNOBIOLOGY, V165, P186, DOI 10.1016/S0171-2985(83)80059-X; COLOMBO MP, 1987, IMMUNOGENETICS, V26, P99, DOI 10.1007/BF00345461; CUYPERS HT, 1984, CELL, V37, P141; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DUDLEY J, 1984, J VIROL, V49, P92, DOI 10.1128/JVI.49.1.92-101.1984; DUDLEY JP, 1986, J VIROL, V57, P385, DOI 10.1128/JVI.57.1.385-388.1986; GOODENOW RS, 1985, SCIENCE, V230, P777, DOI 10.1126/science.2997918; JAHN CL, 1980, CELL, V21, P159, DOI 10.1016/0092-8674(80)90123-3; JENKINS NA, 1981, NATURE, V293, P370, DOI 10.1038/293370a0; KING W, 1985, SCIENCE, V228, P554, DOI 10.1126/science.3838595; MAJORS JE, 1981, NATURE, V289, P253, DOI 10.1038/289253a0; MANN DL, 1983, NATURE, V305, P58, DOI 10.1038/305058a0; MCCOY JL, 1967, CANCER RES, V27, P1743; MERUELO D, 1984, P NATL ACAD SCI-BIOL, V81, P1804, DOI 10.1073/pnas.81.6.1804; MERUELO D, 1983, P NATL ACAD SCI-BIOL, V80, P5032, DOI 10.1073/pnas.80.16.5032; MICHALIDES R, 1985, MOL CELL BIOL, V5, P823, DOI 10.1128/MCB.5.4.823; MICHALIDES R, 1982, J VIROL, V43, P819, DOI 10.1128/JVI.43.3.819-829.1982; PAMPENO CL, 1986, J VIROL, V58, P296, DOI 10.1128/JVI.58.2.296-306.1986; PARMIANI G, 1979, IMMUNOGENETICS, V9, P1, DOI 10.1007/BF01570389; PARMIANI G, 1982, INT J CANCER, V29, P323, DOI 10.1002/ijc.2910290316; ROSSOMANDO A, 1986, IMMUNOGENETICS, V23, P233, DOI 10.1007/BF00373018; SCHNIEKE A, 1983, NATURE, V304, P315, DOI 10.1038/304315a0; SCHWARTZBERG P, 1983, J VIROL, V46, P538, DOI 10.1128/JVI.46.2.538-546.1983; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAYLOR BA, 1984, MOL GEN GENET, V195, P491, DOI 10.1007/BF00341452; TSICHLIS PN, 1983, NATURE, V302, P445, DOI 10.1038/302445a0; VARMUS HE, 1983, MOBILE GENETIC ELEME, P411; WEJMAN JC, 1984, J VIROL, V50, P237, DOI 10.1128/JVI.50.1.237-247.1984; WETTSTEIN PJ, 1986, IMMUNOGENETICS, V23, P156, DOI 10.1007/BF00373816; WIRSCHUBSKY Z, 1986, INT J CANCER, V38, P739, DOI 10.1002/ijc.2910380518	36	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					395	398						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	2896330				2022-12-28	WOS:A1988M947200012
J	DREBIN, JA; LINK, VC; GREENE, MI				DREBIN, JA; LINK, VC; GREENE, MI			MONOCLONAL-ANTIBODIES SPECIFIC FOR THE NEU ONCOGENE PRODUCT DIRECTLY MEDIATE ANTI-TUMOR EFFECTS INVIVO	ONCOGENE			English	Article									HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; UNIV PENN,SCH MED,DEPT LAB MED,DIV IMMUNOL,PHILADELPHIA,PA 19104	Harvard University; Harvard Medical School; University of Pennsylvania								BERG H, 1984, CELL, V36, P963; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; DREBIN JA, 1986, IMMUNOLOGY CANCER, P277; GREENE MI, 1979, AM J PATHOL, V95, P159; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HERLYN D, 1985, J IMMUNOL, V134, P1300; HOLLINGSWORTH MA, 1986, CANCER RES, V46, P2482; HOUGHTON AN, 1986, SEMIN ONCOL, V13, P165; HUDSON L, 1980, PRACTICAL IMMUNOLOGY, P117; JONES JF, 1980, J IMMUNOL, V125, P926; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; MASUI H, 1984, CANCER RES, V44, P1002; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; OI VT, 1984, NATURE, V307, P136, DOI 10.1038/307136a0; PEPYS MB, 1972, NATURE-NEW BIOL, V237, P157, DOI 10.1038/newbio237157a0; REISFELD RA, 1986, SEMIN ONCOL, V13, P153; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; ROTH JA, 1986, J IMMUNOL, V136, P2305; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TROWBRIDGE IS, 1981, NATURE, V294, P171, DOI 10.1038/294171a0; VOLLMERS HP, 1985, CELL, V40, P547, DOI 10.1016/0092-8674(85)90203-X; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; YOKOTA J, 1986, LANCET, V1, P765; YUNG YP, 1977, J IMMUNOL, V119, P1310	33	154	182	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					387	394						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	2896329				2022-12-28	WOS:A1988M947200011
J	BOULTER, CA; WAGNER, EF				BOULTER, CA; WAGNER, EF			THE EFFECTS OF V-SRC EXPRESSION ON THE DIFFERENTIATION OF EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article											BOULTER, CA (corresponding author), EUROPEAN MOLEC BIOL LAB,POSTFACH 102209,D-6900 HEIDELBERG,FED REP GER.		Boulter, Catherine/A-6607-2010	Wagner, Erwin F/0000-0001-7872-0196				ADAMSON ED, 1987, DEVELOPMENT, V99, P449; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ANDERSON SM, 1983, J VIROL, V46, P594, DOI 10.1128/JVI.46.2.594-605.1983; BELL JC, 1986, MOL CELL BIOL, V6, P617, DOI 10.1128/MCB.6.2.617; BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; BOETTIGER D, 1983, MOL CELL BIOL, V3, P1518, DOI 10.1128/MCB.3.8.1518; BOETTIGER D, 1977, CELL, V11, P881, DOI 10.1016/0092-8674(77)90299-9; BOETTIGER D, 1984, CELL, V36, P763, DOI 10.1016/0092-8674(84)90356-8; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; CZERNILOFSKY AP, 1983, NATURE, V301, P736, DOI 10.1038/301736b0; DOLBERG DS, 1984, NATURE, V309, P552, DOI 10.1038/309552a0; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISZMAN MY, 1975, NATURE, V254, P429, DOI 10.1038/254429a0; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; Graham C.F, 1977, CONCEPTS MAMMALIAN E, P315; HEATH JK, 1985, CIBA F SYMP, V116, P3; HEATH JK, 1983, CANCER SURV, V2, P141; HOLTZER H, 1975, P NATL ACAD SCI USA, V72, P4051, DOI 10.1073/pnas.72.10.4051; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KAHN P, 1984, P NATL ACAD SCI-BIOL, V81, P7122, DOI 10.1073/pnas.81.22.7122; KEANE RW, 1984, DEV BIOL, V103, P38, DOI 10.1016/0012-1606(84)90005-8; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KELLERMANN O, 1986, DIFFERENTIATION, V32, P74, DOI 10.1111/j.1432-0436.1986.tb00558.x; LEV Z, 1984, MOL CELL BIOL, V4, P982, DOI 10.1128/MCB.4.5.982; LEVINE JM, 1986, J NEUROSCI, V6, P3374; LEVY BT, 1984, DEV BIOL, V104, P9, DOI 10.1016/0012-1606(84)90031-9; LINNEY E, 1984, NATURE, V308, P470, DOI 10.1038/308470a0; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; MANESS PF, 1986, DEV BIOL, V117, P83, DOI 10.1016/0012-1606(86)90350-7; MANIATIS T, 1982, MOL CLONING LABORATO; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; MUMMERY CL, 1987, DEV BIOL, V121, P10, DOI 10.1016/0012-1606(87)90133-3; PACIFICI M, 1977, CELL, V11, P891, DOI 10.1016/0092-8674(77)90300-2; ROSSANT J, 1982, J EMBRYOL EXP MORPH, V70, P99; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SEJERSEN T, 1985, EXP CELL RES, V160, P19, DOI 10.1016/0014-4827(85)90232-0; SEJERSEN T, 1986, J CELL PHYSIOL, V127, P274, DOI 10.1002/jcp.1041270213; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SLAMON DJ, 1984, P NATL ACAD SCI-BIOL, V81, P7141, DOI 10.1073/pnas.81.22.7141; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SPOONCER E, 1984, NATURE, V310, P228, DOI 10.1038/310228a0; STEWART CL, 1985, EMBO J, V4, P3701, DOI 10.1002/j.1460-2075.1985.tb04138.x; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; WEISS RA, 1982, RNA TUMOUR VIRUSES; YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194	56	37	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					207	214						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3127777				2022-12-28	WOS:A1988M593100001
J	ZHOU, DJ; CASEY, G; CLINE, MJ				ZHOU, DJ; CASEY, G; CLINE, MJ			AMPLIFICATION OF HUMAN INT-2 IN BREAST CANCERS AND SQUAMOUS CARCINOMAS	ONCOGENE			English	Article									ICI PLC,CORP BIOSCI GRP,RUNCORN,CHESHIRE,ENGLAND		ZHOU, DJ (corresponding author), UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT MED,LOS ANGELES,CA 90024, USA.							CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DICKSON C, 1987, NATURE, V326, P823; JOHNSTON RN, 1983, P NATL ACAD SCI-BIOL, V80, P3711, DOI 10.1073/pnas.80.12.3711; JOKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806; KOO FT, 1987, P NATL ACAD SCI US, V84, P2877; MASUDA H, IN PRESS CLIN MOL ME; Moore D H, 1979, Adv Cancer Res, V29, P347, DOI 10.1016/S0065-230X(08)60850-7; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; PETERS G, 1984, NATURE, V309, P273, DOI 10.1038/309273a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VARMUS HE, 1982, CANCER SURV, V2, P309; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	14	160	163	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					279	282						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	2895446				2022-12-28	WOS:A1988M593100011
J	RUSCIANO, D; LORENZONI, P; BURGER, MM				RUSCIANO, D; LORENZONI, P; BURGER, MM			EXPRESSION OF CONSTITUTIVELY ACTIVATED HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR-RECEPTOR (C-MET) IN B16 MELANOMA-CELLS SELECTED FOR ENHANCED LIVER COLONIZATION	ONCOGENE			English	Article						B16 MELANOMA; C-MET; LIVER; METASTASIS	TYROSINE KINASE; B-16 MELANOMA; HOST ORGAN; PROTOONCOGENE; METASTASIS; MOTILITY; LINES	The murine melanoma B16-LS9 cell line was obtained after repeated passages in vivo through the liver of syngeneic mice, and shows an enhanced ability to colonize the liver after intravenous inoculation when compared to its parental, unselected counterpart B16-F1. We have previously shown that paracrine growth effects mainly account for better growth of B16-LS9 in the liver than at other sites, and more recently we reported hepatic transferrin as a factor contributing to efficient growth in the liver. Here we show that increased expression of constitutively activated c-met (the receptor for Hepatocyte Growth Factor/Scatter Factor) consistently occurs during selection of B16 cells through the liver. Constitutive activation of c-met seems to follow its own overexpression and not to depend on an autocrine mechanism. As a consequence, liver-selected B16 melanoma cells have higher tyrosine-kinase activity and higher amounts of tyrosine-phosphorylated proteins than parental B16-F1 or lung-specific B16-F10 cells. Overexpression of constitutively activated c-met enhances motility and invasiveness of B16-LS9 cells, presumably favoring their colonization efficiency in vivo. However, whether levels of c-met expression also determine the organ-specificity of B16 melanoma cells needs further clarification.			RUSCIANO, D (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.			RUSCIANO, DARIO/0000-0002-9577-2585				BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRUNSON KW, 1979, J SUPRAMOL STR CELL, V11, P517, DOI 10.1002/jss.400110410; CHANG JH, 1993, ONCOGENE, V8, P959; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GIORDANO S, 1989, ONCOGENE, V4, P1383; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HALABAN R, 1992, ONCOGENE, V7, P2195; KOMADA M, 1993, ONCOGENE, V8, P2381; MINER KM, 1982, CANCER RES, V42, P4631; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MIZUNO K, 1993, HEPATOCYTE GROWTH FA, P1; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; POSTE G, 1980, CANCER RES, V40, P1636; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RUSCIANO D, 1994, INVAS METAST, V14, P349; RUSCIANO D, 1993, INVAS METAST, V13, P212; SARGENT NSE, 1988, P NATL ACAD SCI USA, V85, P7251, DOI 10.1073/pnas.85.19.7251; TAO T, 1979, INT J CANCER, V23, P854, DOI 10.1002/ijc.2910230618; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; YANAGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P802, DOI 10.1016/0006-291X(92)91803-X; ZHEN Z, 1994, ONCOGENE, V9, P1691	30	45	46	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					1979	1987						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478516				2022-12-28	WOS:A1995TF29700007
J	RUSSO, D; ARTURI, F; SCHLUMBERGER, M; CAILLOU, B; MONIER, R; FILETTI, S; SUAREZ, HG				RUSSO, D; ARTURI, F; SCHLUMBERGER, M; CAILLOU, B; MONIER, R; FILETTI, S; SUAREZ, HG			ACTIVATING MUTATIONS OF THE TSH RECEPTOR IN DIFFERENTIATED THYROID CARCINOMAS	ONCOGENE			English	Note						THYROTROPIN RECEPTOR; HYPERFUNCTIONING; ADENYLYL CYCLASE; CYCLIC AMP RAS ONCOGENE; GSP ONCOGENE	HUMAN THYROTROPIN RECEPTOR; HUMAN ENDOCRINE TUMORS; ALPHA-SUBUNIT; EXPRESSION; ONCOGENE; ADENOMAS; CLONING; GENE; RAS	A series of 14 thyroid carcinomas, characterized for their basal adenyl cyclase activity (ACA), was examined for the presence of activating point mutations in the TSH receptor (TSHR) gene, Sequencing of the carboxyl-part of this gene revealed the presence of a somatic and heterozygotic point mutation in codon 623 in three out of six tumors showing a constitutively enhanced ACA and a poor response to TSH stimulation. The mutation determines the substitution of a serine for an alanine in the third intracellular loop of the receptor, in a region critical for signal transduction. One tumor bearing a TSHR mutation presented also a N-ras point mutation. Both mutations were detected also in a lung metastasis of this tumor, Our data represent the first report of alterations in the TSHR gene in thyroid malign neoplasia, TSHR mutations may indeed participate, as web as the G alpha(s) protein (gsp oncogene), in the oncogenesis of some differentiated thyroid carcinomas presenting increased basal levels of cAMP and a poor response to TSH.	INST RECH SCI CANC,IFC 01,GENET MOLEC LAB,CNRS,UPR 42,F-94801 VILLEJUIF,FRANCE; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,CATTEDRA ENDOCRINOL,I-88100 CATANZARO,ITALY; UNIV REGGIO CALABRIA,FAC FARM,CATTEDRA FARMACOL,I-88100 CATANZARO,ITALY; INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universita Mediterranea di Reggio Calabria; Universita Mediterranea di Reggio Calabria; UNICANCER; Gustave Roussy				ARTURI, Franco/0000-0002-1660-1228				AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; CHAZENBALK GD, 1991, MOL ENDOCRINOL, V5, P1523, DOI 10.1210/mend-5-10-1523; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; DEVRIES MV, 1986, GENE, V50, P313; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; DUMONT JE, 1989, METABOLIC BASIS INHE; GAIDDON C, 1994, J BIOL CHEM, V269, P22663; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LIEBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MATSUO K, 1993, J CLIN ENDOCR METAB, V76, P1446, DOI 10.1210/jc.76.6.1446; MAZZAFERRI EL, 1993, AM J MED, V97, P1446; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PASCHKE R, 1994, J CLIN ENDOCR METAB, V79, P1785, DOI 10.1210/jc.79.6.1785; PORCELLINI A, 1994, J CLIN ENDOCR METAB, V79, P657, DOI 10.1210/jc.79.2.657; RUSSO D, 1995, J CLIN ENDOCR METAB, V80, P1347, DOI 10.1210/jc.80.4.1347; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1990, ONCOGENE, V5, P565; THOMASMORVAN C, 1982, ACTA ENDOCRINOL-COP, V101, P25, DOI 10.1530/acta.0.1010025; WYNFORDTHOMAS D, 1993, CRIT REV ONCOGENESIS, V4, P1; YOSHIMOTO K, 1993, CANCER, V72, P1386, DOI 10.1002/1097-0142(19930815)72:4<1386::AID-CNCR2820720439>3.0.CO;2-J	30	112	119	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1907	1911						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478621				2022-12-28	WOS:A1995TD09400028
J	RAMOSMORALES, F; ROMERO, F; SCHWEIGHOFFER, F; BISMUTH, G; CAMONIS, J; TORTOLERO, M; FISCHER, S				RAMOSMORALES, F; ROMERO, F; SCHWEIGHOFFER, F; BISMUTH, G; CAMONIS, J; TORTOLERO, M; FISCHER, S			THE PROLINE-RICH REGION OF VAV BINDS TO GRB2, AND GRB3-3	ONCOGENE			English	Note						VAV; GRB2; GRB3-3; SH3; PROLINE-RICH; APOPTOSIS	GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; SH3 DOMAINS; RAS; PROTEIN; ACTIVATION; PROTOONCOGENE; ASSOCIATION; HOMOLOGY; GENE	Vav has structural features found in signaling proteins and is expressed only in hematopoietic cells. The recent development of mice Vav (-/-) has confirmed a major role of Vav in early blood cell development. We previously showed that Vav constitutively interacts with glutathione-S-transferase-Grb2. Coimmunoprecipitation experiments supported the idea of a complex formed by Vav-Grb2 in vivo. This complex is of potential interest in signaling of hematopoietic cells. In this work we localize the domains of Vav and Grb2 involved in this interaction. By the use of an in vivo genetic approach (the double hybrid system) and through in vitro experiments (glutathione-S-transferase fusion proteins) me furnish evidence that the interaction between Vav and Grb2 involves the C-SH3 domain of Grb2 and the proline-rich region located in the N-SH3 of Vav. Furthermore this was confirmed by the use of both Vav and Sos derived proline-rich peptides which blocked the binding. Tn addition me show that Vav also interacts with Grb3-3, a naturally occurring Grb2 isoform wich lacks functional SH2 domain.	UNIV SEVILLA,FAC BIOL,DEPT MICROBIOL,E-41080 SEVILLE,SPAIN; RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,F-94403 VITRY,FRANCE; CHU PITIE SALPETRIERE,CERVI,IMMUNOL CELLULARE & TISSULAIRE LAB,CNRS,URA 625,PARIS,FRANCE; INSERM,U248,F-75010 PARIS,FRANCE	University of Sevilla; Sanofi-Aventis; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	RAMOSMORALES, F (corresponding author), HOP COCHIN,INST COCHIN GENET MOLEC,INSERM,U363,27 RUE FAUBOURG ST JACQUES,F-75014 PARIS,FRANCE.		Romero, Francisco/K-2101-2014; Tortolero, Maria/K-5744-2014; Ramos-Morales, Francisco/C-5734-2008	Romero, Francisco/0000-0002-9588-6881; Tortolero, Maria/0000-0003-1797-9940; Ramos-Morales, Francisco/0000-0002-1151-4547				ADAMS JM, 1992, ONCOGENE, V7, P611; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GULBINS E, 1994, J IMMUNOL, V152, P2123; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HOBERT O, 1994, J BIOL CHEM, V269, P20225; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOCH CA, 1991, SCIENCE, V252, P688; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MIKI H, 1994, J BIOL CHEM, V269, P5489; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sherman F., 1986, METHODS YEAST GENETI; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TOBE K, 1993, J BIOL CHEM, V268, P11167; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	41	50	53	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1665	1669						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478592				2022-12-28	WOS:A1995TC53500026
J	YAO, R; COOPER, GM				YAO, R; COOPER, GM			REGULATION OF THE RAS SIGNALING PATHWAY BY GTPASE-ACTIVATING PROTEIN IN PC12 CELLS	ONCOGENE			English	Article						RAS; GAP; PC12 CELLS	NERVE GROWTH-FACTOR; NIH 3T3 CELLS; MAP KINASE; SACCHAROMYCES-CEREVISIAE; COMPLEX-FORMATION; THREONINE KINASE; MAMMALIAN-CELLS; FACTOR RECEPTOR; GENE-PRODUCT; HA-RAS	We have investigated the role of Pas GTPase-activating protein (GAP) in NGF-induced neuronal differentiation by overexpressing both wild-type and membrane-targeted GAP in PC12 cells. Extension of neurites in response to NGF was completely blocked in cells expressing the highest level of membrane-targeted GAP and significantly inhibited in cells expressing either wild-type GAP or lower levels of membrane-targeted GAP. Overexpression of membrane-targeted GAP similarly inhibited induction of differentiation by src, but not by ras or raf oncogenes, indicating that GAP inhibits differentiation of PC12 cells by downregulating Ras function. GAP overexpression also inhibited stimulation of mitogen-activated protein (MAP) kinase and induction of immediate-early genes in response to NGF. In cells expressing wild-type GAP or lower levels of membrane-targeted GAP, the initial activation of MAP kinase and immediate-early gene expression were only partially inhibited. However, GAP expression in these cells resulted in substantial inhibition of sustained MAP kinase activity following NGF treatment, consistent with the inhibition of neurite extension in these cell lines. These results indicate that GAP acts as a negative regulation, rather than an effector, of Ras signaling in PC12 cells.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER; NCI NIH HHS [CA18689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ALALAWI N, 1993, MOL CELL BIOL, V13, P2497, DOI 10.1128/MCB.13.4.2497; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SZEBERENYI J, 1992, ONCOGENE, V7, P2105; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	58	19	20	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1607	1614						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478585				2022-12-28	WOS:A1995TC53500019
J	ROZAKISADCOCK, M; VANDERGEER, P; MBAMALU, G; PAWSON, T				ROZAKISADCOCK, M; VANDERGEER, P; MBAMALU, G; PAWSON, T			MAP KINASE PHOSPHORYLATION OF MSOS1 PROMOTES DISSOCIATION OF MSOS1-SHC AND MSOS1-EGF RECEPTOR COMPLEXES	ONCOGENE			English	Article						MAP KINASE PHOSPHORYLATION; EXCHANGE FACTORS; MSOS1; SHC; EGF RECEPTOR	NUCLEOTIDE EXCHANGE FACTOR; EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; RAS ACTIVATOR; GUANINE-NUCLEOTIDES; TYROSINE KINASES; ADAPTER PROTEIN; C-JUN; GRB2	The mouse protein mSos1 has a central Ras guanine nucleotide exchange domain, and a long proline-rich C-terminal tail which contains several potential binding sites for the SH3 domains of the adaptor protein, Grb2. In fibroblasts, growth factor stimulation results in the recruitment of Grb2-mSos1 into complexes with activated receptors and cytoplasmic phosphoproteins such as Shc, which are apparently involved in Ras activation, and subsequently to an increase in mSos1 phosphorylation on serine and threonine, The catalytic and C-terminal domains of mSos1 contain several potential sites for phosphorylation by mitogen-activated protein kinases. In vitro, purified p42/p44 MAP-kinase selectively phosphorylated the C-terminal tail of mSos1. Comparative tryptic phosphopeptide mapping of mSos1 phosphorylated in vitro by MAP kinase and of mSos1 immunoprecipitated from EGF-stimulated cells, revealed several phosphopeptides in common. These common phosphorylation sites have been mapped to a region encompassing the first three proline (pro)-rich motifs in the tail of mSos1. Furthermore, a region of mSos1 containing the first two pro-rich motifs could associate with MBP kinase activity in vitro. Phosphorylation of mSos1 did not affect binding of Grb2 to mSos1, but appeared to decrease binding of the mSos1-Grb2 complex to She and the EGF-receptor. These findings suggest a potential inhibitory role for MAP-kinase in attenuating nucleotide exchange on Ras, by uncoupling mSos1 from membrane-bound receptor complexes that lead to Ras activation.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAMME MOLEC BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON M5S 1A8, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Pawson, Tony J/E-4578-2013					ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FUCHS A, 1995, J BIOL CHEM, V270, P5695, DOI 10.1074/jbc.270.11.5695; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LEE RM, 1992, J BIOL CHEM, V267, P1088; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON, 1995, CELL; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; WANG W, 1995, IN PRESS NATURE GENE; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	41	76	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1417	1426						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478566				2022-12-28	WOS:A1995RY96700026
J	LYMAN, SD; STOCKING, K; DAVISON, B; FLETCHER, F; JOHNSON, L; ESCOBAR, S				LYMAN, SD; STOCKING, K; DAVISON, B; FLETCHER, F; JOHNSON, L; ESCOBAR, S			STRUCTURAL-ANALYSIS OF HUMAN AND MURINE FLT3 LIGAND GENOMIC LOCI	ONCOGENE			English	Article						FLT3 LIGAND; GROWTH FACTORS; HEMATOPOIESIS; TYROSINE KINASE RECEPTORS	COLONY-STIMULATING FACTOR; MESSENGER-RNA PRECURSORS; CELL GROWTH-FACTOR; MOLECULAR-CLONING; HUMAN CSF-1; KIT-LIGAND; EXPRESSION; GENE; PROTEIN; FORMS	Both the murine and human genomic loci that encode flt3 ligand have been cloned, flt3 ligand is a hematopoietic growth factor that stimulates the proliferation of stem and progenitor cells, The portions of the murine and human flt3 ligand genomic loci encompassing the coding region of the protein are approximately 4.0 kb and 5.9 kb, respectively. The human genomic locus is larger as a result of the presence of repeated sequences within introns I, II, IV, V and VI, The transmembrane isoform of the murine and human flt3 ligand proteins are each encoded within seven exons (1-5+7 and 8), Analyses of flt3 ligand cDNA clones show that alternative splicing of a putative sixth exon results in the generation of a soluble form of the flt3 ligand protein, The sizes of each of the exons are well conserved between species, Murine and human flt3 genomic loci have a similar exon:intron structure compared to the genomic loci encoding Steel factor and colony stimulating factor 1. These proteins, which appear to be ancestrally related, are hematopoietic growth factors that stimulate cells via specific and structurally related tyrosine kinase receptors on the cell surface.			LYMAN, SD (corresponding author), IMMUNEX RES & DEV CORP,51 UNIV ST,SEATTLE,WA 98101, USA.							ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDERSON DM, 1991, CELL GROWTH DIFFER, V2, P373; BRANNAN CI, 1992, GENE DEV, V6, P1832, DOI 10.1101/gad.6.10.1832; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; CERRETTI DP, 1988, MOL IMMUNOL, V25, P761, DOI 10.1016/0161-5890(88)90112-5; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; KAWASAKI ES, 1990, COLONY STIMULATING F, P155; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; Lyman S D, 1995, Curr Opin Hematol, V2, P177; LYMAN SD, 1995, ONCOGENE, V10, P149; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; LYMAN SD, 1994, BLOOD, V83, P2795, DOI 10.1182/blood.V83.10.2795.2795; LYMAN SD, 1994, STEM CELLS, V12, P99; MAJUMDAR MK, 1994, J BIOL CHEM, V269, P1237; MAKALOWSKI W, 1994, TRENDS GENET, V10, P98; MARASKOVSKY E, 1993, CELL, V75, P1157; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; ROSS CA, 1993, TRENDS NEUROSCI, V16, P254, DOI 10.1016/0166-2236(93)90175-L; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529	23	30	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1165	1172						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566977				2022-12-28	WOS:A1995RX18000020
J	LIEBERMANN, DA; HOFFMAN, B; STEINMAN, RA				LIEBERMANN, DA; HOFFMAN, B; STEINMAN, RA			MOLECULAR CONTROLS OF GROWTH ARREST AND APOPTOSIS - P53-DEPENDENT AND INDEPENDENT PATHWAYS	ONCOGENE			English	Review						APOPTOSIS; GROWTH ARREST; P53; DIFFERENTIATION; HEMATOPOIESIS	PROGRAMMED CELL-DEATH; MYELOID LEUKEMIC-CELLS; WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; CONSTITUTIVE C-MYC; ATAXIA-TELANGIECTASIA; TERMINAL DIFFERENTIATION; NUCLEAR ANTIGEN; GENE-EXPRESSION; RESPONSE GENE	Cell homeostasis is regulated by a balance between proliferation, growth arrest and programmed cell death (apoptosis). Until recently, studies on oncogenesis have focused on the regulation of cell proliferation. The recognition that negative growth control, including growth arrest and programmed cell death, must be understood to comprehend how appropriate cell numbers are maintained and how alterations in any part of the equation can contribute to malignancy has led to a burst of work in this field. This review focuses on what has been learned about distinct settings of negative growth control, analyzing p53-dependent and independent pathways of growth arrest and apoptosis either coupled or uncoupled from differentiation, with an emphasis on the use of hematopoietic cells. The importance of understanding the molecular biology of apoptotic and growth arrest pathways in cancer therapy, and future directions to study negative growth control are addressed as well.	UNIV PITTSBURGH, SCH MED, PITTSBURGH CANC INST, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, SCH MED, DEPT MED, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	LIEBERMANN, DA (corresponding author), TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA.							ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ALBERTS B, 1994, MOL BIOL CELL, pCH21; ANTOUN GR, 1991, LEUKEMIA RES, V15, P1029, DOI 10.1016/0145-2126(91)90108-6; ASKEW DS, 1991, ONCOGENE, V6, P1915; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BUSSE PM, 1977, RADIAT RES, V71, P666, DOI 10.2307/3574634; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DIETRICH DR, 1993, CRIT REV TOXICOL, V23, P77, DOI 10.3109/10408449309104075; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; FURUKAWA Y, 1994, CANCER RES, V54, P6533; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUILLOUF C, 1995, IN PRESS ONCOGEN JUN; GUILLOUF C, 1995, IN PRESS BLOOD   MAY; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOFFMANLIEBERMANN B, 1981, INT J CANCER, V28, P615, DOI 10.1002/ijc.2910280514; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IMRAY FP, 1983, MUTAT RES, V112, P369; JIANG HP, 1994, ONCOGENE, V9, P3397; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIYOKAWA H, 1993, P NATL ACAD SCI USA, V90, P6746, DOI 10.1073/pnas.90.14.6746; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KORSMEYER SJ, 1992, BLOOD, V80, P879; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KSHIMOTO T, 1992, SCIENCE, V258, P593; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIEBERMANN D, 1981, INT J CANCER, V28, P285, DOI 10.1002/ijc.2910280306; Liebermann D A, 1994, Curr Opin Hematol, V1, P24; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; LIN EY, 1993, J IMMUNOL, V151, P1979; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; LOTEM J, 1992, BLOOD, V80, P1750; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MARX J, 1993, SCIENCE, V259, P760, DOI 10.1126/science.8430327; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCGEOCH DJ, 1991, NATURE, V353, P609, DOI 10.1038/353609b0; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NATARAJAN AT, 1980, HUM GENET, V54, P183, DOI 10.1007/BF00278969; NEVINS JR, 1992, SCIENCE, V258, P424; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OBERG F, 1991, P NATL ACAD SCI USA, V88, P5567, DOI 10.1073/pnas.88.13.5567; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; QUENSBERY PJ, 1994, WILLIAMS HEMATOLOGY, pCH22; REES JJ, 1994, CELL BIOIL, V124, P1; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; RUSCETTI F, 1993, ANN NY ACAD SCI, V685, P488, DOI 10.1111/j.1749-6632.1993.tb35911.x; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1994, BLOOD, V84, P1036; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIMIZU T, 1995, CANCER RES, V55, P228; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOLARY E, 1994, LEUKEMIA LYMPHOMA, V15, P21, DOI 10.3109/10428199409051674; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STEWART N, 1995, ONCOGENE, V10, P109; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TARUNINA M, 1993, ONCOGENE, V8, P3165; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALDREN CA, 1978, RADIAT RES, V73, P95, DOI 10.2307/3574576; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WANG YS, 1993, ONCOGENE, V8, P3427; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1985, ANTICANCER RES, V5, P131; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YEN A, 1993, CANCER RES, V53, P3085; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743	173	294	301	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	1995	11	1					199	210						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624128				2022-12-28	WOS:A1995RJ29500023
J	MATSUGI, T; KREIDER, BL; DELWEL, R; CLEVELAND, JL; ASKEW, DS; IHLE, JN				MATSUGI, T; KREIDER, BL; DELWEL, R; CLEVELAND, JL; ASKEW, DS; IHLE, JN			THE EVI-1 ZINC-FINGER MYELOID TRANSFORMING PROTEIN BINDS TO GENOMIC FRAGMENTS CONTAINING (GATA)(N) SEQUENCES	ONCOGENE			English	Article						EVI-1; BINDING; GATA ELEMENTS	COLONY-STIMULATING FACTOR; RETROVIRAL INSERTIONS; VIRAL INTEGRATION; GENE; DNA; EXPRESSION; IDENTIFICATION; TRANSCRIPTION; DIFFERENTIATION; SPECIFICITY	The EVI1 gene is activated by chromosomal translocations and inversions in approximately 5% of human acute myeloid leukemia (AML) and by retroviral insertion in approximately 20% of murine myeloid leukemias, EVI1 encodes a nuclear DNA-binding protein having 10 zinc finger motifs in two noncontiguous domains consisting of an amino-terminal domain of seven fingers and a carboxyl domain containing three fingers, To evaluate the sequence specificity of Evi-1 binding and potentially identify genomic targets, whole-genome PCR was utilized to isolate multiple Sau3A fragments which specifically bind to the amino-terminal zinc finger domain, The majority of these clones represented single copy sequences and virtually all contained variable numbers of repeats of the GATA motif, the target sequence for the erythroid-specific transcription factor GATA-1, GST/Evi-1 fusion proteins containing the amino-terminal domain of zinc fingers bound the GATA motif in these clones as well as to those present in the human gamma-globin promoter, similar to the binding of purified GATA-1 protein, By obtaining corresponding large genomic clones for eight of these fragments, transcription units were found associated with two. One corresponded to the glyceraldehyde-3-phosphate dehydrogenase gene and its expression was not affected by Evi-1, The second is a novel gene whose expression is repressed in murine myeloid cell lines that express Evi-1.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; UNIV CINCINNATI, DEPT PATHOL, CINCINNATI, OH USA; ERASMUS UNIV ROTTERDAM, ROTTERDAM, NETHERLANDS; HUMAN GENOME SCI, ROCKVILLE, MD 20859 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University System of Ohio; University of Cincinnati; Erasmus University Rotterdam; GlaxoSmithKline; Human Genome Sciences Inc				Askew, David/0000-0002-6477-2515	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NIDDK NIH HHS [DK 42932, DK 44150] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKEW DS, 1991, ONCOGENE, V6, P2041; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BELLOMO MJ, 1992, CANCER GENET CYTOGEN, V59, P138, DOI 10.1016/0165-4608(92)90208-P; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7344; DURBIN EJ, 1989, CHROMOSOMA, V97, P301, DOI 10.1007/BF00371970; FICHELSON S, 1992, LEUKEMIA, V6, P93; FUNABIKI T, 1994, ONCOGENE, V9, P1575; KELLER AD, 1991, NUCLEIC ACIDS RES, V19, P4675, DOI 10.1093/nar/19.17.4675; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; SINGH L, 1984, CELL, V36, P111, DOI 10.1016/0092-8674(84)90079-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOMPAYRAC L, 1990, P NATL ACAD SCI USA, V87, P3274, DOI 10.1073/pnas.87.9.3274	27	16	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					191	198						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624127				2022-12-28	WOS:A1995RJ29500022
J	LIN, PH; SHENOY, S; GALITSKI, T; SHALLOWAY, D				LIN, PH; SHENOY, S; GALITSKI, T; SHALLOWAY, D			TRANSFORMATION OF MOUSE CELLS BY WILD-TYPE MOUSE C-SRC	ONCOGENE			English	Note						SRC; SPECIES-SPECIFIC; TRANSFORMATION	NIH 3T3 CELLS; PROTEIN-KINASE; V-SRC; NUCLEOTIDE-SEQUENCE; TYROSINE KINASE; TERMINAL REGION; PP60C-SRC; ACTIVATION; P60C-SRC; GENE	Previous studies in which chicken and human c-Src were overexpressed in chicken and rodent cells have indicated that overexpression of wild-type c-Src can not induce complete neoplastic transformation. However, studies with v-Src mutants have demonstrated that species-specific differences can play a significant role in transforming activity. Here we show that, in contrast to chicken c-Src, overexpressed mouse c-Src can induce significant anchorage-independent growth and tumori- genicity when transfected into NIH3T3 mouse cells. The biochemical cause for this difference is unknown. In particular, the protein-tyrosine kinase activities of chicken and mouse c-Src appear to be similar. This result is consistent with the hypothesis that v-Src-induced transformation results from perturbation of signalling pathways modulated by c-Src and highlights the need for caution in controlling for potential species-specific differences in studies of c-Src function.	CORNELL UNIV, BIOCHEM MOLEC & CELL BIOL SECT, ITHACA, NY 14853 USA	Cornell University			Lin, Pei-Hui/I-3011-2015	Lin, Pei-Hui/0000-0002-3894-5099	NATIONAL CANCER INSTITUTE [R01CA008964, R01CA032317] Funding Source: NIH RePORTER; NCI NIH HHS [CA08964, CA32317] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEVY BT, 1984, DEV BIOL, V104, P9, DOI 10.1016/0012-1606(84)90031-9; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; Potts W. M., 1989, ONCOGENE RES, V3, P343; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SHALLOWAY D, 1991, ADV CANCER RES, V57, P185; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VERDERAME MF, 1994, ONCOGENE, V9, P175; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453	35	29	29	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	1995	10	2					401	405						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7530829				2022-12-28	WOS:A1995QC62400020
J	SPANDAU, DF				SPANDAU, DF			DISTINCT CONFORMATIONS OF P53 ARE OBSERVED AT DIFFERENT STAGES OF KERATINOCYTE DIFFERENTIATION	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; SV40-TRANSFORMED CELLS; CELLULAR PROTEIN; GROWTH ARREST; E6 PROTEINS; ANTIGEN; MUTATIONS; BINDING	p53 is a multifunctional protein that has been shown to inhibit the growth of transformed cells, arrest the cell cycle of normal cells, regulate gene transcription and influence cellular differentiation, apoptosis and senescence. This study was undertaken to determine if the expression of p53 in keratinocytes varied during epidermal differentiation. Fresh frozen-sections of normal human epidermis were subjected to immunofluorescence using a panel of anti-p53 monoclonal antibodies. The monoclonal antibody 122 specifically stained the basal layer of the epidermis. No staining was observed in other cell layers of the epidermis using the 122 antibody. When the 240 antibody was used, p53 was only detected in granular layer cells. No other anti-p53 monoclonal antibody stained normal epidermis. Immunofluorescent analyses of cultured keratinocytes revealed staining patterns that correlated with the staining pattern seen in vivo. Immunoprecipitation assays of the cultured keratinocytes indicated that each monoclonal antibody, with the exception of DO-1, could only detect a fraction of the total p53 present in the cultures. This diversity of reactivity was presumed to be due to the masking and exposing of the various epitopes on p53 through the binding of other proteins. Finally, in cultured human keratinocytes, p53 was found to be a relatively stable protein with a half-life of 5 h.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis	SPANDAU, DF (corresponding author), INDIANA UNIV,SCH MED,DEPT DERMATOL,MED LIB BLDG,RM 349,975 W WALNUT ST,INDIANAPOLIS,IN 46202, USA.							AGOFF SN, 1993, SCIENCE, V259, P854; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRITSCHE M, 1993, ONCOGENE, V8, P307; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HELANDER SD, 1993, J AM ACAD DERMATOL, V29, P741, DOI 10.1016/0190-9622(93)70240-T; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KASTAN MB, 1991, CANCER RES, V51, P4279; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAM NJ, 1993, CANCER RES, V53, P2235; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MOLES JP, 1993, ONCOGENE, V8, P583; MONTENARH M, 1992, ONCOGENE, V7, P1673; RADY P, 1992, CANCER RES, V52, P3804; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SUZUKI K, 1992, BIOCHEM BIOPH RES CO, V183, P1175, DOI 10.1016/S0006-291X(05)80314-6; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	39	62	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1861	1868						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	7516060				2022-12-28	WOS:A1994NR68500008
J	TSUKADA, T; TOMOOKA, Y; TAKAI, S; UEDA, Y; NISHIKAWA, S; YAGI, T; TOKUNAGA, T; TAKEDA, N; SUDA, Y; ABE, S; MATSUO, I; IKAWA, Y; AIZAWA, S				TSUKADA, T; TOMOOKA, Y; TAKAI, S; UEDA, Y; NISHIKAWA, S; YAGI, T; TOKUNAGA, T; TAKEDA, N; SUDA, Y; ABE, S; MATSUO, I; IKAWA, Y; AIZAWA, S			ENHANCED PROLIFERATIVE POTENTIAL IN CULTURE OF CELLS FROM P53-DEFICIENT MICE	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; EMBRYONIC STEM-CELLS; GERM-LINE CHIMERAS; WILD-TYPE P53; SPONTANEOUS IMMORTALIZATION; CYCLE CHECKPOINT; EPITHELIAL-CELLS; MESSENGER-RNA; GENE; FIBROBLASTS	Normal somatic cells are endowed with limited doubling potential in culture, and the process of immortalization is an inevitable step in neoplastic transformation of the cells. To examine the roles of p53 in this process, the cells of p53-deficient mice were examined for doubling potential. Fibroblast-like cells from a variety of tissues of these mice proliferated continuously without showing aging or crisis. The aneuploid cells overcome the population with passage, but cloning experiment indicated that chromosomal changes were not essential to this process. The enhanced proliferative potential in culture of cells from the p53-deficient mice was also observed in epithelial cells of lens, mammary glands and seminal vesicles and in neural precursor cells. Proliferation of bone marrow cells in response to stem cell factor was enhanced in long term culture, but not in in vitro colony assay; no permanent cell lines could be obtained. No effects of p53-deficiency were found in proliferation of cardiac muscle cells or hepatocytes.	INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOLEC ONCOL LAB, TSUKUBA, IBARAKI 305, JAPAN; INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, CELL BIOL LAB, TSUKUBA, IBARAKI 305, JAPAN; SAITAMA UNIV, FAC SCI, DEPT REGULAT BIOL, URAWA, SAITAMA 338, JAPAN; NATL MED CTR, CLIN RES INST, DIV GENET, SHINJUKU KU, TOKYO, TOKYO 162, JAPAN; SCI UNIV TOKYO, DEPT APPL BIOL SCI, NODA, CHIBA 278, JAPAN; KUMAMOTO UNIV, SCH MED, INST MOLEC EMBRYOL & GENET, MORPHOGENESIS LAB, KUMAMOTO, KUMAMOTO 860, JAPAN; TOKYO MED & DENT UNIV, SCH MED, DEPT BIOCHEM, TOKYO, TOKYO 113, JAPAN	RIKEN; RIKEN; Saitama University; Tokyo University of Science; Kumamoto University; Tokyo Medical & Dental University (TMDU)								AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; AIZAWA S, 1982, EXP CELL RES, V139, P416, DOI 10.1016/0014-4827(82)90269-5; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GOSHIMA K, 1976, J MOL CELL CARDIOL, V8, P217, DOI 10.1016/0022-2828(76)90038-9; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hogan B, 1986, MANIPULATING MOUSE E, P89; IMAGAWA W, 1982, P NATL ACAD SCI-BIOL, V79, P4074, DOI 10.1073/pnas.79.13.4074; IMAGAWA W, 1984, CELL CULTURE METHODS, V2, P127; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KITANI H, 1991, IN VITRO CELL DEV B, V27, P615; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUZAKI Y, 1992, J IMMUNOL, V149, P1069; MCKNIGHT GS, 1978, CELL, V14, P403; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NEMOTO N, 1993, JPN J CANCER RES, V84, P265, DOI 10.1111/j.1349-7006.1993.tb02866.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOGUCHI PD, 1978, J HISTOCHEM CYTOCHEM, V26, P761, DOI 10.1177/26.9.361885; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; RITTLING SR, 1992, ONCOGENE, V7, P935; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; ROVINSKI B, 1988, ONCOGENE, V2, P445; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; SAWADA N, 1987, IN VITRO CELL DEV B, V23, P267; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUDA T, 1989, BLOOD, V74, P1936; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; SUDA Y, 1987, J CELL PHYSIOL, V133, P197, DOI 10.1002/jcp.1041330127; SUDA Y, 1990, EMBO J, V9, P181, DOI 10.1002/j.1460-2075.1990.tb08094.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TOKUNAGA T, 1992, DEV GROWTH DIFFER, V34, P561; TOMOOKA Y, 1985, IN VITRO CELL DEV B, V21, P237, DOI 10.1007/BF02620935; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; YAGI T, 1993, IN PRESS ANAL BIOCH; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	55	338	343	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3313	3322						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	7504233				2022-12-28	WOS:A1993MG78200015
J	BROWETT, PJ; NORTON, JD				BROWETT, PJ; NORTON, JD			ANALYSIS OF RAS GENE-MUTATIONS AND METHYLATION STATE IN HUMAN LEUKEMIAS	ONCOGENE			English	Article									ROYAL FREE HOSP,SCH MED,DEPT HEMATOL,POND ST,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1986, TRENDS GENET, V2, P188, DOI 10.1016/0168-9525(86)90222-2; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLOOMFIELD CD, 1984, LEUKEMIAS, P163; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BROWETT PJ, 1988, LEUKEMIA RES, V12, P25, DOI 10.1016/S0145-2126(98)80005-2; BROWETT PJ, 1988, LEUKAEMIA, V3, P86; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CATOVSKY D, 1984, LEUKAEMIAS, P266; CHANDLER LA, 1986, CANCER RES, V46, P2944; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; EVA A, 1983, P NATL ACAD SCI-BIOL, V80, P4926, DOI 10.1073/pnas.80.16.4926; EVANS JPM, 1988, BRIT J HAEMATOL, V69, P41, DOI 10.1111/j.1365-2141.1988.tb07600.x; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIORUCCI G, 1988, BIOCHIM BIOPHYS ACTA, V950, P81, DOI 10.1016/0167-4781(88)90076-0; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; GALILI U, 1974, J IMMUNOL, V112, P1628; GREAVES MF, 1986, SCIENCE, V234, P697, DOI 10.1126/science.3535067; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; HIRAI H, 1987, NATURE, V327, P430, DOI 10.1038/327430a0; JANOSSY G, 1986, METHODS HAEMATOLOGY, V13, P97; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; LIU E, 1987, NATURE, V327, P430; LUZZATTO L, 1986, PROG HEMATOL, V14, P303; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NEEDLEMAN SW, 1986, BLOOD, V67, P753; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; NORTON JD, 1988, BLOOD, V71, P178; PADUA RA, 1988, LEUKEMIA, V2, P503; RAMSDEN M, 1985, EMBO J, V4, P1449, DOI 10.1002/j.1460-2075.1985.tb03801.x; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; RIGGS AD, 1983, ADV CANCER RES, V40, P1, DOI 10.1016/S0065-230X(08)60678-8; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1986, BLOOD, V67, P1698; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SHEN WPV, 1987, ONCOGENE, V1, P157; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; SMITH HO, 1976, NUCLEIC ACIDS RES, V3, P2387, DOI 10.1093/nar/3.9.2387; TOKSOZ D, 1989, BRIT J HAEMATOL, V71, P1, DOI 10.1111/j.1365-2141.1989.tb06265.x; VEDEL M, 1983, NUCLEIC ACIDS RES, V11, P4335, DOI 10.1093/nar/11.13.4335; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WODNARFILIPOWICZ A, 1987, ONCOGENE, V1, P457; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; YOSHIKAI Y, 1984, NATURE, V312, P521, DOI 10.1038/312521a0	59	63	64	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					1029	1036						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2668844				2022-12-28	WOS:A1989AJ29700013
J	MOORE, BE; BOSE, HR				MOORE, BE; BOSE, HR			EXPRESSION OF THE C-REL AND C-MYC PROTO-ONCOGENES IN AVIAN-TISSUES	ONCOGENE			English	Article									UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712; UNIV TEXAS,INST CELL RES,AUSTIN,TX 78712	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin					NATIONAL CANCER INSTITUTE [R01CA026169, R01CA033192] Funding Source: NIH RePORTER; NCI NIH HHS [CA 33192, CA 26169] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BROWNELL E, 1986, AM J HUM GENET, V39, P194; BROWNELL E, 1985, MOL CELL BIOL, V5, P2826, DOI 10.1128/MCB.5.10.2826; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; CHEN ISY, 1981, J VIROL, V40, P800, DOI 10.1128/JVI.40.3.800-811.1981; CHEN ISY, 1983, J VIROL, V45, P104, DOI 10.1128/JVI.45.1.104-113.1983; CHEN L, 1988, P NATL ACAD SCI USA, V85, P549, DOI 10.1073/pnas.85.2.549; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; FRANKLIN RB, 1977, VIROLOGY, V83, P313, DOI 10.1016/0042-6822(77)90176-3; GARSON K, 1986, BIOCHEM BIOPH RES CO, V134, P716, DOI 10.1016/S0006-291X(86)80479-X; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; HANNICK M, 1988, 4TH ANN M ONC FRED; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; JONES RE, 1978, VERTEBRATE OVARY COM; KRAWETZ S A, 1984, Biotechniques, V2, P342; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEVINE M, 1988, CELL, V52, P785, DOI 10.1016/0092-8674(88)90418-7; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; REYNOLDS JD, 1987, EUR J IMMUNOL, V17, P503, DOI 10.1002/eji.1830170411; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; Romanoff A., 1960, THE AVIAN EMBRYO, V1, P429; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SEVOIAN M, 1964, AVIAN DIS, V8, P336, DOI 10.2307/1587964; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SIMEK S, 1988, ONCOGENE RES, V2, P103; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STEWARD R, 1988, CELL, V55, P487, DOI 10.1016/0092-8674(88)90035-9; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOIVANEN P, 1974, EUR J IMMUNOL, V4, P405, DOI 10.1002/eji.1830040604; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; WALRO DS, 1987, VIROLOGY, V160, P433, DOI 10.1016/0042-6822(87)90015-8; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WILHELMSEN KC, 1984, J VIROL, V49, P521, DOI 10.1128/JVI.49.2.521-529.1984; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WONG TC, 1981, VIROLOGY, V111, P289, DOI 10.1016/0042-6822(81)90674-7	48	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					845	852						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2666905				2022-12-28	WOS:A1989AE58400005
J	BARNES, D; CLAYTON, L; CHUMBLEY, G; MACLEOD, AR				BARNES, D; CLAYTON, L; CHUMBLEY, G; MACLEOD, AR			ACTIVATION OF THE TRK ONCOGENE BY ALTERNATIVELY SPLICED MUSCLE AND NON-MUSCLE TROPOMYOSIN SEQUENCES	ONCOGENE			English	Note									UNIV CAMBRIDGE,DEPT ANAT,DOWNING ST,CAMBRIDGE CB2 3DY,ENGLAND; MRC,LUDWIG INST CANC RES,CAMBRIDGE CB2 2QH,ENGLAND	University of Cambridge; Ludwig Institute for Cancer Research; University of Cambridge								BLAIR DG, 1982, SCIENCE, V218, P112; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FIERS W, 1978, NATURE, V273, P113, DOI 10.1038/273113a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JEFFREYS AJ, 1977, CELL, V12, P1097, DOI 10.1016/0092-8674(77)90172-6; KOSMA SC, 1988, EMBO J, V7, P147; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7057; MACLEOD AR, 1988, MOL CELL BIOL, V8, P433, DOI 10.1128/MCB.8.1.433; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; REINACH FC, 1986, NATURE, V322, P648, DOI 10.1038/322648a0; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4	19	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					259	262						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2927948				2022-12-28	WOS:A1989U567500020
J	VARNUM, BC; LIM, RW; SUKHATME, VP; HERSCHMAN, HR				VARNUM, BC; LIM, RW; SUKHATME, VP; HERSCHMAN, HR			NUCLEOTIDE-SEQUENCE OF A CDNA-ENCODING TIS11, A MESSAGE INDUCED IN SWISS 3T3 CELLS BY THE TUMOR PROMOTER TETRADECANOYL PHORBOL ACETATE	ONCOGENE			English	Note									UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT BIOL CHEM,WARREN HALL,900 VET AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,BIOMED & ENVIRONM SCI LAB,LOS ANGELES,CA 90024; UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MED,CHICAGO,IL 60637	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of Chicago			Sukhatme, Vikas/W-2776-2019		NIGMS NIH HHS [GM24797, 2T32 GM07104] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007104, R01GM024797] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		JOHNSON MD, 1987, MOL CELL BIOL, V7, P2821, DOI 10.1128/MCB.7.8.2821; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUJUBU DA, 1987, ONCOGENE, V1, P257; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LIM RW, 1987, ONCOGENE, V1, P263; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TIPPETTS MT, 1988, MOL CELL BIOL, V8, P4570, DOI 10.1128/MCB.8.10.4570	10	137	140	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					119	120						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2915901				2022-12-28	WOS:A1989U567400019
J	DEDIEU, JF; GAZIN, C; RIGOLET, M; GALIBERT, F				DEDIEU, JF; GAZIN, C; RIGOLET, M; GALIBERT, F			EVOLUTIONARY CONSERVATION OF THE PRODUCT OF HUMAN C-MYC EXON-1 AND ITS INDUCIBLE EXPRESSION IN A MURINE CELL-LINE	ONCOGENE			English	Article											DEDIEU, JF (corresponding author), HOP ST LOUIS,CTR HAYEM,HEMATOL EXPTL LAB,CNRS,2 PL DR FOURNIER,F-75475 PARIS 10,FRANCE.							ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7978; COLBEREGARAPIN F, 1979, P NATL ACAD SCI USA, V76, P3755, DOI 10.1073/pnas.76.8.3755; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FASEL N, 1982, EMBO J, V1, P3, DOI 10.1002/j.1460-2075.1982.tb01115.x; FINVER SN, 1988, P NATL ACAD SCI USA, V85, P3052, DOI 10.1073/pnas.85.9.3052; FORNSTEDT N, 1984, FEBS LETT, V177, P195, DOI 10.1016/0014-5793(84)81282-X; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GAZIN C, 1986, EMBO J, V5, P2241, DOI 10.1002/j.1460-2075.1986.tb04491.x; GEYSEN HM, 1985, P NATL ACAD SCI USA, V82, P178, DOI 10.1073/pnas.82.1.178; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Griffin B., 1981, DNA TUMOR VIRUSES, P61; GUTIERREZ C, 1987, MOL CELL BIOL, V7, P4594, DOI 10.1128/MCB.7.12.4594; HARRIS LJ, 1982, P NATL ACAD SCI-BIOL, V79, P4175, DOI 10.1073/pnas.79.13.4175; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LINIAL M, 1985, P NATL ACAD SCI USA, V82, P53, DOI 10.1073/pnas.82.1.53; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1980, METHODS ENZYMOLOGY 1, V65; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; SHIH CK, 1984, P NATL ACAD SCI-BIOL, V81, P4697, DOI 10.1073/pnas.81.15.4697; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; VANBENEDEN RJ, 1986, P NATL ACAD SCI USA, V83, P3698; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x	46	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					523	529						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3078958				2022-12-28	WOS:A1988R516300006
J	RAO, VN; MODI, WS; DRABKIN, HD; PATTERSON, D; OBRIEN, SJ; PAPAS, TS; REDDY, ESP				RAO, VN; MODI, WS; DRABKIN, HD; PATTERSON, D; OBRIEN, SJ; PAPAS, TS; REDDY, ESP			THE HUMAN ERG GENE MAPS TO CHROMOSOME-21, BAND-Q22 - RELATIONSHIP TO THE 8-21 TRANSLOCATION OF ACUTE MYELOGENOUS LEUKEMIA	ONCOGENE			English	Article									NCI,MOLEC ONCOL LAB,FREDERICK,MD 21701; NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701; ELEANOR ROOSEVELT INST CANC RES,DENVER,CO 80262; UNIV COLORADO,CTR CANC,DENVER,CO 80262; NCI,PROGRAM RESOURCES INC,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Colorado System; University of Colorado Denver; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			OBRIEN, STEPHEN/ABD-1346-2020	OBRIEN, STEPHEN/0000-0001-7857-0757	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD017449] Funding Source: NIH RePORTER; NIA NIH HHS [AG00029] Funding Source: Medline; NICHD NIH HHS [HD17449] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CANAANI E, 1984, LANCET, V1, P593; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DIAZ MO, 1986, SCIENCE, V231, P265, DOI 10.1126/science.3455787; DRABKIN HA, 1985, P NATL ACAD SCI USA, V82, P464, DOI 10.1073/pnas.82.2.464; EVANS DIK, 1972, LANCET, V2, P1322; JONES C, 1981, SOMAT CELL GENET, V7, P399, DOI 10.1007/BF01542985; KIRKILIONIS AJ, 1986, J PEDIATR-US, V108, P793, DOI 10.1016/S0022-3476(86)81077-0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LESCHOT NJ, 1981, HUM GENET, V57, P220, DOI 10.1007/BF00282029; Maniatis T., 1982, MOL CLONING; MODI WS, 1987, GENE ANAL TECH, V4, P75; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OBRIEN SJ, 1983, NATURE, V302, P839, DOI 10.1038/302839a0; OBRIEN SJ, 1983, NATURE, V303, P74, DOI 10.1038/303074a0; PELLICI PG, 1986, P NATL ACAD SCI USA, V83, P2984; RAO VN, 1987, ONCOGENE RES, V2, P95; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1988, IN PRESS ONCOGENE RE; ROVIGATTI U, 1986, SCIENCE, V232, P398, DOI 10.1126/science.3457468; ROWLEY JD, 1982, SCIENCE, V216, P749, DOI 10.1126/science.7079737; SACCHI N, 1986, SCIENCE, V231, P379, DOI 10.1126/science.3941901; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SINET PM, 1976, EXP CELL RES, V97, P47, DOI 10.1016/0014-4827(76)90653-4; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WATSON DK, 1986, P NATL ACAD SCI USA, V83, P1792, DOI 10.1073/pnas.83.6.1792; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	31	32	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					497	500						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3274086				2022-12-28	WOS:A1988R516300002
J	MARTINSSON, T; STAHL, F; POLLWEIN, P; WENZEL, A; LEVAN, A; SCHWAB, M; LEVAN, G				MARTINSSON, T; STAHL, F; POLLWEIN, P; WENZEL, A; LEVAN, A; SCHWAB, M; LEVAN, G			TUMORIGENICITY OF SEWA MURINE CELLS CORRELATES WITH DEGREE OF C-MYC AMPLIFICATION	ONCOGENE			English	Article									GERMAN CANC RES CTR,INST EXPTL PATHOL,D-6900 HEIDELBERG 1,FED REP GER; GOTHENBURG UNIV,DEPT GENET,S-41124 GOTHENBURG,SWEDEN; UNIV LUND,INST GENET,S-22101 LUND,SWEDEN	Helmholtz Association; German Cancer Research Center (DKFZ); University of Gothenburg; Lund University			Martinsson, Tommy/J-4140-2013	Martinsson, Tommy/0000-0002-9403-3123				ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRADLEY JV, 1968, DISTRIBUTION FREE ST, P68; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CREWS S, 1982, SCIENCE, V218, P1319, DOI 10.1126/science.7146913; HAMLIN JL, 1984, INT REV CYTOL, V90, P31, DOI 10.1016/S0074-7696(08)61487-4; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; LEVAN A, 1978, CYTOGENET CELL GENET, V20, P12, DOI 10.1159/000130836; LEVAN G, 1977, HEREDITAS, V86, P75; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MARTINSSON T, 1982, HEREDITAS, V97, P123, DOI 10.1111/j.1601-5223.1982.tb00720.x; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SANCHEZ O, 1973, LANCET, V2, P269; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHWAB M, 1985, NATURE, V315, P345, DOI 10.1038/315345a0; SEABRIGH.M, 1971, LANCET, V2, P971; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; SUMNER AT, 1972, EXP CELL RES, V75, P304, DOI 10.1016/0014-4827(72)90558-7; [No title captured]	25	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					437	441						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3078951				2022-12-28	WOS:A1988Q773900012
J	BUSCHER, M; RAHMSDORF, HJ; LITFIN, M; KARIN, M; HERRLICH, P				BUSCHER, M; RAHMSDORF, HJ; LITFIN, M; KARIN, M; HERRLICH, P			ACTIVATION OF THE C-FOS GENE BY UV AND PHORBOL ESTER - DIFFERENT SIGNAL TRANSDUCTION PATHWAYS CONVERGE TO THE SAME ENHANCER ELEMENT	ONCOGENE			English	Article									KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH,INST GENET & TOXIKOL,POSTFACH 3640,D-7500 KARLSRUHE 1,FED REP GER; UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,DEPT PHARMACOL,LA JOLLA,CA 92093	Helmholtz Association; Karlsruhe Institute of Technology; University of California System; University of California San Diego								ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANGEL P, 1985, CANCER CELL, V3, P315; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVISSAR S, 1986, EXP CELL RES, V165, P353, DOI 10.1016/0014-4827(86)90589-6; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLACK HS, 1985, CANCER RES, V45, P6254; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; BUSCHER M, 1987, BIOENGINEERING S27, V2; CASEY J, 1977, NUCLEIC ACIDS RES, V4, P1539, DOI 10.1093/nar/4.5.1539; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIDA K, 1986, J BIOL CHEM, V261, P3013; CLARK RB, 1987, BIOCHEM BIOPH RES CO, V145, P666, DOI 10.1016/0006-291X(87)91016-3; COLLETTA G, 1986, SCIENCE, V233, P458, DOI 10.1126/science.3726540; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DELEO VA, 1985, PHOTOCHEM PHOTOBIOL, V41, P51; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GREENGARD P, 1978, SCIENCE, V199, P146, DOI 10.1126/science.22932; GUY GR, 1986, BIOCHEM BIOPH RES CO, V135, P146, DOI 10.1016/0006-291X(86)90954-X; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HERRLICH P, 1986, ADV ENZYME REGUL, V25, P485, DOI 10.1016/0065-2571(86)90030-0; HERRLICH P, 1987, ONCOGENES GROWTH CON, P16; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; HYNES N, 1983, P NATL ACAD SCI-BIOL, V80, P3637, DOI 10.1073/pnas.80.12.3637; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; KAIBUCHI K, 1985, J BIOL CHEM, V260, P1366; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KARIN M, 1985, MOL CELL BIOL, V5, P2866, DOI 10.1128/MCB.5.10.2866; KARIN M, 1984, DNA-J MOLEC CELL BIO, V3, P319, DOI 10.1089/dna.1.1984.3.319; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Krebs E G, 1972, Curr Top Cell Regul, V5, P99; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KUO JF, 1969, P NATL ACAD SCI USA, V64, P1349, DOI 10.1073/pnas.64.4.1349; LASKIN JD, 1985, P NATL ACAD SCI USA, V82, P6158, DOI 10.1073/pnas.82.18.6158; LASKIN JD, 1986, P NATL ACAD SCI USA, V83, P8211, DOI 10.1073/pnas.83.21.8211; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAJORS J, 1983, P NATL ACAD SCI-BIOL, V80, P5866, DOI 10.1073/pnas.80.19.5866; MANIATIS T, 1982, MOL CLONING LABORATO; Maxam A M, 1980, Methods Enzymol, V65, P499; MONTAGUE W, 1971, BIOCHEM J, V122, P115, DOI 10.1042/bj1220115; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PASTI G, 1986, NATURE, V324, P375, DOI 10.1038/324375a0; PONTA H, 1985, P NATL ACAD SCI USA, V82, P1020, DOI 10.1073/pnas.82.4.1020; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RAN W, 1986, P NATL ACAD SCI USA, V83, P8216, DOI 10.1073/pnas.83.21.8216; RODRIGUEZPENA MA, 1984, BIOCHEM BIOPH RES CO, V120, P1053; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SCHONTHAL A, 1988, IN PRESS CELL, V54; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SHIBANUMA M, 1987, EUR J BIOCHEM, V164, P15, DOI 10.1111/j.1432-1033.1987.tb10985.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VALENZENO DP, 1987, PHOTOCHEM PHOTOBIOL, V46, P147, DOI 10.1111/j.1751-1097.1987.tb04749.x; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VERMA IM, 1986, COLD SPRING HARB SYM, V51, P949, DOI 10.1101/SQB.1986.051.01.108; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WOLF M, 1985, NATURE, V317, P546, DOI 10.1038/317546a0	87	281	282	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					301	311						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	2849742				2022-12-28	WOS:A1988Q436700009
J	ZAJDEL, MEB; BLAIR, GE				ZAJDEL, MEB; BLAIR, GE			THE INTRACELLULAR-DISTRIBUTION OF THE TRANSFORMATION-ASSOCIATED PROTEIN P53 IN ADENOVIRUS-TRANSFORMED RODENT CELLS	ONCOGENE			English	Article									UNIV LEEDS,DEPT BIOCHEM,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Leeds			Blair, George Eric/A-5906-2008	Blair, George Eric/0000-0003-0440-1795				BERNARDS R, 1984, BIOCHIM BIOPHYS ACTA, V783, P187, DOI 10.1016/0167-4781(84)90029-0; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; CALARCOGILLAM PD, 1983, CELL, V35, P621, DOI 10.1016/0092-8674(83)90094-6; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FUNG BP, 1985, CELL TISSUE RES, V239, P43, DOI 10.1007/BF00214901; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARWOOD LMJ, 1975, INT J CANCER, V16, P498, DOI 10.1002/ijc.2910160317; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; MULLER W, 1975, EUR J BIOCHEM, V54, P385, DOI 10.1111/j.1432-1033.1975.tb04149.x; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; OSBORN M, 1976, P NATL ACAD SCI USA, V73, P867, DOI 10.1073/pnas.73.3.867; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RODRIGUEZ J, 1960, VIROLOGY, V12, P316, DOI 10.1016/0042-6822(60)90205-1; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SAWADA Y, 1985, VIROLOGY, V147, P413, DOI 10.1016/0042-6822(85)90143-6; SCHAFFNER W, 1980, P NATL ACAD SCI-BIOL, V77, P2163, DOI 10.1073/pnas.77.4.2163; SOMPAYRAC LM, 1983, MOL CELL BIOL, V3, P290, DOI 10.1128/MCB.3.2.290; TUCKER RW, 1979, CELL, V17, P527, DOI 10.1016/0092-8674(79)90261-7; TUFFANELLI DL, 1983, ARCH DERMATOL, V119, P560, DOI 10.1001/archderm.119.7.560; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; ZAJDEL MEB, 1985, BIOCHEM J, V225, P649, DOI 10.1042/bj2250649; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	37	62	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					579	584						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	3290806				2022-12-28	WOS:A1988N841500008
J	KNIGHT, J; BEUG, H; MARSHALL, J; HAYMAN, MJ				KNIGHT, J; BEUG, H; MARSHALL, J; HAYMAN, MJ			ABNORMAL GLYCOSYLATION OF THE ENV-SEA ONCOGENE PRODUCT INHIBITS ITS PROTEOLYTIC CLEAVAGE AND BLOCKS ITS TRANSFORMING ABILITY	ONCOGENE			English	Article									SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-6900 HEIDELBERG,FED REP GER	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; European Molecular Biology Laboratory (EMBL)				Marshall, John/0000-0003-1361-2869	NATIONAL CANCER INSTITUTE [P01CA028146, R01CA042573] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42573, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENEDICT SH, 1985, VIROLOGY, V145, P154, DOI 10.1016/0042-6822(85)90210-7; BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BEUG H, 1982, J CELL PHYSL, V115, P295; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOSCH JV, 1982, VIROLOGY, V119, P122; BOSCH JV, 1984, VIROLOGY, V132, P95; CHAN AML, 1987, ONCOGENE, V1, P229; DEAN M, 1985, NATURE, V318, P285; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FLIESLER SJ, 1986, P NATL ACAD SCI USA, V83, P6435, DOI 10.1073/pnas.83.17.6435; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GROSS V, 1983, J BIOL CHEM, V258, P12201; HADWIGER A, 1986, EMBO J, V5, P689, DOI 10.1002/j.1460-2075.1986.tb04268.x; HAYMAN M, 1978, VIROLOGY, V85, P475, DOI 10.1016/0042-6822(78)90454-3; HAYMAN MJ, 1986, VIROLOGY, V150, P270, DOI 10.1016/0042-6822(86)90287-4; HAYMAN MJ, 1984, NATURE, V309, P460, DOI 10.1038/309460a0; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HORI H, 1984, ARCH BIOCHEM BIOPHYS, V228, P525, DOI 10.1016/0003-9861(84)90019-5; KOWENZ E, 1987, MODERN TRENDS HUMAN, V11, P119; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LYMAN SD, 1987, MOL CELL BIOL, V7, P3287, DOI 10.1128/MCB.7.9.3287; MCDOWELL W, 1987, VIROLOGY, V161, P37, DOI 10.1016/0042-6822(87)90168-1; NICHOLS EJ, 1985, MOL CELL BIOL, V5, P3467, DOI 10.1128/MCB.5.12.3467; NICKAMEYER WS, 1985, J VIROL, V53, P879; PALMERI S, 1982, VIROLOGY, V123, P209; PAN YT, 1983, BIOCHEMISTRY-US, V22, P3975, DOI 10.1021/bi00285a038; PEREZ LG, 1987, J VIROL, V61, P1609, DOI 10.1128/JVI.61.5.1609-1614.1987; PEYRIERAS N, 1983, EMBO J, V2, P823, DOI 10.1002/j.1460-2075.1983.tb01509.x; REPP R, 1985, J BIOL CHEM, V260, P5873; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; ROYERPOKORA B, 1978, CELL, V13, P751, DOI 10.1016/0092-8674(78)90225-8; SAUL R, 1985, P NATL ACAD SCI USA, V82, P93, DOI 10.1073/pnas.82.1.93; SCHLESSINGER S, 1987, VIRUS RES, V2, P139; SCHMIDT JA, 1985, EMBO J, V4, P105, DOI 10.1002/j.1460-2075.1985.tb02323.x; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Stubbs EL, 1935, J EXP MED, V61, P593, DOI 10.1084/jem.61.5.593; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0	43	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					317	326						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	2834683				2022-12-28	WOS:A1988M947200003
J	CIOSSEK, T; LERCH, MM; ULLRICH, A				CIOSSEK, T; LERCH, MM; ULLRICH, A			CLONING, CHARACTERIZATION, AND DIFFERENTIAL EXPRESSION OF MDK2 AND MDK5, 2 NOVEL RECEPTOR TYROSINE KINASES OF THE ECK/EPH FAMILY	ONCOGENE			English	Article						RECEPTOR TYROSINE KINASE; EPH/ECK FAMILY; EMBRYONIC DEVELOPMENT	GROWTH-FACTOR RECEPTOR; EPH GENE; MOUSE; DNA; SEQUENCES; CELLS; ELK	Using a polymerase chain reaction-based strategy for the cloning of developmentally regulated receptor tyrosine kinases, we identified two novel members of the eck/eph-related subfamily which, in analogy with the recently identified mouse developmental kinase 1 (MDK1), were designated MDK2 and MDK5. MDK2 is highly homologous to the mouse kinase Myk-1 and the human kinase Htk, whereas MDK5 represents the mouse homologue of human Hek2. Northern blot analyses of adult mouse tissues revealed a 4.7 kb transcript of MDK2 and a 4.8 kb transcript of MDK5 in various organ systems, including lung, liver, kidney, intestine, muscle, heart, and, in the case of MDK5, also the brain, In addition to the full-length transcripts, smaller fragments were identified that probably represent truncated receptors. Northern blot analysis and in situ hybridization of mouse embryos indicated abundant expression during embryonic development, with preferential involvement of tissues of epithelial and endothelial origin for both kinases and of the spinal cord gray matter for MDK5, Unlike most other members of the eck/eph-related subfamily, the expression of MDK2 and MDK5 is not primarily restricted to neuronal structures, and their abundant presence in various organ systems during embryonic development suggests an important role in gestational growth and differentiation.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society			Lerch, Markus M./E-2206-2016	Lerch, Markus M./0000-0002-9643-8263				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANDRES AC, 1994, ONCOGENE, V9, P1461; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BOHME B, 1993, ONCOGENE, V8, P2857; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIOSSEK T, 1995, ONCOGENE, V9, P97; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENDLY BM, 1990, CANCER RES, V50, P1550; FLETCHER FA, 1994, ONCOGENE, V9, P3241; GANJU P, 1994, ONCOGENE, V9, P1613; GILARDIHEBENSTREIT, 1992, ONCOGENE, V7, P2499; HANKS SK, 1988, SCIENCE, V241, P445; HEIJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAHER PA, 1991, J CELL BIOL, V112, P955, DOI 10.1083/jcb.112.5.955; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; PASQUALE EB, 1989, P NATL ACAD SCI USA, V88, P5449; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SDAMBROOK J, 1989, MOL CLONING LABORATO; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SHAO HN, 1995, J BIOL CHEM, V270, P3467, DOI 10.1074/jbc.270.8.3467; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TAYLOR V, 1994, ONCOGENE, V63, P163; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONDERGEER P, 1994, ANN REV CELL BIOL, V10, P251; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117	56	58	64	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2085	2095						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478528				2022-12-28	WOS:A1995TF29700019
J	CASINI, T; GRAF, T				CASINI, T; GRAF, T			BICISTRONIC RETROVIRAL VECTOR REVEALS CAPACITY OF V-ERBA TO INDUCE ERYTHROLEUKEMIA AND TO COOPERATE WITH V-MYB	ONCOGENE			English	Article						BICISTRONIC RETROVIRUS; AVIAN ACUTE LEUKEMIA; VIRUS; THYROID HORMONE RECEPTOR; ERYTHROBLASTOSIS; ONCOGENE COOPERATIVITY	AVIAN ERYTHROBLASTOSIS VIRUS; CHICKEN ERYTHROID-CELLS; LEUKEMIA-VIRUS; THYROID-HORMONE; MONOCLONAL-ANTIBODIES; SELF-RENEWAL; DIFFERENTIATION; E26; ONCOGENES; GENE	Previous studies have shown that v-erbA and v-myb can induce the proliferation of avian erythroid cells in culture, To study the combined effects of v-erbA and v-myb, the two oncogenes were engineered into a retrovirus bicistronic vector with an internal ribosomal entry site (IRES) or into a vector with a splice acceptor (SPL), This allowed coexpression of the two proteins and a comparison with the same vector containing either v-erbA or v-myb only, Both the erbA IRES and the erbA/myb IRES virus constructs transformed erythroid cells after infection of bone marrow or blastoderm cultures. The erbA/myb IRES virus exhibited a 5-10-fold higher transformed colony forming efficiency than the erbA IRES virus in the blastoderm assay, Surprisingly, when injected into chicken embryos in the presence of helper virus, both viruses induced an erythroleukemia in about half of the animals, In contrast, no leukemia was observed with a myb IRES virus, with spliced vectors containing v-erbA alone or v-erbA in combination with v-myb nor with erbA IRES and erbA/myb IRES viruses produced in the absence of helper virus, The average latency of leukemia induction was shorter for the erbA/myb IRES virus (3.5 weeks) than for the erbA IRES virus (5 weeks), Nevertheless, for both leukemic blasts retained full factor growth, These results show that v-erbA is capable of inducing an erythroleukemia when expressed by a high titer bicistronic retrovirus under conditions of virus spreading and that its in vitro and in vivo transforming potential can be enhanced by v-myb.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Graf, Thomas/B-4252-2015	Graf, Thomas/0000-0003-2774-4117				BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1981, VIROLOGY, V111, P201, DOI 10.1016/0042-6822(81)90665-6; BEUG H, 1989, EUR J CLIN INVEST, V19, P491, DOI 10.1111/j.1365-2362.1989.tb00265.x; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1982, EMBO J, V1, P1069, DOI 10.1002/j.1460-2075.1982.tb01298.x; DAMM K, 1969, NATURE, V339, P593; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; Frykberg L, 1988, Oncogene Res, V3, P313; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; GOLDBERG Y, 1988, EMBO J, V7, P269; GRAESSER F A, 1991, Molecular and Cellular Biology, V11, P3987; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; KAHN P, 1986, CELL, V44, P349; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LUSCHER B, 1990, GENE DEV, V4, P2239; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; METZ T, 1992, ONCOGENE, V7, P597; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOKER AW, 1992, MOL VIROLOGY PRACTIC; STOKER AW, 1909, J VIROL; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	42	15	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1019	1026						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566959				2022-12-28	WOS:A1995RX18000002
J	CHACKALAPARAMPIL, I; BAGRODIA, S; SHALLOWAY, D				CHACKALAPARAMPIL, I; BAGRODIA, S; SHALLOWAY, D			TYROSINE DEPHOSPHORYLATION OF PP60(C-SRC) IS STIMULATED BY A SERINE/THREONINE PHOSPHATASE INHIBITOR	ONCOGENE			English	Article							PROTEIN-KINASE-C; XENOPUS-LAEVIS OOCYTES; OKADAIC ACID; CELL-CYCLE; TUMOR PROMOTERS; AUTOPHOSPHORYLATION SITE; OVEREXPRESSED PP60C-SRC; NEGATIVE REGULATOR; SPONGE TOXIN; H1 KINASE	Incubation of NIH3T3-derived c-src overexpressor cells with okadaic acid, a specific serine/threonine phosphatase inhibitor, stimulates pp60(c-src) kinase activity about 2-3-fold. Activation is blocked if cells are simultaneously treated with orthovanadate, a tyrosine phosphatase inhibitor. Furthermore, okadaic acid treatment induces a small decrease in Tyr 527 phosphorylation of wild-type pp60(c-src) and a large decrease in Tyr 527 phosphorylation of kinase-defective pp60(c-src)(lys 295--> Arg). These results suggest that the activation is mediated by okadaic acid-induced changes in tyrosine phosphorylation of pp60(c-src) involving 'cross-over' from serine/threonine to tyrosine signal transduction pathways. Stimulation of pp60(c-src) activity and Tyr 527 dephosphorylation do not require changes in serine/threonine phosphorylation of pp60(c-src), suggesting that these changes result from modulation of an upstream Tyr 527 phosphatase or kinase which is itself regulated by altered serine/threonine phosphorylation. Since okadaic acid induces a pseudo-mitotic phenotype in rodent cells (K. Yamashita, H. Yasuda, J. Pines, K. Yasumoto, H. Nishitani, M. Ohtsubo, T. Hunter, T. Sugimura and T. Nishimoto, EMBO J., 9: 4331-4338, 1990), it is possible that these phenomena are induced by a biochemical mechanism similar to that which causes transient tyrosine dephosphorylation of pp60(c-src) during mitosis.	CORNELL UNIV, BIOCHEM MOLEC & CELL BIOL SECT, ITHACA, NY 14853 USA	Cornell University					NATIONAL CANCER INSTITUTE [R01CA008964, R01CA047333, R01CA032317] Funding Source: NIH RePORTER; NCI NIH HHS [CA08964, CA32317, CA47333] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAGRODIA S, 1993, MOL CELL BIOL, V13, P1464, DOI 10.1128/MCB.13.3.1464; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRACONI S, 1992, BIOCHEM J, V286, P851, DOI 10.1042/bj2860851; BRAUTIGAN DL, 1991, P NATL ACAD SCI USA, V88, P6696, DOI 10.1073/pnas.88.15.6696; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHERNOFF J, 1983, J BIOL CHEM, V258, P7852; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COOPER JA, 1989, PEPTIDES PROTEIN PHO, P85; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GAVIN AC, 1991, EXP CELL RES, V192, P75, DOI 10.1016/0014-4827(91)90159-R; GOPALAKRISHNA R, 1992, BIOCHEM BIOPH RES CO, V189, P950, DOI 10.1016/0006-291X(92)92296-A; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; GORIS J, 1988, BIOCHEM J, V256, P1029, DOI 10.1042/bj2561029; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; HAYSTEAD TAJ, 1990, EUR J BIOCHEM, V187, P199, DOI 10.1111/j.1432-1033.1990.tb15295.x; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HERMANN J, 1988, EUR J BIOCHEM, V173, P17, DOI 10.1111/j.1432-1033.1988.tb13961.x; HIROTA Y, 1988, MOL CELL BIOL, V8, P1826, DOI 10.1128/MCB.8.4.1826; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; HUNTER T, 1993, CURR OPIN GENET DEV, V3, P1, DOI 10.1016/S0959-437X(05)80333-8; HUNTER T, 1992, CIBA F SYMP, V170, P1; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KAECH S, 1993, ONCOGENE, V8, P575; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MIYASAKA T, 1990, BIOCHEM BIOPH RES CO, V168, P1237, DOI 10.1016/0006-291X(90)91161-K; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; MUSTELIN T, 1990, ONCOGENE, V5, P809; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; OKADA M, 1989, J BIOL CHEM, V264, P20886; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARTANEN J, 1991, ONCOGENE, V6, P2013; PATSCHINSKY T, 1986, J VIROL, V59, P73, DOI 10.1128/JVI.59.1.73-81.1986; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PURCHIO AF, 1985, SCIENCE, V229, P1393, DOI 10.1126/science.2994221; RIME H, 1990, DEV BIOL, V141, P115, DOI 10.1016/0012-1606(90)90106-S; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SASSA T, 1989, BIOCHEM BIOPH RES CO, V159, P939, DOI 10.1016/0006-291X(89)92199-2; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STERNBERG DW, 1993, EMBO J, V12, P323, DOI 10.1002/j.1460-2075.1993.tb05660.x; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; TAKAI A, 1987, FEBS LETT, V217, P81, DOI 10.1016/0014-5793(87)81247-4; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	73	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					1947	1955						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	7516061				2022-12-28	WOS:A1994NR68500019
J	KORHONEN, J; POLVI, A; PARTANEN, J; ALITALO, K				KORHONEN, J; POLVI, A; PARTANEN, J; ALITALO, K			THE MOUSE TIE RECEPTOR TYROSINE KINASE GENE - EXPRESSION DURING EMBRYONIC ANGIOGENESIS	ONCOGENE			English	Article							CAPILLARY ENDOTHELIAL-CELLS; GROWTH-FACTOR; LIGAND-BINDING; CHICK-EMBRYO; IDENTIFICATION; VASCULOGENESIS; DOMAINS; FEATURES; INVITRO; TISSUES	Angiogenesis, the process by which new blood vessels are formed, is essential in reproduction, development, wound repair and oncogenesis. Endothelial receptor tyrosine kinases are Likely to play key roles in the intercellular signalling controlling angiogenesis. We have here analysed the expression of the endothelial receptor tyrosine kinase tie during the earliest stages of vascular development. The mouse tie cDNA was isolated and sequenced and the exon structure of the coding region was determined. The part of the tie gene encoding the extracellular domain was found to be organized in exons specifying the characteristic domains of the Tie polypeptide. Early postimplantation mouse tissues were analysed for tie expression by in situ hybridization. No tie mRNA was detected in 7.5 day mouse embryos. In 8.5 day embryos, tie expression was observed in differentiating angioblasts of the head mesenchyme, in the splanchnopleure and dorsal aorta as well as in migrating endothelial cells of the developing heart. A weak tie signal was also obtained from angioblasts in the blood islands of the yolk sac. Furthermore, tie mRNA was prominent in the endocardium of the embryo and in the endothelial cells forming the lung vasculature. Expression of tie persisted in the lung capillaries of adult mice, but was decreased in the endocardium. These results suggest that the tie receptor tyrosine kinase is involved in angiogenesis and/or maintenance of endothelial cell functions.			KORHONEN, J (corresponding author), UNIV HELSINKI,DEPT PATHOL,MOLEC CANC BIOL LAB,POB 21,SF-00014 HELSINKI,FINLAND.		Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902				APRELIKOVA O, 1992, CANCER RES, V52, P746; ARMSTRONG E, 1993, IN PRESS LEUKEMIA; BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; COFFIN JD, 1988, DEVELOPMENT, V102, P735; CORMIER F, 1988, DEVELOPMENT, V102, P279; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1993, ONCOGENE, V8, P1293; FLAMME I, 1992, DEVELOPMENT, V116, P435; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Folkman J, 1992, Semin Cancer Biol, V3, P65; GALLAND F, 1993, ONCOGENE, V8, P1233; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; GONZALEZCRUSSI F, 1971, AM J ANAT, V130, P441, DOI 10.1002/aja.1001300406; GROSS JL, 1983, P NATL ACAD SCI-BIOL, V80, P2623, DOI 10.1073/pnas.80.9.2623; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOBSON B, 1984, BRIT J CANCER, V49, P405, DOI 10.1038/bjc.1984.66; HORITA K, 1992, BIOCHEM BIOPH RES CO, V189, P1747, DOI 10.1016/0006-291X(92)90280-X; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; Johnson Daniel E., 1993, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KORHONEN J, 1992, BLOOD, V80, P2548; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MILLAUER B, 1993, CELL, V72, P1; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; NODEN DM, 1990, EMBRYONIC ORIGINS DE, P236; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PARDANAUD L, 1987, DEVELOPMENT, V100, P339; PARTANEN J, 1992, Progress in Growth Factor Research, V4, P69, DOI 10.1016/0955-2235(92)90005-3; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARZANI R, 1992, BIOCHEM BIOPH RES CO, V186, P706, DOI 10.1016/0006-291X(92)90804-T; SATO TN, 1993, IN PRESS P NATL ACAD; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; SMITH RA, 1992, DEV COMP IMMUNOL, V6, P359; STEVENS A, 1992, HISTOLOGIE, P103; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; ZETTER BR, 1980, NATURE, V285, P41, DOI 10.1038/285041a0; ZIEGLER SF, 1993, ONCOGENE, V8, P663	45	115	123	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					395	403						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	7507228				2022-12-28	WOS:A1994MW24800006
J	OVERELL, RW; WEISSER, KE; HESS, B; NAMEN, AE; GRABSTEIN, KH				OVERELL, RW; WEISSER, KE; HESS, B; NAMEN, AE; GRABSTEIN, KH			STAGE-SPECIFIC TRANSFORMATION OF MURINE-B LINEAGE CELLS BY RAS AND MYC	ONCOGENE			English	Article									IMMUNEX CORP, DEPT CELLULAR IMMUNOL, SEATTLE, WA 98101 USA; IMMUNEX CORP, DEPT BIOCHEM, SEATTLE, WA 98101 USA	Immunex Corporation; Immunex Corporation	OVERELL, RW (corresponding author), IMMUNEX CORP, DEPT MOLEC BIOL, 51 UNIV ST, SEATTLE, WA 98101 USA.							ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BALTIMORE D, 1979, IMMUNOL REV, V48, P3, DOI 10.1111/j.1600-065X.1979.tb00296.x; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BRAUN J, 1983, J IMMUNOL, V130, P2113; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CEROTTINI JC, 1974, J EXP MED, V140, P703, DOI 10.1084/jem.140.3.703; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; GAUWERKY CE, 1988, ONCOGENE, V2, P431; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GLASEBROOK AL, 1980, J EXP MED, V151, P876, DOI 10.1084/jem.151.4.876; GRABSTEIN K, 1986, J EXP MED, V163, P1405, DOI 10.1084/jem.163.6.1405; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HOLMES KL, 1986, J EXP MED, V164, P443, DOI 10.1084/jem.164.2.443; KLEIN G, 1979, P NATL ACAD SCI USA, V76, P2442, DOI 10.1073/pnas.76.5.2442; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LICHTMAN AH, 1986, NATURE, V324, P489, DOI 10.1038/324489a0; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MANN RB, 1979, AM J PATHOL, V94, P103; MILLER AD, 1985, MOL CELL BIOL, V5, P431, DOI 10.1128/MCB.5.3.431; MISHELL RI, 1967, J EXP MED, V126, P423, DOI 10.1084/jem.126.3.423; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NEWBOLD RF, 1982, NATURE, V299, P633, DOI 10.1038/299633a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; OSMOND DG, 1986, IMMUNOL REV, V93, P103, DOI 10.1111/j.1600-065X.1986.tb01504.x; OVERELL RW, 1988, MOL CELL BIOL, V8, P1803, DOI 10.1128/MCB.8.4.1803; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; POTTER M, 1987, SCIENCE, V235, P787, DOI 10.1126/science.3810165; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SERUNIAN LA, 1986, MOL CELL BIOL, V6, P183, DOI 10.1128/MCB.6.1.183; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; VANSNICK J, 1987, J EXP MED, V165, P641, DOI 10.1084/jem.165.3.641; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; VOGT M, 1986, MOL CELL BIOL, V6, P3545, DOI 10.1128/MCB.6.10.3545; WHITLOCK C, 1985, ANNU REV IMMUNOL, V3, P213; WHITLOCK CA, 1985, ADV IMMUNOL, V37, P73, DOI 10.1016/S0065-2776(08)60338-7; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0; WILLIMAS DE, 1989, UNPUB BLOOD; WU DD, 1987, J IMMUNOL METHODS, V101, P279, DOI 10.1016/0022-1759(87)90161-X	48	15	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1989	4	12					1425	1432						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687765				2022-12-28	WOS:A1989CB65900002
J	SULLIVAN, NF; WILLIS, AE; MOORE, JP; LINDAHL, T				SULLIVAN, NF; WILLIS, AE; MOORE, JP; LINDAHL, T			HIGH-LEVELS OF THE C-MYC PROTEIN IN CELL-LINES OF BLOOM SYNDROME ORIGIN	ONCOGENE			English	Note									CHESTER BEATTY INST CANC RES,LONDON SW3 6JB,ENGLAND	University of London; Institute of Cancer Research - UK	SULLIVAN, NF (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.			Willis, Anne/0000-0002-1470-8531				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; CHAN JYH, 1987, NATURE, V325, P357, DOI 10.1038/325357a0; DETHE G, 1978, NATURE, V274, P756, DOI 10.1038/274756a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EVANS HJ, 1982, SISTER CHROMATID EXC, P184; GERMAN J, 1989, CLIN GENET, V35, P57; German J., 1983, CHROMOSOME MUTATION, P97; HENDERSON EE, 1980, CHEM-BIOL INTERACT, V33, P63, DOI 10.1016/0009-2797(80)90044-7; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MOORE JP, 1987, ONCOGENE RES, V2, P65; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; RUNGER TM, 1989, EMBO J, V8, P1419, DOI 10.1002/j.1460-2075.1989.tb03523.x; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SHIRAISHI Y, 1986, P NATL ACAD SCI USA, V82, P5102; SULLIVAN NF, 1989, ONCOGENE, V4, P1497; VILPO JA, 1989, MUTAT RES, V210, P59, DOI 10.1016/0027-5107(89)90044-4; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WEKSBERG R, 1988, AM J HUM GENET, V42, P816; WILLIS AE, 1989, CARCINOGENESIS, V10, P217, DOI 10.1093/carcin/10.1.217; WILLIS AE, 1987, NATURE, V325, P355, DOI 10.1038/325355a0; WILLIS AE, 1987, P NATL ACAD SCI USA, V84, P8016, DOI 10.1073/pnas.84.22.8016	23	16	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1509	1511						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687770				2022-12-28	WOS:A1989CB65900014
J	ALBINO, AP; NANUS, DM; MENTLE, IR; CORDONCARDO, C; MCNUTT, NS; BRESSLER, J; ANDREEFF, M				ALBINO, AP; NANUS, DM; MENTLE, IR; CORDONCARDO, C; MCNUTT, NS; BRESSLER, J; ANDREEFF, M			ANALYSIS OF RAS ONCOGENES IN MALIGNANT-MELANOMA AND PRECURSOR LESIONS - CORRELATION OF POINT MUTATIONS WITH DIFFERENTIATION PHENOTYPE	ONCOGENE			English	Article									CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021	Cornell University	ALBINO, AP (corresponding author), MEM SLOAN KETTERING CANC CTR,1275 YORK AVE,NEW YORK,NY 10021, USA.				NCI NIH HHS [CA-20194, CA-37907, CA-41305] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA020194, R01CA041305, R01CA037907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN AB, 1985, HUM PATHOL, V16, P87; ADELAIDE J, 1988, ONCOGENE, V2, P413; Albino A P, 1988, Prog Clin Biol Res, V256, P361; ALBINO AP, 1981, J EXP MED, V154, P1764, DOI 10.1084/jem.154.6.1764; ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; ALBINO AP, 1986, J EXP MED, V164, P1710, DOI 10.1084/jem.164.5.1710; ALBINO AP, 1987, BASIC CLIN ASPECTS M, P3; ALBINO AP, 1988, PIGMENT CELL RES S, V1, P169; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ANDREEFF M, 1985, TUMOR ANEUPLOIDY, P81; BALABAN G, 1984, CANCER GENET CYTOGEN, V11, P429, DOI 10.1016/0165-4608(84)90024-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1986, CARCINOGENESIS, V7, P1037, DOI 10.1093/carcin/7.7.1037; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; CAIRNCROSS JG, 1982, P NATL ACAD SCI USA, V79, P561; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; DEMARTINVILLE B, 1983, NUCLEIC ACIDS RES, V11, P5267, DOI 10.1093/nar/11.15.5267; DIPPOLD WG, 1980, P NATL ACAD SCI-BIOL, V77, P6114, DOI 10.1073/pnas.77.10.6114; DRACOPOLI NC, 1985, P NATL ACAD SCI USA, V82, P1470, DOI 10.1073/pnas.82.5.1470; Elder D E, 1980, Am J Dermatopathol, V2, P315, DOI 10.1097/00000372-198000240-00005; ELDER DE, 1980, CANCER, V46, P1787, DOI 10.1002/1097-0142(19801015)46:8<1787::AID-CNCR2820460816>3.0.CO;2-S; ELDER DE, 1984, AM J DERMATOPATH, V6, P55; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GERHARD DS, 1987, NATURE, V325, P73, DOI 10.1038/325073a0; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GREENE MH, 1983, P NATL ACAD SCI-BIOL, V80, P6071, DOI 10.1073/pnas.80.19.6071; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HAYWARD N, 1988, INT J CANCER, V42, P558, DOI 10.1002/ijc.2910420415; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HOUGHTON AN, 1980, P NATL ACAD SCI-BIOL, V77, P4260, DOI 10.1073/pnas.77.7.4260; HOUGHTON AN, 1983, J EXP MED, V158, P53, DOI 10.1084/jem.158.1.53; HOUGHTON AN, 1987, J EXP MED, V164, P812; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LINNENBACH AJ, 1988, P NATL ACAD SCI USA, V85, P74, DOI 10.1073/pnas.85.1.74; MARK A, 1987, NUCLEIC ACIDS RES, V15, P8565, DOI 10.1093/nar/15.20.8565; MCBRIDE LJ, 1988, BIOTECHNIQUES, V6, P362; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; PEDERSEN MI, 1986, CANCER GENET CYTOGEN, V20, P11, DOI 10.1016/0165-4608(86)90103-2; PIEROTTI M, 1987, CUTANEOUS MELANOMA, P339; RADICE P, 1987, ONCOGENE, V2, P91; RAYBAUD F, 1988, CANCER RES, V48, P950; REAL FX, 1988, CANCER RES, V48, P686; REAL FX, 1985, CANCER RES, V45, P4401; REAL FX, 1986, CANCER RES, V46, P4726; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANTOS E, 1983, P NATL ACAD SCI-BIOL, V80, P4679, DOI 10.1073/pnas.80.15.4679; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; SHARPLESS TK, 1979, FLOW CYTOMETRY SORTI, P359; SMOLLER BR, 1989, AM J SURG PATHOL, V13, P680, DOI 10.1097/00000478-198908000-00006; SUTHERLAND C, 1986, BRIT J CANCER, V54, P787, DOI 10.1038/bjc.1986.241; THOMSON TM, 1988, J INVEST DERMATOL, V90, P459, DOI 10.1111/1523-1747.ep12460906; TUCKER MA, 1988, PIGMENT CELL, P95; UEDA R, 1982, P NATL ACAD SCI-BIOL, V79, P4386, DOI 10.1073/pnas.79.14.4386; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; ZIEGLERHEITBROCK HWL, 1985, CANCER RES, V45, P1344; 1984, JAMA-J AM MED ASSOC, V25, P1864	62	188	191	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1363	1374						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2682463				2022-12-28	WOS:A1989AX65900014
J	NIMER, SD; GASSON, JC; HU, K; SMALBERG, I; WILLIAMS, JL; CHEN, ISY; ROSENBLATT, JD				NIMER, SD; GASSON, JC; HU, K; SMALBERG, I; WILLIAMS, JL; CHEN, ISY; ROSENBLATT, JD			ACTIVATION OF THE GM-CSF PROMOTER BY HTLV-I AND HTLV-II TAX PROTEINS	ONCOGENE			English	Article									JONSSON COMPREHENS CANC CTR,LOS ANGEES,CA 90024	UCLA Jonsson Comprehensive Cancer Center	NIMER, SD (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV HEMATOL ONCOL,42-121 CHS,LOS ANGELES,CA 90024, USA.				NATIONAL CANCER INSTITUTE [P01CA032737, R01CA040163] Funding Source: NIH RePORTER; NCI NIH HHS [CA 018011, CA 32737, CA 40163] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAYNEY DW, 1983, ANN INTERN MED, V98, P144, DOI 10.7326/0003-4819-98-2-144; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CANN AJ, 1988, ONCOGENE, V3, P123; CHAN JY, 1986, P NATL ACAD SCI USA, V83, P8669, DOI 10.1073/pnas.83.22.8669; CHEN ISY, 1985, SCIENCE, V230, P570, DOI 10.1126/science.2996140; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DEPPER JM, 1984, J IMMUNOL, V133, P1691; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; GALLO RC, 1983, CANCER RES, V43, P3892; GOLDE DW, 1988, INFLAMMATION BASIC P, P253; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3653, DOI 10.1073/pnas.84.11.3653; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KITADO H, 1987, SCIENCE, V235, P901, DOI 10.1126/science.3027896; KRONKE M, 1985, SCIENCE, V228, P1215, DOI 10.1126/science.2988127; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; MUNKER R, 1986, NATURE, V323, P79, DOI 10.1038/323079a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAGASHIMA K, 1986, J VIROL, V60, P394, DOI 10.1128/JVI.60.2.394-399.1986; NIMER SD, 1988, MOL CELL BIOL, V8, P1979, DOI 10.1128/MCB.8.5.1979; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; ROSENBLATT JD, 1988, SCIENCE, V240, P916, DOI 10.1126/science.2834826; ROSENBLATT JD, 1986, NEW ENGL J MED, V315, P372, DOI 10.1056/NEJM198608073150606; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; SHIMA H, 1986, FEBS LETT, V209, P289, DOI 10.1016/0014-5793(86)81129-2; SHIMOTOHNO K, 1984, P NATL ACAD SCI-BIOL, V81, P1079, DOI 10.1073/pnas.81.4.1079; SHIMOTOHNO K, 1985, P NATL ACAD SCI USA, V82, P3101, DOI 10.1073/pnas.82.10.3101; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SLAMON DJ, 1984, SCIENCE, V226, P61, DOI 10.1126/science.6089351; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; WACHSMAN W, 1986, SEMIN HEMATOL, V23, P246; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; ZUCALI JR, 1986, J CLIN INVEST, V77, P1857, DOI 10.1172/JCI112512	53	104	104	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					671	676						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2660069				2022-12-28	WOS:A1989AA66000001
J	WILKISON, WO; SANDGREN, EP; PALMITER, RD; BRINSTER, RL; BELL, RM				WILKISON, WO; SANDGREN, EP; PALMITER, RD; BRINSTER, RL; BELL, RM			ELEVATION OF 1,2-DIACYLGLYCEROL IN RAS-TRANSFORMED NEONATAL LIVER AND PANCREAS OF TRANSGENIC MICE	ONCOGENE			English	Article									UNIV PENN,SCH VET MED,REPROD PHYSIOL LAB,PHILADELPHIA,PA 19104; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	University of Pennsylvania; University of Washington; University of Washington Seattle; Duke University				Brinster, Ralph/0000-0003-1408-7656	NCI NIH HHS [CA 38635] Funding Source: Medline; NICHD NIH HHS [HD 09172] Funding Source: Medline; PHS HHS [DR 20205] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009172, R37HD009172] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA038635] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES BN, 1960, J BIOL CHEM, V235, P769; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BISHOP WR, 1988, ONCOGENE RES, V2, P205; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GIBBS JB, 1985, TRENDS BIOCHEM SCI, V10, P350, DOI 10.1016/0968-0004(85)90110-0; GRISHAM JW, 1983, SURV SYN PATHOL RES, V1, P49; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LAPETINA EG, 1985, J BIOL CHEM, V260, P1358; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAI JK, 1988, J BIOL CHEM, V263, P12472; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; PREISS J, 1986, J BIOL CHEM, V261, P8597; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; SANDGREN EP, 1989, IN PRESS ONCOGENE; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TOOZE J, 1980, MOL BIOL TUMOR VIRUS; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0	27	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					625	628						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2657577				2022-12-28	WOS:A1989U768800013
J	HENRIKSSON, M; CLASSON, M; INGVARSSON, S; KOSKINEN, P; SUMEGI, J; KLEIN, G; THYBERG, J				HENRIKSSON, M; CLASSON, M; INGVARSSON, S; KOSKINEN, P; SUMEGI, J; KLEIN, G; THYBERG, J			ELEVATED EXPRESSION OF C-MYC AND N-MYC PRODUCES DISTINCT CHANGES IN NUCLEAR FINE-STRUCTURE AND CHROMATIN ORGANIZATION	ONCOGENE			English	Article									UNIV HELSINKI,DEPT VIROL,SF-00290 HELSINKI 29,FINLAND; KAROLINSKA INST,DEPT MED CELL BIOL,S-10401 STOCKHOLM 60,SWEDEN	University of Helsinki; Karolinska Institutet	HENRIKSSON, M (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN.		Koskinen, Päivi J/G-8939-2014; Henriksson, Marie Arsenian/F-5010-2015; Ingvarsson, Sigurdur/E-7448-2011	Ingvarsson, Sigurdur/0000-0003-4125-1714	NCI NIH HHS [5RO1 CA14054-14] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DEPINHO R, 1987, J CELL BIOCHEM, V33, P257, DOI 10.1002/jcb.240330404; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; HAMMARSKJOLD ML, 1986, GENE, V43, P41, DOI 10.1016/0378-1119(86)90006-5; HANCOCK R, 1982, INT REV CYTOL, V79, P165; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; PERRSON H, 1984, SCIENCE, V225, P718; PERSSON H, 1986, MOL CELL BIOL, V6, P942, DOI 10.1128/MCB.6.3.942; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SEJERSEN T, 1987, EXP CELL RES, V172, P304, DOI 10.1016/0014-4827(87)90389-2; SPECTOR DL, 1987, ONCOGENE, V1, P5; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; WINQVIST R, 1984, EMBO J, V3, P2947, DOI 10.1002/j.1460-2075.1984.tb02237.x; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455	28	10	10	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					587	593						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3078963				2022-12-28	WOS:A1988R516300016
J	SONODA, Y; YOSHIMOTO, T; SEKIYA, T				SONODA, Y; YOSHIMOTO, T; SEKIYA, T			HOMOZYGOUS DELETION OF THE MTS1/P16 AND MTS2/P15 GENES AND AMPLIFICATION OF THE CDK4 GENE IN GLIOMA	ONCOGENE			English	Article						GLIOMA; HOMOZYGOUS DELETION; MTS1/P16 GENE; MTS2/P15 GENE; CDK4 GENE	POLYMERASE CHAIN-REACTION; DINUCLEOTIDE REPEAT POLYMORPHISM; HUMAN BRAIN-TUMORS; MUTATIONS; DNA	Loci on chromosome 9p are frequently deleted in several malignant tumors, suggesting the presence of putative tumor suppressor genes. The MTS1/p16 and MTS2/p15 genes on 9p are considered to be candidates. Binding of p15 and p16 cell cycle-regulatory proteins to the cyclin dependent protein kinase CDK4 inhibits CDK4/cyclin D dependent phosphorylation of retinoblastoma protein. We analysed the DNAs from 37 gliomas of several grades of malignancy for allelic loss of chromosome 9p and abberations of the MTS1/p16 and MTS2/p15 genes. We detected losses of one allele and homozygous deletions at loci, including those of the MTS1/p16 and MTS2/p15 genes, in 10 and 3 tumors, respectively. However, we did not detect any tumor-specific mutation in the two genes. The CDK4 gene was amplified in two malignant gliomas without homozygous deletion of the MTS1/p16 and MTS2/p15 genes and one malignant glioma with an allelic loss of the genes. These data suggest that aberrations of the genes coding for components of the cell cycle-regulatory system occured in at least 15 of 37 gliomas.	NATL CANC CTR,RES INST,DIV ONCOGENE,CHUO KU,TOKYO 104,JAPAN; TOHOKU UNIV,SCH MED,DEPT NEUROSURG,AOBA KU,SENDAI,MIYAGI 980,JAPAN	National Cancer Center - Japan; Tohoku University				Sonoda, Yukihiko/0000-0001-7651-1374				BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; COOLEMAN A, 1994, CANCER RES, V54, P344; FOUNTAIN JW, 1993, HUM MOL GENET, V2, P823, DOI 10.1093/hmg/2.6.823-a; FULTS D, 1992, GENOMICS, V14, P799, DOI 10.1016/S0888-7543(05)80191-0; FULTS D, 1990, CANCER RES, V50, P5784; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KHATIB ZA, 1993, CANCER RES, V53, P5535; KWIATKOWSKI DJ, 1992, HUM MOL GENET, V1, P658, DOI 10.1093/hmg/1.8.658-a; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; MAKINO R, 1990, Technique (Philadelphia), V2, P295; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1993, CANCER RES, V53, P2410; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; REIFENBERGER G, 1995, CANCER RES, V55, P731; REIFENBERGER G, 1994, CANCER RES, V54, P4299; REY JA, 1993, CANCER GENET CYTOGEN, V66, P1, DOI 10.1016/0165-4608(93)90140-H; RUBIO MP, 1994, CANCER RES, V54, P4760; SCHMIDT EE, 1994, CANCER RES, V554, P6321; SHIRAISHI M, 1989, CANCER RES, V49, P6474; SUZUKI Y, 1991, ANAL BIOCHEM, V192, P82, DOI 10.1016/0003-2697(91)90188-Y; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; ZULCH KJ, 1979, WHO GENEVA	29	75	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2145	2149						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478535				2022-12-28	WOS:A1995TF29700026
J	CHEN, RH; FIELDS, S; LIPSICK, JS				CHEN, RH; FIELDS, S; LIPSICK, JS			DISSOCIATION OF TRANSCRIPTIONAL ACTIVATION AND ONCOGENIC TRANSFORMATION BY V-MYB	ONCOGENE			English	Article						MYB; TRANSCRIPTION; LEUKEMIA	HIGH-EFFICIENCY TRANSFORMATION; AVIAN-MYELOBLASTOSIS VIRUS; DNA-BINDING DOMAIN; C-MYB; GENE-EXPRESSION; FUNCTIONAL DOMAINS; MAMMALIAN-CELLS; SV40 ENHANCER; MIM-1 GENE; TRANSACTIVATION	nuclear oncoprotein v-Myb is a transcriptional activator in both animal cells and the budding yeast Saccharomyces cerevisiae. Previous studies have suggested that an acidic domain of approximately 50 amino acids (amino acids 204-254 of v-Myb) is necessary and sufficient for transcriptional activation by v-Myb, c-Myb and GAL4-Myb fusion proteins. However, we find that first, none of the acidic residues within this region is essential for transcriptional activation in either animal cells or yeast. Second, transcriptional activation requires cooperation among multiple domains of v-Myb. In animal cells, transcriptional activation by v-Myb requires a central domain (amino acids 234-295), a C-terminal domain (amino acids 295-356), plus either of two more N-terminal domains (amino acids 163-197 or 198-232); in yeast, it requires the central domain plus either the C-terminal domain or a more N-terminal domain (amino acids 163-233). Third, although various subsets of these domains are sufficient for transcriptional activation by v-Myb, all of the domains must be present for transformation of primary hematopoietic cells. These results demonstrate that transcriptional activation by v-Myb is not sufficient for oncogenic transformation.	SUNY STONY BROOK,DEPT MOLEC GENET & MICROBIOL,STONY BROOK,NY 11794; STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stanford University					NCI NIH HHS [CA43592] Funding Source: Medline; NIGMS NIH HHS [GM49065] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049065] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BORTNER DM, 1991, NUCLEIC ACIDS RES, V19, P1533, DOI 10.1093/nar/19.7.1533; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ENGELKE U, 1995, VIROLOGY; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GONDA TJ, 1989, EMBO J, P1777; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GRASSER FA, 1992, ONCOGENE, V7, P1005; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; IWABUCHI K, 1993, ONCOGENE, V8, P1693; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIPSICK JS, 1987, J VIROL, V61, P933, DOI 10.1128/JVI.61.3.933-936.1987; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NERLOV C, 1994, GENE DEV, V8, P250; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUNYAMMALEE B, 1991, ONCOGENE, V6, P11; RAMSAY RG, 1991, ONCOGENE, V6, P1875; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; TANAKA M, 1994, MOL CELL BIOL, V14, P6046, DOI 10.1128/MCB.14.9.6046; TANAKA M, 1994, MOL CELL BIOL, V14, P6056, DOI 10.1128/MCB.14.9.6056; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	51	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1771	1779						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478605				2022-12-28	WOS:A1995TD09400012
J	JURDIC, P; TREILLEUX, I; VANDEL, L; TABONE, E; HUGUIER, S; SERGEANT, A; CASTELLAZZI, M				JURDIC, P; TREILLEUX, I; VANDEL, L; TABONE, E; HUGUIER, S; SERGEANT, A; CASTELLAZZI, M			TUMOR-INDUCTION BY V-JUN HOMODIMERS IN CHICKENS	ONCOGENE			English	Article						V-JUN; HOMODIMERS; VISCERAL TUMORS; LEIOMYOSARCOMA; IMMORTALIZATION; CHICKENS	DNA-BINDING ACTIVITY; AVIAN-SARCOMA VIRUS-17; C-JUN; EMBRYO FIBROBLASTS; TRANSCRIPTION FACTORS; CELL-TRANSFORMATION; TRANSGENIC MICE; PROTEIN-KINASE; FOS-GENE; ONCOGENE	To study the contribution of v-Jun homodimers to oncogenesis, me constructed artificial v-Jun derivatives in which the natural dimerization domain of v-Jun was replaced by an heterologous homodimerization domain from either the viral EB1 or the yeast GCN4 transcription factor. The resulting v-Jun chimeric proteins, called v-Jun(eb1) and v-Jun(gcn4), which can no longer dimerize with Jun or Fos, should only form homodimers in the cell. Helper-independent retroviruses expressing v-Jun, v-Jun(eb1) and v-Jun(gcn4) were generated. AU three viruses transformed primary cultures of chick embryo cells with the same high efficiency and promoted local tumor growth after subcutaneous injection of infected cells in young animals. In contrast, after intravenous injection of viral suspensions into chick embryos, only the chimeric proteins produced internal tumors that were lethal. These tumors were leiomyosarcomas located within the liver and along the digestive tract. Thus, in vivo, v-Jun(eb1) and v-Jun(gcn4) are more potent oncoproteins than v-Jun. These data demonstrate that when forced to accumulate, v-Jun homodimers can induce tumors efficiently. They also show that the oncogenic potential of v-Jun can be regulated through the properties of its dimerization domain.	ECOLE NORMALE SUPER LYON,INSERM,U412,UNITE VIROL HUMAINE,F-69364 LYON 07,FRANCE; CTR LEON BERARD,DEPT ANAT & CYTOL PATHOL,F-69373 LYON 08,FRANCE; LAB BIOL MOLEC & CELLULAIRE,CNRS,UMR 49,F-69373 LYON 08,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet				Vandel, Laurence/0000-0002-3692-2942				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADLER V, 1994, J BIOL CHEM, V269, P11186; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BALL AR, 1988, COLD SPRING HARB SYM, V53, P687, DOI 10.1101/SQB.1988.053.01.078; BERKOFLINT Y, 1994, EMBO J, V13, P646, DOI 10.1002/j.1460-2075.1994.tb06303.x; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3241; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P269; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P491; GABBIANI G, 1971, EXPERIENTIA, V27, P549, DOI 10.1007/BF02147594; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P8837, DOI 10.1073/pnas.90.19.8837; GARCIA M, 1990, J VIROL, V64, P4684, DOI 10.1128/JVI.64.10.4684-4690.1990; GIOT JF, 1991, NUCLEIC ACIDS RES, V19, P1251, DOI 10.1093/nar/19.6.1251; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GROSSI M, 1991, ONCOGENE, V6, P1767; HADMAN M, 1993, ONCOGENE, V8, P1895; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HARTL M, 1995, VIROLOGY, V207, P321, DOI 10.1006/viro.1995.1086; HARTL M, 1991, ONCOGENE, V6, P1623; HARVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARSHALL GM, 1992, VIROLOGY, V188, P373, DOI 10.1016/0042-6822(92)90768-K; MOLDERS H, 1987, ONCOGENE, V1, P377; MORGAN IM, 1994, ONCOGENE, V9, P2793; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MOSCOVICI C, 1982, ADV VIRAL ONCOL, V1, P82; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NISHIZAWA M, 1987, J VIROL, V61, P3733, DOI 10.1128/JVI.61.12.3733-3740.1987; OEHLER T, 1993, ONCOGENE, V8, P1141; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PONTA H, 1992, BIOCHIM BIOPHYS ACTA, V1129, P255, DOI 10.1016/0167-4781(92)90501-P; PURCHASE HG, 1977, INFECT IMMUN, V15, P423, DOI 10.1128/IAI.15.2.423-428.1977; SCHUH AC, 1992, ONCOGENE, V7, P667; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SCHUUR ER, 1993, CELL GROWTH DIFFER, V4, P761; SHALABY F, 1994, ONCOGENE, V9, P2579; SU HY, 1991, ONCOGENE, V6, P1759; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; VANDEL L, 1995, ONCOGENE, V10, P495; VANHOEVEN KH, 1993, AM J SURG PATHOL, V17, P1176, DOI 10.1097/00000478-199311000-00011; VOGT, 1994, VOGT PK, P203; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WONG WY, 1992, ONCOGENE, V7, P2077; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	65	14	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1699	1709						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478597				2022-12-28	WOS:A1995TD09400004
J	SOLOMON, DLC; PHILIPP, A; LAND, H; EILERS, M				SOLOMON, DLC; PHILIPP, A; LAND, H; EILERS, M			EXPRESSION OF CYCLIN D1 MESSENGER-RNA IS NOT UP-REGULATED BY MYC IN RAT FIBROBLASTS	ONCOGENE			English	Note						CYCLIN D1; MYC; ESTROGEN RECEPTOR; TAMOXIFEN	HUMAN C-MYC; DNA-BINDING; ESTROGEN-RECEPTOR; STEROID BINDING; GENE-EXPRESSION; CELL-CYCLE; MAX; SEQUENCE; PROTEIN; DIMERIZATION	Conflicting results have been published regarding the regulation of cyclin D1 mRNA in rat fibroblasts expressing a hormone-regulated Myc protein, MycER. We confirm that activation of MycER with oestrogen rapidly induces cyclin D1 mRNA, even in the presence of cycloheximide. However, we show that this is an artefact resulting from an oestrogen-activated transcriptional activation domain in the oestrogen receptor part of the MycER chimaera. First, addition of 4-hydroxy-tamoxifen (4OHT), which does not activate this domain, allows association of MycER with Max and induces cell proliferation in serum-starved Rat-1-MycER cells without affecting cyclin D1 mRNA levels or the activity of D1 promoter-luciferase constructs. Second, Rat-1 cells expressing a mutant MycER with a hormone-binding domain that still binds 4OHT but no longer binds oestrogen, are driven into the cell cycle in response to 4OHT but fail to up-regulate cyclin D1 mRNA. Finally, Rat-1 cells in which wild-type human c-Myc expression can be induced, also progress into the cell cycle without increased D1 mRNA expression.	ZENTRUM MOLEK BIOL HEIDELBERG,D-69120 HEIDELBERG,GERMANY; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Ruprecht Karls University Heidelberg; Cancer Research UK				Eilers, Martin/0000-0002-0376-6533				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; GAUBATZ S, 1994, MOL CELL BIOL, V6, P3853; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HERBER B, 1994, ONCOGENE, V9, P1295; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1993, ONCOGENE, V8, P3447; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOVEC H, 1994, ONCOGENE, V9, P323; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH R, 1995, GENOMICS, V25, P85, DOI 10.1016/0888-7543(95)80112-Y; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	44	42	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1893	1897						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478619				2022-12-28	WOS:A1995TD09400026
J	TAKITA, J; HAYASHI, Y; KOHNO, T; SHISEKI, M; YAMAGUCHI, N; HANADA, R; YAMAMOTO, K; YOKOTA, J				TAKITA, J; HAYASHI, Y; KOHNO, T; SHISEKI, M; YAMAGUCHI, N; HANADA, R; YAMAMOTO, K; YOKOTA, J			ALLELOTYPE OF NEUROBLASTOMA	ONCOGENE			English	Article						NEUROBLASTOMA; TUMOR SUPPRESSOR GENE; ALLELOTYPE; CHROMOSOME 9	N-MYC AMPLIFICATION; NEURO-BLASTOMA; GENE-MUTATIONS; HETEROZYGOSITY; RETINOBLASTOMA; CHROMOSOME-1; TUMOR; IDENTIFICATION; CARCINOMA; ONCOGENE	Although relatively high incidence of loss of heterozygosity (LOH) on chromosomes 1p, 11q, and 14q have been reported in neuroblastoma, it is still unclear whether or not LOH occurs specifically on these chromosome arms in neuroblastoma since only a few chromosomal arms have been examined for LOH in previous studies. Therefore, we screened 81 cases of tumors for LOH on all 22 autosomes and chromosome X using 35 restriction fragment length polymorphism markers and eight microsatellite markers. High incidence of LOH (>20%) was observed on six chromosome arms; 1p (26%), 2q (30%), 9p (36%), 11q (24%), 14q (22%), and 18q (31%), Frequencies of LOH on other chromosome arms were less than 13%. Patients with 9p LOH in the tumors showed statistically significant association with advanced stage of the disease and poor prognosis (P=0.037 and P=0.003, respectively) independently from N-myc amplification, while LOH on other chromosomes did not show association with stage, prognosis, and N-myc amplification. Thus, besides LOH on chromosomes 1p, 11q, and 14q, LOH on chromosomes 2q, 9p, and 18q also occurs relatively frequently in neuroblastoma, indicating the involvement of multiple tumor suppressor genes in the development of neuroblastoma. It is possible that there is a novel tumor suppressor gene on chromosome 9p which is involved in the progression of neuroblastoma.	NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN; NATL CANC CTR,RES INST,DIV CANC INFORMAT & EPIDEMIOL,CHUO KU,TOKYO 104,JAPAN; UNIV TOKYO,FAC MED,DEPT PEDIAT,BUNKYO KU,TOKYO 113,JAPAN; SAITAMA CHILDRENS MED CTR,DIV HEMATOL ONCOL,IWATSUKI,SAITAMA 339,JAPAN	National Cancer Center - Japan; National Cancer Center - Japan; University of Tokyo; Saitama Children's Medical Center								BERNSTEIN ML, 1992, J CLIN ONCOL, V10, P323, DOI 10.1200/JCO.1992.10.2.323; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HAYASHI Y, 1989, CANCER, V63, P126, DOI 10.1002/1097-0142(19890101)63:1<126::AID-CNCR2820630120>3.0.CO;2-Z; IMAMURA J, 1993, CANCER RES, V53, P4053; JEN J, 1995, CANCER RES, V54, P6353; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOHNO T, 1994, ONCOGENE, V9, P103; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Maniatis T., 1982, MOL CLONING; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NAKAMURA T, 1991, JPN J CLIN ONCOL, V21, P325; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; SUZUKI T, 1989, CANCER RES, V49, P1095; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; TONINI GP, 1993, EUR J CANCER, V29A, P802, DOI 10.1016/S0959-8049(05)80412-5; TSUDA T, 1987, CANCER, V60, P820, DOI 10.1002/1097-0142(19870815)60:4<820::AID-CNCR2820600418>3.0.CO;2-Y; VOGAN K, 1993, CANCER RES, V53, P5269; WEINBERG RA, 1991, SCIENCE, V254, P138	35	90	90	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1829	1834						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478611				2022-12-28	WOS:A1995TD09400018
J	QUANG, CT; PIRONIN, M; VONLINDERN, M; BEUG, H; GHYSDAEL, J				QUANG, CT; PIRONIN, M; VONLINDERN, M; BEUG, H; GHYSDAEL, J			SPI-1 AND MUTANT P53 REGULATE DIFFERENT ASPECTS OF THE PROLIFERATION AND DIFFERENTIATION CONTROL OF PRIMARY ERYTHROID PROGENITORS	ONCOGENE			English	Article						LEUKEMIA; SPI-1; ETS PROTEINS; P53; ERYTHROID PROGENITORS	WILD-TYPE P53; VIRUS-INDUCED ERYTHROLEUKEMIA; AVIAN ERYTHROBLASTOSIS VIRUS; RAT EMBRYO FIBROBLASTS; GROWTH-FACTOR RECEPTOR; SEA ONCOGENE PRODUCT; ETS DOMAIN PROTEIN; V-ERBA; FRIEND-VIRUS; TRANSCRIPTIONAL ACTIVATION	The emergence of leukemic cells in Friend virus complex-induced erythroleukemia is associated with two recurrent genetic alterations, namely the inactivation of the p53 tumor suppressor gene and the overexpression of Spi-1, a member of the Ets family of transcriptional regulators. In order to determine the role of these genetic alterations on the proliferation and differentiation control of erythroblasts, we expressed Spi-1 and the temperature sensitive mutant p53(V135A) in avian primary erythroid progenitors. We show that enforced expression of Spi-1 in erythroblasts obtained from bone marrow cells by expression of the ts-Sea tyrosine kinase inhibits the execution of the differentiation program normally induced in these cells in response to Epo and insulin and following inactivation of ts-Sea function. In contrast, overexpression of p53(V135A) is without effect on the ability of these cells to differentiate into erythrocytes. However, expression of p53(V135A) in erythroid progenitors obtained from bone marrow cells in the presence of SCF, TGF alpha and estradiol, was found to relieve these cells from their absolute TGF alpha requirement for long term proliferation. This phenotype is dependent upon the expression of the mutant form of p53(V135A) as it is not observed at a temperature at which p53(V135A) regains wild type p53 function. Our results show that each of the genetic alterations which characterize Friend erythroleukemic cells affect in a distinct manner the proliferation and differentiation control of primary erythroid progenitors.	CTR UNIV ORSAY,INST CURIE,ONCOL VIRALE & CELLULAIRE LAB,CNRS,UMR 146,F-91405 ORSAY,FRANCE; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			QUANG, christine TRAN/G-7508-2016; von Lindern, Marieke/AAH-2350-2020; GHYSDAEL, Jacques/F-3377-2013					Andrews N C, 1994, Curr Opin Hematol, V1, P119; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1994, CURR OPIN CELL BIOL, V6, P816, DOI 10.1016/0955-0674(94)90050-7; BEUG H, 1992, NUCLEAR PROCESSES ON, P53; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROWE AJ, 1993, ONCOGENE, V8, P181; CROWE AJ, 1991, J VIROL, V65, P2533, DOI 10.1128/JVI.65.5.2533-2538.1991; CROWE AJ, 1993, CELL GROWTH DIFFER, V4, P403; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELIYAHU D, 1988, ONCOGENE, V3, P313; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; FUHRMANN U, 1989, GENE DEV, V3, P2072, DOI 10.1101/gad.3.12b.2072; GANDRILLON O, 1994, ONCOGENE, V9, P749; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GEGONNE A, 1992, NEW BIOL, V4, P512; GHYSDAEL J, 1992, CANCER SURV, V14, P169; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HAYMAN MJ, 1982, J CELL BIOCHEM, V18, P351, DOI 10.1002/jcb.1982.240180308; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KNIGHT J, 1988, ONCOGENE, V2, P317; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; Kowenz E, 1987, Haematol Blood Transfus, V31, P199; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MORIMOTO AM, 1994, J VIROL, V68, P1837, DOI 10.1128/JVI.68.3.1837-1842.1994; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PEACOCK JW, 1990, ONCOGENE, V5, P1769; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; ROVINSKI B, 1988, ONCOGENE, V2, P445; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; STEINLEIN P, 1994, GROWTH FACTORS, V10, P1, DOI 10.3109/08977199409019599; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; WILLIAMS BP, 1988, ONCOGENE, V3, P345; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	80	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1229	1239						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478542				2022-12-28	WOS:A1995RY96700002
J	BEIMLING, P; MOELLING, K				BEIMLING, P; MOELLING, K			ISOLATION AND CHARACTERIZATION OF THE TAX PROTEIN OF HTLV-I	ONCOGENE			English	Note									MAX PLANCK INST MOLEC GENET,ABT SCHUSTER,IHNESTR 73,D-1000 BERLIN 33,FED REP GER	Max Planck Society								ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BEIMLING P, 1985, BIOCHEMISTRY-US, V24, P6349, DOI 10.1021/bi00344a005; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN ISY, 1985, SCIENCE, V230, P570, DOI 10.1126/science.2996140; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUHISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277; GALLO R, 1988, NATURE, V333, P504, DOI 10.1038/333504a0; GERSTEN DM, 1978, J IMMUNOL METHODS, V24, P305, DOI 10.1016/0022-1759(78)90133-3; GILMOUR DS, 1985, MOL CELL BIOL, V5, P2009, DOI 10.1128/MCB.5.8.2009; GOH WC, 1985, SCIENCE, V227, P1227, DOI 10.1126/science.2983419; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOLBROOK NJ, 1984, NUCLEIC ACIDS RES, V12, P5005, DOI 10.1093/nar/12.12.5005; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KIYOKAWA T, 1985, VIROLOGY, V147, P462, DOI 10.1016/0042-6822(85)90149-7; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE TH, 1984, SCIENCE, V226, P57, DOI 10.1126/science.6089350; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RENZ M, 1987, NUCLEIC ACIDS RES, V15, P277, DOI 10.1093/nar/15.1.277; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; WONGSTAAL F, 1983, NATURE, V302, P626, DOI 10.1038/302626a0; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545	43	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					511	516						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2785666				2022-12-28	WOS:A1989U567700017
J	ALI, IU; MERLO, G; CALLAHAN, R; LIDEREAU, R				ALI, IU; MERLO, G; CALLAHAN, R; LIDEREAU, R			THE AMPLIFICATION UNIT ON CHROMOSOME-11Q13 IN AGGRESSIVE PRIMARY HUMAN-BREAST TUMORS ENTAILS THE BCL-1, INT-2 AND HST LOCI	ONCOGENE			English	Article									CTR RENE HUGUENIN,F-92211 ST CLOUD,FRANCE	Rene Huguenin Hospital	ALI, IU (corresponding author), NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892, USA.							ADELAIDE J, 1988, ONCOGENE, V2, P413; ALI IU, 1988, ONCOGENE RES, V3, P139; ALI IU, 1988, IN PRESS MOL DIAGNOS; ALI IU, 1988, BREAST CANCER CELLUL, P25; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BIGNER SH, 1987, CANCER GENET CYTOGEN, V29, P165, DOI 10.1016/0165-4608(87)90045-8; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BRESLOW JL, 1982, P NATL ACAD SCI-BIOL, V79, P6861, DOI 10.1073/pnas.79.22.6861; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; COLLINS SJ, 1983, P NATL ACAD SCI-BIOL, V80, P4813, DOI 10.1073/pnas.80.15.4813; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; DALLAFAVERA R, 1982, NATURE, V299, P61; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DICKSON C, 1987, NATURE, V326, P823; EMANUEL BS, 1985, P NATL ACAD SCI USA, V82, P3736, DOI 10.1073/pnas.82.11.3736; GAZDAR AF, 1985, CANCER RES, V45, P2924; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; KARATHANASIS SK, 1983, NATURE, V304, P371, DOI 10.1038/304371a0; KINZLER KW, 1986, P NATL ACAD SCI USA, V83, P1031, DOI 10.1073/pnas.83.4.1031; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; KOZBOR D, 1984, CANCER RES, V44, P438; LAW ML, 1987, P NATL ACAD SCI USA, V84, P2877, DOI 10.1073/pnas.84.9.2877; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LIDEREAU R, 1986, J NATL CAN I, V77, P687; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; RABBITTS PH, 1988, ONCOGENE, V3, P99; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SHELDON JR, 1983, P NATL ACAD SCI USA, V80, P7289; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; VANDENELSEN P, 1984, NATURE, V312, P413, DOI 10.1038/312413a0; WILLIAMS B, 1987, HUMAN GENE MAPPING, V9, pA731; YOSHIDA MC, 1988, P NATL ACAD SCI USA, V85, P4861, DOI 10.1073/pnas.85.13.4861; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305	44	148	148	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					89	92						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2915903				2022-12-28	WOS:A1989U567400013
J	LEMOINE, NR; MAYALL, ES; WILLIAMS, ED; THURSTON, V; WYNFORDTHOMAS, D				LEMOINE, NR; MAYALL, ES; WILLIAMS, ED; THURSTON, V; WYNFORDTHOMAS, D			AGENT-SPECIFIC RAS ONCOGENE ACTIVATION IN RAT-THYROID TUMORS	ONCOGENE			English	Article											LEMOINE, NR (corresponding author), UNIV WALES COLL MED,DEPT PATHOL,CANC RES CTR,THYROID TUMOUR BIOL RES GRP,CARDIFF CF4 4XN,S GLAM,WALES.							BALMAIN A, 1986, J PATHOL, V149, P3, DOI 10.1002/path.1711490103; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; DONIACH I, 1950, BRIT J CANCER, V4, P223, DOI 10.1038/bjc.1950.22; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GUERRERO I, 1986, LEUKEMIA RES, V10, P851, DOI 10.1016/0145-2126(86)90306-1; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; KNOWLES MA, 1987, ONCOGENE, V1, P143; LEMOINE NR, 1988, CANCER RES, V48, P4459; MCMAHON G, 1986, P NATL ACAD SCI USA, V83, P9418, DOI 10.1073/pnas.83.24.9418; REYNOLDS SH, 1986, P NATL ACAD SCI USA, V83, P33, DOI 10.1073/pnas.83.1.33; SAWEY MJ, 1987, MOL CELL BIOL, V7, P932, DOI 10.1128/MCB.7.2.932; SCHAFFER R, 1980, J CANCER RES CLIN, V96, P281, DOI 10.1007/BF00408100; STEINHOFF D, 1983, TOXICOL APPL PHARM, V60, P161; STOWERS SJ, 1987, CANCER RES, V47, P3212; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; SUKUMAR S, 1986, MOL CELL BIOL, V6, P2716, DOI 10.1128/MCB.6.7.2716; TSUDA H, 1976, J NATL CANCER I, V46, P81; WILLIAMS ED, 1980, RECENT RES CANCER, P47; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	22	66	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					541	544						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3078959				2022-12-28	WOS:A1988R516300009
J	STEINMEYER, K; DEPPERT, W				STEINMEYER, K; DEPPERT, W			DNA-BINDING PROPERTIES OF MURINE-P53	ONCOGENE			English	Article									UNIV ULM,DEPT BIOCHEM,D-7900 ULM,FED REP GER	Ulm University								Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; DEFROMENTEL CC, 1986, EXP CELL RES, V164, P35, DOI 10.1016/0014-4827(86)90452-0; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; Mage M G, 1980, Methods Enzymol, V70, P142; MILNER J, 1986, VIROLOGY, V150, P265, DOI 10.1016/0042-6822(86)90286-2; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; ROSENWIRTH B, 1975, VIROLOGY, V67, P14, DOI 10.1016/0042-6822(75)90399-2; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SEN A, 1978, P NATL ACAD SCI USA, V75, P1647, DOI 10.1073/pnas.75.4.1647; SHOHAT O, 1987, ONCOGENE, V1, P277; SPILLMAN T, 1979, J BIOL CHEM, V254, P3100; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STAUFENBIEL M, 1984, J CELL BIOL, V98, P1886, DOI 10.1083/jcb.98.5.1886; VANDERVLIET PC, 1973, NATURE-NEW BIOL, V246, P170, DOI 10.1038/newbio246170a0; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WEBER K, 1975, EXP CELL RES, V95, P111, DOI 10.1016/0014-4827(75)90615-1; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	25	121	121	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					501	507						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	2978867				2022-12-28	WOS:A1988R516300003
J	STURZBECHER, HW; BRAIN, R; MAIMETS, T; ADDISON, C; RUDGE, K; JENKINS, JR				STURZBECHER, HW; BRAIN, R; MAIMETS, T; ADDISON, C; RUDGE, K; JENKINS, JR			MOUSE P53 BLOCKS SV40 DNA-REPLICATION INVITRO AND DOWNREGULATES T-ANTIGEN DNA HELICASE ACTIVITY	ONCOGENE			English	Article									ESTONIAN BIOCTR,TARTU 202400,ESTONIA,USSR	Estonian Biocentre	STURZBECHER, HW (corresponding author), MARIE CURIE RES INST,CELL PROLIFERAT LAB,OXTED RH8 0TL,SURREY,ENGLAND.		Maimets, Toivo/E-9268-2017	Maimets, Toivo/0000-0001-6461-3365				BRADLEY MK, 1987, P NATL ACAD SCI USA, V84, P4026, DOI 10.1073/pnas.84.12.4026; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CLARK R, 1981, J BIOL CHEM, V256, P1854; COLE CN, 1986, J VIROL, V57, P539, DOI 10.1128/JVI.57.2.539-546.1986; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEB S, 1986, MOL CELL BIOL, V6, P4578, DOI 10.1128/MCB.6.12.4578; DEB S, 1986, MOL CELL BIOL, V6, P1663, DOI 10.1128/MCB.6.5.1663; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DELUCIA AL, 1983, J VIROL, V46, P143, DOI 10.1128/JVI.46.1.143-150.1983; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, V1, P99; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GIACHERIO D, 1979, J BIOL CHEM, V254, P8113; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HANDA H, 1981, J BIOL CHEM, V256, P478; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUBSCHER U, 1985, NUCLEIC ACIDS RES, V13, P5471, DOI 10.1093/nar/13.15.5471; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, ONCOGENE HDB; JENKINS JR, 1988, IN PRESS J VIROL; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LI JJ, 1986, MOL CELL BIOL, V6, P1117, DOI 10.1128/MCB.6.4.1117; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARGOLSKEE RF, 1984, J VIROL, V49, P386, DOI 10.1128/JVI.49.2.386-393.1984; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PAUCHA E, 1986, J VIROL, V57, P50, DOI 10.1128/JVI.57.1.50-64.1986; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROVINSKI B, 1988, ONCOGENE, V2, P445; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SIMMONS DT, 1988, P NATL ACAD SCI USA, V85, P2086, DOI 10.1073/pnas.85.7.2086; SIMMONS DT, 1986, J VIROL, V57, P776, DOI 10.1128/JVI.57.3.776-785.1986; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STAHL H, 1985, J VIROL, V54, P473, DOI 10.1128/JVI.54.2.473-482.1985; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; STURZBECHER HW, 1988, IN PRESS CANCER CELL, V6; TACK LC, 1986, J VIROL, V58, P635, DOI 10.1128/JVI.58.2.635-646.1986; TACK LC, 1988, J VIROL, V62, P1028, DOI 10.1128/JVI.62.3.1028-1037.1988; TEGTMEYER P, 1983, J VIROL, V46, P151, DOI 10.1128/JVI.46.1.151-161.1983; TJIAN R, 1978, CELL, V13, P165, DOI 10.1016/0092-8674(78)90147-2; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WIEKOWSKI M, 1987, J VIROL, V61, P411, DOI 10.1128/JVI.61.2.411-418.1987; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790	62	94	94	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					405	413						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	2856250				2022-12-28	WOS:A1988Q773900008
J	ADELAIDE, J; MATTEI, MG; MARICS, I; RAYBAUD, F; PLANCHE, J; DELAPEYRIERE, O; BIRNBAUM, D				ADELAIDE, J; MATTEI, MG; MARICS, I; RAYBAUD, F; PLANCHE, J; DELAPEYRIERE, O; BIRNBAUM, D			CHROMOSOMAL LOCALIZATION OF THE HST ONCOGENE AND ITS CO-AMPLIFICATION WITH THE INT-2 ONCOGENE IN A HUMAN-MELANOMA	ONCOGENE			English	Article									INSERM,U119,27 BD LEI ROURE,F-13009 MARSEILLE,FRANCE; GRP HOSP TIMONE,HOP ENFANTS,INSERM,U242,F-13385 MARSEILLE 5,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			ADELAIDE, José JA/O-4390-2017	ADELAIDE, José JA/0000-0003-4364-9857; Birnbaum, Daniel/0000-0001-7920-9883				ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BALABAN G, 1984, CANCER GENET CYTOGEN, V11, P429, DOI 10.1016/0165-4608(84)90024-4; BECHER R, 1983, CANCER RES, V43, P5010; BERGMAN EA, 1985, PHYS EARTH PLANET IN, V40, P1, DOI 10.1016/0031-9201(85)90002-0; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; NAKAGAMA H, 1987, JPN J CANCER RES, V78, P651; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NGUYEN C, 1986, J CELL BIOL, V102, P711, DOI 10.1083/jcb.102.3.711; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; PIEROTTI M, 1987, CUTANEOUS MELANOMA, P339; RAYBAUD F, IN PRESS CANCER RES; ROBERTS AB, 1986, CANCER SURV, V5, P405; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WILLIAMS B, 1987, HUMAN GENE MAPPING, V9, pA731	29	140	141	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					413	416						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3283658				2022-12-28	WOS:A1988M947200016
